<SEC-DOCUMENT>0001628908-22-000063.txt : 20220506
<SEC-HEADER>0001628908-22-000063.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220504181056
ACCESSION NUMBER:		0001628908-22-000063
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		22893154

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evh-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d53c1d9c-a1b3-428c-ab91-113966fe5337,g:d0023668-d86c-4a77-8abf-aab325264a20,d:bb64a58c5010458da650c3b7c8dfab74--><html xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:evh="http://www.evolenthealth.com/20220331" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF8xLTEtMS0xLTM4MDQx_67908e72-5a0f-470f-8cc5-2069c3834097">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF8yLTEtMS0xLTM4MDQx_65bdf72c-d388-4cca-a25b-b0f7ffe96257">false</ix:nonNumeric><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF8zLTEtMS0xLTM4MDQx_cbb4b3ec-08f3-4ea8-9571-3db3b2fc06a4">2022</ix:nonNumeric><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF80LTEtMS0xLTM4MDQx_7949ab76-eec9-4dc7-9d13-89145f7cd8a7">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF81LTEtMS0xLTQ3Njk2_bca9aa0e-d5c9-4783-ac00-a9b4da4a1a35">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6f712582849a46cc8b068630eb54d37d_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMC0xLTEtNDc3MjY_af2df6d4-dea4-4789-ae3a-b6fb5553a450">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i5b0b219944a9403581d404035c8810ea_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzMvZnJhZzo3YjJhNjdkMGYyNzQ0ZjgwODlmM2MyM2EyN2Q4OWUwZC90YWJsZTozOGQyZjUzM2YyYjU0OWY2YWVmZTBhOGJlN2IzYmFiZS90YWJsZXJhbmdlOjM4ZDJmNTMzZjJiNTQ5ZjZhZWZlMGE4YmU3YjNiYWJlXzItMS0xLTEtMzgwNDE_f98caff0-70cc-4893-ba2e-ceb26d2854f4">9</ix:nonNumeric><ix:nonNumeric contextRef="i8940680e0d344f24a0605bc5abbeeab2_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzMvZnJhZzo3YjJhNjdkMGYyNzQ0ZjgwODlmM2MyM2EyN2Q4OWUwZC90YWJsZTozOGQyZjUzM2YyYjU0OWY2YWVmZTBhOGJlN2IzYmFiZS90YWJsZXJhbmdlOjM4ZDJmNTMzZjJiNTQ5ZjZhZWZlMGE4YmU3YjNiYWJlXzMtMS0xLTEtMzgwNDE_a5e847fe-79b9-403a-bea6-4d5fd2ecaae9">12</ix:nonNumeric><ix:nonNumeric contextRef="i4661a17748084b22847a6b4088c1f8c0_I20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzMvZnJhZzo3YjJhNjdkMGYyNzQ0ZjgwODlmM2MyM2EyN2Q4OWUwZC90YWJsZTozOGQyZjUzM2YyYjU0OWY2YWVmZTBhOGJlN2IzYmFiZS90YWJsZXJhbmdlOjM4ZDJmNTMzZjJiNTQ5ZjZhZWZlMGE4YmU3YjNiYWJlXzQtMS0xLTEtMzgwNDE_691b6507-1a31-4971-8e18-30289680cc09">12</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ifa07fa21879c47f8a81b631bf261e16f_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDgvZnJhZzplNmMxYmU4OTMxZTM0Mjk5YjFmYTNkMDRhZTg3OGM3Yy90ZXh0cmVnaW9uOmU2YzFiZTg5MzFlMzQyOTliMWZhM2QwNGFlODc4YzdjXzU_825f789a-8531-494f-a1a4-2f2bb0c46f90">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i960ff983ba984eef9fc0e57242acf4ad_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDgvZnJhZzplNmMxYmU4OTMxZTM0Mjk5YjFmYTNkMDRhZTg3OGM3Yy90ZXh0cmVnaW9uOmU2YzFiZTg5MzFlMzQyOTliMWZhM2QwNGFlODc4YzdjXzIxNQ_fa6f3c81-8024-4d93-9c11-c039bdc1b0b9">.0299135</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96988fb77cf47f0ba8eb6166fda7e01_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if299fb55051e4d729c1f4c44566a6f16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1623fa44597143889f19c0188c630b48_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec101c4091a4f46bfd520e8d03792f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59c3d3e7b5d4f4a8874ddebbe1ace67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e9801520f34456b2f8524c63e8e3c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299ef1742b0c49abae14abd4ed0f8174_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aa8e3cb4d874916a84b9d7e08e4666c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f712582849a46cc8b068630eb54d37d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5daef88c2af84a738a5f7ff9de4b9d7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21f2d521de74c5dbb6764b237c3ac1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7fee29877b408198fcd590f13b5985_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293a1a6091d64b118aef6ec8a2d2167a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130e14f026354ba2b836575ebd10bdd2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621d358e78ed4fc2bd3ecd3b820db708_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1cbb67f86274231b6621e78983d84df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e23962c75c49019909c9715c2499c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7eb4df9b7ed4bb382872f97fdb6a757_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc124f8ebb2b48dca7de861265b1df9f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be7adf261ff427c874251aacfa02b7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef9a57b91634689a5fc4d94fc39cc92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44432f28d3a4aecb8eb5918685f3019_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd7879f349a4bfb9adf1f4b67cb4d3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb90b06b13ac482cb1469d573d0ac107_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059aea63706f40babf4ad42f721269d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id145101f6b47482c8c8b1e64aec732ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i924e8357dfb2454f86c7f8d0fd74a114_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cbe563905aa492187f4514b1c567124_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i172d29d14aac4caf8b3c3650d9877ed2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc68586f685749a588829914e464480b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db922f783fb432da34f684d3de92b24_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e1ee4ac4ec44e681da4653910c6586_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33645fe6fe6e4f2b970ee1650d578425_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644591fb6cc54e2096aefb6d12c9ee6d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68b009330794ef1888c6d5fc3c5dfc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icedde2203c2f4932b7525a1653f8a386_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff05ae2c51c48e6afd4afc199a1aa71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib729f13217c547b98e74d1bafa5ea4c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4114c1a397b94102bce6ff2aa93691c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746c3c635d6c45f5b87aefae016c4fb4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ea15c7c5084899ae3932a21f7bcb6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82aee0d988d44d9af8cac23744c8699_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2b71e551c243ae81adfe5562d1b7c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reportingunit"><xbrli:measure>evh:reportingUnit</xbrli:measure></xbrli:unit><xbrli:context id="icead5b03e4c6480db192188178d18afe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136d025dfa994cc69d43c0b193565b0a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdd074577da4a56beeac98f792d2af1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4153f331bc4c5ba00b95d8e87a52dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532067d6f1ec4a09974e220c6f9d2b9f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1244aeda3f374cbdb7295a1b9720eaca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd76d84c4874414b5b69662bb989fcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iae5bc002399c42d7a0dfe095133c2eea_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd02a268c2f44e1b4b8a87043e3237b_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fed4b10d9a94e43b4a7376d75e82ef5_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50dcc4c9e90649d88b6e4ebba21ccd70_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ff05debabc497c8b7183be3cf47025_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486cd92f52f9444ea10b825521601fd1_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d8f0394dcea4227a602bc9f7748104e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0dedbe6375f4957bda96aaf161bdfa5_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f19f381f38447c990722124282e3f6_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05ac80824ef4e7e9360568c9bffff1a_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b184513547b435b881d4872ab81bc09_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a872109d774e4da481cebe223eff04_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6ec7aba15341f6b7511d0a09ecf92a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a4593df2ed48e8bf26fb1a8734b8ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bf389c6898466eb63379d01aaa71b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec4532a4742433aba9506e85893885b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fad50bce4e049c5b3abd06d2db91799_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc0c2e998684f5f950bf9b71a352797_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19591c0223f84cb39b25c549e7cf2367_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f20417b0b048728508db43ea6e2e8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af0d9f0068a4ecaa4d353078136bc50_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768d2ed3578749dd919d8c01b59a765f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54489df7b34f4bc5bd3764871ee2bbd8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia45d563122eb4be993ee23f5113a8e5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526505192a4f43d58f8618791a968597_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4c945d2ec44cc996bde7e53fc1298c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649f6202bc224593b15c50af0d75b73c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0b219944a9403581d404035c8810ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8940680e0d344f24a0605bc5abbeeab2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4661a17748084b22847a6b4088c1f8c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0669761c388c4774877abc5d5d60ea1a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i112e0050ecf247829efb6e3889c6f684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22dc575ff886464484317aca659befbb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2526a6d68f44dd9a2d5c9c76f28f392_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if10ac0d0bbea4997a9ef4b8313c0f3d9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4101ecab0d224b7e94b0b16a3a6e2d35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i080f3a0bebf046f4b42c854af2f46b0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171aed87552d42e6b97ff67bc5456cba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbac2b94ee84dbaa1e6ae52b26777c8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a483ad79bb04d958eac46a38e2f15c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8804d1ca441342f88f29f050b52851ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice301424511e4396aff3b79bc7270a81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7ffa70b61341d8b58e1e5e9dfe4d22_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0854b7c841d4126a9365b4b0019cd6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8439569a0148a890c18386790d2daa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68dcac57fee14e97b585767b7925b959_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fa83669c1e34be09bf9a205994d7995_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id61dcf9495af405097a6842ea0ed0697_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9118ab4a540a4a4a8d447fc14519b568_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b872c69d4344d69ce0a22b7183b681_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b1766ec32064dff97ec361a343c8c8d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f65ab021ad34abdbe85a6520f98dc68_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23605bda701483aa031c60b51c43b27_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d4563528a74ddc8daf7cfcc8df4f4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd83794d6dc499596834a18cd5a2a9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431455fda9da407ea1273e3d11bbbb34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c9d5a6a37649e3b44edf8049cce4da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946bb3ded8914db29f26e0bac8b58b89_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582b4bf2bda24ddea0c9c99086fae38b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f8e91e0319490e9d3eb0783a1bad61_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6249585dffb463e9e429c997c28422b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f06bb46081a46e18e26c25735932a5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie600b5ba08a345c0a7fa00407c5f1679_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699ad28e63e644d292dfeba6e6ddc59c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13595fd727041dbab088d6e82f53317_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40a55a2d4af4c7eb637dd2db2488d47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5ebfa2dbf6474580e79f3a4aa684de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98f030bdbd848349b1157be06b79af8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d8558f0a0f4aed8a935e56b9bcd543_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7029f31fe5d346869ac6af84155da042_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f0caaec00841cdb9b922302d272752_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5893e370c05e4fa4a36f9edae416eaee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fcffe6ed74045c2a108455a95165df3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36781c6539d94067adff3cf0b6de6bba_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916d7cde9f5c4098aafca8f1d4ec92b3_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba9893300544569828a837db24cb5ab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1b52e308b74c7391b12b1ba506c1ee_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7475a5be608b4b7db53a995f1885030a_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3794041ed704c3192959c4746a76918_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac955e87eb245cb84b816f8086941ca_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f603d69a68045f6949859303a9e0100_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15cf99071b0415f8897789050cdcac3_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758bcd0701c042ab91e1fdd9a3e0621c_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df15ce9a58f43aa8838ebd2fc814e18_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad35dd656234df09077c620d5c6d635_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d4ffeef7fe43eab4715bab8e852043_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0e2e0f414904188a0bb7cf06671ce39_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e67d706f964f1bb86ba26006bab411_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic618bc70943b4438aa6de0773ad42f41_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07f72d9ccda44d3b9275c10c3802ea0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5151cda805403099aabb0baf5abfe9_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d85629f38df40019f7bfaf802250bce_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cba20250d344f82bb7c7ee274ac2d08_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecaf5b671d0f48838a69272ed492bd4a_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7101f4c4fc704442967c163ed61da7dd_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46a449af09c45a48017c23edc16be05_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c97925a37bb4a129ad535aed5cd5727_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05179c18e4294269bd473e6439df82c9_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d97f3d7fab4028a29399bf3e18652f_I20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if568378dc7914a2ca879a5b1dfdec339_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b47e659a7674184bd5fb1e6489758c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i977484a58ef44f029d021443bc481e0d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce62f0c759b43c0a265b0f75bccf470_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib26b528f69e84aa8bf0354a45f147957_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11e44058a9da4e57975c9afd2894c3fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5b100104fe48a2989954cdb98067ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7fe6c4a84a34602b32ea482070a2644_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa07fa21879c47f8a81b631bf261e16f_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i960ff983ba984eef9fc0e57242acf4ad_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica8e454931494c86a0acbbb148cef7a4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ae4f2c278c4ce8bb30f6cf187609dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c587e607d8b406d82aa29c34afa0507_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c3abf79b77492d8199a68542ed7752_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968714160637450486f094b7b1293b81_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe91cbc7315a4336b5abff786c768b62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b4eec3a0cb4f27aaa8e6f384025a1e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90c22c98c76421ea4011d8153a44a71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5794d71d0de4903b413840b815950f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b879fd6a8b140139241cedad3dd8363_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd121453f7584e4795edacc5006758f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c697c6c8a12472a8470f212680e6841_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a0e80d686d4db398764b4e17532471_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a6b90e9de04a9795ddcc6e1d3d2f9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5f7ca552444d36af631fb4eeba482a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9859c6985307497fb25bf1057a6361e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69967c2e35354819ade6c5984bf3b729_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68c9b6601e041919a7d54d7305442ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2ce205b8df40f5a8ca6fb448494da9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1ac30734004ea497e9ad4ec8f715ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia647416262ac4cbc82f836c92f6093f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief06047c33e34d79987ca3e17332e58e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i842788784c414a1a91580bb3f7277e7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b639b680fbf43b6814f6de3ecae64d7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a11d327f4c470ca2f791e8e1966028_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia747290a8b204259b52b29bf6aa78a40_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i627eecec9e24428f888feae02bf5a094_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696664e630804b529ae7bb6d3ca89106_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebeb1fce40b34eeda2f1d368b211235e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf15ce52ede4d83af3ac051dc46f9b5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbdfd1a6d91342e6a148aa56505db40e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a81afc686ee45928654d3f1fd757c58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe9aab2682b4fc696fe56048ee7905a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3909b5b33cda4a969569a089a54d7d90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12dff91475cc4bc8b8681e67ab398b2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie053af2f0b7f43e79aa116dad9847e40_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e68408fd524ee7853f44d2c3055dac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0bf322642904e678f0fb49d1674e122_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b281b7c3cb41b7b75ba0b670b05d6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i571e3a3a8fdb4e7fad04e7c5bfc9a5c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459c224721e4472987d0810fa06039dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179d7c9dfd6c48c396b1bae4ecd566f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdcd617addf439bb5ac7946fc074de1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6dfc2db43b94f5d8aae9b35c10ee05b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5813816202a4e338fe7f589fd013674_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9026d99a25d84c75985b0866b64b1bf5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0a5a638b704e06a6d4cda5851b17f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d670a13d5045c0a62849c225ec6a9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0186fb7ca56e461b9781a47361dfd131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0612bc26c446988089e7cded45f213_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0100835413d340b082126f866d8b23d0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeb884e998ab4b6d877b8cc4a40ee355_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41098b957dca4081a3d6580e8917b49c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc670273a9f4d978fd0fa286c1d9c0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f1f40c73a441669cb646b2f251c21b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84334888c1ce4f9596774398cccb24d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c70b95cce0942dc8555c7160e7baec8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932695caa0e3475e8d26b62529c3f9e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2176e74b934dfbab0732b31233603a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b60b44365747aa9dddac9017e65fb6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0bbb5ca4f6640a98bc3bee2e63b3dd2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785637c478644f3baa2265dd139ec9f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362167a0c9b34805a0af2b448541b5bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7f05d669f4496886a6a7a00d768285_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d445fb027342059acb0abc5062875b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24fa32341354c11976ef219f1db4536_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6a736386954271be092327c488a4c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="iecd6828c06c24f6caac1d47d36f0f87f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c783f7550a946bbaf1d21f6f1d5c181_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79be648cb3694442bbf24990de4e33be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1860fdb5d9754126b8f298b7c351df82_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie409a91d5d8847ecb8729ff061b06528_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a20d756ebe344c49afc88a4c8988a92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532454a81aa1485d94751de5cd927545_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a704469f121488395cdba78ef29222f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61686756cdc94fe487cf6ab99ac88a18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dca42daa64b4aff97d52b7b8e251ed1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTMtMS0xLTM4MDQx_c943eec5-0a37-4672-8c00-04b3abf2821c id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTMtMS0xLTM4MDQx_6fd0a3a8-040f-462e-b385-4744c51aa458 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTEtMS0xLTM4MDQx_32c854fb-e4a9-4b6e-b7c4-d48591ef4ca9 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTEtMS0xLTM4MDQx_c7c39c63-a8f0-40c0-9113-19cd02f14912" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMS0xLTEtMzgwNDE_661172f1-58ab-48c2-a568-759fa6e953b4 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMS0xLTEtMzgwNDE_81ef6c46-a72e-41e5-b111-18d2ff049ec4 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMy0xLTEtMzgwNDE_769e699f-2c7b-4b79-81b7-4f27e00c62a8 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMy0xLTEtMzgwNDE_3f9314cc-6eeb-467f-867f-1275cae5becf id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMS0xLTEtMzgwNDE_92c74fa3-30f6-4d04-badb-d1024124696d id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMy0xLTEtMzgwNDE_8c8d976e-4caf-456d-b0e9-f2edbdbdca40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMy0xLTEtMzgwNDE_97157884-4719-4910-82f6-a01524ef325e id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTEtMS0xLTM4MDQx_6b9c5b33-1c7b-477a-b6e8-54b6fcdf1e57 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMS0xLTEtMzgwNDE_196a7221-1ecc-4efc-a498-182fd87e1023 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTMtMS0xLTM4MDQx_b2ea2841-f141-4b34-b324-9c59f559db5b id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTMtMS0xLTM4MDQx_589fce9d-e9d4-4854-b765-72985b41428d id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTEtMS0xLTM4MDQx_8cb7d434-69ac-4c33-975d-3a90e8560b2d id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTEtMS0xLTM4MDQx_752cd560-3755-4dbb-a489-b769fcc23884 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMy0xLTEtMzgwNDE_3680218e-efe6-4126-9699-ed074a978f07 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTEtMS0xLTM4MDQx_03c06028-7880-493c-814e-235966f93b85 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTMtMS0xLTM4MDQx_b4e53bf8-d830-4b84-8101-e40711400838 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTMtMS0xLTM4MDQx_0193734e-ac0b-42ec-a951-e4beb268ad60 id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMS0xLTEtMzgwNDE_81bbfe1c-390a-4b05-9055-6f6690e0e0ee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ibb64a58c5010458da650c3b7c8dfab74_4"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMzA5_01063c5a-1b9c-4e8f-aa40-a0d83ef94c67">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMzEw_6b223ad2-aacb-4b5e-be83-11fcc5bd53cd">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMDY_7d4796eb-274e-40e3-8976-9c9983bae030">March&#160;31, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMTU_e9de08b1-8f01-4bba-ac2e-79211c3a81e8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8zOTc_70d9b112-3a0a-4b2a-9da1-debfbc58f675">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF80Mjc_7de5d9e0-a7a5-40cd-887c-755e2a93572d">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:479.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8wLTEtMS0xLTM4MDQx_778a3ccb-c812-41b7-a4d6-c796b32e1969">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8wLTktMS0xLTM4MDQx_8eced9b4-9012-4552-8243-7ad1e6c0d237">32-0454912</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTEtMS0xLTM4MDQx_cff9bed8-eb2d-4b39-90f5-da29fffb7b23">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTMtMS0xLTM4MDQx_d3b941dd-e57a-44e6-a6b4-c71e74291d3a">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTUtMS0xLTM4MDQx_692cddf9-7df2-41ee-a657-d614a4e65b1e">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTctMS0xLTM4MDQx_8a8c0a5a-ebdf-42e0-ba41-c6fe9ad157b4">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTktMS0xLTM4MDQx_e58440fc-f5c1-472c-b09c-f9c615f7807c">22203</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF81MzU_1cf2ce38-8294-4145-8888-91b88ecd7d5e">571</ix:nonNumeric>) <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF81Mzk_2286acf0-d5c4-4906-a039-de9a54f9b6ca">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6ZjdiZmE3ZjhjMDRmNDFiNzgyYjUzOTVlMWU2MWVjYzgvdGFibGVyYW5nZTpmN2JmYTdmOGMwNGY0MWI3ODJiNTM5NWUxZTYxZWNjOF8xLTAtMS0xLTM4MDQx_abf47759-96c5-4b67-8a0d-b78a0636a49b">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6ZjdiZmE3ZjhjMDRmNDFiNzgyYjUzOTVlMWU2MWVjYzgvdGFibGVyYW5nZTpmN2JmYTdmOGMwNGY0MWI3ODJiNTM5NWUxZTYxZWNjOF8xLTEtMS0xLTM4MDQx_217296cf-6b3b-46d6-b63b-636609854b35">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6ZjdiZmE3ZjhjMDRmNDFiNzgyYjUzOTVlMWU2MWVjYzgvdGFibGVyYW5nZTpmN2JmYTdmOGMwNGY0MWI3ODJiNTM5NWUxZTYxZWNjOF8xLTItMS0xLTM4MDQx_afe8b3d4-9b85-4bd6-b1ce-d114399f1f0d">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xMDQw_2948e92c-d943-4a44-ba39-a66312c7ac51">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xMzYy_4d180602-5180-416b-be4e-0b8616da5d5c">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xNzI5_04eb5460-47a3-4b12-a99f-4320223383bd">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xODEw_f6182d4a-bde7-4023-bc53-b340eed7eb00">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMzEx_50602e75-9f0b-4d4c-a597-fc7a7705558e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMjE1_c93e2128-ec0f-4de2-93bd-a0ca4ff5f57e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of May&#160;2, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ib96988fb77cf47f0ba8eb6166fda7e01_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMjQ2_71a31a79-231f-40a7-a71e-6b73de5cea87">91,594,562</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_259"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_19">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_94">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_94">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_94">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_67">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_67">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_91">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_91">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_211">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_211">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_211">47</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_58">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_52">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_52">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_52">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_277">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_277">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_25">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_256">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_256">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_256">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_262">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_262">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_262">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_55">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_55">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_55">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_214">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_214">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_214">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_241">6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_241">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_241">49</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_268">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibb64a58c5010458da650c3b7c8dfab74_268">50</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units of Evolent Health LLC.</span></div><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_16"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution in the market for value-based care;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, divert management resources, or result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners&#8217; plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions and the impact thereof on the economy resulting from the COVID-19 pandemic and other public health emergencies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new growth opportunities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to governmental payer audits and actions, including whistleblower claims;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to our offshore operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation, including the ongoing class action lawsuit;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any alleged infringement, misappropriation or violation of third-party proprietary rights;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.  Our Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K") and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment.  New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Financial Statements</span></div><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_100"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:325.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQtMS0xLTEtMzgwNDE_add97452-ac96-4d2e-b81b-ee20db982bac">210,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQtMy0xLTEtMzgwNDE_9c0bd92f-130b-439a-a2b6-cee78ed019a1">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzUtMS0xLTEtMzgwNDE_e6843217-55fc-4dbe-bd41-01daa40c4fb6">39,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzUtMy0xLTEtMzgwNDE_48db3d0f-bc67-495a-aba9-cf44cc495269">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMS0xLTEtMzgwNDE_196a7221-1ecc-4efc-a498-182fd87e1023">179,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMy0xLTEtMzgwNDE_97157884-4719-4910-82f6-a01524ef325e">130,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMS0xLTEtMzgwNDE_81bbfe1c-390a-4b05-9055-6f6690e0e0ee">34,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMy0xLTEtMzgwNDE_3680218e-efe6-4126-9699-ed074a978f07">51,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzktMS0xLTEtMzgwNDE_172b2625-9911-4b40-bb80-f82f05325355">463,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzktMy0xLTEtMzgwNDE_600851c2-5ca3-4e99-a322-2683751e1836">523,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEwLTEtMS0xLTM4MDQx_27ef877e-f593-41d2-b30e-92180624bbc5">12,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEwLTMtMS0xLTM4MDQx_42e99070-ef02-49bc-9f51-0ce35a21a075">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzExLTEtMS0xLTM4MDQx_f5970682-d39d-420d-b669-d68a3fce1a3c">3,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzExLTMtMS0xLTM4MDQx_48ba09b8-3879-46f5-b4cd-f4358e4b5217">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEyLTEtMS0xLTM4MDQx_f9e0ca44-5832-4d83-864a-4b28de67b63d">82,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEyLTMtMS0xLTM4MDQx_d2e9c19d-1304-4863-a58c-36085ed4dbfb">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEzLTEtMS0xLTM4MDQx_4166ea71-e9f8-478f-8705-f550906e3097">48,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEzLTMtMS0xLTM4MDQx_b0d515c8-c581-4e91-b1dd-e6453f14be61">50,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTEtMS0xLTM4MDQx_03c06028-7880-493c-814e-235966f93b85">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTMtMS0xLTM4MDQx_0193734e-ac0b-42ec-a951-e4beb268ad60">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE1LTEtMS0xLTM4MDQx_6e5ef67f-e9bb-4e75-831e-9805dc25183a">22,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE1LTMtMS0xLTM4MDQx_115856bb-dd03-4181-9722-5ed209542110">32,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE2LTEtMS0xLTM4MDQx_23ca7ea8-f8ee-4f68-a282-5dac5c48b443">272,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE2LTMtMS0xLTM4MDQx_3304cc5b-6348-48b1-a241-dd37f0cb72f2">279,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE3LTEtMS0xLTM4MDQx_74194ae7-5873-48b6-923c-0aae4119d0e5">426,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE3LTMtMS0xLTM4MDQx_21b1e2f6-933a-4258-a7ee-cd6d7beb829c">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE5LTEtMS0xLTM4MDQx_8013b94a-6692-4b7c-b8b2-5e8b214fc854">1,339,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE5LTMtMS0xLTM4MDQx_db153c49-3cd8-4791-af69-5722a6dfe78d">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTEtMS0xLTM4MDQx_6b9c5b33-1c7b-477a-b6e8-54b6fcdf1e57">64,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTMtMS0xLTM4MDQx_b4e53bf8-d830-4b84-8101-e40711400838">96,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTEtMS0xLTM4MDQx_752cd560-3755-4dbb-a489-b769fcc23884">115,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTMtMS0xLTM4MDQx_b2ea2841-f141-4b34-b324-9c59f559db5b">107,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI2LTEtMS0xLTM4MDQx_18d840cd-f665-4cc1-a3fa-cbeef147bfa8">6,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI2LTMtMS0xLTM4MDQx_4906cd48-5c11-4b19-a312-935f2aa9f56a">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI3LTEtMS0xLTM4MDQx_6d0ad32a-67fe-4ade-b41a-5f2e0dd96b52">19,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI3LTMtMS0xLTM4MDQx_b545cd97-b1b6-4aea-8fa5-285590251c7f">51,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI4LTEtMS0xLTM4MDQx_978756ab-4089-43eb-9d4b-e350e3420f0b">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI4LTMtMS0xLTM4MDQx_7d3de189-012b-43a1-825e-33ac01f928e3">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTEtMS0xLTM4MDQx_8cb7d434-69ac-4c33-975d-3a90e8560b2d">164,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTMtMS0xLTM4MDQx_589fce9d-e9d4-4854-b765-72985b41428d">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMxLTEtMS0xLTM4MDQx_790aa4d4-ae41-4b2f-a02d-b6223aa80379">382,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMxLTMtMS0xLTM4MDQx_de590d78-b23d-43bb-be5c-4a347d1b9861">445,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMyLTEtMS0xLTM4MDQx_4b905e5a-9a6d-4c6c-ae67-ea99b80d2c07">282,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMyLTMtMS0xLTM4MDQx_f3dac29c-26ec-4e32-909c-af5e6a1a2d5b">215,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMzLTEtMS0xLTM4MDQx_5e0e7e39-5d7a-4614-a783-e33e72b93bff">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMzLTMtMS0xLTM4MDQx_cd30636d-b9fc-444b-866f-b611663a0ea1">5,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM0LTEtMS0xLTM4MDQx_43e3f8d0-6469-442a-8245-2f034e4ccbad">56,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM0LTMtMS0xLTM4MDQx_dede132a-c15e-4128-805e-cd6bf1685067">57,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM1LTEtMS0xLTM4MDQx_390b411e-ac2a-4054-bc71-7607edf05502">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM1LTMtMS0xLTM4MDQx_cce30093-51ef-4181-827e-7f46ff785a56">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM3LTEtMS0xLTM4MDQx_9f2bb523-754d-4652-ac57-ba1565e5b675">727,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM3LTMtMS0xLTM4MDQx_09bdaa8a-db30-487f-8ccb-ce8f5f3d33bc">725,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 11)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM4LTEtMS0xLTM4MDQx_e5037d1f-ad70-4a2e-84ef-93437482a2ac"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM4LTMtMS0xLTM4MDQx_8d309b01-e217-49a7-a048-6f7b06637318"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfMjc_004cdd56-1485-42f3-b1fe-4c68208fe9af"><ix:nonFraction unitRef="usdPerShare" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfMjc_0c093b37-2f68-49b5-837f-e963d93770d7">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNDE_bc833343-8dba-4caa-b28f-fcccdf09bd33"><ix:nonFraction unitRef="shares" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNDE_c847e4e7-ebb0-492f-947b-d261d5315ddc">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNjM_d96c129e-ffe0-48c2-a119-8e3ff2596a2b">91,587,896</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNzA_1b147335-b542-4cd9-a1ad-5b5b8f4008f7">90,758,318</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTEtMS0xLTM4MDQx_26f1c8d1-5823-4d65-a632-c0cdbd609d7b">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTMtMS0xLTM4MDQx_6f5c65fd-3016-460e-926a-d4975c4d1992">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQxLTEtMS0xLTM4MDQx_7fbb6116-5e94-4d79-bbe6-f159b9dafaa7">1,224,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQxLTMtMS0xLTM4MDQx_c397dbcd-534a-46d8-ae94-959deb621003">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQyLTEtMS0xLTM4MDQx_b17dce71-3376-42ac-a3a0-cf60269cdb8d">494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQyLTMtMS0xLTM4MDQx_2e04cf42-bbba-4fc9-bb97-6728106bc1c9">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQzLTEtMS0xLTM4MDQx_a5f4bf0d-56e4-4342-a8bb-e91054d7eaac">592,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQzLTMtMS0xLTM4MDQx_780b5014-d45c-43d0-8799-4d5b1d6c88cb">626,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTAtMS0xLTM4MDQxL3RleHRyZWdpb246MmUyNTE4Njk4NDQzNDE1MThhOWUyNzBiZDc2Mzk1ZTdfMjk_2eec9d8d-2ca6-44ad-aa2d-3c443537a314"><ix:nonFraction unitRef="shares" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTAtMS0xLTM4MDQxL3RleHRyZWdpb246MmUyNTE4Njk4NDQzNDE1MThhOWUyNzBiZDc2Mzk1ZTdfMjk_46e3a9fa-9c83-4b7d-8bba-2bbe6cd7000b">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTEtMS0xLTM4MDQx_54efc1cb-0f64-4b71-90c9-71b8e56d15fb">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTMtMS0xLTM4MDQx_7111a95d-051b-48d7-b608-f21413f90cd3">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ1LTEtMS0xLTM4MDQx_849e1e00-74d3-4c91-821a-26502610a90e">611,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ1LTMtMS0xLTM4MDQx_b3a94119-484b-45c9-bcd8-d5f7ba1a32cf">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ2LTEtMS0xLTM4MDQx_2f8a90f9-b1ca-46a8-a5d4-b52e11d1a94d">1,339,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ2LTMtMS0xLTM4MDQx_a051451b-0701-4041-abec-ccba06f0502c">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_103"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(unaudited, in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:404.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMS0xLTEtMzgwNDE_81ef6c46-a72e-41e5-b111-18d2ff049ec4">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMy0xLTEtMzgwNDE_769e699f-2c7b-4b79-81b7-4f27e00c62a8">215,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMS0xLTEtMzgwNDE_92c74fa3-30f6-4d04-badb-d1024124696d">219,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMy0xLTEtMzgwNDE_3f9314cc-6eeb-467f-867f-1275cae5becf">157,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMS0xLTEtMzgwNDE_661172f1-58ab-48c2-a568-759fa6e953b4">58,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMy0xLTEtMzgwNDE_8c8d976e-4caf-456d-b0e9-f2edbdbdca40">58,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzEwLTEtMS0xLTM4MDQx_e55d065e-9d26-483b-b296-ee6a7adfb65f">15,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzEwLTMtMS0xLTM4MDQx_8487d674-3139-4eba-a5e1-0b0419071020">15,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE0LTEtMS0xLTM4MDQx_fbed0857-0dbd-448e-83e1-db13698a3db7">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE0LTMtMS0xLTM4MDQx_3db3fb68-63d3-4dd0-a783-87bebf05b66a">594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE1LTEtMS0xLTM4MDQx_60ae55c4-0219-44f1-93b2-ff70b77d1e3e">299,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE1LTMtMS0xLTM4MDQx_2089d635-867a-4cf8-9512-5f46714f3903">231,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE2LTEtMS0xLTM4MDQx_b1ccb602-2c31-4dee-b127-4afa207b7a39">2,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE2LTMtMS0xLTM4MDQx_1f31f350-be1f-4d90-8db5-a329e9c70814">15,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE3LTEtMS0xLTM4MDQx_e922cac3-67b4-45bc-9eba-8abed983a24f">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE3LTMtMS0xLTM4MDQx_34382c72-def2-48d3-83e1-d64e4d54164f">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE4LTEtMS0xLTM4MDQx_1661b0d8-678f-4585-b1ed-a5441f2c43c3">2,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE4LTMtMS0xLTM4MDQx_6086ac74-f940-4209-ad1e-32c95e6df8bf">6,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIwLTEtMS0xLTM4MDQx_e5e313bb-00e2-40dd-b8a5-cb18249de75b">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIwLTMtMS0xLTM4MDQx_b03b23f4-9a82-4ec1-a890-9059b613579d">7,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIxLTEtMS0xLTM4MDQx_66184bab-0a7c-41b7-ada5-f8ee2b9744d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIxLTMtMS0xLTM4MDQx_b68550cb-4628-46a6-9dd8-1cda22ea7fed">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIyLTEtMS0xLTM4MDQx_cd99e046-381f-46c6-942b-7141d1d3c293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIyLTMtMS0xLTM4MDQx_a5f3c24f-4740-4dc0-9d76-633176eb7a70">19,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIzLTEtMS0xLTM4MDQx_4304c8e2-5a48-49b6-ac12-a12a6ca3b614">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIzLTMtMS0xLTM4MDQx_b3bc9599-afec-4a0f-9de4-dfa674bc1cae">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI0LTEtMS0xLTM4MDQx_97cc307a-3a1d-48bc-a17c-b0c5ac634d55">4,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI0LTMtMS0xLTM4MDQx_2de919c9-c20a-44a7-98b7-18c82fa2ba3b">10,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI1LTEtMS0xLTM4MDQx_85722f6d-24f2-4bc3-a291-c61e01b3414b">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI1LTMtMS0xLTM4MDQx_d6cbffc2-eb96-4502-ad27-689de2bc4b7e">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI2LTEtMS0xLTM4MDQx_57f0dd20-8335-4301-96e4-84ddca884b17">5,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI2LTMtMS0xLTM4MDQx_1d8a1e64-6a92-43e0-8702-d33d507cfc10">11,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI3LTEtMS0xLTM4MDQx_9a961152-7317-41c3-9951-60d1c12b2b55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI3LTMtMS0xLTM4MDQx_a7749027-c4c8-4ee8-9c7c-0b01e3bb01ce">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTEtMS0xLTM4MDQx_382b3d21-64c1-4d03-9c4d-1a88790616e4"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTEtMS0xLTM4MDQx_cf3eff2b-1a09-4e45-8224-6da02de6faf9">5,350</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTMtMS0xLTM4MDQx_54fc92f9-7646-4d5e-8a06-3d5cdd2006db"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTMtMS0xLTM4MDQx_59e2b9e2-6d0e-4880-bd0a-259a3bc8543e">9,807</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTEtMS0xLTM4MDQx_cd7dbb8c-c230-40fa-9e1c-89ddb5150c93"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTEtMS0xLTM4MDQx_dce28e6f-1f46-4e94-8a30-e5f118457bd4">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTMtMS0xLTM4MDQx_0eb11ff2-f1f0-4803-a92f-2075603e4ebc"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTMtMS0xLTM4MDQx_8fd0c4e3-e001-4289-9347-78c01f2ca1dd">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTEtMS0xLTM4MDQx_ba5bd89c-7bb2-45e5-beae-badadc91229f"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTEtMS0xLTM4MDQx_e9701e52-caa5-4c31-bba0-b33b00faf07c">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTMtMS0xLTM4MDQx_25dad0cd-7e70-48be-8c0d-4160671153b1"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTMtMS0xLTM4MDQx_59aff931-3805-409f-822b-3f363a611ead">0.01</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTEtMS0xLTM4MDQx_4143aa38-cafb-40ef-9f5b-83249cc588a4"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTEtMS0xLTM4MDQx_618b89bf-6770-462d-8d7c-741ac05aac7f">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTMtMS0xLTM4MDQx_23cbac1a-20cf-4cc2-8cb1-977e29fd27ed"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTMtMS0xLTM4MDQx_e7474cd7-30ed-4081-bd0f-8c35ff985f9c">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTEtMS0xLTM4MDQx_2e9d5031-9f9a-4199-9215-64564d1aacb6"><ix:nonFraction unitRef="shares" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTEtMS0xLTM4MDQx_cf868fd8-1afd-49d0-acee-5a7af9ce7914">89,509</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTMtMS0xLTM4MDQx_7bc03da2-3c16-44b6-ad25-f05001fcd32a"><ix:nonFraction unitRef="shares" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTMtMS0xLTM4MDQx_99f00915-455f-468d-9856-d443da68441e">84,670</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQzLTEtMS0xLTM4MDQx_9c534833-a48b-4fe8-abec-3a3d64883de2">5,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQzLTMtMS0xLTM4MDQx_67760138-6198-4860-851e-285b241a259b">9,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ1LTEtMS0xLTM4MDQx_bb9343d1-69ed-41e3-834d-0b1a5abec9d0">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ1LTMtMS0xLTM4MDQx_8716c4f1-cc01-467f-893c-05e4e4c5f8d6">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ4LTEtMS0xLTM4MDQx_c19c3e63-cf5f-41ab-9705-04e642f4bfa0">5,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ4LTMtMS0xLTM4MDQx_f5c35c36-b497-41fc-83ee-a5552895fcb5">9,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxMw_e405f0ea-497b-4485-b3e0-1519667e5bd5" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzI1OA_cdf04ab3-2ef2-4d3d-8dd6-d6e99cea8778">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for three months ended March 31, 2021</ix:footnote>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_274"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:727.50pt"><tr><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:108.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ec101c4091a4f46bfd520e8d03792f1_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMS0xLTEtMzgwNDE_8f609fd0-3853-4581-bb5d-1cc664abc6ac">90,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec101c4091a4f46bfd520e8d03792f1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMy0xLTEtMzgwNDE_db2cc1bc-9402-4577-815d-ee5be849a7c7">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59c3d3e7b5d4f4a8874ddebbe1ace67_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtNS0xLTEtMzgwNDE_3d809483-e37a-40f0-b0e9-4037e0209105">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1e9801520f34456b2f8524c63e8e3c0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtNy0xLTEtMzgwNDE_f0f96bca-5870-425f-bbde-34dd27baef99">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i299ef1742b0c49abae14abd4ed0f8174_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtOS0xLTEtMzgwNDE_fb17924d-db20-48ea-b03c-81d49a7213aa">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7aa8e3cb4d874916a84b9d7e08e4666c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMTEtMS0xLTM4MDQx_1df43302-29b9-4ba4-9b20-25a56c976db5">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMTctMS0xLTM4MDQx_88632395-ec41-45a6-9e3b-1c290c2f9df8">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMC0xLTEtNDc3MjY_af2df6d4-dea4-4789-ae3a-b6fb5553a450">Cumulative-effect adjustment from adoption of ASC 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5daef88c2af84a738a5f7ff9de4b9d7c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtNS0xLTEtNDU1NjM_4f55df87-4e42-4cbd-9ecb-ce095d52d5fe">106,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21f2d521de74c5dbb6764b237c3ac1e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtOS0xLTEtNDU1NjM_2c6e4f9a-a8af-4857-8bb7-235427c52571">39,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d7fee29877b408198fcd590f13b5985_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMTMtMS0xLTQ1NTYz_cbb5abdd-cc10-4a59-9e4a-0fa0f2016aa3">66,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtNS0xLTEtMzgwNDE_291568cf-93a8-4eef-afc4-a635ba763dcc">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMTctMS0xLTM4MDQx_fe1ac0fe-35d4-4d52-95ca-68e50b2dee20">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzYtMS0xLTEtMzgwNDE_c19e9bb9-3acf-4625-9492-17481a0ed228">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzYtNS0xLTEtMzgwNDE_8d1ebbad-b0f9-4085-a2af-0d58b77a6f26">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzYtMTctMS0xLTM4MDQx_c638bf94-9b31-4e76-b62b-5d262f5d583f">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctMS0xLTEtMzgwNDE_fdb4e896-4e0c-4b1a-b1da-b2a009475b35">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctMy0xLTEtMzgwNDE_650d58d1-29bd-4ca0-b450-c82412279280">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctNS0xLTEtMzgwNDE_0b9330d6-7927-4f7c-a17d-51170a7c3fa9">4,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctMTctMS0xLTM4MDQx_24dbfb07-5cf3-4600-ac86-644e0a73cbb3">4,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leveraged stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMS0xLTEtNDU1OTM_a8617a7e-0443-4f5b-982d-9ade6560b1f4">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMy0xLTEtNDU1OTM_401715e3-3ef9-468c-927a-575c43824fd6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktNS0xLTEtNDU2MDQ_267e8a29-46a6-4a26-a825-7004941ef696">11,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMTMtMS0xLTQ1NjA0_fe971ec5-e1fe-4e3f-b62b-a38551ff90ad">11,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293a1a6091d64b118aef6ec8a2d2167a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzgtNy0xLTEtMzgwNDE_b0d2d0d1-bb01-45a0-805b-0d3ebf2389bf">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzgtMTctMS0xLTM4MDQx_7df38469-bbd6-4e82-9074-73efeabadd14">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i130e14f026354ba2b836575ebd10bdd2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktOS0xLTEtMzgwNDE_9df9039e-11c7-4f7d-b421-cd72c198d230">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMTctMS0xLTM4MDQx_73dc386d-4542-49af-9072-716e38f76cc1">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i621d358e78ed4fc2bd3ecd3b820db708_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTEtMS0xLTM4MDQx_fb028bbf-4e7c-4762-bc16-bf5262cbcac9">91,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621d358e78ed4fc2bd3ecd3b820db708_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTMtMS0xLTM4MDQx_dab139c9-7be1-44d8-beb7-5f4991f1097e">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1cbb67f86274231b6621e78983d84df_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTUtMS0xLTM4MDQx_c3c3151b-b249-4821-856b-270319e66bcd">1,224,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e23962c75c49019909c9715c2499c3_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTctMS0xLTM4MDQx_3bfb9ddf-8280-4eae-98b6-70d44a1a22b2">494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7eb4df9b7ed4bb382872f97fdb6a757_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTktMS0xLTM4MDQx_51965bc9-2550-452b-84e9-48dc0b1ca321">592,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc124f8ebb2b48dca7de861265b1df9f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTExLTEtMS0zODA0MQ_1dd7cc61-c3fd-4d24-b8d7-8f6e1f107dc8">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTE3LTEtMS0zODA0MQ_75f72642-9b02-46ef-9092-a777fcbfb6c9">611,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3be7adf261ff427c874251aacfa02b7e_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTEtMS0xLTM4MDQx_d08bfbd8-8f62-43ce-8241-a4774aafe151">85,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be7adf261ff427c874251aacfa02b7e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTMtMS0xLTM4MDQx_31176015-1310-4275-bd87-6d92753e0382">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef9a57b91634689a5fc4d94fc39cc92_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTUtMS0xLTM4MDQx_b229ce12-7173-4560-9b80-42cdd01f204e">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id44432f28d3a4aecb8eb5918685f3019_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTctMS0xLTM4MDQx_f2ab0b9f-debc-4516-9991-962a4be1be52">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cd7879f349a4bfb9adf1f4b67cb4d3f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTktMS0xLTM4MDQx_d1df15bc-7e30-4570-aeec-916c5b347c9d">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb90b06b13ac482cb1469d573d0ac107_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTExLTEtMS0zODA0MQ_705446de-4110-47a6-a1e5-896a09253c66">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTE3LTEtMS0zODA0MQ_3c81da30-e1bf-4daf-b14e-5afaf979ea16">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059aea63706f40babf4ad42f721269d8_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIwLTUtMS0xLTM4MDQx_d8b7a8f0-0ae1-4dfe-aca6-2023b45dddb0">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIwLTE3LTEtMS0zODA0MQ_b251ead4-6c84-4eed-b9bd-ca7f14135c0e">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTEtMS0xLTM4MDQx_8df048d2-663a-4424-b19b-faac99fdcc47">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTMtMS0xLTM4MDQx_387cef87-1fc0-4bec-9c33-9ea22493344f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059aea63706f40babf4ad42f721269d8_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTUtMS0xLTM4MDQx_275ced5f-e304-4e21-8b3b-7de4a2c4d0cd">6,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTE3LTEtMS0zODA0MQ_85f052e9-df02-4db6-890f-a459da13b262">6,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTEtMS0xLTM4MDQx_590defce-80dc-4e25-9b8a-47d6aec7e284">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTMtMS0xLTM4MDQx_837c0075-8d93-461e-a4e3-c85acbdfcf20">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i059aea63706f40babf4ad42f721269d8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTUtMS0xLTM4MDQx_d445d24e-db8b-453b-aa55-2ee13ebd327e">2,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTE3LTEtMS0zODA0MQ_702f8d17-1b21-4262-998c-f499d57a5589">2,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id145101f6b47482c8c8b1e64aec732ae_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI3LTctMS0xLTM4MDQx_309e4e75-28da-4315-bd68-8192ceba1ad0">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI3LTE3LTEtMS0zODA0MQ_df49a521-9b85-49fe-9228-2fccb7f6794b">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i924e8357dfb2454f86c7f8d0fd74a114_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI5LTktMS0xLTM4MDQx_d3d3737c-e444-408c-8a52-8dc395ed5a23">9,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI5LTE3LTEtMS0zODA0MQ_401d4383-3c77-4872-b784-20294f0b6ae4">9,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cbe563905aa492187f4514b1c567124_I20210331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTEtMS0xLTM4MDQx_8a3ec736-930b-4f72-8859-72110c1e13c3">86,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cbe563905aa492187f4514b1c567124_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTMtMS0xLTM4MDQx_e4562f9a-2c6c-463b-84e8-c40340c33b62">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d29d14aac4caf8b3c3650d9877ed2_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTUtMS0xLTM4MDQx_1a36b272-448f-4a19-a3ff-3c779856295c">1,236,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc68586f685749a588829914e464480b_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTctMS0xLTM4MDQx_6dceae8e-1809-4951-8024-67a31266010f">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6db922f783fb432da34f684d3de92b24_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTktMS0xLTM4MDQx_8494a955-646d-4020-ab6c-bdab253499dc">598,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62e1ee4ac4ec44e681da4653910c6586_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTExLTEtMS0zODA0MQ_ba00a895-494f-4e27-82d0-d5ca70abf0ef">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTE3LTEtMS0zODA0MQ_78ba85e8-f284-4635-bf68-65aeeea2cb8a">617,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_109"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMtMS0xLTEtMzgwNDE_821a6a12-9e2c-46e1-9783-40974d0e23ae">5,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMtMy0xLTEtMzgwNDE_18d05de4-3983-4a6d-9153-7a95aecad4ff">9,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUtMS0xLTEtMzgwNDE_e6d1a916-60aa-48fb-99da-385547d915ba">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUtMy0xLTEtMzgwNDE_4988f072-82b4-4824-b121-27e1a41a8afc">594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYtMS0xLTEtMzgwNDE_8dbdd63f-b70b-40ba-9694-a635aa5ed217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYtMy0xLTEtMzgwNDE_543c410c-f517-4357-9829-75ab776c26b4">1,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzctMS0xLTEtMzgwNDE_6ee2e3ad-44e6-4127-a75d-1635fc7e9cab">596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzctMy0xLTEtMzgwNDE_edf1e839-d9be-40a1-9938-2f89fd55334a">7,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMS0xLTEtNDY2MDU_8d90ede9-3d3f-486d-b944-637194cd2594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMy0xLTEtNDY2MDU_0b608ad8-7a4d-47f9-9444-f7a5ba7c9479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMS0xLTEtMzgwNDE_1cb9ed4f-805d-4e7c-9c93-195bed2050d0">15,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMy0xLTEtMzgwNDE_b86d1102-d718-4e60-83d9-f8e6bb723ea0">15,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEwLTEtMS0xLTM4MDQx_6f526aa4-0084-4d6c-b71a-3fdf8bd88c8b">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEwLTMtMS0xLTM4MDQx_8c48c698-4ed9-4c50-8e43-b7f04fe5004d">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzExLTEtMS0xLTM4MDQx_3518321a-e873-4001-88fb-95160815222e">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzExLTMtMS0xLTM4MDQx_3277c118-5cbb-4c97-9b90-08096bcfe8d1">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEyLTEtMS0xLTM4MDQx_48a2f275-8785-403e-8afc-8a75d4c0077f">11,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEyLTMtMS0xLTM4MDQx_ce172b68-1079-4096-9d1e-0879ddedacbc">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEzLTEtMS0xLTM4MDQx_ab1c9d74-abe0-4914-9e40-117e9cccef51">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEzLTMtMS0xLTM4MDQx_41c6eb47-97b6-4792-9c07-824e1cf329bc">4,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE1LTEtMS0xLTM4MDQx_216b5e7d-4d8d-4cec-b4d2-589d6e501a07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE1LTMtMS0xLTM4MDQx_e70dd052-86d6-4be0-ae14-27202eb2b2a4">22,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE3LTEtMS0xLTM4MDQx_b96d893f-05cd-4798-adc6-77e701895ebc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE3LTMtMS0xLTM4MDQx_a3d9eb84-08ce-4dd5-a26d-7d2403546c98">19,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash inflows (outflows), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE4LTEtMS0xLTM4MDQx_f994a1e3-088f-476c-a212-dd51a0db7a04">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE4LTMtMS0xLTM4MDQx_4ea4433d-f327-4e67-8ab0-e1d0c751a1b2">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIwLTEtMS0xLTM4MDQx_7c91db59-c2f0-483d-970e-54d6bd10a7fb">46,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIwLTMtMS0xLTM4MDQx_33c87f60-f478-4752-ae78-6021a3d88bae">63,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIxLTEtMS0xLTM4MDQx_debfb735-fa62-40cc-b23d-78addd766597">6,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIxLTMtMS0xLTM4MDQx_f99787a1-00c6-4b0b-942f-53c7c477e682">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIyLTEtMS0xLTM4MDQx_f66bface-b970-44d5-84bf-72b49cb0955e">1,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIyLTMtMS0xLTM4MDQx_ee9bfedd-348a-430d-a56a-3d3224150a4f">1,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIzLTEtMS0xLTM4MDQx_9f079f59-4b00-4405-87a3-536320870727">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIzLTMtMS0xLTM4MDQx_88e18232-93b0-4882-a804-efeacdf66745">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI0LTEtMS0xLTM4MDQx_47e1133d-72a9-46a6-851e-5ff1dfc9f767">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI0LTMtMS0xLTM4MDQx_06202b71-2fc2-458a-b62a-24ba22cd1be2">9,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI1LTEtMS0xLTM4MDQx_3eda37a9-999e-466e-9e5f-b58058a9faa7">32,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI1LTMtMS0xLTM4MDQx_0f3e7d17-8a62-4f52-84a5-2f1bb370963a">28,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI2LTEtMS0xLTM4MDQx_25ef9798-2c66-414d-850b-2aea444eef28">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI2LTMtMS0xLTM4MDQx_1a65d362-2098-4a67-8354-5fb9694aeb86">2,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI3LTEtMS0xLTM4MDQx_3d126dba-263f-4590-add3-c35c85a127d5">7,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI3LTMtMS0xLTM4MDQx_35a379f8-2599-48ad-b85c-8d68159bd8e7">32,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI4LTEtMS0xLTM4MDQx_346457e9-f47b-485e-ac82-8d83b40bb460">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI4LTMtMS0xLTM4MDQx_8055c30a-3669-4f6e-ae4b-9a3ebbaf89cf">2,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI5LTEtMS0xLTM4MDQx_e2303a10-1541-4759-9b8b-b09f12d66c05">1,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI5LTMtMS0xLTM4MDQx_4b7f8d79-0fd6-48c1-a0b4-28966ad4ccf4">771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMwLTEtMS0xLTM4MDQx_47d0801f-68ff-414d-8866-1416a4764038">514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMwLTMtMS0xLTM4MDQx_6bd51faf-7e0b-425c-81ac-84ba8c594ba7">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMxLTEtMS0xLTM4MDQx_76641571-35fb-4bb0-be26-58d74c90bc7b">57,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMxLTMtMS0xLTM4MDQx_7f3abf4b-419c-425a-b908-bafa70acb84a">48,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMzLTEtMS0xLTM4MDQx_ee5c1a41-4435-40ed-aa6c-0b5e464c7321">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMzLTMtMS0xLTM4MDQx_de255977-7bad-459f-965a-713856a029b0">1,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM0LTEtMS0xLTM4MDQx_b4f6147e-c878-40d4-9f38-9b18e846da7e">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM0LTMtMS0xLTM4MDQx_a4fa6526-80da-4399-9550-338e16eedfa4">42,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of non-strategic assets and divestiture of discontinued operations, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM2LTEtMS0xLTM4MDQx_dbc47b0c-bba3-4baa-8d86-b2a8871a9e1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM2LTMtMS0xLTM4MDQx_758dc843-8df0-447d-8480-258f94677314">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM3LTEtMS0xLTM4MDQx_1d52c5db-fcbb-4b8e-88b1-4ea25f324354">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM3LTMtMS0xLTM4MDQx_9ef2f001-4561-43fd-9a6a-40f124af7b18">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQxLTEtMS0xLTM4MDQx_fab48fb9-6866-4ba7-bce3-804e85cdcefa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQxLTMtMS0xLTM4MDQx_74c4adc7-76bd-4456-9f67-de33238be445">2,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQyLTEtMS0xLTM4MDQx_3a53737f-c87a-4e89-bd3d-500a93345aea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQyLTMtMS0xLTM4MDQx_66c00d50-8315-46ef-8fc5-507cc4fc0dcf">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQzLTEtMS0xLTM4MDQx_2b5deec2-e59e-4359-a62a-326db0ca1806">8,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQzLTMtMS0xLTM4MDQx_c0b53325-1c59-4aa2-aa1b-9e2efda0a6a1">5,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ1LTEtMS0xLTM4MDQx_6bc62432-7bd7-415c-9050-97721da9cf85">16,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ1LTMtMS0xLTM4MDQx_82bab799-715f-40ec-9ce2-a659ff59c041">45,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ3LTEtMS0xLTM4MDQx_12dc0bdb-f521-4a9c-9656-8bc7ad46c4d9">34,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ3LTMtMS0xLTM4MDQx_feea45c4-6cbd-4c7f-b298-b9b307d02137">39,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment and termination of Credit Agreement including settlement of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ5LTEtMS0xLTM4MDQx_aa1c1571-256f-4733-96e8-943085700bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ5LTMtMS0xLTM4MDQx_6ed21f59-2bdc-4dca-9f94-98515766f755">98,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUzLTEtMS0xLTM4MDQx_a7458769-b4fd-45ca-b5ab-4fbebc86b8af">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUzLTMtMS0xLTM4MDQx_e447279f-c767-4de3-a11d-b3196731f909">6,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU0LTEtMS0xLTM4MDQx_f38796ae-4c00-4b50-b43e-17feeabe74fb">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU0LTMtMS0xLTM4MDQx_c595338a-7c00-4818-966b-31400fde10e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of equity awards</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU1LTEtMS0xLTM4MDQx_ec450b76-4389-49b8-9605-98e10c78f6a0">16,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU1LTMtMS0xLTM4MDQx_5df6a3f9-1689-4bc0-8cc8-587795ae724d">2,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU2LTEtMS0xLTM4MDQx_4c71b5f6-461b-4c49-a707-f848a088f980">51,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU2LTMtMS0xLTM4MDQx_7db3902b-58f5-4c4d-b846-919f66af71bd">55,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU3LTEtMS0xLTM4MDQx_6946f6b6-49ec-4a53-9c9c-72a0109b945d">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU3LTMtMS0xLTM4MDQx_d0d6a118-b1c9-4f97-927c-b869100f9c2a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU4LTEtMS0xLTM4MDQx_668e4ed7-f764-4042-b971-203136eef524">92,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU4LTMtMS0xLTM4MDQx_beabbeb6-f8e9-46a3-98c4-a2dce3c29ac0">57,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTEtMS0xLTM4MDQx_32c854fb-e4a9-4b6e-b7c4-d48591ef4ca9">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTMtMS0xLTM4MDQx_6fd0a3a8-040f-462e-b385-4744c51aa458">361,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTEtMS0xLTM4MDQx_c7c39c63-a8f0-40c0-9113-19cd02f14912">262,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTMtMS0xLTM4MDQx_c943eec5-0a37-4672-8c00-04b3abf2821c">303,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4" footnoteRole="http://www.xbrl.org/2003/role/footnote">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTUvZnJhZzozZDYxNzQwZGMyNTM0ZDNmYTRkZDdjNTM0YjNmOWYwZC90ZXh0cmVnaW9uOjNkNjE3NDBkYzI1MzRkM2ZhNGRkN2M1MzRiM2Y5ZjBkXzE4MjY_18fe2fbf-d578-4303-b260-0437cd2f4732" continuedAt="id98c3d879d98413ca28f7e8f7242d6b4" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id98c3d879d98413ca28f7e8f7242d6b4" continuedAt="if9a669add0af42679e7ac406a46082f9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of March&#160;31, 2022, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTUvZnJhZzozZDYxNzQwZGMyNTM0ZDNmYTRkZDdjNTM0YjNmOWYwZC90ZXh0cmVnaW9uOjNkNjE3NDBkYzI1MzRkM2ZhNGRkN2M1MzRiM2Y5ZjBkXzUzMA_b54b7fc6-2dad-46bc-98d8-751477ee6348">210.2</ix:nonFraction> million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9a669add0af42679e7ac406a46082f9">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTI4_12b3b727-764c-4fe8-9e76-0a13fa6e782e" continuedAt="i111dda73daa54fcf8f984684b1e3d468" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i111dda73daa54fcf8f984684b1e3d468" continuedAt="i861ff19d4a8a460db373437be9abb724"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTI1_622b64ee-e892-415b-9faf-9fc38d0cb8d5" continuedAt="ic8a99ed4857a4d5aa0c5171aa1bb7ebd" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8a99ed4857a4d5aa0c5171aa1bb7ebd">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTY5_420f5c57-a6f2-45bf-8364-291f34b63959" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQ5NDc4MDIzNzA1NjQ_5c26909d-7cd3-4bda-93e9-29109f8d59ab" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i861ff19d4a8a460db373437be9abb724" continuedAt="i460984930d824b88909c688a67f2c2d1"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTQx_34bdc171-630e-4ae8-be1d-fabb76c0d964" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTQz_875d9a40-c123-46cc-8b9f-eb23bd838bce" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644591fb6cc54e2096aefb6d12c9ee6d_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzItMS0xLTEtMzgwNDE_eb239c37-8caa-4158-86fa-9d816c7e5c27">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68b009330794ef1888c6d5fc3c5dfc7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzItMy0xLTEtMzgwNDE_e3ec3ac5-7a81-4092-aeff-9f92ef9fc7e3">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icedde2203c2f4932b7525a1653f8a386_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzMtMS0xLTEtMzgwNDE_aaa352d5-3ed7-43c9-b132-2bd633de436f">11,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff05ae2c51c48e6afd4afc199a1aa71_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzMtMy0xLTEtMzgwNDE_50dfdaf4-9c82-4e9b-a9a5-138e4c5d19fe">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib729f13217c547b98e74d1bafa5ea4c9_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzQtMS0xLTEtMzgwNDE_8ce5294f-9e91-4781-b6e5-90f9bd8e1aff">38,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4114c1a397b94102bce6ff2aa93691c0_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzQtMy0xLTEtMzgwNDE_4e3b6443-8984-4c56-9243-282a875b73b5">73,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746c3c635d6c45f5b87aefae016c4fb4_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzUtMS0xLTEtMzgwNDE_511653bb-689b-493b-bd11-21b9cf6be49a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ea15c7c5084899ae3932a21f7bcb6b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzUtMy0xLTEtMzgwNDE_533c78cb-b35c-4d45-a00e-168d770a4143">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzYtMS0xLTEtMzgwNDE_db111ec5-cec2-4f3e-a859-7006cc696b7a">52,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzYtMy0xLTEtMzgwNDE_01727218-7530-46d4-8e3d-109f8e04e52a">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzgtMS0xLTEtMzgwNDE_c5f7aa4c-5958-4293-9f92-95cab7c7cca1">39,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzgtMy0xLTEtMzgwNDE_173d9752-8b8b-4dd2-adef-f22cd5a6d1c0">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzktMS0xLTEtMzgwNDE_284798e0-d064-4c0d-956d-c18804a76ebb">39,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzktMy0xLTEtMzgwNDE_3a59ed05-d8b3-4a9e-a5e6-62ab3f6d2080">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzExLTEtMS0xLTM4MDQx_8dfffa29-e626-4d7b-a701-0431e479bca7">12,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzExLTMtMS0xLTM4MDQx_75664d35-7b11-4a82-afd9-5b38ad787b56">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzEyLTEtMS0xLTM4MDQx_358601ec-e4bb-4009-a222-0bcee01b08d6">12,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzEyLTMtMS0xLTM4MDQx_8f822718-8e52-4c9c-91f9-c30eeda5ba34">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March&#160;31, 2022 and December 31, 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="ib82aee0d988d44d9af8cac23744c8699_I20220331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQyMDQ_48b1916c-d71a-42aa-8f73-7a7f50d9d722">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3f2b71e551c243ae81adfe5562d1b7c2_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQyMTE_21f9e1b4-3caa-48d8-b2cd-4c081cfd2bde">11.7</ix:nonFraction> million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQ5NDc4MDIzNzA2MDY_e67df718-d620-48c7-819b-1f9956187427" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzItMS0xLTEtMzgwNDE_5f8bf9e6-c84e-4b79-be19-be4005a743b4">210,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzItMy0xLTEtMzgwNDE_ad144810-123b-43df-8a28-be2ec8b185c1">236,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzMtMS0xLTEtMzgwNDE_bcbf2452-2549-4113-a046-245acc59059c">52,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzMtMy0xLTEtMzgwNDE_0826400a-a064-41f4-aa39-7762abf26a3e">67,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:RestrictedInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzQtMS0xLTEtMzgwNDE_2bf1da2a-dece-4a21-95bf-3a35d4c4bd36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:RestrictedInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzQtMy0xLTEtMzgwNDE_83d6755f-834e-4492-8cbf-14980076645a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzUtMS0xLTEtMzgwNDE_18694352-6875-4a4b-b641-a8d647f87feb">262,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzUtMy0xLTEtMzgwNDE_e1b998b9-c7f4-4a31-9810-ae5a0b8fdcd7">303,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</span></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTkx_d1ee08ae-beed-439a-91da-3074d5ed3b17" continuedAt="i1a5575098a2542858fc1c49abc880357" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i460984930d824b88909c688a67f2c2d1" continuedAt="if22c7686382243d4a7d226bf7623892d"><ix:continuation id="i1a5575098a2542858fc1c49abc880357"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTc3_6eafbade-5c0f-4dd8-a0b8-926a2dc99b72" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has <ix:nonFraction unitRef="reportingunit" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzEzNjAx_0af6db66-7f41-4ec4-b5d9-d4a3812ed8b1">three</ix:nonFraction> reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTMz_f97e7e2e-324a-490d-b97a-3508fe165566" continuedAt="ic0754548bea344fc882d49ebe2828016" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTg0_d14a9319-87d7-4d6f-879c-b948469af0e1" continuedAt="i07dbabdbfcb94a0d9c8ed38c2424105c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icead5b03e4c6480db192188178d18afe_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzAtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNGNiMDQ0YjUyMGE0ZWVjYTE2NTI0MzVkMzkzMGE0OV80_e8731da5-b17e-4fee-b7fb-7b0f5b80f2fe">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i136d025dfa994cc69d43c0b193565b0a_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzAtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNGNiMDQ0YjUyMGE0ZWVjYTE2NTI0MzVkMzkzMGE0OV85_67bc5930-94dd-455b-be63-523b0906702a">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2cdd074577da4a56beeac98f792d2af1_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzEtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjpmZGJlNGRlOWM5ODY0MDc0ODA3OTYxODgyZjBlYWUyYl80_8c232509-255b-4071-8b21-a8e2cf7e5b5f">10</ix:nonNumeric> - <ix:nonNumeric contextRef="idf4153f331bc4c5ba00b95d8e87a52dd_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzEtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjpmZGJlNGRlOWM5ODY0MDc0ODA3OTYxODgyZjBlYWUyYl85_0c98cd7e-3544-4c53-8183-f699303c1f84">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i532067d6f1ec4a09974e220c6f9d2b9f_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzItMS0xLTEtMzgwNDE_0de36afc-be7e-4b5e-b519-0544e9566cd6">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1244aeda3f374cbdb7295a1b9720eaca_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzMtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNmNkMDlhYzUyZmU0NzVhODJiYjUyN2YzMjU2N2QwMF80_cd2f29de-57c5-439c-a5f8-27c083817f57">3</ix:nonNumeric> - <ix:nonNumeric contextRef="idcd76d84c4874414b5b69662bb989fcc_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzMtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNmNkMDlhYzUyZmU0NzVhODJiYjUyN2YzMjU2N2QwMF85_454f15d1-0951-469b-b4df-3a7cbbdf96a7">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0754548bea344fc882d49ebe2828016">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.</ix:continuation> See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQ5NDc4MDIzNzE1NjE_3e059319-d5ae-478c-9847-290b1be4abf5" continuedAt="i9f5a3ea2eedf46008a4bed1d8e9f891e" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f5a3ea2eedf46008a4bed1d8e9f891e">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss)</ix:continuation> and were $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE2NDkyNjc0ODgxMDA_073e4071-a37c-4202-b8d6-b457f1a5d029">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE2NDkyNjc0ODgxMTQ_aae813ab-65d1-43ca-873a-1608b61cca01">3.4</ix:nonFraction>&#160;million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTk2_4723dce7-40a6-4a78-b5f2-05141f76ff9d" continuedAt="i7fab229dbb774916a458bfa4f222b74f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if22c7686382243d4a7d226bf7623892d" continuedAt="i3545a3a6c9594725b5a4dba82916d5ca"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7fab229dbb774916a458bfa4f222b74f" continuedAt="i26b63fc7200d46b5821d447a1493a84b">have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i26b63fc7200d46b5821d447a1493a84b">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</ix:continuation> See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="evh:RightOfOffsetPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTM0_2f12713b-495b-42dd-a2ee-7bb23bd506d4" continuedAt="i7af955c58c474d9580379514bdfecfe9" escape="true">Right of Offset</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7af955c58c474d9580379514bdfecfe9">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</ix:continuation> As of March&#160;31, 2022 and December&#160;31, 2021, approximately <ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE3NzAw_98c681e5-f4f0-4fa2-a25d-7574bc531a8b">35</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE3NzA3_54e9706f-7330-43ba-9f33-7af0d1d4e3d0">42</ix:nonFraction>% of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE3ODMy_7361dda1-e5d8-4cc1-82d9-337a7707bf47">39</ix:nonFraction>% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTg2_911e64b6-ce73-43f8-bfed-ea68bf6aa7aa" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTk3_b2f816f0-43e0-4e70-a991-e0ba60ba425e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3545a3a6c9594725b5a4dba82916d5ca">See Note 6 for further discussion of our policies related to revenue recognition.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzQ5MTE_d7cc7ff6-78cb-4c81-bfae-6dcdc85c8b34" continuedAt="i4fb360951a074f72a0ec72cec0d5336a" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4fb360951a074f72a0ec72cec0d5336a"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzQ5MTg_041ce27e-3cd2-4c4b-9c28-f483c5ef244e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $<ix:nonFraction unitRef="usd" contextRef="iae5bc002399c42d7a0dfe095133c2eea_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTUzODc_0040db08-574b-4bec-8e23-e53e50298442">39.8</ix:nonFraction>&#160;million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="iffd02a268c2f44e1b4b8a87043e3237b_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTUzNzE_cb1ea1f0-1fea-4cf7-8b6f-f3d05ed77607">106.2</ix:nonFraction>&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $<ix:nonFraction unitRef="usd" contextRef="i4fed4b10d9a94e43b4a7376d75e82ef5_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTU0MDI_ed8dc5cd-cc9f-40c0-ab23-37294662d887">25.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i50dcc4c9e90649d88b6e4ebba21ccd70_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTU0MTc_9632c727-cfe9-4c2b-9b72-1f4e614cea71">41.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwODE0_7898e5e4-23d9-4e28-97ae-ecde2e46e7d5" continuedAt="i3f81659a4c4e44899c414e18e54e668f" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3f81659a4c4e44899c414e18e54e668f" continuedAt="i625772d656e040aca59a52c509e8785e"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including <ix:nonFraction unitRef="number" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE1Ng_206c4b9c-0e6d-4a35-9b1a-12f59cbace29">100</ix:nonFraction>% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach  end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzcxNw_dd3bc47e-d03b-43e9-9b9f-c82b19d704a0">117.7</ix:nonFraction> million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3Xzg1Ng_3476e2ce-4303-4eea-9104-f8a31b810a66">46.5</ix:nonFraction> million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3Xzg4Mg_75c137dd-a1eb-44b9-a16b-cf6d8e312664">1.8</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzkzMg_b35682ac-5917-454f-8718-38f1afb719ea">56.6</ix:nonFraction> million as of October 1, 2021, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3Xzk4Mw_d2d1e341-b3e2-44e1-97c8-cfd1ffd9611f">45.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwMDI_e521b31f-8264-4a0d-8cbe-714b2112426f">14.6</ix:nonFraction> million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwODEx_29c90a2a-6046-4dbf-94c6-c3bdb66f6a61" continuedAt="i75d60a5796374fa1a50c950212478cc9" escape="true"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwODA2_ae9df10d-c6db-4a8e-b672-944029aca69a" continuedAt="i160146883c7043f0b994118d550d60c6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzEtMS0xLTEtMzgwNDE_06ae427f-f8b2-4983-be91-5a7f99340401">46,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzItMS0xLTEtMzgwNDE_d2fdb66d-05a9-446f-af5f-c7f0cfeb741c">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzMtMS0xLTEtMzgwNDE_db6160e9-465b-42cc-9c33-418a9a4968e9">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzQtMS0xLTEtMzgwNDE_5a0dadc3-58d3-468c-b138-ec2e991b83a3">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i625772d656e040aca59a52c509e8785e"><div><ix:continuation id="i75d60a5796374fa1a50c950212478cc9"><ix:continuation id="i160146883c7043f0b994118d550d60c6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzctMS0xLTEtMzgwNDE_09758a06-d78a-43ee-8f6b-ecc0d14cfbb5">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzgtMS0xLTEtMzgwNDE_cf3b800f-97e4-4715-8519-d7b2c4160137">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzktMS0xLTEtMzgwNDE_24380fe5-b65d-452a-89a1-2a65787043cb">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzEwLTEtMS0xLTM4MDQx_280d4bc6-a4da-4c0a-93f1-4498eea81222">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzExLTEtMS0xLTM4MDQx_ac4ab145-f5df-44cc-9fcd-9b9afb9466d6">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486cd92f52f9444ea10b825521601fd1_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE0LTEtMS0xLTM4MDQx_185a9028-d158-408e-b1c7-37f3f15f3d83">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8f0394dcea4227a602bc9f7748104e_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE1LTEtMS0xLTM4MDQx_dd7d79da-635d-4977-9945-4ae3ec167daa">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0dedbe6375f4957bda96aaf161bdfa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE2LTEtMS0xLTM4MDQx_36a9e0ff-1462-46bc-82b9-3424e9e14975">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE3LTEtMS0xLTM4MDQx_01d0daa7-1d52-4588-be3b-d41397908681">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIwLTEtMS0xLTM4MDQx_92e7565a-6b47-4e4f-967b-07a1e1e980ba">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIxLTEtMS0xLTM4MDQx_3bc19c7b-46c6-42e6-9dfa-1c47c41e996d">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIyLTEtMS0xLTM4MDQx_e4a1ca35-9afe-4398-86d9-095537ec5d54">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIzLTEtMS0xLTM4MDQx_ad97ea23-72d0-4c50-b21e-c4e6b8cce2f7">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI0LTEtMS0xLTM4MDQx_c43b6da4-691e-4c15-a2e6-829f69816b19">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI1LTEtMS0xLTM4MDQx_cccd7353-a7e4-4464-91bd-e7c06d4e4cfc">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI2LTEtMS0xLTM4MDQx_497426c7-6a4a-4cf5-af1f-cc8515dcabb2">6,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI4LTEtMS0xLTM4MDQx_eac05443-9107-4f0f-9bbc-cbbf9c191844">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI5LTEtMS0xLTM4MDQx_28e8da31-0677-42d5-9fd7-bb296fe32f96">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="i78f19f381f38447c990722124282e3f6_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE2Njg_11f57119-cea1-4577-98ff-f1d7c8b61eb1">13</ix:nonNumeric> years, <ix:nonNumeric contextRef="ic05ac80824ef4e7e9360568c9bffff1a_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE2NzI_f29a651b-59cc-4614-9309-97ff7eda0035">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i6b184513547b435b881d4872ab81bc09_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE2ODA_e25e3a58-072e-43c5-8c28-1956adb7351c">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $<ix:nonFraction unitRef="usd" contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzMxNDY_6a4668c2-3275-4ba0-b7a0-b0280e06db53">69.6</ix:nonFraction>&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized by the end of the third quarter of 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzI5OTU_64038fdf-2005-4fe8-8ed2-198766a29023" continuedAt="ieab6a6dc285845919846c0ac397d48f9" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieab6a6dc285845919846c0ac397d48f9" continuedAt="i3e580a067c1941c9a3d3e2388cdee54c">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3e580a067c1941c9a3d3e2388cdee54c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzI5OTY_d12e9bba-d07f-4b95-91d1-ec6267d84bf2" continuedAt="ie4946b6b90064dd699b7633f7ad033fe" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a872109d774e4da481cebe223eff04_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzMtMS0xLTEtMzgwNDE_11fe2111-502d-4718-954f-be3f8f0cb51f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6ec7aba15341f6b7511d0a09ecf92a_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzQtMS0xLTEtMzgwNDE_a12d9e2b-7eeb-42ea-a774-dad6fed2b746">44,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzUtMS0xLTEtMzgwNDE_bad940bb-e728-4e43-9bb9-6671fe4cdd11">44,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzgtMS0xLTEtMzgwNDE_38c60e8c-4d2b-41b2-8448-85102a3f8c14">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzktMS0xLTEtMzgwNDE_4dd90c40-3013-43bc-a8fd-878b448c4b6d">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzEwLTEtMS0xLTM4MDQx_2d91c46c-656d-473b-b249-327cdf8d287e">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzExLTEtMS0xLTM4MDQx_58770323-d274-4755-bde3-1f50831fc619">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzEyLTEtMS0xLTM4MDQx_0b7ec3f0-438b-4669-b4ac-54f4518737ae">45,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzEzLTEtMS0xLTM4MDQx_c07c398d-e240-43d4-b7aa-f7beee09b233">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE0LTEtMS0xLTM4MDQx_6120d51e-2650-4b54-9735-ab7e0abb2335">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE1LTEtMS0xLTM4MDQx_3eed60e4-a5d2-4486-abcd-b54dc61eef7c">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE2LTEtMS0xLTM4MDQx_daadcef0-28d9-443d-9dfe-08be9f793907">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE3LTEtMS0xLTM4MDQx_25a07fc7-a4c0-4e7b-a8a6-5989ad2072a0">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE4LTEtMS0xLTM4MDQx_ef62478c-213c-4f32-ad17-71ba403256cf">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE5LTEtMS0xLTM4MDQx_b5352268-40d1-4838-8fcc-3312f4069e6f">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="i39a4593df2ed48e8bf26fb1a8734b8ca_D20210101-20210331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzE5NDA_963bfdd7-1ba0-4b57-ac25-7a248e2c2b9e">2.8</ix:nonFraction>&#160;million for the three months ended March 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="i39a4593df2ed48e8bf26fb1a8734b8ca_D20210101-20210331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzIzMzQ_41244551-7f7b-4366-91dc-96b0639a4f63">1.1</ix:nonFraction> million for the three months ended March 31, 2021. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. <ix:continuation id="ie4946b6b90064dd699b7633f7ad033fe" continuedAt="i3cd2eec526be416eb9fa4a26943c5f85">Cash flows related to the True Health business during the three months ended March 31, 2021:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i3cd2eec526be416eb9fa4a26943c5f85"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:89.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZToxMzY0YTg5Y2MyNTQ0MjA3YWI2ZjQ2NmIzODZmODZkOS90YWJsZXJhbmdlOjEzNjRhODljYzI1NDQyMDdhYjZmNDY2YjM4NmY4NmQ5XzItMS0xLTEtMzgwNDE_5d7425a4-7f9f-4284-8efe-f31fa638c0c0">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZToxMzY0YTg5Y2MyNTQ0MjA3YWI2ZjQ2NmIzODZmODZkOS90YWJsZXJhbmdlOjEzNjRhODljYzI1NDQyMDdhYjZmNDY2YjM4NmY4NmQ5XzMtMS0xLTEtMzgwNDE_700d6183-d065-4bb1-91b9-4029f80cf54b">2,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMzQ5_c307e95e-f166-476c-9ba7-83aaa0d917f2" continuedAt="idbd6d99a2be7415ea4794387606d408d" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idbd6d99a2be7415ea4794387606d408d" continuedAt="i1688b92a44f14cb19975e0142886a5c8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Transformation revenue is <ix:nonFraction unitRef="number" contextRef="i26bf389c6898466eb63379d01aaa71b6_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzE2NDkyNjc0NTI2OTA_78ee783a-727c-4ef4-a3cf-b0f85bdfd26e">0.7</ix:nonFraction>% of total revenue for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1688b92a44f14cb19975e0142886a5c8" continuedAt="id9960fdcd5cd4749a91b06ac5de264cf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMzUw_260af21a-e046-470d-b6ae-3384845dfdd2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec4532a4742433aba9506e85893885b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtMS0xLTEtMzgwNDE_4cac7cf0-9f27-46db-82e9-285adf044027">66,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fad50bce4e049c5b3abd06d2db91799_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtMy0xLTEtMzgwNDE_5554e550-bada-4050-9fce-e1bdedede235">60,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc0c2e998684f5f950bf9b71a352797_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtNy0xLTEtMzgwNDE_6a8c4ea0-ada6-45d8-8336-8851be90a24b">63,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19591c0223f84cb39b25c549e7cf2367_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtOS0xLTEtMzgwNDE_5ee17177-f08f-469e-81a7-413368f9e954">43,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f20417b0b048728508db43ea6e2e8a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtMS0xLTEtMzgwNDE_18b8e9bc-0f2a-4bcb-a345-8e66e395e28e">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af0d9f0068a4ecaa4d353078136bc50_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtMy0xLTEtMzgwNDE_c604e914-d00b-4f15-aa7e-bff3ad671a15">8,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768d2ed3578749dd919d8c01b59a765f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtNy0xLTEtMzgwNDE_a5f8dadc-ce4b-4f68-8c90-b522ab439e31">99,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54489df7b34f4bc5bd3764871ee2bbd8_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtOS0xLTEtMzgwNDE_997d763d-b522-4da4-bcf1-e5d0e32c0556">85,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45d563122eb4be993ee23f5113a8e5c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtMS0xLTEtMzgwNDE_eae75511-18a3-476c-9843-64056bfc52d0">35,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526505192a4f43d58f8618791a968597_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtMy0xLTEtMzgwNDE_1f7baa3d-0c20-4603-a78b-81dbd4777375">15,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4c945d2ec44cc996bde7e53fc1298c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtNy0xLTEtMzgwNDE_d2e529d2-948c-4b70-8bdd-31aafce498d8">27,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649f6202bc224593b15c50af0d75b73c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtOS0xLTEtMzgwNDE_346b051b-126b-40ae-a29c-4891749e79cb">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtMS0xLTEtMzgwNDE_5ffa4604-2b53-4a88-a0bc-4c966194123a">106,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtMy0xLTEtMzgwNDE_221e44db-2fba-42a7-8a23-02d8dbe473e9">84,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtNy0xLTEtMzgwNDE_d3f5822e-2af8-4991-9fe4-b04849eca2af">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtOS0xLTEtMzgwNDE_9a712451-1d7e-4a68-9212-88809b9b784f">130,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzUxMTQ_5fc3fab6-aaa4-4eda-8fcc-bda9b9b351a4">162.0</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of March&#160;31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id9960fdcd5cd4749a91b06ac5de264cf" continuedAt="i293446ef0e8a43e8a6b0c7f70f594375"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="i5b0b219944a9403581d404035c8810ea_I20220331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzU3MzM_44dc41f1-6e06-48bb-8621-bf116b877426">37</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8940680e0d344f24a0605bc5abbeeab2_I20220331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzU3Mzc_0655ad80-a889-462e-87a2-e49b93314661">64</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4661a17748084b22847a6b4088c1f8c0_I20220331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzU3NDQ_bc1b33a4-ffb2-40d1-9c61-a45f6bf3b9e9">84</ix:nonFraction>% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMzUy_062fc00c-295d-4a57-8e8c-699156f832fb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzItMS0xLTEtMzgwNDE_1d6d7b86-5981-45b5-8159-ba56ea142599">176,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzItMy0xLTEtMzgwNDE_139c3f32-ea9b-4031-b23d-04968030ec51">129,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzMtMS0xLTEtMzgwNDE_d3214735-ea4a-4ddc-9657-8fd33c5abf2a">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzMtMy0xLTEtMzgwNDE_35d50cde-32a8-4737-8ac8-c71433df4648">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzUtMS0xLTEtMzgwNDE_a63d7b9b-9620-49a9-973c-5b05d784e4fd">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzUtMy0xLTEtMzgwNDE_5e513c37-32ba-459e-9b45-5d3948875be9">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzYtMS0xLTEtMzgwNDE_8a313f91-c2f0-4a05-8c9d-495b3fb2a7d3">4,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzYtMy0xLTEtMzgwNDE_15a850a5-7faa-4ff6-afbe-c8177fbb3b73">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the three months ended March 31, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzEtMS0xLTEtMzgwNDE_551b572b-1be6-40eb-92ac-1456786edf5d">16,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzItMS0xLTEtMzgwNDE_61e6eb95-82d9-43a4-ab8b-70fe9fd3dd44">10,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzMtMS0xLTEtMzgwNDE_cbac8009-2210-4fe4-8289-836ecde047ae">11,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzQtMS0xLTEtMzgwNDE_dbae582d-e209-48c5-817c-c1fc8428a5a8">17,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzgwNjI_5d63562c-75cf-4e5a-a683-22085cfaa105">26.5</ix:nonFraction>&#160;million for the three months ended March 31, 2022 due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i0669761c388c4774877abc5d5d60ea1a_I20220331" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg3NjA_dee94c94-03d1-409e-8080-ff1221d25c20">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i112e0050ecf247829efb6e3889c6f684_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg3Njc_74746879-40a3-4703-876d-f4dfbd20c95e">5.2</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of  $<ix:nonFraction unitRef="usd" contextRef="i22dc575ff886464484317aca659befbb_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg5ODI_efb9df2c-45c2-48e1-916e-591e28ac7f3f">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie2526a6d68f44dd9a2d5c9c76f28f392_D20210101-20210331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg5ODY_e968e9a2-7a84-4f53-aa47-c551201dfbd7">0.4</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i293446ef0e8a43e8a6b0c7f70f594375"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="if10ac0d0bbea4997a9ef4b8313c0f3d9_I20220331" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk3NzA_0a1dbbb4-2d46-4a93-ac96-b349f5913c92">18.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4101ecab0d224b7e94b0b16a3a6e2d35_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk3Nzc_f58871a5-2f1d-48c1-8c84-f45fb9e7bda3">27.4</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of  $<ix:nonFraction unitRef="usd" contextRef="i080f3a0bebf046f4b42c854af2f46b0b_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk5OTE_af53a03d-5967-4e87-9140-5294a0a4a6a8">10.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i171aed87552d42e6b97ff67bc5456cba_D20210101-20210331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk5OTU_5c5c76ea-91a9-4efb-b4ab-31f38c12ce84">2.7</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or <ix:nonNumeric contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" name="us-gaap:CapitalizedContractCostAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMjM1_9cbb77ea-6d2c-47c8-8f93-fd321aadcac6">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzMxMjQ_2a5ecdd3-e5e5-4bd9-bfbf-1361a35a5635" continuedAt="i5db2dda791e740df90390f478162679c" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5db2dda791e740df90390f478162679c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three months ended March 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three months ended March 31, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;March&#160;31, 2022,&#160;<ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzIzNTI_7e0c09a1-aa91-46e9-9c30-a69184161485">87</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="iadbac2b94ee84dbaa1e6ae52b26777c8_I20220331" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzIzNjk_7ee5c0e8-17f2-48e1-9599-6fa70f009401">4</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i7a483ad79bb04d958eac46a38e2f15c9_I20220331" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI0MTA_c5f57b1d-35ae-474c-9aeb-eaa6560b74dc">6</ix:nonFraction>% past due less than 120 days and at December 31, 2021, <ix:nonFraction unitRef="number" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI0Njc_c1ec4aaf-6283-42b2-9d2b-812c3ba12dfa">90</ix:nonFraction>% was current, <ix:nonFraction unitRef="number" contextRef="i8804d1ca441342f88f29f050b52851ca_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI0ODQ_fb369e31-7ce4-44c2-af8a-d95d806f4823">2</ix:nonFraction>% was past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="ice301424511e4396aff3b79bc7270a81_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI1MjU_8b8aa150-8160-48c0-91c2-80dc530bddcd">3</ix:nonFraction>% past due less than 120 days. As of&#160;March&#160;31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI2MzE_8e1c56bf-75b7-450b-869f-c24ca6085cbc">194.8</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI2Mzg_df75e1f2-d739-4f80-9abd-a4898de521f5">171.5</ix:nonFraction>&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzQ5NDc4MDIzMjg2NTM_05f5ea4a-e8b3-43bd-9aba-d9d5f3793ff6">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzQ5NDc4MDIzMjg2MzM_f3bc5f9f-4ea3-42d4-af66-c215c527e572">3.4</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzMxMjU_223b3ea4-c9ea-4296-8bcd-b83315fb08b0" continuedAt="i2af3a7b3ec0a47bc9f08b56f23198cc3" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the three months ended March 31, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i2af3a7b3ec0a47bc9f08b56f23198cc3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzItMS0xLTEtMzgwNDE_c747fe55-6ef2-485d-9fe9-62d94490f3fd">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzItMy0xLTEtMzgwNDE_1de813f6-6c6a-49ea-907e-d52510bb33b6">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzUtMS0xLTEtMzgwNDE_84795591-7d15-4907-8c19-83f51f765ce4">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzUtMy0xLTEtMzgwNDE_769951c0-a3ea-4df4-9023-9342bbee9678">2,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzctMS0xLTEtMzgwNDE_04a05e58-7c79-4535-9750-687d130c2806">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzctMy0xLTEtMzgwNDE_4ac15cdf-b59c-4f34-8356-33dd39d9c105">9,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_139"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzY1OA_6dc8127c-707e-47b3-bf45-c9baaedcc331" continuedAt="ib38c69926b3b4016a35506adc688d98a" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib38c69926b3b4016a35506adc688d98a"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzY2MA_0c750754-7b6b-44b3-9dfb-468e3fb4e07a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7ffa70b61341d8b58e1e5e9dfe4d22_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzItMS0xLTEtMzgwNDE_382158f3-2634-4f06-8b33-8318a758d7ae">24,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0854b7c841d4126a9365b4b0019cd6c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzItMy0xLTEtMzgwNDE_4b58cee6-af54-4999-a408-db978402a7fe">21,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8439569a0148a890c18386790d2daa_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzMtMS0xLTEtMzgwNDE_9b5d67ab-5573-4fb0-a8ed-a1795cd7c4e7">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dcac57fee14e97b585767b7925b959_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzMtMy0xLTEtMzgwNDE_8d425e0e-5f85-4319-8e7e-207d618406d7">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa83669c1e34be09bf9a205994d7995_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzQtMS0xLTEtMzgwNDE_1b8cd8ba-2123-46c5-832d-54fc43848cb2">166,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61dcf9495af405097a6842ea0ed0697_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzQtMy0xLTEtMzgwNDE_7343051b-9f2b-45f5-b55f-eb469029c76b">159,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9118ab4a540a4a4a8d447fc14519b568_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzUtMS0xLTEtMzgwNDE_c23de175-848a-46c3-bb68-7dc1dd90ea06">15,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b872c69d4344d69ce0a22b7183b681_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzUtMy0xLTEtMzgwNDE_f3613db5-bfe3-449f-8aa9-10b7fe63b873">15,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzYtMS0xLTEtMzgwNDE_bfd378be-b848-4386-bfa6-a162f41e8642">209,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzYtMy0xLTEtMzgwNDE_ca0fa23c-184f-49c7-98b5-f7a9dbd70384">200,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzctMS0xLTEtMzgwNDE_2574596d-ff2c-4c1b-b39d-5e4dcb86794f">126,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzctMy0xLTEtMzgwNDE_25914d9c-a670-4568-a577-21b0359fd613">119,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzgtMS0xLTEtMzgwNDE_78d368ae-9244-455d-bca5-7e4627a79504">82,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzgtMy0xLTEtMzgwNDE_197a0a5a-e8e1-4b12-9013-f505b9855c11">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i9b1766ec32064dff97ec361a343c8c8d_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzEzOQ_4e71d819-7ed0-449f-90ec-4c7b0d8286ba">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f65ab021ad34abdbe85a6520f98dc68_D20210101-20210331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzE0Mw_c2b0558f-5d04-4902-9ebb-5024dab4ec1a">5.5</ix:nonFraction> million of internal-use software development costs for the three months ended March 31, 2022 and 2021, respectively. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i0fa83669c1e34be09bf9a205994d7995_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzM0Mg_5217fa9c-fb46-49b4-9c6d-2278e97da681">70.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id61dcf9495af405097a6842ea0ed0697_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzM0OQ_3aa6682d-4e67-4c1b-85d7-94845816ce6a">71.2</ix:nonFraction> million as of March&#160;31, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzQ0Ng_d50da9c5-bc23-409a-a8b0-c1a95fe01f31">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzQ1MA_98adf256-23aa-4027-ae6a-1807dd4a71b5">7.8</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzYyNg_55d417f2-281d-4b46-b35f-a75ef90ce30d">6.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzYzMA_8b26ff80-370e-4225-8601-1640ebe006c6">6.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzg3OTA_db3abeb0-d25f-4087-b7fc-503db135d734" continuedAt="if234420e30c34fce858d9854d8025604" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if234420e30c34fce858d9854d8025604" continuedAt="i14e8dd5eb7fe42e28ceb4ad7a78cec25"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reportingunit" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzM1Ng_b62475e8-a6d7-4052-ad69-8fe6c0cced3c">three</ix:nonFraction> reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended March 31, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test of October 31, 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i14e8dd5eb7fe42e28ceb4ad7a78cec25" continuedAt="i594bcb0864314d228976d2f8134e225c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our <ix:nonFraction unitRef="reportingunit" contextRef="ic23605bda701483aa031c60b51c43b27_D20211001-20211031" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzQ5NDc4MDIzNDA1NDY_0896582b-791e-4692-b866-1291938aac47">three</ix:nonFraction> reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzg3OTI_a1f77e18-63f8-4f3f-849f-d5a29ec5e5d7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58d4563528a74ddc8daf7cfcc8df4f4b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMS0xLTEtMzgwNDE_61c31cfc-983f-450d-b70a-08dc1705f762">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd83794d6dc499596834a18cd5a2a9c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMy0xLTEtMzgwNDE_3964ed10-14cc-4dc2-9945-29157023263a">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtNS0xLTEtMzgwNDE_46a37f1e-7393-4be3-8b9b-dfd82d2ea1ec">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMS0xLTEtMzgwNDE_79f9b295-73c0-4b07-9ce1-8996413a6745">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMy0xLTEtMzgwNDE_f12c6bdc-39b3-41b3-8d10-c14f5f3efe6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctNS0xLTEtMzgwNDE_26da7f6d-61e4-42c1-acd2-f49d2a9e262b">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzgtMS0xLTEtMzgwNDE_708c6548-9852-45d6-b307-8059d8f499ed">214,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzgtMy0xLTEtMzgwNDE_01388d69-edd9-45d8-bf8f-224815654a1c">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzgtNS0xLTEtMzgwNDE_c1a7ba9e-c2a1-4f12-9281-ec8eed29f6ea">426,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431455fda9da407ea1273e3d11bbbb34_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMS0xLTEtNDc5Njg_65939184-e425-450d-a636-e9d2cdfacf4b">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c9d5a6a37649e3b44edf8049cce4da_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMy0xLTEtNDc5Njg_55377ebe-77e0-4fc0-9c7d-d607ac44e246">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtNS0xLTEtNDc5Njg_d31ef0f1-1807-45f4-8f0a-4f82595bde18">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzYtMS0xLTEtNDc5Njg_5b4fddfc-105e-4830-89c3-c028342896a9">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzYtMy0xLTEtNDc5Njg_44fee891-1ea8-457a-ada3-7caea6b788d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzYtNS0xLTEtNDc5Njg_201c6704-56c1-4569-9abe-2c29e92454ae">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946bb3ded8914db29f26e0bac8b58b89_I20210331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMS0xLTEtNDc5Njg_f37c9fe3-bdae-47f3-9182-30a6e2db6818">214,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMy0xLTEtNDc5Njg_ef1e341f-2125-421e-a28c-58a2dce329a3">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctNS0xLTEtNDc5Njg_98f58a68-230a-4fac-860a-43236a29c741">349,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzc2Mjk_105722ab-23b0-4d7b-809c-af3061b7b1d9"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzc2Mjk_bb3a9962-73b1-49fe-b740-64e40ef36c45">575.5</ix:nonFraction></ix:nonFraction> million as of both December 31, 2021 and 2020.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i07dbabdbfcb94a0d9c8ed38c2424105c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of March&#160;31, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i582b4bf2bda24ddea0c9c99086fae38b_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMS0xLTEtMzgwNDE_348179ae-9c01-4316-bb40-0523b8d116df">12.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f8e91e0319490e9d3eb0783a1bad61_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMy0xLTEtMzgwNDE_93fd1e5d-c33f-46e8-97d4-6e200e3ef9bc">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f8e91e0319490e9d3eb0783a1bad61_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItNS0xLTEtMzgwNDE_b515cb3a-5ae2-468c-a3e0-91963f208895">8,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f8e91e0319490e9d3eb0783a1bad61_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItNy0xLTEtMzgwNDE_2ad7d295-4d64-448c-9b34-e14d92ccd615">17,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6249585dffb463e9e429c997c28422b_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItOS0xLTEtMzgwNDE_e8c58816-114b-42aa-a633-50c1138c6a8a">12.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f06bb46081a46e18e26c25735932a5f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMTEtMS0xLTM4MDQx_57084e23-1651-4f7d-96da-e2ce72445e09">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f06bb46081a46e18e26c25735932a5f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMTMtMS0xLTM4MDQx_d6a2a6d7-93db-4672-9e47-5c679dd055a4">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f06bb46081a46e18e26c25735932a5f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMTUtMS0xLTM4MDQx_f0803850-cbbb-4de3-8f3f-d82ae3f614c1">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie600b5ba08a345c0a7fa00407c5f1679_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMS0xLTEtMzgwNDE_31a414e5-13a5-42ff-a322-a55fbe648629">14.7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMy0xLTEtMzgwNDE_b2d99ee3-6116-4040-86db-fecb9e48d7b3">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtNS0xLTEtMzgwNDE_3e62beb5-348b-4937-8036-9f88d04c1292">76,912</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtNy0xLTEtMzgwNDE_ded66647-c290-47ee-9506-5b27c70487dd">234,107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i699ad28e63e644d292dfeba6e6ddc59c_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtOS0xLTEtMzgwNDE_c8c903ee-a83e-416d-a065-b6e0dd45ee5f">14.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMTEtMS0xLTM4MDQx_57b86d9c-d4db-4f8f-9098-4f7699e55325">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMTMtMS0xLTM4MDQx_4dfd536a-c17b-4ced-9886-3590a287fcc7">72,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMTUtMS0xLTM4MDQx_94433d93-7d26-474c-b71e-a5d2c2e1eb90">238,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i532067d6f1ec4a09974e220c6f9d2b9f_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMS0xLTEtMzgwNDE_b67fee40-a062-44ea-a568-3527db53f3bc">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMy0xLTEtMzgwNDE_4ab38408-31c5-4f83-9524-8fb00a1a0edf">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtNS0xLTEtMzgwNDE_6ad75947-edc5-444e-841d-429acde99851">75,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtNy0xLTEtMzgwNDE_3e61d58b-0c5c-4859-a7d1-88fc34331ee1">12,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if13595fd727041dbab088d6e82f53317_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtOS0xLTEtMzgwNDE_98a49051-7133-4a8e-8b9e-1bb93a23e7d5">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMTEtMS0xLTM4MDQx_f8a2bb60-c944-428a-b4d7-e11d18e68824">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMTMtMS0xLTM4MDQx_e302efe4-6870-43e9-bea4-01cba81b2d3b">73,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMTUtMS0xLTM4MDQx_af504759-6293-4055-bbc4-cfaf927a00af">14,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie40a55a2d4af4c7eb637dd2db2488d47_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMS0xLTEtMzgwNDE_dc5b22a0-a707-4c04-a751-3f7436626f2d">1.1</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMy0xLTEtMzgwNDE_177bda43-cb40-4b22-b37a-00e2490d3d19">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtNS0xLTEtMzgwNDE_b904aa53-4448-4681-b49a-4ca735cea82e">1,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtNy0xLTEtMzgwNDE_7bf0c6f2-c951-4626-88a6-7598b9aade7a">218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife5ebfa2dbf6474580e79f3a4aa684de_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtOS0xLTEtMzgwNDE_8ac888ca-84ab-4dbc-ac60-bdf031bf3d84">1.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98f030bdbd848349b1157be06b79af8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMTEtMS0xLTM4MDQx_ee7d24eb-2394-4423-8198-57bafa56e32c">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98f030bdbd848349b1157be06b79af8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMTMtMS0xLTM4MDQx_085b86bd-dcf4-41b9-a711-c8d40263af1a">950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98f030bdbd848349b1157be06b79af8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMTUtMS0xLTM4MDQx_baa5ae82-3f58-4e27-8693-d1699b1d735c">268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7d8558f0a0f4aed8a935e56b9bcd543_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMS0xLTEtMzgwNDE_287fcb59-0bb4-4bae-ae40-69a8a50ffb29">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7029f31fe5d346869ac6af84155da042_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMy0xLTEtMzgwNDE_46de5438-7fe0-463c-9924-70d1487cd5b9">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7029f31fe5d346869ac6af84155da042_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtNS0xLTEtMzgwNDE_6f89dea9-614c-4367-bf2f-f164a3fb8ec6">8,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7029f31fe5d346869ac6af84155da042_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtNy0xLTEtMzgwNDE_93e97798-fbb0-47fb-a49b-5db005c60f23">7,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96f0caaec00841cdb9b922302d272752_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtOS0xLTEtMzgwNDE_f3aa8039-0a6e-4f87-8f47-44c318ff72f0">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5893e370c05e4fa4a36f9edae416eaee_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMTEtMS0xLTM4MDQx_d2ef12db-583a-4f55-bdcd-a417aff53270">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5893e370c05e4fa4a36f9edae416eaee_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMTMtMS0xLTM4MDQx_da9ebe0e-c2b4-49bd-8119-692b070e3d98">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5893e370c05e4fa4a36f9edae416eaee_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMTUtMS0xLTM4MDQx_6d8f5e3b-7714-4cc6-9e44-abaf1b83d2dd">8,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMy0xLTEtMzgwNDE_07c69233-46af-42d4-9103-67862f967a17">442,195</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctNS0xLTEtMzgwNDE_c1c57381-4ec5-4668-99dc-fa9778ece966">169,982</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctNy0xLTEtMzgwNDE_807c5fba-7eaf-40a8-8721-ca355b7e204d">272,213</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMTEtMS0xLTM4MDQx_e403c038-cc3f-4d4b-8c1b-61f96d061a0d">442,376</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMTMtMS0xLTM4MDQx_6e283e17-c536-4ca5-92f4-c0a36ffacc8c">162,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMTUtMS0xLTM4MDQx_91971b6c-826f-4620-9add-8037fe60058a">279,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for both the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgyNjI_afda52b7-9186-41b5-992b-eab201bb4d62"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgyNjI_bc5619cc-3971-4b26-89bc-bacc2f7229cb">7.5</ix:nonFraction></ix:nonFraction> million, excluding $<ix:nonFraction unitRef="usd" contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgzMDA_a2defb56-8351-40e7-a298-b3c10b764564"><ix:nonFraction unitRef="usd" contextRef="i5fcffe6ed74045c2a108455a95165df3_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgzMDA_b278dcc2-ebdb-43ed-9228-63354b5459cc">0.2</ix:nonFraction></ix:nonFraction>&#160;million of amortization expense related to discontinued operations for the three months ended March 31, 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i594bcb0864314d228976d2f8134e225c"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzg3OTc_3bb4c37e-d71a-4316-9e6d-0953bfdbb20b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2022, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzAtMS0xLTEtMzgwNDE_713169f2-e28f-4681-afc9-6e4d47b76c73">21,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzEtMS0xLTEtMzgwNDE_5dad5127-dcb3-4967-80ba-02429e35e445">26,760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzItMS0xLTEtMzgwNDE_b18f6421-91ce-4c55-8b04-2678f9b4c8a4">20,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzMtMS0xLTEtMzgwNDE_c05956e7-ec3b-4a53-b69d-ab4ca6f0da05">19,330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzQtMS0xLTEtMzgwNDE_7cd4ffcf-9df2-460b-b60b-917ff95fbd38">19,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzUtMS0xLTEtMzgwNDE_4d98f35f-fec2-444f-851c-63da71034410">164,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzYtMS0xLTEtMzgwNDE_9b75d173-35f5-42d5-a971-e968d9488833">272,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three months ended March 31, 2022, that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzIwMzA0_029a2efe-dd15-425d-89dc-0855f7e8eeef" continuedAt="i645eb5f7cdce4102a7f004a2f1421531" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i645eb5f7cdce4102a7f004a2f1421531" continuedAt="i7e823a7cf3dd4a79b5ef14d83f59dbd7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzc4_91f01612-0f6b-4594-8dbc-d8b9b3d802d9">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNQ_37ac25a0-67d6-4d91-a682-f23f015069e4">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMzMw_088d18d2-0529-4425-a798-a2f13484a354">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQwMQ_ada855a2-cfd5-4632-bb09-bc6ad0a5f2b1">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ5MA_bc79144d-ce76-47f7-b310-9dd047545260">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="i916d7cde9f5c4098aafca8f1d4ec92b3_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzUwNQ_7c2ac4d8-28f8-47b9-9da9-315c895fd13e">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzU4NQ_6a5154e4-8050-46e5-b66c-68922bf74705">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEwNTc_af659a23-0d54-4459-a4fa-7f83bd8bec6c">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzNjU_f863ca0b-7e20-44bb-8781-edf41835f8f4">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ba9893300544569828a837db24cb5ab_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzNzI_86224039-e69e-4b2a-83af-a6397c16644d">1.0</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4MjE_0316d408-2889-4021-a6d2-68901a672f63">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5Mzc_dfd84b1d-3056-4a94-832b-a6d79c0e8ce7">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzI4MTU_603d1df9-f558-4303-a370-eae82cd54193">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i6c1b52e308b74c7391b12b1ba506c1ee_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzI5NjQ_3cf70d73-6e79-48be-ab2e-07d11a42992c">38.1</ix:nonFraction>&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMxOTE_9b7ad27d-a157-4628-b9c3-35ac62dde2b9">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7475a5be608b4b7db53a995f1885030a_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMxOTg_d10107a8-9363-4c10-a355-df21532a3669">1.3</ix:nonFraction>&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i6c1b52e308b74c7391b12b1ba506c1ee_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMzMjk_33507f17-2a9e-4202-b01e-0499a6fc82fa">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMzMzM_da8c98af-0f14-471f-8ea5-37b60657737d">1.7</ix:nonFraction>&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="ic3794041ed704c3192959c4746a76918_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ5NDc4MDIzNjA3OTE_9bcfc6f5-f8f8-4506-83eb-7db89a0f9d2b">38.1</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="ifac955e87eb245cb84b816f8086941ca_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczOTQ_b07ebe0f-c27e-4af8-9e1e-e02f118d80aa">1.3</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $<ix:nonFraction unitRef="usd" contextRef="i3f603d69a68045f6949859303a9e0100_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczNzg_3ecc01ec-961e-4692-aec4-94f409f58b23">11.7</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i4fed4b10d9a94e43b4a7376d75e82ef5_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczMTQ_ed8dc5cd-cc9f-40c0-ab23-37294662d887">25.1</ix:nonFraction>&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7e823a7cf3dd4a79b5ef14d83f59dbd7" continuedAt="i9294d4fa2f3a4c26818a2baad20c1e66"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzM3MjA_7ed3b2ed-7b2d-4d36-ae67-c716aaf94240">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ba9893300544569828a837db24cb5ab_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzM3Mjc_245ab96f-bdec-42a2-b896-5a8bfa429ebf">1.9</ix:nonFraction> million of interest expense related to the amortization of the issuance costs for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQwNzI_450635f1-f1b8-42c4-8b46-e2e4201b7513">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ0OTM_8a7d2fbd-ff42-44fa-9540-b7e53af72782">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ1NDg_6705f28f-bfd0-48b8-86a8-75fa8d30ffe2">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ2MDQ_8ad61c91-88a3-4b8e-b04a-66be34b07079">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ4NDI_17609fae-54c6-4da3-b4e9-7650cd7d5d55">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="id15cf99071b0415f8897789050cdcac3_I20191230" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzU1MTc_6b3d6a84-acf0-4f05-9135-ef553c3f05f6">75.0</ix:nonFraction> million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i758bcd0701c042ab91e1fdd9a3e0621c_I20191230" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzU2NDk_dd52b2e6-59aa-4c3b-b574-622f55743a8c">50.0</ix:nonFraction> million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $<ix:nonFraction unitRef="usd" contextRef="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMDQ3_6cf84581-47b7-4175-9815-4b8437faa8b0">98.6</ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="usd" contextRef="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108" decimals="-5" name="evh:PaymentsOfMakeWholePremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMDY2_0e5ac3e1-e158-4061-9576-a74c41e1b233">9.7</ix:nonFraction>&#160;million for the make-whole premium as well as $<ix:nonFraction unitRef="usd" contextRef="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMTA3_c65d82ef-b859-4785-8fd0-40d131082ad4">0.2</ix:nonFraction>&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $<ix:nonFraction unitRef="usd" contextRef="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMjIw_d80a01c8-5356-4901-9872-8017671bb8f7">19.2</ix:nonFraction>&#160;million, representing the remaining unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMjg2_d3fe241c-9ac1-467f-b59f-42120eb959b2">9.5</ix:nonFraction>&#160;million, the make-whole premium and $<ix:nonFraction unitRef="usd" contextRef="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108" decimals="-3" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMzE3_31c1a8f2-da6e-407d-a78e-f529d6ab1622">35</ix:nonFraction>&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4df15ce9a58f43aa8838ebd2fc814e18_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNTQz_80791888-07c9-4579-adc8-d103f2fb6aef">1,513,786</ix:nonFraction> shares of Class A common stock at a per share purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i4df15ce9a58f43aa8838ebd2fc814e18_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNjE2_0d2a70a6-8f2c-42ae-b201-344fb609867a">8.05</ix:nonFraction>. The holders could exercise the warrants at any time until <ix:nonNumeric contextRef="i8ad35dd656234df09077c620d5c6d635_D20191230-20191230" name="evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNjc4_b932b3b4-8f60-4c4a-a075-dd9ab30f47ba">thirty days</ix:nonNumeric> after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $<ix:nonFraction unitRef="usd" contextRef="if8d4ffeef7fe43eab4715bab8e852043_D20210108-20210108" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyMTA0_cf9e3ca7-7c4a-49d1-b49d-05bac8cb634c">13.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyMTU3_04d50ca0-73d1-4f00-bbb4-2f7449041532">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyMTk0_c006be00-abe5-48a1-be2f-03c0babaa00a">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNDYy_31370b50-38fd-467a-a96d-d1bac2b23e9b">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="ie0e2e0f414904188a0bb7cf06671ce39_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNDc4_7844dbd1-465a-4674-a5f5-6ded8bf7ce93">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="id3e67d706f964f1bb86ba26006bab411_I20181022" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNTc5_a54e56c0-60a2-4ed8-97dd-1f1c41e1f487">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="ic618bc70943b4438aa6de0773ad42f41_I20181024" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNzA3_e114ccda-58fd-4dee-8896-c444604a80af">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMDQ3_c006be00-abe5-48a1-be2f-03c0babaa00a">1.50</ix:nonFraction>%&#160;per annum. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMTAy_27c7d08b-7a7c-4ca3-a1e3-02eb068f57ef"><ix:nonFraction unitRef="usd" contextRef="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMTAy_ac8fbd92-ed63-45f8-8327-b455760c6931"><ix:nonFraction unitRef="usd" contextRef="if07f72d9ccda44d3b9275c10c3802ea0_D20200101-20200331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMTAy_ae922a4a-7a1d-4a0c-aa48-ea228ce89cfc">0.6</ix:nonFraction></ix:nonFraction></ix:nonFraction> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9294d4fa2f3a4c26818a2baad20c1e66" continuedAt="ib8051254412c47c9ad4a52abbc8ea0e9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million for the three months ended March 31, 2022 and 2021 respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE0MDMz_4251d73f-38eb-4f8c-9865-2b380df89405">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE0MTQ5_e7fea321-c8d3-4ad4-a0e5-4d04255f4a98">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1MDIw_55108c47-4665-4e7c-b060-0dc2da0142b4">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i9a5151cda805403099aabb0baf5abfe9_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1MTY5_f1312e0e-c534-4836-b6d7-603460cf4e58">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1Mzgw_a6834860-00ff-4fc0-bb2f-dce57faa1ae0">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0d85629f38df40019f7bfaf802250bce_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1Mzg3_65f0042b-5a04-40d5-af4c-d019e1db5cf8">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i9a5151cda805403099aabb0baf5abfe9_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1NTE4_f1312e0e-c534-4836-b6d7-603460cf4e58">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1NTIy_a6834860-00ff-4fc0-bb2f-dce57faa1ae0">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="i2cba20250d344f82bb7c7ee274ac2d08_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczMzQ_19862b0e-e0bf-46db-acee-eac2c9ee6b2d">71.8</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="iecaf5b671d0f48838a69272ed492bd4a_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczNDk_e339c3b4-56c3-4075-a959-458b938f51d7">2.5</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i7101f4c4fc704442967c163ed61da7dd_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczNjM_f0583771-1fee-4b7f-ab5b-f88503d2be36">28.1</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i50dcc4c9e90649d88b6e4ebba21ccd70_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczMzE_9632c727-cfe9-4c2b-9b72-1f4e614cea71">41.3</ix:nonFraction>&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1OTA5_e87eac58-33bc-4bbf-a7f0-bde1300cc578">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1OTEz_a6e554dc-1299-46d6-b2a0-4e388e98d40f">2.4</ix:nonFraction> million for the three months ended March 31, 2022 and 2021 respectively, in interest expense related to the amortization of the issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2Mjcx_567d7c9b-ae13-40bb-b54c-ab5f497ac6ba">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2Njcw_0590da6c-27f9-4a8f-b279-f1e5e9e2aa96">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NzI1_4ad591fa-9f1b-47ae-a814-d18b5bbe5420">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2Nzgx_b08fbd59-f17a-40eb-9a70-d564e40964d5">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3MDE5_91aa04eb-ade1-4c4c-b28c-dd6b412fc545">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ie46a449af09c45a48017c23edc16be05_I20171231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3MTg3_56b7f715-4e30-4f86-b5ba-e643bb1715ec">125.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="ie46a449af09c45a48017c23edc16be05_I20171231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3MjI0_fcdd450b-6dc5-41ed-9097-6f406c613593">2.00</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5c97925a37bb4a129ad535aed5cd5727_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3NDQ3_98863a47-cb19-454c-ade2-aa387f112694">120.4</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="ie46a449af09c45a48017c23edc16be05_I20171231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3NDYz_782e3dfb-0382-4f45-aca0-ad9e0cf0ff16">4.6</ix:nonFraction> million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib8051254412c47c9ad4a52abbc8ea0e9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4Mzg5_08e0bb72-a0cf-4581-a85e-be595d4ae3e5">84.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4NDUz_9b8de5a2-4823-49fb-a53c-f51cec063f8a">84.2</ix:nonFraction>&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4NTg2_1a49dcf0-75cf-4af4-877d-4b6a8eb4afd0">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4NzMw_a7aec461-24bf-413b-988d-2613f6315899">4.8</ix:nonFraction>&#160;million, including an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4Nzcz_29d48128-675b-4edb-8f6e-1cf6a5542964">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4ODQ2_1552b8c2-1bff-4317-aa6a-769c406bc3e5">14.0</ix:nonFraction>&#160;million of the 2021 Notes with $<ix:nonFraction unitRef="usd" contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4ODcy_b151c322-d95b-4447-8d06-e5bd718f1ff5">13.9</ix:nonFraction>&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MDQ2_cc10082e-2ea0-46dd-a1e4-18789090941d">26.7</ix:nonFraction>&#160;million were settled, at the option of the holders, by converting $<ix:nonFraction unitRef="usd" contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MTA3_0b7a162d-cc47-401c-aa2e-9439f58ad911">26.3</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $<ix:nonFraction unitRef="usd" contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MTkw_d5551fc2-03d5-46f3-87f0-62bf2b7a30bc">0.4</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $<ix:nonFraction unitRef="usd" contextRef="i32d97f3d7fab4028a29399bf3e18652f_I20211201" decimals="-5" name="evh:DebtConversionOriginalDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MzQ1_bb5da9e6-5add-4d84-839c-ded0e1ad7aac">28.5</ix:nonFraction>&#160;million resulting in a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5Mzk0_fde483a8-b9ae-4885-bca7-0105f9f69750">2.2</ix:nonFraction>&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of March&#160;31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzIwMzA2_cb13b0a0-ee5f-4782-bcc4-ab1b127a1d97" continuedAt="i7254f17b4d86457796007c19c99e7e44" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2022 and December 31, 2021 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i7254f17b4d86457796007c19c99e7e44"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if568378dc7914a2ca879a5b1dfdec339_I20220331" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzMtMS0xLTEtMzgwNDE_7245a982-1e61-46b8-9357-3a8c708dfffc">114,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b47e659a7674184bd5fb1e6489758c6_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzMtMy0xLTEtMzgwNDE_8852edd1-3e70-48cd-bec3-b0a0af12ea32">89,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if568378dc7914a2ca879a5b1dfdec339_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzQtMS0xLTEtMzgwNDE_4a1521eb-9040-442b-ba21-131f816b4c95">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b47e659a7674184bd5fb1e6489758c6_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzQtMy0xLTEtMzgwNDE_e0a874ca-f4a9-497f-8323-3bc003346b56">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if568378dc7914a2ca879a5b1dfdec339_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzUtMS0xLTEtMzgwNDE_de2ffc32-deb0-4e26-90b3-dbc8f2e60d83">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b47e659a7674184bd5fb1e6489758c6_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzUtMy0xLTEtMzgwNDE_db7ffd31-482a-44a2-8a3d-5baae76f6a81">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzYtMS0xLTEtMzgwNDE_78c9504c-7f50-419f-938b-41c22c3c2a86">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ba9893300544569828a837db24cb5ab_D20210101-20210331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzYtMy0xLTEtMzgwNDE_480b21ad-2386-4ddb-a095-8a99c5a7b83c">2.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i977484a58ef44f029d021443bc481e0d_I20220331" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzctMS0xLTEtMzgwNDE_b0653d7a-149c-4914-b162-eb01787ab4af">209,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce62f0c759b43c0a265b0f75bccf470_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzctMy0xLTEtMzgwNDE_6160ac57-de5f-475b-bae9-b60c4f5fe66d">195,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b528f69e84aa8bf0354a45f147957_I20220331" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEwLTEtMS0xLTM4MDQx_47c1b1e8-5d98-421a-aceb-d1d3cf2001ca">167,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e44058a9da4e57975c9afd2894c3fe_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEwLTMtMS0xLTM4MDQx_066fa7db-8cc5-4e4d-b75f-9f3a8b42ed31">126,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b528f69e84aa8bf0354a45f147957_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzExLTEtMS0xLTM4MDQx_1887ba42-8873-46fb-bd0f-f3f6aa022e75">4,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e44058a9da4e57975c9afd2894c3fe_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzExLTMtMS0xLTM4MDQx_d8592488-c77b-4cb7-b864-49e507315f91">46,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b528f69e84aa8bf0354a45f147957_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEyLTEtMS0xLTM4MDQx_bf768c43-694a-4cb4-8a4b-218c5ba7898d">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e44058a9da4e57975c9afd2894c3fe_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEyLTMtMS0xLTM4MDQx_3406eced-65c7-4f9a-970b-d9ff2319980b">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEzLTEtMS0xLTM4MDQx_d0d88a97-81aa-41b7-971d-741344efca97">3.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEzLTMtMS0xLTM4MDQx_2473ad2f-4e8b-4327-9273-e66dfb0f6f8a">3.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5b100104fe48a2989954cdb98067ee_I20220331" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzE0LTEtMS0xLTM4MDQx_be090238-3679-454a-99f6-7b92d1be44f6">203,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fe6c4a84a34602b32ea482070a2644_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzE0LTMtMS0xLTM4MDQx_9fb80921-29bf-466f-913b-232cfb479e77">177,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEyNDM0_0d68a6fe-d385-4ff4-bf3a-eb86fa22d6bf" continuedAt="i4bf42140582a47a6a216ce7bfea2cbc8" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4bf42140582a47a6a216ce7bfea2cbc8" continuedAt="id5a04c59ac5045f995ce27deac94ae07"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $<ix:nonFraction unitRef="usd" contextRef="ica8e454931494c86a0acbbb148cef7a4_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzE2NDkyNjc0NjU3OTY_1461000e-3810-4fb3-981a-375909d88fe7">13.7</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction unitRef="usd" contextRef="ie4ae4f2c278c4ce8bb30f6cf187609dc_I20211231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzE3Nw_7956c7a5-3638-4acc-b51b-f301d33dcf49">15.4</ix:nonFraction> million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $<ix:nonFraction unitRef="usd" contextRef="i1c587e607d8b406d82aa29c34afa0507_I20220331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzQ5NDc4MDIzNDkxNzk_b5402c1d-c265-4bd8-af97-8d83170fb993">13.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i32c3abf79b77492d8199a68542ed7752_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzMwNQ_735f211c-b2c5-4352-aaaf-2ea1b8da81de">15.4</ix:nonFraction> million, respectively, in restricted cash and restricted investments as collateral as of March&#160;31, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between June 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id5a04c59ac5045f995ce27deac94ae07" continuedAt="i38a4fe384e104fcd82578c1eb5d1fa3d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March&#160;31, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i38a4fe384e104fcd82578c1eb5d1fa3d" continuedAt="i360a9bbebb044c718cf20e333dd1b704"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEyNDQ2_462e3cfa-aec3-43d3-bf5d-fff480ea7988" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AssumedPremiumsWritten" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzItMS0xLTEtMzgwNDE_0566d688-aadd-4a62-8d65-3d38c1f662cd">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:AssumedPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzItMy0xLTEtMzgwNDE_25727b34-eeff-4251-bbe4-920a76ee18bf">8,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzQtMS0xLTEtMzgwNDE_453e8ae8-1c39-45b6-816e-33bf112c2f0b">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzQtMy0xLTEtMzgwNDE_08d77855-c5e2-486c-aee0-911f3f2b42f3">10,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzYtMS0xLTEtMzgwNDE_3057f990-0ae9-4037-92fc-f1b72a1e757d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzYtMy0xLTEtMzgwNDE_9732f88d-9ea7-4942-aac8-6825c46e8f48">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzctMS0xLTEtMzgwNDE_6e998c14-7513-4522-b521-143e22944e15">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzctMy0xLTEtMzgwNDE_8ceae88d-931a-40d6-8d0f-5e45786ed80a">2,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzgtMS0xLTEtMzgwNDE_e91b5c5e-f2b4-4a47-a87f-29118cec57bf">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzgtMy0xLTEtMzgwNDE_193af5e4-5143-4e0e-9023-cdd14376d126">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzktMS0xLTEtMzgwNDE_d080c36d-3aef-4d48-ab12-5597ece7360d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzktMy0xLTEtMzgwNDE_dfef1c77-0892-43a3-b253-3e0296b2861b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:ProceedsFromReinsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzEwLTEtMS0xLTM4MDQx_77d83b4b-35b9-4ccf-ab81-bc163ecb1068">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:ProceedsFromReinsurance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzEwLTMtMS0xLTM4MDQx_7c642c9f-c6fc-4ef4-b366-af68e0be6092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzExLTEtMS0xLTM4MDQx_a4793306-2cb8-45f8-b8fb-3771412d6c71">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzExLTMtMS0xLTM4MDQx_e6a4ad5f-ee4b-4328-89e7-efb5ad00b7d2">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="INF" name="evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzYwNDc_a1cc361d-b68e-40c2-9436-089223f84c0f">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed on December 2, 2021. The case alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, and was again stayed pending a decision on the Company&#8217;s third motion to dismiss. The Eastern District of Virginia granted in part and denied in part the motion to dismiss the third amended complaint on March 18, 2022. The case is again in discovery phase. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i360a9bbebb044c718cf20e333dd1b704" continuedAt="i1c3a4290e48f41a0a3f07f9c448bf481"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lincolnshire Police Pension Fund, derivatively on behalf o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. The case had been stayed until the decision on the Company&#8217;s motion to dismiss  the third amended was decided on March 18, 2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health., Frank Williams, Nicky McGrane, and Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal district court. Briefing on the motion to dismiss is ongoing and will be completed in July.  Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March&#160;31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEwMDYw_3990ab43-aed9-4640-9d84-bc37bd98ad38">99.6</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEwMDcw_fbe33cb8-33bf-40a0-9df4-37ff9de0cb59">262.8</ix:nonFraction> million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEwMjIx_d7e7eac9-1b6e-4b38-8409-1a99ad79a834">0.4</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEyNDM3_21fda8d2-2a38-412d-9903-fdca4ab921d6" continuedAt="i51496dafa92f4bb5ac12382b3bf165e1" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable as of March&#160;31, 2022 and December&#160;31, 2021:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i51496dafa92f4bb5ac12382b3bf165e1" continuedAt="i61c0c05cf8414e5b9bf8def0412cf6b8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i968714160637450486f094b7b1293b81_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzEtMS0xLTEtNDcxMjI_5220f3f3-beb5-423e-be0e-4c01d44457cd">35.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe91cbc7315a4336b5abff786c768b62_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzEtMy0xLTEtNDcxMjI_e25cc4c9-bc7c-4cbf-8ee3-e7ccd89e9e1f">46.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2b4eec3a0cb4f27aaa8e6f384025a1e_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzItMS0xLTEtMzgwNDE_abde8831-1721-45b9-abfa-5e1d3132314b">27.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id90c22c98c76421ea4011d8153a44a71_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzQtMy0xLTEtMzgwNDE_d1f19d74-4e9e-464c-a373-ee2e444d2bed">10.4</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i61c0c05cf8414e5b9bf8def0412cf6b8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5794d71d0de4903b413840b815950f5_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzItMS0xLTEtMzgwNDE_a9922c45-8dd8-436a-9ca0-853e75523884">23.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b879fd6a8b140139241cedad3dd8363_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzItMy0xLTEtMzgwNDE_e8c52487-e480-4e81-aa5d-f5ea78abacec">28.8</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd121453f7584e4795edacc5006758f9_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzQtMS0xLTEtMzgwNDE_0f4f2a2c-3bb7-4479-96ac-920d6232e81f">11.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c697c6c8a12472a8470f212680e6841_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzQtMy0xLTEtMzgwNDE_2dbbf4ac-592b-43e9-a745-d1a9422956e9">14.7</ix:nonFraction>%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $<ix:nonFraction unitRef="usd" contextRef="i6f6ec7aba15341f6b7511d0a09ecf92a_D20210101-20210331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzExMzc4_2fa1f3dd-bcfa-4f75-af13-29cfe1f9383a">44.8</ix:nonFraction>&#160;million of True Health premium revenue reclassified to discontinued operations for the three months ended March 31, 2021.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1c3a4290e48f41a0a3f07f9c448bf481">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyNTg_da9deca5-0b9b-4af4-a963-b20692c2fe0d" continuedAt="i6fa46e936d7f47198c4b761c25f3010d" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6fa46e936d7f47198c4b761c25f3010d" continuedAt="i90224c7ed3574eca8d4e99275e8290f4">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i90224c7ed3574eca8d4e99275e8290f4" continuedAt="i362072c603cf4eb1a541e4083502d12b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="i55a0e80d686d4db398764b4e17532471_I20220331" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzI2NjM_361d7829-4436-477e-ac12-46eb4bd30072">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1a6b90e9de04a9795ddcc6e1d3d2f9a_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyOTg1MzQ4ODY2MzA_f6d154ff-4e51-4a34-b0ec-b610ed722c5c">3.8</ix:nonFraction> million in letters of credit as of March&#160;31, 2022 and December&#160;31, 2021. As of March&#160;31, 2022 and December&#160;31, 2021, the Company held $<ix:nonFraction unitRef="usd" contextRef="i55a0e80d686d4db398764b4e17532471_I20220331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyOTg1MzQ4ODY2Mzk_af698761-c51d-475e-9535-6ebb0956a00b">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1a6b90e9de04a9795ddcc6e1d3d2f9a_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyOTg1MzQ4ODY2NDc_6f36dd28-af57-41c5-84a4-ac360629260d">3.8</ix:nonFraction> million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyNTk_df281ee9-d67e-4c66-a2ca-a31f99a1ade8" continuedAt="i265b71cc061a4302877ad2bad673321c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of March&#160;31, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a5f7ca552444d36af631fb4eeba482a_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzEtMi0xLTEtMzgwNDE_33292197-bacb-4599-b682-93d88e0b5fb0">9.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5f7ca552444d36af631fb4eeba482a_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzEtNC0xLTEtMzgwNDE_2ba78ae8-4858-411e-8ada-32361c76a4d5">34,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5f7ca552444d36af631fb4eeba482a_I20220331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzEtNi0xLTEtMzgwNDE_0048c33f-2924-4a69-b3c7-fe1f217bf532">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9859c6985307497fb25bf1057a6361e2_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzItMi0xLTEtMzgwNDE_db058b2e-35bf-4457-8608-87c2d9601262">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9859c6985307497fb25bf1057a6361e2_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzItNC0xLTEtMzgwNDE_58a24c2e-0e34-40c5-8444-f22b44228cf9">40,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9859c6985307497fb25bf1057a6361e2_I20220331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzItNi0xLTEtMzgwNDE_c9d19b8c-4440-49cd-bb84-83f028b0741f">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69967c2e35354819ade6c5984bf3b729_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzMtMi0xLTEtMzgwNDE_18f31c0e-ec38-4bdb-a0ec-ac4efcd1b17b">4.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69967c2e35354819ade6c5984bf3b729_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzMtNC0xLTEtMzgwNDE_a74b9fd9-6aad-46d2-9c0c-47738d084253">2,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69967c2e35354819ade6c5984bf3b729_I20220331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzMtNi0xLTEtMzgwNDE_eddc9c01-4fdb-4fae-b822-d07c010338c4">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzQtMi0xLTEtMzgwNDE_6bca6efd-e60a-4618-a694-498b3278090b">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzQtNC0xLTEtMzgwNDE_c5b9b2ba-45ab-4c5f-b210-348e1bf5c0bb">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzQtNi0xLTEtMzgwNDE_e1524c20-ac5e-4ab3-9bc2-8ebb7ee82764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib68c9b6601e041919a7d54d7305442ef_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzUtMi0xLTEtMzgwNDE_4a5c2801-9e21-4242-bbe7-1de7b10c93dd">0.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68c9b6601e041919a7d54d7305442ef_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzUtNC0xLTEtMzgwNDE_296bc07f-1668-491f-a40e-7f0e44af17a8">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68c9b6601e041919a7d54d7305442ef_I20220331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzUtNi0xLTEtMzgwNDE_da4051f9-1507-47d8-ae71-bfb64aa66b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyNjA_553f8aee-f02c-4151-97cf-65c64c0b9335" continuedAt="i22783fe535854f3cbafa1c42e4f8af50" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzItMS0xLTEtMzgwNDE_dd8697d8-a116-4427-b81c-fc011d575ceb">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzItMy0xLTEtMzgwNDE_4c3e42a2-2145-4af3-87b3-e82fe0ceeb75">4,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzUtMS0xLTEtMzgwNDE_8f1db6e9-ad7e-439f-a7e7-90a367f7f4cc">1,326</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzUtMy0xLTEtMzgwNDE_191ca1f8-4446-4841-a55d-afb465fcec50">1,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzYtMS0xLTEtMzgwNDE_460a3402-bfd7-411b-a506-b4cb42da1ca8">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzYtMy0xLTEtMzgwNDE_a3763369-69b8-46fb-a020-ebe7455b010d">6,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i265b71cc061a4302877ad2bad673321c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of March&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzEtMS0xLTEtMzgwNDE_f1a88dcd-c829-429d-876a-7a9e9961ed48">7,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzItMS0xLTEtMzgwNDE_2eb50af1-7960-43d6-9aea-9d2e890d53d8">9,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzMtMS0xLTEtMzgwNDE_a3da0e4b-0e80-41d0-a686-16a4338edfd4">8,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzQtMS0xLTEtMzgwNDE_5d80b19c-79d1-4b3d-9df1-99a9bb8c6986">8,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzUtMS0xLTEtMzgwNDE_c9544361-df92-4f3d-b5fa-ee7222d094e1">7,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzYtMS0xLTEtMzgwNDE_f4040368-b2b5-456a-8753-70165f1b2ef6">39,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzctMS0xLTEtMzgwNDE_98c8ebdb-6ef8-4390-8a64-be1bfa58ed37">82,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzktMS0xLTEtMzgwNDE_fc5e6bfa-d256-4a87-bcf4-4c2b255df672">19,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzEwLTEtMS0xLTM4MDQx_f99b7056-b37b-4a6f-89c2-63b07e0e8d7a">62,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i362072c603cf4eb1a541e4083502d12b"><ix:continuation id="i22783fe535854f3cbafa1c42e4f8af50"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpkNzNhMjE1NDUwMjY0MmNjOWI0MzdhNzA2NTRlMDIyYi90YWJsZXJhbmdlOmQ3M2EyMTU0NTAyNjQyY2M5YjQzN2E3MDY1NGUwMjJiXzItMS0xLTEtMzgwNDE_d202c939-a561-4777-9a64-ca26f2fae655">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpkNzNhMjE1NDUwMjY0MmNjOWI0MzdhNzA2NTRlMDIyYi90YWJsZXJhbmdlOmQ3M2EyMTU0NTAyNjQyY2M5YjQzN2E3MDY1NGUwMjJiXzMtMS0xLTEtMzgwNDE_8ab61e12-66ca-4b11-aeb2-74e10c95679d">8.6</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_157"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90ZXh0cmVnaW9uOjJjMDc4NzhkY2M0NTRmODc5Y2RkYmM3OThmNTkwMGFkXzM1MQ_78de40af-4ccf-4720-adfd-f1973361260e" continuedAt="i47fc5335eaf640e7ad8371b1a7a2d1a7" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i47fc5335eaf640e7ad8371b1a7a2d1a7"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90ZXh0cmVnaW9uOjJjMDc4NzhkY2M0NTRmODc5Y2RkYmM3OThmNTkwMGFkXzM1OA_f0ad463b-3e7d-4128-9ac0-d12d425619ad" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:414.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzItMS0xLTEtMzgwNDE_57f0dd20-8335-4301-96e4-84ddca884b17">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzItMy0xLTEtMzgwNDE_1d8a1e64-6a92-43e0-8702-d33d507cfc10">11,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzMtMS0xLTEtMzgwNDE_9a961152-7317-41c3-9951-60d1c12b2b55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzMtMy0xLTEtMzgwNDE_a7749027-c4c8-4ee8-9c7c-0b01e3bb01ce">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available for common shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMS0xLTEtMzgwNDE_9ba54fe5-83ce-448a-b6b3-c312f441dc20"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMS0xLTEtMzgwNDE_eeec7d83-a5c5-4e50-a788-71cb22150cde">5,350</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMy0xLTEtMzgwNDE_679c7ddc-6f4f-40c6-9a7b-aef415d27a7c"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMy0xLTEtMzgwNDE_f190c853-9848-453d-b694-895a8718d8c1">9,807</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMS0xLTEtMzgwNDE_2e9d5031-9f9a-4199-9215-64564d1aacb6"><ix:nonFraction unitRef="shares" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMS0xLTEtMzgwNDE_cf868fd8-1afd-49d0-acee-5a7af9ce7914">89,509</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMy0xLTEtMzgwNDE_7bc03da2-3c16-44b6-ad25-f05001fcd32a"><ix:nonFraction unitRef="shares" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMy0xLTEtMzgwNDE_99f00915-455f-468d-9856-d443da68441e">84,670</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTEtMS0xLTM4MDQx_cd7dbb8c-c230-40fa-9e1c-89ddb5150c93"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTEtMS0xLTM4MDQx_dce28e6f-1f46-4e94-8a30-e5f118457bd4">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTMtMS0xLTM4MDQx_0eb11ff2-f1f0-4803-a92f-2075603e4ebc"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTMtMS0xLTM4MDQx_8fd0c4e3-e001-4289-9347-78c01f2ca1dd">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTEtMS0xLTM4MDQx_ba5bd89c-7bb2-45e5-beae-badadc91229f"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTEtMS0xLTM4MDQx_e9701e52-caa5-4c31-bba0-b33b00faf07c">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTMtMS0xLTM4MDQx_25dad0cd-7e70-48be-8c0d-4160671153b1"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTMtMS0xLTM4MDQx_59aff931-3805-409f-822b-3f363a611ead">0.01</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTEtMS0xLTM4MDQx_4143aa38-cafb-40ef-9f5b-83249cc588a4"><ix:nonFraction unitRef="usdPerShare" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTEtMS0xLTM4MDQx_618b89bf-6770-462d-8d7c-741ac05aac7f">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTMtMS0xLTM4MDQx_23cbac1a-20cf-4cc2-8cb1-977e29fd27ed"><ix:nonFraction unitRef="usdPerShare" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTMtMS0xLTM4MDQx_e7474cd7-30ed-4081-bd0f-8c35ff985f9c">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90ZXh0cmVnaW9uOjJjMDc4NzhkY2M0NTRmODc5Y2RkYmM3OThmNTkwMGFkXzM1Mw_73736635-65ba-441d-8f08-c9f07634aa5c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:414.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice2ce205b8df40f5a8ca6fb448494da9_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzMtMS0xLTEtMzgwNDE_2be93ea5-1a80-494b-bf05-622be2944eed">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc1ac30734004ea497e9ad4ec8f715ed_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzMtMy0xLTEtMzgwNDE_78d38632-be22-4393-9a1d-bc0b690afaee">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia647416262ac4cbc82f836c92f6093f2_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzQtMS0xLTEtMzgwNDE_38be8822-fe98-4062-a735-92753af667f2">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief06047c33e34d79987ca3e17332e58e_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzQtMy0xLTEtMzgwNDE_30ea467b-2580-4199-bd03-7d37b5d4c141">1,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i842788784c414a1a91580bb3f7277e7a_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzUtMS0xLTEtMzgwNDE_a7d60452-2903-4718-aad6-30a26037aa92">11,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b639b680fbf43b6814f6de3ecae64d7_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzUtMy0xLTEtMzgwNDE_ecd4af67-84dc-4a72-9fd7-02fc10592192">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzYtMS0xLTEtMzgwNDE_dc57be5e-bf98-4143-960b-86aad278dde1">15,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzYtMy0xLTEtMzgwNDE_da8a29c5-893d-47c1-95af-dbeebc22cebd">16,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_265"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzMzMA_33135634-af36-479b-bff6-69eba8700f81" continuedAt="i107fba49838443498cdb54751a025828" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i107fba49838443498cdb54751a025828" continuedAt="i58e80ead63b74f92b391af6bfc39afa0"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzMzMQ_ee74bb28-2c1e-4c08-ac4a-f91ce0b9e00c" continuedAt="i5517ecbd8933469a8ae5b28054cc5f86" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:414.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a11d327f4c470ca2f791e8e1966028_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzMtNS0xLTEtMzgwNDE_66124c1d-c39a-4b8a-ae6c-1f1942682a15">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia747290a8b204259b52b29bf6aa78a40_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzMtNy0xLTEtMzgwNDE_2d6b3719-b96d-4d17-85a8-d78b3fe892f8">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627eecec9e24428f888feae02bf5a094_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzUtNS0xLTEtMzgwNDE_0ca446d4-86d2-4f66-8204-ebffae5a8dce">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696664e630804b529ae7bb6d3ca89106_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzUtNy0xLTEtMzgwNDE_8c1bf336-afdc-4248-8d47-57ae8a20b8f7">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebeb1fce40b34eeda2f1d368b211235e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzYtNS0xLTEtMzgwNDE_ffaaf996-81e5-4235-9351-c83c84b5ce45">775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf15ce52ede4d83af3ac051dc46f9b5_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzYtNy0xLTEtMzgwNDE_280f1363-ae2d-4a95-8ec7-6f73607e30ad">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdfd1a6d91342e6a148aa56505db40e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzctNS0xLTEtMzgwNDE_a900f5f6-4f4a-4c6f-a4ae-eaacc14f1e21">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81afc686ee45928654d3f1fd757c58_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzctNy0xLTEtMzgwNDE_e2a618c5-36ee-4762-a677-c237120b1436">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzgtNS0xLTEtMzgwNDE_b7a9b088-ce7a-4f71-a2dd-f86c459a50ef">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzgtNy0xLTEtMzgwNDE_3c89c9fc-5646-4b06-a27a-ab4c621ded38">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe9aab2682b4fc696fe56048ee7905a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzExLTUtMS0xLTM4MDQx_18505f20-c915-4048-a018-a2348a018578">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3909b5b33cda4a969569a089a54d7d90_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzExLTctMS0xLTM4MDQx_9218c4fc-9edd-45d4-83f4-e897f739e957">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i58e80ead63b74f92b391af6bfc39afa0"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i5517ecbd8933469a8ae5b28054cc5f86"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:414.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12dff91475cc4bc8b8681e67ab398b2e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEyLTUtMS0xLTM4MDQx_e5be4906-00fa-442e-aaea-25455eb4996d">4,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie053af2f0b7f43e79aa116dad9847e40_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEyLTctMS0xLTM4MDQx_9ae22f10-17ce-4473-b2fd-34790803b267">3,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEzLTUtMS0xLTM4MDQx_b7a9b088-ce7a-4f71-a2dd-f86c459a50ef">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEzLTctMS0xLTM4MDQx_3c89c9fc-5646-4b06-a27a-ab4c621ded38">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzE3OA_b597c4cd-5b54-4131-9b3e-22333effd89e"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzE3OA_f8aba802-987a-46c7-963e-e5866a673ef8">No</ix:nonFraction></ix:nonFraction> stock-based compensation was capitalized as software development costs for the three months ended March 31, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzMzMg_c0a3d829-a35f-4a75-a72b-0b026cd939f8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i627eecec9e24428f888feae02bf5a094_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzItNS0xLTEtMzgwNDE_23ab9db3-66ea-4c0a-9728-3dd16f2eb6d3">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696664e630804b529ae7bb6d3ca89106_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzItNy0xLTEtMzgwNDE_0efabf35-479a-47f9-9477-7eb2b838effd">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbdfd1a6d91342e6a148aa56505db40e_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzMtNS0xLTEtMzgwNDE_6656da2f-0b11-4753-a63c-c0263224598b">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a81afc686ee45928654d3f1fd757c58_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzMtNy0xLTEtMzgwNDE_f0a79745-b0f1-4d2c-9234-ae6a9d5b46c9">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzE2MzU_50c66c01-5a80-4905-8c52-834f10a65fa9" continuedAt="i33e9302598534bdebb6cf92925d75c7f" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i33e9302598534bdebb6cf92925d75c7f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzQ5NDc4MDIzMjY5OTU_b554041c-292e-4c01-89bd-e8fb85e5e695">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzIxNw_220c9098-306b-47f0-af27-27a0fe186179">0.6</ix:nonFraction>&#160;million was recognized for the three months ended March 31, 2022 and 2021, respectively, which resulted in effective tax rates of (<ix:nonFraction unitRef="number" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzIxOTkwMjMyNTc0ODk_cf67f111-cd08-4ac9-87dc-3e7d8116477d">29.0</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzIxOTkwMjMyNTc0ODU_859ce482-a8bd-4f8f-90ea-f8789fc01859">5.8</ix:nonFraction>)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three months ended March 31, 2022 primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzgxMg_e3faeacf-e6c3-4c61-8935-ff1c521089d5">0.6</ix:nonFraction> million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of March&#160;31, 2022, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="INF" name="evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzEzMzc_1631332e-f866-4160-a009-079e4218ddfb">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.</span></div></ix:continuation><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_175"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzMxNzA_8b75cf25-945c-4128-81d1-221f8e01e5f7" continuedAt="i495938376a7d46e28275d9b1efaa15ce" escape="true">Investments in Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i495938376a7d46e28275d9b1efaa15ce"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="id9e68408fd524ee7853f44d2c3055dac_I20220331" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEyNDY_b2413f6b-66ca-4b0c-b287-41a94378ae8e">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if0bf322642904e678f0fb49d1674e122_I20220331" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEyNTM_b343157e-19e8-4291-8766-57ec198973a7">38</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i80b281b7c3cb41b7b75ba0b670b05d6b_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxOTkwMjMyNTk4MzM_9604f321-e124-4081-a59b-792339a54d4a">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i571e3a3a8fdb4e7fad04e7c5bfc9a5c7_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxOTkwMjMyNTk4NDE_b18323c3-92fc-44eb-8a74-e4b2fcd24ef0">39</ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i80b281b7c3cb41b7b75ba0b670b05d6b_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNTU_6a85c017-f80b-4ab6-ac2d-8c3abece3f4d"><ix:nonFraction unitRef="number" contextRef="id9e68408fd524ee7853f44d2c3055dac_I20220331" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNTU_d746efa5-1120-4d76-8e7c-64bce43a4ff1">25</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if0bf322642904e678f0fb49d1674e122_I20220331" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNjI_2857913b-cd26-422e-a5e9-389f1aefe42a"><ix:nonFraction unitRef="number" contextRef="i571e3a3a8fdb4e7fad04e7c5bfc9a5c7_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNjI_66318e1a-a171-4e1f-9a7f-82711b2166c2">40</ix:nonFraction></ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzE4MTE_01b1769d-72da-4a63-859c-40c90175e0c0">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzE4MTU_f314f41d-26fc-4796-84f1-7357d9756bbb">7.8</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="i459c224721e4472987d0810fa06039dd_D20220101-20220331" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxMjQ_9d41a992-4b2f-4695-b2ae-73d2f3500cb3">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i179d7c9dfd6c48c396b1bae4ecd566f5_D20210101-20210331" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxMjg_245166b2-4cb4-41c7-bdc9-2002da5d3d68">6.3</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_181"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYwOTI_77e0cb39-05f0-43ec-abaf-2b7705996dad" continuedAt="id3667daca87844c694164594a3d31a59" escape="true"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYxMDM_244c910c-a3bc-484a-994c-26e66b745418" continuedAt="if48e0025dafc403a8ce5f2089feff150" escape="true">Fair Value Measurement</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if48e0025dafc403a8ce5f2089feff150" continuedAt="i304b3e5409154b5ebc311f76458a1de7"><ix:continuation id="id3667daca87844c694164594a3d31a59" continuedAt="ia9d6d6f168e04ba5878196bba0d2019c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYxMDU_210f1496-0ba9-4da9-b97f-68d222acfde5" continuedAt="i05a725759faf4c33800f4010c884e58f" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i05a725759faf4c33800f4010c884e58f" continuedAt="iefdb046a8ba5424bb0382ff0e226bc12"> </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iefdb046a8ba5424bb0382ff0e226bc12"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bdcd617addf439bb5ac7946fc074de1_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtMS0xLTEtMzgwNDE_965f44cd-a215-4f81-a5b5-7073e67a0017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6dfc2db43b94f5d8aae9b35c10ee05b_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtMy0xLTEtMzgwNDE_24abe4a2-b853-4894-bbeb-915cf78cc33b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5813816202a4e338fe7f589fd013674_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtNS0xLTEtMzgwNDE_c4bf2830-f074-49a8-b90f-4ebc0de5f741">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9026d99a25d84c75985b0866b64b1bf5_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtNy0xLTEtMzgwNDE_82a32403-720b-4b27-95ad-50a7d14cb38d">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bdcd617addf439bb5ac7946fc074de1_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtMS0xLTEtMzgwNDE_de9f00d5-1c20-4053-8585-bf85c90dac8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6dfc2db43b94f5d8aae9b35c10ee05b_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtMy0xLTEtMzgwNDE_f822effe-d60a-450a-a01e-ba939a8b6c8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5813816202a4e338fe7f589fd013674_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtNS0xLTEtMzgwNDE_40f64c76-9316-4c73-984a-1deec9a78bbe">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9026d99a25d84c75985b0866b64b1bf5_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtNy0xLTEtMzgwNDE_c3dd4584-c949-4f27-bc76-d387263b7f1b">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0a5a638b704e06a6d4cda5851b17f0_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctMS0xLTEtMzgwNDE_a9ac25cb-df4a-4344-85ff-0ff1a7977a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d670a13d5045c0a62849c225ec6a9c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctMy0xLTEtMzgwNDE_7e911bb5-b072-4028-b9b3-9dc3d1e17c22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0186fb7ca56e461b9781a47361dfd131_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctNS0xLTEtMzgwNDE_13a42278-14a2-4474-9b3c-c09863060584">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0612bc26c446988089e7cded45f213_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctNy0xLTEtMzgwNDE_54d9edf0-46f5-43c2-9ffb-77f3e1986090">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0a5a638b704e06a6d4cda5851b17f0_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtMS0xLTEtMzgwNDE_9ae276e0-290b-4afa-92c4-c95449182d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d670a13d5045c0a62849c225ec6a9c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtMy0xLTEtMzgwNDE_788bec61-8688-427b-b988-5d1ca80cce3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0186fb7ca56e461b9781a47361dfd131_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtNS0xLTEtMzgwNDE_c1d61995-183e-4f2c-be2e-f03bc1356425">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0612bc26c446988089e7cded45f213_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtNy0xLTEtMzgwNDE_6768395f-7c58-4e57-b8fb-1bf1848c51f2">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i304b3e5409154b5ebc311f76458a1de7"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYwODU_860d7f7f-7452-404f-baee-2a85371e99ea" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzItMS0xLTEtMzgwNDE_c21dc479-3318-47f8-b640-0f6334052f65">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzItMy0xLTEtMzgwNDE_906249db-fdf9-45d6-ae5c-bed848fb4066">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzQtMS0xLTEtMzgwNDE_c5e9acfe-389e-4c43-a20f-ade259e6865f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzQtMy0xLTEtMzgwNDE_c5239425-cf10-4576-8586-064ae9a8f28b">13,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzUtMS0xLTEtMzgwNDE_715e29ae-7237-4644-80f8-b33b0688c618">3,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzUtMy0xLTEtMzgwNDE_88a9495a-f6bb-47c4-a0b5-eb20913817dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzYtMS0xLTEtMzgwNDE_b2add986-918b-4943-9bea-72436551469a">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzYtMy0xLTEtMzgwNDE_b244e312-6272-4102-8b67-c0fac1d5cde0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYxMTQ_71c6b294-5a5c-4f87-a1f4-e5eba530ced1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5813816202a4e338fe7f589fd013674_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo0OTRjYjUzNDExODU0ZTlmYjZiNzIyYjMyMTBiMDYwYS90YWJsZXJhbmdlOjQ5NGNiNTM0MTE4NTRlOWZiNmI3MjJiMzIxMGIwNjBhXzMtMS0xLTEtNDQ4OTE_bab4f669-e73c-4869-ad33-c3e8770b3b13">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0100835413d340b082126f866d8b23d0_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo0OTRjYjUzNDExODU0ZTlmYjZiNzIyYjMyMTBiMDYwYS90YWJsZXJhbmdlOjQ5NGNiNTM0MTE4NTRlOWZiNmI3MjJiMzIxMGIwNjBhXzMtNy0xLTEtNDQ4OTc_02d51c43-a201-43e3-9a85-3d9e39672cfc">35,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaeb884e998ab4b6d877b8cc4a40ee355_I20220331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo0OTRjYjUzNDExODU0ZTlmYjZiNzIyYjMyMTBiMDYwYS90YWJsZXJhbmdlOjQ5NGNiNTM0MTE4NTRlOWZiNmI3MjJiMzIxMGIwNjBhXzQtNy0xLTEtNDQ4OTc_96b29450-869f-4459-84e9-d5971fd202ff">7.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0186fb7ca56e461b9781a47361dfd131_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTowNGJlMjM3NGY1NzM0MjY3YjZjNGJlZDM2MDZjN2YxOS90YWJsZXJhbmdlOjA0YmUyMzc0ZjU3MzQyNjdiNmM0YmVkMzYwNmM3ZjE5XzMtMS0xLTEtMzgwNDE_627514f1-0402-4d44-a2d1-465c127e2e0c">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41098b957dca4081a3d6580e8917b49c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTowNGJlMjM3NGY1NzM0MjY3YjZjNGJlZDM2MDZjN2YxOS90YWJsZXJhbmdlOjA0YmUyMzc0ZjU3MzQyNjdiNmM0YmVkMzYwNmM3ZjE5XzMtNy0xLTEtMzgwNDE_9cef639d-b98d-4bb8-882a-7c670d164208">30,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9dc670273a9f4d978fd0fa286c1d9c0c_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTowNGJlMjM3NGY1NzM0MjY3YjZjNGJlZDM2MDZjN2YxOS90YWJsZXJhbmdlOjA0YmUyMzc0ZjU3MzQyNjdiNmM0YmVkMzYwNmM3ZjE5XzQtNy0xLTEtMzgwNDE_1e1ce715-00d7-44c1-8daa-970233401f6b">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia9d6d6f168e04ba5878196bba0d2019c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90ZXh0cmVnaW9uOjYwODljMDQ1NTU3NzQ4OTA5NjNmNjU2MmRjZTVhMWNhXzEzMTM_54973900-6ed2-4f56-877e-e30c24be09ea" continuedAt="i2922b0c74b2d494ea91ce5d94b7ce5ec" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2922b0c74b2d494ea91ce5d94b7ce5ec" continuedAt="ib15984dd26f940998452c64726a7eed4"> </ix:continuation></span></div><ix:continuation id="ib15984dd26f940998452c64726a7eed4" continuedAt="ie6dd83e760624efe9ef2b7e2d7691023"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie6dd83e760624efe9ef2b7e2d7691023"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90ZXh0cmVnaW9uOjYwODljMDQ1NTU3NzQ4OTA5NjNmNjU2MmRjZTVhMWNhXzEzMTc_a884ee3d-fc66-493a-83da-99a2a4c356cf" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzMtMS0xLTEtMzgwNDE_8ac9548f-5c56-4808-a6fe-bbf9c9685383">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzMtMy0xLTEtMzgwNDE_664ee373-909d-463a-b70b-8976c6672df4">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzQtMS0xLTEtMzgwNDE_f9fc4bfd-7206-4046-b465-bd49bd9287eb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzQtMy0xLTEtMzgwNDE_8f7c17bc-141c-4582-a2f3-3520474d0feb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzUtMS0xLTEtMzgwNDE_41bd3d42-567d-482c-bf22-56cd08671bd4">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzUtMy0xLTEtMzgwNDE_828d0002-3427-46bb-bc6c-417404db6670">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzgtMS0xLTEtMzgwNDE_ccc93c5a-8725-4320-8dde-e6f9335c8539">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzgtMy0xLTEtMzgwNDE_e5af2d6f-3345-49b0-bf5e-41759a6d65b4">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzktMS0xLTEtMzgwNDE_4a8cb18a-eec1-42db-ad27-3fe02e6fbdc2">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzktMy0xLTEtMzgwNDE_78c16d3b-a7c6-442f-b624-a79f03435078">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzEwLTEtMS0xLTM4MDQx_d57a3ba6-2c9c-4c4b-9470-3c02c1692d4b">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzEwLTMtMS0xLTM4MDQx_65275d89-40ef-4f61-8d07-d397d91cc8b7">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:427.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84334888c1ce4f9596774398cccb24d4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzQtMS0xLTEtMzgwNDE_023afedb-748b-48fd-a3e3-59c5045fc00a">32,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c70b95cce0942dc8555c7160e7baec8_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzQtMy0xLTEtMzgwNDE_5607e38c-d5a1-4cab-a805-8cdb7aa02cb6">15,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932695caa0e3475e8d26b62529c3f9e0_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzctMS0xLTEtMzgwNDE_bd28f3f3-e51b-4feb-9afb-d253691c1fc1">26,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2176e74b934dfbab0732b31233603a_D20210101-20210331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzctMy0xLTEtMzgwNDE_7f83af3d-60e8-4132-b4b0-f73e2fa78bf6">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b60b44365747aa9dddac9017e65fb6_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzgtMS0xLTEtMzgwNDE_8213c725-315c-466f-8580-f67f330859c3">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bbb5ca4f6640a98bc3bee2e63b3dd2_D20210101-20210331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzgtMy0xLTEtMzgwNDE_24330461-6476-40fe-a80c-96b3899b7bf9">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90ZXh0cmVnaW9uOjBiOThhNjMzYmNlNjRjNjk4MTYyMjdhYzQ3YTMzNGUyXzE1MTI_512eeb79-4a41-4fb4-9272-c399b2af3f4e" continuedAt="i3f830fa887094594bfc992575878c2bf" escape="true">Repositioning and Other Changes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3f830fa887094594bfc992575878c2bf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90ZXh0cmVnaW9uOjBiOThhNjMzYmNlNjRjNjk4MTYyMjdhYzQ3YTMzNGUyXzE1MTM_ec83b11d-919f-4281-a8c2-c672b9a6090d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785637c478644f3baa2265dd139ec9f4_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzEtMS0xLTEtNDg4MjU_72242e77-f227-4346-938a-f2b301bc67d5">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362167a0c9b34805a0af2b448541b5bb_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzItMy0xLTEtMzgwNDE_b81382f5-1719-43f1-a99e-1558a7f1af35">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7f05d669f4496886a6a7a00d768285_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzItMS0xLTEtNDg4MjU_7e8ac20a-63fd-4620-b928-3780692e029e">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d445fb027342059acb0abc5062875b_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzMtMy0xLTEtMzgwNDE_11a51662-223b-49a3-95c7-8946f1a85f21">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24fa32341354c11976ef219f1db4536_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzMtMS0xLTEtNDg4MjU_353f3370-88e1-40a9-8b45-9671a1cbbdd3">5,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6a736386954271be092327c488a4c4_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzQtMy0xLTEtMzgwNDE_8bb1486c-2595-4e5e-994c-378ffc69b18a">3,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzQtMS0xLTEtNDg4MjU_e027be72-ec72-4070-8f76-cbf28b526765">8,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzUtMy0xLTEtMzgwNDE_bb2d6799-c137-41f0-b614-b1a7d4886fcd">5,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_190"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzM0Mzg_6eaa2606-05c1-46c7-85dd-02ded4a82a34" continuedAt="ie6117c7c370e4dc9a0aa0c958d8579e0" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie6117c7c370e4dc9a0aa0c958d8579e0" continuedAt="i43971548ad574936abb79e7309afed45"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into <ix:nonFraction unitRef="segment" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzI5Ng_d4102f92-f85a-4b42-8e65-d2714a079e9b">two</ix:nonFraction> reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzM0NDA_e1bfa57a-4d1e-499c-bb16-f62744735768" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd6828c06c24f6caac1d47d36f0f87f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtMS0xLTEtMzgwNDE_c5443c34-5bc4-4fd5-b319-12865f051acc">107,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c783f7550a946bbaf1d21f6f1d5c181_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtMy0xLTEtMzgwNDE_3310c92b-9034-4854-9afc-0e7fa21043a4">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79be648cb3694442bbf24990de4e33be_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtNS0xLTEtMzgwNDE_9984645e-9edd-4961-8619-ebf82ca367ae">460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1860fdb5d9754126b8f298b7c351df82_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtNy0xLTEtMzgwNDE_8ffa371b-5636-44a8-9bdb-2c52d9d60d38">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie409a91d5d8847ecb8729ff061b06528_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtOS0xLTEtMzgwNDE_9c61af7b-32b1-4a90-b7c9-381e6a552e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtMTEtMS0xLTM4MDQx_0000d229-98d3-4ad7-8f91-bb4eb64f33c4">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a20d756ebe344c49afc88a4c8988a92_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTEtMS0xLTM4MDQx_2fce27db-ec56-4620-ac56-da526829531d">85,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532454a81aa1485d94751de5cd927545_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTMtMS0xLTM4MDQx_231964bf-38f5-4c17-8600-2b21d2750657">130,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a704469f121488395cdba78ef29222f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTUtMS0xLTM4MDQx_7ad7a558-e9f2-41f9-a908-73f62fdfb5a7">438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61686756cdc94fe487cf6ab99ac88a18_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTctMS0xLTM4MDQx_13ef98b4-51e5-4147-ab9c-94a7ceafba8d">215,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dca42daa64b4aff97d52b7b8e251ed1_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTktMS0xLTM4MDQx_9c1d0ad8-89e7-42af-8072-b036b7c12404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTExLTEtMS0zODA0MQ_267bd634-607d-421b-be40-b5c58c7f1378">215,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd6828c06c24f6caac1d47d36f0f87f_D20220101-20220331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTEtMS0xLTM4MDQx_f90e7489-568b-4ce1-bcf0-bb87a5dd35c8">8,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c783f7550a946bbaf1d21f6f1d5c181_D20220101-20220331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTMtMS0xLTM4MDQx_53b8e890-bf89-47d1-a7ff-4ee8db5f7a7e">22,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1860fdb5d9754126b8f298b7c351df82_D20220101-20220331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTUtMS0xLTM4MDQx_d9e99a7b-4a58-43a8-8a6c-7c720bbed15a">30,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie409a91d5d8847ecb8729ff061b06528_D20220101-20220331" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTctMS0xLTM4MDQx_06f02fd2-0ff2-404c-a691-50992069226e">6,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTktMS0xLTM4MDQx_5737139e-709a-45e1-bfe3-d5581765e351">24,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a20d756ebe344c49afc88a4c8988a92_D20210101-20210331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTEtMS0xLTM4MDQx_384c1214-08f9-4052-9b21-a8e8e3365e47">5,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532454a81aa1485d94751de5cd927545_D20210101-20210331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTMtMS0xLTM4MDQx_d3916846-ee9d-432a-9113-5851b9a98e4b">15,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61686756cdc94fe487cf6ab99ac88a18_D20210101-20210331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTUtMS0xLTM4MDQx_5c907675-004d-43ec-8bcc-9986d7ed2978">21,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dca42daa64b4aff97d52b7b8e251ed1_D20210101-20210331" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTctMS0xLTM4MDQx_38f1e6a9-5610-426d-89dd-d3dcb536e7e6">7,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTktMS0xLTM4MDQx_d7bc7836-cd06-4a72-9e76-8a04f72ee5cb">14,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i43971548ad574936abb79e7309afed45"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzM0NDI_afbe4a8e-f2db-4d1b-9bac-3b8cc42c702f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzItMS0xLTEtMzgwNDE_bc4e44ba-1b60-4292-9160-554bd8346fdb">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzItMy0xLTEtMzgwNDE_e1c8e105-343a-4a66-bc22-c8b07072928e">9,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzQtMS0xLTEtMzgwNDE_e922cac3-67b4-45bc-9eba-8abed983a24f">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzQtMy0xLTEtMzgwNDE_bd120e3c-5278-4f3e-931a-dc0c9a71501b">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzUtMS0xLTEtMzgwNDE_1661b0d8-678f-4585-b1ed-a5441f2c43c3">2,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzUtMy0xLTEtMzgwNDE_1a43bbd8-fabf-49ad-9c96-07fd5a5b9ef1">6,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzYtMS0xLTEtMzgwNDE_d79a5e0f-2368-4b0c-9c0b-c9d1fe7746e6">1,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzYtMy0xLTEtMzgwNDE_95859495-29f1-4c24-8118-a30ae70578a2">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzctMS0xLTEtMzgwNDE_3deee8a6-ba6b-4b93-b73d-27b511064e0a">15,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzctMy0xLTEtMzgwNDE_54586aec-394a-4b3e-879e-c00dd952744d">15,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzktMS0xLTEtMzgwNDE_59dce7d8-3de6-48b7-9eee-f7abcc25727a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzktMy0xLTEtMzgwNDE_79fd5414-5bbc-4817-a138-97ab5bcbf28f">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEwLTEtMS0xLTM4MDQx_43f12d82-bcab-4f06-9478-418720bd50a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEwLTMtMS0xLTM4MDQx_19ae8b78-bdf6-43e7-9020-cf146a649e19">19,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEzLTEtMS0xLTM4MDQx_46e0ab21-34b1-47b2-b637-f965077a3fef">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEzLTMtMS0xLTM4MDQx_251c7e4f-e044-4fdd-8861-0a5a0e641580">7,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE1LTEtMS0xLTM4MDQx_676be44a-a679-4e97-b0e7-6249dc649dcd">6,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE1LTMtMS0xLTM4MDQx_9de83ae0-e76d-4cba-8010-99c1eb774ee8">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE3LTEtMS0xLTM4MDQx_818d89a8-d2cc-4278-a7a2-2866dc2d990a">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE3LTMtMS0xLTM4MDQx_d8a51639-b63e-4a13-ac52-d8b9ba1644f3">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE5LTEtMS0xLTM4MDQx_1ed5d0c0-3e54-4076-98b4-dc3abbe1ee84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE5LTMtMS0xLTM4MDQx_2cb8f6d6-7850-4ea2-9eb7-72aadc64ff39">5,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIwLTEtMS0xLTM4MDQx_c6539c79-c65f-4f19-ac54-a14aec7caee9">5,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIwLTMtMS0xLTM4MDQx_74da227b-02d6-4ce0-8a40-dfb84e9bce92">3,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIxLTEtMS0xLTM4MDQx_2a43d66f-e1f8-4ac6-bdda-d35cff0dfb1c">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIxLTMtMS0xLTM4MDQx_0aef6bbe-4adb-4f99-818f-e591227be05c">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIyLTEtMS0xLTM4MDQx_0be038f0-bd97-4e15-96e0-a61263edff20">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIyLTMtMS0xLTM4MDQx_b4e0beb9-2cd2-485e-8df0-19dbd26cfe28">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIzLTEtMS0xLTM4MDQx_6551c2cd-e682-4169-8587-b6e8e8f35fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIzLTMtMS0xLTM4MDQx_5cf5dee1-2022-451f-9a29-366fdcda981f">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:TransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI0LTEtMS0xLTM4MDQx_219694df-ab44-4301-b604-94b7a79e0b65">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI0LTMtMS0xLTM4MDQx_6fb024fe-5508-471b-b346-fb41e40996e4">1,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI1LTEtMS0xLTM4MDQx_2d5e4735-cd60-4f58-9648-6364ebe594d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI1LTMtMS0xLTM4MDQx_4d2b4a53-a0da-4287-9f26-6b281d2549ba">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI2LTEtMS0xLTM4MDQx_ff048afc-28a6-4358-87d0-b87653c154b4">24,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI2LTMtMS0xLTM4MDQx_ddbab18b-fc2f-4a0b-8e48-c28169fa26be">14,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzMyMDU_cdf04ab3-2ef2-4d3d-8dd6-d6e99cea8778">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_193"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21. <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90ZXh0cmVnaW9uOmQ5NmY5N2Y4OGFhMjRmMTVhNzQ4ZGM4ZTAwZjlkMzhmXzQ3NzM_84c5b98d-e9af-4ae5-b28e-2f942a1c5a1a" continuedAt="ic2269e6f736e4bc086972aec3e98c246" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic2269e6f736e4bc086972aec3e98c246" continuedAt="i27ec3b0beeef4f09b88dd9df2f15fb17"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i27ec3b0beeef4f09b88dd9df2f15fb17"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90ZXh0cmVnaW9uOmQ5NmY5N2Y4OGFhMjRmMTVhNzQ4ZGM4ZTAwZjlkMzhmXzQ3NzU_bdaf24e4-4fb0-45bf-839a-61788ea90451" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58d4563528a74ddc8daf7cfcc8df4f4b_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtMS0xLTEtMzgwNDE_9671389b-44d0-4c26-be38-d65a31ac50ec">25,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd83794d6dc499596834a18cd5a2a9c_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtMy0xLTEtMzgwNDE_6d4e4000-a13a-4d37-b183-e7cc12c54f88">145,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtNS0xLTEtMzgwNDE_bb84aed9-192e-4bf9-a965-ea40a7cb938c">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431455fda9da407ea1273e3d11bbbb34_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtNy0xLTEtMzgwNDE_0db31cba-d5ce-4b8c-8af6-f8997094c8b8">122,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c9d5a6a37649e3b44edf8049cce4da_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtOS0xLTEtMzgwNDE_23301783-8f1d-446f-8708-ab27ee2664a3">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtMTEtMS0xLTM4MDQx_42eaf065-b918-46be-b261-e2a4c2efea05">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtMS0xLTEtMzgwNDE_4c96b5da-f2e9-4cac-93fd-9445aba7762e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtMy0xLTEtMzgwNDE_a6216665-967b-41fc-9038-97adc4221eb5">102,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtNS0xLTEtMzgwNDE_fac81aa4-1abd-4ec3-9e9c-0e4abc9a9566">102,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtNy0xLTEtMzgwNDE_25fc126c-acf5-4ae7-9bf3-198b4c98b204">104,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtOS0xLTEtMzgwNDE_b4deafea-76e1-469b-8244-7ec507785591">4,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtMTEtMS0xLTM4MDQx_6a4cb935-5b27-428d-b8e0-0fb8666c56e8">108,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtMS0xLTEtMzgwNDE_f8274f0b-1adb-46a9-9e97-b46adc06d67a">8,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtMy0xLTEtMzgwNDE_51177393-66ac-4575-8454-63d043884088">14,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtNS0xLTEtMzgwNDE_381c5428-60ca-437b-ad7c-0471da50d915">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtNy0xLTEtMzgwNDE_079c141d-25e9-49cf-87ba-b52b535ccfbc">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtOS0xLTEtMzgwNDE_fad30ade-4956-464a-bbd9-278e30d66292">4,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtMTEtMS0xLTM4MDQx_5c2b2466-ee8e-4ade-ac36-856291675f13">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctMS0xLTEtMzgwNDE_e26209b7-001d-4b1d-88f9-1049c1a312d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctMy0xLTEtMzgwNDE_bbc2fd73-19a4-42b2-90cf-bcd12f0afd38">47,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctNS0xLTEtMzgwNDE_18427b95-709a-4a24-a959-3bc15ac09632">47,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctNy0xLTEtMzgwNDE_40e49ece-2e3d-4271-b3c6-05add52f66f3">30,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctOS0xLTEtMzgwNDE_1ad4fb43-2a14-4275-9975-4f14eae264e3">11,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctMTEtMS0xLTM4MDQx_76b4a2c6-7731-442a-9608-c800f24b258e">41,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtMS0xLTEtMzgwNDE_2acb5b86-80db-455f-9615-8636db5c0c94">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtMy0xLTEtMzgwNDE_2bbb1d01-c3e0-4402-b9f9-21bf32ce759b">59,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtNS0xLTEtMzgwNDE_391af99a-49e5-4411-9d6c-ae6ac28e7406">59,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtNy0xLTEtMzgwNDE_62e3cc6c-4001-4810-8bf5-178cb76acbee">38,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtOS0xLTEtMzgwNDE_4d0d78fc-e801-4853-af55-788008e490bb">10,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtMTEtMS0xLTM4MDQx_2747e613-9294-4a1f-82dd-edba4915af07">48,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktMS0xLTEtMzgwNDE_b8c304a4-1e99-4174-9db3-39ac92aea55a">7,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktMy0xLTEtMzgwNDE_71e79ba3-e926-4a4a-9720-c48740a940c4">9,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktNS0xLTEtMzgwNDE_f2c3079d-ba03-46d1-8cbd-c680927c0c5a">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktNy0xLTEtMzgwNDE_a6573786-7ea8-4bf4-8010-fd785d610586">35,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktOS0xLTEtMzgwNDE_913caca7-3459-4c92-8c95-34c81a868601">13,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktMTEtMS0xLTM4MDQx_47b9d962-c7a2-4405-be84-df3bfbe5b93c">22,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTEtMS0xLTM4MDQx_5023f5a5-8259-4363-bbd8-c7de0441e4dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTMtMS0xLTM4MDQx_29bb0e1f-13f2-49e1-8de0-ca00421e437d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTUtMS0xLTM4MDQx_ba3dcd94-dc12-4718-a47e-a7a93f43f8bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTctMS0xLTM4MDQx_eda4ec7f-bf49-4a81-95bd-44fb9d543c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTktMS0xLTM4MDQx_3bddb666-69fb-43d3-80fc-8035dbcd7110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTExLTEtMS0zODA0MQ_41bea09b-a54b-4f1f-a75e-2a4e01156be6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTEtMS0xLTM4MDQx_edbf612f-e661-41a0-b18e-45af6da653c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTMtMS0xLTM4MDQx_6773646f-3a08-4c05-942a-61eda586ef22">9,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTUtMS0xLTM4MDQx_da2246ca-dd8b-401e-914c-8f19b0532d0a">9,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946bb3ded8914db29f26e0bac8b58b89_I20210331" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTctMS0xLTM4MDQx_0f0a4364-ff7f-42ba-848b-9774354a322b">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTktMS0xLTM4MDQx_da1a4699-c8e8-4920-adb0-f04764708acb">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTExLTEtMS0zODA0MQ_33bb739d-3f4c-4a49-8724-1e2375d19369">6,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTEtMS0xLTM4MDQx_c9616fc3-a9f7-42da-95c3-b9de2f9a3921">17,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTMtMS0xLTM4MDQx_fda207d5-0961-4c67-b7f6-dccd97d950b6">146,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTUtMS0xLTM4MDQx_a54c8367-2c55-434e-890e-fbcd7b4baf7b">164,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946bb3ded8914db29f26e0bac8b58b89_I20210331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTctMS0xLTM4MDQx_c0a866d3-d512-46af-97ab-91eb4699aed8">160,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTktMS0xLTM4MDQx_18ec019e-bbb6-476b-a752-8a64623d8739">47,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTExLTEtMS0zODA0MQ_3f774038-0d96-4f0b-a5c5-97ad5e9f0a57">207,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_202"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22.  <ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90ZXh0cmVnaW9uOmEyZjJmNjhhNWY5YjQzNmZhN2U4ZDQ4NmI2YzMzMWZkXzEzOA_b862bc76-cc21-4e9b-99cb-23b215af9e8a" continuedAt="i33c28575c7254a5da55ea4c95702ff61" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i33c28575c7254a5da55ea4c95702ff61"><ix:nonNumeric contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90ZXh0cmVnaW9uOmEyZjJmNjhhNWY5YjQzNmZhN2U4ZDQ4NmI2YzMzMWZkXzEzNA_62fe730e-b854-49fa-92f5-2e6c30bfa919" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzgtMS0xLTEtMzgwNDE_9017f36f-e013-4bb4-9d2c-94cf7c1984dd">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzgtMy0xLTEtMzgwNDE_92673e09-c908-4c98-8877-e9dd3419f476">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzExLTEtMS0xLTM4MDQx_8887a09d-dbb9-4c7c-9df4-d2444d153a9a">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzExLTMtMS0xLTM4MDQx_bcb2dd2f-88b1-4e91-8b31-76c25de15f14">3,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzEyLTEtMS0xLTM4MDQx_144e1301-efab-49c4-962a-0cb9810037ad">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzEyLTMtMS0xLTM4MDQx_f1a2561e-6205-45b2-a854-e05754a577e2">2,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements presented in &#8220;Part I &#8211; Item 1. Financial Statements&#8221; of this Form 10-Q; our 2021 Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; and our current reports on Form 8-K filed in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_70"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models.  We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in value-based care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our operations and allocate resources across two reportable segments: Evolent Health Services and Clinical Solutions. The Company&#8217;s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses since our inception, in part because we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health&#8217;s Response to COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the services we provide and market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition or results of operations or our outlook. As of March&#160;31, 2022, we had cash and cash equivalents of $210.2 million and as of the date the financial statements were available to be issued, we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has also affected global access to capital and caused significant volatility in financial markets. In addition, we have and are experiencing varying levels of inflation resulting in part from higher labor costs. Significant deterioration of the U.S. and global economies or rapid increases in inflation could have a significant adverse impact on our future liquidity needs. Although the impact of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants such as Omicron and the effectiveness of vaccines. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent&#8217;s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish uninterrupted high-quality service to our partners. Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel, Chief Compliance Officer and Chief Talent Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities.  Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors and we will continue to work with them regarding our collective obligations to Evolent&#8217;s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent has instituted a voluntary return to the office. Fully vaccinated employees and those who have provided an approved religious or medical exemption are permitted to return to the Company&#8217;s offices in-person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends. In evaluating our health plan partners, we focused on possible changes in membership and medical utilization trends.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two most significant service offerings in terms of revenue are specialty care management and administrative simplification services.&#160;Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic.  </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million of True Health premium revenue reclassified to discontinued operations for the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Vital Decisions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, and the Company entered into a definitive agreement for the Company to acquire Vital Decisions. On October 1, 2021, we consummated the acquisition of Vital Decisions for $46.5 million in cash and the issuance of 1.8 million shares of Class A common stock. Vital Decisions reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. The transaction closed on October 1, 2021. Refer to Note 4 for additional discussion regarding the Vital Decisions transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Conversion and Repayment of 2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss). Refer to Note 10 for additional discussion regarding conversion and repayment of our 2021 Notes.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of True Health New Mexico</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 11, 2021, Evolent LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into the SPA with Bright HealthCare, pursuant to which EH Holdings agreed to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of $22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the one-year anniversary of the True Health Closing based in part on actual medical claims experience. The True Health Closing occurred on March 31, 2021 and the Company has had no continuing involvement with True Health subsequent to the Closing except a pre-existing services agreement for claims processing and other health plan administrative functions. As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health results of operations for the three months ended March 31, 2021 are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.  Refer to Note 5 for additional discussion regarding the True Health sale. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repositioning Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including the assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A included in our 2021 Form 10-K contains a detailed discussion of our critical accounting policies and estimates. There have been no material changes to our critical accounting policies and estimates since our 2021 Form 10-K. See &#8220;Item 1. Financial Statements - Note 2&#8221; in this Form 10-Q for a summary of our significant accounting policies and see &#8220;Item 1. Financial Statements - Note 3&#8221; in this Form 10-Q for information regarding the Company&#8217;s adoption of new accounting standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price plus the fair value of any non-controlling interests in the acquiree over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit&#8217;s fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit&#8217;s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest fair value of our single reporting unit was below the carrying value. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the three months ended March 31, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We will perform our annual impairment test of October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard on January 1, 2022 however, it did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method as of January 1, 2022, with adjustments which reduced additional paid-in capital by $106.2&#160;million and increased retained earnings by $39.8&#160;million and increased the net carrying amount of the 2024 Notes and 2025 Notes by $25.1&#160;million and $41.3&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_82"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from transformation services and platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.  Subsequent to the consolidation of EVH Passport on September 1, 2020, our cost of revenue includes the consolidated impact of the run out of EVH Passport&#8217;s operations, consisting principally of updates to EVH Passport&#8217;s claims reserve based on actual claims payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lives on Platform and PMPM Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services Lives on Platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions Lives on Platform are calculated by summing the Clinical Solutions Lives on Platform in our Performance suite and New Century Health Technology and Services suite Lives on Platform. Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services average per member per month (&#8220;PMPM&#8221;) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services segment membership during the period reported divided by the number of months in the period. Clinical Solutions Performance suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance suite membership during the period reported divided by the number of months in the period. New Century Health Technology and Services suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services suite during the period reported divided by the average of the beginning and ending New Century Heath Technology and Services Suite membership during the period reported divided by the number of months in the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses lives on platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:333.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.1%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123.2%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299,855&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Three Months Ended March 31, 2022 to 2021 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $82.0 million, or 38.1%, to $297.1 million for the three months ended March 31, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with  existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,858&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment increased by $22.0 million for the three months ended March 31, 2022, as compared to 2021 due to expansion of services with existing customers. Revenue from our Clinical Solutions segment increased by $60.0 million for the three months ended March 31, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s lives on platform as of March&#160;31, 2022 and 2021 and PMPM fees for the three months ended March 31, 2022 and 2021 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We had 41 and 39 operating partners as of March&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the three months ended March 31, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.361%"><tr><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $61.9 million, or 39.2%, to $219.7 million for the three months ended March 31, 2022, as compared to 2021. Cost of revenue increased by approximately $38.6 million due to higher claims activity in our Clinical Solutions segment, $8.3 million due to higher personnel costs due to increased headcount and expected benefits accruals to employees, $9.9 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers and $9.6 million for the acceleration of amortization of contract costs for certain customers. Approximately $0.8 million and $0.6 million of total personnel costs was attributable to stock-based compensation expense for the three months ended March 31, 2022 and 2021, respectively. Cost of revenue represented 74.0% and 73.4% of total revenue for the three months ended March 31, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the three months ended March 31, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $0.3 million, or 0.6%, to $58.9 million for the three months ended March 31, 2022, as compared to 2021. The increase is driven primarily by higher personnel fees due to increased headcount and expected benefits accruals to employees of $8.3 million and higher stock compensation of $1.4 million offset, in part by lower professional fees from the Repositioning Plan and shareholder advisory services of $7.4 million and the termination of certain leases of $2.5 million. Approximately $4.5 million and $3.1 million of total personnel costs were attributable to stock-based compensation expense for the three months ended March 31, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $0.5&#160;million and $2.0&#160;million of total selling, general and administrative expenses for the three months ended March 31, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.8% and 27.2% of total revenue for the three months ended March 31, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses decreased $0.1 million, or 0.5%, to $15.1 million for the three months ended March 31, 2022, as compared to 2021. The decrease was due primarily to lower amortization on customer relationships of $0.6 million. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a gain (loss) on change in fair value of contingent consideration of&#160;$6.1 million&#160;and&#160;$(0.6) million for the three months ended March 31, 2022 and 2021, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering into the warrant agreements compared to the liabilities acquired as a result of the acquisition of Vital Decisions in October 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest from investing cash in money market funds and interest from both our short-term and long-term investments. We recorded interest income of $0.1 million for both the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes, 2025 Notes and Credit Agreement with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $2.2 million and $6.3 million for the three months ended March 31, 2022 and 2021, respectively. The decrease in interest expense during the three months ended March 31, 2022 compared to 2021 is driven primarily by the adoption of ASU 2020-06 combined with the termination of the Ares Credit Agreement in January 2021. See &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; in this Form 10-Q for the information related to interest expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Equity Method Investees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated its proportional share of the investees&#8217; earnings and losses each reporting period. The Company&#8217;s proportional share of the gains from its equity method investments was approximately $0.6 million and $7.8 million for the three months ended March 31, 2022 and 2021 , respectively. The change in gain from equity method investees for the three months ended March 31, 2022 compared to 2021 is driven primarily by the sale of our Florida equity investee&#8217;s membership during the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Transfer of Membership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, EVH Passport received a cash payment from Molina in the amount of $23.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive based on the number of such enrollees. The remaining 50% was received in the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Repayment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $1.2 million and $0.6 million in income tax expense for the three months ended March 31, 2022 and 2021, respectively, which resulted in effective tax rates of (29.0)% and (5.8)% respectively. The difference between our effective tax rate and our statutory rate is due primarily to the fact that the Company maintains a full valuation allowance recorded against its net deferred tax assets, with the exception of certain indefinite-lived components.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss from Discontinued Operations, Net of Tax</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2021, the Company determined that True Health met the held for sale criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements. The True Health Closing occurred on March 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in the loss from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million  for the three months ended March 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_85"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_88"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $2.8 million and $15.9 million for the three months ended March 31, 2022 and 2021, respectively. Net cash and restricted cash used in operating activities was $57.4 million and $48.2 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had $210.2 million of cash and cash equivalents and $52.6 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part I - Item 1.  Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,163)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $57.4 million for the three months ended March 31, 2022 were primarily due to our net loss of $5.4 million, non-cash items including depreciation and amortization expenses of $15.1 million, stock-based compensation expense of $5.3 million amortization of contract cost assets of $11.7 million and change in fair value of contingent consideration of $6.1 million. Our operating cash inflows were affected by the timing of our customer and vendor payments driven by increases in accounts receivables and prepaid expenses and other assets and reductions in reserves for claims and performance-based arrangements and accrued compensation and employee benefits contributed approximately $91.9 million to our cash outflows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $48.2 million for the three months ended March 31, 2021 were due primarily to our net loss of $9.8 million, a loss on the repayment and termination of our Credit Agreement of $19.2 million, a gain on the disposal of assets of $1.9 million, gain on the transfer of memberships of $23.0 million and non cash items including depreciation and amortization expenses of $15.3 million and stock-based compensation expense of $3.7 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and claims reserves contributed approximately $30.7 million to our cash outflows. Those cash outflows were partially offset by an increase in accounts payable, accrued expenses and accrued compensation and employee benefits contributed and a decrease in prepaid expenses and other current assets of approximately $27.3 million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $16.8 million in the three months ended March 31, 2022 were primarily attributable to $23.0 million from the transfer of membership and release of Passport escrow offset, in part by, $8.5 million of investments in internal-use software and purchases of property and equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $46.0 million in the three months ended March 31, 2021 were primarily attributable to cash flows of $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $9.4 million offset, in part by $5.9 million from investments in internal-use software and purchases of property and equipment and $3.0 million of purchases of investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $51.4 million in the three months ended March 31, 2022 were primarily related to a $34.4 million decrease in net working capital balances held on behalf of our partners for claims processing services and $16.2 million from taxes withheld for restricted stock unit vesting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $55.6 million in the three months ended March 31, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part by a $39.0 million decrease in net working capital balances held on behalf of our partners for claims processing services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the three months ended March 31, 2021 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2022. Our estimated contractual obligations (in thousands) as of March&#160;31, 2022, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023-2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025-2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt interest and termination payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt principal repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Operating leases for facilities includes $4.7 million due for leases that have not yet commenced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the three months ended March 31, 2022, accounts receivable, net, increased due primarily to the timing of cash receipts from existing customers combined with modest receivables from new customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $52.6 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $38.9 million, collateral for letters of credit required as security deposits for facility leases of $2.3 million, amounts held with financial institutions for risk-sharing arrangements of $11.5 million as of March&#160;31, 2022. See &#8220;Part I - Item 1. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had cash and cash equivalents and restricted cash and restricted investments of $262.8 million, which consisted of bank deposits with FDIC participating banks of $261.6 million, bank deposits in international banks of $1.2 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $289.6 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. Refer to the discussion in &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation loss of $0.1 million for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_211"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of March&#160;31, 2022, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_58"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Part I &#8211; Item 1. Financial Statements and Supplementary Data - Note 11 - Commitments and Contingencies - Litigation Matters.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part I, Item 1A. &#8220;Risk Factors&#8221; in our 2021 Form 10-K, and other documents filed with the SEC include discussions of our risk factors. There have been no material changes from the risk factors described in our 2021 Form 10-K for the quarterly period ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_256"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_262"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_214"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_241"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibb64a58c5010458da650c3b7c8dfab74_244"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000056/a71216exhibit21.htm">2.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000056/a71216exhibit21.htm">Agreement and Plan of Merger, dated July 12, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as the Securityholders&#8217; Representative, filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on July 14, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000066/a10316exhibit22.htm">2.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000066/a10316exhibit22.htm">First Amendment to Agreement and Plan of Merger, dated October 3, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as securityholders&#8217; representative, filed as Exhibit 2.2 to the Company&#8217;s Report on Form 8-K filed with the SEC on October 3, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000069/a912188-kexhibit21.htm">2.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000069/a912188-kexhibit21.htm">Agreement and Plan of Merger, dated September 7, 2018, by and among Evolent Health, Inc., Evolent Health LLC, Element Merger Sub, Inc., NCIS Holdings, Inc. and New Century Investment, LLC, in the capacity set forth therein, filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on September 12, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">2.4*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company&#8217;s Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:47pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">2.6*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">Purchase Agreement and Agreement and Plan of Merger, dated August 2, 2021, by and among Evolent Health, Inc., Evolent Health LLC, EV Thunder Merger Sub, LLC, WindRose Health Investors III, L.P., Vital Decisions Acquisition, LLC and WindRose Health Investors, LLC, as the representative,  filed as Exhibit 2.1 to the Company&#8217;s report on Form 8-K filed with the SEC on August 4, 2021 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit101.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit101.htm">Form of Corporate PSU Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit102.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit102.htm">Form of Business Unit PSU Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33122exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q, formatted as Inline XBRL</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="ibb64a58c5010458da650c3b7c8dfab74_268"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registrant</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controller</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  May&#160;4, 2022 </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a33122exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i53e8c067217644dcafbbd97cbc830688_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VOLENT HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2015 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">PERFORMANCE STOCK UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of &#91;DATE&#93; between EVOLENT HEALTH, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and ____________.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Performance Stock Unit Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) sets forth the terms and conditions of an award for a target number of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">____ </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (such number, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Target Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) performance stock units (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) (each such performance stock unit, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) that are granted to you under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  This Award constitutes an unfunded and unsecured promise of the Company to deliver (or to cause to be delivered ) to you, subject to the terms of this Award Agreement, one share of the Company&#8217;s Class A Common Stock, $0.01 par value (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), or cash equal to the Fair Market Value of one Share, for each PSU ultimately earned by you, as set forth in this Award Agreement.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">THIS AWARD IS SUBJECT TO ALL TERMS AND CONDITIONS OF THE PLAN AND THIS AWARD AGREEMENT, INCLUDING THE DISPUTE RESOLUTION PROVISIONS SET FORTH IN SECTION 13 OF THIS AWARD AGREEMENT.  BY SIGNING YOUR NAME BELOW, YOU SHALL HAVE CONFIRMED YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AWARD AGREEMENT.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">The Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Award is made pursuant to the Plan, all the terms of which are hereby incorporated in this Award Agreement.  In the event of any conflict between the terms of the Plan and the terms of this Award Agreement, the terms of the Plan shall govern.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Capitalized terms used in this Award Agreement that are not defined in this Award Agreement have the meanings as used or defined in the Plan.  As used in this Award Agreement, the following terms have the meanings set forth below&#58;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means a day that is not a Saturday, a Sunday or a day on which banking institutions are legally permitted to be closed in the City of New York.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 3(b) and (c).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Cumulative Adjusted EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; for the Performance Period means the Company&#8217;s cumulative earnings for the applicable Performance Period before interest, taxes, depreciation and amortization, and before stock-based compensation, acquisition expenses and similar non-recurring items, in a manner consistent with the Company&#8217;s publicly-reported adjusted EBITDA.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the occurrence, without your written consent, of any of the events or circumstances set forth in clauses (a) through (d) below&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;a material reduction in your annual base salary or target bonus opportunity as the same may be increased from time to time&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;your assignment to duties inconsistent in any material respect with your position, authority or responsibilities with the Company, or any other action or omission by the Company, which results in each case in a material diminution of your position, authority or responsibilities&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;a relocation of your principal work location by more than 50 miles from such location as of immediately prior to the Change of Control&#59; or</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;any material breach of this Award Agreement by the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Good Reason shall not exist unless you give the Company notice of the event giving rise to Good Reason within 60 days of the date you have knowledge of such event.  Such notice shall specifically delineate such claimed breach and shall inform the Company that it is required to cure such breach (if curable) within 90 days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) after such notice is given in accordance with Section 15 of this Award Agreement.  If such breach is not so cured (or is not curable), you may resign for Good Reason within three months following the end of the Cure Period.  If such breach is cured within the Cure Period or if such breach is not cured but you do not resign for Good Reason within three months following the end of the Cure Period, Good Reason shall not exist hereunder.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the period commencing on &#91;.&#93; and ending on &#91;.&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Replacement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means an award, which, upon a Change of Control, is provided to you as a replacement or substitution for this Award and which&#58; (i) is of the same type as this Award (or a different type from this Award, provided that the Committee, as constituted immediately prior to the Change of Control, finds such type acceptable)&#59; (ii) has an intrinsic value at least equal to the value of this Award&#59; (iii) relates to publicly traded equity securities of the Company or its successor in the Change of Control or another entity that is affiliated with the Company or its successor following the Change of Control&#59; (iv) has terms and conditions that comply with the provisions of Section 6(c) of this Agreement&#59; (v) has vesting conditions that continue on the same terms as set forth in this Award&#59; and (vi) has other terms and conditions that are not less favorable to you than the terms and conditions of this Award (including the provisions that would apply in the event of a subsequent Change of Control). Without limiting the generality of the foregoing, a Replacement Award may take the form of a continuation of this Award if the requirements of the preceding sentence are satisfied. The determination of whether the conditions set forth in clauses (i) through (vi) are satisfied shall be made by the Committee, as constituted immediately before the Change of Control, in its sole discretion.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the Company&#8217;s total recognized revenue from customers in a calendar year associated with the Company&#8217;s customer contracts, in a manner consistent with the Company&#8217;s publicly-reported financials.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Revenue Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the lesser of (i) &#91;.&#93; and (ii) the Revenue of the Company for the Company&#8217;s &#91;.&#93; fiscal year divided by the Revenue of the Company for the Company&#8217;s &#91;.&#93; fiscal year.  The Revenue of the Company for the &#91;.&#93; fiscal year was &#91;.&#93;.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means Section 409A of the Code and the regulations and other interpretive guidance promulgated thereunder, as in effect from time to time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Subject to the service-vesting provisions set forth in Section 4 of this Award Agreement, the total number of PSUs you earn will be determined at the end of the Performance Period based on the Company Value, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Except as set forth in Section 3(c), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the product of (i) the Cumulative Adjusted EBITDA for the Performance Period, (ii) the Revenue Ratio, and (iii) &#91;.&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;In determining the portion of the Company Value attributable to any business that is acquired by the Company and becomes part of the Company during the Performance Period (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), the following rules shall apply&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;The Company Value shall first be determined without regard to the Acquired Business based on the Cumulative Adjusted EBITDA and Revenue Ratio for the Company (without taking the Acquired Business into account) in accordance with Section 3(b).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;The value of the Acquired Business shall be determined as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(A)&#160;&#160;&#160;&#160;The Cumulative Adjusted EBITDA attributable to the Acquired Business shall be determined by adding all Adjusted EBITDA referable to the Acquired Business from the date of acquisition by the Company through to &#91;.&#93;.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(B)&#160;&#160;&#160;&#160;The Revenue Ratio for the Acquired Business shall be the lesser of (i) &#91;.&#93; and (ii) the Revenue attributable to the Acquired Business for the &#91;.&#93; fiscal year of the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">divided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the annualized revenue of the Acquired Business for the most recent completed fiscal year of the Acquired Business prior to the date of acquisition by the Company. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(C)&#160;&#160;&#160;&#160;Multiply the product of (A) and (B) above by &#91;.&#93;.  </font></div><div style="padding-left:72pt;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(D)&#160;&#160;&#160;&#160;The value determined in (C) shall be reduced by the product of (1) the purchase price to the Company of the Acquired Business and the (2) fraction obtained by dividing the number of full months in the Performance Period that follow the date of the acquisition of the Acquired Business by &#91;.&#93;.  </font></div><div style="text-align:justify;text-indent:180pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;The Company Value, including the value of the Acquired Company, for the Performance Period shall be the sum of the amounts in Section 3(c)(i) and Section 3(c)(ii)(D).</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;In the event of a Change of Control following the date of the Company&#8217;s acquisition of the Acquired Business and prior to the last day of the Performance Period, the value attributable to the Acquired Business (prior to reduction for a portion of the purchase price to the Company of the Acquired Business in accordance with Section 3(c)(ii)(D)), shall be determined in accordance with Section 6(b)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided however that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> the target Cumulative Adjusted EBITDA and the target Revenue for the Acquired Business for any fiscal quarter that has not been completed through the date of the Change of Control shall be determined by the Committee in good faith, taking into account, among other things, the internal business targets for the Acquired Business established by the Company for the Performance Period in connection with the acquisition of the Acquired Business. </font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;No later than 50 days following the end of the Performance Period, the Committee will review and certify in writing (i) the level of Cumulative Adjusted EBITDA achieved for the Performance Period, (ii) the Revenue Ratio, (iii) the Company Value, and (iv) the number of PSUs that you have earned, if any, for the Performance Period.  The Committee&#8217;s certification shall be final, conclusive and binding on you, and on all other persons, to the maximum extent permitted by law.   </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Committee shall, to the extent and in such manner as it deems appropriate, adjust or modify the Performance Goals set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> for the Performance Period (i) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development affecting the Company, or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), (ii) in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), or the financial statements of the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), or (iii) in recognition of changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange, accounting principles, law or business conditions.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Service Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.   The PSUs are subject to forfeiture until vested, as described in this Award Agreement.  Except as otherwise provided in Section 6 below, your PSUs will vest and become nonforfeitable on &#91;.&#93;, provided that you remain continuously employed by the Company or any of its Subsidiaries from the grant date of this Award through such vesting date.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Forfeiture of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Except as set forth in Section 6, if your service with the Company and all of its Subsidiaries terminates for any reason before &#91;.&#93;, all of your PSUs shall be immediately forfeited and you shall be entitled to no further payments or benefits with respect thereto.  Further, if you breach any restrictive covenant contained in any arrangements with the Company or a Subsidiary (including this Award Agreement) to which you are subject, all your PSUs shall be immediately forfeited, and you shall be entitled to no further payments or benefits with respect thereto.  Furthermore, any PSUs awarded pursuant to this Award Agreement and any Shares issued to you or cash paid to you under this Award Agreement upon settlement of such PSUs shall be subject to any recoupment or clawback policy the Company maintains, as in effect from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;If a Change of Control occurs during the Performance Period, and your Award does not remain outstanding following the Change of Control and the acquiror or successor entity neither assumes nor provides a substitute for your Award that meets the requirements of a Replacement Award, then you will be deemed to have earned that number of PSUs as described in Section 6(b) below, effective as of the date of the Change of Control, and your Award shall become vested and nonforfeitable pursuant to Section 4 on &#91;.&#93;, provided that, except as set forth in Section 6(c) or (d) below, you remain continuously employed by the Company or any of its Subsidiaries through &#91;.&#93;.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;The number of PSUs earned shall be the determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, based on the Company Value determined as of the date of the Change of Control, as follows&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;For any fiscal quarter in the Performance Period that has been completed as of the date of the Change of Control, Cumulative Adjusted EBITDA shall be determined based on the actual Adjusted EBITDA for such quarter&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;For any fiscal quarter in the Performance Period that has not been completed as of the date of the Change of Control, Cumulative Adjusted EBITDA shall be determined based on the target Adjusted EBITDA for each such quarter, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> hereto&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;The Revenue Ratio shall be determined by using the target Revenue of the Company for any quarter in &#91;.&#93; which has not been completed as of the Change of Control, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> hereto, and the actual Revenue of the Company for any quarter in &#91;.&#93; that has been completed prior to the Change of Control.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;If you are not subject to a Severance and Change-in-Control Agreement with the Company, and if, within twelve (12) months following the date of the Change of Control but prior to &#91;.&#93;, your employment is terminated by the Company or the acquiror or successor entity without Cause or by you for Good Reason, the service vesting requirements of Section 4 shall automatically be deemed satisfied, and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;If you are subject to a Severance and Change-in-Control Agreement with the Company and, within the Change in Control Protection Period, as defined in your Severance and Change-in-Control Agreement, but prior to &#91;.&#93;, your employment is terminated by the Company or the acquiror or successor entity without Cause or by you for Good Reason, as those terms are defined in your Severance and Change-in-Control Agreement, then, subject to satisfaction of the release and other requirements of your Severance and Change-in-Control Agreement, the service vesting requirements of Section 4 shall automatically be deemed satisfied, and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination.  For the avoidance of doubt, notwithstanding anything in your Severance and Change-in-Control Agreement to the contrary, any PSUs not earned at the time of the Change of Control pursuant to Section 6(b) above shall be forfeited at the time of the Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Settlement of PSUs earned under this Award Agreement shall be, at the Committee&#8217;s sole discretion, either (i) in Shares, which the Company shall deliver to you or your legal representative, (ii) in an amount in cash equal to the Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Committee in accordance with applicable withholding requirements) of the Shares to be delivered in satisfaction of the PSUs, or (iii) in a combination of Shares and cash.  Settlement shall take place within sixty (60) days following the end of the Performance Period, or, in the event of a termination of employment described in Section 6(c) or (d), within sixty (60) days following your termination date.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You shall not have any rights or privileges of a stockholder with respect to the PSUs subject to this Award Agreement unless and until certificates representing such Shares are actually issued to you or your legal representative or an entry is recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator) in settlement of this Award.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Transferability of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Unless otherwise provided by the Committee in its discretion, PSUs may not be sold, assigned, alienated, transferred, pledged, attached or otherwise encumbered except as provided in Section 9(a) of the Plan.  Any purported sale, assignment, alienation, transfer, pledge, attachment or other encumbrance of PSUs in violation of the provisions of this Section 9 and Section 9(a) of the Plan shall be void.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding, Consents and Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The delivery of Shares or cash pursuant to Section 7 of this Award Agreement is conditioned on satisfaction of any applicable withholding taxes in accordance with this Section 10 and Section 9(d) of the Plan.  No later than the date as of which an amount first becomes includible in your gross income for Federal, state, local or foreign income tax purposes with respect to any PSUs you shall pay to the Company, or make arrangements satisfactory to the Company regarding the payment of, any Federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld with respect to such amount.  In the event that there is withholding tax liability in connection with the settlement of the PSUs you may satisfy, in whole or in part, any withholding tax liability by having the Company withhold from the number of Shares or cash you would be entitled to receive upon settlement of the PSUs an amount in cash or a number of Shares having a Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Committee in accordance with applicable withholding requirements) equal to such withholding tax liability.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Your rights in respect of the PSUs are conditioned on the receipt to the full satisfaction of the Committee of any required consents that the Committee may determine to be necessary or advisable (including your consent to the Company&#8217;s supplying to any third-party recordkeeper of the Plan such personal information as the Committee deems advisable to administer the Plan).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company may affix to certificates for Shares issued pursuant to this Award Agreement any legend that the Committee determines to be necessary or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">advisable (including to reflect any restrictions to which you may be subject under any applicable securities laws).  The Company may advise the transfer agent to place a stop order against any legended Shares.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Successors and Assigns of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The terms and conditions of this Award Agreement shall be binding upon and shall inure to the benefit of the Company and its successors and assigns.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Committee Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Committee shall have full and plenary discretion with respect to any actions to be taken or determinations to be made in connection with this Award Agreement, and its determinations shall be final, binding and conclusive.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Jurisdiction and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You and the Company irrevocably submit to the exclusive jurisdiction of (i) the United States District Court for the Eastern District of Virginia and (ii) the courts of the State of Virginia for the purposes of any suit, action or other proceeding arising out of this Award Agreement or the Plan.  You and the Company agree to commence any such action, suit or proceeding either in the United States District Court for the Eastern District of Virginia or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the courts of the State of Virginia.  You and the Company further agree that service of any process, summons, notice or document by U.S. registered mail to the other party&#8217;s address set forth below shall be effective service of process for any action, suit or proceeding in Virginia with respect to any matters to which you have submitted to jurisdiction in this Section 13(a).  You and the Company irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising out of this Award Agreement or the Plan in (A) the United States District Court for the Eastern District of Virginia or (B) the courts of the State of Virginia, and hereby and thereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You and the Company hereby waive, to the fullest extent permitted by applicable law, any right either of you may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Award Agreement or the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You hereby agree to keep confidential the existence of, and any information concerning, a dispute described in this Section 13, except that you may disclose information concerning such dispute to the court that is considering such dispute or to your legal counsel (provided that such counsel agrees not to disclose any such information other than as necessary to the prosecution or defense of the dispute).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In consideration of the grant of PSUs under this Award Agreement and as a condition to the receipt of the PSUs pursuant to this Award Agreement, you agree that&#58;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;You acknowledge that the Company and its Affiliates continually develop Confidential Information (as defined below), that you may develop Confidential Information for the Company or its Affiliates and that you may learn of Confidential Information during the course of your employment.  You will comply with the policies and procedures of the Company and its Affiliates for protecting Confidential Information and shall not disclose to any person or use, other than as required by applicable law or for the proper performance of your duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained by you incident to your employment or other association with the Company or any of its Affiliates.  You understand that this restriction shall continue to apply after your employment terminates, regardless of the reason for such termination.  The confidentiality obligation under this Section 14 shall not apply to information which is generally known or readily available to the public at the time of disclosure or becomes generally known through no wrongful act on the part of you or any other person having an obligation of confidentiality to the Company or any of its Affiliates or is required to be disclosed in order to enforce this Award Agreement.</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;All documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the Company or its Affiliates and any copies, in whole or in part, thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), whether or not prepared by the you, shall be the sole and exclusive property of the Company and its Affiliates.  You shall safeguard all Documents and shall surrender to the Company at the time your employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in your possession or control.</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means any and all information of the Company and its Affiliates that is not generally known by those with whom the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete or do business, and any and all information, whether or not publicly known in whole or in part, which, if disclosed by the Company or any of its Affiliates, would assist in competition against them.  Confidential Information includes without limitation such information relating to (A) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates, (B) the products and services of the Company and its Affiliates, (C) the costs, sources of supply, financial performance and strategic plans of the Company and its Affiliates, (D) the identity and special needs of the customers of the Company and its Affiliates and (E) the people and organizations with whom the Company and its Affiliates have business relationships and the nature and substance of those relationships.  Confidential Information also includes any information that the Company or any of its Affiliates has received, or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not be disclosed.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;You agree and acknowledge that the business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) of the Company is any business activity engaged in, or actively contemplated by the Company (or any Subsidiary) to be engaged in, by the Company (or any Subsidiary) and with which you are or were involved on or prior to your date of termination.</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;You agree that, except as the Company expressly agrees in writing, during your employment with the Company and for the 12-month period following termination of your employment for any reason, you shall not within the Territory (defined below), directly or indirectly, as an owner, partner, affiliate, stockholder, joint venturer, director, employee, consultant, contractor, principal, trustee or licensor, or in any other similar capacity whatsoever, of or for any person or entity (other than for the Company)&#58;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(A)&#160;&#160;&#160;&#160;engage in, own, manage, operate, sell, finance, control, advise or participate in the ownership, management, operation, sales, finance or control of, be employed or employed by, or be connected in any manner with, any business that competes with (1) the Business or (2) if you have provided services directly to any health maintenance organization, health insurance company or similar health insurance plan, owned or operated by a customer of the Company, during the twelve-month period preceding the termination of your employment with the Company, such customer (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  Notwithstanding this Section 14(b)(ii)(A), you may accept employment with a Competitor whose business is diversified, provided that (I) such employment is with a portion of the Competitor&#8217;s business that does not provide products or services that are the same as, are similar to, or compete with the Company&#8217;s products or services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Competing Products or Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) and (II) prior to your acceptance of such employment with Competitor, the Company receives separate written assurances satisfactory to the Company from such Competitor and from you that you will not provide any Competing Products or Services&#59;</font></div><div style="text-align:justify;text-indent:144pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(B)&#160;&#160;&#160;&#160;approach, solicit, divert, interfere with, or take away, the business or patronage of any of the actual or prospective members, customers, or clients of the Company, for a purpose that is competitive with the Business&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(C)&#160;&#160;&#160;&#160;contact, recruit, solicit, hire, retain, or employ (whether as an employee, consultant, agent, independent contractor, or otherwise) any person who is, or who at any time during the 6-month period prior to your date of termination had been, employed or engaged by the Company, or induce or take any action which is intended to induce any such person to terminate his or her employment or relationship, or otherwise cease his or her relationship, with the Company, or interfere in any manner with the contractual or employment relationship between the Company and any employee of or any other person engaged by the Company.</font></div><div style="text-indent:144pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the United States of America and any other country with respect to which you have been involved on behalf of the Company.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in Section 14(b)(ii) of this Award Agreement, you are permitted to own, individually, as a passive investor (with no director designation rights, voting rights or veto rights or other special governance or voting rights), up to a one percent (1%) interest in any publicly traded entity that is a Competitor.</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;You shall disclose in writing all of your relationships as a director, employee, consultant, contractor, principal, trustee, licensor, agent, or otherwise, with a Competitor or other business entity, to the Company for the 12-month period after your date of termination. You shall not disparage the Company or any of its officers, directors, or employees&#59; provided, however, that this Section 14(b)(iv) shall not prohibit or constrain truthful testimony by you compelled by any valid legal process or valid legal dispute resolution process.  Notwithstanding anything herein to the contrary, nothing in this Section 14 shall prevent either party hereto from enforcing such party&#8217;s rights or remedies hereunder or that such party may otherwise be entitled to enforce or assert under any other agreement or applicable law, or shall limit such rights or remedies in any way.</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(v)&#160;&#160;&#160;&#160;During the 12-month period following your date of termination, you shall notify in writing any prospective new employer or entity otherwise seeking to engage you that the provisions of this Section 14 exist prior to accepting employment or such other engagement.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The terms of this Section 14 are reasonable and necessary in light of your position with the Company and responsibility and knowledge of the operations of the Company and its Subsidiaries and are not more restrictive than necessary to protect the legitimate interests of the parties hereto.  In addition, any breach of the covenants contained in this Section 14 would cause irreparable harm to the Company, its Subsidiaries and Affiliates, and there would be no adequate remedy at law or in damages to compensate the Company, its Subsidiaries and Affiliates for any such breach.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Protected Rights&#59; Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, this Award Agreement is not intended to, and shall be interpreted in a manner that does not, limit or restrict you from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Exchange Act).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;Under the Defend Trade Secrets Act&#58; (A) no person will be held criminally or civilly liable under federal or state trade secret law for disclosure of a trade secret (as defined in the Economic Espionage Act) that is&#58; (1) made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected violation of law, or, (2) made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal so that it is not made public, and (B) a person who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the person and use the trade secret information in the court proceeding, if the person files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All notices, requests, demands and other communications required or permitted to be given under the terms of this Award Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">three Business Days after they have been mailed by U.S. certified or registered mail, return receipt requested, postage prepaid, addressed to the other party as set forth below&#58;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"></td><td style="width:34.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Evolent Health, Inc.<br>800 N. Glebe Road, Suite 500<br>Arlington, VA 22203<br>Attention&#58; General Counsel<br></font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to you&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">To your address as most recently supplied to the Company and set forth in the Company&#8217;s records</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The parties may change the address to which notices under this Award Agreement shall be sent by providing written notice to the other in the manner specified above.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Award Agreement shall be deemed to be made in the State of Delaware, and the validity, construction and effect of this Award Agreement in all respects shall be determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Headings and Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Headings are given to the Sections and subsections of this Award Agreement solely as a convenience to facilitate reference.  Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Award Agreement or any provision thereof.  Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Award Agreement, they shall be deemed to be followed by the words &#8220;but not limited to&#8221;.  The term &#8220;or&#8221; is not exclusive.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment of this Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate this Award Agreement prospectively or retroactively&#59; provided, however, that, except as set forth in Section 19(d) of this Award Agreement, any such waiver, amendment, alteration, suspension, discontinuance, cancelation or termination that would impair your rights under this Award Agreement shall not to that extent be effective without your consent (it being understood, notwithstanding the foregoing proviso, that this Award Agreement and the PSUs shall be subject to the provisions of Section 7(c) of the Plan).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;It is intended that the provisions of this Award Agreement be exempt from or comply with Section 409A, and all provisions of this Award Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Neither you nor any of your creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section 409A) payable under this Award Agreement to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to you or for your benefit under this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Award Agreement may not be reduced by, or offset against, any amount owing by you to the Company or any of its Affiliates.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;If, at the time of your separation from service (within the meaning of Section 409A), (i) you shall be a specified employee (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable hereunder constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A, then the Company shall not pay such amount on the otherwise scheduled payment date but shall instead pay it, without interest, on the first Business Day after such six-month period.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Notwithstanding any provision of this Award Agreement to the contrary, in light of the uncertainty with respect to the proper application of Section 409A, the Company reserves the right to make amendments to this Award Agreement as the Company deems necessary or desirable to avoid the imposition of taxes or penalties under Section 409A. In any case, you shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on you or for your account in connection with this Award Agreement (including any taxes and penalties under Section 409A), and neither the Company nor any of its Affiliates shall have any obligation to indemnify or otherwise hold you harmless from any or all of such taxes or penalties.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Award Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  You and the Company hereby acknowledge and agree that signatures delivered by facsimile or electronic means (including by &#8220;pdf&#8221;) shall be deemed effective for all purposes.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i53e8c067217644dcafbbd97cbc830688_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">APPENDIX A</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The number of PSUs that you actually earn for the Performance Period will vary in accordance with the Company Value for the Performance Period, as set out in the table below. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If the  Company Value falls between tiers, the actual percentage of the Target Number of PSUs earned shall be determined by linear interpolation between the percentages listed on a straight-line basis.  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Performance Level</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Company Value</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Percentage of Target Number of PSUs Earned<br></font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Below Threshold<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Threshold<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Target<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Target Plus<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Maximum<br></font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i53e8c067217644dcafbbd97cbc830688_45"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">APPENDIX B</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ADJUSTED EBITDA AND REVENUE TARGETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">FOR THE PERFORMANCE PERIOD BY QUARTER</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="background-color:#929292;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ADJUSTED EBITDA ($ MM)</font></div></td><td colspan="18" style="background-color:#929292;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">REVENUE ($ MM)</font></div></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a33122exhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i24a861af0d304059aa4ce7be719fd5a7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VOLENT HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2015 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">PERFORMANCE STOCK UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of &#91;DATE&#93; between EVOLENT HEALTH, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and ____________.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Performance Stock Unit Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) sets forth the terms and conditions of an award for a target number of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">______</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (such number, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Target Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) performance stock units (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) (each such performance stock unit, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) that are granted to you under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  This Award constitutes an unfunded and unsecured promise of the Company to deliver (or to cause to be delivered ) to you, subject to the terms of this Award Agreement, one share of the Company&#8217;s Class A Common Stock, $0.01 par value (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), or cash equal to the Fair Market Value of one Share, for each PSU ultimately earned by you, as set forth in this Award Agreement.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">THIS AWARD IS SUBJECT TO ALL TERMS AND CONDITIONS OF THE PLAN AND THIS AWARD AGREEMENT, INCLUDING THE DISPUTE RESOLUTION PROVISIONS SET FORTH IN SECTION 13 OF THIS AWARD AGREEMENT.  BY SIGNING YOUR NAME BELOW, YOU SHALL HAVE CONFIRMED YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AWARD AGREEMENT.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">The Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Award is made pursuant to the Plan, all the terms of which are hereby incorporated in this Award Agreement.  In the event of any conflict between the terms of the Plan and the terms of this Award Agreement, the terms of the Plan shall govern.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Capitalized terms used in this Award Agreement that are not defined in this Award Agreement have the meanings as used or defined in the Plan.  As used in this Award Agreement, the following terms have the meanings set forth below&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 3(c).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means a day that is not a Saturday, a Sunday or a day on which banking institutions are legally permitted to be closed in the City of New York.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business Unit Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 3 (b) and (c). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Cumulative Adjusted EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; for the Performance Period means the cumulative earnings of the Business Unit for the Performance Period before interest, taxes, depreciation and amortization, and before stock-based compensation, acquisition expenses and similar non-recurring items, in a manner consistent with the Company&#8217;s publicly-reported adjusted EBITDA.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Disposition of the Business Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the sale, in a single transaction or series of related transactions, of substantially all the assets of the Business Unit to an entity that is not an Affiliate.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the occurrence, without your written consent, of any of the events or circumstances set forth in clauses (a) through (d) below&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;a material reduction in your annual base salary or target bonus opportunity as the same may be increased from time to time&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;your assignment to duties inconsistent in any material respect with your position, authority or responsibilities with the Company, or any other action or omission by the Company, which results in each case in a material diminution of your position, authority or responsibilities&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;a relocation of your principal work location by more than 50 miles from such location as of immediately prior to the Change of Control&#59; or</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;any material breach of this Award Agreement by the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Good Reason shall not exist unless you give the Company notice of the event giving rise to Good Reason within 60 days of the date you have knowledge of such event.  Such notice shall specifically delineate such claimed breach and shall inform the Company that it is required to cure such breach (if curable) within 90 days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) after such notice is given in accordance with Section 15 of this Award Agreement.  If such breach is not so cured (or is not curable), you may resign for Good Reason within three months following the end of the Cure Period.  If such breach is cured within the Cure Period or if such breach is not cured but you do not resign for Good Reason within three months following the end of the Cure Period, Good Reason shall not exist hereunder.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the period commencing on &#91;.&#93; and ending on &#91;.&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Replacement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means an award, which, upon a Disposition of the Business Unit or a Change of Control, is provided to you as a replacement or substitution for this Award and which&#58; (i) is of the same type as this Award (or a different type from this Award, provided that the Committee, as constituted immediately prior to the Disposition of the Business Unit or Change of Control, finds such type acceptable)&#59; (ii) has an intrinsic value at least equal to the value of this Award&#59; (iii) relates to publicly traded equity securities of the Company or its successor in the Change of Control or another entity that is affiliated with the Company or its successor following the Change of Control&#59; (iv) has terms and conditions that comply with the provisions of Section 6(c) of this Agreement&#59; (v) has vesting conditions that continue on the same terms as set forth in this Award&#59; and (vi) has other terms and conditions that are not less favorable to you than the terms and conditions of this Award (including the provisions that would apply in the event of a subsequent Change of Control). Without limiting the generality of the foregoing, a Replacement Award may take the form of a continuation of this Award if the requirements of the preceding sentence are satisfied. The determination of whether the conditions set forth in clauses (i) through (vi) are satisfied shall be made by the Committee, as constituted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">immediately before the Disposition of the Business Unit or Change of Control, in its sole discretion. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means total recognized revenue from customers in a calendar year associated with the Business Unit&#8217;s customer contracts, in a manner consistent with the Company&#8217;s publicly-reported financials, plus any intercompany revenue received from other business units of the Company. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Revenue Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the lesser of (i) &#91;.&#93; and (ii) the Revenue of the Business Unit for the &#91;.&#93;fiscal year of the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">divided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the Revenue of the Business Unit for the &#91;.&#93;fiscal year of the Company.  The Revenue of the Business Unit for the &#91;.&#93; fiscal year of the Company &#91;was&#93;&#91;is expected to be&#93; &#91;.&#93;&#8221;.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means Section 409A of the Code and the regulations and other interpretive guidance promulgated thereunder, as in effect from time to time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Subject to the service-vesting provisions set forth in Section 4 of this Award Agreement, the total number of PSUs you earn for the Performance Period will be determined at the end of the Performance Period based on the Business Unit Value, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Except as set forth in Section 3(c), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business Unit Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the product of (i) the Cumulative Adjusted EBITDA for the Performance Period, (ii) the Revenue Ratio, and (iii) &#91;.&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;In determining the portion of the Business Unit Value attributable to any business that is acquired by the Company and becomes part of the Business Unit during the Performance Period (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), the following rules shall apply&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;The Business Unit Value of the Business Unit shall first be determined without regard to the Acquired Business based on the Cumulative Adjusted EBITDA and Revenue Ratio for the original Business Unit in accordance with Section 3(b).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;The Business Unit Value of the Acquired Business shall be determined as follows&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(A)&#160;&#160;&#160;&#160;The Cumulative Adjusted EBITDA for the Acquired Business shall be determined by adding all Adjusted EBITDA referable to the Acquired Business from the date of acquisition by the Company through to &#91;.&#93;.</font></div><div style="text-align:justify;text-indent:180pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(B)&#160;&#160;&#160;&#160;The Revenue Ratio for the Acquired Business shall be the lesser of (i) &#91;.&#93; and (ii) the Revenue of the Acquired Business for the &#91;.&#93; fiscal year of the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">divided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the annualized revenue of the Acquired Business for the most recent completed fiscal year of the Acquired Business prior to the date of acquisition by the Company. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:180pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(C)&#160;&#160;&#160;&#160;Multiply the product of (A) and (B) above by &#91;.&#93;.  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(D)&#160;&#160;&#160;&#160;The value determined in (C) shall be reduced by the product of (1) the purchase price to the Company of the Acquired Business and the (2) fraction obtained by dividing the number of full months in the Performance Period that follow the date of the acquisition of the Acquired Business by &#91;.&#93;.   </font></div><div style="text-align:justify;text-indent:180pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;The Business Value for the Business Unit, including the Acquired Company, for the Performance Period shall be the sum of the amounts in Section 3(c)(i) and Section 3(c)(ii)(D).</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;In the event of a Disposition of the Business Unit or a Change of Control following the date of the Company&#8217;s acquisition of the Acquired Business and prior to the last day of the Performance Period, the Business Unit Value attributable to the Acquired Business (prior to reduction for a portion of the purchase price to the Company of the Acquired Business in accordance with Section 3(c)(ii)(D)), shall be determined in accordance with Section 6(b) in the same manner as the original Business Unit&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided however that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> the target Cumulative Adjusted EBITDA and the target Revenue for the Acquired Business for any fiscal quarter that has not been completed through the date of the Disposition of the Business Unit or the Change of Control shall be determined by the Committee in good faith, taking into account, among other things, the internal business targets for the Acquired Business established by the Company for the Performance Period in connection with the acquisition of the Acquired Business. </font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;No later than 50 days following the end of the Performance Period, the Committee will review and certify in writing (i) the level of Cumulative Adjusted EBITDA achieved for the Performance Period, (ii) the Revenue Ratio, (iii) the Business Unit Value, and (iv) the number of PSUs that you have earned, if any, for the Performance Period.  The Committee&#8217;s certification shall be final, conclusive and binding on you, and on all other persons, to the maximum extent permitted by law.      </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Committee shall, to the extent and in such manner as it deems appropriate, adjust or modify the Performance Goals set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> for the Performance Period (i) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development affecting the Business Unit or the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), (ii) in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Business Unit or the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), or the financial statements of the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), or (iii) in recognition of changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange, accounting principles, law or business conditions.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Service Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.   The PSUs are initially subject to forfeiture, and, except as otherwise provided in Section 6 below, will vest and become nonforfeitable on &#91;.&#93;, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">provided that you remain continuously employed by the Company or any of its Subsidiaries from the grant date of this Award through such date.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Forfeiture of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Except as set forth in Section 6, if your service with the Company and all of its Subsidiaries terminates for any reason before &#91;.&#93;, your PSUs shall be immediately forfeited and you shall be entitled to no further payments or benefits with respect thereto.  Further, if you breach any restrictive covenant contained in any arrangements with the Company or a Subsidiary (including this Award Agreement) to which you are subject, all your PSUs shall be immediately forfeited, and you shall be entitled to no further payments or benefits with respect thereto.  Furthermore, any PSUs awarded pursuant to this Award Agreement and any Shares issued to you or cash paid to you under this Award Agreement upon settlement of such PSUs shall be subject to any recoupment or clawback policy the Company maintains, as in effect from time to time.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Disposition of Business Unit&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;If, during the Performance Period, there occurs a Disposition of the Business Unit or a Change of Control, if your Award does not remain outstanding and the acquiror or successor entity neither assumes nor provides a substitute for your Award that meets the requirements of a Replacement Award, then you will be deemed to have earned that number of PSUs as described in Section 6(b) below, effective as of the date of the Disposition of the Business Unit or the Change of Control (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Transaction Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and your Award shall become vested and nonforfeitable pursuant to Section 4 on &#91;.&#93;, provided that, except as set forth in Section 6(c) or (d) below, you remain continuously employed by the Company or any of its Subsidiaries through such date.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;The number of PSUs earned shall be the determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, based on the Business Unit Value determined as of the Transaction Date, as follows&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;For any fiscal quarter in the Performance Period that has been completed as of the Transaction Date, Cumulative Adjusted EBITDA shall be determined based on the actual Adjusted EBITDA for the Business Unit for such quarter&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;For any fiscal quarter in the Performance Period that has not been completed as of the Transaction Date, Cumulative Adjusted EBITDA shall be determined based on the target Adjusted EBITDA for each such quarter, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> hereto&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;The Revenue Ratio shall be determined by using the target Revenue for any quarter in &#91;.&#93;which has not been completed as of the Transaction Date, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> hereto, and the actual Revenue for any quarter in &#91;.&#93;that has been completed prior to the Transaction Date.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;If you are not subject to a Severance and Change-in-Control Agreement with the Company, and if, within twelve (12) months following the Transaction Date but prior to &#91;.&#93;, your employment is terminated by the Company or the acquiror or successor entity without Cause or by you for Good Reason, the service vesting requirements of Section 4 shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">automatically be deemed satisfied, and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;If you are subject to a Severance and Change-in-Control Agreement with the Company and, within the Change in Control Protection Period, as defined in your Severance and Change-in-Control Agreement, but prior to &#91;.&#93;, your employment is terminated by the Company or the acquiror or successor entity without Cause or by you for Good Reason, as those terms are defined in your Severance and Change-in-Control Agreement, then, subject to satisfaction of the release and other requirements of your Severance and Change-in-Control Agreement, the service vesting requirements of Section 4 shall automatically be deemed satisfied, and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination.  For the avoidance of doubt, notwithstanding anything in your Severance and Change-in-Control Agreement to the contrary, any PSUs not earned at the time of the Change of Control pursuant to Section 6(b) above shall be forfeited at the time of the Change of Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Settlement of PSUs earned under this Award Agreement shall be, at the Committee&#8217;s sole discretion, either (i) in Shares, which the Company shall deliver to you or your legal representative, (ii) in an amount in cash equal to the Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Committee in accordance with applicable withholding requirements) of the Shares to be delivered in satisfaction of the PSUs, or (iii) in a combination of Shares and cash.  Settlement shall take place within sixty (60) days following the end of the applicable Performance Period, or, in the event of a termination of employment described in Section 6(c) or (d), within sixty (60) days following your termination date.   </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You shall not have any rights or privileges of a stockholder with respect to the PSUs subject to this Award Agreement unless and until certificates representing such Shares are actually issued to you or your legal representative or an entry is recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator) in settlement of this Award.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Transferability of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Unless otherwise provided by the Committee in its discretion, PSUs may not be sold, assigned, alienated, transferred, pledged, attached or otherwise encumbered except as provided in Section 9(a) of the Plan.  Any purported sale, assignment, alienation, transfer, pledge, attachment or other encumbrance of PSUs in violation of the provisions of this Section 9 and Section 9(a) of the Plan shall be void.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding, Consents and Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The delivery of Shares or cash pursuant to Section 7 of this Award Agreement is conditioned on satisfaction of any applicable withholding taxes in accordance with this Section 10 and Section 9(d) of the Plan.  No later than the date as of which an amount first becomes includible in your gross income for Federal, state, local or foreign income tax purposes with respect to any PSUs you shall pay to the Company, or make arrangements satisfactory to the Company regarding the payment of, any Federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld with respect to such amount.  In the event that there is withholding tax liability in connection with the settlement of the PSUs you may satisfy, in whole or in part, any withholding tax liability by having the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Company withhold from the number of Shares or cash you would be entitled to receive upon settlement of the PSUs an amount in cash or a number of Shares having a Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Committee in accordance with applicable withholding requirements) equal to such withholding tax liability.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Your rights in respect of the PSUs are conditioned on the receipt to the full satisfaction of the Committee of any required consents that the Committee may determine to be necessary or advisable (including your consent to the Company&#8217;s supplying to any third-party recordkeeper of the Plan such personal information as the Committee deems advisable to administer the Plan).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company may affix to certificates for Shares issued pursuant to this Award Agreement any legend that the Committee determines to be necessary or advisable (including to reflect any restrictions to which you may be subject under any applicable securities laws).  The Company may advise the transfer agent to place a stop order against any legended Shares.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Successors and Assigns of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The terms and conditions of this Award Agreement shall be binding upon and shall inure to the benefit of the Company and its successors and assigns.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Committee Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Committee shall have full and plenary discretion with respect to any actions to be taken or determinations to be made in connection with this Award Agreement, and its determinations shall be final, binding and conclusive.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Jurisdiction and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You and the Company irrevocably submit to the exclusive jurisdiction of (i) the United States District Court for the Eastern District of Virginia and (ii) the courts of the State of Virginia for the purposes of any suit, action or other proceeding arising out of this Award Agreement or the Plan.  You and the Company agree to commence any such action, suit or proceeding either in the United States District Court for the Eastern District of Virginia or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the courts of the State of Virginia.  You and the Company further agree that service of any process, summons, notice or document by U.S. registered mail to the other party&#8217;s address set forth below shall be effective service of process for any action, suit or proceeding in Virginia with respect to any matters to which you have submitted to jurisdiction in this Section 13(a).  You and the Company irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising out of this Award Agreement or the Plan in (A) the United States District Court for the Eastern District of Virginia or (B) the courts of the State of Virginia, and hereby and thereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You and the Company hereby waive, to the fullest extent permitted by applicable law, any right either of you may have to a trial by jury in respect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">to any litigation directly or indirectly arising out of, under or in connection with this Award Agreement or the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  You hereby agree to keep confidential the existence of, and any information concerning, a dispute described in this Section 13, except that you may disclose information concerning such dispute to the court that is considering such dispute or to your legal counsel (provided that such counsel agrees not to disclose any such information other than as necessary to the prosecution or defense of the dispute).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In consideration of the grant of PSUs under this Award Agreement and as a condition to the receipt of the PSUs pursuant to this Award Agreement, you agree that&#58;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;You acknowledge that the Company and its Affiliates continually develop Confidential Information (as defined below), that you may develop Confidential Information for the Company or its Affiliates and that you may learn of Confidential Information during the course of your employment.  You will comply with the policies and procedures of the Company and its Affiliates for protecting Confidential Information and shall not disclose to any person or use, other than as required by applicable law or for the proper performance of your duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained by you incident to your employment or other association with the Company or any of its Affiliates.  You understand that this restriction shall continue to apply after your employment terminates, regardless of the reason for such termination.  The confidentiality obligation under this Section 14 shall not apply to information which is generally known or readily available to the public at the time of disclosure or becomes generally known through no wrongful act on the part of you or any other person having an obligation of confidentiality to the Company or any of its Affiliates or is required to be disclosed in order to enforce this Award Agreement.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;All documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the Company or its Affiliates and any copies, in whole or in part, thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), whether or not prepared by the you, shall be the sole and exclusive property of the Company and its Affiliates.  You shall safeguard all Documents and shall surrender to the Company at the time your employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in your possession or control.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means any and all information of the Company and its Affiliates that is not generally known by those with whom the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete or do business, and any and all information, whether or not publicly known in whole or in part, which, if disclosed by the Company or any of its Affiliates, would assist in competition against them.  Confidential Information includes without limitation such information relating to (A) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates, (B) the products and services of the Company and its Affiliates, (C) the costs, sources of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">supply, financial performance and strategic plans of the Company and its Affiliates, (D) the identity and special needs of the customers of the Company and its Affiliates and (E) the people and organizations with whom the Company and its Affiliates have business relationships and the nature and substance of those relationships.  Confidential Information also includes any information that the Company or any of its Affiliates has received, or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not be disclosed.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;You agree and acknowledge that the business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) of the Company is any business activity engaged in, or actively contemplated by the Company (or any Subsidiary) to be engaged in, by the Company (or any Subsidiary) and with which you are or were involved on or prior to your date of termination.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;You agree that, except as the Company expressly agrees in writing, during your employment with the Company and for the 12-month period following termination of your employment for any reason, you shall not within the Territory (defined below), directly or indirectly, as an owner, partner, affiliate, stockholder, joint venturer, director, employee, consultant, contractor, principal, trustee or licensor, or in any other similar capacity whatsoever, of or for any person or entity (other than for the Company)&#58;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(A)&#160;&#160;&#160;&#160;engage in, own, manage, operate, sell, finance, control, advise or participate in the ownership, management, operation, sales, finance or control of, be employed or employed by, or be connected in any manner with, any business that competes with (1) the Business or (2) if you have provided services directly to any health maintenance organization, health insurance company or similar health insurance plan, owned or operated by a customer of the Company, during the twelve-month period preceding the termination of your employment with the Company, such customer (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  Notwithstanding this Section 14(b)(ii)(A), you may accept employment with a Competitor whose business is diversified, provided that (I) such employment is with a portion of the Competitor&#8217;s business that does not provide products or services that are the same as, are similar to, or compete with the Company&#8217;s products or services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Competing Products or Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) and (II) prior to your acceptance of such employment with Competitor, the Company receives separate written assurances satisfactory to the Company from such Competitor and from you that you will not provide any Competing Products or Services&#59;</font></div><div style="text-align:justify;text-indent:144pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(B)&#160;&#160;&#160;&#160;approach, solicit, divert, interfere with, or take away, the business or patronage of any of the actual or prospective members, customers, or clients of the Company, for a purpose that is competitive with the Business&#59; or</font></div><div style="text-align:justify;text-indent:144pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(C)&#160;&#160;&#160;&#160;contact, recruit, solicit, hire, retain, or employ (whether as an employee, consultant, agent, independent contractor, or otherwise) any person who is, or who at any time during the 6-month period prior to your date of termination had been, employed or engaged by the Company, or induce or take </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">any action which is intended to induce any such person to terminate his or her employment or relationship, or otherwise cease his or her relationship, with the Company, or interfere in any manner with the contractual or employment relationship between the Company and any employee of or any other person engaged by the Company.</font></div><div style="text-indent:144pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the United States of America and any other country with respect to which you have been involved on behalf of the Company.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in Section 14(b)(ii) of this Award Agreement, you are permitted to own, individually, as a passive investor (with no director designation rights, voting rights or veto rights or other special governance or voting rights), up to a one percent (1%) interest in any publicly traded entity that is a Competitor.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;You shall disclose in writing all of your relationships as a director, employee, consultant, contractor, principal, trustee, licensor, agent, or otherwise, with a Competitor or other business entity, to the Company for the 12-month period after your date of termination. You shall not disparage the Company or any of its officers, directors, or employees&#59; provided, however, that this Section 14(b)(iv) shall not prohibit or constrain truthful testimony by you compelled by any valid legal process or valid legal dispute resolution process.  Notwithstanding anything herein to the contrary, nothing in this Section 14 shall prevent either party hereto from enforcing such party&#8217;s rights or remedies hereunder or that such party may otherwise be entitled to enforce or assert under any other agreement or applicable law, or shall limit such rights or remedies in any way.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(v)&#160;&#160;&#160;&#160;During the 12-month period following your date of termination, you shall notify in writing any prospective new employer or entity otherwise seeking to engage you that the provisions of this Section 14 exist prior to accepting employment or such other engagement.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The terms of this Section 14 are reasonable and necessary in light of your position with the Company and responsibility and knowledge of the operations of the Company and its Subsidiaries and are not more restrictive than necessary to protect the legitimate interests of the parties hereto.  In addition, any breach of the covenants contained in this Section 14 would cause irreparable harm to the Company, its Subsidiaries and Affiliates, and there would be no adequate remedy at law or in damages to compensate the Company, its Subsidiaries and Affiliates for any such breach.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Protected Rights&#59; Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, this Award Agreement is not intended to, and shall be interpreted in a manner that does not, limit or restrict you from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Exchange Act).  </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;Under the Defend Trade Secrets Act&#58; (A) no person will be held criminally or civilly liable under federal or state trade secret law for disclosure of a trade secret (as defined in the Economic Espionage Act) that is&#58; (1) made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected violation of law, or, (2) made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal so that it is not made public, and (B) a person who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the person and use the trade secret information in the court proceeding, if the person files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All notices, requests, demands and other communications required or permitted to be given under the terms of this Award Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three Business Days after they have been mailed by U.S. certified or registered mail, return receipt requested, postage prepaid, addressed to the other party as set forth below&#58;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"></td><td style="width:34.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Evolent Health, Inc.<br>800 N. Glebe Road, Suite 500<br>Arlington, VA 22203<br>Attention&#58; General Counsel<br></font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to you&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">To your address as most recently supplied to the Company and set forth in the Company&#8217;s records</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The parties may change the address to which notices under this Award Agreement shall be sent by providing written notice to the other in the manner specified above.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Award Agreement shall be deemed to be made in the State of Delaware, and the validity, construction and effect of this Award Agreement in all respects shall be determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Headings and Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Headings are given to the Sections and subsections of this Award Agreement solely as a convenience to facilitate reference.  Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Award Agreement or any provision thereof.  Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Award Agreement, they shall be deemed to be followed by the words &#8220;but not limited to&#8221;.  The term &#8220;or&#8221; is not exclusive.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment of this Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate this Award Agreement prospectively or retroactively&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> that, except as set forth in Section 19(d) of this Award Agreement, any such waiver, amendment, alteration, suspension, discontinuance, cancelation or termination that would impair your rights under this Award Agreement shall not to that extent be effective without your consent (it being understood, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">notwithstanding the foregoing proviso, that this Award Agreement and the PSUs shall be subject to the provisions of Section 7(c) of the Plan).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;It is intended that the provisions of this Award Agreement be exempt from or comply with Section 409A, and all provisions of this Award Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Neither you nor any of your creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section 409A) payable under this Award Agreement to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to you or for your benefit under this Award Agreement may not be reduced by, or offset against, any amount owing by you to the Company or any of its Affiliates.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;If, at the time of your separation from service (within the meaning of Section 409A), (i) you shall be a specified employee (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable hereunder constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A, then the Company shall not pay such amount on the otherwise scheduled payment date but shall instead pay it, without interest, on the first Business Day after such six-month period.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Notwithstanding any provision of this Award Agreement to the contrary, in light of the uncertainty with respect to the proper application of Section 409A, the Company reserves the right to make amendments to this Award Agreement as the Company deems necessary or desirable to avoid the imposition of taxes or penalties under Section 409A. In any case, you shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on you or for your account in connection with this Award Agreement (including any taxes and penalties under Section 409A), and neither the Company nor any of its Affiliates shall have any obligation to indemnify or otherwise hold you harmless from any or all of such taxes or penalties.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Award Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  You and the Company hereby acknowledge and agree that signatures delivered by facsimile or electronic means (including by &#8220;pdf&#8221;) shall be deemed effective for all purposes.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i24a861af0d304059aa4ce7be719fd5a7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">APPENDIX A</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The number of PSUs that you actually earn for the Performance Period will vary in accordance with the Business Unity Value for the Performance Period, as set out in the table below. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If the  Business Unit Value falls between tiers, the actual percentage of the Target Number of PSUs earned shall be determined by linear interpolation between the percentages listed on a straight-line basis.  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Performance Level</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Business Unit Value</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Percentage of Target Number of PSUs Earned<br></font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Below Threshold<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Threshold<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Target<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Target Plus<br></font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Maximum<br></font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i24a861af0d304059aa4ce7be719fd5a7_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">APPENDIX B</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ADJUSTED EBITDA AND REVENUE TARGETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">FOR THE PERFORMANCE PERIOD BY QUARTER</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#929292;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BUSINESS UNIT</font></td><td colspan="18" style="background-color:#929292;border-bottom:1pt solid #000000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ADJUSTED EBITDA ($ MM)</font></div></td><td colspan="18" style="background-color:#929292;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">REVENUE ($ MM)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Quarter</font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Annual</font></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;.&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;.&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a33122exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i97d88adcf9c4409d9455edbcb27b3cdf_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a33122exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i37a2d40fafd74ae9ac575fbe009e05f1_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a33122exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1165f0d9b2bf48e19548b0ebe4254e97_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a33122exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9fe7461fad7842abbacab62c5e96aa52_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>evh-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d53c1d9c-a1b3-428c-ab91-113966fe5337,g:d0023668-d86c-4a77-8abf-aab325264a20-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.evolenthealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>2110103 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>2411406 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>2112104 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsTables" roleURI="http://www.evolenthealth.com/role/TransactionsTables">
        <link:definition>2313302 - Disclosure - Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsVitalDecisionsDetails" roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails">
        <link:definition>2414407 - Disclosure - Transactions - Vital Decisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations">
        <link:definition>2115105 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables">
        <link:definition>2316303 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofResultsofOperationsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails">
        <link:definition>2417408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCashFlowsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails">
        <link:definition>2418409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>2119106 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>2320304 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails">
        <link:definition>2421410 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>2422411 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>2423412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>2423412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>2424413 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>2425414 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>2126107 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>2327305 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>2428415 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>2429416 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>2130108 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>2331306 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2432417 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>2133109 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>2334307 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>2435418 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>2436419 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>2437420 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails">
        <link:definition>2438421 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>2139110 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>2340308 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>2441422 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtCreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails">
        <link:definition>2442423 - Disclosure - Long-term Debt - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtWarrantAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails">
        <link:definition>2443424 - Disclosure - Long-term Debt - Warrant Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>2444425 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>2445426 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>2446427 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>2147111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>2348309 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2449428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesReinsuranceAgreementsDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails">
        <link:definition>2450429 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails">
        <link:definition>2451430 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>2152112 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>2353310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>2454431 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesPrimaryOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails">
        <link:definition>2455432 - Disclosure - Leases - Primary Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2456433 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>2457434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>2457434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>2458435 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.evolenthealth.com/role/LossPerCommonShare">
        <link:definition>2159113 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareTables">
        <link:definition>2360311 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails">
        <link:definition>2461436 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2462437 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>2163114 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables">
        <link:definition>2364312 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>2465438 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails">
        <link:definition>2466439 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
        <link:definition>2467440 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>2168115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2469441 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees">
        <link:definition>2170116 - Disclosure - Investments in Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvesteesDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails">
        <link:definition>2471442 - Disclosure - Investments in Equity Method Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>2172117 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>2373313 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>2474443 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>2475444 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>2476445 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>2177118 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>2378314 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>2479446 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>2480447 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChanges" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges">
        <link:definition>2181119 - Disclosure - Repositioning and Other Changes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesTables" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables">
        <link:definition>2382315 - Disclosure - Repositioning and Other Changes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesDetails" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails">
        <link:definition>2483448 - Disclosure - Repositioning and Other Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolenthealth.com/role/SegmentReporting">
        <link:definition>2184120 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolenthealth.com/role/SegmentReportingTables">
        <link:definition>2385316 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>2486449 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>2487450 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>2488451 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>2189121 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>2390317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>2491452 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>2192122 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>2393318 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>2494453 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_ProceedsFromReinsurance" abstract="false" name="ProceedsFromReinsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ClinicalSolutionsSegmentMember" abstract="true" name="ClinicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TrueHealthMember" abstract="true" name="TrueHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" abstract="false" name="TaxReceivablesAgreementPercentofTaxSavingstobePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MolinaHealthcareMember" abstract="true" name="MolinaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ProceedsFromMaturityOfInvestments" abstract="false" name="ProceedsFromMaturityOfInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransformationServicesMember" abstract="true" name="TransformationServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" abstract="false" name="CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfOffsetPolicyPolicyTextBlock" abstract="false" name="RightOfOffsetPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_VitalDecisionsMember" abstract="true" name="VitalDecisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" abstract="false" name="PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" abstract="false" name="PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightofUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" abstract="false" name="CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" abstract="true" name="MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforOtherContractualCommitmentsMember" abstract="true" name="RestrictedCashforOtherContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" abstract="false" name="CostofGoodsandServicesSoldExcludingDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" abstract="false" name="AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_GainLossOnDispositionOfAssetsOperatingActivities" abstract="false" name="GainLossOnDispositionOfAssetsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfUseAssetAcquiredAndDisposedOf" abstract="false" name="RightOfUseAssetAcquiredAndDisposedOf" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" abstract="false" name="TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" abstract="false" name="ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityComponentOfLongTermDebtMember" abstract="true" name="EquityComponentOfLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" abstract="false" name="CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsRevenueMember" abstract="true" name="PremiumsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ProfessionalServicesRestructuringMember" abstract="true" name="ProfessionalServicesRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_InitialTermLoanFacilityMember" abstract="true" name="InitialTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsOfMakeWholePremium" abstract="false" name="PaymentsOfMakeWholePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationIncludingOnetimeAdjustment" abstract="false" name="SharebasedCompensationIncludingOnetimeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PlatformsAndOperationsServicesMember" abstract="true" name="PlatformsAndOperationsServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorCreditFacilitiesMember" abstract="true" name="SeniorCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareholderAdvisoryServices" abstract="false" name="ShareholderAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_EmployeeSeveranceAndTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtConversionOriginalDebtFairValue" abstract="false" name="DebtConversionOriginalDebtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" abstract="false" name="PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_GainOnTransferOfMembership" abstract="false" name="GainOnTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossfromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DeferredFinancingFeesMember" abstract="true" name="DeferredFinancingFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>evh-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d53c1d9c-a1b3-428c-ab91-113966fe5337,g:d0023668-d86c-4a77-8abf-aab325264a20-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e537117c-e1f2-4425-a3f2-9ec58cf74398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_207b1052-4b46-4970-9931-48e9bc22d8db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e537117c-e1f2-4425-a3f2-9ec58cf74398" xlink:to="loc_us-gaap_AdditionalPaidInCapital_207b1052-4b46-4970-9931-48e9bc22d8db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_711ac609-676e-4dcc-8a38-ae2a70828aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e537117c-e1f2-4425-a3f2-9ec58cf74398" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_711ac609-676e-4dcc-8a38-ae2a70828aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_daae3144-4fe3-444c-8a1c-94209dda002c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e537117c-e1f2-4425-a3f2-9ec58cf74398" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_daae3144-4fe3-444c-8a1c-94209dda002c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9c94d31e-45b5-4d2b-8005-d0f892cf2295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e537117c-e1f2-4425-a3f2-9ec58cf74398" xlink:to="loc_us-gaap_CommonStockValue_9c94d31e-45b5-4d2b-8005-d0f892cf2295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5e6edac2-8006-4b71-b185-75615605b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e537117c-e1f2-4425-a3f2-9ec58cf74398" xlink:to="loc_us-gaap_TreasuryStockValue_5e6edac2-8006-4b71-b185-75615605b5c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_950a1ba2-c04f-49f1-805f-da58421e1176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc34f290-0b0b-4a51-ba96-a9be0f79fb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_950a1ba2-c04f-49f1-805f-da58421e1176" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc34f290-0b0b-4a51-ba96-a9be0f79fb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_e3981488-a189-453e-a59f-3f792ef219b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_950a1ba2-c04f-49f1-805f-da58421e1176" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_e3981488-a189-453e-a59f-3f792ef219b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e25665b8-2157-472a-ac2a-daeba598ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_950a1ba2-c04f-49f1-805f-da58421e1176" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e25665b8-2157-472a-ac2a-daeba598ed77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_31987fb8-1de5-406d-9553-88f0fbf803b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_950a1ba2-c04f-49f1-805f-da58421e1176" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_31987fb8-1de5-406d-9553-88f0fbf803b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c848b76c-2ae8-45b5-b2a0-e4d72fc3cfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:to="loc_us-gaap_AccountsPayableCurrent_c848b76c-2ae8-45b5-b2a0-e4d72fc3cfe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1b9fbd45-1f15-41ed-8a1a-b460e478cbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1b9fbd45-1f15-41ed-8a1a-b460e478cbf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_85afe77b-7a88-42b3-bbe8-c1bddd767f9e" xlink:href="evh-20220331.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_85afe77b-7a88-42b3-bbe8-c1bddd767f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d23dd2f-badb-45ce-b7fc-5b18ac508b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d23dd2f-badb-45ce-b7fc-5b18ac508b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c4bd7897-a4fe-47eb-a82b-75f8317f29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c4bd7897-a4fe-47eb-a82b-75f8317f29c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2618962-b13c-493e-a014-4fa7652e6144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f9ba201-c480-4188-a22f-0661f01fd30b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2618962-b13c-493e-a014-4fa7652e6144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a1c78633-164a-472c-951d-4f1328193d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b87a016-1654-46aa-8762-60d3ae3153b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a1c78633-164a-472c-951d-4f1328193d52" xlink:to="loc_us-gaap_Liabilities_6b87a016-1654-46aa-8762-60d3ae3153b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5b6d88b4-3228-4288-abe0-4337bad1652c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a1c78633-164a-472c-951d-4f1328193d52" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5b6d88b4-3228-4288-abe0-4337bad1652c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ddac2fa9-7e2e-4448-aa23-3dd54c0b43ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a1c78633-164a-472c-951d-4f1328193d52" xlink:to="loc_us-gaap_StockholdersEquity_ddac2fa9-7e2e-4448-aa23-3dd54c0b43ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_cfc2b5fd-84b4-478f-8798-f2066e4b90ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_cfc2b5fd-84b4-478f-8798-f2066e4b90ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3ba327aa-9c97-4b88-b926-30d140dfd575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_AssetsCurrent_3ba327aa-9c97-4b88-b926-30d140dfd575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd0c789e-f2ac-4496-bbb9-7b560f9ebcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd0c789e-f2ac-4496-bbb9-7b560f9ebcbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e771cdf5-0acf-4b03-8b9f-bb4f46107733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e771cdf5-0acf-4b03-8b9f-bb4f46107733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_56c9fe5d-3946-492a-a8c3-7cea546c117b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_56c9fe5d-3946-492a-a8c3-7cea546c117b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_446e0858-3104-4400-9c15-354dfa0e7f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_446e0858-3104-4400-9c15-354dfa0e7f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_597928ae-75a3-4f9c-ab7a-58de754b51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_597928ae-75a3-4f9c-ab7a-58de754b51c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_91061c56-250b-42c6-97a5-65da9cfe07bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_Goodwill_91061c56-250b-42c6-97a5-65da9cfe07bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_730f1e75-93d9-428e-8665-3299f326f7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c893bfca-d02d-4ef8-911b-4652411e7271" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_730f1e75-93d9-428e-8665-3299f326f7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_51cc399c-5a24-45bd-bbc1-fa2ec7e32271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_06ba377b-7e34-4d8f-a2ca-aa84f687ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51cc399c-5a24-45bd-bbc1-fa2ec7e32271" xlink:to="loc_us-gaap_LiabilitiesCurrent_06ba377b-7e34-4d8f-a2ca-aa84f687ed60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_64a2fb9d-6757-4012-a370-930fff4436f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51cc399c-5a24-45bd-bbc1-fa2ec7e32271" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_64a2fb9d-6757-4012-a370-930fff4436f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ceb30e90-35af-4484-beb4-4209034acd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51cc399c-5a24-45bd-bbc1-fa2ec7e32271" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ceb30e90-35af-4484-beb4-4209034acd18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1ae97cb6-d245-49f3-b537-15953d5b0ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51cc399c-5a24-45bd-bbc1-fa2ec7e32271" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1ae97cb6-d245-49f3-b537-15953d5b0ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_63e4e61c-213c-4cee-a08f-0281b10ab1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51cc399c-5a24-45bd-bbc1-fa2ec7e32271" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_63e4e61c-213c-4cee-a08f-0281b10ab1f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f25d9fd5-a3e8-4058-8d8f-d8ce67cce8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d80e045f-c032-409f-85a1-6c391fba3814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f25d9fd5-a3e8-4058-8d8f-d8ce67cce8d5" xlink:to="loc_us-gaap_NetIncomeLoss_d80e045f-c032-409f-85a1-6c391fba3814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_633a166c-3749-405e-be48-6b62730d4625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f25d9fd5-a3e8-4058-8d8f-d8ce67cce8d5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_633a166c-3749-405e-be48-6b62730d4625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9c903c15-dd81-4c5f-b110-9fec8b2d59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ee7b26b8-7090-4c51-a7c8-577575cde08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9c903c15-dd81-4c5f-b110-9fec8b2d59a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ee7b26b8-7090-4c51-a7c8-577575cde08b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cf68ce29-b86f-4d5e-89ad-01c553b00a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9c903c15-dd81-4c5f-b110-9fec8b2d59a7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cf68ce29-b86f-4d5e-89ad-01c553b00a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be74b974-cc39-443d-9f12-4ee1c49eba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e2195077-e193-47cc-b0cb-dd3caba8da2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_be74b974-cc39-443d-9f12-4ee1c49eba1c" xlink:to="loc_us-gaap_OperatingExpenses_e2195077-e193-47cc-b0cb-dd3caba8da2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c93f2510-9b68-4976-b86a-74dd0180d41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_be74b974-cc39-443d-9f12-4ee1c49eba1c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c93f2510-9b68-4976-b86a-74dd0180d41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b9ffc39e-8dc3-4996-ae25-aad7497b4748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9a092497-8e82-4f6d-a6a7-4d162330c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b9ffc39e-8dc3-4996-ae25-aad7497b4748" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9a092497-8e82-4f6d-a6a7-4d162330c4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_75ff7fdc-c4c2-48e7-bc83-6e2029015975" xlink:href="evh-20220331.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b9ffc39e-8dc3-4996-ae25-aad7497b4748" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_75ff7fdc-c4c2-48e7-bc83-6e2029015975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_53546f3e-950f-4989-bf53-6e9fea3e62db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b9ffc39e-8dc3-4996-ae25-aad7497b4748" xlink:to="loc_us-gaap_DepreciationAndAmortization_53546f3e-950f-4989-bf53-6e9fea3e62db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56f2efa8-9a00-4394-a407-a8513b4e5b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b9ffc39e-8dc3-4996-ae25-aad7497b4748" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56f2efa8-9a00-4394-a407-a8513b4e5b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9c1e1f3d-5c88-4305-943b-842a3863ed98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_86c88864-0038-42ac-9b38-a790a3f6c6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9c1e1f3d-5c88-4305-943b-842a3863ed98" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_86c88864-0038-42ac-9b38-a790a3f6c6a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b6d464ec-10e5-4d5f-bfd1-8ab2a6e472d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9c1e1f3d-5c88-4305-943b-842a3863ed98" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b6d464ec-10e5-4d5f-bfd1-8ab2a6e472d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eeb2221e-8e0e-4402-a010-6fdc4126008b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eeb2221e-8e0e-4402-a010-6fdc4126008b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5cbcc494-bc44-4f7e-8612-4d4760642986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5cbcc494-bc44-4f7e-8612-4d4760642986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9ff292e7-f849-4262-8834-7653cbe27fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9ff292e7-f849-4262-8834-7653cbe27fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c24b56d1-765f-4972-8ecd-7a639dce6744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_us-gaap_OperatingIncomeLoss_c24b56d1-765f-4972-8ecd-7a639dce6744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f016fe0a-b2a6-43b3-9d6a-58c6d43bb37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f016fe0a-b2a6-43b3-9d6a-58c6d43bb37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f80a5d74-8b90-4cf9-baa7-31933f73a83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_us-gaap_InterestExpense_f80a5d74-8b90-4cf9-baa7-31933f73a83b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_151b1d6e-61ea-4c12-be4e-30a574ad1a9f" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ee0f42-3354-408f-ae75-78d58d229c25" xlink:to="loc_evh_GainOnTransferOfMembership_151b1d6e-61ea-4c12-be4e-30a574ad1a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_54da4735-3e7b-40bb-a104-327d3d2d6152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03f1c44c-1c0e-454d-90db-19176fae9e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_54da4735-3e7b-40bb-a104-327d3d2d6152" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03f1c44c-1c0e-454d-90db-19176fae9e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a1fedb40-9e03-42da-8ea2-17b82281913b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_54da4735-3e7b-40bb-a104-327d3d2d6152" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a1fedb40-9e03-42da-8ea2-17b82281913b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ca35f8b-46c1-415e-ba92-966b105d54a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d63f7e64-2899-446f-8eba-1373fe2d7775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ca35f8b-46c1-415e-ba92-966b105d54a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d63f7e64-2899-446f-8eba-1373fe2d7775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c51f5570-ee0c-44a2-aef8-7f2908e06bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ca35f8b-46c1-415e-ba92-966b105d54a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c51f5570-ee0c-44a2-aef8-7f2908e06bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7a0b6b6e-aac1-43e6-9722-876944333baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_42affc5d-3318-494c-8c78-a2333b448e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_7a0b6b6e-aac1-43e6-9722-876944333baa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_42affc5d-3318-494c-8c78-a2333b448e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_255cf90c-f211-4105-9c55-e6b66447f92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_7a0b6b6e-aac1-43e6-9722-876944333baa" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_255cf90c-f211-4105-9c55-e6b66447f92d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f5164e1-f66d-4848-9fd5-5c897313b8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48787108-de85-47fb-bf27-61c5ea061179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f5164e1-f66d-4848-9fd5-5c897313b8d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48787108-de85-47fb-bf27-61c5ea061179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abaac0a3-dc68-409c-b1ae-b828aa31409a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f5164e1-f66d-4848-9fd5-5c897313b8d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abaac0a3-dc68-409c-b1ae-b828aa31409a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97ca2736-8188-43af-85da-9de37de58133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f5164e1-f66d-4848-9fd5-5c897313b8d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97ca2736-8188-43af-85da-9de37de58133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a5c98e3-003c-45a5-b92b-17c5bb284c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f5164e1-f66d-4848-9fd5-5c897313b8d4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a5c98e3-003c-45a5-b92b-17c5bb284c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3a716480-55dd-462b-a8c6-6be41b5fe400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_ShareBasedCompensation_3a716480-55dd-462b-a8c6-6be41b5fe400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c7d450f7-b14d-4a49-ac03-29d6de0b550a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c7d450f7-b14d-4a49-ac03-29d6de0b550a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3561686f-43a6-409f-90ee-d106dbdbd55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3561686f-43a6-409f-90ee-d106dbdbd55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_3311f236-ac80-46b6-85ca-46de6188f29b" xlink:href="evh-20220331.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_3311f236-ac80-46b6-85ca-46de6188f29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bb093f42-7db4-4259-ada0-da9de9a0bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bb093f42-7db4-4259-ada0-da9de9a0bcce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_f2fc0d4a-a2a8-446c-9026-b8d1be94dc83" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_f2fc0d4a-a2a8-446c-9026-b8d1be94dc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d0c660f7-7c91-4173-b82c-66ccd09e53b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d0c660f7-7c91-4173-b82c-66ccd09e53b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92cb7066-4ac9-427f-ac66-c8897353e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92cb7066-4ac9-427f-ac66-c8897353e6af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d6654534-32a9-42cb-bdc4-b885524c0529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d6654534-32a9-42cb-bdc4-b885524c0529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f682e390-2b83-4db6-ab0b-1b251e8d80aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f682e390-2b83-4db6-ab0b-1b251e8d80aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_688e8a52-2a70-4b81-9c06-40c881c58cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_688e8a52-2a70-4b81-9c06-40c881c58cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_be66defd-8a2b-4063-b340-211ec5e6d4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_be66defd-8a2b-4063-b340-211ec5e6d4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4fede5fe-8979-48a8-9ad4-8be9acd3f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4fede5fe-8979-48a8-9ad4-8be9acd3f64e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_f0b41c53-3bdb-4fa1-984a-5c3a2c587024" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_f0b41c53-3bdb-4fa1-984a-5c3a2c587024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_9e185355-930d-4d09-8b67-86a7551fdaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_9e185355-930d-4d09-8b67-86a7551fdaf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_a9800d79-51ca-4f97-8bf0-a6a4f6f26432" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_evh_GainOnTransferOfMembership_a9800d79-51ca-4f97-8bf0-a6a4f6f26432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_948ddf7e-5362-4158-a588-1e299d19eaa2" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_948ddf7e-5362-4158-a588-1e299d19eaa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9decfd19-0f15-41b7-b97f-74faad7a68b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9decfd19-0f15-41b7-b97f-74faad7a68b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_a89eacc8-509c-4f49-ace5-04915ad154ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_a89eacc8-509c-4f49-ace5-04915ad154ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_eb2d4810-024f-438d-926d-d34cde09f8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_eb2d4810-024f-438d-926d-d34cde09f8bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_56afb2da-d9b0-4ee9-bd76-c6d49a705b54" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_56afb2da-d9b0-4ee9-bd76-c6d49a705b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6b4adec9-b515-4375-972c-dcc31063a66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6b4adec9-b515-4375-972c-dcc31063a66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b26cb8e-8d9e-4c8e-93bf-fd220432bf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_NetIncomeLoss_9b26cb8e-8d9e-4c8e-93bf-fd220432bf5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_12a65b24-3d64-4faf-9f2e-680fa9185ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11f2bcd0-883d-4978-a0bb-9d995e61f73d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_12a65b24-3d64-4faf-9f2e-680fa9185ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_9fcf3d64-cfd0-4116-9cf0-fd2360c80932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_9fcf3d64-cfd0-4116-9cf0-fd2360c80932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_f277515c-6689-451a-9727-a08f7180f4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_f277515c-6689-451a-9727-a08f7180f4d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_b61627de-441c-4d9c-ac56-70a1b4b26731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_b61627de-441c-4d9c-ac56-70a1b4b26731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_1d44c93c-0428-4290-b4b8-6b818919bccd" xlink:href="evh-20220331.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_1d44c93c-0428-4290-b4b8-6b818919bccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_eb8c4735-b80b-4131-898d-c875301012f5" xlink:href="evh-20220331.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_eb8c4735-b80b-4131-898d-c875301012f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4b6d4593-5500-4389-921a-56cbb8287e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4b6d4593-5500-4389-921a-56cbb8287e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2b58f9d3-079a-4751-b700-46dfdc2e66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d369d0-028a-4aee-ae1c-407d64630666" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2b58f9d3-079a-4751-b700-46dfdc2e66e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55ba7ff1-718e-4e35-a957-2568de5bffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_f357f9fb-9880-4d7e-b316-c14afb87626d" xlink:href="evh-20220331.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55ba7ff1-718e-4e35-a957-2568de5bffa0" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_f357f9fb-9880-4d7e-b316-c14afb87626d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_39a1761a-3218-4d4b-b8a1-a9094c3fde99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55ba7ff1-718e-4e35-a957-2568de5bffa0" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_39a1761a-3218-4d4b-b8a1-a9094c3fde99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_689ccbdd-e767-487f-b210-7902dbef2618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55ba7ff1-718e-4e35-a957-2568de5bffa0" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_689ccbdd-e767-487f-b210-7902dbef2618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ac3a6b73-f356-42aa-ae73-eceefef740bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55ba7ff1-718e-4e35-a957-2568de5bffa0" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ac3a6b73-f356-42aa-ae73-eceefef740bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019be632-94c6-4dfe-b315-ca9d7489faf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55ba7ff1-718e-4e35-a957-2568de5bffa0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019be632-94c6-4dfe-b315-ca9d7489faf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_32d13b9d-04e1-4f59-8723-1a0f86295e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ff2d2768-fdb9-48cd-b253-6d524f01a40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_32d13b9d-04e1-4f59-8723-1a0f86295e4c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ff2d2768-fdb9-48cd-b253-6d524f01a40f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_948037b3-9002-40f2-b680-139c3674f937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1e71fe9b-b79c-4c87-bc20-cb9a1d442cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_948037b3-9002-40f2-b680-139c3674f937" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1e71fe9b-b79c-4c87-bc20-cb9a1d442cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_219d45bb-f49e-446a-ba46-b4bf5cc266ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_99979794-ca09-449c-babb-a842ffcbcee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_219d45bb-f49e-446a-ba46-b4bf5cc266ef" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_99979794-ca09-449c-babb-a842ffcbcee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_1f7d5fe2-9329-4b55-a752-da229743cbf2" xlink:href="evh-20220331.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_219d45bb-f49e-446a-ba46-b4bf5cc266ef" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_1f7d5fe2-9329-4b55-a752-da229743cbf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_a651cfb4-af8d-4206-9a88-0495310a1b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_219d45bb-f49e-446a-ba46-b4bf5cc266ef" xlink:to="loc_us-gaap_RestrictedInvestments_a651cfb4-af8d-4206-9a88-0495310a1b09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#TransactionsVitalDecisionsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8898bd48-c79c-4bea-a89b-117561770489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_06aa691a-192b-4519-8ae6-317261ad85af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8898bd48-c79c-4bea-a89b-117561770489" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_06aa691a-192b-4519-8ae6-317261ad85af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_98ca84d7-c5ae-4857-880b-460c5f79eda0" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8898bd48-c79c-4bea-a89b-117561770489" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_98ca84d7-c5ae-4857-880b-460c5f79eda0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_18e768c2-52ff-4c17-960e-f3be306a930c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8898bd48-c79c-4bea-a89b-117561770489" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_18e768c2-52ff-4c17-960e-f3be306a930c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4f5747b1-7ef1-4a94-8881-66e24fc993f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8898bd48-c79c-4bea-a89b-117561770489" xlink:to="loc_us-gaap_Goodwill_4f5747b1-7ef1-4a94-8881-66e24fc993f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_04c82db5-9247-492c-8bdc-ffdd451613b6" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_04c82db5-9247-492c-8bdc-ffdd451613b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_77953239-4bc7-4be7-854b-fe1fc45dd018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_77953239-4bc7-4be7-854b-fe1fc45dd018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_f711e0e3-c458-495a-9efe-979e7faabbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_f711e0e3-c458-495a-9efe-979e7faabbd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d91ce6e5-bd94-4b89-bbb9-7f9950e9078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d91ce6e5-bd94-4b89-bbb9-7f9950e9078b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_c4a0f178-2053-4c3f-95a0-e00aa97fc31c" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_c4a0f178-2053-4c3f-95a0-e00aa97fc31c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1ddbf9aa-88ce-4115-b031-9a942526a4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6b285c6e-f3b1-45ab-afe8-c803cc968fba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1ddbf9aa-88ce-4115-b031-9a942526a4e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1308f22-a613-473a-a0f0-6e4149f6e070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53ad639d-2111-4b8d-9f77-5f0b5f137a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1308f22-a613-473a-a0f0-6e4149f6e070" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53ad639d-2111-4b8d-9f77-5f0b5f137a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e9cb46ab-2594-4663-a79a-d9870be136a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1308f22-a613-473a-a0f0-6e4149f6e070" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e9cb46ab-2594-4663-a79a-d9870be136a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a3ee4509-55d8-427f-b936-3536092b087c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1308f22-a613-473a-a0f0-6e4149f6e070" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a3ee4509-55d8-427f-b936-3536092b087c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d6d7bf00-686b-4868-9458-b400241fa948" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_13570c0f-c560-4a74-9bf7-c2c6ffe5650f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d6d7bf00-686b-4868-9458-b400241fa948" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_13570c0f-c560-4a74-9bf7-c2c6ffe5650f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6d31eca5-3bf7-42cc-96c2-40c89eda15fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d6d7bf00-686b-4868-9458-b400241fa948" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6d31eca5-3bf7-42cc-96c2-40c89eda15fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_3de90a74-dffe-4f93-a6ce-7d787c200c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d6d7bf00-686b-4868-9458-b400241fa948" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_3de90a74-dffe-4f93-a6ce-7d787c200c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_93cc243b-eec5-43c4-b663-c1910ecb9f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d6d7bf00-686b-4868-9458-b400241fa948" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_93cc243b-eec5-43c4-b663-c1910ecb9f1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_14f40356-c940-4e2e-aa44-d1d967be4a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2143c2d7-4fd1-469b-9fb4-0a225db34b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_14f40356-c940-4e2e-aa44-d1d967be4a59" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2143c2d7-4fd1-469b-9fb4-0a225db34b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_4d94b89c-2e8a-4c8a-ac2d-dffaf1b49d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_14f40356-c940-4e2e-aa44-d1d967be4a59" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_4d94b89c-2e8a-4c8a-ac2d-dffaf1b49d22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8fe11bce-7654-4450-a919-5bb1f4245ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e3b80b66-0e34-4978-9a3b-fa7fb628568c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8fe11bce-7654-4450-a919-5bb1f4245ea8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e3b80b66-0e34-4978-9a3b-fa7fb628568c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_104f4f7b-ddb7-4fdd-96fe-99e3db555c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8fe11bce-7654-4450-a919-5bb1f4245ea8" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_104f4f7b-ddb7-4fdd-96fe-99e3db555c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4175770c-eadc-4e0f-bb8c-55fabec3e606" xlink:href="evh-20220331.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8fe11bce-7654-4450-a919-5bb1f4245ea8" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4175770c-eadc-4e0f-bb8c-55fabec3e606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_528f50cf-ef6b-41a9-8729-8dca1770f647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8fe11bce-7654-4450-a919-5bb1f4245ea8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_528f50cf-ef6b-41a9-8729-8dca1770f647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1cc11735-21fd-47b2-bd88-198acdebf137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0d36d6fd-86ba-4f0f-948f-f937310eabb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1cc11735-21fd-47b2-bd88-198acdebf137" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0d36d6fd-86ba-4f0f-948f-f937310eabb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_b57b5677-5034-4ef0-8598-620a11fd019e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1cc11735-21fd-47b2-bd88-198acdebf137" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_b57b5677-5034-4ef0-8598-620a11fd019e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_25ba0e85-ea8b-458a-89e5-f0a37408bf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5746eaae-83db-4543-9a44-cf8b80340ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_25ba0e85-ea8b-458a-89e5-f0a37408bf30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5746eaae-83db-4543-9a44-cf8b80340ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_98bf4ab6-ce2c-4614-9ad7-0fe6f6f44792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_25ba0e85-ea8b-458a-89e5-f0a37408bf30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_98bf4ab6-ce2c-4614-9ad7-0fe6f6f44792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_f72f67aa-7c48-4ca1-bb68-bc0fa95da6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_25ba0e85-ea8b-458a-89e5-f0a37408bf30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_f72f67aa-7c48-4ca1-bb68-bc0fa95da6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_5d2e7021-3b18-4ba1-b1d1-1e4cfb7a6752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_25ba0e85-ea8b-458a-89e5-f0a37408bf30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_5d2e7021-3b18-4ba1-b1d1-1e4cfb7a6752" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a076b28b-c062-465f-aced-1819aacccf62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_da8901f9-1124-48c4-8803-6073fdb6dcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a076b28b-c062-465f-aced-1819aacccf62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_da8901f9-1124-48c4-8803-6073fdb6dcdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_349925f8-c224-4ae4-a69f-d8100df73ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a076b28b-c062-465f-aced-1819aacccf62" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_349925f8-c224-4ae4-a69f-d8100df73ee7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd65b12c-cdd1-4c6f-9270-7435db4821e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_48966ced-917c-47c1-97d4-0d77670c007a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd65b12c-cdd1-4c6f-9270-7435db4821e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_48966ced-917c-47c1-97d4-0d77670c007a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_73aaf415-5ca0-4dad-a7f4-b30f7e6d3570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd65b12c-cdd1-4c6f-9270-7435db4821e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_73aaf415-5ca0-4dad-a7f4-b30f7e6d3570" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_369ea65b-a56b-48fc-93a9-a41ac3e05e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_369ea65b-a56b-48fc-93a9-a41ac3e05e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_06d519e2-306e-465e-9de2-0bd1a1def334" xlink:href="evh-20220331.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_06d519e2-306e-465e-9de2-0bd1a1def334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a1db6a5d-2ce8-43d1-a322-f783f558c41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a1db6a5d-2ce8-43d1-a322-f783f558c41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fcb5bfba-7867-484f-a3f8-9f0e8ae11c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fcb5bfba-7867-484f-a3f8-9f0e8ae11c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_97cd5f5e-3a28-4077-b0f5-6dd427543f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_97cd5f5e-3a28-4077-b0f5-6dd427543f1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c59f0242-bb7c-4676-afbe-9fae4f63b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_76050c2c-374b-43d3-a217-8bc8f142abc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c59f0242-bb7c-4676-afbe-9fae4f63b979" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_4f9cd5e7-d221-42c4-a068-277162607a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d2262c90-e06e-4a1f-b329-3bc92a46cf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_4f9cd5e7-d221-42c4-a068-277162607a2d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d2262c90-e06e-4a1f-b329-3bc92a46cf14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_076f9ebf-88a5-4157-aca1-5b45f32654cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_4f9cd5e7-d221-42c4-a068-277162607a2d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_076f9ebf-88a5-4157-aca1-5b45f32654cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5f03ded4-2c95-4d28-b72f-0c5e4748bd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_197b84e6-8dc4-42f5-912c-689f829b9507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5f03ded4-2c95-4d28-b72f-0c5e4748bd32" xlink:to="loc_us-gaap_OperatingLeaseCost_197b84e6-8dc4-42f5-912c-689f829b9507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_5ed2fc65-d926-4604-8e33-084fcdfdee98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5f03ded4-2c95-4d28-b72f-0c5e4748bd32" xlink:to="loc_us-gaap_VariableLeaseCost_5ed2fc65-d926-4604-8e33-084fcdfdee98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afe2173c-02c3-499f-9fab-4a9fbafdd9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6ec32977-8724-47da-8d68-9c0198b4983e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afe2173c-02c3-499f-9fab-4a9fbafdd9ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6ec32977-8724-47da-8d68-9c0198b4983e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e8cc15eb-9c9d-4b60-8dfe-8c218f581402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afe2173c-02c3-499f-9fab-4a9fbafdd9ad" xlink:to="loc_us-gaap_OperatingLeaseLiability_e8cc15eb-9c9d-4b60-8dfe-8c218f581402" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ec053503-5571-460f-b0c2-9bddfca5a265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ec053503-5571-460f-b0c2-9bddfca5a265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8ae54f8f-8f41-4e1a-a99b-9cf7a476075e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8ae54f8f-8f41-4e1a-a99b-9cf7a476075e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b2541fca-2385-4221-a9b4-9c5335516fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b2541fca-2385-4221-a9b4-9c5335516fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f7ead0b7-27d2-4a35-8041-064d6ce24870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f7ead0b7-27d2-4a35-8041-064d6ce24870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_819ed7f3-becf-4b3d-a02e-204caa0a86b4" xlink:href="evh-20220331.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_819ed7f3-becf-4b3d-a02e-204caa0a86b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a47e4e5d-a237-4f50-99cf-6ecb6393bb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d0724fb-f549-4ab0-8404-0dad85aaeef4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a47e4e5d-a237-4f50-99cf-6ecb6393bb33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c9131b7e-04ad-4ed2-9800-c9b0f914304e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a8d5e39-7233-49e4-a4b7-837431c17926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c9131b7e-04ad-4ed2-9800-c9b0f914304e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a8d5e39-7233-49e4-a4b7-837431c17926" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_60466f8b-48fc-467d-a32e-b85337fa55c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_60466f8b-48fc-467d-a32e-b85337fa55c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_947a6473-da21-4a0a-8783-b4b0773fd196" xlink:href="evh-20220331.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_947a6473-da21-4a0a-8783-b4b0773fd196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_77b47aa6-3aeb-48d6-8432-68fabccf9e2b" xlink:href="evh-20220331.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_77b47aa6-3aeb-48d6-8432-68fabccf9e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_51c65f90-3954-40b9-af87-65996b8f0c6b" xlink:href="evh-20220331.xsd#evh_ShareholderAdvisoryServices"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_evh_ShareholderAdvisoryServices_51c65f90-3954-40b9-af87-65996b8f0c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_1e8fa0cc-6d69-467d-a900-0d708828d8ef" xlink:href="evh-20220331.xsd#evh_TransactionCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_evh_TransactionCosts_1e8fa0cc-6d69-467d-a900-0d708828d8ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_04221047-64c1-477d-8a5f-e299e43012f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_04221047-64c1-477d-8a5f-e299e43012f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2dc414e1-d66e-46ea-8869-e0765639077e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2dc414e1-d66e-46ea-8869-e0765639077e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b6324153-f26d-441f-ae9c-29dcc48ad68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_RestructuringCharges_b6324153-f26d-441f-ae9c-29dcc48ad68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb308214-c094-4b6c-b140-eb861dffe10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb308214-c094-4b6c-b140-eb861dffe10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e90e06dc-1421-4c32-a7bb-17208e01136b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_DepreciationAndAmortization_e90e06dc-1421-4c32-a7bb-17208e01136b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6fe5778-cc0f-47e5-bb37-3b102025d74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6fe5778-cc0f-47e5-bb37-3b102025d74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e5d923c3-78a2-4bd6-9cc7-2e0d6b6020bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e5d923c3-78a2-4bd6-9cc7-2e0d6b6020bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_154624c9-2151-417d-bdc5-7a4e12b95a04" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_evh_GainOnTransferOfMembership_154624c9-2151-417d-bdc5-7a4e12b95a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bf3253a0-cd58-4767-a2f0-72dea5778f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_InterestExpense_bf3253a0-cd58-4767-a2f0-72dea5778f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fc406325-9e12-41dd-805e-89e7948f26c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fc406325-9e12-41dd-805e-89e7948f26c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_746dcb5d-e4ef-4428-ae96-11a0e72c1cee" xlink:href="evh-20220331.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_746dcb5d-e4ef-4428-ae96-11a0e72c1cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7815a3be-ec7a-4b10-84da-7137872a4f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_70abfec1-6472-40cb-ae67-7b23722916d4" xlink:to="loc_us-gaap_SeveranceCosts1_7815a3be-ec7a-4b10-84da-7137872a4f6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_348a5e51-a4e7-418e-a580-62f1bdc82404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0651a7e9-27c2-4461-b488-df800b560947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_348a5e51-a4e7-418e-a580-62f1bdc82404" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0651a7e9-27c2-4461-b488-df800b560947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9dd09334-5ce2-4cbf-89a5-015009fb0053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_348a5e51-a4e7-418e-a580-62f1bdc82404" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9dd09334-5ce2-4cbf-89a5-015009fb0053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_16f01d6a-7df7-4fce-951c-1929f958a5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_348a5e51-a4e7-418e-a580-62f1bdc82404" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_16f01d6a-7df7-4fce-951c-1929f958a5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_1dd33f05-0871-44ba-ae66-6e7f6fe8158b" xlink:href="evh-20220331.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_348a5e51-a4e7-418e-a580-62f1bdc82404" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_1dd33f05-0871-44ba-ae66-6e7f6fe8158b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>evh-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d53c1d9c-a1b3-428c-ab91-113966fe5337,g:d0023668-d86c-4a77-8abf-aab325264a20-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="i66db02c0311b4e30aca59ef0129af667_CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a8edc745-0e9f-4dbd-b357-97d83645df35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_SharesIssued_a8edc745-0e9f-4dbd-b357-97d83645df35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf909dba-27c1-4bf8-a822-8aad9c88c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockholdersEquity_bf909dba-27c1-4bf8-a822-8aad9c88c1b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2772713-5d91-47f8-b773-96615df4f663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2772713-5d91-47f8-b773-96615df4f663" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_feecd7bd-be17-4fe3-8e1c-ff74cd96bc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_feecd7bd-be17-4fe3-8e1c-ff74cd96bc40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_882ae7a1-7871-4b6c-8a3e-02c941972074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_882ae7a1-7871-4b6c-8a3e-02c941972074" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3b23ef43-30ae-4f81-ae15-47b886ef0e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3b23ef43-30ae-4f81-ae15-47b886ef0e3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_06159d5e-6d06-4788-8e45-6c61e43790fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_06159d5e-6d06-4788-8e45-6c61e43790fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbd7cc-674b-449d-84e9-efc4ea716221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbd7cc-674b-449d-84e9-efc4ea716221" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5d268e06-68a9-41ae-b595-39fc07b58f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5d268e06-68a9-41ae-b595-39fc07b58f71" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4c49acf6-4ef9-4790-ac44-5103742285e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4c49acf6-4ef9-4790-ac44-5103742285e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25224165-1505-4c95-9dc2-2635f1af42bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_NetIncomeLoss_25224165-1505-4c95-9dc2-2635f1af42bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d8a3b6ce-e0a5-4fff-9ac7-eb0650b874b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93d1c57a-3879-4ffc-9ee2-e15df21a9215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ad704b5d-c47e-449b-95f8-0f78075f0586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ad704b5d-c47e-449b-95f8-0f78075f0586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:to="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60a3eadb-ec80-4f8f-baee-5f2497fbb57d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:to="loc_us-gaap_EquityComponentDomain_60a3eadb-ec80-4f8f-baee-5f2497fbb57d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:to="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7af8a2e7-e6a0-49fd-9c68-f24bf8bd933d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_CommonStockMember_7af8a2e7-e6a0-49fd-9c68-f24bf8bd933d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cc902dd0-e056-40b4-ad4d-845e92d8c780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cc902dd0-e056-40b4-ad4d-845e92d8c780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7b96890b-39fa-4ea9-ab1c-593dbeccb4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7b96890b-39fa-4ea9-ab1c-593dbeccb4b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ebe5a2bd-d4bd-439f-964f-d3e24554e1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_RetainedEarningsMember_ebe5a2bd-d4bd-439f-964f-d3e24554e1d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2dde61d7-c9ec-4a28-9dc3-6045364cd10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_TreasuryStockMember_2dde61d7-c9ec-4a28-9dc3-6045364cd10e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9543efd6-7dd7-49b8-9416-471f0432089b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9543efd6-7dd7-49b8-9416-471f0432089b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45321601-d53b-4ef4-80c9-7e70351490b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45321601-d53b-4ef4-80c9-7e70351490b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_647c053c-fbc7-4a86-a9ff-03ff9797084d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45321601-d53b-4ef4-80c9-7e70351490b8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_647c053c-fbc7-4a86-a9ff-03ff9797084d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="i7cd8cbb2749245728ebeaf42baad6a91_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_1e8d82b1-749e-4de8-b961-26539c7a3435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_1e8d82b1-749e-4de8-b961-26539c7a3435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_097269ec-8a33-4772-9686-88cb9ee7185f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_097269ec-8a33-4772-9686-88cb9ee7185f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_9613e276-cd76-4118-82b3-b087f9d688c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_9613e276-cd76-4118-82b3-b087f9d688c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_18c5338a-48d5-42dd-9ac6-966fa42d3126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_18c5338a-48d5-42dd-9ac6-966fa42d3126" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f41c241c-30fb-4480-a727-0d2a97baa2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f41c241c-30fb-4480-a727-0d2a97baa2a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_2e9e7491-e1e5-428f-ba37-ca92dd0892d6" xlink:href="evh-20220331.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_2e9e7491-e1e5-428f-ba37-ca92dd0892d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_f695b7d2-f711-4f9e-b7ae-93c707e5d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_f695b7d2-f711-4f9e-b7ae-93c707e5d6a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_df13981b-a6fc-4940-a97e-40629267d4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedInvestments_df13981b-a6fc-4940-a97e-40629267d4b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7abd052-a3f1-4a8a-a5da-ed107771938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7abd052-a3f1-4a8a-a5da-ed107771938b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_798b132a-8e4f-4616-9086-15606582ca33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_798b132a-8e4f-4616-9086-15606582ca33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_5c911be6-6041-4320-b69e-ea9e8e71e88b" xlink:href="evh-20220331.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_5c911be6-6041-4320-b69e-ea9e8e71e88b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_108371b9-eaf4-4207-b8c4-8bec15c4f84d" xlink:href="evh-20220331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_108371b9-eaf4-4207-b8c4-8bec15c4f84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_82224a1e-99ac-4084-86f3-9a13496a27ce" xlink:href="evh-20220331.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_82224a1e-99ac-4084-86f3-9a13496a27ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_8a2b823a-aaf9-4e01-81f3-cb9f72c8ac98" xlink:href="evh-20220331.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_8a2b823a-aaf9-4e01-81f3-cb9f72c8ac98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_b670dd54-3737-4b54-adc4-4cc2439dca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_us-gaap_BankTimeDepositsMember_b670dd54-3737-4b54-adc4-4cc2439dca3f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="i9b9c0237596644eab8a5e917658a9a40_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22af3b61-f2e3-4eca-9086-a610c84e1d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e94e1e1a-101b-4550-b951-8c0695e052e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22af3b61-f2e3-4eca-9086-a610c84e1d98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e94e1e1a-101b-4550-b951-8c0695e052e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22af3b61-f2e3-4eca-9086-a610c84e1d98" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2e975dc-e736-4c0d-b861-d3151aca2ec7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2e975dc-e736-4c0d-b861-d3151aca2ec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_918ed5a0-d356-4c34-8b11-12490abb400e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_TradeNamesMember_918ed5a0-d356-4c34-8b11-12490abb400e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3f66bc28-a606-4387-8813-7d7b8ef1e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3f66bc28-a606-4387-8813-7d7b8ef1e44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6f6ead58-fdcb-4bc2-963d-e8a2b0af9e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6f6ead58-fdcb-4bc2-963d-e8a2b0af9e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_0383959f-ab3d-4a0a-897a-4baddab66ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_0383959f-ab3d-4a0a-897a-4baddab66ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:to="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_166dafac-4b8d-46ae-ac57-553d7beb3e22_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:to="loc_srt_RangeMember_166dafac-4b8d-46ae-ac57-553d7beb3e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:to="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_40589e31-924a-4ccb-ac01-e802cb4e5db3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:to="loc_srt_MinimumMember_40589e31-924a-4ccb-ac01-e802cb4e5db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9cc4ac4-0f33-4390-94eb-2bcbb2fd465a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:to="loc_srt_MaximumMember_a9cc4ac4-0f33-4390-94eb-2bcbb2fd465a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="iccba9152ff324f56949b27e3d42275f1_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d30f3679-95c9-47dd-9546-595594c2d327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:to="loc_us-gaap_StockholdersEquity_d30f3679-95c9-47dd-9546-595594c2d327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f1722343-73ee-4ef9-992f-483e3816249e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:to="loc_us-gaap_LongTermDebt_f1722343-73ee-4ef9-992f-483e3816249e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c476b90e-7a8f-4fea-96dc-17fb42034524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:to="loc_us-gaap_EquityComponentDomain_c476b90e-7a8f-4fea-96dc-17fb42034524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:to="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b49c5f41-5a93-4027-9f6d-a8cb704080ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:to="loc_us-gaap_RetainedEarningsMember_b49c5f41-5a93-4027-9f6d-a8cb704080ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_45ae5255-13c5-4d27-800d-fb6b3537e316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_45ae5255-13c5-4d27-800d-fb6b3537e316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e78e3b2-f336-4996-8d5b-26658cf40a3d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e78e3b2-f336-4996-8d5b-26658cf40a3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cb54b28-3c61-456c-95f2-3e0dfbd37bab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cb54b28-3c61-456c-95f2-3e0dfbd37bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff107202-d4a2-4614-8272-f40707d3a0c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cb54b28-3c61-456c-95f2-3e0dfbd37bab" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff107202-d4a2-4614-8272-f40707d3a0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35197489-835a-4be2-8c1e-797952a49b22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35197489-835a-4be2-8c1e-797952a49b22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_ecde9912-ecc7-48f4-b57f-bd8c1f27c6bf" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_ecde9912-ecc7-48f4-b57f-bd8c1f27c6bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_b0174524-ace9-4aaa-9405-a21b3bc20f18" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_b0174524-ace9-4aaa-9405-a21b3bc20f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_78fb1cab-5efd-46b1-8936-b7bda6f8a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_78fb1cab-5efd-46b1-8936-b7bda6f8a56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_385cbc82-4cb4-4030-bcb8-a60e89ec810e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_78fb1cab-5efd-46b1-8936-b7bda6f8a56a" xlink:to="loc_us-gaap_SeniorNotesMember_385cbc82-4cb4-4030-bcb8-a60e89ec810e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3078a2dd-b594-4818-a246-1436e7890676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3078a2dd-b594-4818-a246-1436e7890676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_bcf55380-4767-4a71-84ec-9df40cad592d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3078a2dd-b594-4818-a246-1436e7890676" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_bcf55380-4767-4a71-84ec-9df40cad592d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#TransactionsVitalDecisionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended" id="i584ca29054c54d0c938df70804a15620_TransactionsVitalDecisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7dbbddf3-1158-4fa0-8455-29b5477c01df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7dbbddf3-1158-4fa0-8455-29b5477c01df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4b2a8eea-9fba-424e-9249-3a669d51bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4b2a8eea-9fba-424e-9249-3a669d51bdf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bfda60a8-75f2-4fd1-906d-d3191f3005c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bfda60a8-75f2-4fd1-906d-d3191f3005c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fdfed0d-cd6f-4dfc-8e45-7c776e8baff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fdfed0d-cd6f-4dfc-8e45-7c776e8baff0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7612c2f3-aeef-4317-ac4f-34b7df4db7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7612c2f3-aeef-4317-ac4f-34b7df4db7f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d27f0b41-90d4-4eff-bd6b-a1cff3495a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d27f0b41-90d4-4eff-bd6b-a1cff3495a68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_b76c604a-8e47-4371-82de-6ec619d62f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_b76c604a-8e47-4371-82de-6ec619d62f95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55e85963-5bff-41d6-9073-16ee826a5125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55e85963-5bff-41d6-9073-16ee826a5125" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2df3538e-8a95-4b6a-a7b7-52d84f5ddce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2df3538e-8a95-4b6a-a7b7-52d84f5ddce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9a34091c-ad39-4335-a51b-c0faba6c0a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9a34091c-ad39-4335-a51b-c0faba6c0a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_62b5535e-bf3b-4635-8fa1-c75e82012c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_62b5535e-bf3b-4635-8fa1-c75e82012c66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d0620489-5d84-40b8-a63c-45e4ad00993a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d0620489-5d84-40b8-a63c-45e4ad00993a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e6ee355b-b6bf-44be-91ef-8a6cdf21a68c" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e6ee355b-b6bf-44be-91ef-8a6cdf21a68c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_bb4bdcf8-70fb-4b9d-8575-235e4c315871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_bb4bdcf8-70fb-4b9d-8575-235e4c315871" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1bb4c4b0-e416-456b-961e-e6581138de70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_bb4bdcf8-70fb-4b9d-8575-235e4c315871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1bb4c4b0-e416-456b-961e-e6581138de70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4ae24d56-71b4-4590-8ae5-cf0526f3be25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4ae24d56-71b4-4590-8ae5-cf0526f3be25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_cc7ce8c0-4b79-4a05-a453-9be7ffe4db4f" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_cc7ce8c0-4b79-4a05-a453-9be7ffe4db4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_ca1d48cf-f957-4ee0-908a-efb058689caa" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_ca1d48cf-f957-4ee0-908a-efb058689caa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_aa864514-917d-4f7e-a8b6-d0edcfa993ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_aa864514-917d-4f7e-a8b6-d0edcfa993ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_17496bff-3af3-4f90-85b0-a9f51080fb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_17496bff-3af3-4f90-85b0-a9f51080fb25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2e85e874-2678-43d5-9ce5-1739a03a04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2e85e874-2678-43d5-9ce5-1739a03a04dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_708f43f0-2d00-40aa-8567-b09b1ce65dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_708f43f0-2d00-40aa-8567-b09b1ce65dbc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80a8f042-81e2-4a6c-83ec-b4ced8bde8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_Goodwill_80a8f042-81e2-4a6c-83ec-b4ced8bde8b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_47494148-5930-46a4-b378-1432c7da7847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_47494148-5930-46a4-b378-1432c7da7847" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f2d2bdc-5b4b-4d3c-a601-faa756c41f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f2d2bdc-5b4b-4d3c-a601-faa756c41f27" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a69dc12e-8970-4728-96e8-0857579fb1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a69dc12e-8970-4728-96e8-0857579fb1dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00ca311d-616f-4f0c-ae74-21781fa47ee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00ca311d-616f-4f0c-ae74-21781fa47ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4bc159e-604d-4337-bc95-090adce64ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4bc159e-604d-4337-bc95-090adce64ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_866c8709-d8a8-47a1-82c6-69866177e090" xlink:href="evh-20220331.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4bc159e-604d-4337-bc95-090adce64ff0" xlink:to="loc_evh_VitalDecisionsMember_866c8709-d8a8-47a1-82c6-69866177e090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_182c4eaa-1314-4a9c-b02e-62062b1683ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:to="loc_us-gaap_CustomerRelationshipsMember_182c4eaa-1314-4a9c-b02e-62062b1683ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_21e4b136-bb20-4a95-ad49-e86ec92c707c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_21e4b136-bb20-4a95-ad49-e86ec92c707c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_78c7bf66-4d2b-4388-8929-73da3d12082c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:to="loc_us-gaap_TradeNamesMember_78c7bf66-4d2b-4388-8929-73da3d12082c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended" id="i9b1366fdc9f243e1803035d7ede321b2_DiscontinuedOperationsSummaryofResultsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a612dd73-dd3e-412d-a93a-0eab3d7eeed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_RevenuesAbstract_a612dd73-dd3e-412d-a93a-0eab3d7eeed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_51948cc5-f020-4aa9-8958-753920fc3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a612dd73-dd3e-412d-a93a-0eab3d7eeed7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_51948cc5-f020-4aa9-8958-753920fc3fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7824dc39-dd4d-462a-a0c8-4e15cfda8399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7824dc39-dd4d-462a-a0c8-4e15cfda8399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4d96df69-420b-4df3-84ea-4ade18495387" xlink:href="evh-20220331.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4d96df69-420b-4df3-84ea-4ade18495387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c661232e-44db-4e99-a05b-b3d42c4b65e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c661232e-44db-4e99-a05b-b3d42c4b65e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_25d4387f-a628-456b-9ec0-35de75e5946e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_25d4387f-a628-456b-9ec0-35de75e5946e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_428124f7-897c-4574-aade-614f574c076e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_428124f7-897c-4574-aade-614f574c076e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_497d7bac-c11e-41bd-90e2-7c78f86b6fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_497d7bac-c11e-41bd-90e2-7c78f86b6fee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_608092b2-1977-424e-b606-d928b2822b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_608092b2-1977-424e-b606-d928b2822b26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_efa46236-f495-447b-ba7e-b3ac807d92cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_efa46236-f495-447b-ba7e-b3ac807d92cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_dd6c4319-d200-42ce-80b7-7af92edd8b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_dd6c4319-d200-42ce-80b7-7af92edd8b96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_67d2c937-602b-48dd-a952-18f2f921f23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_67d2c937-602b-48dd-a952-18f2f921f23d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_07fe1120-47de-4efe-bd60-b3d9489acc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_07fe1120-47de-4efe-bd60-b3d9489acc66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aeffa830-1389-4c8c-90ee-42bd9bd98137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aeffa830-1389-4c8c-90ee-42bd9bd98137" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_06273013-963a-450e-b80d-971ce76fc259_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_06273013-963a-450e-b80d-971ce76fc259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2f1c41ad-b91b-4c32-b6f6-b40aca200063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2f1c41ad-b91b-4c32-b6f6-b40aca200063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b72fd7d7-5bb7-49ec-a8ff-d0964b723c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2f1c41ad-b91b-4c32-b6f6-b40aca200063" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b72fd7d7-5bb7-49ec-a8ff-d0964b723c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7eea8b5c-60ae-42c5-abc3-795602605b25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7eea8b5c-60ae-42c5-abc3-795602605b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00ce89b9-c380-4fe0-9e1b-ff3dc586fdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00ce89b9-c380-4fe0-9e1b-ff3dc586fdc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_0c4d0f54-6955-4607-b9f4-a66d49ee6c31" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00ce89b9-c380-4fe0-9e1b-ff3dc586fdc2" xlink:to="loc_evh_TrueHealthMember_0c4d0f54-6955-4607-b9f4-a66d49ee6c31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_83cee9e5-ae42-48f4-9391-c9175ceb2e22_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:to="loc_srt_ProductsAndServicesDomain_83cee9e5-ae42-48f4-9391-c9175ceb2e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:to="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_0b2f4258-91a1-49f7-9ca5-4b769ed4a9f6" xlink:href="evh-20220331.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_0b2f4258-91a1-49f7-9ca5-4b769ed4a9f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_02ac66b2-4b30-4739-ab4e-b8f91b52ede5" xlink:href="evh-20220331.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:to="loc_evh_PremiumsRevenueMember_02ac66b2-4b30-4739-ab4e-b8f91b52ede5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_0e2e183f-9914-4519-911f-35908e2dcce8" xlink:href="evh-20220331.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:to="loc_evh_ServicesAgreementsMember_0e2e183f-9914-4519-911f-35908e2dcce8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended" id="i5660b39e20f54a20a217747003091eeb_DiscontinuedOperationsSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7a7571ca-6a57-4298-8bac-977083b85db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7a7571ca-6a57-4298-8bac-977083b85db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_192a536c-95a0-4c29-b990-096458e0ebe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_192a536c-95a0-4c29-b990-096458e0ebe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74ff679a-d348-42cd-9669-5da722cf214e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74ff679a-d348-42cd-9669-5da722cf214e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_db16277c-f2c7-45a4-9422-9789f127461c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_db16277c-f2c7-45a4-9422-9789f127461c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_36aa3962-5192-4564-a83e-19aebdd06e6f" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_db16277c-f2c7-45a4-9422-9789f127461c" xlink:to="loc_evh_TrueHealthMember_36aa3962-5192-4564-a83e-19aebdd06e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f603ff63-4acb-4c6c-9f5d-55fce207500e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f603ff63-4acb-4c6c-9f5d-55fce207500e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e3b21497-b1cd-4187-b3f0-a93a8408bc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e3b21497-b1cd-4187-b3f0-a93a8408bc99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c6d07323-cc50-4413-a792-40efde793e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e3b21497-b1cd-4187-b3f0-a93a8408bc99" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c6d07323-cc50-4413-a792-40efde793e9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended" id="i9fb35bef50d04031a49bcdb7660c8188_RevenueRecognitionAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8b1f1147-0cf3-4117-85da-f7f001a26b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_25bcea42-8e24-4160-8a41-bcd82b426466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8b1f1147-0cf3-4117-85da-f7f001a26b4e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_25bcea42-8e24-4160-8a41-bcd82b426466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8b1f1147-0cf3-4117-85da-f7f001a26b4e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57d70644-0e45-4f02-8173-68325d39ec8f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:to="loc_srt_ProductsAndServicesDomain_57d70644-0e45-4f02-8173-68325d39ec8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8586c3d-10c9-48c9-99af-d3a3d4ad1071" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:to="loc_srt_ProductsAndServicesDomain_a8586c3d-10c9-48c9-99af-d3a3d4ad1071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_b16cf48a-ede7-4f95-8eba-230ebe8fe5db" xlink:href="evh-20220331.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a8586c3d-10c9-48c9-99af-d3a3d4ad1071" xlink:to="loc_evh_TransformationServicesMember_b16cf48a-ede7-4f95-8eba-230ebe8fe5db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_53382892-2705-4c51-a86c-fb5e3bad0665_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_53382892-2705-4c51-a86c-fb5e3bad0665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88b035aa-7edc-448d-9b73-e0d0f7028c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88b035aa-7edc-448d-9b73-e0d0f7028c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8de797ca-7b2b-4af2-8742-e0f43ebfea6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88b035aa-7edc-448d-9b73-e0d0f7028c6c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8de797ca-7b2b-4af2-8742-e0f43ebfea6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5e6813d1-0f88-425d-9f33-523280948152_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5e6813d1-0f88-425d-9f33-523280948152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_18fd3138-0789-4b54-995f-37945388a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_18fd3138-0789-4b54-995f-37945388a3a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_6b341ea0-2435-48e0-937c-feeec4b242ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_18fd3138-0789-4b54-995f-37945388a3a3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_6b341ea0-2435-48e0-937c-feeec4b242ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i416666c9fea742d7b49c6e6a2c20ac80_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_218f8c3c-b1ec-4238-97b3-ea2f12c660e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6190029-9cb4-4422-b6f8-d83accac2a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_218f8c3c-b1ec-4238-97b3-ea2f12c660e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6190029-9cb4-4422-b6f8-d83accac2a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_218f8c3c-b1ec-4238-97b3-ea2f12c660e4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0c433640-81ca-43d2-8ff0-7b42bcbd8044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:to="loc_us-gaap_SegmentDomain_0c433640-81ca-43d2-8ff0-7b42bcbd8044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:to="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_6e4059bc-ac9a-41bc-9a9f-c654f946a7b5" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_6e4059bc-ac9a-41bc-9a9f-c654f946a7b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_42957931-bfbe-4c1f-9639-fdc982f7099d" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_42957931-bfbe-4c1f-9639-fdc982f7099d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:to="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8cef12b-1fa8-41ef-a380-1eea159f6907_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8cef12b-1fa8-41ef-a380-1eea159f6907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:to="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_bd416de8-7ab3-4e2e-9a68-bacac879f9b0" xlink:href="evh-20220331.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:to="loc_evh_MedicaidCustomersMember_bd416de8-7ab3-4e2e-9a68-bacac879f9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_cb938925-0bf6-4a95-a20f-0b4575cefc08" xlink:href="evh-20220331.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:to="loc_evh_MedicareCustomersMember_cb938925-0bf6-4a95-a20f-0b4575cefc08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_ef55204a-e777-4e81-961f-ce02616dae61" xlink:href="evh-20220331.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:to="loc_evh_CommercialAndOtherCustomersMember_ef55204a-e777-4e81-961f-ce02616dae61" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="ie82af4778b40483b979b0a9798ee0edc_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_8e12cbf7-3912-4c6d-aa81-745f0846c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_8e12cbf7-3912-4c6d-aa81-745f0846c32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2e368414-ce0b-482e-b5cc-19f79187d746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2e368414-ce0b-482e-b5cc-19f79187d746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_922880e7-0aac-418c-89d9-2adbf462f61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_922880e7-0aac-418c-89d9-2adbf462f61e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="i54c796f006e04403a9f50ec2a2ea8e76_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_8e12cbf7-3912-4c6d-aa81-745f0846c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_8e12cbf7-3912-4c6d-aa81-745f0846c32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2e368414-ce0b-482e-b5cc-19f79187d746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2e368414-ce0b-482e-b5cc-19f79187d746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="icac07f37979c4187b36cddb3e6f216f4_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_e622da2c-7491-41af-bad0-60a80aa183da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostNet_e622da2c-7491-41af-bad0-60a80aa183da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_4f0d6847-65e7-46ef-bc42-7ece2339a986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_4f0d6847-65e7-46ef-bc42-7ece2339a986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_a8bf5151-40dd-4892-97f0-f1180d83a030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_a8bf5151-40dd-4892-97f0-f1180d83a030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_bcdf4531-eb74-4ac1-8b85-d404af6d6418_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_bcdf4531-eb74-4ac1-8b85-d404af6d6418_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_f9b8b3f5-32c2-42f0-82ac-29c89fd847af" xlink:href="evh-20220331.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:to="loc_evh_BonusesAndCommissionsMember_f9b8b3f5-32c2-42f0-82ac-29c89fd847af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_8d3d44a6-2219-4649-9127-1d104fdc5b0b" xlink:href="evh-20220331.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:to="loc_evh_ContractFulfillmentCostsMember_8d3d44a6-2219-4649-9127-1d104fdc5b0b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="icec129941a0249c2bfc97bd34010115e_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_f77ca055-2053-41c9-9223-3b90c08e282b" xlink:href="evh-20220331.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_f77ca055-2053-41c9-9223-3b90c08e282b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_4292ad8f-e919-4703-b1d5-2f616e3f7cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_4292ad8f-e919-4703-b1d5-2f616e3f7cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_908c7633-c0bb-4c86-ae33-c9c682dde1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_AccountsReceivableNet_908c7633-c0bb-4c86-ae33-c9c682dde1ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a2822b0e-6820-42a5-8d57-2f5237421c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a2822b0e-6820-42a5-8d57-2f5237421c07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_918dca81-dd56-4dbc-9da1-3179793be734_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_918dca81-dd56-4dbc-9da1-3179793be734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_a8d80cf8-4df8-4196-bfc0-e1bd93c16bab" xlink:href="evh-20220331.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_a8d80cf8-4df8-4196-bfc0-e1bd93c16bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_623562f8-6823-4ef6-a958-4577501929ab" xlink:href="evh-20220331.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_623562f8-6823-4ef6-a958-4577501929ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="idb605eb0cde648fcbcde5e7d16696fb8_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_99752634-e622-4d51-9143-65ab546994e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_99752634-e622-4d51-9143-65ab546994e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93fccbab-9409-4d3a-9b70-07127a632616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93fccbab-9409-4d3a-9b70-07127a632616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e94ddb6b-ec62-4201-a175-c44491b598ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e94ddb6b-ec62-4201-a175-c44491b598ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fd749f81-f515-46d4-896e-b88a7d72033c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fd749f81-f515-46d4-896e-b88a7d72033c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cac5f417-9064-4d71-badd-576d3f006b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_Depreciation_cac5f417-9064-4d71-badd-576d3f006b34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5eff9b9-c877-44bd-ba29-7ffc8cfd42b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5eff9b9-c877-44bd-ba29-7ffc8cfd42b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9698821-a28a-43d9-91b6-55eba78dfd8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9698821-a28a-43d9-91b6-55eba78dfd8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2dd22007-94f4-41fc-a324-da99a76a4797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_ComputerEquipmentMember_2dd22007-94f4-41fc-a324-da99a76a4797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7ea5ada3-5a62-45da-ab1e-dcf425add10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7ea5ada3-5a62-45da-ab1e-dcf425add10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_777d21ce-84ce-41ad-bda2-cc850f5077d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_777d21ce-84ce-41ad-bda2-cc850f5077d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e74bdada-8d27-4bba-a31f-ee98b00483ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e74bdada-8d27-4bba-a31f-ee98b00483ca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended" id="i0e04cd3e58d4419db38bcf5d5404eac7_GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:to="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e811312-54c0-4abb-9be9-b6fd2a707f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:to="loc_us-gaap_Goodwill_3e811312-54c0-4abb-9be9-b6fd2a707f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_89e506b9-c7dd-4787-b0e8-37eafb7c8faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_89e506b9-c7dd-4787-b0e8-37eafb7c8faf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8b416751-221b-490c-afb1-cf41a9204d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_61dfefa0-504e-45c4-89a6-f73ec2ef5c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_61dfefa0-504e-45c4-89a6-f73ec2ef5c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d66da07-efe7-43ef-b07f-68def793f7ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:to="loc_us-gaap_SegmentDomain_7d66da07-efe7-43ef-b07f-68def793f7ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:to="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_22c3f59c-66a6-4110-8d18-afa152f285f2" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_22c3f59c-66a6-4110-8d18-afa152f285f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_0415a22a-ba2d-4455-a6dd-4885688230ee" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_0415a22a-ba2d-4455-a6dd-4885688230ee" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="ia2fb64e5e5f441049029947237cf8fa0_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2800b76d-1ea0-4bad-b4a0-4f30c7dfab27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2800b76d-1ea0-4bad-b4a0-4f30c7dfab27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_154d44e8-f989-4222-8001-a723f1ebf966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_154d44e8-f989-4222-8001-a723f1ebf966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a9b69632-cc28-4404-94f5-5528143f5422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a9b69632-cc28-4404-94f5-5528143f5422" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_493e0343-e3c5-4600-9bc3-27df2e5c0641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_493e0343-e3c5-4600-9bc3-27df2e5c0641" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4051408d-cea1-493e-97d0-97bd2f9773e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4051408d-cea1-493e-97d0-97bd2f9773e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7976a54e-e7ac-403b-8815-6cd8c0aaa475_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7976a54e-e7ac-403b-8815-6cd8c0aaa475_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e8b439ee-f9fc-47be-beba-0d369a498566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_TradeNamesMember_e8b439ee-f9fc-47be-beba-0d369a498566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e29cbb8b-b3f9-4140-a12e-d8ec48c0324c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e29cbb8b-b3f9-4140-a12e-d8ec48c0324c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3698c502-dda6-4046-ae08-331a713b45cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3698c502-dda6-4046-ae08-331a713b45cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_38bbd6fe-fdcf-4926-aaa2-74abe8afb5e0" xlink:href="evh-20220331.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_evh_BelowMarketLeasesMember_38bbd6fe-fdcf-4926-aaa2-74abe8afb5e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_f1bd9888-2246-43f4-a04e-a47799edf983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_f1bd9888-2246-43f4-a04e-a47799edf983" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f898a34e-d8d0-4f83-991b-68b8326ccad5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f898a34e-d8d0-4f83-991b-68b8326ccad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_829676b2-5eeb-4d6d-9c95-8dbf5a3c71b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_829676b2-5eeb-4d6d-9c95-8dbf5a3c71b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fe048ccd-6db9-4972-9b89-bfa3e2ea877c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_829676b2-5eeb-4d6d-9c95-8dbf5a3c71b2" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fe048ccd-6db9-4972-9b89-bfa3e2ea877c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_efb2c7fe-3166-491b-9a0d-8dcd66c3852b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_efb2c7fe-3166-491b-9a0d-8dcd66c3852b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f50fafa4-97de-45dc-8015-1918ab424af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f50fafa4-97de-45dc-8015-1918ab424af0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_53e40917-5ffc-4943-8bd6-bb51c6b9569c" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f50fafa4-97de-45dc-8015-1918ab424af0" xlink:to="loc_evh_TrueHealthMember_53e40917-5ffc-4943-8bd6-bb51c6b9569c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="i1b02c6ca67e340c5b1ac2bc48b6e5675_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8e21349a-633b-43b1-8b98-75c9c0cf1b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8e21349a-633b-43b1-8b98-75c9c0cf1b50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07d6cf06-fb2e-4910-8941-1020c42965a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07d6cf06-fb2e-4910-8941-1020c42965a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_700b5d01-f1c8-44f5-974e-078a4df2371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_700b5d01-f1c8-44f5-974e-078a4df2371d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_58dd5f1a-649c-4911-980e-0d6ea912adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_58dd5f1a-649c-4911-980e-0d6ea912adb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6623195a-1b8d-4b54-9e1c-c9cbc7e7ab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6623195a-1b8d-4b54-9e1c-c9cbc7e7ab7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_95eff42e-1786-4b8c-adf7-a69fd87cf4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_95eff42e-1786-4b8c-adf7-a69fd87cf4b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_28f87ec8-5db3-443e-acdb-7b8d9a22aa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_InterestExpenseDebt_28f87ec8-5db3-443e-acdb-7b8d9a22aa7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5c417402-1981-477b-a848-a456036d7b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5c417402-1981-477b-a848-a456036d7b23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b3c21a49-bfb1-4f5e-9241-290e96f408c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b3c21a49-bfb1-4f5e-9241-290e96f408c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_cfa47426-ae2c-4102-826e-927cfc2adb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_cfa47426-ae2c-4102-826e-927cfc2adb22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_150d0e07-97a4-43af-b6fb-a07b942e21b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_LongTermDebt_150d0e07-97a4-43af-b6fb-a07b942e21b7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f5ae9315-b403-4e69-b669-6995479dc9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f5ae9315-b403-4e69-b669-6995479dc9e1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_c68dfc5e-c176-4f2d-bb2d-25aa4da0290b" xlink:href="evh-20220331.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_c68dfc5e-c176-4f2d-bb2d-25aa4da0290b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31c98cd0-c56b-4448-8fc1-d60d0133e910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31c98cd0-c56b-4448-8fc1-d60d0133e910" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2c3349d-2fd4-49fc-b09e-82517586d2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_StockholdersEquity_e2c3349d-2fd4-49fc-b09e-82517586d2ad" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dadeca0b-b52d-4f22-b3f9-24625d3e0236" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dadeca0b-b52d-4f22-b3f9-24625d3e0236" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_b05f1df0-b4d6-457c-bb49-d9020230660d" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_b05f1df0-b4d6-457c-bb49-d9020230660d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_de4fb170-6e41-44b8-999c-12609b96f8d4" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_de4fb170-6e41-44b8-999c-12609b96f8d4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_053bcc92-d3c5-42d5-8304-48bd0404ccf7" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_053bcc92-d3c5-42d5-8304-48bd0404ccf7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_21fec984-66f2-4296-af3e-59e051dbf4f3" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_21fec984-66f2-4296-af3e-59e051dbf4f3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_b5c92424-8a87-4856-8f5d-dee9dfb2d435" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_b5c92424-8a87-4856-8f5d-dee9dfb2d435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_00a6f978-9391-4511-8913-a4284375f30b" xlink:href="evh-20220331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_00a6f978-9391-4511-8913-a4284375f30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_09b03ef6-8469-4d25-b8be-b1cf38b6095d" xlink:href="evh-20220331.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:to="loc_evh_NewNotesMember_09b03ef6-8469-4d25-b8be-b1cf38b6095d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ddf5735e-172c-4c74-8b20-bad41db1ea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ddf5735e-172c-4c74-8b20-bad41db1ea02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6e626afe-bd05-4ec2-aae9-eab2d9937af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ddf5735e-172c-4c74-8b20-bad41db1ea02" xlink:to="loc_us-gaap_SeniorNotesMember_6e626afe-bd05-4ec2-aae9-eab2d9937af6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:to="loc_us-gaap_EquityComponentDomain_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:to="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5b229e3b-c2ec-4a72-a475-054e50c6a391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:to="loc_us-gaap_CommonStockMember_5b229e3b-c2ec-4a72-a475-054e50c6a391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6abcaea0-63b6-4c52-9577-236be5721f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6abcaea0-63b6-4c52-9577-236be5721f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8619bc7a-39d5-4bcf-af57-bcbcd68670de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:to="loc_us-gaap_RetainedEarningsMember_8619bc7a-39d5-4bcf-af57-bcbcd68670de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d5f65ea1-3f24-421d-ac1b-b9a4275914cf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d5f65ea1-3f24-421d-ac1b-b9a4275914cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1d1b24ad-7cbb-44a7-a2f6-97fa7be67e0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1d1b24ad-7cbb-44a7-a2f6-97fa7be67e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c9ec69ce-89ff-4034-a21c-81eac5230beb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1d1b24ad-7cbb-44a7-a2f6-97fa7be67e0b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c9ec69ce-89ff-4034-a21c-81eac5230beb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fb911e8c-0e2c-402e-8dbd-d23462468fa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fb911e8c-0e2c-402e-8dbd-d23462468fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7b0eac42-fa93-4be5-997d-f5a4ee0359f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7b0eac42-fa93-4be5-997d-f5a4ee0359f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_c6ba162e-d5d4-442a-b613-0e8dd35c3e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7b0eac42-fa93-4be5-997d-f5a4ee0359f9" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_c6ba162e-d5d4-442a-b613-0e8dd35c3e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_548aae0d-879a-45a2-b1f7-ea814ce351cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_548aae0d-879a-45a2-b1f7-ea814ce351cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_b8782876-ced0-4c95-8c45-7286734bfeee" xlink:href="evh-20220331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_b8782876-ced0-4c95-8c45-7286734bfeee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_e79b2ecb-e3be-41a7-9ee6-9734a90e8957" xlink:href="evh-20220331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:to="loc_evh_DeferredFinancingFeesMember_e79b2ecb-e3be-41a7-9ee6-9734a90e8957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_44d26137-01f3-466e-b880-2f410690c295_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:to="loc_us-gaap_ClassOfStockDomain_44d26137-01f3-466e-b880-2f410690c295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_023069d4-a33b-489e-a295-4148144ae4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:to="loc_us-gaap_ClassOfStockDomain_023069d4-a33b-489e-a295-4148144ae4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8da34036-38eb-4068-9ed1-6b5ca4f45c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_023069d4-a33b-489e-a295-4148144ae4b9" xlink:to="loc_us-gaap_CommonClassAMember_8da34036-38eb-4068-9ed1-6b5ca4f45c75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended" id="i87b5c7b81ed84677887ee51f5cabd6af_LongtermDebtCreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8c00926d-a20c-4b37-aa52-68b189bd23bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8c00926d-a20c-4b37-aa52-68b189bd23bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a40e3897-d709-4c95-9c1f-c400fd130690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a40e3897-d709-4c95-9c1f-c400fd130690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_946f5d70-c88e-4c13-814b-62bffaaf73d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_946f5d70-c88e-4c13-814b-62bffaaf73d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_e81b7701-d1e2-45cd-a491-dbb04c117f16" xlink:href="evh-20220331.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_evh_PaymentsOfMakeWholePremium_e81b7701-d1e2-45cd-a491-dbb04c117f16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3ff5337e-bd74-48dc-b424-dec9c51c1cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_InterestPaidNet_3ff5337e-bd74-48dc-b424-dec9c51c1cf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ffef1f48-f87d-411a-b1eb-972435bbc833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ffef1f48-f87d-411a-b1eb-972435bbc833" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_af5adafd-accf-4245-9df3-4c1cf8a09903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_af5adafd-accf-4245-9df3-4c1cf8a09903" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_a8cbcd86-6984-4aba-ada2-1ce1e833769c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_LegalFees_a8cbcd86-6984-4aba-ada2-1ce1e833769c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0308cc37-d06a-4b4a-8e38-741330363e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0308cc37-d06a-4b4a-8e38-741330363e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_76dc33f9-673e-43db-ad59-0c1643acdca7" xlink:href="evh-20220331.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:to="loc_evh_InitialTermLoanFacilityMember_76dc33f9-673e-43db-ad59-0c1643acdca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_3c3179f0-6d1f-4cdb-8389-55d1c8dfebad" xlink:href="evh-20220331.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:to="loc_evh_CreditAgreementMember_3c3179f0-6d1f-4cdb-8389-55d1c8dfebad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_a32a8661-d59e-40b6-a650-9dbfc93071b5" xlink:href="evh-20220331.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:to="loc_evh_SeniorCreditFacilitiesMember_a32a8661-d59e-40b6-a650-9dbfc93071b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6c9a5bb1-90c8-4452-9945-11b5c0091fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:to="loc_us-gaap_SecuredDebtMember_6c9a5bb1-90c8-4452-9945-11b5c0091fd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a551f802-a857-486a-8b2d-476c2a44a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:to="loc_us-gaap_LineOfCreditMember_a551f802-a857-486a-8b2d-476c2a44a9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_df7a1839-8004-4625-bc80-f27fc29eb3cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:to="loc_us-gaap_CreditFacilityDomain_df7a1839-8004-4625-bc80-f27fc29eb3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0fb8317e-de90-45bc-9a2f-2a64becfdf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:to="loc_us-gaap_CreditFacilityDomain_0fb8317e-de90-45bc-9a2f-2a64becfdf06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_13fad76a-2887-43a8-81ef-75a6abd3a428" xlink:href="evh-20220331.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0fb8317e-de90-45bc-9a2f-2a64becfdf06" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_13fad76a-2887-43a8-81ef-75a6abd3a428" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended" id="i2ff308f09c214aa8a16027b998bfc2ae_LongtermDebtWarrantAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_195ce4f0-2bf7-47b1-852d-008e77cc2fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_195ce4f0-2bf7-47b1-852d-008e77cc2fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a52f2dbc-f095-4e30-af4d-914c06d38df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a52f2dbc-f095-4e30-af4d-914c06d38df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_0f44f81e-ed38-4a5f-bbec-7a9311162b73" xlink:href="evh-20220331.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_0f44f81e-ed38-4a5f-bbec-7a9311162b73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_38b768c6-8503-45b2-ae8f-724e3f9d967b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_38b768c6-8503-45b2-ae8f-724e3f9d967b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5ee0730d-3e51-4ede-8f67-413faf881810_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5ee0730d-3e51-4ede-8f67-413faf881810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ee8ad23d-c842-4af7-b200-25708b903a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ee8ad23d-c842-4af7-b200-25708b903a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_dd02f25d-4863-46b9-ad7b-2e51a38677c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ee8ad23d-c842-4af7-b200-25708b903a47" xlink:to="loc_us-gaap_CommonClassAMember_dd02f25d-4863-46b9-ad7b-2e51a38677c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="i92565988632f44c5b5717e959289cb4c_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f6de96d9-b118-4fd8-ba77-a0da7fe8b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f6de96d9-b118-4fd8-ba77-a0da7fe8b75d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33f67335-be64-4f18-a494-ede700fac2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33f67335-be64-4f18-a494-ede700fac2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c56dd774-2537-4268-860b-ed0ae29ca772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_InterestExpenseDebt_c56dd774-2537-4268-860b-ed0ae29ca772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c4c67ec3-2f27-4a1c-ab6f-7f29ebc8865a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c4c67ec3-2f27-4a1c-ab6f-7f29ebc8865a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_94a6b220-9f0d-4335-86ca-502b32ad908c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_94a6b220-9f0d-4335-86ca-502b32ad908c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_77b65971-0783-4e37-86b7-4b6e62a18caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_77b65971-0783-4e37-86b7-4b6e62a18caa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ac39c4ba-4198-4268-9d6c-89e61c411730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_LongTermDebt_ac39c4ba-4198-4268-9d6c-89e61c411730" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e4e723d2-4bf0-4b3a-a6bb-bc440aac8ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e4e723d2-4bf0-4b3a-a6bb-bc440aac8ad1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cca4e918-8c32-48ff-aad5-af741586b53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cca4e918-8c32-48ff-aad5-af741586b53a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35a5d6fc-33a4-4f0a-a3e6-0bb28d843ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_StockholdersEquity_35a5d6fc-33a4-4f0a-a3e6-0bb28d843ac0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c1fbb81f-6614-4ff5-affb-b3a39af15686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c1fbb81f-6614-4ff5-affb-b3a39af15686" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_fe128b22-64d5-4416-a506-a66ee0408d89" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_fe128b22-64d5-4416-a506-a66ee0408d89" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_f38ced6d-a3df-4989-8938-a7338c945403" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_f38ced6d-a3df-4989-8938-a7338c945403" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_f3e44b1c-0357-46cb-b7d6-38db314bc7bb" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_f3e44b1c-0357-46cb-b7d6-38db314bc7bb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_00c69092-93fd-4eba-908d-83b4db2c527a" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_00c69092-93fd-4eba-908d-83b4db2c527a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_31e39d98-532a-426c-90e8-8d94c38a131d" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_31e39d98-532a-426c-90e8-8d94c38a131d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fd6823f7-1f85-477a-9539-676c3ac5e88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fd6823f7-1f85-477a-9539-676c3ac5e88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ae8f19c3-e22f-46e2-8866-920b44bf68fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fd6823f7-1f85-477a-9539-676c3ac5e88f" xlink:to="loc_us-gaap_SeniorNotesMember_ae8f19c3-e22f-46e2-8866-920b44bf68fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_530a7372-6da0-4680-9540-7e3282145d32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_530a7372-6da0-4680-9540-7e3282145d32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f935116d-6495-49ae-8fce-d4032bf8d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f935116d-6495-49ae-8fce-d4032bf8d4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_7d99f0ed-f6c4-42f3-b126-5814c25f5fb5" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f935116d-6495-49ae-8fce-d4032bf8d4d9" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_7d99f0ed-f6c4-42f3-b126-5814c25f5fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb7aff1a-2ecb-4af8-889b-066d9629ffee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:to="loc_us-gaap_EquityComponentDomain_fb7aff1a-2ecb-4af8-889b-066d9629ffee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:to="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3274312f-3e62-4a01-9ca6-de2b830e6aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:to="loc_us-gaap_CommonStockMember_3274312f-3e62-4a01-9ca6-de2b830e6aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b02ebaf2-f4f6-4fbc-b2cc-24a03aed1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b02ebaf2-f4f6-4fbc-b2cc-24a03aed1b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c6d79e85-ee80-43ac-b98b-c24255f82a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:to="loc_us-gaap_RetainedEarningsMember_c6d79e85-ee80-43ac-b98b-c24255f82a60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_61f7e8f7-753c-4303-ada5-4604c85d04aa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_61f7e8f7-753c-4303-ada5-4604c85d04aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c277e13c-a19a-479c-8082-d1fd8182c8d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c277e13c-a19a-479c-8082-d1fd8182c8d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0ee14616-2af3-476d-95c0-bc54a474f449" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c277e13c-a19a-479c-8082-d1fd8182c8d9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0ee14616-2af3-476d-95c0-bc54a474f449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_cef24e37-e734-4114-adf3-f2ff9e469eda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:to="loc_us-gaap_TypeOfAdoptionMember_cef24e37-e734-4114-adf3-f2ff9e469eda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7c1426e5-6531-4e79-95d1-f73f84012a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7c1426e5-6531-4e79-95d1-f73f84012a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_e5223a7c-17d8-4beb-86fd-f49ed7061208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7c1426e5-6531-4e79-95d1-f73f84012a96" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_e5223a7c-17d8-4beb-86fd-f49ed7061208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c88bd7b4-5261-4e93-8843-5ba51e77b1c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c88bd7b4-5261-4e93-8843-5ba51e77b1c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_019849d6-05e4-4318-a115-dfaafb550902" xlink:href="evh-20220331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_019849d6-05e4-4318-a115-dfaafb550902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_61c0e84e-1d25-4b41-bbbc-a84609fd0590" xlink:href="evh-20220331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:to="loc_evh_DeferredFinancingFeesMember_61c0e84e-1d25-4b41-bbbc-a84609fd0590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_63672847-aa2e-4f64-bca2-9bfec5fe721c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:to="loc_us-gaap_ClassOfStockDomain_63672847-aa2e-4f64-bca2-9bfec5fe721c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2e15c386-cc39-4876-ab7e-fedec83e789e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:to="loc_us-gaap_ClassOfStockDomain_2e15c386-cc39-4876-ab7e-fedec83e789e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3b125ff0-6610-4ec7-9227-926a7fbd59fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2e15c386-cc39-4876-ab7e-fedec83e789e" xlink:to="loc_us-gaap_CommonClassAMember_3b125ff0-6610-4ec7-9227-926a7fbd59fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="ied207a841d2a40babc77e84fba2d2a6d_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_67028aa6-e09a-4bbd-9b8c-2d643e9a160b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_67028aa6-e09a-4bbd-9b8c-2d643e9a160b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49ef6604-e59b-480a-8d3b-143662ff575b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49ef6604-e59b-480a-8d3b-143662ff575b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1006c5c6-1d63-44d2-83d6-f55940b32787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_1006c5c6-1d63-44d2-83d6-f55940b32787" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_59ab4781-15e1-44d9-a7db-9c3b1c96c041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_59ab4781-15e1-44d9-a7db-9c3b1c96c041" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0f1ec708-1c3f-4206-b4db-fd2307987087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0f1ec708-1c3f-4206-b4db-fd2307987087" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_374beb56-3804-45ec-a1a2-29de8de09acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_374beb56-3804-45ec-a1a2-29de8de09acc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ece2361d-b3e6-43e6-87e2-4a593928b68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ece2361d-b3e6-43e6-87e2-4a593928b68d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_b76a6fe4-b789-4312-942a-23e8afa6933b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_b76a6fe4-b789-4312-942a-23e8afa6933b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_938aeb55-34d2-44c9-a458-57730848a39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_938aeb55-34d2-44c9-a458-57730848a39e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_b1447475-3536-4556-a770-02bf88e24276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_b1447475-3536-4556-a770-02bf88e24276" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue_9e0e9cf5-326e-4a82-96b6-63ec51ce9ff2" xlink:href="evh-20220331.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_evh_DebtConversionOriginalDebtFairValue_9e0e9cf5-326e-4a82-96b6-63ec51ce9ff2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2b9a5b6f-1634-4a96-a8cb-c5e0d1833375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2b9a5b6f-1634-4a96-a8cb-c5e0d1833375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7f3db232-9715-47fc-9b02-1bcfd499db96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2b9a5b6f-1634-4a96-a8cb-c5e0d1833375" xlink:to="loc_us-gaap_SeniorNotesMember_7f3db232-9715-47fc-9b02-1bcfd499db96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:to="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1dd1e47f-8014-4f1f-9664-7a9968ced267_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1dd1e47f-8014-4f1f-9664-7a9968ced267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_c7f5a2de-e81a-444d-8e83-bcdd263e1c8c" xlink:href="evh-20220331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_c7f5a2de-e81a-444d-8e83-bcdd263e1c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_c8c15b6e-efcd-4c2c-af1a-e1035b520a57" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_c8c15b6e-efcd-4c2c-af1a-e1035b520a57" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="i1f7f7d35e57d46279c375c2a93238ea5_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5ab58a7e-e27d-431c-a61b-723aaa30123c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_ConvertibleDebt_5ab58a7e-e27d-431c-a61b-723aaa30123c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3f72fe88-2cba-414b-9661-be7f7a6ea116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3f72fe88-2cba-414b-9661-be7f7a6ea116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_730694cd-dcb1-4f1d-843d-62b5c21236eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_730694cd-dcb1-4f1d-843d-62b5c21236eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_252893bc-81d8-48cb-b7f5-d25291854718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_252893bc-81d8-48cb-b7f5-d25291854718" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_55b7211c-8985-4d18-b238-918b90c60d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_LongTermDebtFairValue_55b7211c-8985-4d18-b238-918b90c60d02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f57fb53-d393-425e-a67b-1a4f0d5c114f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f57fb53-d393-425e-a67b-1a4f0d5c114f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1052979e-93a0-4988-9419-85716b3f74e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1052979e-93a0-4988-9419-85716b3f74e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c679041b-e402-4f68-b953-c9484ce9b504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1052979e-93a0-4988-9419-85716b3f74e7" xlink:to="loc_us-gaap_SeniorNotesMember_c679041b-e402-4f68-b953-c9484ce9b504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0262665-0ff8-4835-b53d-caf0824b1c0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0262665-0ff8-4835-b53d-caf0824b1c0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_6fb8e7e3-56c3-4ea8-a5e5-b21847f52a53" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_6fb8e7e3-56c3-4ea8-a5e5-b21847f52a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_4fac5ac6-0070-45c5-8777-f6e3cb5ee4b9" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_4fac5ac6-0070-45c5-8777-f6e3cb5ee4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3d54927-a3d7-49bc-a721-04ae03d2d57f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3d54927-a3d7-49bc-a721-04ae03d2d57f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe0f025-e3af-4308-8bb9-ba3dd2b54bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe0f025-e3af-4308-8bb9-ba3dd2b54bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_644d47cc-6c69-49c6-bf7d-612f15ffb283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe0f025-e3af-4308-8bb9-ba3dd2b54bff" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_644d47cc-6c69-49c6-bf7d-612f15ffb283" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i3129d494c33747b98ab7ad42c5dc11b7_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_393aea05-4707-4ce2-8ad3-aa9415a2a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_393aea05-4707-4ce2-8ad3-aa9415a2a0fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_a58ad4b9-ea73-4706-8bd0-ad955fc37d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_a58ad4b9-ea73-4706-8bd0-ad955fc37d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_aa1b294a-4dcf-476a-bff1-96f8de39a59c" xlink:href="evh-20220331.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_aa1b294a-4dcf-476a-bff1-96f8de39a59c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_701df148-d7d7-4b5c-9d31-a47ce358e0ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:to="loc_us-gaap_CreditFacilityDomain_701df148-d7d7-4b5c-9d31-a47ce358e0ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_69aa1205-657e-4906-a507-687758709301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:to="loc_us-gaap_CreditFacilityDomain_69aa1205-657e-4906-a507-687758709301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_28924d11-aa5b-4001-b3ac-f0fb05b5d4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_69aa1205-657e-4906-a507-687758709301" xlink:to="loc_us-gaap_LetterOfCreditMember_28924d11-aa5b-4001-b3ac-f0fb05b5d4b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c50074c4-1037-4374-8b6b-bd8e12828ff4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c50074c4-1037-4374-8b6b-bd8e12828ff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42e2f037-3ad0-4bab-9a16-e199a28f5389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42e2f037-3ad0-4bab-9a16-e199a28f5389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ff705800-4d63-48e7-a3d3-bd79d8e40ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42e2f037-3ad0-4bab-9a16-e199a28f5389" xlink:to="loc_us-gaap_LineOfCreditMember_ff705800-4d63-48e7-a3d3-bd79d8e40ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1f3ac050-2217-4c2f-b605-166202a1f0f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1f3ac050-2217-4c2f-b605-166202a1f0f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_37014275-6efd-4d58-96ce-c18c8363c806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_37014275-6efd-4d58-96ce-c18c8363c806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_c96609e4-2079-40ba-ae0b-5ab2d563e4be" xlink:href="evh-20220331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_37014275-6efd-4d58-96ce-c18c8363c806" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_c96609e4-2079-40ba-ae0b-5ab2d563e4be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended" id="ia060839485924b51b2e24ce964261f04_CommitmentsandContingenciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_de63431d-2f31-45e8-b209-b0b74b63769b" xlink:href="evh-20220331.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_de63431d-2f31-45e8-b209-b0b74b63769b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_addf44c7-f257-44c8-bf0a-de1db22688e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_addf44c7-f257-44c8-bf0a-de1db22688e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_69fecfa6-3fb9-47f6-9109-ae4c1a41b51a" xlink:href="evh-20220331.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_69fecfa6-3fb9-47f6-9109-ae4c1a41b51a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fd15539c-50d9-4a04-9aa9-62a74fed2edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fd15539c-50d9-4a04-9aa9-62a74fed2edd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_b6ac5a62-483b-4028-a850-852fab97d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_b6ac5a62-483b-4028-a850-852fab97d1e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cb5390f1-a8d3-4ad9-9022-822ea11337a0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:to="loc_srt_NameOfMajorCustomerDomain_cb5390f1-a8d3-4ad9-9022-822ea11337a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:to="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_7b06ddbc-356f-458d-bd71-defcd34c1d5a" xlink:href="evh-20220331.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:to="loc_evh_FloridaBlueMedicareIncMember_7b06ddbc-356f-458d-bd71-defcd34c1d5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_db134240-2d7a-4abe-b57b-fca5b627af9e" xlink:href="evh-20220331.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_db134240-2d7a-4abe-b57b-fca5b627af9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_0dcc2a5e-d7d5-429a-8864-ae3b90c5f390" xlink:href="evh-20220331.xsd#evh_MolinaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:to="loc_evh_MolinaHealthcareMember_0dcc2a5e-d7d5-429a-8864-ae3b90c5f390" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1149b022-113d-49e0-a41b-7c71e55320b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1149b022-113d-49e0-a41b-7c71e55320b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_12f886f2-1b95-4fc5-94c1-241aeee21c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1149b022-113d-49e0-a41b-7c71e55320b4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_12f886f2-1b95-4fc5-94c1-241aeee21c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f334ab07-20b5-4667-bae9-f882cc0acb39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f334ab07-20b5-4667-bae9-f882cc0acb39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8115c6d7-340f-4c77-b142-4a3602e3c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:to="loc_us-gaap_AccountsReceivableMember_8115c6d7-340f-4c77-b142-4a3602e3c40e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f8dab1ca-0294-4fe6-98a4-4d8dc35f4c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f8dab1ca-0294-4fe6-98a4-4d8dc35f4c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d7a1ce75-fc91-4ece-aeac-6997b23a5b95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:to="loc_us-gaap_ReceivableTypeDomain_d7a1ce75-fc91-4ece-aeac-6997b23a5b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4f81bf7b-8a32-4765-bca7-ed33f4d7a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:to="loc_us-gaap_ReceivableTypeDomain_4f81bf7b-8a32-4765-bca7-ed33f4d7a8c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_c04397e1-2713-46fe-add2-d97b321bf268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_4f81bf7b-8a32-4765-bca7-ed33f4d7a8c4" xlink:to="loc_us-gaap_FinanceReceivablesMember_c04397e1-2713-46fe-add2-d97b321bf268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6afd9f91-5685-457b-9106-3a5e7c3d0275_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:to="loc_srt_ProductsAndServicesDomain_6afd9f91-5685-457b-9106-3a5e7c3d0275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f52c591-92c0-4bd7-8d7a-fc1742de9126" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:to="loc_srt_ProductsAndServicesDomain_2f52c591-92c0-4bd7-8d7a-fc1742de9126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_2688321e-b90d-4926-8bfb-ee1e3eb64d78" xlink:href="evh-20220331.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2f52c591-92c0-4bd7-8d7a-fc1742de9126" xlink:to="loc_evh_PremiumsRevenueMember_2688321e-b90d-4926-8bfb-ee1e3eb64d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_22f9382f-ab11-4836-9576-b4bfd3fa0d42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_22f9382f-ab11-4836-9576-b4bfd3fa0d42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f41aea35-f269-47d4-8667-8b8f23acc987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f41aea35-f269-47d4-8667-8b8f23acc987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e684223f-b40c-426b-a19a-09f234658e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f41aea35-f269-47d4-8667-8b8f23acc987" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e684223f-b40c-426b-a19a-09f234658e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9cce4caa-2d87-4b63-8195-2e5f9819bee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9cce4caa-2d87-4b63-8195-2e5f9819bee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8921be19-030c-4ec0-8676-5f6b84920fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8921be19-030c-4ec0-8676-5f6b84920fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_a8dfb866-c42c-4c9c-a608-960f584f73bb" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8921be19-030c-4ec0-8676-5f6b84920fa1" xlink:to="loc_evh_TrueHealthMember_a8dfb866-c42c-4c9c-a608-960f584f73bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i59e153addf454ddea9161ca29f7feb6a_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8163dea2-ace2-4155-b4a3-a10d21953974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8163dea2-ace2-4155-b4a3-a10d21953974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_7f6a65d5-a1c4-4b02-9ed1-505b6f54d66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_7f6a65d5-a1c4-4b02-9ed1-505b6f54d66e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_1ea5be73-42d5-4e91-99e1-4d92bec921be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:to="loc_us-gaap_OtherCommitmentsDomain_1ea5be73-42d5-4e91-99e1-4d92bec921be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_cd14d45e-bc26-425f-89ed-f2d467a75d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:to="loc_us-gaap_OtherCommitmentsDomain_cd14d45e-bc26-425f-89ed-f2d467a75d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_e0a10f55-b088-4ab0-a545-be872711a1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_cd14d45e-bc26-425f-89ed-f2d467a75d0e" xlink:to="loc_us-gaap_LeaseAgreementsMember_e0a10f55-b088-4ab0-a545-be872711a1a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended" id="ic6cb6223bcf84b0baf5335fc92776eb2_LeasesPrimaryOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9d78c85b-c52b-4ea1-a840-26dcac1525d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9d78c85b-c52b-4ea1-a840-26dcac1525d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea04eb78-f95f-44fa-b33c-a5f4e791e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea04eb78-f95f-44fa-b33c-a5f4e791e67c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_a02da9d7-fea0-4e7b-b194-e1bf19b1b8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_a02da9d7-fea0-4e7b-b194-e1bf19b1b8fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:to="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_567ef474-633b-42bc-95ff-a87ae56bdc43_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:to="loc_srt_SegmentGeographicalDomain_567ef474-633b-42bc-95ff-a87ae56bdc43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:to="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_a99c9d1e-5ba7-47da-b030-90d8587b8e0c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_VA_a99c9d1e-5ba7-47da-b030-90d8587b8e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_9456d196-573e-4be5-89fe-49cf35bc580f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_IL_9456d196-573e-4be5-89fe-49cf35bc580f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_35fdf246-5fa4-4000-bcb7-24a8563b2ed7" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_NJ_35fdf246-5fa4-4000-bcb7-24a8563b2ed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_2fec63ca-5c20-4151-9c7b-32d1554c0a3f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_country_IN_2fec63ca-5c20-4151-9c7b-32d1554c0a3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_089fb037-a7c4-43d7-8d8e-0db9b61a2563" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_CA_089fb037-a7c4-43d7-8d8e-0db9b61a2563" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i79dd9181089042499916eebc056f5454_LossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419dc683-ff9f-4ed6-9537-e8a4b6ca00ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c01a3e14-4130-4a3a-827f-f22621841d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419dc683-ff9f-4ed6-9537-e8a4b6ca00ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c01a3e14-4130-4a3a-827f-f22621841d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419dc683-ff9f-4ed6-9537-e8a4b6ca00ad" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d185ce9-fac1-4ee0-b37a-7086489819d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d185ce9-fac1-4ee0-b37a-7086489819d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_21907713-d644-4324-a49c-296e6d38de61" xlink:href="evh-20220331.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_21907713-d644-4324-a49c-296e6d38de61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d30e7788-63da-4438-9611-00dbba2f4851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d30e7788-63da-4438-9611-00dbba2f4851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_75d93575-b1aa-4c2b-971e-bc681a3c5f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:to="loc_us-gaap_ConvertibleDebtMember_75d93575-b1aa-4c2b-971e-bc681a3c5f59" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="iee4273375b834fdfaf756e2f466cfb16_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf0195ce-c799-4cda-a716-44c959cbc0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1139b837-d254-4115-801f-1757251d139e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf0195ce-c799-4cda-a716-44c959cbc0bd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1139b837-d254-4115-801f-1757251d139e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf0195ce-c799-4cda-a716-44c959cbc0bd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:to="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3580e856-bc08-4581-b7ab-d9576b917586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3580e856-bc08-4581-b7ab-d9576b917586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a565ee1c-146b-434a-887b-6162d86ecd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a565ee1c-146b-434a-887b-6162d86ecd2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_3f5a9936-c226-435e-9528-1556b0223cac" xlink:href="evh-20220331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_3f5a9936-c226-435e-9528-1556b0223cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60cfc09f-4ffc-4a86-b376-229adbf48fcf" xlink:href="evh-20220331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60cfc09f-4ffc-4a86-b376-229adbf48fcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b2202064-3e52-42bf-a7dc-d88021caf23a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b2202064-3e52-42bf-a7dc-d88021caf23a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_888ab673-9a0a-47e4-8ba6-9c15f44fbf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:to="loc_us-gaap_CostOfSalesMember_888ab673-9a0a-47e4-8ba6-9c15f44fbf06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997110a0-f6a9-4c4a-a28d-f418da5ccec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997110a0-f6a9-4c4a-a28d-f418da5ccec8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended" id="ic65fa366a0f94dfbb34ae07acd45fcbe_StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc72ba1-581d-4c20-98cc-df756ab65d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6bec24cd-7bda-4f0c-8de9-abe2b2641426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc72ba1-581d-4c20-98cc-df756ab65d93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6bec24cd-7bda-4f0c-8de9-abe2b2641426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc72ba1-581d-4c20-98cc-df756ab65d93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:to="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5508a964-1c9f-41bd-b8d6-dd92c492032b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5508a964-1c9f-41bd-b8d6-dd92c492032b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6406c22f-d994-4c9e-85f4-c9dacb5df30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6406c22f-d994-4c9e-85f4-c9dacb5df30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9d6a0b9b-2d6c-4e4e-b3c5-edc1f30f6303" xlink:href="evh-20220331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9d6a0b9b-2d6c-4e4e-b3c5-edc1f30f6303" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended" id="i4e4822ddb56f4e88b0261673815eb385_InvestmentsinEquityMethodInvesteesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_1232adad-71b6-4e36-88f0-4229108af946" xlink:href="evh-20220331.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_1232adad-71b6-4e36-88f0-4229108af946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_ccc14796-ce5f-4d02-bfc8-074cd9dbd458" xlink:href="evh-20220331.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_ccc14796-ce5f-4d02-bfc8-074cd9dbd458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_78789f54-6a44-476b-b2db-7d0e9954fbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_78789f54-6a44-476b-b2db-7d0e9954fbc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_1a2ccce2-ca51-4683-956c-1af54c623f5f" xlink:href="evh-20220331.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_1a2ccce2-ca51-4683-956c-1af54c623f5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8ca4b62-aae9-4e5f-a058-6893eb7e8685_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:to="loc_srt_RangeMember_c8ca4b62-aae9-4e5f-a058-6893eb7e8685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:to="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f692604c-f03c-412f-b971-3bb34898fabc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:to="loc_srt_MinimumMember_f692604c-f03c-412f-b971-3bb34898fabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d6a1ca8-c1a5-4567-b789-24c35b0e2786" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:to="loc_srt_MaximumMember_5d6a1ca8-c1a5-4567-b789-24c35b0e2786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7614c25f-831a-48a5-9ffc-9008461db92c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:to="loc_us-gaap_RelatedPartyDomain_7614c25f-831a-48a5-9ffc-9008461db92c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_08b3032b-4247-4792-bc4f-58a9a0eea9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:to="loc_us-gaap_RelatedPartyDomain_08b3032b-4247-4792-bc4f-58a9a0eea9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_d6f99a37-4e0c-46e3-af1e-b58dfed961da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_08b3032b-4247-4792-bc4f-58a9a0eea9dc" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_d6f99a37-4e0c-46e3-af1e-b58dfed961da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_316c5f82-efe9-4819-8efc-84ea83937ded_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_316c5f82-efe9-4819-8efc-84ea83937ded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0ba01a74-c5b7-4d6b-bbd3-7c4e9429475d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0ba01a74-c5b7-4d6b-bbd3-7c4e9429475d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_6af16c72-b554-494c-b2e5-8b55471911e8" xlink:href="evh-20220331.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0ba01a74-c5b7-4d6b-bbd3-7c4e9429475d" xlink:to="loc_evh_ServicesAgreementsMember_6af16c72-b554-494c-b2e5-8b55471911e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="ief441d3460d744e6871fa7fc40325325_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0cba7ca4-fe9b-4ada-a7a3-3509ad265d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0cba7ca4-fe9b-4ada-a7a3-3509ad265d6c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3e6837c-5570-4b53-bee6-4c4621cecd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3e6837c-5570-4b53-bee6-4c4621cecd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_98e10e35-9be8-405f-9e03-e9d5f01f6bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_98e10e35-9be8-405f-9e03-e9d5f01f6bed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0cba7ca4-fe9b-4ada-a7a3-3509ad265d6c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f531db99-6b8b-45af-9cea-918fabafd13e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f531db99-6b8b-45af-9cea-918fabafd13e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_36f43be7-b7af-4baa-9b7b-59e713b168b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_36f43be7-b7af-4baa-9b7b-59e713b168b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0bcc6ba9-1225-4479-aacf-b64f875a9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0bcc6ba9-1225-4479-aacf-b64f875a9b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_717b2f80-d05f-4b60-8253-230a293289d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_717b2f80-d05f-4b60-8253-230a293289d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e8d835e4-c228-4a0b-87ce-d6439baa2e19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e8d835e4-c228-4a0b-87ce-d6439baa2e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cbe830cf-2ad1-4bc3-bfda-948af02d8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cbe830cf-2ad1-4bc3-bfda-948af02d8cf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c7b9870d-699f-4d9a-b4dd-a40ae19acd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_cbe830cf-2ad1-4bc3-bfda-948af02d8cf2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c7b9870d-699f-4d9a-b4dd-a40ae19acd87" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="if39fa6602e2047cd8c55d7936bbda188_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37691441-c695-41f8-8243-0c7e9863c070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37691441-c695-41f8-8243-0c7e9863c070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_03485071-b1f0-4d34-b17e-49a284d50de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_03485071-b1f0-4d34-b17e-49a284d50de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7cbc171b-e0d9-46a5-a014-524cafbb4e8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7cbc171b-e0d9-46a5-a014-524cafbb4e8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_327d0e41-0632-46a4-a756-e718da22ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_327d0e41-0632-46a4-a756-e718da22ae76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48e1f20e-5b83-4899-9e39-afb57a73115e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_327d0e41-0632-46a4-a756-e718da22ae76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48e1f20e-5b83-4899-9e39-afb57a73115e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_661a8834-a0b5-494a-9107-8f34e6797693_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_661a8834-a0b5-494a-9107-8f34e6797693_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67902d71-3900-4413-b51a-55b72d5427c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67902d71-3900-4413-b51a-55b72d5427c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d07fca36-ae6a-4293-84f3-dfe05f895d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67902d71-3900-4413-b51a-55b72d5427c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d07fca36-ae6a-4293-84f3-dfe05f895d6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4f6bde59-4d51-44da-8073-6e82760a8d4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4f6bde59-4d51-44da-8073-6e82760a8d4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_cc716211-f880-46ec-b4ac-3ec7019ee827" xlink:href="evh-20220331.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_cc716211-f880-46ec-b4ac-3ec7019ee827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7c75425e-4f85-4e98-9e6d-584e515f6c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7c75425e-4f85-4e98-9e6d-584e515f6c1e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="i5cd395fb445b453ea6d91ed539677356_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:to="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f42ac008-54a1-49e9-a27c-4e768e3714f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f42ac008-54a1-49e9-a27c-4e768e3714f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2054374-94f7-456a-b371-61352e39e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2054374-94f7-456a-b371-61352e39e2dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_743463fa-cd56-4860-b1d6-b968fc09a162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_743463fa-cd56-4860-b1d6-b968fc09a162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:to="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d0bb10d8-66d7-4cb3-a458-010b6e9d2122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:to="loc_us-gaap_AccountsPayableCurrent_d0bb10d8-66d7-4cb3-a458-010b6e9d2122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2d6412f2-f379-426c-8985-fefe0cd784f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2d6412f2-f379-426c-8985-fefe0cd784f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_61be5f62-6618-4c21-82a4-ebd0190f4a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_61be5f62-6618-4c21-82a4-ebd0190f4a71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4e045985-041d-4bd2-8c24-fda473bfe11a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:to="loc_us-gaap_RelatedPartyDomain_4e045985-041d-4bd2-8c24-fda473bfe11a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a92f70ca-cad0-4210-965e-213412f90a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:to="loc_us-gaap_RelatedPartyDomain_a92f70ca-cad0-4210-965e-213412f90a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cf51591f-89d8-4ba3-b9f8-495d7e206837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a92f70ca-cad0-4210-965e-213412f90a76" xlink:to="loc_srt_AffiliatedEntityMember_cf51591f-89d8-4ba3-b9f8-495d7e206837" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="i83e246eee6bb4628a61d660c71c6b074_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_d72c6430-1436-4208-b9e2-7b4fec990362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:to="loc_us-gaap_RevenueFromRelatedParties_d72c6430-1436-4208-b9e2-7b4fec990362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ea29ea21-b60e-46fd-8a75-0fb5f5907dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ea29ea21-b60e-46fd-8a75-0fb5f5907dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c922c39b-7152-4bba-b249-cedd5d103c59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:to="loc_us-gaap_RelatedPartyDomain_c922c39b-7152-4bba-b249-cedd5d103c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c79dd5d6-4854-439a-900f-c62906e117ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:to="loc_us-gaap_RelatedPartyDomain_c79dd5d6-4854-439a-900f-c62906e117ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_39c3930d-696b-4057-a987-0bf87234278d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c79dd5d6-4854-439a-900f-c62906e117ec" xlink:to="loc_srt_AffiliatedEntityMember_39c3930d-696b-4057-a987-0bf87234278d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97e77366-96c9-4ee4-bc4a-00ce29ab918e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97e77366-96c9-4ee4-bc4a-00ce29ab918e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2e6dc63e-f46f-4b9b-974b-8e73ab1b1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:to="loc_us-gaap_CostOfSalesMember_2e6dc63e-f46f-4b9b-974b-8e73ab1b1b17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea989257-909e-43d6-841c-796916df3549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea989257-909e-43d6-841c-796916df3549" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RepositioningandOtherChangesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended" id="i251f6a7810b640bbb9fff9b3ff68ed6e_RepositioningandOtherChangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8d3cee43-5a37-421e-a2c2-7997db253f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:to="loc_us-gaap_RestructuringCharges_8d3cee43-5a37-421e-a2c2-7997db253f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_db9179a0-1a4c-4147-8a91-8689b1f5b278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_db9179a0-1a4c-4147-8a91-8689b1f5b278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_231f43ef-ea25-4859-b33c-ed3eb93b0a03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_231f43ef-ea25-4859-b33c-ed3eb93b0a03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_fe14eb46-9db2-47a3-818f-2a577fbd3c88" xlink:href="evh-20220331.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_fe14eb46-9db2-47a3-818f-2a577fbd3c88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_329110fb-c95c-4dc7-af4d-dbcb80ada75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:to="loc_us-gaap_FacilityClosingMember_329110fb-c95c-4dc7-af4d-dbcb80ada75e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_5097aa69-6b50-4274-bc47-24580573941b" xlink:href="evh-20220331.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_5097aa69-6b50-4274-bc47-24580573941b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="i5fbf1f3395c24c3fb142b3ca747e20ec_SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_503c71e8-b53d-4548-a3a4-6a1b77581226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_503c71e8-b53d-4548-a3a4-6a1b77581226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_6ff8423b-c3a2-4e9e-adfb-5cdb422dc29c" xlink:href="evh-20220331.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_6ff8423b-c3a2-4e9e-adfb-5cdb422dc29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:to="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9cff38ad-b00a-4d8b-8773-2060562c1b6f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:to="loc_srt_ConsolidationItemsDomain_9cff38ad-b00a-4d8b-8773-2060562c1b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:to="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_03411768-16ff-4127-9b7c-4c3951d1ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:to="loc_us-gaap_IntersegmentEliminationMember_03411768-16ff-4127-9b7c-4c3951d1ba91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f3d842af-71c1-40e4-999a-540dba8de41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:to="loc_us-gaap_OperatingSegmentsMember_f3d842af-71c1-40e4-999a-540dba8de41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_15052008-aa5d-4004-b02b-25eac8ad4905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:to="loc_us-gaap_CorporateNonSegmentMember_15052008-aa5d-4004-b02b-25eac8ad4905" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_24178e35-95c2-4309-8a35-15d3586bc761_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:to="loc_us-gaap_SegmentDomain_24178e35-95c2-4309-8a35-15d3586bc761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:to="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_1c584abc-9b6b-4a45-a098-aa5deebff45f" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_1c584abc-9b6b-4a45-a098-aa5deebff45f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_4204cdd2-d005-48ab-a8de-7bada19f47e9" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_4204cdd2-d005-48ab-a8de-7bada19f47e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended" id="i932ccb0141204785ab58aa8680d84c70_ReservesforClaimsandPerformanceBasedArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_5dbf5e00-8287-4206-8f7c-86656bc66d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_5dbf5e00-8287-4206-8f7c-86656bc66d0f" xlink:to="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a936a873-e995-4ed1-81ef-330e2bf8551b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a936a873-e995-4ed1-81ef-330e2bf8551b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fe63ab23-6ca7-4041-975e-a81278aa0545" xlink:href="evh-20220331.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fe63ab23-6ca7-4041-975e-a81278aa0545" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ca798272-29b1-4d6b-9c2a-9cd677211b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ca798272-29b1-4d6b-9c2a-9cd677211b25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e3da5069-9943-45c6-b062-42423a739da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e3da5069-9943-45c6-b062-42423a739da8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_81f3d6f8-475b-49c0-b22b-62985699685a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_81f3d6f8-475b-49c0-b22b-62985699685a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_de5b66bf-42a5-4916-be92-2fd102c1e8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_de5b66bf-42a5-4916-be92-2fd102c1e8df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_0cd22ef1-9af1-4c50-9238-97a69d078ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_0cd22ef1-9af1-4c50-9238-97a69d078ca8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_63f820ab-459d-40ac-88e8-64e266892517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_63f820ab-459d-40ac-88e8-64e266892517" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_12c9d466-ddcb-4066-a7db-79f8c1c7b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_5dbf5e00-8287-4206-8f7c-86656bc66d0f" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7b1d63eb-7a6d-4401-a3be-34199e31efea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:to="loc_us-gaap_SegmentDomain_7b1d63eb-7a6d-4401-a3be-34199e31efea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:to="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_c380b17d-bbcf-40e8-9348-bd1bb7c8512d" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_c380b17d-bbcf-40e8-9348-bd1bb7c8512d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_cffd5a0b-6970-4eb2-a050-04e0ea6b8e55" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_cffd5a0b-6970-4eb2-a050-04e0ea6b8e55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>evh-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d53c1d9c-a1b3-428c-ab91-113966fe5337,g:d0023668-d86c-4a77-8abf-aab325264a20-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_aecbc9fe-8b98-4235-a071-ee0122ef69a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_28889f47-5846-492d-9cdf-70a3227412fa_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_ca64fc48-35fa-4c16-bf8f-088764cf374a_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_f61899e9-f11c-40c2-bf0d-f24884bf59f0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_092ddc89-9803-446d-8178-adca4146f0ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88a695de-bf5b-4b62-a7c4-abcb51646f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_d63b9e6b-8bb5-4d28-b31c-d0364a8847f4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ab7db0bc-0401-43be-8689-0cb5f48b3085_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3527a746-971f-4327-b95f-af32a339a509_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_279b2d89-1d8d-4f30-aca3-4b9765d70a6c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_19c092da-1d0e-46a8-998d-fdfcd2bb87f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of allocation of purchase price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_03fd64cb-7c48-4553-a218-1de7c4039b56_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_04eed59b-3c33-4c01-bbc0-3b0f4fd00460_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_839fdb08-d6a5-45dc-90c8-bb0e4e93c70e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b4ce99b-f3fc-44a3-a526-4a807123579e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ce3252f8-7c65-492f-9166-1dd054e98267_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f8f4d16d-8343-4912-a51f-2fa1a36649c1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ff5897de-a8e1-4a3b-afed-60f63fcb9d05_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_8dc87393-fcbc-42ad-ac66-d72bba027b38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_aff1856a-2ef4-4871-944d-214f59e5c0af_periodStartLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_946291c6-039b-451b-a2d8-d900c251ec8c_periodEndLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_52185934-2d2c-4bf7-926e-f00a6a496e14_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e8ccbf16-0af4-42ea-9c21-ce29c36bb761_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset and liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_2cda51dc-654d-4d69-96c0-fd4ca1dcd5cc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52b70d0b-a35d-4a99-9314-924cba59a983_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_81ef83fb-4231-46c8-9540-a0d68e6ec65b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_445067ef-c1f2-4f8f-be32-7678de5734e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6bc28c11-f88e-4277-bfed-e2a961afb36d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d9dfb7bd-29ea-4bb3-9b55-d192f4800050_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a7986a2c-a52f-419e-b7fd-bb0f8dac19ab_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_3e90fa42-48a6-43ad-a8ba-1f9ca566deb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f8aa4468-4e7e-4a27-b313-2f5424a575cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4110dd01-2e9e-4093-b60f-2f17dc563379_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ee22c537-8d80-4efc-970f-f73d8cbf5b85_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f89625d3-1d73-45f3-8320-72092de2af4f_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized and unrealized losses, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_37c4e8ef-4b0a-4d00-a16e-cc3a6acdacfb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_126d7e3b-e4f1-4471-bf48-7bfb983001b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2318eeb-bda1-4892-81ca-cb8fdc9b5026_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2de749ef-6e9b-439d-bf10-bbaefaa400ac_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f09c7514-106d-4bcd-ab81-ac1b7bc2944d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4d6075b4-da0d-42b8-87a9-baf20887feb4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6d58fc30-7be9-41fb-8883-dc3c54177fe2_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ca224f43-ac4c-40ef-a43e-7ca85943ec81_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_cfe5e157-da7f-463d-99dd-4cf6f1e7d1e4_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_bce9c9ea-352c-4cfc-87c1-cb5de1f15fd8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7743c1cf-eca3-4cf7-af7d-f30d0608b00a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b24dc0dc-b27b-46c7-86fe-3e0b4a319986_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_afca2a42-6fb4-4459-a5b7-ceb9bb834c10_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbe6e612-2ef5-4b88-8aba-133cd9cdcb32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4731342b-25c9-47e9-b9a7-663118e05147_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_632b558a-fa9a-4c49-9dbd-83f1102a1d8f_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:href="evh-20220331.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_29f9d7d5-8fdf-4e51-a81d-ebfe0610b4f7_terseLabel_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_label_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:href="evh-20220331.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:to="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_4d03b581-1da7-40b7-addd-a625d8645716_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of liabilities at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e17a32c7-50b7-4e08-b1bd-e2e643647106_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5440e9f1-aaeb-42ba-bc1b-56e7a1b4f6f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_bfbc6f91-876c-450b-801b-5fdd3b83219a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_18013ebe-2bb4-4a0b-8879-87088309c79c_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20220331.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_fa56d6bc-fc38-43c8-b8d1-23fb0d7005f7_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_b3751c26-995c-4068-be9e-34518113ed35_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_30ddf868-87fa-40d5-a3d0-6619bfdc7c65_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_940709d8-2d22-4aed-8596-b7b3cadf6dfa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b6083f85-177b-4ac4-bfb7-96a9b9f6c5f4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0e705ad2-421c-4bd3-a712-f715293e321f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_419a898e-0416-4aa6-8153-972e75806b01_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e9096efe-dca1-4d2f-bbda-e0b44dfc5085_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_dcbf96ef-7cdb-4d48-8c12-3df04978e64b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4114c749-80b8-44c9-a88b-1c531f4e8f11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c6b1dacb-b0bd-45aa-b0c9-cf084037e02e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d347a220-96ec-4ba5-bd53-3c8bcc0bc372_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2e1915f7-2702-4650-b1e1-08037e5b6486_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e6d6192f-34fd-42ee-927c-f48fac19f833_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (in percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3b16ab18-cd08-4c42-ac41-b0d17a78fdc3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_be11d297-3c40-4b60-a476-66c65b4da16a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_21bd23d0-093e-4c34-93af-3f15ca1568d5_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_eb17900b-e15c-4805-9121-e75ca281c6c5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_fe572bbf-7e2c-44f1-afd5-bfecf133f6de_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20220331.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5e8c52d8-78fa-471e-82f0-527cb81e786b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4cbddb46-82d0-4de3-b38c-b568026dccb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_e2529a9d-ea8a-4d8e-b9a6-cc1da5375fd4_negatedLabel_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_label_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:href="evh-20220331.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:to="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_52f35af5-e6f6-44ae-9435-9aebcda57394_terseLabel_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="evh-20220331.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_d940effd-4872-4b09-9555-55216f88b312_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fb8f888b-c384-403f-a945-66b53ccd7b5a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsRevenueMember_cb6a5ff8-1e6f-4830-9e24-55f0a7595b5d_terseLabel_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_label_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember" xlink:href="evh-20220331.xsd#evh_PremiumsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsRevenueMember" xlink:to="lab_evh_PremiumsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_d055f815-cef0-4f32-a960-ecccfed2e73e_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20220331.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a0657f80-bc27-4464-8e28-659a77a6f050_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dec3209d-c5cb-4663-9b53-fcc5be9f430a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1997c975-c620-4afc-8826-63fb6fa5b29e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or Input Ranges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_3a954ebe-41db-4de6-b832-4bb65e106acb_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c8bcdf2d-aec2-4466-ac3c-95a56ecaa00e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_784869a6-96c9-479a-85da-667043f442f7_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_83879327-fb2a-41db-a40e-ea427e576475_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20220331.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_91704379-3d90-41c0-b734-c9919104d230_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_651eb365-db2a-4a70-89bd-8a8dcdd968ba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to prior period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a3c8cb57-5ba0-459e-8f49-4e2a6c178d25_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized as software development costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d3e0117-9b56-457c-a4a4-74179e466c56_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_55356ad4-fe26-4c83-8530-a8d049e20f46_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20220331.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_763e3a1d-3799-4930-929f-fdd81ffc9f05_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_label_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy [Policy Text Block]</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:href="evh-20220331.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:to="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_35d967bd-0906-4b00-8394-ab9f67cc0802_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ba87cc2f-f1aa-4321-aeb9-db9c67a50270_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_b51bc15a-57eb-490d-935f-abb860c9cd4b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to prior period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_250d2096-5a53-4be8-a1c8-6b493769f49f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ca74db7f-9050-40d5-9c9f-f3033a215d2c_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f714c676-0dc0-4a0e-9ccb-98f410e11362_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_e70485de-f579-49d6-ab52-7089971ec947_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_356b2f2a-87f0-48c4-9970-ae5c5daca372_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_ce6c286e-8373-41a0-a226-1fafe21580ff_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_54b68922-b4da-4820-9e00-11e20573807e_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_fb2e4eb7-e7a8-4be0-be1c-ad7003eaec00_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_845920ee-97f6-471b-9825-f57d1e1cfc5d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_44eba7f0-b6ab-45ce-b0f3-50adb8fb8094_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7ec6a686-c309-41b6-9d93-a388d83c96e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_e5a384aa-bd0e-4acd-a3ff-d39f24299286_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a1ec22f4-6685-4d87-b63a-2c5ea3224033_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_14de3981-68a9-4a89-bf99-96cd7a6e825f_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_95b60c20-8660-4949-91d1-027ae482e1ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4fd204f8-64cc-4737-bdca-6af4250d3e3e_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7a30cbb1-81d0-41df-95db-d9db07c78507_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_a6149a3a-f1e1-42c3-99a8-33037d4b12c5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d7635f68-8f6f-44c1-9369-c47126f47fcd_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_44dce46c-3685-4c98-aac0-aa31c1d41751_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4e2f8d82-9378-44a4-952c-2538a517f066_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e5eb68ef-6896-4b60-b0e4-a97e3a1c303a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash inflows (outflows), net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_d37685ca-bbd1-4eef-8abc-dece28cef2a1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_fcc9655e-0ea7-444d-9f2b-aaa660ec1dd2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted funds</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2d0a06f8-9912-4939-a296-09aafa96f20d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_742633b2-abda-42c2-843e-d3e93f7de73e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_7d042c97-2818-4879-bde8-5d8c628dd115_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_df81a8e6-51dc-4eb2-b8ae-f448c23787d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_98f52157-bce2-44cb-a78a-075856d3afc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_259eacd6-721e-4ac8-9801-c58972e767c6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3dbd2c2a-4dce-40b3-8ab4-5df29543249f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9a07f2cf-e523-49ac-88c5-7ab030b997df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_6794d59d-3df7-4e59-8264-6b6d81981338_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8faae7a0-2e56-46e6-8b5a-1f84e10cf842_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d2c339ff-04dd-45ec-b423-0f08b6b88fc9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e47fc7b1-2505-4b07-a131-4a0d08990e7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7c77e973-48c5-487d-b863-b53bcd8523af_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d0699012-e63e-4dae-8105-11d190059c25_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_878d6c8c-127f-4af9-b9a9-f06594d3aee7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_e8ac9eec-5893-4d5c-bf30-c4a76594126c_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e75f7cfc-e224-443a-9bd7-3ebfe495c601_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_81356f78-a3b3-48a9-8650-4fde635afca9_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_548d8933-de9e-4f54-97db-f604f2219874_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6ca27713-ca92-4bc3-bd56-ada99e0289ff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6b224dc9-71ac-4970-bd94-3c5cbc320ffd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_169f6099-a855-4ac4-845a-5ce7ba2ee2c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_2ec66bf1-214c-4239-9ec9-b949c83fef87_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_542065e9-47be-42f4-8bf0-3a82934af748_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_efa192de-07b4-440d-81f4-c66cbf29b43c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_86e2e49b-2bbf-4324-945e-57b65a67f743_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_e661294d-60e4-409b-8737-07076fe24d49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_2c67bafb-1504-42e0-adba-e6f754b9cb63_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Receivable</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f9b19181-8ea0-4311-9bab-db36159b4cb6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_ed365762-fc13-47b8-bca1-f54ac261d11d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_61047e02-4ac3-4ee5-85aa-db1134a483ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_aae239c8-bb25-457e-a585-da39897ffb2c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9811c89-0e1c-459b-b474-c0eb9f4ad51c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_78d5552c-eed4-4dd6-96a2-3f7405261eba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_834f3408-a25d-499d-bea8-b1dcccdcab23_terseLabel_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember" xlink:href="evh-20220331.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_InitialTermLoanFacilityMember" xlink:to="lab_evh_InitialTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9f1498e7-edbf-4ec1-a369-b31f971faf43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_02d8819b-e58b-48c9-8d0e-bca08b5fbe06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0bec738e-2e50-4e4e-87a6-e0e931fd1dd7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0d3a8861-af0e-4082-92e5-1a22d361de58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_d036cb32-e432-4ddf-af8b-836090d2b126_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dbaf874e-c227-4055-8cc1-67e63355d4af_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_748a52f4-bc91-436d-ad83-b7dac5258c54_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20220331.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_074ebb2b-b116-4006-b14d-0538e385bd94_terseLabel_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_label_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt [Member]</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_documentation_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember" xlink:href="evh-20220331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityComponentOfLongTermDebtMember" xlink:to="lab_evh_EquityComponentOfLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_44e518d1-fbdd-453e-ac11-8a90134d2401_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_79d10596-ed67-46b8-9d1a-619d7fa6b11f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3b5e6530-4a56-4629-b586-6d9e052ed185_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_50d0f7ae-59ce-4d75-8aa6-21e9d9dbb05a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3d12389d-0e57-43f3-8484-9f7927a454cc_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_27229b58-a57e-4cbe-8cca-33e0da491f23_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_f8a31cde-0c91-421c-97e7-f3531b56ef0b_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7faed7ae-14e6-472e-98b5-1cc2ed7f2e6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f948c08b-16e1-4f4a-b4b8-eaa5225af2a6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0f77f091-3e43-4a55-9115-5019a4c60230_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3c9ba59f-79eb-4f3c-82aa-f8cee8a5d3f2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5dbfef13-80fc-4711-8da3-bcebfc761dde_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_8bd01cf9-3f07-463b-bc93-87d92381a81c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_fa3d8688-2229-463a-865c-9f6b89750936_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_ff0a5dc1-c79f-45bc-b302-a92ba234c3d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants agreed to be sold (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_fde31bd5-1049-4172-a8ae-a4310ff0ba20_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e81ca6e2-369c-440a-bb3b-f1f8e2710bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0b3d33f4-b45c-4eb0-808e-01cc44059a1e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_f265b5d0-e746-42e5-a045-a72dd95619c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c9d7ccc4-7367-49d2-9807-11b880d49995_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromReinsurance_55f363e0-3e34-4f92-a14d-8cb8c0ddc745_negatedLabel_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance payments paid (received)</link:label>
    <link:label id="lab_evh_ProceedsFromReinsurance_label_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reinsurance</link:label>
    <link:label id="lab_evh_ProceedsFromReinsurance_documentation_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromReinsurance" xlink:href="evh-20220331.xsd#evh_ProceedsFromReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromReinsurance" xlink:to="lab_evh_ProceedsFromReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f114d8f3-7a6b-4e72-81e6-2e57c725ac1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_a8b166ec-a622-4836-a568-5da11386553c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_802c36d2-b68b-4d5b-861f-ce1413110a40_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_85512bf7-13e0-4ab7-af54-4bba5fd39680_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_519f970d-bec8-4f97-ac5c-ca302fe0c2be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_945aa841-afd8-4103-9ed9-548562837c10_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_63c18cd3-b0d4-4713-8002-be79b39e3f31_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_a6bdc956-0071-484b-a11b-6689d32b87b6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2b66bcd2-2218-48ae-a1ce-7cb36cb693ab_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_36d2db59-f516-4daf-bc39-627a2b759260_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_38bb4df5-6cc1-4774-860e-e93f2b276363_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_aa5533e8-56ad-4871-a8ee-69b7b309a2d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_84644572-c518-4d03-9045-b54d98e43284_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7e61cd4e-eed5-458e-81c6-6cae09266bad_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_d81afe7b-7a51-4dfb-995a-991bb87c9bc3_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c078448f-34b2-4197-9b5a-12625e069aea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_76ff6890-4f4a-4afa-9478-f389370e37cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_fedc3440-ab59-448f-bed0-05ef2ab33e79_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_279a6e17-699e-41e3-97ca-c3ca6c750037_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83273b4b-f010-4153-a9c6-8b67697d6f7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_39a1052b-3bb4-4fab-9cdd-c96c8eeb9b4e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ec11e305-a9cf-4098-b9dd-c108f5a238e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_00665958-eb10-4796-91d6-ed38cdaae720_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:to="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_531d4e56-ff43-4872-803d-400cd53be3ef_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_ec760acf-d337-42ad-8759-e5bd24e2c766_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_1b6f04c8-7230-46c8-839d-be0b6d611eb7_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20220331.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_5063e5bd-2724-46f0-acd5-8b8ab8aa6c53_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e50f015e-9079-4d9f-80a8-db57b54e4707_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_80cd5eed-a218-4117-97e3-6b5aff03bcdf_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_b4c641f3-9c34-4a5a-941d-0d7ccd2ba862_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0771c4c6-7ee0-4e67-b115-5831ef7a13c7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_335fdfca-bee9-454f-8e13-fc7642888624_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_e3a4653c-0ce2-41d1-8e42-37ccecbe8d0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cbebbd15-71ca-403a-a8c1-9304919ec109_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 91,587,896 and 90,758,318 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c76b4857-a523-4885-a7a7-6aeff0c20908_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_558b3d1f-82b4-42ac-804a-115d93d65b69_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c0616737-1fdc-45bf-8325-e1a8acfb90ce_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f5026352-35b3-41fe-8bdd-3821894143bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f9f81dcc-917f-4d5e-8acc-9afce115bd4e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11dc373b-1e01-4161-be2e-e60f95a23e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1b2a63a2-44df-4605-91e4-8d4675d5bbaa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f7f5a9af-c1c4-4048-a51e-d1e9750afd7b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_891790d4-55fe-4608-ba54-3dba428aa6d6_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e4d1f090-cb44-4476-91be-efbc0d19443a_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_770e6113-4b93-4475-987b-9f01e3d54760_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_a488fe5c-b4e2-46d6-a5ec-c06997b82dc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_35f0da40-60ca-4a42-9c5c-3e8ce595b56c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_f0cbd650-bce4-43e1-b623-789f31507c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_f3347958-267c-43b7-9a86-281660ab9f6a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_12d6b779-aa17-4b02-a26a-29ef6514c1fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based awards granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_f7f56bc2-3aaf-4522-9e41-4a07d7b0cf01_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a59a7987-551a-471b-8e59-2551507bc40b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9194ac4d-d604-4397-ac6b-980412dac711_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_d878d16f-d941-401f-a473-49e4e145206b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_38569b04-1991-4a4d-a78e-ee95f8f2b41d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_9488345b-76a8-4c52-b2d9-725e8cfd1f11_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_03e972b3-aeea-4d29-a000-155beeaab53b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_49eac428-3bc6-42ac-b338-b29d7311470d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_34496d3e-3f10-446b-99fa-21d48df6ed7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_50d7a594-9da0-40e4-bcf6-f03ed9638cc6_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_3f2c36fa-10a3-48c3-81c3-5eb712364dc9_terseLabel_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, fair value</link:label>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_label_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Fair Value</link:label>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_documentation_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue" xlink:href="evh-20220331.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtConversionOriginalDebtFairValue" xlink:to="lab_evh_DebtConversionOriginalDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9300e93f-5186-4b2f-9f5e-13ff10a96cd4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d85aaa37-858e-4199-935b-175654ccdedf_netLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_583675ac-a535-4155-b94b-7e88b7341183_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20220331.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_56e2097d-f154-473e-a29f-1ca6253c3ae0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7623230f-b035-4045-a9cc-b93266e76839_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_443b3676-6f9c-4bbb-8f09-ec000f396899_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f6591836-1b2a-4a22-8dc0-db7881738b9d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_57f1ce45-593f-4e0f-bbb6-95fa248e54e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_67672ed6-547a-4d99-b7ed-f27843f3ad17_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a6ef2d4-f68d-4089-8521-38d9db1f6c6a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9fc67ccf-2a41-4164-a711-a14c3fe63283_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_9a85d0ba-0a4f-4a66-a12b-ebc3bb7b3c2d_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20220331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3b37d0d1-1376-45ae-bf93-e720dd85af79_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ee97a750-4795-413c-9a4b-743d4c908d76_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_70147066-e9f2-49e7-98ad-e7fbe44379a4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_f8834636-ffe1-4078-a8f2-a89f00d0d128_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20220331.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_94b03ce5-61cf-4512-918c-8381227f84a6_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_label_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:href="evh-20220331.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:to="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b099f6c9-f83a-4479-9ea1-b7910fe7008f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_cf78dc78-91e9-47a1-a82b-892506a09d15_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b4a341b-b87e-4c90-b9c8-6e4024b9913a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_60faa756-43f9-4189-b5cf-331ed28e4c2e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d3f9a8af-e9ee-450c-a59d-ba4a17155627_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VitalDecisionsMember_052ca1f1-1717-4bd0-97ad-256bda924085_terseLabel_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_label_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions [Member]</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_documentation_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember" xlink:href="evh-20220331.xsd#evh_VitalDecisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VitalDecisionsMember" xlink:to="lab_evh_VitalDecisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ce3d5829-97d0-4eb8-90ab-54f26a3b0bc8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_3fac1c09-124e-4032-89c0-a862483d6897_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4d05af21-5e61-4404-aa9b-9fbf5d165c2c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ccc070ca-fe55-414b-b3b7-93108ab2df53_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_474272d8-c0e7-44db-8fa6-0cd6cd2e6a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_5451290a-a9e7-4914-8652-8fee500cc7a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fe86c476-22f6-43fb-bf19-8f634545893a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_edb2c57d-edfc-4e20-aae7-828a37c6d99a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97a1ed96-533a-409a-ba98-fd1273b58da7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainOnTransferOfMembership_bb6b8edb-b570-49e4-82fc-33223b6ca6ff_terseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_4e6a47b7-7a6f-4aa3-88cf-06585749f3c0_negatedTerseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_label_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainOnTransferOfMembership" xlink:to="lab_evh_GainOnTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_58c06184-c8c6-45c1-8128-7994dcdaa977_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_2ebca668-0f1b-4d68-849e-580972eebc23_verboseLabel_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to current period</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:href="evh-20220331.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:to="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_d5d8a4a8-9850-45b4-92f1-347d680ea0d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3e9877ff-34bd-4601-8a32-d94b2160da6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_fc5b662f-f1a5-4c42-8ae4-928698c2fe2f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning and Other Changes</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_11c724b7-2ccc-4a45-ba51-731de6109faf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1787caff-4343-4b3d-9cd4-d767a645e513_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f772db51-3e8c-4594-9fbe-29716a914aa8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_b1f726e6-d79d-488c-8ad4-f25f3367dc9d_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_22594ad6-9ad3-47d9-964b-2613f281def5_terseLabel_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of make-whole premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_label_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_documentation_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium" xlink:href="evh-20220331.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsOfMakeWholePremium" xlink:to="lab_evh_PaymentsOfMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_14e05c63-fa4c-4fce-a987-d15d817e7784_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20220331.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b7b47038-033c-4df8-9425-f56a2883bf1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_94ea9e7a-9d6e-419c-a8c5-c7a08de84df5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_99c67efb-61e4-46b9-8449-b6dd55ec0b0d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c8d9e437-c22a-448f-a143-babffe2f08b9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_436aba86-5df5-47e8-ae46-2e9cf04b6818_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fed7ff91-a559-4d6f-b45f-eb50c0128d5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_263f3f71-9449-4e7b-818b-c6bb71c7e3f4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_3ad39585-ab55-49a7-86b4-0df9fde93668_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_fbbb7e24-d1e8-4dad-acf1-0c8312cfcd3a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_74130ef3-b44e-4ec5-995c-4d1239d4b036_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20220331.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_2ca22a97-23aa-4208-b633-4e8c41cbe2e3_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space consolidation</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0c7f3187-e410-4029-a022-c5597c7e9801_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_57d7f1de-a5e2-40ed-83d2-e04d1ca9c69e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f46b2fd-95f5-4f4a-a2ae-b3bf58c18ba5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3edf49ed-1067-4c7f-9804-aedf46826632_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_bb78fca9-cdf3-4704-99d9-eba6ca5502a4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term receivables</link:label>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_501a707c-b6f8-4f2a-9af1-8e6de638ad27_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_6cb9b71d-fdbd-403c-9836-321f6db63323_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment and termination of Credit Agreement including settlement of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_88776b94-acdd-40e1-b110-714b33a09921_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f6130b0a-b7a7-4c0a-88a9-729e78530685_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8cc0872-9e14-4eea-8b83-b07cfe2efe08_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ef552ded-328b-42b1-8ae3-b9feac410f85_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of primary office leases and maturity of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_2ce0b2ab-f58f-4d87-8b8d-0293a5ead174_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b02e86c3-11d9-45f0-808f-1fe58be11ab0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_68be7d84-9fc2-45c5-909b-b8fdf5ba8111_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e5a0cde1-2497-4572-8ed1-affdbe25f416_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_649153d8-3d37-433f-bd81-24dc27b74a0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_66d71737-f5fa-4bbb-bf6b-6d0de73b17cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f7446f6e-3a45-4db7-ab7f-56afa8c20f72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_31246f4d-42de-44ca-99e0-46e35f20f0f7_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20220331.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4a3bd906-baa1-48d9-9177-18b730ee68f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0fbb9cd7-8e2a-49cf-8d6e-f6cdc221c06c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3d0b4a8e-8b3c-4795-9164-0ff3fb12ca7f_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2f212cff-be30-4b6d-8a12-f973ae9779f6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_e48418e1-b8bd-4e70-ac59-7f408dbcaf13_terseLabel_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which warrants or rights exercisable, after maturity of credit agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_label_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_documentation_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:href="evh-20220331.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:to="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_61f2673c-263d-4df1-a487-6b932d5ce33b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5bfe4e2b-9546-47de-88d3-4278c7a02fc7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_285447f0-7e59-472b-aaf1-1fa311e53e3a_totalLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tangible assets acquired</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_25559931-689d-49c2-9914-ac19bace35f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash flow, supplemental disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_3d6b9bd0-443e-404b-b0ea-1f917dac3f6b_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20220331.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_76c960f5-354e-4897-9489-6f252ef7493d_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c1e8dd3-5b55-43ad-86d9-6b556b2a9220_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_b96bc907-3ea8-438c-90ca-015c1f2552b2_terseLabel_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_label_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring [Member]</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_documentation_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember" xlink:href="evh-20220331.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProfessionalServicesRestructuringMember" xlink:to="lab_evh_ProfessionalServicesRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_dca04860-b5da-472c-b4c7-d9a408a11d7d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle outstanding warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bac8cc57-2626-4f49-90f5-aed1ba979af3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_ad6f6135-5f37-4537-9d0a-9a933a38a52c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_8b05fd93-a6d7-487f-9c55-4c32e7cd2b56_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2e8f70de-54db-4607-b4ec-2a74566965fb_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_88a5c0cf-6b45-4cce-99d4-2811a6846212_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_139029d4-35a4-451c-b163-b0004bdf1b24_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_57420b41-58d1-42f4-8dd7-8e27a9d88bce_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ac0e4eed-4114-440c-9324-2a0b7d2b3ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_0f0817a7-603a-45e7-9d96-327dbf0aa6f2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cd9a2ba5-29be-4f37-9974-8a67b27a7a20_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_960566bf-86f1-44c0-abbe-f284d47ed9f6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6a988450-f012-4604-9133-7511607bcfc8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b3499c3d-b773-4419-b294-17aa68f4df1f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_70c07e03-c84e-4ecc-a6c6-c26a4bdb0c63_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c31cfed5-9a68-4ee9-9e05-fa83d16bfedb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5bcad75f-1fe0-4a50-a6a4-462628e07960_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredFinancingFeesMember_246b9009-315a-43bd-8a67-cf1b1a8e5083_terseLabel_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_label_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees [Member]</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_documentation_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember" xlink:href="evh-20220331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredFinancingFeesMember" xlink:to="lab_evh_DeferredFinancingFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2cb8282d-ea68-4706-bd89-68da21c7d327_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_dd43def0-8daa-43d5-be06-5842d20da00e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_01e39983-eb19-4e81-ad7f-1a8b59f3974a_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_00b0b9bd-1e70-4778-a316-ab82d0d2ca48_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_e98968bb-0927-463a-b777-62c8fba85a45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_d347eaf9-7b74-41b0-b45d-0e62f1b02adc_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims expenses</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:href="evh-20220331.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9c53ae4d-e6de-4cf8-948e-e99311eaae69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfaf6838-b7e9-450b-8766-4a9bd7cffb1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_30b20eb3-f0cd-4f13-9dfc-c7d68fbf0612_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_928414ae-d5a0-44cf-b99e-c0cc6613c8c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2af5b728-0902-4482-9196-a0d2d6d4c749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net assets acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c57d85b0-f083-4c57-8ec6-d4a1d9f71066_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_6b55c3af-7f31-47b4-aa71-b3615a59d098_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of revenue from segments to consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareMember_f8198ed9-8c8b-447a-8aa9-82a9ad4ed112_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember" xlink:href="evh-20220331.xsd#evh_MolinaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareMember" xlink:to="lab_evh_MolinaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b588e7a3-7ba0-409a-ae3e-2e7eb797e09a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_c1377b03-8525-4a5d-a51f-80bf462f6c3e_terseLabel_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_label_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember" xlink:href="evh-20220331.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorCreditFacilitiesMember" xlink:to="lab_evh_SeniorCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4dce81b5-f311-4fe1-b213-44c6ce08ef77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e7211d8a-2593-4973-ae84-3f62e7e8136f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_ece6c7bf-408a-4b67-9c62-588b042fdf57_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_85041fd3-298f-4d0b-a14a-f8b5d492e8d5_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20220331.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a1961e19-c798-4c2e-81a6-2e63edb00565_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_735c674a-84bb-4177-a7d5-5259ffaf7f38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8d2ceaa7-efef-4b68-832d-6aa280ec971d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_18c2e157-3f2d-4b1a-9993-74e83a4d376c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_fe933d05-eb84-413a-8a03-9a3cc7861f8b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of premiums and claims assumed</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_c24345a4-3b9d-49d9-9618-436ef8f6b0c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_6922d122-7ace-4325-860f-b80c4fe3838b_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Total</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d6b0bf00-1761-4a6c-b314-fbe1fd73ad79_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3224a5c8-3327-40b3-90c6-c4194a506634_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_80a0a08d-a922-4668-9625-6240b3f98275_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474456cd-5927-4440-afe7-5257319e9177_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ffc2cf82-cab0-4886-8cea-871d2736cf74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c7031a39-e66d-4a0d-810c-6ba083c57b2d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_f859e6af-de9f-4d36-8005-f15fee40e228_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_99309860-3cce-4624-830c-9707e3e42dbd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2687eaea-7cdd-4645-b909-ed5b084141af_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f1efa854-76a4-4047-938c-c37dc0a055fe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_33a5e39c-7111-46af-af91-03b00ecdc6d5_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_dd1dd33f-bc33-4dbc-8ee2-b1d7c84248b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1e203a50-e27a-4caf-8513-01b4c09797e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d53363bd-f6a1-4e0e-952b-1074b8c806e6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_14294fe2-e1b9-49f6-a8c4-da1dbf999e00_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks (less than)</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20220331.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6cc28dd4-620c-485f-bdac-2bb1f987fdf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7b0be53-c256-48d9-af5e-545a949de2c2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6ed1c256-d3e8-48b3-afb7-69b90dbfdab0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_25e6b693-ee9a-486d-b643-b74385f8ca85_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_31b11edf-40a8-40ef-b36a-7f94e44abc5f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on extinguishment of debt, including fees paid to lenders</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59ee4485-3850-4b38-b636-49592dbe9a17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e277915-65b7-436c-80de-9b7212c45a6c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1deaed8d-3809-4598-b719-282edbfe3315_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6a16bc23-8105-4f99-9f40-f0cff4e090b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_10324b94-bd0f-454e-92cf-767b189ee138_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b1aeb693-5e48-45a6-a425-2f3955aa17ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f685a1b8-3dbf-4b4e-9ac1-e41186dcfbe6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_6d6622ba-f407-46f3-848a-63fc41db4dad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4f68da29-352b-4f2c-b5f0-b165c000ab6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9d4bf4ab-9085-4531-a31c-9ce260abcd4e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_52fb86d7-c544-4820-b01f-80620ce072f7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_0fb327aa-f234-42ca-a7d1-4bdd69f3644f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_455e2b10-c301-44b1-aad8-2ea04073736b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_40221641-f2f9-4630-9e0f-1a07563775f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_a7903dc9-bdce-447e-8da2-114c3a3af196_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20220331.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e6125798-57c5-45f8-9336-dca83bd8e144_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a652038b-13ba-48b1-be40-d6146ac9a4ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_75fdaf7c-7a1c-4a7f-a14d-a8f6ad3982b9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_afc947ca-a455-4481-bd89-ab7ac1040f04_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_6c2e952f-b069-43d2-98fe-825666636dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_36660a3c-0910-4c26-b97d-b938cb5b6c20_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e727e54a-bf06-4a77-8072-8030e15b6cf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_50232a28-38f0-4c62-901b-3447ca92b551_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Class A common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5c6d8bc4-46b4-4335-a780-213d53dbeb88_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransformationServicesMember_ca0295df-c728-4297-91c1-54fd724f531a_terseLabel_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services</link:label>
    <link:label id="lab_evh_TransformationServicesMember_label_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services [Member]</link:label>
    <link:label id="lab_evh_TransformationServicesMember_documentation_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember" xlink:href="evh-20220331.xsd#evh_TransformationServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransformationServicesMember" xlink:to="lab_evh_TransformationServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fcb106c6-29a9-4fba-a5a1-e0d18b05f237_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_70a92cc0-bd1a-4c75-87a0-768976589f81_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_e228b109-b0af-4cde-8c81-3609178f231c_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20220331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_8c4941fc-87f0-489f-b0d6-44e8a6cd4bbf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_d8388966-98e4-41f1-80f7-cf692e4713a9_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20220331.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_36666dd9-dd3c-4c48-b6e2-d3ace8cb0bc6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthMember_ed5dc048-0218-4a28-bd84-b81de64e03b1_terseLabel_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthMember_label_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health [Member]</link:label>
    <link:label id="lab_evh_TrueHealthMember_documentation_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthMember" xlink:to="lab_evh_TrueHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_922fede6-878d-4188-860d-b25fcb3b0772_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_8071fe10-857f-4c74-a7d2-462dc7f36ff2_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_d8a10a54-2653-490b-88da-1ef4ef883984_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_48523245-8ad5-41cd-a387-89aa3bbb249a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_29608691-08e1-442a-ad9f-f4358d8c71f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements (up to)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15588782-43ca-4512-b66f-6e5a69b4ed7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransactionCosts_45b3aa5a-4fdc-484e-b14f-c3d7cbab9ef4_negatedLabel_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_evh_TransactionCosts_label_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_evh_TransactionCosts_documentation_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts" xlink:href="evh-20220331.xsd#evh_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransactionCosts" xlink:to="lab_evh_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_eed752e1-6789-4110-b374-e5f0933c3d01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_b413c23a-6d11-4d8c-8916-4f544aa830f5_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of non-strategic assets and divestiture of discontinued operations, net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:href="evh-20220331.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:to="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_f335df60-144a-4534-a0a2-51a30187a517_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20220331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d804a5c4-9f49-417c-a162-bf38de4d517a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_40a30078-fe4f-4aee-920f-d61872dbf6e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_f1e5c82c-91fe-47af-80c3-ff4399377ba6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4793e1ef-3b13-44a1-a279-215cbd32e2bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_df9a0ccc-a0b9-4313-a35d-4ef7a91b3cbd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_be9778e3-d4e6-4402-8723-d69ac45dc62d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_7fa9dd7c-3f85-46eb-b42a-0081c537b874_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_975a398b-890b-49e4-a0bf-62a4c9171a61_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_5e01da4a-982c-4827-a257-a3a7930374f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on reserves for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3e67ff7f-6221-485b-921b-744c6b6243a2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_dc8364a3-19b8-4b47-874e-649d3f673a7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_45eccc8a-8985-4a25-a1eb-ae4cb516ad7a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f8c0ca24-d275-451a-b43c-d869d435eb8e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_54002e5d-8ec8-4a19-9f9d-84b4d83fdf8b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_d4c7a4a6-1f00-4e96-84d0-5f78fc8e3dfe_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c9a5da69-70bd-4c2c-ad22-85c533506fd2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2049deba-87d5-44ca-844d-309be456de71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75dfe8c8-2ec0-4e59-b2f0-b7826ae5c1c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CreditAgreementMember_fd966967-aca8-47d6-9c38-ac5ce2e905fe_terseLabel_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_evh_CreditAgreementMember_label_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_evh_CreditAgreementMember_documentation_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember" xlink:href="evh-20220331.xsd#evh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CreditAgreementMember" xlink:to="lab_evh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3f6a6864-9837-49bb-941c-e5ad9e363735_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_60a0aa80-3ddc-4e2c-96ee-464a062fd405_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_55dbb9cd-8909-46f5-bdea-c90e8800a212_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_e5315543-0d25-47e4-bfa3-d1fc44ad1670_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_3a87380a-70bd-4f8e-ad0f-89b099c60c21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_09d8bec4-9ca4-43a1-9710-17e0c79f241d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c4700648-dec9-432d-b858-de2154c24e96_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_93eaaad8-76d2-4d53-adec-982809a55363_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0642f73b-8eb6-4c42-b2ba-773a1a157bf4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_382baba1-b9e5-41a2-a7eb-a9242ba1b356_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ef16879a-4995-4e0f-b5f6-a1532e490dbf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7eff06e4-45a7-41da-ad5a-8334217ee513_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_38803ccc-2428-45e3-b848-8a6ead7cd9b6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ef3cfbf1-d662-4739-8860-e0a25dd4d6e9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f18a230a-424c-4879-a69d-60af672a9dc2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6750fd46-d3e9-425c-84eb-87952a28921d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_980ca327-3ab3-49a4-9f12-143c88373872_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity in claims reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_d4a6f30e-4679-48e2-a66a-f069ad9e2214_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_422f9334-c117-4929-8fad-3174e269159a_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_187ebd11-82c2-4110-80c3-25a0dbd64a73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_3e413ba7-90dc-459b-be69-6e5286337bd7_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestments_fbb54d40-eb13-44ab-a179-3e85d97ff82b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments included in restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments" xlink:to="lab_us-gaap_RestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e0b3827e-c7e1-4c84-a60e-0c365e364a0f_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_0628c2b0-02cd-40b7-843b-e22d3e0a651b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e806dd8c-b2ad-49b4-910b-08f5559ede48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6a92f51d-bcc6-44d7-bc5b-a7d742c04ef4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_21543d14-050b-4c9c-9fa9-9dfdbb8fbb01_terseLabel_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-neutral expected earnout consideration</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_label_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration [Member]</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_documentation_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:href="evh-20220331.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:to="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_751a808e-0103-4778-b4c0-a04444e057b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_ef3fbcb5-f32d-4e36-8f35-17b8f5b38652_terseLabel_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from long-term services agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20220331.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_ccd3ee99-6731-42d3-8268-fa03b9285e76_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20220331.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6737de53-430e-40ea-9005-b7c934f9717a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_a762594e-f133-4132-b772-e3ffb297f081_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5164d01c-16f3-4a31-9d38-b72a393ed61f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_744ab969-2302-4831-999a-d09f5644fd29_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_6028cd63-2930-40f7-9624-fa6bac07a420_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_57f4e896-f4e9-4f52-a9c0-fdeb31489ef2_negatedLabel_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on discontinued operations</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_label_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_documentation_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:href="evh-20220331.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:to="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1fac646a-e643-4546-86a9-725b0e95b833_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8d88a7b9-cb7f-4c36-9f6a-c90e5f74cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3ac368c4-86e5-46ff-be78-c22bff830af2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_191a363c-fd4b-4cd0-8733-a3b28a3dab35_terseLabel_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_documentation_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:href="evh-20220331.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_a0287935-03ab-47c4-951c-142667445ab8_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims assumed</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_672e9b3a-8859-4eca-bccf-97f0e0063829_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_6d77bbcf-7eae-4daa-acff-181dbd966cce_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1ffafcf8-81eb-4eb4-b768-45c3b5e44a68_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_72f2b5c0-819c-4b92-9e3d-618565bf97db_terseLabel_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_label_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment [Member]</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClinicalSolutionsSegmentMember" xlink:to="lab_evh_ClinicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_f45e7353-14be-4690-bbf5-77334f2453eb_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6c5a0a1-27ad-4852-ad6f-d3e650f2d97a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_964e571d-b6c9-4c5b-8109-9bd9a95d992c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a3b5282d-8551-4890-bb64-84810bca996a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4ead0593-1fd2-43f8-8ff1-1eb4610315b5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_2c3f0b9d-b127-4bbf-b709-1d4c0ad2467f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_269945e9-0c13-46ef-ad1d-586ada9080b4_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_7c04cd39-2775-44e5-bcd5-b648d54ed52d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_33a4d540-5094-420e-a33d-4bf32b9994bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_2c10c440-f65f-4a9a-bd2e-63391422684b_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20220331.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_abbb27f4-9d54-485a-8e17-17a9920b2e36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_88bc6588-14a5-4f1f-a8f4-21f89825799e_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Edison, NJ</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_1e53e99b-298c-4f32-99bc-8d7342d6d964_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_21f5aaea-d2d4-4f9f-81b2-6b07437d5f77_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c8450402-8eff-410b-a435-937173351250_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_971c5acb-1632-4e29-aa74-1e6efab07832_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b339fbab-3696-4453-97ac-364ff605e059_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_dd90e5de-394e-4b10-b254-7ddf9d648e7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_43490179-260f-4214-ad48-711fb82c9364_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fc16420d-91f9-4601-90eb-88da46d29572_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8c41eaab-7e9d-43f6-84e0-a587551ab12c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_9973b2e4-a008-40c0-a2c8-e8b5ef416ce6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0ac04464-a66b-41a1-8692-c1bbcb99cd12_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d0629bf7-cae4-4771-a5b9-fb2138162a46_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_2852bed7-c9ca-41b7-bc5d-c6ced73d3584_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ea566089-a3ca-4ecb-9a60-06553d6541c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_c008cdf6-2fb3-4246-bafd-d830f9bf6f1a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_20b6e9cb-249a-4e3e-ac28-5f5a93cdca23_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_863c2a74-30a1-4d8f-8d76-3c2335a0bc95_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e4427eba-bde6-4b4f-8eb8-d9041511d3f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bb699f8b-35ec-4a6a-b1f9-3f4074f2d19d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_dfdacb74-bb99-427e-862d-074673a70f02_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_64422902-8220-433c-a308-befa81f3cd06_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_label_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_documentation_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments" xlink:href="evh-20220331.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromMaturityOfInvestments" xlink:to="lab_evh_ProceedsFromMaturityOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_16a3f81b-36da-4e2b-8ee8-e301a5413564_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_082a9ad1-cfad-4934-8daf-80df6d5636dc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_b64b11fd-b047-4ff4-8971-7fb5dfcc74b3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_2de1ee54-cbc2-4349-bc24-b72421be2aa1_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_87e8e9e8-3d65-4fa6-a74f-acf863fb0f0a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_862780d6-5c70-46c2-b64b-0c6709db6128_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_e8b2916f-a847-41ac-8542-dcf7c5018036_terseLabel_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and termination benefits</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_label_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits [Member]</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_documentation_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:href="evh-20220331.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:to="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_8a214e35-e0b5-4cb0-8e38-74fe33ac8bc3_terseLabel_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DDTL Facility</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:href="evh-20220331.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:to="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_dd3dc135-e019-4b03-b151-a6e68c34388c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_030849d6-1548-4143-98f6-8a3782e1e556_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_0c7f41c5-68ae-4107-af10-47be212610c4_negatedTerseLabel_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_label_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_documentation_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:href="evh-20220331.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:to="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a39492d4-7187-4c97-93df-07b76ef16a82_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_bce0e615-b5f4-4ae2-bce9-a89cc31b1161_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_1309fa86-e481-4f36-aa7a-7334d67ddf45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_99278984-e188-4959-9c1c-fe5d2e9a1fe1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fcbc58cb-7e95-4bea-9c37-45f83a8a2ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9e756158-7023-4584-ab21-c8213dcb0fd3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fc0a7caa-2775-44f4-a689-1a971a5ac094_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8ad355b0-40c8-499e-8357-b87c90c4acac_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2e75a9d0-1778-439f-9282-650806cf3ee9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d613f4b1-9eed-42c6-9093-1e1a59f88329_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_ebad442e-6c2e-406a-a6f7-74ecccfa6b88_verboseLabel_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platform and operations</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_label_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_documentation_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember" xlink:href="evh-20220331.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PlatformsAndOperationsServicesMember" xlink:to="lab_evh_PlatformsAndOperationsServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_2190ede2-26b0-41f8-97e5-21f4f07fde1c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units for goodwill testing</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9833543a-894e-48e8-8bd3-7d80c9806d88_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a973824b-8f41-44f7-80b6-e8652821bab2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6764477b-2922-4ebb-b4ea-d0bcbd51e9f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_99733ea8-9d03-4e0a-af2f-02e3fe90cd38_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20220331.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ab868db6-cc09-4cfc-86af-42e4858ada6e_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b8925164-ed53-4a63-8087-428cd67801c0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f442d951-3561-431e-857d-a2fa6808978f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderAdvisoryServices_f5a1c6a4-8c02-4ecb-a621-a5d1d2ae4a5b_negatedLabel_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategy and shareholder advisory expenses</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_label_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_documentation_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices" xlink:href="evh-20220331.xsd#evh_ShareholderAdvisoryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderAdvisoryServices" xlink:to="lab_evh_ShareholderAdvisoryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ec25957a-76bb-4b76-89e3-67818f7134f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_7877087f-225b-4228-b15e-ada253e4c866_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent of cash savings paid to shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:href="evh-20220331.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a1d4dcd7-6d0b-4582-815a-3c9510cb2d59_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f4bfb7cd-aea3-426f-8cef-b4ef1a2b2c1d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_83ac349e-ea2d-4eb0-b2b6-ce9e97e03567_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_083099d8-6e3b-401c-ad62-f92a4a4c9de6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e6ea9bb9-06ca-43ca-aca0-83116dfe1042_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_b1b09a20-ed5a-41a8-a836-5d538099bbee_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_f82de591-2b61-4670-8858-3b4ccded2614_terseLabel_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims-related administrative expenses</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_label_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_documentation_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:href="evh-20220331.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:to="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_47d3ed88-30b0-46c9-a67d-aaffc0da6abb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e1ac681c-6fc1-46d3-a094-e22f841b595e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0886bf2f-2fde-4cf0-9d82-f0fe82aee598_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_789c2eb1-17cf-4559-aeb5-991992dbc07b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_1f47eb66-5ee9-430e-aae4-99c6fdc06241_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e200b90c-35a3-4d6f-a0cb-e1f58dbbba83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future estimated amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e851747e-247f-41e4-979b-eba65c686e32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_eeac6ac4-73c1-49ea-b826-4d9d0e61ad07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Gross Difference, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8317f973-c1f5-47b3-af3d-89908ec6e181_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cc6b772b-708f-44b3-bc41-28f76e9e7885_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8cea3b85-8558-4625-b669-2fc180bf62dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_8a85a883-ce3c-4d91-a61d-4413197c4e8b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_165462b7-d93c-4f51-b429-cac023136320_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a0f4e991-b6ae-414a-9341-9c61d0d882e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_4ff0620c-b86e-4180-a2dd-8d81a3e5185e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_72424fc6-424c-47ba-a93c-3e987d797480_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f85720cf-df45-4a62-9d9e-8a0919bafaf6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_aa600234-81f3-45e3-bb64-57f90e44a250_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_0d1384ba-4c77-4def-8418-7fdfbc84b152_negatedLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_33b040c5-1722-4f27-bee4-37122fbe8042_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_272531c3-e693-4ab1-8460-77cf63dbfdd8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_22ce8575-8077-4d70-b94e-4be355ef24f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_1091948d-86c9-49a3-927e-be9edcb086ca_negatedLabel_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:href="evh-20220331.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:to="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_54366c7c-74f9-4fbe-ba9c-a990ab81b3aa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_24f7440f-0639-44c6-8688-b20b0a71bd6e_terseLabel_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="evh-20220331.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b491329-0d08-4783-92f3-2fce31b489ba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_de4d87bd-0dbf-41a8-a097-ada68b30588e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1db2844-5415-41cb-9e4e-9bdbb136e510_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c5908b45-d8bd-400a-bc11-9f21c1f42050_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cd05c388-4cf7-4e44-bc59-5331e1c89fd2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4b6db11c-1181-415f-80da-bf7ae0f3b0f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_acf93200-6393-4bad-b647-c299fefcb03e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1b50ed91-8f19-4e40-836d-0f5378e64f71_terseLabel_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="evh-20220331.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3ed64058-7fee-4970-a4c5-53cf27fe0fdb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f0ef4621-044b-41bf-ab5e-3d90087e2f83_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, Basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_679df6b9-5e5a-44a8-8389-1b028833cc39_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20220331.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_607fc1e3-00fb-47aa-bb3c-ea30a279f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_74bfe145-decf-4e10-b39a-3d67a5f8e5db_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_3283ac66-6cb1-4f42-82e0-068384a7b5bd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c39935d4-e958-438b-a664-b247a730d6de_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f19dd7be-9057-42ac-b4a1-b5882aab0306_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_eeb42cbd-b18b-4d5c-9a24-5a8556944b70_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e045ea1-a9cf-4530-93cb-5682b878ab99_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fa34275-46fc-4ca7-b00b-3245893e1306_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81aaca11-8259-4940-8929-f214d063dcc7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9d9dbd4-dd75-4870-9cef-ef2a19bbb22b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_7192db91-f193-4864-a769-aa2bbb033db8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_1b132693-1c8d-4b70-b509-b8a50de2d832_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cd181634-fb3b-4809-95ae-308ca46aa871_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_937da610-d8df-4b44-9004-89265167d2b0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_628d38a6-2617-47fe-8397-957bf0943b1e_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_b8ec7911-5fa1-44f7-8fff-c9f2aed2efae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8983d27a-f177-4438-979a-696ac6059836_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0a7d4d48-c873-4895-add9-6a136f42c590_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_adc0dc8c-b1d8-435d-974e-9decf6460580_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a1aab411-7eb9-4c4e-ac8e-9a8bcdf7aa42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d3031576-d628-4b34-b1ac-b5427b6d9490_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ec2433c4-7cd1-4825-8cfa-f001ea1d8f68_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_cb48d46d-d5ae-4a3d-b40b-9855b3ea4b76_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e225687e-83fc-48a6-84d9-b3b291090dd8_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_96c4ef47-ac38-4986-b12a-03b23f443c1e_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_a9a082c5-a623-4a69-a81a-1b12d49b2398_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0ebd1e0f-bec5-49aa-80f4-311f2b8f21f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1a53619b-f12d-4833-8612-d17766442dfb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a00a1c2d-578a-4baf-b089-cc2cc67f8e7e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9763903d-92a3-4a66-8bbb-69024d27cdea_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e5aeda3-17ca-4555-9866-b0904a11c511_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbfe9830-49e7-4cb4-9ca7-9fec89fefee3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_806de7c4-78a2-4238-b112-5fc01b68e44d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_588ff483-2c94-4c43-b690-c9cf8e92302a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_2568510d-3baf-41c9-bb83-b7565b3e3028_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_62ecce9d-dedc-437f-a289-303f3152daed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c90052f0-78df-4972-8b02-4438f06ef7c7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0e7d6c46-a153-448c-9c84-0b39430e0a9e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fbdb8076-08ed-4df6-93d4-ab04e64b28f7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ae23bf41-8e68-474e-9289-113b8b30e735_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_e759ac9e-daa5-499d-af73-c4d502923be4_negatedTerseLabel_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_label_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_documentation_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:href="evh-20220331.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:to="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7f2da26e-777f-4683-bc2c-b7dffa711916_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_10226380-2b09-4b98-9689-0055774c3fbe_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20220331.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5b7de43a-5d06-4383-813b-2f683bfa9abb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_e0fff549-fb97-47ea-85df-d9e8d0651cc7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_48ae0d97-06ed-400d-a6ad-fa5a5da827d3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9dfcd220-d79f-42b1-a845-23632ca7ab84_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4a31f979-42d8-4370-945d-ba2242068d6e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_79c10af6-ec17-48e1-8e2d-51da6c35a5bf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_238132dc-48e4-4c81-a2a8-891a98064a30_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_53e56a4f-da50-4f29-ad84-0615c974a292_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA to net loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_73f53cfe-8bac-4e94-a142-4fa52f9b29d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b76e1d66-3bbb-4a0a-a7ee-50d6efa3a10d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c005a0c4-623e-4d90-814a-c8ec26cc2728_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0a9f89e1-ea2c-4209-bdbe-189e0e82ce10_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1e465ea6-0b5d-4f20-b840-771d96a97b6c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_649aa554-959e-4eac-af47-ae58dda431fb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_852aa2ad-b6b8-48f0-8172-1f590c61deb8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b641b7d0-727c-4bd4-b945-5e3bfd321748_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_ae25bd8c-9f1f-43a0-8f3f-e42e17562c95_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_b5d88a66-baf2-4f38-8b46-f65c71c6fb9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1a534816-68d7-44f5-88ad-2b31d47ca7f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions and business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8638220c-0182-4dd7-9af5-80b5e525653e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_41bb8acc-c490-4953-baf3-06e6d7496b1d_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance premiums assumed</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsWritten" xlink:to="lab_us-gaap_AssumedPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_a1055109-530f-4e01-9874-7d65510ac0f1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments" xlink:to="lab_us-gaap_RestrictedCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_6ef04409-9f0b-45e0-b147-de35db87c8a4_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:href="evh-20220331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_908a18b7-1690-48cd-8ea4-8ec67de39874_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a417945f-8968-42e5-9fe8-5db20f308db8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_136e0fc2-18d3-43ce-bbdf-ebb3d7162ead_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_d7e0bf3a-6b6f-461e-afe9-e0eb40f45a39_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20220331.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a38ff075-f0f3-4a01-aa52-aea43ec8bd44_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_23ea2095-ddbf-4314-b2df-fffa364e13b3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_8fdf4e5f-0878-473f-b48f-18a5d2a9d187_terseLabel_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_label_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold, Excluding Depreciation and Amortization</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_documentation_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold, Excluding Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:href="evh-20220331.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:to="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_24c4e2cd-5dd5-4b89-84fd-7feff7135f75_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20220331.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_66ba9374-7c72-4005-9655-798a6622ea3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_315ea3dd-2469-4010-befc-cbcae6d204df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fa0b0d7e-f8ba-4b39-9070-63445d2dba24_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_613fdf35-2c2b-4d69-ae47-b4fdc782a6a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_4c88e924-2bb5-49db-a6f2-af08c28cb85c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3e6f4ee0-fb52-4f93-a61b-1f80d41819f3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_6efba888-d8f5-46ea-adda-468b6dd6efc4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_aa44cf3e-f65e-429a-8ba5-14e400112c6d_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_205a153c-4b6e-4d26-ae82-b1fe8bce6a59_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a2cd70b6-a20a-439d-98a7-293460a81022_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_02356195-9fe3-4415-97fd-a7e26ea6505a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_07458e05-2fad-469b-873a-042b193e2707_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_f6013626-3e2f-44e8-9945-d19807733a33_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_711bc897-393f-4285-a969-fc6d10e62add_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20220331.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e21f9159-98a4-4e9e-b7e7-681bc5db100d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_a9fc0b54-d337-447a-a677-37ced910e357_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c29aaf79-7d04-4d8a-94ee-7cf7b78a9855_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change during the year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_656c19e8-996f-4c73-b467-54c0e80e5244_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_26d32520-631a-4446-9e52-28abdd3e8cdf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_12271864-74e2-44e4-9faa-259b728ae6de_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20220331.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_b7ee6331-b216-4043-95ba-9c65e15720cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ea9f495-1f12-4274-860d-95b1e3407066_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ef474c1f-90f2-44e4-ab78-6452b62d11a7_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_2b911321-7894-4b24-af91-f4adf8bace99_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_766dee1e-1bdb-4fe7-ac72-e78f215c1745_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_8206fac7-73a9-41c4-b44b-238fdc773cab_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_bff9b02d-1bfc-465b-a792-6794d913a749_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of offset, percentage of accounts receivable netted against claims payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:href="evh-20220331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ecfaf723-fe23-4267-bc14-a9d3feb0b2fa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0cb31fa6-ffb2-41db-8ac9-a6142bab0ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_146a6352-6fde-4f08-9924-5a1d016f0dec_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_403cb2d3-0ddf-4dcc-84e2-6bdca462654f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_81f29560-a65e-4b6d-9389-9b60ab225f3a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_59565324-b4c7-43e6-8f8b-93b9ed1cd411_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of offset, percentage of accounts receivable, net eligible for net basis settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:href="evh-20220331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>evh-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d53c1d9c-a1b3-428c-ab91-113966fe5337,g:d0023668-d86c-4a77-8abf-aab325264a20-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPage" xlink:type="simple" xlink:href="evh-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_35e9c51a-7718-439f-8690-c294cb5833c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_DocumentType_35e9c51a-7718-439f-8690-c294cb5833c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3bb9687a-a5bd-466f-b7cd-de1f258dc2dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_DocumentQuarterlyReport_3bb9687a-a5bd-466f-b7cd-de1f258dc2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2c4cf726-56cd-467e-bc33-b199cf7f4b02" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_DocumentPeriodEndDate_2c4cf726-56cd-467e-bc33-b199cf7f4b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e7a27eb5-6db9-4eff-9f25-b13c54024045" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_DocumentTransitionReport_e7a27eb5-6db9-4eff-9f25-b13c54024045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_213de6f2-4dff-4d44-a11d-3defe96e634e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityFileNumber_213de6f2-4dff-4d44-a11d-3defe96e634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_417875ac-42fa-4287-8d2b-03311fda5fcd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityRegistrantName_417875ac-42fa-4287-8d2b-03311fda5fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_55f78871-c911-43e9-ad55-601ad1f76001" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityIncorporationStateCountryCode_55f78871-c911-43e9-ad55-601ad1f76001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0789fa59-0994-445f-8c1a-b3af05f7f8e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityTaxIdentificationNumber_0789fa59-0994-445f-8c1a-b3af05f7f8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3f210eb3-9859-4129-a83a-29333ab4386c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityAddressAddressLine1_3f210eb3-9859-4129-a83a-29333ab4386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_09c3fa50-8478-423c-a6a8-5829e92c916a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityAddressAddressLine2_09c3fa50-8478-423c-a6a8-5829e92c916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0e9ea67c-512f-4aab-9bd8-64426b084472" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityAddressCityOrTown_0e9ea67c-512f-4aab-9bd8-64426b084472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2f4ead15-f23a-4de3-91d5-59e141d95e15" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityAddressStateOrProvince_2f4ead15-f23a-4de3-91d5-59e141d95e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7de5ca7-fd45-4719-965f-03ceaa83bb4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityAddressPostalZipCode_d7de5ca7-fd45-4719-965f-03ceaa83bb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0c9e454c-70e9-4fd4-ae29-df09d2b3deb5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_CityAreaCode_0c9e454c-70e9-4fd4-ae29-df09d2b3deb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_07d5782a-c003-4b14-93f3-a59780b2439e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_LocalPhoneNumber_07d5782a-c003-4b14-93f3-a59780b2439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7b4b9778-a162-42ba-b07f-7c3e3be5cbc5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_Security12bTitle_7b4b9778-a162-42ba-b07f-7c3e3be5cbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ddfc93ae-2aac-4c37-83a9-d0d1b1e2a2b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_TradingSymbol_ddfc93ae-2aac-4c37-83a9-d0d1b1e2a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bcbc200c-d10b-4fc4-8069-98ff75e3453e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_SecurityExchangeName_bcbc200c-d10b-4fc4-8069-98ff75e3453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6c4d8101-378c-4a1f-be2c-2cf7a7b36b00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityCurrentReportingStatus_6c4d8101-378c-4a1f-be2c-2cf7a7b36b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d594e2cd-c4ea-4893-aef0-87c1cd07890f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityInteractiveDataCurrent_d594e2cd-c4ea-4893-aef0-87c1cd07890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ef669761-ef7e-4201-8709-0ed283d45d3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityFilerCategory_ef669761-ef7e-4201-8709-0ed283d45d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_43ed7225-0252-4967-a379-41e20c3bc9e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntitySmallBusiness_43ed7225-0252-4967-a379-41e20c3bc9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_69c09988-f0ba-4fb8-97c4-4e6521b3b81a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityEmergingGrowthCompany_69c09988-f0ba-4fb8-97c4-4e6521b3b81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8e34a8c8-6ea7-4225-86c3-9bd5b6995615" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityShellCompany_8e34a8c8-6ea7-4225-86c3-9bd5b6995615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5e200fa5-00a7-48db-b7ea-f1ca6f8b5166" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5e200fa5-00a7-48db-b7ea-f1ca6f8b5166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ad15e2c4-ec13-4e07-b5ab-9fa8e1eacd52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_EntityCentralIndexKey_ad15e2c4-ec13-4e07-b5ab-9fa8e1eacd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4b5466eb-dbd5-4a1c-80d9-0ac43a874c35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_AmendmentFlag_4b5466eb-dbd5-4a1c-80d9-0ac43a874c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_31b337c1-d3de-46c2-9ef1-06bc6b50f640" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_DocumentFiscalYearFocus_31b337c1-d3de-46c2-9ef1-06bc6b50f640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fb44022d-3274-450c-b83d-732c29356045" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fb44022d-3274-450c-b83d-732c29356045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_77e02bd7-75d4-4a28-91e3-a5ad590a59f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9b6b87-11cd-4bbb-9035-f6a8754bbf19" xlink:to="loc_dei_CurrentFiscalYearEndDate_77e02bd7-75d4-4a28-91e3-a5ad590a59f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_01c96267-3fc1-4694-8f2e-5b76139f6583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01c96267-3fc1-4694-8f2e-5b76139f6583" xlink:to="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0b71b47-2b9c-4c1d-bd1f-f3a83fa2191d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0b71b47-2b9c-4c1d-bd1f-f3a83fa2191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_c120402a-4d9c-4cb2-b769-f559f8030d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_c120402a-4d9c-4cb2-b769-f559f8030d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_22d8b1f8-4188-4078-9d79-85d312baea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_22d8b1f8-4188-4078-9d79-85d312baea1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_572d6645-e057-44a5-a666-2ac1ced4703e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_572d6645-e057-44a5-a666-2ac1ced4703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b4d3931b-158b-4cbe-8a84-f1422cbdcfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f8bc1b0e-ee4d-476e-bd50-b3a2aee31c0c" xlink:to="loc_us-gaap_AssetsCurrent_b4d3931b-158b-4cbe-8a84-f1422cbdcfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_49fa3b50-12c0-46c1-81a0-16a0c93b0843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_49fa3b50-12c0-46c1-81a0-16a0c93b0843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e17732d6-01dd-4459-95d0-e72496cd13ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e17732d6-01dd-4459-95d0-e72496cd13ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b3d97712-6ff3-42b8-994f-534c8bfd0354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b3d97712-6ff3-42b8-994f-534c8bfd0354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_07e0c835-bb4d-48ee-8267-8260e1f9688b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_07e0c835-bb4d-48ee-8267-8260e1f9688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c72ed661-3eed-481e-8ed9-3dc55f079d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c72ed661-3eed-481e-8ed9-3dc55f079d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_59a56ece-7fd8-442a-b120-cd26b0d2bec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_59a56ece-7fd8-442a-b120-cd26b0d2bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a0572659-192a-4b90-a58c-06022bb31460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a0572659-192a-4b90-a58c-06022bb31460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_945ada18-7c05-42c4-a56e-984a24e71a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_Goodwill_945ada18-7c05-42c4-a56e-984a24e71a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_91aef278-c89a-430c-9281-97350088d479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71f08501-5eeb-4b6f-9855-3c197f7febc6" xlink:to="loc_us-gaap_Assets_91aef278-c89a-430c-9281-97350088d479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7180232-ac26-4c0d-ac85-44dfb2e47eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01c96267-3fc1-4694-8f2e-5b76139f6583" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7180232-ac26-4c0d-ac85-44dfb2e47eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7180232-ac26-4c0d-ac85-44dfb2e47eef" xlink:to="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0bcf0fb4-d506-44e0-a32a-964f31bea7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_us-gaap_AccountsPayableCurrent_0bcf0fb4-d506-44e0-a32a-964f31bea7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ddf13f12-c357-4a86-ab8b-3946e8f5440e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ddf13f12-c357-4a86-ab8b-3946e8f5440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d674a14e-f00b-446c-8081-4ac93bc13b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d674a14e-f00b-446c-8081-4ac93bc13b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_008db558-1a3c-4de6-b5bf-ff4f18b5b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_008db558-1a3c-4de6-b5bf-ff4f18b5b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbbf9be9-4a16-48ee-a87d-11cafa0327a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbbf9be9-4a16-48ee-a87d-11cafa0327a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_84f41b8c-10ec-4830-9e6e-52ef9c1304fa" xlink:href="evh-20220331.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_84f41b8c-10ec-4830-9e6e-52ef9c1304fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8f3be6a7-5456-4333-969f-b1c88603cdab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d276a3e-a114-40c3-8bc7-4578669811f7" xlink:to="loc_us-gaap_LiabilitiesCurrent_8f3be6a7-5456-4333-969f-b1c88603cdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ad53aac6-01e5-4f51-bd4b-c4ee0739df5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ad53aac6-01e5-4f51-bd4b-c4ee0739df5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fbcd6fd5-5ddd-4395-8384-e74b25e68a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fbcd6fd5-5ddd-4395-8384-e74b25e68a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_91341fee-a3e5-43ff-a0ae-ded71ea4c607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_91341fee-a3e5-43ff-a0ae-ded71ea4c607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_452fa119-4a89-43ca-a503-d78c5e6633d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_452fa119-4a89-43ca-a503-d78c5e6633d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_01ddd2fb-6fe2-4c2f-baf7-fa70225a80f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9626da9d-efa4-4120-b52b-5d2de8ecde4f" xlink:to="loc_us-gaap_Liabilities_01ddd2fb-6fe2-4c2f-baf7-fa70225a80f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6d392c67-2b86-449a-b65f-fffbcbec6bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7180232-ac26-4c0d-ac85-44dfb2e47eef" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6d392c67-2b86-449a-b65f-fffbcbec6bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7180232-ac26-4c0d-ac85-44dfb2e47eef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ed8d1fd-7165-4a7c-a096-23a2ff6c76dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:to="loc_us-gaap_CommonStockValue_9ed8d1fd-7165-4a7c-a096-23a2ff6c76dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_536926ed-3471-4fac-b770-f15113665224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_536926ed-3471-4fac-b770-f15113665224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2920dc25-cf57-46e3-b5e0-067178952d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2920dc25-cf57-46e3-b5e0-067178952d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f8ef93cd-e255-437e-8453-b122e844e4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f8ef93cd-e255-437e-8453-b122e844e4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6c859092-c73e-47ab-aef5-cb6d47a4a60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:to="loc_us-gaap_TreasuryStockValue_6c859092-c73e-47ab-aef5-cb6d47a4a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_15d9599b-3ee5-40fb-8d5e-15f569f4bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_83c1dfa6-352d-4960-8b93-75f59bb5726f" xlink:to="loc_us-gaap_StockholdersEquity_15d9599b-3ee5-40fb-8d5e-15f569f4bfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b70e115d-ce62-46da-90c4-89ace4acc958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7180232-ac26-4c0d-ac85-44dfb2e47eef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b70e115d-ce62-46da-90c4-89ace4acc958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0442597d-7305-49fd-9a95-4af41c7bb105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3ac41bfc-8a7d-4f1e-8ba3-bee026dde479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0442597d-7305-49fd-9a95-4af41c7bb105" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3ac41bfc-8a7d-4f1e-8ba3-bee026dde479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_72677a57-cfbd-4176-a220-e8eafc96c066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0442597d-7305-49fd-9a95-4af41c7bb105" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_72677a57-cfbd-4176-a220-e8eafc96c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f83cfb0c-9c1e-4bdd-abe1-7cd560fb654f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0442597d-7305-49fd-9a95-4af41c7bb105" xlink:to="loc_us-gaap_CommonStockSharesIssued_f83cfb0c-9c1e-4bdd-abe1-7cd560fb654f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_3e9283a5-9f78-4600-8340-8bb099909dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0442597d-7305-49fd-9a95-4af41c7bb105" xlink:to="loc_us-gaap_TreasuryStockShares_3e9283a5-9f78-4600-8340-8bb099909dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47896d27-4dce-4936-91ca-bd7ef434c051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47896d27-4dce-4936-91ca-bd7ef434c051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_fdf112c3-ca2e-44bd-9553-c0c1645dce05" xlink:href="evh-20220331.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_fdf112c3-ca2e-44bd-9553-c0c1645dce05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_189b4e36-6727-4c55-b2ab-d054f3e4cbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_189b4e36-6727-4c55-b2ab-d054f3e4cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ff26087b-569a-473f-96e3-396b015866a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:to="loc_us-gaap_DepreciationAndAmortization_ff26087b-569a-473f-96e3-396b015866a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d4aa7485-8f56-430c-b125-5c5cf6790911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d4aa7485-8f56-430c-b125-5c5cf6790911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_596128e6-be42-4e0e-bed6-e24e93cbaa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b769083d-0b33-4efa-aa81-ee03325e5eaf" xlink:to="loc_us-gaap_OperatingExpenses_596128e6-be42-4e0e-bed6-e24e93cbaa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_16ccf3cd-c10a-42f8-b35d-ad9bd5aeaaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_OperatingIncomeLoss_16ccf3cd-c10a-42f8-b35d-ad9bd5aeaaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ded1bcd1-9094-45fc-8cde-5d1ab152feeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ded1bcd1-9094-45fc-8cde-5d1ab152feeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1bab9297-04ed-4e83-9461-1a77dd689c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_InterestExpense_1bab9297-04ed-4e83-9461-1a77dd689c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09bca53b-0b6e-49b4-865a-255e73ec0b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09bca53b-0b6e-49b4-865a-255e73ec0b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_7c7b62c0-0c93-4361-8ec5-1f08cbc7a1dd" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_evh_GainOnTransferOfMembership_7c7b62c0-0c93-4361-8ec5-1f08cbc7a1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc462d78-481e-4210-8139-6f1cca75cd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc462d78-481e-4210-8139-6f1cca75cd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_abe80d96-8be0-48dc-a3c1-9643cbe7c2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_abe80d96-8be0-48dc-a3c1-9643cbe7c2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_475f1144-457a-4555-9d65-52e37250248f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_475f1144-457a-4555-9d65-52e37250248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bd6a3329-b8ab-47a1-b3e0-72fdc644c677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bd6a3329-b8ab-47a1-b3e0-72fdc644c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_fc7bf27c-6543-48ac-9bc5-5328d395f9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_fc7bf27c-6543-48ac-9bc5-5328d395f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_33e79420-c6d8-47fd-883f-7a29dcb7d006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_33e79420-c6d8-47fd-883f-7a29dcb7d006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_36e43825-c370-4cb8-8f5d-ca652e9d79e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_36e43825-c370-4cb8-8f5d-ca652e9d79e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bd32f536-3955-4065-954e-33f87d460725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bd32f536-3955-4065-954e-33f87d460725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_38f47c73-812c-436b-b09c-e026765d4f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_38f47c73-812c-436b-b09c-e026765d4f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_f4ef0eda-d11b-4d82-b572-5ddfa20e943d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_38f47c73-812c-436b-b09c-e026765d4f31" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_f4ef0eda-d11b-4d82-b572-5ddfa20e943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_be0ed4a7-f296-4056-9782-58b898941031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_f4ef0eda-d11b-4d82-b572-5ddfa20e943d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_be0ed4a7-f296-4056-9782-58b898941031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3459131d-ae95-45dd-bee0-25c7037fd4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_f4ef0eda-d11b-4d82-b572-5ddfa20e943d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3459131d-ae95-45dd-bee0-25c7037fd4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f21f990c-1db9-47e2-86f5-cfaf4239c702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_f4ef0eda-d11b-4d82-b572-5ddfa20e943d" xlink:to="loc_us-gaap_EarningsPerShareBasic_f21f990c-1db9-47e2-86f5-cfaf4239c702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_543df82e-2f1f-4297-80e7-6f3d9baea0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_38f47c73-812c-436b-b09c-e026765d4f31" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_543df82e-2f1f-4297-80e7-6f3d9baea0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6fba8031-269a-4c82-9420-9bff77f13640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_543df82e-2f1f-4297-80e7-6f3d9baea0f4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6fba8031-269a-4c82-9420-9bff77f13640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_dced63a6-6b06-4fc3-9747-f36c60cd82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_543df82e-2f1f-4297-80e7-6f3d9baea0f4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_dced63a6-6b06-4fc3-9747-f36c60cd82fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b24cb41-5d78-424c-a3d9-90e025af9322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_543df82e-2f1f-4297-80e7-6f3d9baea0f4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b24cb41-5d78-424c-a3d9-90e025af9322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8ba648bc-d740-4965-8714-3af2660a869a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8ba648bc-d740-4965-8714-3af2660a869a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_35153e45-de17-4332-9dbd-d3a903f98e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8ba648bc-d740-4965-8714-3af2660a869a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_35153e45-de17-4332-9dbd-d3a903f98e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_318a04e2-a8a7-40df-8252-9b4c3d24a8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8ba648bc-d740-4965-8714-3af2660a869a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_318a04e2-a8a7-40df-8252-9b4c3d24a8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_22cb1f2b-60fe-47a3-a0a9-6fb5ea0a8a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c06a6117-f166-4183-b9d4-4a0c4e0d593e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_22cb1f2b-60fe-47a3-a0a9-6fb5ea0a8a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b90ae0d9-3d0d-4aa6-a9ad-aa4e933c695b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_22cb1f2b-60fe-47a3-a0a9-6fb5ea0a8a76" xlink:to="loc_us-gaap_NetIncomeLoss_b90ae0d9-3d0d-4aa6-a9ad-aa4e933c695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f9ad1b7a-bb77-4cc1-815d-01a75cfeddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_22cb1f2b-60fe-47a3-a0a9-6fb5ea0a8a76" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f9ad1b7a-bb77-4cc1-815d-01a75cfeddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e0d214ca-1d10-4b28-b7f5-0313e0ad26e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f9ad1b7a-bb77-4cc1-815d-01a75cfeddf2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e0d214ca-1d10-4b28-b7f5-0313e0ad26e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc48cf12-f1de-4e80-a781-aaaf429232ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_22cb1f2b-60fe-47a3-a0a9-6fb5ea0a8a76" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc48cf12-f1de-4e80-a781-aaaf429232ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_652f1d8d-2119-4fc7-8da2-cedbd22d3c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_528f6fc3-b4ad-4768-a147-fca9eebabe59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_652f1d8d-2119-4fc7-8da2-cedbd22d3c6c" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_528f6fc3-b4ad-4768-a147-fca9eebabe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_80ca181d-4dc6-4228-a255-0566c7649955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_80ca181d-4dc6-4228-a255-0566c7649955" xlink:to="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60a3eadb-ec80-4f8f-baee-5f2497fbb57d" xlink:to="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7af8a2e7-e6a0-49fd-9c68-f24bf8bd933d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_CommonStockMember_7af8a2e7-e6a0-49fd-9c68-f24bf8bd933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cc902dd0-e056-40b4-ad4d-845e92d8c780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cc902dd0-e056-40b4-ad4d-845e92d8c780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7b96890b-39fa-4ea9-ab1c-593dbeccb4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7b96890b-39fa-4ea9-ab1c-593dbeccb4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ebe5a2bd-d4bd-439f-964f-d3e24554e1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_RetainedEarningsMember_ebe5a2bd-d4bd-439f-964f-d3e24554e1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2dde61d7-c9ec-4a28-9dc3-6045364cd10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8634411-a36b-4cd8-be6a-deb949f5ed71" xlink:to="loc_us-gaap_TreasuryStockMember_2dde61d7-c9ec-4a28-9dc3-6045364cd10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45321601-d53b-4ef4-80c9-7e70351490b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9543efd6-7dd7-49b8-9416-471f0432089b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45321601-d53b-4ef4-80c9-7e70351490b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_647c053c-fbc7-4a86-a9ff-03ff9797084d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45321601-d53b-4ef4-80c9-7e70351490b8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_647c053c-fbc7-4a86-a9ff-03ff9797084d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1ee9e21-af45-4029-a329-179fbb4d1f5d" xlink:to="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a8edc745-0e9f-4dbd-b357-97d83645df35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_SharesIssued_a8edc745-0e9f-4dbd-b357-97d83645df35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf909dba-27c1-4bf8-a822-8aad9c88c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockholdersEquity_bf909dba-27c1-4bf8-a822-8aad9c88c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2772713-5d91-47f8-b773-96615df4f663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2772713-5d91-47f8-b773-96615df4f663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_feecd7bd-be17-4fe3-8e1c-ff74cd96bc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_feecd7bd-be17-4fe3-8e1c-ff74cd96bc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_882ae7a1-7871-4b6c-8a3e-02c941972074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_882ae7a1-7871-4b6c-8a3e-02c941972074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3b23ef43-30ae-4f81-ae15-47b886ef0e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3b23ef43-30ae-4f81-ae15-47b886ef0e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_06159d5e-6d06-4788-8e45-6c61e43790fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_06159d5e-6d06-4788-8e45-6c61e43790fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbd7cc-674b-449d-84e9-efc4ea716221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbd7cc-674b-449d-84e9-efc4ea716221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5d268e06-68a9-41ae-b595-39fc07b58f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5d268e06-68a9-41ae-b595-39fc07b58f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4c49acf6-4ef9-4790-ac44-5103742285e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4c49acf6-4ef9-4790-ac44-5103742285e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25224165-1505-4c95-9dc2-2635f1af42bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_NetIncomeLoss_25224165-1505-4c95-9dc2-2635f1af42bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d8a3b6ce-e0a5-4fff-9ac7-eb0650b874b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_SharesIssued_d8a3b6ce-e0a5-4fff-9ac7-eb0650b874b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93d1c57a-3879-4ffc-9ee2-e15df21a9215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b838da83-8014-48b9-88db-b1eaec2473a6" xlink:to="loc_us-gaap_StockholdersEquity_93d1c57a-3879-4ffc-9ee2-e15df21a9215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ad704b5d-c47e-449b-95f8-0f78075f0586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7aa7e67-518a-45d6-9302-e618ae259cbe" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ad704b5d-c47e-449b-95f8-0f78075f0586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7371ae56-7374-4242-99f8-a4685f386764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7371ae56-7374-4242-99f8-a4685f386764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ded4e8c-37f4-42f8-a70f-2de4eb37d09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7371ae56-7374-4242-99f8-a4685f386764" xlink:to="loc_us-gaap_NetIncomeLoss_0ded4e8c-37f4-42f8-a70f-2de4eb37d09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7371ae56-7374-4242-99f8-a4685f386764" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_80de20b8-093c-4ee8-8b33-db8ae80bbb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_80de20b8-093c-4ee8-8b33-db8ae80bbb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_e4955abb-6608-4783-a101-48f20e1c9b21" xlink:href="evh-20220331.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_e4955abb-6608-4783-a101-48f20e1c9b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86b81866-70da-459f-aa85-5118736ed1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86b81866-70da-459f-aa85-5118736ed1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_20ca35fb-955c-41c0-9d4b-915698b20f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_20ca35fb-955c-41c0-9d4b-915698b20f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_eca83979-4837-45df-a7b8-1a88a9ea4d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_eca83979-4837-45df-a7b8-1a88a9ea4d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1b5ddbdf-d6d9-4324-821d-c054ed763b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_ShareBasedCompensation_1b5ddbdf-d6d9-4324-821d-c054ed763b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f19daabb-b041-4fd7-9442-ec5046b30c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f19daabb-b041-4fd7-9442-ec5046b30c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_20fbef02-0291-492b-8ecb-7faacb77bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_20fbef02-0291-492b-8ecb-7faacb77bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_779b9f0a-3e94-4dac-87e7-e4a59347a6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_779b9f0a-3e94-4dac-87e7-e4a59347a6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_a9c406d1-2f4e-4b66-9dbe-1880175f3718" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_evh_GainOnTransferOfMembership_a9c406d1-2f4e-4b66-9dbe-1880175f3718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e5b9249-baeb-4c22-8128-caa2d7f47b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e5b9249-baeb-4c22-8128-caa2d7f47b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fcf0de20-004e-4f94-bbf0-6e6722b1d9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fcf0de20-004e-4f94-bbf0-6e6722b1d9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_0444cda2-019a-4c3a-9e74-f928db41bfe7" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_0444cda2-019a-4c3a-9e74-f928db41bfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0225ce8d-78e4-47e6-9a07-448f6f1c998a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0225ce8d-78e4-47e6-9a07-448f6f1c998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_9441fca3-2a2e-490e-ad67-fb5e677d0d05" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_9441fca3-2a2e-490e-ad67-fb5e677d0d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1705bd7d-eaa7-49fb-91b4-ca0f1a2adda1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1705bd7d-eaa7-49fb-91b4-ca0f1a2adda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a14efdfd-5eb9-41a8-8383-c516316b1675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a14efdfd-5eb9-41a8-8383-c516316b1675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9033bdf7-cb79-4295-aa4a-bd3749ae08c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9033bdf7-cb79-4295-aa4a-bd3749ae08c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_78df3e71-8ef0-4c52-9f53-70b32aab6b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_78df3e71-8ef0-4c52-9f53-70b32aab6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_5ddd30f5-9127-411a-99cc-b4eb7283b20e" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_5ddd30f5-9127-411a-99cc-b4eb7283b20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_ef8c84dc-44c2-4256-ab2a-15def0252de8" xlink:href="evh-20220331.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_ef8c84dc-44c2-4256-ab2a-15def0252de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fca44ea8-aae3-45a8-8c18-68952a452bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fca44ea8-aae3-45a8-8c18-68952a452bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_838c931b-8de3-4a89-95da-f7c455891a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_882cd7da-1e51-45bb-9ec4-2628a417fbc2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_838c931b-8de3-4a89-95da-f7c455891a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dec59d2f-bdac-4352-9a7b-72a4a85cef73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42f3f08-b7ad-4b88-be17-0053965946cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dec59d2f-bdac-4352-9a7b-72a4a85cef73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9abd0975-39f2-486a-9c57-0c2d45e55076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9abd0975-39f2-486a-9c57-0c2d45e55076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_0f381fc6-ae69-4960-8552-73e10999d07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_0f381fc6-ae69-4960-8552-73e10999d07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_bbaedd57-c15b-4ab3-81f3-85d41bf29abc" xlink:href="evh-20220331.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_bbaedd57-c15b-4ab3-81f3-85d41bf29abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_1f9dce16-8990-4e7a-8564-4aef10fdc0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_1f9dce16-8990-4e7a-8564-4aef10fdc0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_6f5f232b-5ff4-4389-acf2-168ba1cab023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_6f5f232b-5ff4-4389-acf2-168ba1cab023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_a180545a-964e-4f4f-94fa-e129e79cc11b" xlink:href="evh-20220331.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_a180545a-964e-4f4f-94fa-e129e79cc11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_008a1fe3-60e6-4d3f-a274-2929c67e2199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_008a1fe3-60e6-4d3f-a274-2929c67e2199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfbc6473-4d3b-41c9-b56f-bde091866ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9eab1472-524a-4fc6-a59f-b0de5107cd34" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfbc6473-4d3b-41c9-b56f-bde091866ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_84e63d8d-d01a-4c91-8c18-d7f64bbaf193" xlink:href="evh-20220331.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_84e63d8d-d01a-4c91-8c18-d7f64bbaf193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6548ec95-a323-4c62-958e-a5926e321428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6548ec95-a323-4c62-958e-a5926e321428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7aff7672-26c5-4e6e-bf2b-a20b2019ec35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7aff7672-26c5-4e6e-bf2b-a20b2019ec35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0fb7066b-db58-4978-a031-77aa6b018cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_0fb7066b-db58-4978-a031-77aa6b018cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7b3c2472-668a-498d-9919-c665c14943b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7b3c2472-668a-498d-9919-c665c14943b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a7939da-a670-4103-8f58-4dd4553cf0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7cd71331-e3df-4723-b89a-6cf0c319a026" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a7939da-a670-4103-8f58-4dd4553cf0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aee86a1d-52e7-482f-b837-4754a5c1223e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aee86a1d-52e7-482f-b837-4754a5c1223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8266ee1e-07ef-4809-a5d7-31f6702b2739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8266ee1e-07ef-4809-a5d7-31f6702b2739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3c9421a-0a74-4983-afa3-7532e27684a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3c9421a-0a74-4983-afa3-7532e27684a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dd9f0a7-e982-4059-a34e-85d266dd83dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa846d08-e6ea-4649-95e3-73e5c5a9c728" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dd9f0a7-e982-4059-a34e-85d266dd83dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20220331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0fb10fdd-89b0-4707-b5de-ac75783b0163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e0cf61d2-2f99-4f48-bde8-f4e8fd0186f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0fb10fdd-89b0-4707-b5de-ac75783b0163" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e0cf61d2-2f99-4f48-bde8-f4e8fd0186f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f5f91b3-ad83-4858-bf78-97210607cf39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7765950f-da2e-48b6-b67e-d53782d925f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f5f91b3-ad83-4858-bf78-97210607cf39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7765950f-da2e-48b6-b67e-d53782d925f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_21f2e3f6-e541-4460-bd8b-ff5af9d449be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0841356c-0c29-48d2-9fad-bdcc32bbbfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_21f2e3f6-e541-4460-bd8b-ff5af9d449be" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0841356c-0c29-48d2-9fad-bdcc32bbbfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_96ec9dd6-10e1-47e0-8d20-6e2fbbfe291b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_96ec9dd6-10e1-47e0-8d20-6e2fbbfe291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b2f75c35-aff1-4373-954c-21fdc1cfaad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_UseOfEstimates_b2f75c35-aff1-4373-954c-21fdc1cfaad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_83b14136-327d-4430-a7f6-c774005aba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_83b14136-327d-4430-a7f6-c774005aba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1f10746a-1612-4be8-99bb-6e3d2475e3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1f10746a-1612-4be8-99bb-6e3d2475e3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_7ddae41a-b5fb-45eb-af98-ff0aea10a742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_7ddae41a-b5fb-45eb-af98-ff0aea10a742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f84c5dec-a5ed-4f04-8415-9260fe8cbfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f84c5dec-a5ed-4f04-8415-9260fe8cbfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_139cd9ef-6c4a-4927-81e3-22a23e71f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_139cd9ef-6c4a-4927-81e3-22a23e71f7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a1218059-aa7e-4da2-b2e3-cdf6fbd1d484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a1218059-aa7e-4da2-b2e3-cdf6fbd1d484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_68083a2e-20c8-4267-97de-d46acc6ab1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_68083a2e-20c8-4267-97de-d46acc6ab1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock_e4dc9ee9-ba1d-4c96-9438-37b345c2fb88" xlink:href="evh-20220331.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_evh_RightOfOffsetPolicyPolicyTextBlock_e4dc9ee9-ba1d-4c96-9438-37b345c2fb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_86fd7edc-a6fc-4086-aa0b-0ffe9a783a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_86fd7edc-a6fc-4086-aa0b-0ffe9a783a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_525daf3b-ffe5-4443-9767-842fbf3007fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_525daf3b-ffe5-4443-9767-842fbf3007fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d4faaacd-1ead-4a25-b512-021ac67e51c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d4faaacd-1ead-4a25-b512-021ac67e51c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a1402428-3d7e-4d91-a44b-d0a6d4c16d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04043b0f-71c3-459f-b750-0402e745d598" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a1402428-3d7e-4d91-a44b-d0a6d4c16d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_87da7c72-1fc9-466d-95d8-b3f48f4899c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9a199b28-8844-43c1-9d13-bcceaf45957f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_87da7c72-1fc9-466d-95d8-b3f48f4899c1" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9a199b28-8844-43c1-9d13-bcceaf45957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d9a3e30c-cb27-457f-aa14-623136cc3472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_87da7c72-1fc9-466d-95d8-b3f48f4899c1" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d9a3e30c-cb27-457f-aa14-623136cc3472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_06dc07f4-cd5f-4448-939d-0b4804481de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_87da7c72-1fc9-466d-95d8-b3f48f4899c1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_06dc07f4-cd5f-4448-939d-0b4804481de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ecb82f22-36b8-426e-9927-a8bb4c03833a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ecb82f22-36b8-426e-9927-a8bb4c03833a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_798b132a-8e4f-4616-9086-15606582ca33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_5c911be6-6041-4320-b69e-ea9e8e71e88b" xlink:href="evh-20220331.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_5c911be6-6041-4320-b69e-ea9e8e71e88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_108371b9-eaf4-4207-b8c4-8bec15c4f84d" xlink:href="evh-20220331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_108371b9-eaf4-4207-b8c4-8bec15c4f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_82224a1e-99ac-4084-86f3-9a13496a27ce" xlink:href="evh-20220331.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_82224a1e-99ac-4084-86f3-9a13496a27ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_8a2b823a-aaf9-4e01-81f3-cb9f72c8ac98" xlink:href="evh-20220331.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_8a2b823a-aaf9-4e01-81f3-cb9f72c8ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_b670dd54-3737-4b54-adc4-4cc2439dca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3cf0c608-3ce6-4fa0-beca-260b309419d2" xlink:to="loc_us-gaap_BankTimeDepositsMember_b670dd54-3737-4b54-adc4-4cc2439dca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_d55f6bb6-d0d7-4f4b-9214-906e16702496" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_1e8d82b1-749e-4de8-b961-26539c7a3435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_1e8d82b1-749e-4de8-b961-26539c7a3435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_097269ec-8a33-4772-9686-88cb9ee7185f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_097269ec-8a33-4772-9686-88cb9ee7185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_9613e276-cd76-4118-82b3-b087f9d688c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_9613e276-cd76-4118-82b3-b087f9d688c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_18c5338a-48d5-42dd-9ac6-966fa42d3126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_18c5338a-48d5-42dd-9ac6-966fa42d3126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f41c241c-30fb-4480-a727-0d2a97baa2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f41c241c-30fb-4480-a727-0d2a97baa2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_2e9e7491-e1e5-428f-ba37-ca92dd0892d6" xlink:href="evh-20220331.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_2e9e7491-e1e5-428f-ba37-ca92dd0892d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_f695b7d2-f711-4f9e-b7ae-93c707e5d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_f695b7d2-f711-4f9e-b7ae-93c707e5d6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_df13981b-a6fc-4940-a97e-40629267d4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_RestrictedInvestments_df13981b-a6fc-4940-a97e-40629267d4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7abd052-a3f1-4a8a-a5da-ed107771938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_1b9feeb7-3e8d-464e-ae3e-37094b416986" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7abd052-a3f1-4a8a-a5da-ed107771938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7fb430c2-4d7f-480c-9c29-483b786d1c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_944f5749-ad87-4997-aef1-520f626f781c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7fb430c2-4d7f-480c-9c29-483b786d1c20" xlink:to="loc_us-gaap_NumberOfReportingUnits_944f5749-ad87-4997-aef1-520f626f781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d73cc30e-ce35-4974-8c91-454b788a385b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d73cc30e-ce35-4974-8c91-454b788a385b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2e975dc-e736-4c0d-b861-d3151aca2ec7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_918ed5a0-d356-4c34-8b11-12490abb400e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_TradeNamesMember_918ed5a0-d356-4c34-8b11-12490abb400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3f66bc28-a606-4387-8813-7d7b8ef1e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3f66bc28-a606-4387-8813-7d7b8ef1e44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6f6ead58-fdcb-4bc2-963d-e8a2b0af9e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6f6ead58-fdcb-4bc2-963d-e8a2b0af9e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_0383959f-ab3d-4a0a-897a-4baddab66ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e14a352f-6ce5-4e25-aeca-efa3aad667b7" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_0383959f-ab3d-4a0a-897a-4baddab66ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:to="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_166dafac-4b8d-46ae-ac57-553d7beb3e22" xlink:to="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_40589e31-924a-4ccb-ac01-e802cb4e5db3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:to="loc_srt_MinimumMember_40589e31-924a-4ccb-ac01-e802cb4e5db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9cc4ac4-0f33-4390-94eb-2bcbb2fd465a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_778a4211-38d2-4c8a-b55e-fd97f06c0e14" xlink:to="loc_srt_MaximumMember_a9cc4ac4-0f33-4390-94eb-2bcbb2fd465a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22af3b61-f2e3-4eca-9086-a610c84e1d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7adec55a-19ad-496a-bef4-f014b0d4c2e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22af3b61-f2e3-4eca-9086-a610c84e1d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e94e1e1a-101b-4550-b951-8c0695e052e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22af3b61-f2e3-4eca-9086-a610c84e1d98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e94e1e1a-101b-4550-b951-8c0695e052e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cdc00010-c13d-4b1c-abf6-9e4d24ba336e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6dcadbfa-78b2-437b-a935-c7a7d072a737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cdc00010-c13d-4b1c-abf6-9e4d24ba336e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6dcadbfa-78b2-437b-a935-c7a7d072a737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_6b1632f5-32a2-4c63-bfb9-d17a3fd808e3" xlink:href="evh-20220331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cdc00010-c13d-4b1c-abf6-9e4d24ba336e" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_6b1632f5-32a2-4c63-bfb9-d17a3fd808e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_06d44640-577e-405b-a35e-52d2e9aa479d" xlink:href="evh-20220331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cdc00010-c13d-4b1c-abf6-9e4d24ba336e" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_06d44640-577e-405b-a35e-52d2e9aa479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20220331.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8d0b2c3c-1178-40f6-bf41-ec465590e4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b4072605-d48e-4fbb-8d4b-3f6865400a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8d0b2c3c-1178-40f6-bf41-ec465590e4a0" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b4072605-d48e-4fbb-8d4b-3f6865400a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_232d1e84-c64c-494e-8d2f-77d3b3662a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_232d1e84-c64c-494e-8d2f-77d3b3662a06" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c476b90e-7a8f-4fea-96dc-17fb42034524" xlink:to="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b49c5f41-5a93-4027-9f6d-a8cb704080ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:to="loc_us-gaap_RetainedEarningsMember_b49c5f41-5a93-4027-9f6d-a8cb704080ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_45ae5255-13c5-4d27-800d-fb6b3537e316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_02a059b3-afe3-4aab-95b8-86b2d1ece1c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_45ae5255-13c5-4d27-800d-fb6b3537e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cb54b28-3c61-456c-95f2-3e0dfbd37bab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e78e3b2-f336-4996-8d5b-26658cf40a3d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cb54b28-3c61-456c-95f2-3e0dfbd37bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff107202-d4a2-4614-8272-f40707d3a0c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9cb54b28-3c61-456c-95f2-3e0dfbd37bab" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff107202-d4a2-4614-8272-f40707d3a0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_35197489-835a-4be2-8c1e-797952a49b22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_ecde9912-ecc7-48f4-b57f-bd8c1f27c6bf" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_ecde9912-ecc7-48f4-b57f-bd8c1f27c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_b0174524-ace9-4aaa-9405-a21b3bc20f18" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5705a3e-b8e8-4a17-9c87-62f032ca8581" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_b0174524-ace9-4aaa-9405-a21b3bc20f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_78fb1cab-5efd-46b1-8936-b7bda6f8a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68fa5203-5d58-43af-93e0-fb6a4a0ac9d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_78fb1cab-5efd-46b1-8936-b7bda6f8a56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_385cbc82-4cb4-4030-bcb8-a60e89ec810e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_78fb1cab-5efd-46b1-8936-b7bda6f8a56a" xlink:to="loc_us-gaap_SeniorNotesMember_385cbc82-4cb4-4030-bcb8-a60e89ec810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3078a2dd-b594-4818-a246-1436e7890676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1fe0a7cc-7ba1-4e5f-86ba-f6c510cae9ce" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3078a2dd-b594-4818-a246-1436e7890676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_bcf55380-4767-4a71-84ec-9df40cad592d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3078a2dd-b594-4818-a246-1436e7890676" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_bcf55380-4767-4a71-84ec-9df40cad592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f21d6a75-cec6-412a-902e-069a91db9fc4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d30f3679-95c9-47dd-9546-595594c2d327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:to="loc_us-gaap_StockholdersEquity_d30f3679-95c9-47dd-9546-595594c2d327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f1722343-73ee-4ef9-992f-483e3816249e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a50603f8-a20e-4e05-abc7-6752b8449688" xlink:to="loc_us-gaap_LongTermDebt_f1722343-73ee-4ef9-992f-483e3816249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20220331.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9005b28-9529-490d-816d-0a68351920f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7af0f6af-38e6-4c19-a075-b73343b7784b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9005b28-9529-490d-816d-0a68351920f8" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7af0f6af-38e6-4c19-a075-b73343b7784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="simple" xlink:href="evh-20220331.xsd#TransactionsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4645ee2e-29f0-402b-8865-35c755be85ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1683e5c4-07e6-4a36-86b1-b11ec8376e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4645ee2e-29f0-402b-8865-35c755be85ad" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1683e5c4-07e6-4a36-86b1-b11ec8376e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb20428-57a5-4000-b81a-c836515d70fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4645ee2e-29f0-402b-8865-35c755be85ad" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfb20428-57a5-4000-b81a-c836515d70fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#TransactionsVitalDecisionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bed5d5c3-cac5-4321-9bef-510c84901e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bed5d5c3-cac5-4321-9bef-510c84901e4a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4bc159e-604d-4337-bc95-090adce64ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00ca311d-616f-4f0c-ae74-21781fa47ee1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4bc159e-604d-4337-bc95-090adce64ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_866c8709-d8a8-47a1-82c6-69866177e090" xlink:href="evh-20220331.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4bc159e-604d-4337-bc95-090adce64ff0" xlink:to="loc_evh_VitalDecisionsMember_866c8709-d8a8-47a1-82c6-69866177e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c29fa2c-3e7a-4f51-9fdc-b20a722f4281" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_182c4eaa-1314-4a9c-b02e-62062b1683ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:to="loc_us-gaap_CustomerRelationshipsMember_182c4eaa-1314-4a9c-b02e-62062b1683ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_21e4b136-bb20-4a95-ad49-e86ec92c707c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_21e4b136-bb20-4a95-ad49-e86ec92c707c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_78c7bf66-4d2b-4388-8929-73da3d12082c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fcbcf8a-ee6d-4785-b8c3-ea39a7c21537" xlink:to="loc_us-gaap_TradeNamesMember_78c7bf66-4d2b-4388-8929-73da3d12082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94e4bdac-1852-4020-93e8-7506b199cd4f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7dbbddf3-1158-4fa0-8455-29b5477c01df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7dbbddf3-1158-4fa0-8455-29b5477c01df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4b2a8eea-9fba-424e-9249-3a669d51bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4b2a8eea-9fba-424e-9249-3a669d51bdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bfda60a8-75f2-4fd1-906d-d3191f3005c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bfda60a8-75f2-4fd1-906d-d3191f3005c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fdfed0d-cd6f-4dfc-8e45-7c776e8baff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fdfed0d-cd6f-4dfc-8e45-7c776e8baff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7612c2f3-aeef-4317-ac4f-34b7df4db7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7612c2f3-aeef-4317-ac4f-34b7df4db7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d27f0b41-90d4-4eff-bd6b-a1cff3495a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d27f0b41-90d4-4eff-bd6b-a1cff3495a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_b76c604a-8e47-4371-82de-6ec619d62f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_b76c604a-8e47-4371-82de-6ec619d62f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55e85963-5bff-41d6-9073-16ee826a5125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_c96fe1e2-1a1e-461c-9f41-8c300a1a4f93" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55e85963-5bff-41d6-9073-16ee826a5125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2df3538e-8a95-4b6a-a7b7-52d84f5ddce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2df3538e-8a95-4b6a-a7b7-52d84f5ddce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9a34091c-ad39-4335-a51b-c0faba6c0a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9a34091c-ad39-4335-a51b-c0faba6c0a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_62b5535e-bf3b-4635-8fa1-c75e82012c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_62b5535e-bf3b-4635-8fa1-c75e82012c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d0620489-5d84-40b8-a63c-45e4ad00993a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d0620489-5d84-40b8-a63c-45e4ad00993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e6ee355b-b6bf-44be-91ef-8a6cdf21a68c" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e4e84b9f-a7e8-43b4-8b01-363d707bdca3" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e6ee355b-b6bf-44be-91ef-8a6cdf21a68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_bb4bdcf8-70fb-4b9d-8575-235e4c315871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_bb4bdcf8-70fb-4b9d-8575-235e4c315871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1bb4c4b0-e416-456b-961e-e6581138de70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_bb4bdcf8-70fb-4b9d-8575-235e4c315871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1bb4c4b0-e416-456b-961e-e6581138de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4ae24d56-71b4-4590-8ae5-cf0526f3be25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4ae24d56-71b4-4590-8ae5-cf0526f3be25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_cc7ce8c0-4b79-4a05-a453-9be7ffe4db4f" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_cc7ce8c0-4b79-4a05-a453-9be7ffe4db4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_ca1d48cf-f957-4ee0-908a-efb058689caa" xlink:href="evh-20220331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_ca1d48cf-f957-4ee0-908a-efb058689caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_aa864514-917d-4f7e-a8b6-d0edcfa993ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_aa864514-917d-4f7e-a8b6-d0edcfa993ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_17496bff-3af3-4f90-85b0-a9f51080fb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_17496bff-3af3-4f90-85b0-a9f51080fb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2e85e874-2678-43d5-9ce5-1739a03a04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2e85e874-2678-43d5-9ce5-1739a03a04dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_708f43f0-2d00-40aa-8567-b09b1ce65dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_3ea9928e-c9ef-44d5-923e-d9c5e67e1e80" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_708f43f0-2d00-40aa-8567-b09b1ce65dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80a8f042-81e2-4a6c-83ec-b4ced8bde8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_Goodwill_80a8f042-81e2-4a6c-83ec-b4ced8bde8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_47494148-5930-46a4-b378-1432c7da7847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_47494148-5930-46a4-b378-1432c7da7847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f2d2bdc-5b4b-4d3c-a601-faa756c41f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f2d2bdc-5b4b-4d3c-a601-faa756c41f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a69dc12e-8970-4728-96e8-0857579fb1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f27d4136-4f74-4f22-b926-284e21360c25" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a69dc12e-8970-4728-96e8-0857579fb1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7adc284e-68fe-483c-ba9e-d01573e7ac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e2babda4-2ccf-4fe5-a4e7-679b62876b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7adc284e-68fe-483c-ba9e-d01573e7ac6a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e2babda4-2ccf-4fe5-a4e7-679b62876b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d7874852-f801-4554-9395-5e1ad09f50e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_4f33e91b-293b-462a-83ac-dec2bdd61a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d7874852-f801-4554-9395-5e1ad09f50e7" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_4f33e91b-293b-462a-83ac-dec2bdd61a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d4f72017-bc0c-4fd4-ab43-7e1d1913e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d4f72017-bc0c-4fd4-ab43-7e1d1913e53e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2f1c41ad-b91b-4c32-b6f6-b40aca200063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_06273013-963a-450e-b80d-971ce76fc259" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2f1c41ad-b91b-4c32-b6f6-b40aca200063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b72fd7d7-5bb7-49ec-a8ff-d0964b723c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2f1c41ad-b91b-4c32-b6f6-b40aca200063" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b72fd7d7-5bb7-49ec-a8ff-d0964b723c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00ce89b9-c380-4fe0-9e1b-ff3dc586fdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7eea8b5c-60ae-42c5-abc3-795602605b25" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00ce89b9-c380-4fe0-9e1b-ff3dc586fdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_0c4d0f54-6955-4607-b9f4-a66d49ee6c31" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00ce89b9-c380-4fe0-9e1b-ff3dc586fdc2" xlink:to="loc_evh_TrueHealthMember_0c4d0f54-6955-4607-b9f4-a66d49ee6c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_83cee9e5-ae42-48f4-9391-c9175ceb2e22" xlink:to="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_0b2f4258-91a1-49f7-9ca5-4b769ed4a9f6" xlink:href="evh-20220331.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_0b2f4258-91a1-49f7-9ca5-4b769ed4a9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_02ac66b2-4b30-4739-ab4e-b8f91b52ede5" xlink:href="evh-20220331.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:to="loc_evh_PremiumsRevenueMember_02ac66b2-4b30-4739-ab4e-b8f91b52ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_0e2e183f-9914-4519-911f-35908e2dcce8" xlink:href="evh-20220331.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddcf166d-fbf6-4b4c-86ca-ead2ae39d676" xlink:to="loc_evh_ServicesAgreementsMember_0e2e183f-9914-4519-911f-35908e2dcce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fb77b046-2cc0-4359-9ca2-d388096cabe5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a612dd73-dd3e-412d-a93a-0eab3d7eeed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_RevenuesAbstract_a612dd73-dd3e-412d-a93a-0eab3d7eeed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_51948cc5-f020-4aa9-8958-753920fc3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a612dd73-dd3e-412d-a93a-0eab3d7eeed7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_51948cc5-f020-4aa9-8958-753920fc3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7824dc39-dd4d-462a-a0c8-4e15cfda8399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7824dc39-dd4d-462a-a0c8-4e15cfda8399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4d96df69-420b-4df3-84ea-4ade18495387" xlink:href="evh-20220331.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4d96df69-420b-4df3-84ea-4ade18495387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c661232e-44db-4e99-a05b-b3d42c4b65e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c661232e-44db-4e99-a05b-b3d42c4b65e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_25d4387f-a628-456b-9ec0-35de75e5946e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_25d4387f-a628-456b-9ec0-35de75e5946e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_428124f7-897c-4574-aade-614f574c076e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14911b67-1d34-4966-be0b-bbcb665300f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_428124f7-897c-4574-aade-614f574c076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_497d7bac-c11e-41bd-90e2-7c78f86b6fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_497d7bac-c11e-41bd-90e2-7c78f86b6fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_608092b2-1977-424e-b606-d928b2822b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_608092b2-1977-424e-b606-d928b2822b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_efa46236-f495-447b-ba7e-b3ac807d92cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_efa46236-f495-447b-ba7e-b3ac807d92cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_dd6c4319-d200-42ce-80b7-7af92edd8b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_dd6c4319-d200-42ce-80b7-7af92edd8b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_67d2c937-602b-48dd-a952-18f2f921f23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_67d2c937-602b-48dd-a952-18f2f921f23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_07fe1120-47de-4efe-bd60-b3d9489acc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_07fe1120-47de-4efe-bd60-b3d9489acc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aeffa830-1389-4c8c-90ee-42bd9bd98137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d3d6b0ae-dabb-4758-a750-027f5f450190" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aeffa830-1389-4c8c-90ee-42bd9bd98137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_52314858-292c-4a93-86a0-07ef1b8fb5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_52314858-292c-4a93-86a0-07ef1b8fb5ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_db16277c-f2c7-45a4-9422-9789f127461c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_74ff679a-d348-42cd-9669-5da722cf214e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_db16277c-f2c7-45a4-9422-9789f127461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_36aa3962-5192-4564-a83e-19aebdd06e6f" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_db16277c-f2c7-45a4-9422-9789f127461c" xlink:to="loc_evh_TrueHealthMember_36aa3962-5192-4564-a83e-19aebdd06e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e3b21497-b1cd-4187-b3f0-a93a8408bc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f603ff63-4acb-4c6c-9f5d-55fce207500e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e3b21497-b1cd-4187-b3f0-a93a8408bc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c6d07323-cc50-4413-a792-40efde793e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e3b21497-b1cd-4187-b3f0-a93a8408bc99" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c6d07323-cc50-4413-a792-40efde793e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3d5b131e-9831-4435-a732-26e5a62f5f58" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7a7571ca-6a57-4298-8bac-977083b85db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7a7571ca-6a57-4298-8bac-977083b85db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_192a536c-95a0-4c29-b990-096458e0ebe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1ccb456-7da9-4e3d-b9dd-fb1f57888de2" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_192a536c-95a0-4c29-b990-096458e0ebe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59cc4aa9-be13-4220-9ad5-c3bd9bee5ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7ac468f1-7b0a-47a5-9e7d-4d1d325dc2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59cc4aa9-be13-4220-9ad5-c3bd9bee5ecd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7ac468f1-7b0a-47a5-9e7d-4d1d325dc2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6c593d0-99c6-442a-bc32-52c75072b4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_209d13a6-12dc-4869-a913-06c77a6ea97c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6c593d0-99c6-442a-bc32-52c75072b4ad" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_209d13a6-12dc-4869-a913-06c77a6ea97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d2a8d135-a3e1-4599-ae88-e7db51e92e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6c593d0-99c6-442a-bc32-52c75072b4ad" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d2a8d135-a3e1-4599-ae88-e7db51e92e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_83bc4c08-7488-4087-8cef-c2cb5a929ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_83bc4c08-7488-4087-8cef-c2cb5a929ab1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8586c3d-10c9-48c9-99af-d3a3d4ad1071" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_57d70644-0e45-4f02-8173-68325d39ec8f" xlink:to="loc_srt_ProductsAndServicesDomain_a8586c3d-10c9-48c9-99af-d3a3d4ad1071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_b16cf48a-ede7-4f95-8eba-230ebe8fe5db" xlink:href="evh-20220331.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a8586c3d-10c9-48c9-99af-d3a3d4ad1071" xlink:to="loc_evh_TransformationServicesMember_b16cf48a-ede7-4f95-8eba-230ebe8fe5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88b035aa-7edc-448d-9b73-e0d0f7028c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_53382892-2705-4c51-a86c-fb5e3bad0665" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88b035aa-7edc-448d-9b73-e0d0f7028c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8de797ca-7b2b-4af2-8742-e0f43ebfea6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88b035aa-7edc-448d-9b73-e0d0f7028c6c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8de797ca-7b2b-4af2-8742-e0f43ebfea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_18fd3138-0789-4b54-995f-37945388a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5e6813d1-0f88-425d-9f33-523280948152" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_18fd3138-0789-4b54-995f-37945388a3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_6b341ea0-2435-48e0-937c-feeec4b242ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_18fd3138-0789-4b54-995f-37945388a3a3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_6b341ea0-2435-48e0-937c-feeec4b242ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8b1f1147-0cf3-4117-85da-f7f001a26b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_046e57e2-4adb-4174-9e96-78ee7632e891" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8b1f1147-0cf3-4117-85da-f7f001a26b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_25bcea42-8e24-4160-8a41-bcd82b426466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8b1f1147-0cf3-4117-85da-f7f001a26b4e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_25bcea42-8e24-4160-8a41-bcd82b426466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e52e8dc5-1b48-4942-9514-de83c6524c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e52e8dc5-1b48-4942-9514-de83c6524c7b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0c433640-81ca-43d2-8ff0-7b42bcbd8044" xlink:to="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_6e4059bc-ac9a-41bc-9a9f-c654f946a7b5" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_6e4059bc-ac9a-41bc-9a9f-c654f946a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_42957931-bfbe-4c1f-9639-fdc982f7099d" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8d6cc1af-e708-40c5-9837-53ac63f9c254" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_42957931-bfbe-4c1f-9639-fdc982f7099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:to="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e8cef12b-1fa8-41ef-a380-1eea159f6907" xlink:to="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_bd416de8-7ab3-4e2e-9a68-bacac879f9b0" xlink:href="evh-20220331.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:to="loc_evh_MedicaidCustomersMember_bd416de8-7ab3-4e2e-9a68-bacac879f9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_cb938925-0bf6-4a95-a20f-0b4575cefc08" xlink:href="evh-20220331.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:to="loc_evh_MedicareCustomersMember_cb938925-0bf6-4a95-a20f-0b4575cefc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_ef55204a-e777-4e81-961f-ce02616dae61" xlink:href="evh-20220331.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1219444b-41c0-42a6-99ea-47454dde8bbf" xlink:to="loc_evh_CommercialAndOtherCustomersMember_ef55204a-e777-4e81-961f-ce02616dae61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_218f8c3c-b1ec-4238-97b3-ea2f12c660e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_baa28630-08b1-4f18-be68-7f7140f3fd7d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_218f8c3c-b1ec-4238-97b3-ea2f12c660e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6190029-9cb4-4422-b6f8-d83accac2a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_218f8c3c-b1ec-4238-97b3-ea2f12c660e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6190029-9cb4-4422-b6f8-d83accac2a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11ecb958-25fc-4d8c-b265-9692b6bb79d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_56e50be8-5f7d-4bd6-ab72-1fa0ca9c53b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11ecb958-25fc-4d8c-b265-9692b6bb79d6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_56e50be8-5f7d-4bd6-ab72-1fa0ca9c53b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11ecb958-25fc-4d8c-b265-9692b6bb79d6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_922880e7-0aac-418c-89d9-2adbf462f61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_922880e7-0aac-418c-89d9-2adbf462f61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_effb2d09-7999-40f1-808a-7f0401069ce0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_8e12cbf7-3912-4c6d-aa81-745f0846c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_8e12cbf7-3912-4c6d-aa81-745f0846c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2e368414-ce0b-482e-b5cc-19f79187d746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_2254197b-151b-406a-a2dd-50ff930e98ab" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2e368414-ce0b-482e-b5cc-19f79187d746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_1c6b8bdc-b564-48ec-afa6-2679f2a228e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_1c6b8bdc-b564-48ec-afa6-2679f2a228e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_c3ef0214-1b0e-438b-aead-72295d11aefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:to="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_c3ef0214-1b0e-438b-aead-72295d11aefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8fd56d6b-97a6-443f-ba59-004a34211490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8fd56d6b-97a6-443f-ba59-004a34211490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6fa89a78-47c6-4226-8134-22711f593e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6fa89a78-47c6-4226-8134-22711f593e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_a97a3252-0769-49bb-b21d-4351950a2b01" xlink:href="evh-20220331.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_a97a3252-0769-49bb-b21d-4351950a2b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6fe5eabf-28d7-4c8e-b6a7-b0c8ce1c4aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_a97a3252-0769-49bb-b21d-4351950a2b01" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6fe5eabf-28d7-4c8e-b6a7-b0c8ce1c4aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_86f2392a-b572-4d08-a0a4-7bb551344822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_a97a3252-0769-49bb-b21d-4351950a2b01" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_86f2392a-b572-4d08-a0a4-7bb551344822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_5113113c-f843-4674-ab4c-4c478e0d1412" xlink:href="evh-20220331.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_a97a3252-0769-49bb-b21d-4351950a2b01" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_5113113c-f843-4674-ab4c-4c478e0d1412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_123a89e4-0f9f-43c5-8866-8c1a13da8ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_a97a3252-0769-49bb-b21d-4351950a2b01" xlink:to="loc_us-gaap_ContractWithCustomerLiability_123a89e4-0f9f-43c5-8866-8c1a13da8ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_310d6bfb-965e-4387-a6f7-d89457099c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_24d1a4f2-9448-41ef-8f17-f73a1e8a6953" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_310d6bfb-965e-4387-a6f7-d89457099c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_165e485d-8e94-431b-9f32-e67d6d8302d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_165e485d-8e94-431b-9f32-e67d6d8302d8" xlink:to="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_bcdf4531-eb74-4ac1-8b85-d404af6d6418" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_f9b8b3f5-32c2-42f0-82ac-29c89fd847af" xlink:href="evh-20220331.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:to="loc_evh_BonusesAndCommissionsMember_f9b8b3f5-32c2-42f0-82ac-29c89fd847af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_8d3d44a6-2219-4649-9127-1d104fdc5b0b" xlink:href="evh-20220331.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_5cc80772-b820-4ec0-a8e3-ae4562347a58" xlink:to="loc_evh_ContractFulfillmentCostsMember_8d3d44a6-2219-4649-9127-1d104fdc5b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_c1e4a135-d7fc-4eab-aa23-98dde2c5f96c" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_e622da2c-7491-41af-bad0-60a80aa183da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostNet_e622da2c-7491-41af-bad0-60a80aa183da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_4f0d6847-65e7-46ef-bc42-7ece2339a986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_4f0d6847-65e7-46ef-bc42-7ece2339a986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_a8bf5151-40dd-4892-97f0-f1180d83a030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_437f4b03-1482-4e9b-bf80-9f44280e18b1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_a8bf5151-40dd-4892-97f0-f1180d83a030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20220331.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_bd1ff376-6d58-424e-96fb-ab3af4598962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_5d47b760-120e-4224-ac01-16d6ab3acdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_bd1ff376-6d58-424e-96fb-ab3af4598962" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_5d47b760-120e-4224-ac01-16d6ab3acdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20220331.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_75841b91-e5fb-48ad-9f39-493241affd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_32284c8e-9e9c-44da-b3ac-cf70962b60ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_75841b91-e5fb-48ad-9f39-493241affd6b" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_32284c8e-9e9c-44da-b3ac-cf70962b60ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_a9c9b721-a637-43ca-9126-b7a62e89b63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_a9c9b721-a637-43ca-9126-b7a62e89b63f" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_918dca81-dd56-4dbc-9da1-3179793be734" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_a8d80cf8-4df8-4196-bfc0-e1bd93c16bab" xlink:href="evh-20220331.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_a8d80cf8-4df8-4196-bfc0-e1bd93c16bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_623562f8-6823-4ef6-a958-4577501929ab" xlink:href="evh-20220331.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_83d557a9-19fa-480c-83ab-2140464500ad" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_623562f8-6823-4ef6-a958-4577501929ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_a6e6dbe9-b53f-4f3b-8944-66f8b6c56ace" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_f77ca055-2053-41c9-9223-3b90c08e282b" xlink:href="evh-20220331.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_f77ca055-2053-41c9-9223-3b90c08e282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_4292ad8f-e919-4703-b1d5-2f616e3f7cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_4292ad8f-e919-4703-b1d5-2f616e3f7cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_908c7633-c0bb-4c86-ae33-c9c682dde1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_AccountsReceivableNet_908c7633-c0bb-4c86-ae33-c9c682dde1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a2822b0e-6820-42a5-8d57-2f5237421c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_376f1847-30af-4783-acd7-8b8b5f0b4b4c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a2822b0e-6820-42a5-8d57-2f5237421c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_d89201c4-a124-4274-b5ec-d1a03449dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d4e447d4-4ae0-43d3-8297-60bf3a982652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_d89201c4-a124-4274-b5ec-d1a03449dc51" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d4e447d4-4ae0-43d3-8297-60bf3a982652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2e4d0b45-1afd-4a29-bbce-77e3797e3b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d4e447d4-4ae0-43d3-8297-60bf3a982652" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2e4d0b45-1afd-4a29-bbce-77e3797e3b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1749c884-b871-4d66-8070-007aba3f7bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d4e447d4-4ae0-43d3-8297-60bf3a982652" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1749c884-b871-4d66-8070-007aba3f7bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2d6bcac8-2f42-4e84-8245-a32ad7babafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d4e447d4-4ae0-43d3-8297-60bf3a982652" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2d6bcac8-2f42-4e84-8245-a32ad7babafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20220331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_32c45184-ad1a-496b-88df-82440f69698f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_932882e4-1c48-4160-9e6d-1a9a06aa2a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_32c45184-ad1a-496b-88df-82440f69698f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_932882e4-1c48-4160-9e6d-1a9a06aa2a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20220331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6d73b6a4-d783-46c4-8892-855342324ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d8b4471a-edef-4dff-8710-4df64d00ada5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6d73b6a4-d783-46c4-8892-855342324ea6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d8b4471a-edef-4dff-8710-4df64d00ada5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6c64c1a0-61c7-48d2-9354-f1f05f83a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6c64c1a0-61c7-48d2-9354-f1f05f83a6c6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9698821-a28a-43d9-91b6-55eba78dfd8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2dd22007-94f4-41fc-a324-da99a76a4797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_ComputerEquipmentMember_2dd22007-94f4-41fc-a324-da99a76a4797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7ea5ada3-5a62-45da-ab1e-dcf425add10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7ea5ada3-5a62-45da-ab1e-dcf425add10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_777d21ce-84ce-41ad-bda2-cc850f5077d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_777d21ce-84ce-41ad-bda2-cc850f5077d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e74bdada-8d27-4bba-a31f-ee98b00483ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28f3baa1-b62c-40d1-9a25-78f77c8f2fd7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e74bdada-8d27-4bba-a31f-ee98b00483ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_31b347c2-66d1-48e6-8b60-f9a97ccb0015" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_99752634-e622-4d51-9143-65ab546994e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_99752634-e622-4d51-9143-65ab546994e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93fccbab-9409-4d3a-9b70-07127a632616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93fccbab-9409-4d3a-9b70-07127a632616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e94ddb6b-ec62-4201-a175-c44491b598ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e94ddb6b-ec62-4201-a175-c44491b598ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fd749f81-f515-46d4-896e-b88a7d72033c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fd749f81-f515-46d4-896e-b88a7d72033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cac5f417-9064-4d71-badd-576d3f006b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_Depreciation_cac5f417-9064-4d71-badd-576d3f006b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5eff9b9-c877-44bd-ba29-7ffc8cfd42b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cde53488-1523-46a8-8264-3de3b3e42c5c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5eff9b9-c877-44bd-ba29-7ffc8cfd42b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d58127a2-3b45-476a-a582-d32d18167f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_eae029ae-b9d8-4862-870f-34faab6a4f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d58127a2-3b45-476a-a582-d32d18167f3a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_eae029ae-b9d8-4862-870f-34faab6a4f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d19bb96-a1e6-41d0-9484-5c8b3163e8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_56f1ff3f-d670-47b2-88df-aa9b4d8026de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d19bb96-a1e6-41d0-9484-5c8b3163e8df" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_56f1ff3f-d670-47b2-88df-aa9b4d8026de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_35b415be-7df3-4881-abbc-2ebb4b147aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d19bb96-a1e6-41d0-9484-5c8b3163e8df" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_35b415be-7df3-4881-abbc-2ebb4b147aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b508905b-a259-40aa-9898-3a429c44dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d19bb96-a1e6-41d0-9484-5c8b3163e8df" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b508905b-a259-40aa-9898-3a429c44dc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_929831e5-8693-4c23-ac4a-4b6dee064e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_5bf05a68-4d43-490c-9bbe-0c9578ac8787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_929831e5-8693-4c23-ac4a-4b6dee064e44" xlink:to="loc_us-gaap_NumberOfReportingUnits_5bf05a68-4d43-490c-9bbe-0c9578ac8787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5d11ea9-a9d2-4176-bc0a-72b0b87c4144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_f954dbd2-31af-4213-95d7-5cbb3323fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5d11ea9-a9d2-4176-bc0a-72b0b87c4144" xlink:to="loc_us-gaap_NumberOfReportingUnits_f954dbd2-31af-4213-95d7-5cbb3323fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5d11ea9-a9d2-4176-bc0a-72b0b87c4144" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d66da07-efe7-43ef-b07f-68def793f7ce" xlink:to="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_22c3f59c-66a6-4110-8d18-afa152f285f2" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_22c3f59c-66a6-4110-8d18-afa152f285f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_0415a22a-ba2d-4455-a6dd-4885688230ee" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b50beecf-aa7f-4405-b321-287b5cd06acb" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_0415a22a-ba2d-4455-a6dd-4885688230ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5d4f24d8-7693-4f04-a8c7-742afb7f2ed4" xlink:to="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:to="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e811312-54c0-4abb-9be9-b6fd2a707f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:to="loc_us-gaap_Goodwill_3e811312-54c0-4abb-9be9-b6fd2a707f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_89e506b9-c7dd-4787-b0e8-37eafb7c8faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_89e506b9-c7dd-4787-b0e8-37eafb7c8faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8b416751-221b-490c-afb1-cf41a9204d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_278f28ee-b426-4880-bfef-a46186112494" xlink:to="loc_us-gaap_Goodwill_8b416751-221b-490c-afb1-cf41a9204d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_61dfefa0-504e-45c4-89a6-f73ec2ef5c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8f1f5797-7df7-4496-b064-b191ea359e0a" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_61dfefa0-504e-45c4-89a6-f73ec2ef5c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97311046-9219-409e-8e09-1e16cc43f62d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97311046-9219-409e-8e09-1e16cc43f62d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7976a54e-e7ac-403b-8815-6cd8c0aaa475" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e8b439ee-f9fc-47be-beba-0d369a498566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_TradeNamesMember_e8b439ee-f9fc-47be-beba-0d369a498566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e29cbb8b-b3f9-4140-a12e-d8ec48c0324c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e29cbb8b-b3f9-4140-a12e-d8ec48c0324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3698c502-dda6-4046-ae08-331a713b45cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3698c502-dda6-4046-ae08-331a713b45cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_38bbd6fe-fdcf-4926-aaa2-74abe8afb5e0" xlink:href="evh-20220331.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_evh_BelowMarketLeasesMember_38bbd6fe-fdcf-4926-aaa2-74abe8afb5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_f1bd9888-2246-43f4-a04e-a47799edf983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef3df210-07f3-4cb1-87a8-b851a27a6219" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_f1bd9888-2246-43f4-a04e-a47799edf983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_829676b2-5eeb-4d6d-9c95-8dbf5a3c71b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f898a34e-d8d0-4f83-991b-68b8326ccad5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_829676b2-5eeb-4d6d-9c95-8dbf5a3c71b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fe048ccd-6db9-4972-9b89-bfa3e2ea877c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_829676b2-5eeb-4d6d-9c95-8dbf5a3c71b2" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fe048ccd-6db9-4972-9b89-bfa3e2ea877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f50fafa4-97de-45dc-8015-1918ab424af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_efb2c7fe-3166-491b-9a0d-8dcd66c3852b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f50fafa4-97de-45dc-8015-1918ab424af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_53e40917-5ffc-4943-8bd6-bb51c6b9569c" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f50fafa4-97de-45dc-8015-1918ab424af0" xlink:to="loc_evh_TrueHealthMember_53e40917-5ffc-4943-8bd6-bb51c6b9569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7a98adca-839e-47e7-9806-243e1fb6569a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2800b76d-1ea0-4bad-b4a0-4f30c7dfab27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2800b76d-1ea0-4bad-b4a0-4f30c7dfab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_154d44e8-f989-4222-8001-a723f1ebf966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_154d44e8-f989-4222-8001-a723f1ebf966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a9b69632-cc28-4404-94f5-5528143f5422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a9b69632-cc28-4404-94f5-5528143f5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_493e0343-e3c5-4600-9bc3-27df2e5c0641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_493e0343-e3c5-4600-9bc3-27df2e5c0641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4051408d-cea1-493e-97d0-97bd2f9773e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c24d1e99-742d-4810-8ca1-27af228c2766" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4051408d-cea1-493e-97d0-97bd2f9773e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ae7acd31-c852-4739-9354-bde085a967b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ae7acd31-c852-4739-9354-bde085a967b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_56fb525f-51d0-4bc7-9534-9abf9e79ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_56fb525f-51d0-4bc7-9534-9abf9e79ec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6ef2e67a-97c6-43b2-bb6e-918d64208a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6ef2e67a-97c6-43b2-bb6e-918d64208a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4fefc9da-f4f5-4f74-a7d9-7cf28f2c74e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4fefc9da-f4f5-4f74-a7d9-7cf28f2c74e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47de6784-fecc-4a79-9353-9fbf17f35cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47de6784-fecc-4a79-9353-9fbf17f35cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0ccf8340-13ac-4f07-bf9a-bb42a03ead22" xlink:href="evh-20220331.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0ccf8340-13ac-4f07-bf9a-bb42a03ead22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_342d1534-a69c-4802-9c4e-558e56e2ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_313bb615-599b-4717-9036-7acb3bbc739a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_342d1534-a69c-4802-9c4e-558e56e2ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b3cfeae2-12ad-4f41-9b89-b3290a1e78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ff83e969-8ed0-4aeb-92a6-906c78a2fc10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b3cfeae2-12ad-4f41-9b89-b3290a1e78c7" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ff83e969-8ed0-4aeb-92a6-906c78a2fc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fcd917ce-1f9e-40ff-812f-cf878e4f2188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_7c616d27-dd62-4120-888e-9852f7611e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcd917ce-1f9e-40ff-812f-cf878e4f2188" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_7c616d27-dd62-4120-888e-9852f7611e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ea2517a4-9d1e-4c5a-a9bb-271e696b6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ea2517a4-9d1e-4c5a-a9bb-271e696b6e97" xlink:to="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_23c734f9-e5c8-4fcb-8cc7-cb69db2e65b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_b5c92424-8a87-4856-8f5d-dee9dfb2d435" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_b5c92424-8a87-4856-8f5d-dee9dfb2d435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_00a6f978-9391-4511-8913-a4284375f30b" xlink:href="evh-20220331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_00a6f978-9391-4511-8913-a4284375f30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_09b03ef6-8469-4d25-b8be-b1cf38b6095d" xlink:href="evh-20220331.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d7e962a-76c0-4517-a94d-14dbaa0f874e" xlink:to="loc_evh_NewNotesMember_09b03ef6-8469-4d25-b8be-b1cf38b6095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ddf5735e-172c-4c74-8b20-bad41db1ea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c2cfde9-2170-42b3-83fb-ad0a58ae5bf0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ddf5735e-172c-4c74-8b20-bad41db1ea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6e626afe-bd05-4ec2-aae9-eab2d9937af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ddf5735e-172c-4c74-8b20-bad41db1ea02" xlink:to="loc_us-gaap_SeniorNotesMember_6e626afe-bd05-4ec2-aae9-eab2d9937af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c7622bfc-fb5a-4ee4-bed4-34dc7446ef52" xlink:to="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5b229e3b-c2ec-4a72-a475-054e50c6a391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:to="loc_us-gaap_CommonStockMember_5b229e3b-c2ec-4a72-a475-054e50c6a391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6abcaea0-63b6-4c52-9577-236be5721f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6abcaea0-63b6-4c52-9577-236be5721f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8619bc7a-39d5-4bcf-af57-bcbcd68670de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb3a5fc4-117c-4179-8b1b-8c8fb9ffb179" xlink:to="loc_us-gaap_RetainedEarningsMember_8619bc7a-39d5-4bcf-af57-bcbcd68670de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1d1b24ad-7cbb-44a7-a2f6-97fa7be67e0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d5f65ea1-3f24-421d-ac1b-b9a4275914cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1d1b24ad-7cbb-44a7-a2f6-97fa7be67e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c9ec69ce-89ff-4034-a21c-81eac5230beb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1d1b24ad-7cbb-44a7-a2f6-97fa7be67e0b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c9ec69ce-89ff-4034-a21c-81eac5230beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7b0eac42-fa93-4be5-997d-f5a4ee0359f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fb911e8c-0e2c-402e-8dbd-d23462468fa9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7b0eac42-fa93-4be5-997d-f5a4ee0359f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_c6ba162e-d5d4-442a-b613-0e8dd35c3e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7b0eac42-fa93-4be5-997d-f5a4ee0359f9" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_c6ba162e-d5d4-442a-b613-0e8dd35c3e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_548aae0d-879a-45a2-b1f7-ea814ce351cf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_b8782876-ced0-4c95-8c45-7286734bfeee" xlink:href="evh-20220331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_b8782876-ced0-4c95-8c45-7286734bfeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_e79b2ecb-e3be-41a7-9ee6-9734a90e8957" xlink:href="evh-20220331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90e010c0-44ea-47e2-bf4b-1a650f98fbfd" xlink:to="loc_evh_DeferredFinancingFeesMember_e79b2ecb-e3be-41a7-9ee6-9734a90e8957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_023069d4-a33b-489e-a295-4148144ae4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_44d26137-01f3-466e-b880-2f410690c295" xlink:to="loc_us-gaap_ClassOfStockDomain_023069d4-a33b-489e-a295-4148144ae4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8da34036-38eb-4068-9ed1-6b5ca4f45c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_023069d4-a33b-489e-a295-4148144ae4b9" xlink:to="loc_us-gaap_CommonClassAMember_8da34036-38eb-4068-9ed1-6b5ca4f45c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7254c07f-b8fc-434f-bff8-d866824a1096" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8e21349a-633b-43b1-8b98-75c9c0cf1b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8e21349a-633b-43b1-8b98-75c9c0cf1b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07d6cf06-fb2e-4910-8941-1020c42965a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_07d6cf06-fb2e-4910-8941-1020c42965a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_700b5d01-f1c8-44f5-974e-078a4df2371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_700b5d01-f1c8-44f5-974e-078a4df2371d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_58dd5f1a-649c-4911-980e-0d6ea912adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_58dd5f1a-649c-4911-980e-0d6ea912adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6623195a-1b8d-4b54-9e1c-c9cbc7e7ab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6623195a-1b8d-4b54-9e1c-c9cbc7e7ab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_95eff42e-1786-4b8c-adf7-a69fd87cf4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_95eff42e-1786-4b8c-adf7-a69fd87cf4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_28f87ec8-5db3-443e-acdb-7b8d9a22aa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_InterestExpenseDebt_28f87ec8-5db3-443e-acdb-7b8d9a22aa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5c417402-1981-477b-a848-a456036d7b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5c417402-1981-477b-a848-a456036d7b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b3c21a49-bfb1-4f5e-9241-290e96f408c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b3c21a49-bfb1-4f5e-9241-290e96f408c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_cfa47426-ae2c-4102-826e-927cfc2adb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_cfa47426-ae2c-4102-826e-927cfc2adb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_150d0e07-97a4-43af-b6fb-a07b942e21b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_LongTermDebt_150d0e07-97a4-43af-b6fb-a07b942e21b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f5ae9315-b403-4e69-b669-6995479dc9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f5ae9315-b403-4e69-b669-6995479dc9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_c68dfc5e-c176-4f2d-bb2d-25aa4da0290b" xlink:href="evh-20220331.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_c68dfc5e-c176-4f2d-bb2d-25aa4da0290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31c98cd0-c56b-4448-8fc1-d60d0133e910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31c98cd0-c56b-4448-8fc1-d60d0133e910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2c3349d-2fd4-49fc-b09e-82517586d2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_us-gaap_StockholdersEquity_e2c3349d-2fd4-49fc-b09e-82517586d2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dadeca0b-b52d-4f22-b3f9-24625d3e0236" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dadeca0b-b52d-4f22-b3f9-24625d3e0236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_b05f1df0-b4d6-457c-bb49-d9020230660d" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_b05f1df0-b4d6-457c-bb49-d9020230660d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_de4fb170-6e41-44b8-999c-12609b96f8d4" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_de4fb170-6e41-44b8-999c-12609b96f8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_053bcc92-d3c5-42d5-8304-48bd0404ccf7" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_053bcc92-d3c5-42d5-8304-48bd0404ccf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_21fec984-66f2-4296-af3e-59e051dbf4f3" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d2646e83-3c56-48bd-8250-33d31f80af36" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_21fec984-66f2-4296-af3e-59e051dbf4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_58f913ab-dc09-4b83-a4f2-068d53248fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_58f913ab-dc09-4b83-a4f2-068d53248fb2" xlink:to="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0308cc37-d06a-4b4a-8e38-741330363e58" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_76dc33f9-673e-43db-ad59-0c1643acdca7" xlink:href="evh-20220331.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:to="loc_evh_InitialTermLoanFacilityMember_76dc33f9-673e-43db-ad59-0c1643acdca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_3c3179f0-6d1f-4cdb-8389-55d1c8dfebad" xlink:href="evh-20220331.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:to="loc_evh_CreditAgreementMember_3c3179f0-6d1f-4cdb-8389-55d1c8dfebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_a32a8661-d59e-40b6-a650-9dbfc93071b5" xlink:href="evh-20220331.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a090c7a-4551-45cf-964d-e85e7960336e" xlink:to="loc_evh_SeniorCreditFacilitiesMember_a32a8661-d59e-40b6-a650-9dbfc93071b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c2d1bb3e-f7cd-48f2-92e3-e071c9f2eabf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6c9a5bb1-90c8-4452-9945-11b5c0091fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:to="loc_us-gaap_SecuredDebtMember_6c9a5bb1-90c8-4452-9945-11b5c0091fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a551f802-a857-486a-8b2d-476c2a44a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89f8b9d1-f7e9-477d-a923-21b1a4ce7704" xlink:to="loc_us-gaap_LineOfCreditMember_a551f802-a857-486a-8b2d-476c2a44a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0fb8317e-de90-45bc-9a2f-2a64becfdf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_df7a1839-8004-4625-bc80-f27fc29eb3cb" xlink:to="loc_us-gaap_CreditFacilityDomain_0fb8317e-de90-45bc-9a2f-2a64becfdf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_13fad76a-2887-43a8-81ef-75a6abd3a428" xlink:href="evh-20220331.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0fb8317e-de90-45bc-9a2f-2a64becfdf06" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_13fad76a-2887-43a8-81ef-75a6abd3a428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_829d49d7-19ac-4b09-ae36-c89fb28d2230" xlink:to="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8c00926d-a20c-4b37-aa52-68b189bd23bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8c00926d-a20c-4b37-aa52-68b189bd23bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a40e3897-d709-4c95-9c1f-c400fd130690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a40e3897-d709-4c95-9c1f-c400fd130690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_946f5d70-c88e-4c13-814b-62bffaaf73d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_946f5d70-c88e-4c13-814b-62bffaaf73d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_e81b7701-d1e2-45cd-a491-dbb04c117f16" xlink:href="evh-20220331.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_evh_PaymentsOfMakeWholePremium_e81b7701-d1e2-45cd-a491-dbb04c117f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3ff5337e-bd74-48dc-b424-dec9c51c1cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_InterestPaidNet_3ff5337e-bd74-48dc-b424-dec9c51c1cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ffef1f48-f87d-411a-b1eb-972435bbc833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ffef1f48-f87d-411a-b1eb-972435bbc833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_af5adafd-accf-4245-9df3-4c1cf8a09903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_af5adafd-accf-4245-9df3-4c1cf8a09903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_a8cbcd86-6984-4aba-ada2-1ce1e833769c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57d1c106-313a-488c-886b-667a540a8bcc" xlink:to="loc_us-gaap_LegalFees_a8cbcd86-6984-4aba-ada2-1ce1e833769c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7557714b-4102-4bd5-af0b-4613cdc19f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7557714b-4102-4bd5-af0b-4613cdc19f91" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ee8ad23d-c842-4af7-b200-25708b903a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5ee0730d-3e51-4ede-8f67-413faf881810" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ee8ad23d-c842-4af7-b200-25708b903a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_dd02f25d-4863-46b9-ad7b-2e51a38677c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ee8ad23d-c842-4af7-b200-25708b903a47" xlink:to="loc_us-gaap_CommonClassAMember_dd02f25d-4863-46b9-ad7b-2e51a38677c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d5db6e85-9448-491c-87ae-9eab9079e361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_195ce4f0-2bf7-47b1-852d-008e77cc2fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_195ce4f0-2bf7-47b1-852d-008e77cc2fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a52f2dbc-f095-4e30-af4d-914c06d38df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a52f2dbc-f095-4e30-af4d-914c06d38df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_0f44f81e-ed38-4a5f-bbec-7a9311162b73" xlink:href="evh-20220331.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_0f44f81e-ed38-4a5f-bbec-7a9311162b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_38b768c6-8503-45b2-ae8f-724e3f9d967b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e15c18fd-c4f5-4248-a576-d32780374cf3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_38b768c6-8503-45b2-ae8f-724e3f9d967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b6cf1481-df06-41ea-965b-39fd54e62d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b6cf1481-df06-41ea-965b-39fd54e62d53" xlink:to="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fd6823f7-1f85-477a-9539-676c3ac5e88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5f18888b-4a60-46ed-aea7-7f7cd8ee33bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fd6823f7-1f85-477a-9539-676c3ac5e88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ae8f19c3-e22f-46e2-8866-920b44bf68fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fd6823f7-1f85-477a-9539-676c3ac5e88f" xlink:to="loc_us-gaap_SeniorNotesMember_ae8f19c3-e22f-46e2-8866-920b44bf68fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f935116d-6495-49ae-8fce-d4032bf8d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_530a7372-6da0-4680-9540-7e3282145d32" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f935116d-6495-49ae-8fce-d4032bf8d4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_7d99f0ed-f6c4-42f3-b126-5814c25f5fb5" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f935116d-6495-49ae-8fce-d4032bf8d4d9" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_7d99f0ed-f6c4-42f3-b126-5814c25f5fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb7aff1a-2ecb-4af8-889b-066d9629ffee" xlink:to="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3274312f-3e62-4a01-9ca6-de2b830e6aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:to="loc_us-gaap_CommonStockMember_3274312f-3e62-4a01-9ca6-de2b830e6aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b02ebaf2-f4f6-4fbc-b2cc-24a03aed1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b02ebaf2-f4f6-4fbc-b2cc-24a03aed1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c6d79e85-ee80-43ac-b98b-c24255f82a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7059e798-6a1f-4541-a601-68acb5ee6a8e" xlink:to="loc_us-gaap_RetainedEarningsMember_c6d79e85-ee80-43ac-b98b-c24255f82a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c277e13c-a19a-479c-8082-d1fd8182c8d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_61f7e8f7-753c-4303-ada5-4604c85d04aa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c277e13c-a19a-479c-8082-d1fd8182c8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0ee14616-2af3-476d-95c0-bc54a474f449" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c277e13c-a19a-479c-8082-d1fd8182c8d9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0ee14616-2af3-476d-95c0-bc54a474f449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7c1426e5-6531-4e79-95d1-f73f84012a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cef24e37-e734-4114-adf3-f2ff9e469eda" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7c1426e5-6531-4e79-95d1-f73f84012a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_e5223a7c-17d8-4beb-86fd-f49ed7061208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7c1426e5-6531-4e79-95d1-f73f84012a96" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_e5223a7c-17d8-4beb-86fd-f49ed7061208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c88bd7b4-5261-4e93-8843-5ba51e77b1c3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_019849d6-05e4-4318-a115-dfaafb550902" xlink:href="evh-20220331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_019849d6-05e4-4318-a115-dfaafb550902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_61c0e84e-1d25-4b41-bbbc-a84609fd0590" xlink:href="evh-20220331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f070a094-e7c0-4f93-862d-80aa1ea3145e" xlink:to="loc_evh_DeferredFinancingFeesMember_61c0e84e-1d25-4b41-bbbc-a84609fd0590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2e15c386-cc39-4876-ab7e-fedec83e789e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63672847-aa2e-4f64-bca2-9bfec5fe721c" xlink:to="loc_us-gaap_ClassOfStockDomain_2e15c386-cc39-4876-ab7e-fedec83e789e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3b125ff0-6610-4ec7-9227-926a7fbd59fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2e15c386-cc39-4876-ab7e-fedec83e789e" xlink:to="loc_us-gaap_CommonClassAMember_3b125ff0-6610-4ec7-9227-926a7fbd59fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_849d77ba-8271-4109-abe0-1aa297635bb3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f6de96d9-b118-4fd8-ba77-a0da7fe8b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f6de96d9-b118-4fd8-ba77-a0da7fe8b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33f67335-be64-4f18-a494-ede700fac2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33f67335-be64-4f18-a494-ede700fac2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c56dd774-2537-4268-860b-ed0ae29ca772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_InterestExpenseDebt_c56dd774-2537-4268-860b-ed0ae29ca772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c4c67ec3-2f27-4a1c-ab6f-7f29ebc8865a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c4c67ec3-2f27-4a1c-ab6f-7f29ebc8865a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_94a6b220-9f0d-4335-86ca-502b32ad908c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_94a6b220-9f0d-4335-86ca-502b32ad908c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_77b65971-0783-4e37-86b7-4b6e62a18caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_77b65971-0783-4e37-86b7-4b6e62a18caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ac39c4ba-4198-4268-9d6c-89e61c411730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_LongTermDebt_ac39c4ba-4198-4268-9d6c-89e61c411730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e4e723d2-4bf0-4b3a-a6bb-bc440aac8ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e4e723d2-4bf0-4b3a-a6bb-bc440aac8ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cca4e918-8c32-48ff-aad5-af741586b53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cca4e918-8c32-48ff-aad5-af741586b53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35a5d6fc-33a4-4f0a-a3e6-0bb28d843ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_StockholdersEquity_35a5d6fc-33a4-4f0a-a3e6-0bb28d843ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c1fbb81f-6614-4ff5-affb-b3a39af15686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c1fbb81f-6614-4ff5-affb-b3a39af15686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_fe128b22-64d5-4416-a506-a66ee0408d89" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_fe128b22-64d5-4416-a506-a66ee0408d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_f38ced6d-a3df-4989-8938-a7338c945403" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_f38ced6d-a3df-4989-8938-a7338c945403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_f3e44b1c-0357-46cb-b7d6-38db314bc7bb" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_f3e44b1c-0357-46cb-b7d6-38db314bc7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_00c69092-93fd-4eba-908d-83b4db2c527a" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_00c69092-93fd-4eba-908d-83b4db2c527a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_31e39d98-532a-426c-90e8-8d94c38a131d" xlink:href="evh-20220331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c6db7592-aca7-4c9c-aa71-7ab501d94433" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_31e39d98-532a-426c-90e8-8d94c38a131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_53a1655d-57ad-4801-ad74-77b7b1f5aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_53a1655d-57ad-4801-ad74-77b7b1f5aedc" xlink:to="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2b9a5b6f-1634-4a96-a8cb-c5e0d1833375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a0a0635-6523-46e0-8aa8-c4c02eb3b85d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2b9a5b6f-1634-4a96-a8cb-c5e0d1833375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7f3db232-9715-47fc-9b02-1bcfd499db96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2b9a5b6f-1634-4a96-a8cb-c5e0d1833375" xlink:to="loc_us-gaap_SeniorNotesMember_7f3db232-9715-47fc-9b02-1bcfd499db96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:to="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1dd1e47f-8014-4f1f-9664-7a9968ced267" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_c7f5a2de-e81a-444d-8e83-bcdd263e1c8c" xlink:href="evh-20220331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_c7f5a2de-e81a-444d-8e83-bcdd263e1c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_c8c15b6e-efcd-4c2c-af1a-e1035b520a57" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0d45f8b-2b78-406b-bb77-e4964041ecef" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_c8c15b6e-efcd-4c2c-af1a-e1035b520a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1bd89d5-e30a-4548-b15b-69da2f23770b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_67028aa6-e09a-4bbd-9b8c-2d643e9a160b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_67028aa6-e09a-4bbd-9b8c-2d643e9a160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49ef6604-e59b-480a-8d3b-143662ff575b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49ef6604-e59b-480a-8d3b-143662ff575b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1006c5c6-1d63-44d2-83d6-f55940b32787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_1006c5c6-1d63-44d2-83d6-f55940b32787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_59ab4781-15e1-44d9-a7db-9c3b1c96c041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_59ab4781-15e1-44d9-a7db-9c3b1c96c041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0f1ec708-1c3f-4206-b4db-fd2307987087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0f1ec708-1c3f-4206-b4db-fd2307987087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_374beb56-3804-45ec-a1a2-29de8de09acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_374beb56-3804-45ec-a1a2-29de8de09acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ece2361d-b3e6-43e6-87e2-4a593928b68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ece2361d-b3e6-43e6-87e2-4a593928b68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_b76a6fe4-b789-4312-942a-23e8afa6933b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_b76a6fe4-b789-4312-942a-23e8afa6933b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_938aeb55-34d2-44c9-a458-57730848a39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_938aeb55-34d2-44c9-a458-57730848a39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_b1447475-3536-4556-a770-02bf88e24276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_b1447475-3536-4556-a770-02bf88e24276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue_9e0e9cf5-326e-4a82-96b6-63ec51ce9ff2" xlink:href="evh-20220331.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b261a2b5-a1e0-46af-b554-0c2602b136c3" xlink:to="loc_evh_DebtConversionOriginalDebtFairValue_9e0e9cf5-326e-4a82-96b6-63ec51ce9ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_073671a0-2b0e-4a0a-a167-88a64f474e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_073671a0-2b0e-4a0a-a167-88a64f474e5f" xlink:to="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1052979e-93a0-4988-9419-85716b3f74e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6f57fb53-d393-425e-a67b-1a4f0d5c114f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1052979e-93a0-4988-9419-85716b3f74e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c679041b-e402-4f68-b953-c9484ce9b504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1052979e-93a0-4988-9419-85716b3f74e7" xlink:to="loc_us-gaap_SeniorNotesMember_c679041b-e402-4f68-b953-c9484ce9b504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0262665-0ff8-4835-b53d-caf0824b1c0e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_6fb8e7e3-56c3-4ea8-a5e5-b21847f52a53" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_6fb8e7e3-56c3-4ea8-a5e5-b21847f52a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_4fac5ac6-0070-45c5-8777-f6e3cb5ee4b9" xlink:href="evh-20220331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_391692b8-15d7-4a10-a997-6c52a3a55a50" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_4fac5ac6-0070-45c5-8777-f6e3cb5ee4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe0f025-e3af-4308-8bb9-ba3dd2b54bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3d54927-a3d7-49bc-a721-04ae03d2d57f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe0f025-e3af-4308-8bb9-ba3dd2b54bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_644d47cc-6c69-49c6-bf7d-612f15ffb283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe0f025-e3af-4308-8bb9-ba3dd2b54bff" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_644d47cc-6c69-49c6-bf7d-612f15ffb283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f0772f4-3192-4c8a-9f9c-941b09041f26" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5ab58a7e-e27d-431c-a61b-723aaa30123c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_ConvertibleDebt_5ab58a7e-e27d-431c-a61b-723aaa30123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3f72fe88-2cba-414b-9661-be7f7a6ea116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3f72fe88-2cba-414b-9661-be7f7a6ea116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_730694cd-dcb1-4f1d-843d-62b5c21236eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_730694cd-dcb1-4f1d-843d-62b5c21236eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_252893bc-81d8-48cb-b7f5-d25291854718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_252893bc-81d8-48cb-b7f5-d25291854718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_55b7211c-8985-4d18-b238-918b90c60d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd237d63-160f-4471-aa8f-7a6e3a1d466d" xlink:to="loc_us-gaap_LongTermDebtFairValue_55b7211c-8985-4d18-b238-918b90c60d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf751a06-16d3-4b8e-ac9f-0c252a134be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_be9d7627-1262-4e19-8f11-9cf4f0a51613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf751a06-16d3-4b8e-ac9f-0c252a134be5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_be9d7627-1262-4e19-8f11-9cf4f0a51613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01d96c85-d747-4541-8abe-6cb539c9f0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_d8883a8f-96e3-4838-ab07-f5b49a294d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01d96c85-d747-4541-8abe-6cb539c9f0a4" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_d8883a8f-96e3-4838-ab07-f5b49a294d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ceb181c7-e00d-48d4-902b-034072e481d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01d96c85-d747-4541-8abe-6cb539c9f0a4" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ceb181c7-e00d-48d4-902b-034072e481d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f4e22195-8bbf-469e-b0d0-e444e45a3efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f4e22195-8bbf-469e-b0d0-e444e45a3efd" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_69aa1205-657e-4906-a507-687758709301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_701df148-d7d7-4b5c-9d31-a47ce358e0ca" xlink:to="loc_us-gaap_CreditFacilityDomain_69aa1205-657e-4906-a507-687758709301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_28924d11-aa5b-4001-b3ac-f0fb05b5d4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_69aa1205-657e-4906-a507-687758709301" xlink:to="loc_us-gaap_LetterOfCreditMember_28924d11-aa5b-4001-b3ac-f0fb05b5d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42e2f037-3ad0-4bab-9a16-e199a28f5389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c50074c4-1037-4374-8b6b-bd8e12828ff4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42e2f037-3ad0-4bab-9a16-e199a28f5389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ff705800-4d63-48e7-a3d3-bd79d8e40ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42e2f037-3ad0-4bab-9a16-e199a28f5389" xlink:to="loc_us-gaap_LineOfCreditMember_ff705800-4d63-48e7-a3d3-bd79d8e40ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_37014275-6efd-4d58-96ce-c18c8363c806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1f3ac050-2217-4c2f-b605-166202a1f0f5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_37014275-6efd-4d58-96ce-c18c8363c806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_c96609e4-2079-40ba-ae0b-5ab2d563e4be" xlink:href="evh-20220331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_37014275-6efd-4d58-96ce-c18c8363c806" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_c96609e4-2079-40ba-ae0b-5ab2d563e4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_63ba3668-540f-4994-8e25-64abb3232d93" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_393aea05-4707-4ce2-8ad3-aa9415a2a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_393aea05-4707-4ce2-8ad3-aa9415a2a0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_a58ad4b9-ea73-4706-8bd0-ad955fc37d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_a58ad4b9-ea73-4706-8bd0-ad955fc37d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_aa1b294a-4dcf-476a-bff1-96f8de39a59c" xlink:href="evh-20220331.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dbd66770-e3cd-4311-a1b4-ddef7b2ffac9" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_aa1b294a-4dcf-476a-bff1-96f8de39a59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingenciesReinsuranceAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten_e020c8b3-6c0e-4026-a3af-2cb50aa40584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_us-gaap_AssumedPremiumsWritten_e020c8b3-6c0e-4026-a3af-2cb50aa40584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_4b00805a-8b8b-40b1-baf7-7cc120ee8a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_4b00805a-8b8b-40b1-baf7-7cc120ee8a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_a1f4080f-74f0-470c-95f2-162bdbb1e67f" xlink:href="evh-20220331.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_a1f4080f-74f0-470c-95f2-162bdbb1e67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_3378fdd5-9380-4d83-9d3c-01dd1a026833" xlink:href="evh-20220331.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_3378fdd5-9380-4d83-9d3c-01dd1a026833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_5dd0dd1d-9234-4ccc-a80a-168af830d89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_5dd0dd1d-9234-4ccc-a80a-168af830d89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_75bcc779-93d1-48f9-8676-83f26fe7acc7" xlink:href="evh-20220331.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_75bcc779-93d1-48f9-8676-83f26fe7acc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromReinsurance_743016da-216a-4554-a6c6-58de8cf83345" xlink:href="evh-20220331.xsd#evh_ProceedsFromReinsurance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_evh_ProceedsFromReinsurance_743016da-216a-4554-a6c6-58de8cf83345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6c340c10-ad5b-4925-90ff-75599fb53b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416111be-cd9f-43c6-820c-70fd8a0d4919" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6c340c10-ad5b-4925-90ff-75599fb53b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c1e50e0-22f4-4879-82ad-247d87731349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c1e50e0-22f4-4879-82ad-247d87731349" xlink:to="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cb5390f1-a8d3-4ad9-9022-822ea11337a0" xlink:to="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_7b06ddbc-356f-458d-bd71-defcd34c1d5a" xlink:href="evh-20220331.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:to="loc_evh_FloridaBlueMedicareIncMember_7b06ddbc-356f-458d-bd71-defcd34c1d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_db134240-2d7a-4abe-b57b-fca5b627af9e" xlink:href="evh-20220331.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_db134240-2d7a-4abe-b57b-fca5b627af9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_0dcc2a5e-d7d5-429a-8864-ae3b90c5f390" xlink:href="evh-20220331.xsd#evh_MolinaHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2a66944b-0fd2-43c2-bdfe-cc6b6bbb1173" xlink:to="loc_evh_MolinaHealthcareMember_0dcc2a5e-d7d5-429a-8864-ae3b90c5f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1149b022-113d-49e0-a41b-7c71e55320b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_89f1959a-1cf4-47e6-b48e-d9fe6563bbe9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1149b022-113d-49e0-a41b-7c71e55320b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_12f886f2-1b95-4fc5-94c1-241aeee21c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1149b022-113d-49e0-a41b-7c71e55320b4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_12f886f2-1b95-4fc5-94c1-241aeee21c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f334ab07-20b5-4667-bae9-f882cc0acb39" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8115c6d7-340f-4c77-b142-4a3602e3c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:to="loc_us-gaap_AccountsReceivableMember_8115c6d7-340f-4c77-b142-4a3602e3c40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f8dab1ca-0294-4fe6-98a4-4d8dc35f4c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d451aa9-dc08-4dc1-81d7-59632a1e7302" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f8dab1ca-0294-4fe6-98a4-4d8dc35f4c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4f81bf7b-8a32-4765-bca7-ed33f4d7a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d7a1ce75-fc91-4ece-aeac-6997b23a5b95" xlink:to="loc_us-gaap_ReceivableTypeDomain_4f81bf7b-8a32-4765-bca7-ed33f4d7a8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_c04397e1-2713-46fe-add2-d97b321bf268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_4f81bf7b-8a32-4765-bca7-ed33f4d7a8c4" xlink:to="loc_us-gaap_FinanceReceivablesMember_c04397e1-2713-46fe-add2-d97b321bf268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f52c591-92c0-4bd7-8d7a-fc1742de9126" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6afd9f91-5685-457b-9106-3a5e7c3d0275" xlink:to="loc_srt_ProductsAndServicesDomain_2f52c591-92c0-4bd7-8d7a-fc1742de9126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_2688321e-b90d-4926-8bfb-ee1e3eb64d78" xlink:href="evh-20220331.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2f52c591-92c0-4bd7-8d7a-fc1742de9126" xlink:to="loc_evh_PremiumsRevenueMember_2688321e-b90d-4926-8bfb-ee1e3eb64d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f41aea35-f269-47d4-8667-8b8f23acc987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22f9382f-ab11-4836-9576-b4bfd3fa0d42" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f41aea35-f269-47d4-8667-8b8f23acc987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e684223f-b40c-426b-a19a-09f234658e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f41aea35-f269-47d4-8667-8b8f23acc987" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e684223f-b40c-426b-a19a-09f234658e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8921be19-030c-4ec0-8676-5f6b84920fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9cce4caa-2d87-4b63-8195-2e5f9819bee5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8921be19-030c-4ec0-8676-5f6b84920fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_a8dfb866-c42c-4c9c-a608-960f584f73bb" xlink:href="evh-20220331.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8921be19-030c-4ec0-8676-5f6b84920fa1" xlink:to="loc_evh_TrueHealthMember_a8dfb866-c42c-4c9c-a608-960f584f73bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_810187d2-d836-4a20-9257-3f7d2436395c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_de63431d-2f31-45e8-b209-b0b74b63769b" xlink:href="evh-20220331.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_de63431d-2f31-45e8-b209-b0b74b63769b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_addf44c7-f257-44c8-bf0a-de1db22688e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_addf44c7-f257-44c8-bf0a-de1db22688e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_69fecfa6-3fb9-47f6-9109-ae4c1a41b51a" xlink:href="evh-20220331.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_69fecfa6-3fb9-47f6-9109-ae4c1a41b51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fd15539c-50d9-4a04-9aa9-62a74fed2edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fd15539c-50d9-4a04-9aa9-62a74fed2edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_b6ac5a62-483b-4028-a850-852fab97d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e4c4f576-2932-4116-b088-5bd8cb9466af" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_b6ac5a62-483b-4028-a850-852fab97d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bba42132-9e16-4ce6-ab63-f16fdab098a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a7c21a9d-c1a4-44ce-87c6-7eea46572360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bba42132-9e16-4ce6-ab63-f16fdab098a6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a7c21a9d-c1a4-44ce-87c6-7eea46572360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_445b329f-a43a-48a8-a5fa-0a5d9860a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f102f904-9a10-4a64-8fee-29b35cec551d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_445b329f-a43a-48a8-a5fa-0a5d9860a4ee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f102f904-9a10-4a64-8fee-29b35cec551d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_30e2e467-0501-4bea-81f4-54e16c6c4547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_445b329f-a43a-48a8-a5fa-0a5d9860a4ee" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_30e2e467-0501-4bea-81f4-54e16c6c4547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_00ec2d90-af7a-47dc-9a24-c20e73af5474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00ec2d90-af7a-47dc-9a24-c20e73af5474" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_cd14d45e-bc26-425f-89ed-f2d467a75d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1ea5be73-42d5-4e91-99e1-4d92bec921be" xlink:to="loc_us-gaap_OtherCommitmentsDomain_cd14d45e-bc26-425f-89ed-f2d467a75d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_e0a10f55-b088-4ab0-a545-be872711a1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_cd14d45e-bc26-425f-89ed-f2d467a75d0e" xlink:to="loc_us-gaap_LeaseAgreementsMember_e0a10f55-b088-4ab0-a545-be872711a1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8c791e7b-c888-4f89-a54f-518278f836fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8163dea2-ace2-4155-b4a3-a10d21953974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8163dea2-ace2-4155-b4a3-a10d21953974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_7f6a65d5-a1c4-4b02-9ed1-505b6f54d66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e3aa4a00-b8c9-4210-afc5-703e62291e4b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_7f6a65d5-a1c4-4b02-9ed1-505b6f54d66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4ed9542e-e4d6-4fe1-a4a2-a6b0a0c22fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ed9542e-e4d6-4fe1-a4a2-a6b0a0c22fd2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:to="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_567ef474-633b-42bc-95ff-a87ae56bdc43" xlink:to="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_a99c9d1e-5ba7-47da-b030-90d8587b8e0c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_VA_a99c9d1e-5ba7-47da-b030-90d8587b8e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_9456d196-573e-4be5-89fe-49cf35bc580f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_IL_9456d196-573e-4be5-89fe-49cf35bc580f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_35fdf246-5fa4-4000-bcb7-24a8563b2ed7" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_NJ_35fdf246-5fa4-4000-bcb7-24a8563b2ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_2fec63ca-5c20-4151-9c7b-32d1554c0a3f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_country_IN_2fec63ca-5c20-4151-9c7b-32d1554c0a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_089fb037-a7c4-43d7-8d8e-0db9b61a2563" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9027f611-2166-4672-92a9-fd5a9a8a737b" xlink:to="loc_stpr_CA_089fb037-a7c4-43d7-8d8e-0db9b61a2563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9cec6a98-5f30-4c1c-8abd-2da3514824c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9d78c85b-c52b-4ea1-a840-26dcac1525d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9d78c85b-c52b-4ea1-a840-26dcac1525d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea04eb78-f95f-44fa-b33c-a5f4e791e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea04eb78-f95f-44fa-b33c-a5f4e791e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_a02da9d7-fea0-4e7b-b194-e1bf19b1b8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9050a3da-67fc-49c2-9e4c-7a286b31455a" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_a02da9d7-fea0-4e7b-b194-e1bf19b1b8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e32879dc-fe8a-43e5-b04d-dfbe3ab09035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5d798b42-d5a6-4f89-b219-6bf1562419ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e32879dc-fe8a-43e5-b04d-dfbe3ab09035" xlink:to="loc_us-gaap_OperatingLeaseCost_5d798b42-d5a6-4f89-b219-6bf1562419ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cde19a79-ac50-49c3-a684-b4bacf4e29d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e32879dc-fe8a-43e5-b04d-dfbe3ab09035" xlink:to="loc_us-gaap_VariableLeaseCost_cde19a79-ac50-49c3-a684-b4bacf4e29d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_08b645ae-0173-4912-b602-38d44848a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e32879dc-fe8a-43e5-b04d-dfbe3ab09035" xlink:to="loc_us-gaap_LeaseCost_08b645ae-0173-4912-b602-38d44848a4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7a64a2c7-25d3-4101-9958-b902676ea160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7a64a2c7-25d3-4101-9958-b902676ea160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2390303f-1ad7-4e17-b8ba-2ef86d80e7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2390303f-1ad7-4e17-b8ba-2ef86d80e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6a084a6d-74ce-4beb-8790-15048e8410c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6a084a6d-74ce-4beb-8790-15048e8410c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8387ccac-be2a-479d-a6be-09a6ecc4c3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8387ccac-be2a-479d-a6be-09a6ecc4c3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4dbe3f1-b689-4fae-8c0f-c5d34de6c4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4dbe3f1-b689-4fae-8c0f-c5d34de6c4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9ffb232c-127f-4801-a493-9670ca5e5f51" xlink:href="evh-20220331.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9ffb232c-127f-4801-a493-9670ca5e5f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a559cd95-aaab-4e48-8384-d326f1bc702c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a559cd95-aaab-4e48-8384-d326f1bc702c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_1d163380-d258-4a3f-b850-16a10dde946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_1d163380-d258-4a3f-b850-16a10dde946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c6e45dcc-31b2-4556-a0af-8438b955d714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_1d163380-d258-4a3f-b850-16a10dde946a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c6e45dcc-31b2-4556-a0af-8438b955d714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9f56b917-11bd-4c38-9d09-0683e193e4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_18103dba-dd80-48ac-84e2-66e3a3fae654" xlink:to="loc_us-gaap_OperatingLeaseLiability_9f56b917-11bd-4c38-9d09-0683e193e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9026575f-1348-4126-851b-6fdd0a0f016b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_247444a8-fc42-47ec-a09b-b03940ec11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9026575f-1348-4126-851b-6fdd0a0f016b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_247444a8-fc42-47ec-a09b-b03940ec11d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1ec4e688-4494-41c7-a9fb-bee4cdb34680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9026575f-1348-4126-851b-6fdd0a0f016b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1ec4e688-4494-41c7-a9fb-bee4cdb34680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="evh-20220331.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cb50e9c2-bc36-4d92-891e-33ab4a794330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8c42c661-aeda-475b-88db-2c501911f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb50e9c2-bc36-4d92-891e-33ab4a794330" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8c42c661-aeda-475b-88db-2c501911f5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="evh-20220331.xsd#LossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_afb5ae22-0603-4097-aefa-61066b108b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a256caed-b017-41eb-b307-613c62c2a807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_afb5ae22-0603-4097-aefa-61066b108b1c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a256caed-b017-41eb-b307-613c62c2a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c9e468e5-1362-41bb-878e-9d584cf1775d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_afb5ae22-0603-4097-aefa-61066b108b1c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c9e468e5-1362-41bb-878e-9d584cf1775d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LossPerCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_7af2a61b-fb2a-4f09-9507-67dcac14a803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_7af2a61b-fb2a-4f09-9507-67dcac14a803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_54687496-9f41-449e-8307-781d186225ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_54687496-9f41-449e-8307-781d186225ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e3161fdb-7b3c-4782-a8df-654a46a6936b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e3161fdb-7b3c-4782-a8df-654a46a6936b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b19dbaa7-e574-4e6f-8ddd-4d9a120ebefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b19dbaa7-e574-4e6f-8ddd-4d9a120ebefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f8bd5419-f2ce-4b0b-9dca-228fcdba069b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f8bd5419-f2ce-4b0b-9dca-228fcdba069b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a566380-5cd0-4d2e-8dd7-a8dfb2e89cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a566380-5cd0-4d2e-8dd7-a8dfb2e89cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7838f8-8832-4138-b069-a8981629bdaa" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b21cd72a-a251-42e2-9275-044cfdf61723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b21cd72a-a251-42e2-9275-044cfdf61723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f0d4319d-5d82-432d-8fe2-4fe065d9646a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f0d4319d-5d82-432d-8fe2-4fe065d9646a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16664760-7db1-4605-96c9-47d0a720a7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16664760-7db1-4605-96c9-47d0a720a7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_45395e5e-068f-4a86-a253-7e5bbb899b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_45395e5e-068f-4a86-a253-7e5bbb899b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5297a782-e494-4bd3-a272-3b0c6c629b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5297a782-e494-4bd3-a272-3b0c6c629b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3e31de70-ffc1-410d-956e-87958bf1e1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ef100b88-a51f-49f5-9202-a0bcb7b5d2eb" xlink:to="loc_us-gaap_EarningsPerShareBasic_3e31de70-ffc1-410d-956e-87958bf1e1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4f5ca2ab-f87c-43f7-b410-af30a51d6375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f5ca2ab-f87c-43f7-b410-af30a51d6375" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d185ce9-fac1-4ee0-b37a-7086489819d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_21907713-d644-4324-a49c-296e6d38de61" xlink:href="evh-20220331.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_21907713-d644-4324-a49c-296e6d38de61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d30e7788-63da-4438-9611-00dbba2f4851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d30e7788-63da-4438-9611-00dbba2f4851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_75d93575-b1aa-4c2b-971e-bc681a3c5f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fa60f1c-0f95-4f16-9c54-60e23e54d729" xlink:to="loc_us-gaap_ConvertibleDebtMember_75d93575-b1aa-4c2b-971e-bc681a3c5f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419dc683-ff9f-4ed6-9537-e8a4b6ca00ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_882d3f66-dc41-4621-9832-b4d75a31dba1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419dc683-ff9f-4ed6-9537-e8a4b6ca00ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c01a3e14-4130-4a3a-827f-f22621841d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419dc683-ff9f-4ed6-9537-e8a4b6ca00ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c01a3e14-4130-4a3a-827f-f22621841d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b2fce-3974-446c-ac07-ff863b191eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fc81fda8-3bf6-4f90-8a56-aa0b26e622b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b2fce-3974-446c-ac07-ff863b191eee" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fc81fda8-3bf6-4f90-8a56-aa0b26e622b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71597266-2889-4d40-bbdd-2b7972efd572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_941c1b62-f45e-402a-a643-c91d54f9ccf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71597266-2889-4d40-bbdd-2b7972efd572" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_941c1b62-f45e-402a-a643-c91d54f9ccf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_ba6148d9-c5d4-4955-a725-eaff2219dd03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71597266-2889-4d40-bbdd-2b7972efd572" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_ba6148d9-c5d4-4955-a725-eaff2219dd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50b5e996-2583-4e67-8129-4e1d50cd4ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50b5e996-2583-4e67-8129-4e1d50cd4ca4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:to="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ad59ad21-e78d-4f26-ace7-82b74e2cf1e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3580e856-bc08-4581-b7ab-d9576b917586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3580e856-bc08-4581-b7ab-d9576b917586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a565ee1c-146b-434a-887b-6162d86ecd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a565ee1c-146b-434a-887b-6162d86ecd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_3f5a9936-c226-435e-9528-1556b0223cac" xlink:href="evh-20220331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_3f5a9936-c226-435e-9528-1556b0223cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60cfc09f-4ffc-4a86-b376-229adbf48fcf" xlink:href="evh-20220331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b68318b-8d6f-415b-ad2f-ed35d38c9d3d" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60cfc09f-4ffc-4a86-b376-229adbf48fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b2202064-3e52-42bf-a7dc-d88021caf23a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_888ab673-9a0a-47e4-8ba6-9c15f44fbf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:to="loc_us-gaap_CostOfSalesMember_888ab673-9a0a-47e4-8ba6-9c15f44fbf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997110a0-f6a9-4c4a-a28d-f418da5ccec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ced60cc7-f6f6-44fd-b816-6486de1edd71" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997110a0-f6a9-4c4a-a28d-f418da5ccec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf0195ce-c799-4cda-a716-44c959cbc0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4101a25c-c4a5-44cd-946a-806afc74ef09" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf0195ce-c799-4cda-a716-44c959cbc0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1139b837-d254-4115-801f-1757251d139e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf0195ce-c799-4cda-a716-44c959cbc0bd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1139b837-d254-4115-801f-1757251d139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f0413a7-13aa-4507-b674-b14b9fa75868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_28886e16-5c69-413a-9fee-eba7ff2bccdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f0413a7-13aa-4507-b674-b14b9fa75868" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_28886e16-5c69-413a-9fee-eba7ff2bccdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3831045b-8f77-4671-a443-42f68471ce8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3831045b-8f77-4671-a443-42f68471ce8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:to="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5508a964-1c9f-41bd-b8d6-dd92c492032b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6406c22f-d994-4c9e-85f4-c9dacb5df30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6406c22f-d994-4c9e-85f4-c9dacb5df30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9d6a0b9b-2d6c-4e4e-b3c5-edc1f30f6303" xlink:href="evh-20220331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_caf3fb41-ce33-4c40-91b8-2a7db1df0d8a" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9d6a0b9b-2d6c-4e4e-b3c5-edc1f30f6303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc72ba1-581d-4c20-98cc-df756ab65d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3338b1d5-deb9-457d-b372-7de60e7d3394" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc72ba1-581d-4c20-98cc-df756ab65d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6bec24cd-7bda-4f0c-8de9-abe2b2641426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc72ba1-581d-4c20-98cc-df756ab65d93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6bec24cd-7bda-4f0c-8de9-abe2b2641426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed4b69fa-335d-4df4-8535-413b5088ed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_274e97a6-b84d-44cf-a14b-34f7eb66ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed4b69fa-335d-4df4-8535-413b5088ed2b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_274e97a6-b84d-44cf-a14b-34f7eb66ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_66692442-5929-4729-b71b-efd52fd0d19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_38894859-8768-4927-af0a-4ecf18d8f978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66692442-5929-4729-b71b-efd52fd0d19d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_38894859-8768-4927-af0a-4ecf18d8f978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7b3d526-4306-4635-a4e3-e7e047bb7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66692442-5929-4729-b71b-efd52fd0d19d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7b3d526-4306-4635-a4e3-e7e047bb7ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1b73a82b-6fe8-4619-ad73-1ccb71977fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66692442-5929-4729-b71b-efd52fd0d19d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1b73a82b-6fe8-4619-ad73-1ccb71977fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_19f6f9af-f35e-4334-a215-7f8e75c80d7b" xlink:href="evh-20220331.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66692442-5929-4729-b71b-efd52fd0d19d" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_19f6f9af-f35e-4334-a215-7f8e75c80d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20220331.xsd#InvestmentsinEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cb568609-60ab-4714-890f-12e91c10f6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_4282783c-a72f-42e4-8cf9-7d6931d9f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cb568609-60ab-4714-890f-12e91c10f6fb" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_4282783c-a72f-42e4-8cf9-7d6931d9f05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a4174635-34fb-4d23-876f-7d6d83cb51ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a4174635-34fb-4d23-876f-7d6d83cb51ad" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c8ca4b62-aae9-4e5f-a058-6893eb7e8685" xlink:to="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f692604c-f03c-412f-b971-3bb34898fabc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:to="loc_srt_MinimumMember_f692604c-f03c-412f-b971-3bb34898fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d6a1ca8-c1a5-4567-b789-24c35b0e2786" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_759999e9-4389-4986-b253-185681dbddd3" xlink:to="loc_srt_MaximumMember_5d6a1ca8-c1a5-4567-b789-24c35b0e2786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_08b3032b-4247-4792-bc4f-58a9a0eea9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7614c25f-831a-48a5-9ffc-9008461db92c" xlink:to="loc_us-gaap_RelatedPartyDomain_08b3032b-4247-4792-bc4f-58a9a0eea9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_d6f99a37-4e0c-46e3-af1e-b58dfed961da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_08b3032b-4247-4792-bc4f-58a9a0eea9dc" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_d6f99a37-4e0c-46e3-af1e-b58dfed961da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0ba01a74-c5b7-4d6b-bbd3-7c4e9429475d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_316c5f82-efe9-4819-8efc-84ea83937ded" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0ba01a74-c5b7-4d6b-bbd3-7c4e9429475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_6af16c72-b554-494c-b2e5-8b55471911e8" xlink:href="evh-20220331.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0ba01a74-c5b7-4d6b-bbd3-7c4e9429475d" xlink:to="loc_evh_ServicesAgreementsMember_6af16c72-b554-494c-b2e5-8b55471911e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b27d9fb5-9d59-4f38-b4c8-1166c8514382" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_1232adad-71b6-4e36-88f0-4229108af946" xlink:href="evh-20220331.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_1232adad-71b6-4e36-88f0-4229108af946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_ccc14796-ce5f-4d02-bfc8-074cd9dbd458" xlink:href="evh-20220331.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_ccc14796-ce5f-4d02-bfc8-074cd9dbd458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_78789f54-6a44-476b-b2db-7d0e9954fbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_78789f54-6a44-476b-b2db-7d0e9954fbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_1a2ccce2-ca51-4683-956c-1af54c623f5f" xlink:href="evh-20220331.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6ec891a7-d99d-4bcf-a09f-d4401cab5b97" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_1a2ccce2-ca51-4683-956c-1af54c623f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_166c32a0-2062-4ea4-b3fe-633ea513fe5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2e8f4dc4-964f-4ce8-9737-140d4e4a879d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_166c32a0-2062-4ea4-b3fe-633ea513fe5e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2e8f4dc4-964f-4ce8-9737-140d4e4a879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0702f58-0b7f-4ec8-9a10-7ab86ca1df8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a32e4dcc-8beb-423f-a872-0c80df85c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0702f58-0b7f-4ec8-9a10-7ab86ca1df8c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a32e4dcc-8beb-423f-a872-0c80df85c85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2b960085-31ff-4972-9fea-cfe2ea93647e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0702f58-0b7f-4ec8-9a10-7ab86ca1df8c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2b960085-31ff-4972-9fea-cfe2ea93647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_895c8506-521e-4787-8b13-a34b35606733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0702f58-0b7f-4ec8-9a10-7ab86ca1df8c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_895c8506-521e-4787-8b13-a34b35606733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_932ea1a6-8328-4925-91a1-a4847e8d897f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_932ea1a6-8328-4925-91a1-a4847e8d897f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f531db99-6b8b-45af-9cea-918fabafd13e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_36f43be7-b7af-4baa-9b7b-59e713b168b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_36f43be7-b7af-4baa-9b7b-59e713b168b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0bcc6ba9-1225-4479-aacf-b64f875a9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0bcc6ba9-1225-4479-aacf-b64f875a9b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_717b2f80-d05f-4b60-8253-230a293289d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_547a550c-fddf-4514-885c-e4f59f349c86" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_717b2f80-d05f-4b60-8253-230a293289d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cbe830cf-2ad1-4bc3-bfda-948af02d8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e8d835e4-c228-4a0b-87ce-d6439baa2e19" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cbe830cf-2ad1-4bc3-bfda-948af02d8cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c7b9870d-699f-4d9a-b4dd-a40ae19acd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_cbe830cf-2ad1-4bc3-bfda-948af02d8cf2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c7b9870d-699f-4d9a-b4dd-a40ae19acd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0cba7ca4-fe9b-4ada-a7a3-3509ad265d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f22c930d-efcf-4766-8ca1-5486d5f8403e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0cba7ca4-fe9b-4ada-a7a3-3509ad265d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0cba7ca4-fe9b-4ada-a7a3-3509ad265d6c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3e6837c-5570-4b53-bee6-4c4621cecd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3e6837c-5570-4b53-bee6-4c4621cecd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_98e10e35-9be8-405f-9e03-e9d5f01f6bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8cd71e1b-c56c-4c68-bbcf-65e204a98d83" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_98e10e35-9be8-405f-9e03-e9d5f01f6bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e781f09a-3272-4a0a-9eb5-3fa75e216147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18d61da3-111f-419d-a845-053b6ca2e68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e781f09a-3272-4a0a-9eb5-3fa75e216147" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18d61da3-111f-419d-a845-053b6ca2e68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb24fa35-cb70-43de-a434-3015ad2db732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18d61da3-111f-419d-a845-053b6ca2e68b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb24fa35-cb70-43de-a434-3015ad2db732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ef4a5136-1416-4d82-bac0-e154b1f45477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18d61da3-111f-419d-a845-053b6ca2e68b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ef4a5136-1416-4d82-bac0-e154b1f45477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9a3513f2-b4df-4607-b28f-670f915e7ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18d61da3-111f-419d-a845-053b6ca2e68b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9a3513f2-b4df-4607-b28f-670f915e7ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_480ce87d-f3da-4431-9bc9-5156ffbd27e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18d61da3-111f-419d-a845-053b6ca2e68b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_480ce87d-f3da-4431-9bc9-5156ffbd27e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b9728443-5f23-4d50-b74b-6689ab200054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b9728443-5f23-4d50-b74b-6689ab200054" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_327d0e41-0632-46a4-a756-e718da22ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7cbc171b-e0d9-46a5-a014-524cafbb4e8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_327d0e41-0632-46a4-a756-e718da22ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48e1f20e-5b83-4899-9e39-afb57a73115e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_327d0e41-0632-46a4-a756-e718da22ae76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48e1f20e-5b83-4899-9e39-afb57a73115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67902d71-3900-4413-b51a-55b72d5427c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_661a8834-a0b5-494a-9107-8f34e6797693" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67902d71-3900-4413-b51a-55b72d5427c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d07fca36-ae6a-4293-84f3-dfe05f895d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67902d71-3900-4413-b51a-55b72d5427c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d07fca36-ae6a-4293-84f3-dfe05f895d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4f6bde59-4d51-44da-8073-6e82760a8d4f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_cc716211-f880-46ec-b4ac-3ec7019ee827" xlink:href="evh-20220331.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_cc716211-f880-46ec-b4ac-3ec7019ee827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7c75425e-4f85-4e98-9e6d-584e515f6c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ce62b29-29ee-448d-ab74-2386ed88b816" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7c75425e-4f85-4e98-9e6d-584e515f6c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4e6939da-bf16-4a7d-8b5e-38b62522dc12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37691441-c695-41f8-8243-0c7e9863c070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37691441-c695-41f8-8243-0c7e9863c070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_03485071-b1f0-4d34-b17e-49a284d50de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_02203f57-6d6d-4351-afe2-8cca8f0a1cbc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_03485071-b1f0-4d34-b17e-49a284d50de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20220331.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6a0bac64-d7f7-406d-af5e-29098e8c1462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6e1430a5-2402-4cfc-8914-21ce80ea7281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6a0bac64-d7f7-406d-af5e-29098e8c1462" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6e1430a5-2402-4cfc-8914-21ce80ea7281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20220331.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6d933177-07ca-47dd-bb45-57a804d84fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_99606e54-b4e1-43f7-a803-e9a69d91a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6d933177-07ca-47dd-bb45-57a804d84fce" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_99606e54-b4e1-43f7-a803-e9a69d91a62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_44315d5e-159b-4f50-ba5c-eb9571d306e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_44315d5e-159b-4f50-ba5c-eb9571d306e8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a92f70ca-cad0-4210-965e-213412f90a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4e045985-041d-4bd2-8c24-fda473bfe11a" xlink:to="loc_us-gaap_RelatedPartyDomain_a92f70ca-cad0-4210-965e-213412f90a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cf51591f-89d8-4ba3-b9f8-495d7e206837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a92f70ca-cad0-4210-965e-213412f90a76" xlink:to="loc_srt_AffiliatedEntityMember_cf51591f-89d8-4ba3-b9f8-495d7e206837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a73107d3-f6b0-48d2-a25f-c9519b33165a" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:to="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f42ac008-54a1-49e9-a27c-4e768e3714f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f42ac008-54a1-49e9-a27c-4e768e3714f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2054374-94f7-456a-b371-61352e39e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2054374-94f7-456a-b371-61352e39e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_743463fa-cd56-4860-b1d6-b968fc09a162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe4b7d7-eea6-4883-98a0-26c23fde7564" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_743463fa-cd56-4860-b1d6-b968fc09a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_42a472d8-231c-4c79-ba8e-ea55ab6f2add" xlink:to="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d0bb10d8-66d7-4cb3-a458-010b6e9d2122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:to="loc_us-gaap_AccountsPayableCurrent_d0bb10d8-66d7-4cb3-a458-010b6e9d2122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2d6412f2-f379-426c-8985-fefe0cd784f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2d6412f2-f379-426c-8985-fefe0cd784f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_61be5f62-6618-4c21-82a4-ebd0190f4a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_914006de-71e2-4482-948a-9f103c46ecfb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_61be5f62-6618-4c21-82a4-ebd0190f4a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_05797604-0247-4835-9438-649ede52325d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_05797604-0247-4835-9438-649ede52325d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c79dd5d6-4854-439a-900f-c62906e117ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c922c39b-7152-4bba-b249-cedd5d103c59" xlink:to="loc_us-gaap_RelatedPartyDomain_c79dd5d6-4854-439a-900f-c62906e117ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_39c3930d-696b-4057-a987-0bf87234278d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c79dd5d6-4854-439a-900f-c62906e117ec" xlink:to="loc_srt_AffiliatedEntityMember_39c3930d-696b-4057-a987-0bf87234278d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97e77366-96c9-4ee4-bc4a-00ce29ab918e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2e6dc63e-f46f-4b9b-974b-8e73ab1b1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:to="loc_us-gaap_CostOfSalesMember_2e6dc63e-f46f-4b9b-974b-8e73ab1b1b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea989257-909e-43d6-841c-796916df3549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b42c0f-fcb6-4611-b4d3-e6b6d91763f7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea989257-909e-43d6-841c-796916df3549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad439e78-7a62-49f8-afdf-08d6ecf583c3" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_d72c6430-1436-4208-b9e2-7b4fec990362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:to="loc_us-gaap_RevenueFromRelatedParties_d72c6430-1436-4208-b9e2-7b4fec990362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ea29ea21-b60e-46fd-8a75-0fb5f5907dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_550505e0-afc7-4d0c-b241-5d26c7469a04" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ea29ea21-b60e-46fd-8a75-0fb5f5907dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="simple" xlink:href="evh-20220331.xsd#RepositioningandOtherChanges"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_be718fcf-0ee3-4c6a-b1d3-c90156f70572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4b690fa5-48d9-485d-89a6-42bef0276fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_be718fcf-0ee3-4c6a-b1d3-c90156f70572" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4b690fa5-48d9-485d-89a6-42bef0276fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="simple" xlink:href="evh-20220331.xsd#RepositioningandOtherChangesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1681ebf8-9472-452f-9ebb-0853569ec713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_347fc3d5-b7a3-4064-a0c0-813123c1e7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1681ebf8-9472-452f-9ebb-0853569ec713" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_347fc3d5-b7a3-4064-a0c0-813123c1e7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#RepositioningandOtherChangesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6596b775-25e6-477f-bf23-8db7053f4f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6596b775-25e6-477f-bf23-8db7053f4f68" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_231f43ef-ea25-4859-b33c-ed3eb93b0a03" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_fe14eb46-9db2-47a3-818f-2a577fbd3c88" xlink:href="evh-20220331.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_fe14eb46-9db2-47a3-818f-2a577fbd3c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_329110fb-c95c-4dc7-af4d-dbcb80ada75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:to="loc_us-gaap_FacilityClosingMember_329110fb-c95c-4dc7-af4d-dbcb80ada75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_5097aa69-6b50-4274-bc47-24580573941b" xlink:href="evh-20220331.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc8423a4-907c-4cfe-90c4-b8c360f9a0e3" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_5097aa69-6b50-4274-bc47-24580573941b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e4a65953-1ab8-4d62-a29c-51460a573c00" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8d3cee43-5a37-421e-a2c2-7997db253f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:to="loc_us-gaap_RestructuringCharges_8d3cee43-5a37-421e-a2c2-7997db253f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_db9179a0-1a4c-4147-8a91-8689b1f5b278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bcfcf1e6-e8de-4475-b92a-6db9f17b9e8d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_db9179a0-1a4c-4147-8a91-8689b1f5b278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2c14a9a1-0c4d-41b1-94f9-0fd275346c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1df2153e-db22-409e-85d8-afae8f98a169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2c14a9a1-0c4d-41b1-94f9-0fd275346c44" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1df2153e-db22-409e-85d8-afae8f98a169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6c11c2c8-bdd7-4ef1-bb53-5e54017f3fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_648037e4-cd30-4a04-b469-f0f039db1f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6c11c2c8-bdd7-4ef1-bb53-5e54017f3fab" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_648037e4-cd30-4a04-b469-f0f039db1f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f2fc29b6-f895-42a7-99b2-dd1b6d610c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6c11c2c8-bdd7-4ef1-bb53-5e54017f3fab" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f2fc29b6-f895-42a7-99b2-dd1b6d610c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3e873580-6cfe-4e51-9523-0e78f6b70a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_46af92b1-3e11-4dd3-af05-5aa18d5c60ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3e873580-6cfe-4e51-9523-0e78f6b70a45" xlink:to="loc_us-gaap_NumberOfOperatingSegments_46af92b1-3e11-4dd3-af05-5aa18d5c60ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d1bc249d-e05b-40da-8097-d59f758fc932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d1bc249d-e05b-40da-8097-d59f758fc932" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:to="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9cff38ad-b00a-4d8b-8773-2060562c1b6f" xlink:to="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_03411768-16ff-4127-9b7c-4c3951d1ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:to="loc_us-gaap_IntersegmentEliminationMember_03411768-16ff-4127-9b7c-4c3951d1ba91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f3d842af-71c1-40e4-999a-540dba8de41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:to="loc_us-gaap_OperatingSegmentsMember_f3d842af-71c1-40e4-999a-540dba8de41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_15052008-aa5d-4004-b02b-25eac8ad4905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6a761fdc-db66-421f-b7cc-0eb4325d1a82" xlink:to="loc_us-gaap_CorporateNonSegmentMember_15052008-aa5d-4004-b02b-25eac8ad4905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_24178e35-95c2-4309-8a35-15d3586bc761" xlink:to="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_1c584abc-9b6b-4a45-a098-aa5deebff45f" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_1c584abc-9b6b-4a45-a098-aa5deebff45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_4204cdd2-d005-48ab-a8de-7bada19f47e9" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d637110a-ccfe-4df5-a90d-dbe56b9aadaa" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_4204cdd2-d005-48ab-a8de-7bada19f47e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_c04e0905-a80a-4037-bfea-a7156c21e620" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_503c71e8-b53d-4548-a3a4-6a1b77581226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_503c71e8-b53d-4548-a3a4-6a1b77581226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_6ff8423b-c3a2-4e9e-adfb-5cdb422dc29c" xlink:href="evh-20220331.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_f45ee102-6c56-4ec2-bef7-e50d608e449a" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_6ff8423b-c3a2-4e9e-adfb-5cdb422dc29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20220331.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_26dff8ec-a656-4105-810f-54fd2c2bd793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_NetIncomeLoss_26dff8ec-a656-4105-810f-54fd2c2bd793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2b32e12f-e6a9-45b1-8916-271c9894d792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2b32e12f-e6a9-45b1-8916-271c9894d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d914996f-febc-400b-bc52-8ef629e24446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_InterestExpense_d914996f-febc-400b-bc52-8ef629e24446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b70d307-9f84-4579-8427-5f602bb419e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b70d307-9f84-4579-8427-5f602bb419e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a335c899-03d3-4c45-ba24-401ff8803add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_DepreciationAndAmortization_a335c899-03d3-4c45-ba24-401ff8803add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_9a7d2fb7-a2ff-4ff7-a13f-2c2aa9e89387" xlink:href="evh-20220331.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_evh_GainOnTransferOfMembership_9a7d2fb7-a2ff-4ff7-a13f-2c2aa9e89387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea4b7af2-c0c4-4766-8fa1-1948f58dc712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea4b7af2-c0c4-4766-8fa1-1948f58dc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_776eda93-d5e8-4318-847c-218d542b661f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_776eda93-d5e8-4318-847c-218d542b661f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4aa895db-9e9c-45cd-b622-2aa4b5cb4f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4aa895db-9e9c-45cd-b622-2aa4b5cb4f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_26832262-1995-4489-a6a4-810a3e6e85cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_26832262-1995-4489-a6a4-810a3e6e85cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a970b40c-2242-462e-b3c3-3d873be00de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_RestructuringCharges_a970b40c-2242-462e-b3c3-3d873be00de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_32b4f88f-3f20-4f3b-bd84-773597048372" xlink:href="evh-20220331.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_32b4f88f-3f20-4f3b-bd84-773597048372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_181e1bb2-9003-40bc-bb59-a7cc5143ba30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_SeveranceCosts1_181e1bb2-9003-40bc-bb59-a7cc5143ba30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_ac215135-ecc1-455f-bb02-a34dfcccb307" xlink:href="evh-20220331.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_ac215135-ecc1-455f-bb02-a34dfcccb307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_4947a249-b52b-4e22-9ad5-44c0ab2bc626" xlink:href="evh-20220331.xsd#evh_ShareholderAdvisoryServices"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_evh_ShareholderAdvisoryServices_4947a249-b52b-4e22-9ad5-44c0ab2bc626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_74872489-7470-441f-a43b-b544001db4e0" xlink:href="evh-20220331.xsd#evh_TransactionCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_evh_TransactionCosts_74872489-7470-441f-a43b-b544001db4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b835a1f9-2bdd-4dda-b48b-e0cf5d26fbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b835a1f9-2bdd-4dda-b48b-e0cf5d26fbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_91bd6d4b-d669-4722-b290-2e762d4551d9" xlink:href="evh-20220331.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_91bd6d4b-d669-4722-b290-2e762d4551d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_73c78f1c-86ce-4e29-bf58-162e8e12c1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_209f73a3-1d3a-4efd-a457-c34b9160af02" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_73c78f1c-86ce-4e29-bf58-162e8e12c1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20220331.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_893d5f63-7488-4ae7-ac9b-1f2126f5f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_5bfbcc7d-402f-4bba-8f6e-60bcce2c7b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_893d5f63-7488-4ae7-ac9b-1f2126f5f9b2" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_5bfbcc7d-402f-4bba-8f6e-60bcce2c7b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20220331.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_3675c319-15fe-49ea-bf6e-adc9cb69463c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_20eb2ad4-6f0f-4276-a17a-4c8f0de45795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_3675c319-15fe-49ea-bf6e-adc9cb69463c" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_20eb2ad4-6f0f-4276-a17a-4c8f0de45795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_f1bcb9de-488a-48c8-8472-cc514165d86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_f1bcb9de-488a-48c8-8472-cc514165d86b" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7b1d63eb-7a6d-4401-a3be-34199e31efea" xlink:to="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_c380b17d-bbcf-40e8-9348-bd1bb7c8512d" xlink:href="evh-20220331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_c380b17d-bbcf-40e8-9348-bd1bb7c8512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_cffd5a0b-6970-4eb2-a050-04e0ea6b8e55" xlink:href="evh-20220331.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_35f68517-0ea8-4416-a818-2f526e262f06" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_cffd5a0b-6970-4eb2-a050-04e0ea6b8e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_5dbf5e00-8287-4206-8f7c-86656bc66d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_473bfd6a-6ce5-4eda-abda-c2b19d2e805f" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_5dbf5e00-8287-4206-8f7c-86656bc66d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_5dbf5e00-8287-4206-8f7c-86656bc66d0f" xlink:to="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a936a873-e995-4ed1-81ef-330e2bf8551b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a936a873-e995-4ed1-81ef-330e2bf8551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fe63ab23-6ca7-4041-975e-a81278aa0545" xlink:href="evh-20220331.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fe63ab23-6ca7-4041-975e-a81278aa0545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ca798272-29b1-4d6b-9c2a-9cd677211b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ca798272-29b1-4d6b-9c2a-9cd677211b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e3da5069-9943-45c6-b062-42423a739da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e3da5069-9943-45c6-b062-42423a739da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_81f3d6f8-475b-49c0-b22b-62985699685a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_81f3d6f8-475b-49c0-b22b-62985699685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_de5b66bf-42a5-4916-be92-2fd102c1e8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_de5b66bf-42a5-4916-be92-2fd102c1e8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_0cd22ef1-9af1-4c50-9238-97a69d078ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_0cd22ef1-9af1-4c50-9238-97a69d078ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_63f820ab-459d-40ac-88e8-64e266892517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_63f820ab-459d-40ac-88e8-64e266892517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_12c9d466-ddcb-4066-a7db-79f8c1c7b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_7bc3d528-1fea-413e-b3ba-80537d8f634b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_12c9d466-ddcb-4066-a7db-79f8c1c7b3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20220331.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_79a928bd-914b-4035-8cf7-af49fde32386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_838967a2-cf08-4be7-b636-b7535c26c9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_79a928bd-914b-4035-8cf7-af49fde32386" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_838967a2-cf08-4be7-b636-b7535c26c9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20220331.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_85812759-7d6f-4586-ba8f-7128fe8b1b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0fc9632d-22ae-41fe-9c01-184f28b21ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_85812759-7d6f-4586-ba8f-7128fe8b1b9e" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0fc9632d-22ae-41fe-9c01-184f28b21ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20220331.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_5ac5a43e-4e20-4a98-8b46-f894393109e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2f34ebb0-b086-4b1c-a076-ce61cd92ba95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_5ac5a43e-4e20-4a98-8b46-f894393109e0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2f34ebb0-b086-4b1c-a076-ce61cd92ba95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_84775736-906b-401b-a478-2d8ecd2a2009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2f34ebb0-b086-4b1c-a076-ce61cd92ba95" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_84775736-906b-401b-a478-2d8ecd2a2009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_a03e6bf9-508e-48c4-8dc8-6dc8fac268ed" xlink:href="evh-20220331.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_5ac5a43e-4e20-4a98-8b46-f894393109e0" xlink:to="loc_evh_CashFlowLesseeAbstract_a03e6bf9-508e-48c4-8dc8-6dc8fac268ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3ca99239-06cc-4630-ab9d-df1bb4982c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_a03e6bf9-508e-48c4-8dc8-6dc8fac268ed" xlink:to="loc_us-gaap_OperatingLeasePayments_3ca99239-06cc-4630-ab9d-df1bb4982c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_ddce66f3-1c45-4e31-be9f-d8b7d053278e" xlink:href="evh-20220331.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_a03e6bf9-508e-48c4-8dc8-6dc8fac268ed" xlink:to="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_ddce66f3-1c45-4e31-be9f-d8b7d053278e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950662616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,594,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950285784">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 210,158<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,647<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">179,270<span></span>
</td>
<td class="nump">130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,313<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">463,388<span></span>
</td>
<td class="nump">523,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,981<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,877<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,485<span></span>
</td>
<td class="nump">50,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,211<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,041<span></span>
</td>
<td class="nump">32,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">272,213<span></span>
</td>
<td class="nump">279,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">426,274<span></span>
</td>
<td class="nump">426,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,339,149<span></span>
</td>
<td class="nump">1,419,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">64,036<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">115,068<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,390<span></span>
</td>
<td class="nump">51,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">164,238<span></span>
</td>
<td class="nump">171,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">382,465<span></span>
</td>
<td class="nump">445,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">282,598<span></span>
</td>
<td class="nump">215,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,999<span></span>
</td>
<td class="nump">5,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,354<span></span>
</td>
<td class="nump">57,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">727,940<span></span>
</td>
<td class="nump">725,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 91,587,896 and 90,758,318 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">916<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,224,250<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(494)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(592,340)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">611,209<span></span>
</td>
<td class="nump">693,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,339,149<span></span>
</td>
<td class="nump">$ 1,419,458<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947858200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">91,587,896<span></span>
</td>
<td class="nump">90,758,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683949335432">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 297,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">219,739<span></span>
</td>
<td class="nump">157,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,932<span></span>
</td>
<td class="nump">58,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,106<span></span>
</td>
<td class="nump">15,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,078<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299,855<span></span>
</td>
<td class="nump">231,016<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,798)<span></span>
</td>
<td class="num">(15,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,241)<span></span>
</td>
<td class="num">(6,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">596<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,148)<span></span>
</td>
<td class="num">(10,579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,350)<span></span>
</td>
<td class="num">(11,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,350)<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,509<span></span>
</td>
<td class="nump">84,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,509<span></span>
</td>
<td class="nump">84,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,482)<span></span>
</td>
<td class="num">$ (9,838)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods and Services Sold, Excluding Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947736888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943552664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (278)<span></span>
</td>
<td class="num">$ (589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">6,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(2,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">617,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">1,236,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(598,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(4,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(4,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(11,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(11,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 611,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 1,224,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (494)<span></span>
</td>
<td class="num">$ (592,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950826024">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Used In Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,078<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnDispositionOfAssetsOperatingActivities', window );">Gain on discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(596)<span></span>
</td>
<td class="num">(7,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,106<span></span>
</td>
<td class="nump">15,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,346<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,689<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">539<span></span>
</td>
<td class="nump">4,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash inflows (outflows), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(357)<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,299)<span></span>
</td>
<td class="num">(63,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,071)<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(1,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">426<span></span>
</td>
<td class="nump">9,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,220<span></span>
</td>
<td class="num">(9,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,435)<span></span>
</td>
<td class="num">(28,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,056)<span></span>
</td>
<td class="nump">32,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset', window );">Right-of-use operating assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,992)<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(514)<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57,442)<span></span>
</td>
<td class="num">(48,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions and business combinations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(1,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,969<span></span>
</td>
<td class="nump">42,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet', window );">Disposal of non-strategic assets and divestiture of discontinued operations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromMaturityOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,508)<span></span>
</td>
<td class="num">(5,941)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash provided by investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,766<span></span>
</td>
<td class="nump">45,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Used In Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,371)<span></span>
</td>
<td class="nump">39,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment and termination of Credit Agreement including settlement of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">309<span></span>
</td>
<td class="nump">6,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,214)<span></span>
</td>
<td class="num">(2,687)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash used in financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(51,376)<span></span>
</td>
<td class="num">(55,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(92,156)<span></span>
</td>
<td class="num">(57,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">361,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 262,786<span></span>
</td>
<td class="nump">$ 303,769<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnDispositionOfAssetsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Assets, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnDispositionOfAssetsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromMaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromMaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947605432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of March&#160;31, 2022, the Company had unrestricted cash and cash equivalents of $210.2 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div>Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140684033266296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March&#160;31, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $4.1&#160;million and $3.4&#160;million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of March&#160;31, 2022 and December&#160;31, 2021, approximately 35% and 42% of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2022, approximately 39% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div>See Note 6 for further discussion of our policies related to revenue recognition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947614856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947603304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach  end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized by the end of the third quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947653560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued OperationsOn January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the three months ended March 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the three months ended March 31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:89.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947811560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Transformation revenue is 0.7% of total revenue for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,858&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $162.0 million of transaction price to performance obligations that are unsatisfied as of March&#160;31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 37%, 64% and 84% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the three months ended March 31, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $26.5&#160;million for the three months ended March 31, 2022 due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2022 and December 31, 2021, the Company had $3.9 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of  $1.4 million and $0.4 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2022 and December 31, 2021, the Company had $18.1 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of  $10.3 million and $2.7 million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683948118008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three months ended March 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three months ended March 31, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;March&#160;31, 2022,&#160;87% were current, 4%&#160;were past due less than 60 days, with 6% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;March&#160;31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$194.8 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$2.2 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,383)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947738520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $6.4 million and $5.5 million of internal-use software development costs for the three months ended March 31, 2022 and 2021, respectively. The net book value of capitalized internal-use software development costs was $70.9 million and $71.2 million as of March&#160;31, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $7.6 million and $7.8 million for the three months ended March 31, 2022 and 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.7 million, $6.7 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947605432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended March 31, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test of October 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of March&#160;31, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,195&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,213&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for both the three months ended March 31, 2022 and 2021 was $7.5 million, excluding $0.2&#160;million of amortization expense related to discontinued operations for the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2022, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three months ended March 31, 2022, that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947701000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $1.0 million and $1.0 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded $0.2 million and $1.9 million of interest expense related to the amortization of the issuance costs for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $13.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.6 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million for the three months ended March 31, 2022 and 2021 respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded $0.3 million and $2.4 million for the three months ended March 31, 2022 and 2021 respectively, in interest expense related to the amortization of the issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of March&#160;31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947697640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.7&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.7&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of March&#160;31, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between June 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March&#160;31, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed on December 2, 2021. The case alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, and was again stayed pending a decision on the Company&#8217;s third motion to dismiss. The Eastern District of Virginia granted in part and denied in part the motion to dismiss the third amended complaint on March 18, 2022. The case is again in discovery phase. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lincolnshire Police Pension Fund, derivatively on behalf o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. The case had been stayed until the decision on the Company&#8217;s motion to dismiss  the third amended was decided on March 18, 2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health., Frank Williams, Nicky McGrane, and Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal district court. Briefing on the motion to dismiss is ongoing and will be completed in July.  Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March&#160;31, 2022, approximately 99.6% of our $262.8 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million of True Health premium revenue reclassified to discontinued operations for the three months ended March 31, 2021.</span></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947725832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of March&#160;31, 2022 and December&#160;31, 2021. As of March&#160;31, 2022 and December&#160;31, 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of March&#160;31, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of March&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947672600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available for common shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683952699112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation was capitalized as software development costs for the three months ended March 31, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683948121592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense of $1.2 million and $0.6&#160;million was recognized for the three months ended March 31, 2022 and 2021, respectively, which resulted in effective tax rates of (29.0)% and (5.8)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three months ended March 31, 2022 primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had unrecognized tax benefits of $0.6 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of March&#160;31, 2022, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947645784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Equity Method Investees</a></td>
<td class="text">Investments in Equity Method Investees<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $0.6 million and $7.8 million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $3.6 million and $6.3 million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947657336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140684033215192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:427.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947667272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Repositioning and Other Changes</a></td>
<td class="text">Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947697640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,011)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683948139896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,024)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI http://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947671592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950204856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationIn our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div>Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that </span></div>have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPolicyPolicyTextBlock', window );">Right of Offset</a></td>
<td class="text">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950237464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March&#160;31, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of March&#160;31, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,195&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,213&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950443976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of allocation of purchase price</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947839768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the three months ended March 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the three months ended March 31, 2021. </span></div>Cash flows related to the True Health business during the three months ended March 31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:89.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943214952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,858&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with customer, asset and liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the three months ended March 31, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947603304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the three months ended March 31, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,383)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947729560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950824792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of March&#160;31, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,195&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,213&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future estimated amortization of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2022, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947685528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2022 and December 31, 2021 (in thousands):<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951628680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Summary of premiums and claims assumed</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of major customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable as of March&#160;31, 2022 and December&#160;31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million of True Health premium revenue reclassified to discontinued operations for the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947703784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of primary office leases and maturity of lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of March&#160;31, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of March&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951625304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of basic and diluted earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available for common shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947708696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based compensation expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of share-based awards granted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947979512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of liabilities at fair value on recurring basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in contingent consideration measured at fair value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947677384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of March&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:427.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947628888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Costs associated with the Repositioning Plan</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951660808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of revenue from segments to consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,011)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Adjusted EBITDA to net loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947698200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Activity in claims reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,024)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683948137080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of cash flow, supplemental disclosures</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947710152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 210,158<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943975080">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,647<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,647<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,981<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,981<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted investments included in restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">262,786<span></span>
</td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">$ 303,769<span></span>
</td>
<td class="nump">$ 361,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,499<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,855<span></span>
</td>
<td class="nump">73,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Bank time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951670552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details) - reportingUnit<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938675336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683948788264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable', window );">Right of offset, percentage of accounts receivable netted against claims payable</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement', window );">Right of offset, percentage of accounts receivable, net eligible for net basis settlement</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683937942520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 611,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="nump">$ 617,298<span></span>
</td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="num">(592,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="num">(598,985)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 1,224,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="nump">$ 1,236,847<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938007224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Vital Decisions (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,274<span></span>
</td>
<td class="nump">$ 349,022<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">2,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">6,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">77,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943450808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Results of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense', window );">Claims expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,763<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes and non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Platform and operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Claims Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683949343800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows provided by operating activities</a></td>
<td class="nump">$ 5,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash flows used in investing activities</a></td>
<td class="num">$ (2,494)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951635432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation Services | Revenues | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943290072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 297,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,858<span></span>
</td>
<td class="nump">84,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66,914<span></span>
</td>
<td class="nump">60,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">8,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,111<span></span>
</td>
<td class="nump">15,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">130,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63,587<span></span>
</td>
<td class="nump">43,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,566<span></span>
</td>
<td class="nump">85,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27,046<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938571320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 162.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938691752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 176,300<span></span>
</td>
<td class="nump">$ 129,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivables</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">4,019<span></span>
</td>
<td class="nump">$ 4,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="nump">16,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="num">(10,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="nump">11,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">17,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 26,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943956536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 11,689<span></span>
</td>
<td class="nump">$ 3,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized contract cost, amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950322776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 194,800<span></span>
</td>
<td class="nump">$ 171,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 2,171<span></span>
</td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">$ 9,383<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951639192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="num">$ (7,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="num">(2,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">$ (2,171)<span></span>
</td>
<td class="num">$ (9,383)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950700264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 209,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(126,409)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,098)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">82,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">24,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">166,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">70,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 15,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951623912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details) - reportingUnit<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943470856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing | reportingUnit</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,274<span></span>
</td>
<td class="nump">349,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,334<span></span>
</td>
<td class="nump">214,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,311<span></span>
</td>
<td class="nump">214,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,963<span></span>
</td>
<td class="nump">134,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,963<span></span>
</td>
<td class="nump">$ 134,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943583736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 442,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">169,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">272,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">12 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">8,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 17,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">14 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 311,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">76,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 234,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 87,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">75,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 12,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 16,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">8,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 7,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938675032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 21,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">26,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">20,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">19,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">19,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">164,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 272,213<span></span>
</td>
<td class="nump">$ 279,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683940763496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,000<span></span>
</td>
<td class="nump">$ 4,370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(611,209,000)<span></span>
</td>
<td class="num">(617,298,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="num">(868,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,224,250,000)<span></span>
</td>
<td class="num">(1,236,847,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,340,000<span></span>
</td>
<td class="nump">598,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">$ 589,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943556632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (19,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember', window );">Initial Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt issuance cost</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit | DDTL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">98,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsOfMakeWholePremium', window );">Payments of make-whole premium</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsOfMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsOfMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943253528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement', window );">Period during which warrants or rights exercisable, after maturity of credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments to settle outstanding warrants</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683942357576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (611,209,000)<span></span>
</td>
<td class="num">$ (617,298,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">4,370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="num">(868,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,224,250,000)<span></span>
</td>
<td class="num">(1,236,847,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,340,000<span></span>
</td>
<td class="nump">598,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">$ 589,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938625256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Face amount of debt repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtConversionOriginalDebtFairValue', window );">Debt conversion, original debt, fair value</a></td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtConversionOriginalDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Original Debt, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtConversionOriginalDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943823944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">$ 114,672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">2,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 209,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">167,926,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">4,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 203,648,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950741720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid', window );">Percent of tax savings to be paid</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 11,499<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683937785544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Reinsurance Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedPremiumsWritten', window );">Reinsurance premiums assumed</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 8,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed', window );">Claims assumed</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">10,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims', window );">Claims-related administrative expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet', window );">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(2,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">4,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables', window );">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromReinsurance', window );">Reinsurance payments paid (received)</a></td>
<td class="num">(330)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premiums Written And Policyholder Benefits And Claims Incurred, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reinsurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of policy benefits and costs incurred for policies assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943310904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 262,786<span></span>
</td>
<td class="nump">$ 303,769<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
<td class="nump">$ 361,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks (less than)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember', window );">Premiums | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23.90%<span></span>
</td>
<td class="nump">28.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MolinaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938761048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683937902376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Primary Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 82,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 34,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 40,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Edison, NJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 2,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950237464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,274<span></span>
</td>
<td class="nump">$ 4,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 6,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683948994504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 7,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">9,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">8,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">8,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">7,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">39,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">82,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">19,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 62,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947716952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683949030296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (11,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="num">(5,350)<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">89,509<span></span>
</td>
<td class="nump">84,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">89,509<span></span>
</td>
<td class="nump">84,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share, Basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943437736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">15,499<span></span>
</td>
<td class="nump">16,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">11,582<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683940691576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 5,346<span></span>
</td>
<td class="nump">$ 3,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4,546<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,108<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683947743608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized as software development costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943226280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Share-based Awards Granted (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">917,000<span></span>
</td>
<td class="nump">939,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">479,000<span></span>
</td>
<td class="nump">319,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950255528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="num">(29.00%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders', window );">Tax receivable agreement, percent of cash savings paid to shareholders</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943471672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">$ 7,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement', window );">Income from long-term services agreement</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943478008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 32,600<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">32,600<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">32,600<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 32,600<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683951896568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Realized and unrealized losses, net</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 32,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683944131816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 32,600<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 32,600<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Risk-neutral expected earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">35,185<span></span>
</td>
<td class="nump">30,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">0.0743<span></span>
</td>
<td class="nump">0.0604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683942229640">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 179,270<span></span>
</td>
<td class="nump">$ 130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,313<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,211<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">64,036<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">115,068<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">334<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683950733816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - Affiliated Entity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue</a></td>
<td class="nump">$ 32,064<span></span>
</td>
<td class="nump">$ 15,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">26,461<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683940741544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember', window );">Severance and termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Office space consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140684033266296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683943839320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 297,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,255<span></span>
</td>
<td class="nump">14,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,858<span></span>
</td>
<td class="nump">84,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">130,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">297,057<span></span>
</td>
<td class="nump">215,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,413<span></span>
</td>
<td class="nump">21,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,318<span></span>
</td>
<td class="nump">85,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,217<span></span>
</td>
<td class="nump">5,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">130,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,196<span></span>
</td>
<td class="nump">15,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,158)<span></span>
</td>
<td class="num">$ (7,011)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683944099992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,241)<span></span>
</td>
<td class="num">(6,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1,202)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="num">(15,106)<span></span>
</td>
<td class="num">(15,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(6,078)<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">178<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationIncludingOnetimeAdjustment', window );">Stock-based compensation expense</a></td>
<td class="num">(5,346)<span></span>
</td>
<td class="num">(3,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments', window );">Amortization of contract cost assets</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareholderAdvisoryServices', window );">Strategy and shareholder advisory expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransactionCosts', window );">Acquisition costs</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(1,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Gain from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="nump">24,255<span></span>
</td>
<td class="nump">$ 14,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationIncludingOnetimeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Including One-time Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationIncludingOnetimeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareholderAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholder Advisory Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareholderAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683938643016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">$ 171,294<span></span>
</td>
<td class="nump">$ 178,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current period</a></td>
<td class="nump">102,664<span></span>
</td>
<td class="nump">108,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior period</a></td>
<td class="nump">6,511<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current period</a></td>
<td class="nump">47,724<span></span>
</td>
<td class="nump">41,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior period</a></td>
<td class="nump">59,491<span></span>
</td>
<td class="nump">48,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">22,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="num">(9,016)<span></span>
</td>
<td class="nump">6,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">164,238<span></span>
</td>
<td class="nump">207,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">25,618<span></span>
</td>
<td class="nump">122,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior period</a></td>
<td class="num">(8,465)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior period</a></td>
<td class="num">(483)<span></span>
</td>
<td class="nump">38,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(7,982)<span></span>
</td>
<td class="nump">35,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">17,636<span></span>
</td>
<td class="nump">160,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">145,676<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current period</a></td>
<td class="nump">102,664<span></span>
</td>
<td class="nump">4,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior period</a></td>
<td class="nump">14,976<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current period</a></td>
<td class="nump">47,724<span></span>
</td>
<td class="nump">11,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior period</a></td>
<td class="nump">59,974<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="nump">9,942<span></span>
</td>
<td class="num">(13,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="num">(9,016)<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">$ 146,602<span></span>
</td>
<td class="nump">$ 47,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140683949300536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">$ 670<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">3,830<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfUseAssetAcquiredAndDisposedOf', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (2,157)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfUseAssetAcquiredAndDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Acquired And Disposed Of</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfUseAssetAcquiredAndDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>evh-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:evh="http://www.evolenthealth.com/20220331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20220331.xsd" xlink:type="simple"/>
    <context id="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib96988fb77cf47f0ba8eb6166fda7e01_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if299fb55051e4d729c1f4c44566a6f16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1623fa44597143889f19c0188c630b48_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0ec101c4091a4f46bfd520e8d03792f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic59c3d3e7b5d4f4a8874ddebbe1ace67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1e9801520f34456b2f8524c63e8e3c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i299ef1742b0c49abae14abd4ed0f8174_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7aa8e3cb4d874916a84b9d7e08e4666c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f712582849a46cc8b068630eb54d37d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5daef88c2af84a738a5f7ff9de4b9d7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia21f2d521de74c5dbb6764b237c3ac1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d7fee29877b408198fcd590f13b5985_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i293a1a6091d64b118aef6ec8a2d2167a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i130e14f026354ba2b836575ebd10bdd2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i621d358e78ed4fc2bd3ecd3b820db708_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id1cbb67f86274231b6621e78983d84df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i69e23962c75c49019909c9715c2499c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7eb4df9b7ed4bb382872f97fdb6a757_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc124f8ebb2b48dca7de861265b1df9f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3be7adf261ff427c874251aacfa02b7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ef9a57b91634689a5fc4d94fc39cc92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id44432f28d3a4aecb8eb5918685f3019_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cd7879f349a4bfb9adf1f4b67cb4d3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb90b06b13ac482cb1469d573d0ac107_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i059aea63706f40babf4ad42f721269d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id145101f6b47482c8c8b1e64aec732ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i924e8357dfb2454f86c7f8d0fd74a114_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0cbe563905aa492187f4514b1c567124_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i172d29d14aac4caf8b3c3650d9877ed2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc68586f685749a588829914e464480b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6db922f783fb432da34f684d3de92b24_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62e1ee4ac4ec44e681da4653910c6586_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33645fe6fe6e4f2b970ee1650d578425_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i644591fb6cc54e2096aefb6d12c9ee6d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia68b009330794ef1888c6d5fc3c5dfc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icedde2203c2f4932b7525a1653f8a386_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibff05ae2c51c48e6afd4afc199a1aa71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib729f13217c547b98e74d1bafa5ea4c9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4114c1a397b94102bce6ff2aa93691c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i746c3c635d6c45f5b87aefae016c4fb4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i46ea15c7c5084899ae3932a21f7bcb6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib82aee0d988d44d9af8cac23744c8699_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3f2b71e551c243ae81adfe5562d1b7c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icead5b03e4c6480db192188178d18afe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i136d025dfa994cc69d43c0b193565b0a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2cdd074577da4a56beeac98f792d2af1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf4153f331bc4c5ba00b95d8e87a52dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i532067d6f1ec4a09974e220c6f9d2b9f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1244aeda3f374cbdb7295a1b9720eaca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idcd76d84c4874414b5b69662bb989fcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iae5bc002399c42d7a0dfe095133c2eea_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="iffd02a268c2f44e1b4b8a87043e3237b_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i4fed4b10d9a94e43b4a7376d75e82ef5_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i50dcc4c9e90649d88b6e4ebba21ccd70_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i80ff05debabc497c8b7183be3cf47025_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i486cd92f52f9444ea10b825521601fd1_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i5d8f0394dcea4227a602bc9f7748104e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="id0dedbe6375f4957bda96aaf161bdfa5_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i78f19f381f38447c990722124282e3f6_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic05ac80824ef4e7e9360568c9bffff1a_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i6b184513547b435b881d4872ab81bc09_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if2a872109d774e4da481cebe223eff04_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f6ec7aba15341f6b7511d0a09ecf92a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i39a4593df2ed48e8bf26fb1a8734b8ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26bf389c6898466eb63379d01aaa71b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ec4532a4742433aba9506e85893885b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fad50bce4e049c5b3abd06d2db91799_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2fc0c2e998684f5f950bf9b71a352797_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19591c0223f84cb39b25c549e7cf2367_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76f20417b0b048728508db43ea6e2e8a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7af0d9f0068a4ecaa4d353078136bc50_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i768d2ed3578749dd919d8c01b59a765f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54489df7b34f4bc5bd3764871ee2bbd8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia45d563122eb4be993ee23f5113a8e5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i526505192a4f43d58f8618791a968597_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d4c945d2ec44cc996bde7e53fc1298c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i649f6202bc224593b15c50af0d75b73c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b0b219944a9403581d404035c8810ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8940680e0d344f24a0605bc5abbeeab2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4661a17748084b22847a6b4088c1f8c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0669761c388c4774877abc5d5d60ea1a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i112e0050ecf247829efb6e3889c6f684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22dc575ff886464484317aca659befbb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie2526a6d68f44dd9a2d5c9c76f28f392_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if10ac0d0bbea4997a9ef4b8313c0f3d9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4101ecab0d224b7e94b0b16a3a6e2d35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i080f3a0bebf046f4b42c854af2f46b0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i171aed87552d42e6b97ff67bc5456cba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iadbac2b94ee84dbaa1e6ae52b26777c8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7a483ad79bb04d958eac46a38e2f15c9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8804d1ca441342f88f29f050b52851ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice301424511e4396aff3b79bc7270a81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a7ffa70b61341d8b58e1e5e9dfe4d22_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0854b7c841d4126a9365b4b0019cd6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd8439569a0148a890c18386790d2daa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i68dcac57fee14e97b585767b7925b959_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fa83669c1e34be09bf9a205994d7995_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id61dcf9495af405097a6842ea0ed0697_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9118ab4a540a4a4a8d447fc14519b568_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib9b872c69d4344d69ce0a22b7183b681_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b1766ec32064dff97ec361a343c8c8d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f65ab021ad34abdbe85a6520f98dc68_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic23605bda701483aa031c60b51c43b27_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i58d4563528a74ddc8daf7cfcc8df4f4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dd83794d6dc499596834a18cd5a2a9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i431455fda9da407ea1273e3d11bbbb34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9c9d5a6a37649e3b44edf8049cce4da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i946bb3ded8914db29f26e0bac8b58b89_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i582b4bf2bda24ddea0c9c99086fae38b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i94f8e91e0319490e9d3eb0783a1bad61_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6249585dffb463e9e429c997c28422b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f06bb46081a46e18e26c25735932a5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie600b5ba08a345c0a7fa00407c5f1679_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i699ad28e63e644d292dfeba6e6ddc59c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if13595fd727041dbab088d6e82f53317_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie40a55a2d4af4c7eb637dd2db2488d47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ife5ebfa2dbf6474580e79f3a4aa684de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib98f030bdbd848349b1157be06b79af8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7d8558f0a0f4aed8a935e56b9bcd543_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7029f31fe5d346869ac6af84155da042_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96f0caaec00841cdb9b922302d272752_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5893e370c05e4fa4a36f9edae416eaee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fcffe6ed74045c2a108455a95165df3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36781c6539d94067adff3cf0b6de6bba_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i916d7cde9f5c4098aafca8f1d4ec92b3_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ba9893300544569828a837db24cb5ab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c1b52e308b74c7391b12b1ba506c1ee_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i7475a5be608b4b7db53a995f1885030a_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic3794041ed704c3192959c4746a76918_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ifac955e87eb245cb84b816f8086941ca_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i3f603d69a68045f6949859303a9e0100_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="id15cf99071b0415f8897789050cdcac3_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i758bcd0701c042ab91e1fdd9a3e0621c_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i4df15ce9a58f43aa8838ebd2fc814e18_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i8ad35dd656234df09077c620d5c6d635_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="if8d4ffeef7fe43eab4715bab8e852043_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i95a9a6090d0f49cd96fafd1325f2b417_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ie0e2e0f414904188a0bb7cf06671ce39_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="id3e67d706f964f1bb86ba26006bab411_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="ic618bc70943b4438aa6de0773ad42f41_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if07f72d9ccda44d3b9275c10c3802ea0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9a5151cda805403099aabb0baf5abfe9_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i0d85629f38df40019f7bfaf802250bce_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i2cba20250d344f82bb7c7ee274ac2d08_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="iecaf5b671d0f48838a69272ed492bd4a_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i7101f4c4fc704442967c163ed61da7dd_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ie46a449af09c45a48017c23edc16be05_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5c97925a37bb4a129ad535aed5cd5727_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i05179c18e4294269bd473e6439df82c9_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="i32d97f3d7fab4028a29399bf3e18652f_I20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="if568378dc7914a2ca879a5b1dfdec339_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3b47e659a7674184bd5fb1e6489758c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i977484a58ef44f029d021443bc481e0d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ce62f0c759b43c0a265b0f75bccf470_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib26b528f69e84aa8bf0354a45f147957_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i11e44058a9da4e57975c9afd2894c3fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f5b100104fe48a2989954cdb98067ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7fe6c4a84a34602b32ea482070a2644_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa07fa21879c47f8a81b631bf261e16f_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i960ff983ba984eef9fc0e57242acf4ad_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ica8e454931494c86a0acbbb148cef7a4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4ae4f2c278c4ce8bb30f6cf187609dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c587e607d8b406d82aa29c34afa0507_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i32c3abf79b77492d8199a68542ed7752_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i968714160637450486f094b7b1293b81_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe91cbc7315a4336b5abff786c768b62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2b4eec3a0cb4f27aaa8e6f384025a1e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id90c22c98c76421ea4011d8153a44a71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5794d71d0de4903b413840b815950f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b879fd6a8b140139241cedad3dd8363_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icd121453f7584e4795edacc5006758f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c697c6c8a12472a8470f212680e6841_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i55a0e80d686d4db398764b4e17532471_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic1a6b90e9de04a9795ddcc6e1d3d2f9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a5f7ca552444d36af631fb4eeba482a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9859c6985307497fb25bf1057a6361e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i69967c2e35354819ade6c5984bf3b729_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib68c9b6601e041919a7d54d7305442ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ice2ce205b8df40f5a8ca6fb448494da9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifc1ac30734004ea497e9ad4ec8f715ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia647416262ac4cbc82f836c92f6093f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief06047c33e34d79987ca3e17332e58e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i842788784c414a1a91580bb3f7277e7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0b639b680fbf43b6814f6de3ecae64d7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0a11d327f4c470ca2f791e8e1966028_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia747290a8b204259b52b29bf6aa78a40_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i627eecec9e24428f888feae02bf5a094_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i696664e630804b529ae7bb6d3ca89106_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iebeb1fce40b34eeda2f1d368b211235e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibaf15ce52ede4d83af3ac051dc46f9b5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibbdfd1a6d91342e6a148aa56505db40e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a81afc686ee45928654d3f1fd757c58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iabe9aab2682b4fc696fe56048ee7905a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3909b5b33cda4a969569a089a54d7d90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12dff91475cc4bc8b8681e67ab398b2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie053af2f0b7f43e79aa116dad9847e40_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id9e68408fd524ee7853f44d2c3055dac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if0bf322642904e678f0fb49d1674e122_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i80b281b7c3cb41b7b75ba0b670b05d6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i571e3a3a8fdb4e7fad04e7c5bfc9a5c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i459c224721e4472987d0810fa06039dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i179d7c9dfd6c48c396b1bae4ecd566f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3bdcd617addf439bb5ac7946fc074de1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6dfc2db43b94f5d8aae9b35c10ee05b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie5813816202a4e338fe7f589fd013674_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9026d99a25d84c75985b0866b64b1bf5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9f0a5a638b704e06a6d4cda5851b17f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9d670a13d5045c0a62849c225ec6a9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0186fb7ca56e461b9781a47361dfd131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e0612bc26c446988089e7cded45f213_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0100835413d340b082126f866d8b23d0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaeb884e998ab4b6d877b8cc4a40ee355_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i41098b957dca4081a3d6580e8917b49c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dc670273a9f4d978fd0fa286c1d9c0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53f1f40c73a441669cb646b2f251c21b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84334888c1ce4f9596774398cccb24d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c70b95cce0942dc8555c7160e7baec8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i932695caa0e3475e8d26b62529c3f9e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a2176e74b934dfbab0732b31233603a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11b60b44365747aa9dddac9017e65fb6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id0bbb5ca4f6640a98bc3bee2e63b3dd2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i785637c478644f3baa2265dd139ec9f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i362167a0c9b34805a0af2b448541b5bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a7f05d669f4496886a6a7a00d768285_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64d445fb027342059acb0abc5062875b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id24fa32341354c11976ef219f1db4536_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e6a736386954271be092327c488a4c4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iecd6828c06c24f6caac1d47d36f0f87f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c783f7550a946bbaf1d21f6f1d5c181_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79be648cb3694442bbf24990de4e33be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1860fdb5d9754126b8f298b7c351df82_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie409a91d5d8847ecb8729ff061b06528_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0a20d756ebe344c49afc88a4c8988a92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i532454a81aa1485d94751de5cd927545_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a704469f121488395cdba78ef29222f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i61686756cdc94fe487cf6ab99ac88a18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4dca42daa64b4aff97d52b7b8e251ed1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reportingunit">
        <measure>evh:reportingUnit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF8xLTEtMS0xLTM4MDQx_67908e72-5a0f-470f-8cc5-2069c3834097">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF8yLTEtMS0xLTM4MDQx_65bdf72c-d388-4cca-a25b-b0f7ffe96257">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF8zLTEtMS0xLTM4MDQx_cbb4b3ec-08f3-4ea8-9571-3db3b2fc06a4">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF80LTEtMS0xLTM4MDQx_7949ab76-eec9-4dc7-9d13-89145f7cd8a7">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF83L2ZyYWc6Yzk5MjhlOTZkMjVkNDVlYmE0OTNhZmQzNDI1ZGUwOTcvdGFibGU6NmE2N2NkN2YyM2QzNDJkZjljOGZhN2ZjNWJlZDkyZmQvdGFibGVyYW5nZTo2YTY3Y2Q3ZjIzZDM0MmRmOWM4ZmE3ZmM1YmVkOTJmZF81LTEtMS0xLTQ3Njk2_bca9aa0e-d5c9-4783-ac00-a9b4da4a1a35">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i6f712582849a46cc8b068630eb54d37d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMC0xLTEtNDc3MjY_af2df6d4-dea4-4789-ae3a-b6fb5553a450">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i5b0b219944a9403581d404035c8810ea_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzMvZnJhZzo3YjJhNjdkMGYyNzQ0ZjgwODlmM2MyM2EyN2Q4OWUwZC90YWJsZTozOGQyZjUzM2YyYjU0OWY2YWVmZTBhOGJlN2IzYmFiZS90YWJsZXJhbmdlOjM4ZDJmNTMzZjJiNTQ5ZjZhZWZlMGE4YmU3YjNiYWJlXzItMS0xLTEtMzgwNDE_f98caff0-70cc-4893-ba2e-ceb26d2854f4">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i8940680e0d344f24a0605bc5abbeeab2_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzMvZnJhZzo3YjJhNjdkMGYyNzQ0ZjgwODlmM2MyM2EyN2Q4OWUwZC90YWJsZTozOGQyZjUzM2YyYjU0OWY2YWVmZTBhOGJlN2IzYmFiZS90YWJsZXJhbmdlOjM4ZDJmNTMzZjJiNTQ5ZjZhZWZlMGE4YmU3YjNiYWJlXzMtMS0xLTEtMzgwNDE_a5e847fe-79b9-403a-bea6-4d5fd2ecaae9">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i4661a17748084b22847a6b4088c1f8c0_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzMvZnJhZzo3YjJhNjdkMGYyNzQ0ZjgwODlmM2MyM2EyN2Q4OWUwZC90YWJsZTozOGQyZjUzM2YyYjU0OWY2YWVmZTBhOGJlN2IzYmFiZS90YWJsZXJhbmdlOjM4ZDJmNTMzZjJiNTQ5ZjZhZWZlMGE4YmU3YjNiYWJlXzQtMS0xLTEtMzgwNDE_691b6507-1a31-4971-8e18-30289680cc09">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ifa07fa21879c47f8a81b631bf261e16f_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDgvZnJhZzplNmMxYmU4OTMxZTM0Mjk5YjFmYTNkMDRhZTg3OGM3Yy90ZXh0cmVnaW9uOmU2YzFiZTg5MzFlMzQyOTliMWZhM2QwNGFlODc4YzdjXzU_825f789a-8531-494f-a1a4-2f2bb0c46f90"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i960ff983ba984eef9fc0e57242acf4ad_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDgvZnJhZzplNmMxYmU4OTMxZTM0Mjk5YjFmYTNkMDRhZTg3OGM3Yy90ZXh0cmVnaW9uOmU2YzFiZTg5MzFlMzQyOTliMWZhM2QwNGFlODc4YzdjXzIxNQ_fa6f3c81-8024-4d93-9c11-c039bdc1b0b9"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMzA5_01063c5a-1b9c-4e8f-aa40-a0d83ef94c67">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMzEw_6b223ad2-aacb-4b5e-be83-11fcc5bd53cd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMDY_7d4796eb-274e-40e3-8976-9c9983bae030">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMTU_e9de08b1-8f01-4bba-ac2e-79211c3a81e8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8zOTc_70d9b112-3a0a-4b2a-9da1-debfbc58f675">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF80Mjc_7de5d9e0-a7a5-40cd-887c-755e2a93572d">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8wLTEtMS0xLTM4MDQx_778a3ccb-c812-41b7-a4d6-c796b32e1969">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8wLTktMS0xLTM4MDQx_8eced9b4-9012-4552-8243-7ad1e6c0d237">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTEtMS0xLTM4MDQx_cff9bed8-eb2d-4b39-90f5-da29fffb7b23">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTMtMS0xLTM4MDQx_d3b941dd-e57a-44e6-a6b4-c71e74291d3a">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTUtMS0xLTM4MDQx_692cddf9-7df2-41ee-a657-d614a4e65b1e">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTctMS0xLTM4MDQx_8a8c0a5a-ebdf-42e0-ba41-c6fe9ad157b4">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6MTkzMjAyN2ZmMjcxNDk3NGJlMzVlNzBjYjU5ODA5OTYvdGFibGVyYW5nZToxOTMyMDI3ZmYyNzE0OTc0YmUzNWU3MGNiNTk4MDk5Nl8zLTktMS0xLTM4MDQx_e58440fc-f5c1-472c-b09c-f9c615f7807c">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF81MzU_1cf2ce38-8294-4145-8888-91b88ecd7d5e">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF81Mzk_2286acf0-d5c4-4906-a039-de9a54f9b6ca">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6ZjdiZmE3ZjhjMDRmNDFiNzgyYjUzOTVlMWU2MWVjYzgvdGFibGVyYW5nZTpmN2JmYTdmOGMwNGY0MWI3ODJiNTM5NWUxZTYxZWNjOF8xLTAtMS0xLTM4MDQx_abf47759-96c5-4b67-8a0d-b78a0636a49b">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6ZjdiZmE3ZjhjMDRmNDFiNzgyYjUzOTVlMWU2MWVjYzgvdGFibGVyYW5nZTpmN2JmYTdmOGMwNGY0MWI3ODJiNTM5NWUxZTYxZWNjOF8xLTEtMS0xLTM4MDQx_217296cf-6b3b-46d6-b63b-636609854b35">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGFibGU6ZjdiZmE3ZjhjMDRmNDFiNzgyYjUzOTVlMWU2MWVjYzgvdGFibGVyYW5nZTpmN2JmYTdmOGMwNGY0MWI3ODJiNTM5NWUxZTYxZWNjOF8xLTItMS0xLTM4MDQx_afe8b3d4-9b85-4bd6-b1ce-d114399f1f0d">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xMDQw_2948e92c-d943-4a44-ba39-a66312c7ac51">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xMzYy_4d180602-5180-416b-be4e-0b8616da5d5c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xNzI5_04eb5460-47a3-4b12-a99f-4320223383bd">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8xODEw_f6182d4a-bde7-4023-bc53-b340eed7eb00">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMzEx_50602e75-9f0b-4d4c-a597-fc7a7705558e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMjE1_c93e2128-ec0f-4de2-93bd-a0ca4ff5f57e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib96988fb77cf47f0ba8eb6166fda7e01_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF80L2ZyYWc6MWI2ZGE2NmU3ODA2NDRlOGJkYzMxYjNmOTMzZTA1NTAvdGV4dHJlZ2lvbjoxYjZkYTY2ZTc4MDY0NGU4YmRjMzFiM2Y5MzNlMDU1MF8yMjQ2_71a31a79-231f-40a7-a71e-6b73de5cea87"
      unitRef="shares">91594562</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQtMS0xLTEtMzgwNDE_add97452-ac96-4d2e-b81b-ee20db982bac"
      unitRef="usd">210158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQtMy0xLTEtMzgwNDE_9c0bd92f-130b-439a-a2b6-cee78ed019a1"
      unitRef="usd">266280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzUtMS0xLTEtMzgwNDE_e6843217-55fc-4dbe-bd41-01daa40c4fb6"
      unitRef="usd">39647000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzUtMy0xLTEtMzgwNDE_48db3d0f-bc67-495a-aba9-cf44cc495269"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMS0xLTEtMzgwNDE_196a7221-1ecc-4efc-a498-182fd87e1023"
      unitRef="usd">179270000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMy0xLTEtMzgwNDE_97157884-4719-4910-82f6-a01524ef325e"
      unitRef="usd">130604000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMS0xLTEtMzgwNDE_81bbfe1c-390a-4b05-9055-6f6690e0e0ee"
      unitRef="usd">34313000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMy0xLTEtMzgwNDE_3680218e-efe6-4126-9699-ed074a978f07"
      unitRef="usd">51391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzktMS0xLTEtMzgwNDE_172b2625-9911-4b40-bb80-f82f05325355"
      unitRef="usd">463388000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzktMy0xLTEtMzgwNDE_600851c2-5ca3-4e99-a322-2683751e1836"
      unitRef="usd">523960000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEwLTEtMS0xLTM4MDQx_27ef877e-f593-41d2-b30e-92180624bbc5"
      unitRef="usd">12981000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEwLTMtMS0xLTM4MDQx_42e99070-ef02-49bc-9f51-0ce35a21a075"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzExLTEtMS0xLTM4MDQx_f5970682-d39d-420d-b669-d68a3fce1a3c"
      unitRef="usd">3679000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzExLTMtMS0xLTM4MDQx_48ba09b8-3879-46f5-b4cd-f4358e4b5217"
      unitRef="usd">5458000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEyLTEtMS0xLTM4MDQx_f9e0ca44-5832-4d83-864a-4b28de67b63d"
      unitRef="usd">82877000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEyLTMtMS0xLTM4MDQx_d2e9c19d-1304-4863-a58c-36085ed4dbfb"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEzLTEtMS0xLTM4MDQx_4166ea71-e9f8-478f-8705-f550906e3097"
      unitRef="usd">48485000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzEzLTMtMS0xLTM4MDQx_b0d515c8-c581-4e91-b1dd-e6453f14be61"
      unitRef="usd">50203000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTEtMS0xLTM4MDQx_03c06028-7880-493c-814e-235966f93b85"
      unitRef="usd">7211000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTMtMS0xLTM4MDQx_0193734e-ac0b-42ec-a951-e4beb268ad60"
      unitRef="usd">6790000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE1LTEtMS0xLTM4MDQx_6e5ef67f-e9bb-4e75-831e-9805dc25183a"
      unitRef="usd">22041000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE1LTMtMS0xLTM4MDQx_115856bb-dd03-4181-9722-5ed209542110"
      unitRef="usd">32624000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE2LTEtMS0xLTM4MDQx_23ca7ea8-f8ee-4f68-a282-5dac5c48b443"
      unitRef="usd">272213000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE2LTMtMS0xLTM4MDQx_3304cc5b-6348-48b1-a241-dd37f0cb72f2"
      unitRef="usd">279784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE3LTEtMS0xLTM4MDQx_74194ae7-5873-48b6-923c-0aae4119d0e5"
      unitRef="usd">426274000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE3LTMtMS0xLTM4MDQx_21b1e2f6-933a-4258-a7ee-cd6d7beb829c"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE5LTEtMS0xLTM4MDQx_8013b94a-6692-4b7c-b8b2-5e8b214fc854"
      unitRef="usd">1339149000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE5LTMtMS0xLTM4MDQx_db153c49-3cd8-4791-af69-5722a6dfe78d"
      unitRef="usd">1419458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTEtMS0xLTM4MDQx_6b9c5b33-1c7b-477a-b6e8-54b6fcdf1e57"
      unitRef="usd">64036000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTMtMS0xLTM4MDQx_b4e53bf8-d830-4b84-8101-e40711400838"
      unitRef="usd">96084000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTEtMS0xLTM4MDQx_752cd560-3755-4dbb-a489-b769fcc23884"
      unitRef="usd">115068000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTMtMS0xLTM4MDQx_b2ea2841-f141-4b34-b324-9c59f559db5b"
      unitRef="usd">107241000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI2LTEtMS0xLTM4MDQx_18d840cd-f665-4cc1-a3fa-cbeef147bfa8"
      unitRef="usd">6445000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI2LTMtMS0xLTM4MDQx_4906cd48-5c11-4b19-a312-935f2aa9f56a"
      unitRef="usd">7069000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI3LTEtMS0xLTM4MDQx_6d0ad32a-67fe-4ade-b41a-5f2e0dd96b52"
      unitRef="usd">19390000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI3LTMtMS0xLTM4MDQx_b545cd97-b1b6-4aea-8fa5-285590251c7f"
      unitRef="usd">51861000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI4LTEtMS0xLTM4MDQx_978756ab-4089-43eb-9d4b-e350e3420f0b"
      unitRef="usd">13288000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI4LTMtMS0xLTM4MDQx_7d3de189-012b-43a1-825e-33ac01f928e3"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTEtMS0xLTM4MDQx_8cb7d434-69ac-4c33-975d-3a90e8560b2d"
      unitRef="usd">164238000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTMtMS0xLTM4MDQx_589fce9d-e9d4-4854-b765-72985b41428d"
      unitRef="usd">171294000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMxLTEtMS0xLTM4MDQx_790aa4d4-ae41-4b2f-a02d-b6223aa80379"
      unitRef="usd">382465000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMxLTMtMS0xLTM4MDQx_de590d78-b23d-43bb-be5c-4a347d1b9861"
      unitRef="usd">445493000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMyLTEtMS0xLTM4MDQx_4b905e5a-9a6d-4c6c-ae67-ea99b80d2c07"
      unitRef="usd">282598000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMyLTMtMS0xLTM4MDQx_f3dac29c-26ec-4e32-909c-af5e6a1a2d5b"
      unitRef="usd">215676000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMzLTEtMS0xLTM4MDQx_5e0e7e39-5d7a-4614-a783-e33e72b93bff"
      unitRef="usd">4999000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzMzLTMtMS0xLTM4MDQx_cd30636d-b9fc-444b-866f-b611663a0ea1"
      unitRef="usd">5531000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM0LTEtMS0xLTM4MDQx_43e3f8d0-6469-442a-8245-2f034e4ccbad"
      unitRef="usd">56354000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM0LTMtMS0xLTM4MDQx_dede132a-c15e-4128-805e-cd6bf1685067"
      unitRef="usd">57722000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM1LTEtMS0xLTM4MDQx_390b411e-ac2a-4054-bc71-7607edf05502"
      unitRef="usd">1524000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM1LTMtMS0xLTM4MDQx_cce30093-51ef-4181-827e-7f46ff785a56"
      unitRef="usd">1403000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM3LTEtMS0xLTM4MDQx_9f2bb523-754d-4652-ac57-ba1565e5b675"
      unitRef="usd">727940000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM3LTMtMS0xLTM4MDQx_09bdaa8a-db30-487f-8ccb-ce8f5f3d33bc"
      unitRef="usd">725825000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM4LTEtMS0xLTM4MDQx_e5037d1f-ad70-4a2e-84ef-93437482a2ac"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzM4LTMtMS0xLTM4MDQx_8d309b01-e217-49a7-a048-6f7b06637318"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfMjc_004cdd56-1485-42f3-b1fe-4c68208fe9af"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfMjc_0c093b37-2f68-49b5-837f-e963d93770d7"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNDE_bc833343-8dba-4caa-b28f-fcccdf09bd33"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNDE_c847e4e7-ebb0-492f-947b-d261d5315ddc"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNjM_d96c129e-ffe0-48c2-a119-8e3ff2596a2b"
      unitRef="shares">91587896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTAtMS0xLTM4MDQxL3RleHRyZWdpb246N2Y5YzAyNzdlMjFjNGFlOGFmYzgwYWJjOWQwYWU1MTdfNzA_1b147335-b542-4cd9-a1ad-5b5b8f4008f7"
      unitRef="shares">90758318</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTEtMS0xLTM4MDQx_26f1c8d1-5823-4d65-a632-c0cdbd609d7b"
      unitRef="usd">916000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQwLTMtMS0xLTM4MDQx_6f5c65fd-3016-460e-926a-d4975c4d1992"
      unitRef="usd">908000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQxLTEtMS0xLTM4MDQx_7fbb6116-5e94-4d79-bbe6-f159b9dafaa7"
      unitRef="usd">1224250000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQxLTMtMS0xLTM4MDQx_c397dbcd-534a-46d8-ae94-959deb621003"
      unitRef="usd">1340989000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQyLTEtMS0xLTM4MDQx_b17dce71-3376-42ac-a3a0-cf60269cdb8d"
      unitRef="usd">-494000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQyLTMtMS0xLTM4MDQx_2e04cf42-bbba-4fc9-bb97-6728106bc1c9"
      unitRef="usd">-362000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQzLTEtMS0xLTM4MDQx_a5f4bf0d-56e4-4342-a8bb-e91054d7eaac"
      unitRef="usd">-592340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQzLTMtMS0xLTM4MDQx_780b5014-d45c-43d0-8799-4d5b1d6c88cb"
      unitRef="usd">-626779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTAtMS0xLTM4MDQxL3RleHRyZWdpb246MmUyNTE4Njk4NDQzNDE1MThhOWUyNzBiZDc2Mzk1ZTdfMjk_2eec9d8d-2ca6-44ad-aa2d-3c443537a314"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTAtMS0xLTM4MDQxL3RleHRyZWdpb246MmUyNTE4Njk4NDQzNDE1MThhOWUyNzBiZDc2Mzk1ZTdfMjk_46e3a9fa-9c83-4b7d-8bba-2bbe6cd7000b"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTEtMS0xLTM4MDQx_54efc1cb-0f64-4b71-90c9-71b8e56d15fb"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ0LTMtMS0xLTM4MDQx_7111a95d-051b-48d7-b608-f21413f90cd3"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ1LTEtMS0xLTM4MDQx_849e1e00-74d3-4c91-821a-26502610a90e"
      unitRef="usd">611209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ1LTMtMS0xLTM4MDQx_b3a94119-484b-45c9-bcd8-d5f7ba1a32cf"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ2LTEtMS0xLTM4MDQx_2f8a90f9-b1ca-46a8-a5d4-b52e11d1a94d"
      unitRef="usd">1339149000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzQ2LTMtMS0xLTM4MDQx_a051451b-0701-4041-abec-ccba06f0502c"
      unitRef="usd">1419458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMS0xLTEtMzgwNDE_81ef6c46-a72e-41e5-b111-18d2ff049ec4"
      unitRef="usd">297057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMy0xLTEtMzgwNDE_769e699f-2c7b-4b79-81b7-4f27e00c62a8"
      unitRef="usd">215071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMS0xLTEtMzgwNDE_92c74fa3-30f6-4d04-badb-d1024124696d"
      unitRef="usd">219739000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMy0xLTEtMzgwNDE_3f9314cc-6eeb-467f-867f-1275cae5becf"
      unitRef="usd">157832000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMS0xLTEtMzgwNDE_661172f1-58ab-48c2-a568-759fa6e953b4"
      unitRef="usd">58932000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMy0xLTEtMzgwNDE_8c8d976e-4caf-456d-b0e9-f2edbdbdca40"
      unitRef="usd">58591000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzEwLTEtMS0xLTM4MDQx_e55d065e-9d26-483b-b296-ee6a7adfb65f"
      unitRef="usd">15106000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzEwLTMtMS0xLTM4MDQx_8487d674-3139-4eba-a5e1-0b0419071020"
      unitRef="usd">15187000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE0LTEtMS0xLTM4MDQx_fbed0857-0dbd-448e-83e1-db13698a3db7"
      unitRef="usd">6078000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE0LTMtMS0xLTM4MDQx_3db3fb68-63d3-4dd0-a783-87bebf05b66a"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE1LTEtMS0xLTM4MDQx_60ae55c4-0219-44f1-93b2-ff70b77d1e3e"
      unitRef="usd">299855000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE1LTMtMS0xLTM4MDQx_2089d635-867a-4cf8-9512-5f46714f3903"
      unitRef="usd">231016000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE2LTEtMS0xLTM4MDQx_b1ccb602-2c31-4dee-b127-4afa207b7a39"
      unitRef="usd">-2798000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE2LTMtMS0xLTM4MDQx_1f31f350-be1f-4d90-8db5-a329e9c70814"
      unitRef="usd">-15945000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE3LTEtMS0xLTM4MDQx_e922cac3-67b4-45bc-9eba-8abed983a24f"
      unitRef="usd">117000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE3LTMtMS0xLTM4MDQx_34382c72-def2-48d3-83e1-d64e4d54164f"
      unitRef="usd">123000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE4LTEtMS0xLTM4MDQx_1661b0d8-678f-4585-b1ed-a5441f2c43c3"
      unitRef="usd">2241000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzE4LTMtMS0xLTM4MDQx_6086ac74-f940-4209-ad1e-32c95e6df8bf"
      unitRef="usd">6337000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIwLTEtMS0xLTM4MDQx_e5e313bb-00e2-40dd-b8a5-cb18249de75b"
      unitRef="usd">596000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIwLTMtMS0xLTM4MDQx_b03b23f4-9a82-4ec1-a890-9059b613579d"
      unitRef="usd">7783000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:GainOnTransferOfMembership
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIxLTEtMS0xLTM4MDQx_66184bab-0a7c-41b7-ada5-f8ee2b9744d5"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIxLTMtMS0xLTM4MDQx_b68550cb-4628-46a6-9dd8-1cda22ea7fed"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIyLTEtMS0xLTM4MDQx_cd99e046-381f-46c6-942b-7141d1d3c293"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIyLTMtMS0xLTM4MDQx_a5f3c24f-4740-4dc0-9d76-633176eb7a70"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIzLTEtMS0xLTM4MDQx_4304c8e2-5a48-49b6-ac12-a12a6ca3b614"
      unitRef="usd">178000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzIzLTMtMS0xLTM4MDQx_b3bc9599-afec-4a0f-9de4-dfa674bc1cae"
      unitRef="usd">-14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI0LTEtMS0xLTM4MDQx_97cc307a-3a1d-48bc-a17c-b0c5ac634d55"
      unitRef="usd">-4148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI0LTMtMS0xLTM4MDQx_2de919c9-c20a-44a7-98b7-18c82fa2ba3b"
      unitRef="usd">-10579000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI1LTEtMS0xLTM4MDQx_85722f6d-24f2-4bc3-a291-c61e01b3414b"
      unitRef="usd">1202000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI1LTMtMS0xLTM4MDQx_d6cbffc2-eb96-4502-ad27-689de2bc4b7e"
      unitRef="usd">611000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI2LTEtMS0xLTM4MDQx_57f0dd20-8335-4301-96e4-84ddca884b17"
      unitRef="usd">-5350000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI2LTMtMS0xLTM4MDQx_1d8a1e64-6a92-43e0-8702-d33d507cfc10"
      unitRef="usd">-11190000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI3LTEtMS0xLTM4MDQx_9a961152-7317-41c3-9951-60d1c12b2b55"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzI3LTMtMS0xLTM4MDQx_a7749027-c4c8-4ee8-9c7c-0b01e3bb01ce"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTEtMS0xLTM4MDQx_382b3d21-64c1-4d03-9c4d-1a88790616e4"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTEtMS0xLTM4MDQx_cf3eff2b-1a09-4e45-8224-6da02de6faf9"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTMtMS0xLTM4MDQx_54fc92f9-7646-4d5e-8a06-3d5cdd2006db"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzMwLTMtMS0xLTM4MDQx_59e2b9e2-6d0e-4880-bd0a-259a3bc8543e"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTEtMS0xLTM4MDQx_cd7dbb8c-c230-40fa-9e1c-89ddb5150c93"
      unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTEtMS0xLTM4MDQx_dce28e6f-1f46-4e94-8a30-e5f118457bd4"
      unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTMtMS0xLTM4MDQx_0eb11ff2-f1f0-4803-a92f-2075603e4ebc"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM0LTMtMS0xLTM4MDQx_8fd0c4e3-e001-4289-9347-78c01f2ca1dd"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTEtMS0xLTM4MDQx_ba5bd89c-7bb2-45e5-beae-badadc91229f"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTEtMS0xLTM4MDQx_e9701e52-caa5-4c31-bba0-b33b00faf07c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTMtMS0xLTM4MDQx_25dad0cd-7e70-48be-8c0d-4160671153b1"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM1LTMtMS0xLTM4MDQx_59aff931-3805-409f-822b-3f363a611ead"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTEtMS0xLTM4MDQx_4143aa38-cafb-40ef-9f5b-83249cc588a4"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTEtMS0xLTM4MDQx_618b89bf-6770-462d-8d7c-741ac05aac7f"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTMtMS0xLTM4MDQx_23cbac1a-20cf-4cc2-8cb1-977e29fd27ed"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzM3LTMtMS0xLTM4MDQx_e7474cd7-30ed-4081-bd0f-8c35ff985f9c"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTEtMS0xLTM4MDQx_2e9d5031-9f9a-4199-9215-64564d1aacb6"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTEtMS0xLTM4MDQx_cf868fd8-1afd-49d0-acee-5a7af9ce7914"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTMtMS0xLTM4MDQx_7bc03da2-3c16-44b6-ad25-f05001fcd32a"
      unitRef="shares">84670000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQwLTMtMS0xLTM4MDQx_99f00915-455f-468d-9856-d443da68441e"
      unitRef="shares">84670000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQzLTEtMS0xLTM4MDQx_9c534833-a48b-4fe8-abec-3a3d64883de2"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQzLTMtMS0xLTM4MDQx_67760138-6198-4860-851e-285b241a259b"
      unitRef="usd">-9807000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ1LTEtMS0xLTM4MDQx_bb9343d1-69ed-41e3-834d-0b1a5abec9d0"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ1LTMtMS0xLTM4MDQx_8716c4f1-cc01-467f-893c-05e4e4c5f8d6"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ4LTEtMS0xLTM4MDQx_c19c3e63-cf5f-41ab-9705-04e642f4bfa0"
      unitRef="usd">-5482000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzQ4LTMtMS0xLTM4MDQx_f5c35c36-b497-41fc-83ee-a5552895fcb5"
      unitRef="usd">-9838000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzI1OA_cdf04ab3-2ef2-4d3d-8dd6-d6e99cea8778"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i0ec101c4091a4f46bfd520e8d03792f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMS0xLTEtMzgwNDE_8f609fd0-3853-4581-bb5d-1cc664abc6ac"
      unitRef="shares">90759000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0ec101c4091a4f46bfd520e8d03792f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMy0xLTEtMzgwNDE_db2cc1bc-9402-4577-815d-ee5be849a7c7"
      unitRef="usd">908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic59c3d3e7b5d4f4a8874ddebbe1ace67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtNS0xLTEtMzgwNDE_3d809483-e37a-40f0-b0e9-4037e0209105"
      unitRef="usd">1340989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1e9801520f34456b2f8524c63e8e3c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtNy0xLTEtMzgwNDE_f0f96bca-5870-425f-bbde-34dd27baef99"
      unitRef="usd">-362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i299ef1742b0c49abae14abd4ed0f8174_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtOS0xLTEtMzgwNDE_fb17924d-db20-48ea-b03c-81d49a7213aa"
      unitRef="usd">-626779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7aa8e3cb4d874916a84b9d7e08e4666c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMTEtMS0xLTM4MDQx_1df43302-29b9-4ba4-9b20-25a56c976db5"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMtMTctMS0xLTM4MDQx_88632395-ec41-45a6-9e3b-1c290c2f9df8"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5daef88c2af84a738a5f7ff9de4b9d7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtNS0xLTEtNDU1NjM_4f55df87-4e42-4cbd-9ecb-ce095d52d5fe"
      unitRef="usd">-106172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia21f2d521de74c5dbb6764b237c3ac1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtOS0xLTEtNDU1NjM_2c6e4f9a-a8af-4857-8bb7-235427c52571"
      unitRef="usd">39789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d7fee29877b408198fcd590f13b5985_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMTMtMS0xLTQ1NTYz_cbb5abdd-cc10-4a59-9e4a-0fa0f2016aa3"
      unitRef="usd">-66383000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtNS0xLTEtMzgwNDE_291568cf-93a8-4eef-afc4-a635ba763dcc"
      unitRef="usd">5346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzUtMTctMS0xLTM4MDQx_fe1ac0fe-35d4-4d52-95ca-68e50b2dee20"
      unitRef="usd">5346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzYtMS0xLTEtMzgwNDE_c19e9bb9-3acf-4625-9492-17481a0ed228"
      unitRef="shares">37000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzYtNS0xLTEtMzgwNDE_8d1ebbad-b0f9-4085-a2af-0d58b77a6f26"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzYtMTctMS0xLTM4MDQx_c638bf94-9b31-4e76-b62b-5d262f5d583f"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctMS0xLTEtMzgwNDE_fdb4e896-4e0c-4b1a-b1da-b2a009475b35"
      unitRef="shares">334000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctMy0xLTEtMzgwNDE_650d58d1-29bd-4ca0-b450-c82412279280"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctNS0xLTEtMzgwNDE_0b9330d6-7927-4f7c-a17d-51170a7c3fa9"
      unitRef="usd">-4986000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzctMTctMS0xLTM4MDQx_24dbfb07-5cf3-4600-ac86-644e0a73cbb3"
      unitRef="usd">-4983000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMS0xLTEtNDU1OTM_a8617a7e-0443-4f5b-982d-9ade6560b1f4"
      unitRef="shares">458000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16d2275990864c0bb0115cd0635471b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMy0xLTEtNDU1OTM_401715e3-3ef9-468c-927a-575c43824fd6"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id36126c117d84ccd843b500634a7ee1c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktNS0xLTEtNDU2MDQ_267e8a29-46a6-4a26-a825-7004941ef696"
      unitRef="usd">-11236000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMTMtMS0xLTQ1NjA0_fe971ec5-e1fe-4e3f-b62b-a38551ff90ad"
      unitRef="usd">-11231000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i293a1a6091d64b118aef6ec8a2d2167a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzgtNy0xLTEtMzgwNDE_b0d2d0d1-bb01-45a0-805b-0d3ebf2389bf"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzgtMTctMS0xLTM4MDQx_7df38469-bbd6-4e82-9074-73efeabadd14"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i130e14f026354ba2b836575ebd10bdd2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktOS0xLTEtMzgwNDE_9df9039e-11c7-4f7d-b421-cd72c198d230"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzktMTctMS0xLTM4MDQx_73dc386d-4542-49af-9072-716e38f76cc1"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i621d358e78ed4fc2bd3ecd3b820db708_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTEtMS0xLTM4MDQx_fb028bbf-4e7c-4762-bc16-bf5262cbcac9"
      unitRef="shares">91588000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i621d358e78ed4fc2bd3ecd3b820db708_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTMtMS0xLTM4MDQx_dab139c9-7be1-44d8-beb7-5f4991f1097e"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1cbb67f86274231b6621e78983d84df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTUtMS0xLTM4MDQx_c3c3151b-b249-4821-856b-270319e66bcd"
      unitRef="usd">1224250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69e23962c75c49019909c9715c2499c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTctMS0xLTM4MDQx_3bfb9ddf-8280-4eae-98b6-70d44a1a22b2"
      unitRef="usd">-494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if7eb4df9b7ed4bb382872f97fdb6a757_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTktMS0xLTM4MDQx_51965bc9-2550-452b-84e9-48dc0b1ca321"
      unitRef="usd">-592340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc124f8ebb2b48dca7de861265b1df9f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTExLTEtMS0zODA0MQ_1dd7cc61-c3fd-4d24-b8d7-8f6e1f107dc8"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzExLTE3LTEtMS0zODA0MQ_75f72642-9b02-46ef-9092-a777fcbfb6c9"
      unitRef="usd">611209000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i3be7adf261ff427c874251aacfa02b7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTEtMS0xLTM4MDQx_d08bfbd8-8f62-43ce-8241-a4774aafe151"
      unitRef="shares">85895000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3be7adf261ff427c874251aacfa02b7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTMtMS0xLTM4MDQx_31176015-1310-4275-bd87-6d92753e0382"
      unitRef="usd">859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ef9a57b91634689a5fc4d94fc39cc92_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTUtMS0xLTM4MDQx_b229ce12-7173-4560-9b80-42cdd01f204e"
      unitRef="usd">1229320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id44432f28d3a4aecb8eb5918685f3019_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTctMS0xLTM4MDQx_f2ab0b9f-debc-4516-9991-962a4be1be52"
      unitRef="usd">-278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cd7879f349a4bfb9adf1f4b67cb4d3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTktMS0xLTM4MDQx_d1df15bc-7e30-4570-aeec-916c5b347c9d"
      unitRef="usd">-589178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb90b06b13ac482cb1469d573d0ac107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTExLTEtMS0zODA0MQ_705446de-4110-47a6-a1e5-896a09253c66"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzE3LTE3LTEtMS0zODA0MQ_3c81da30-e1bf-4daf-b14e-5afaf979ea16"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i059aea63706f40babf4ad42f721269d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIwLTUtMS0xLTM4MDQx_d8b7a8f0-0ae1-4dfe-aca6-2023b45dddb0"
      unitRef="usd">3706000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIwLTE3LTEtMS0zODA0MQ_b251ead4-6c84-4eed-b9bd-ca7f14135c0e"
      unitRef="usd">3706000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTEtMS0xLTM4MDQx_8df048d2-663a-4424-b19b-faac99fdcc47"
      unitRef="shares">594000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTMtMS0xLTM4MDQx_387cef87-1fc0-4bec-9c33-9ea22493344f"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i059aea63706f40babf4ad42f721269d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTUtMS0xLTM4MDQx_275ced5f-e304-4e21-8b3b-7de4a2c4d0cd"
      unitRef="usd">6512000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIxLTE3LTEtMS0zODA0MQ_85f052e9-df02-4db6-890f-a459da13b262"
      unitRef="usd">6518000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTEtMS0xLTM4MDQx_590defce-80dc-4e25-9b8a-47d6aec7e284"
      unitRef="shares">290000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i0d0c36fb7e4f49d9b02f807397467edb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTMtMS0xLTM4MDQx_837c0075-8d93-461e-a4e3-c85acbdfcf20"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i059aea63706f40babf4ad42f721269d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTUtMS0xLTM4MDQx_d445d24e-db8b-453b-aa55-2ee13ebd327e"
      unitRef="usd">-2691000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzIyLTE3LTEtMS0zODA0MQ_702f8d17-1b21-4262-998c-f499d57a5589"
      unitRef="usd">-2688000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id145101f6b47482c8c8b1e64aec732ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI3LTctMS0xLTM4MDQx_309e4e75-28da-4315-bd68-8192ceba1ad0"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI3LTE3LTEtMS0zODA0MQ_df49a521-9b85-49fe-9228-2fccb7f6794b"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i924e8357dfb2454f86c7f8d0fd74a114_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI5LTktMS0xLTM4MDQx_d3d3737c-e444-408c-8a52-8dc395ed5a23"
      unitRef="usd">-9807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzI5LTE3LTEtMS0zODA0MQ_401d4383-3c77-4872-b784-20294f0b6ae4"
      unitRef="usd">-9807000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0cbe563905aa492187f4514b1c567124_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTEtMS0xLTM4MDQx_8a3ec736-930b-4f72-8859-72110c1e13c3"
      unitRef="shares">86779000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0cbe563905aa492187f4514b1c567124_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTMtMS0xLTM4MDQx_e4562f9a-2c6c-463b-84e8-c40340c33b62"
      unitRef="usd">868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i172d29d14aac4caf8b3c3650d9877ed2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTUtMS0xLTM4MDQx_1a36b272-448f-4a19-a3ff-3c779856295c"
      unitRef="usd">1236847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc68586f685749a588829914e464480b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTctMS0xLTM4MDQx_6dceae8e-1809-4951-8024-67a31266010f"
      unitRef="usd">-309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6db922f783fb432da34f684d3de92b24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTktMS0xLTM4MDQx_8494a955-646d-4020-ab6c-bdab253499dc"
      unitRef="usd">-598985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62e1ee4ac4ec44e681da4653910c6586_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTExLTEtMS0zODA0MQ_ba00a895-494f-4e27-82d0-d5ca70abf0ef"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNzQvZnJhZzoxZDc4ZjM1OWU1Nzc0Njk3YTJlMDU3MDgwZGFmYzk2MS90YWJsZTplMjFlYzU0NDU2YzI0ZjRjODAyMDg3YTVkNTBmY2JkOC90YWJsZXJhbmdlOmUyMWVjNTQ0NTZjMjRmNGM4MDIwODdhNWQ1MGZjYmQ4XzMxLTE3LTEtMS0zODA0MQ_78ba85e8-f284-4635-bf68-65aeeea2cb8a"
      unitRef="usd">617298000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMtMS0xLTEtMzgwNDE_821a6a12-9e2c-46e1-9783-40974d0e23ae"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMtMy0xLTEtMzgwNDE_18d05de4-3983-4a6d-9153-7a95aecad4ff"
      unitRef="usd">-9807000</us-gaap:NetIncomeLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUtMS0xLTEtMzgwNDE_e6d1a916-60aa-48fb-99da-385547d915ba"
      unitRef="usd">6078000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUtMy0xLTEtMzgwNDE_4988f072-82b4-4824-b121-27e1a41a8afc"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYtMS0xLTEtMzgwNDE_8dbdd63f-b70b-40ba-9694-a635aa5ed217"
      unitRef="usd">0</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYtMy0xLTEtMzgwNDE_543c410c-f517-4357-9829-75ab776c26b4"
      unitRef="usd">1904000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzctMS0xLTEtMzgwNDE_6ee2e3ad-44e6-4127-a75d-1635fc7e9cab"
      unitRef="usd">596000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzctMy0xLTEtMzgwNDE_edf1e839-d9be-40a1-9938-2f89fd55334a"
      unitRef="usd">7783000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMS0xLTEtNDY2MDU_8d90ede9-3d3f-486d-b944-637194cd2594"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMy0xLTEtNDY2MDU_0b608ad8-7a4d-47f9-9444-f7a5ba7c9479"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMS0xLTEtMzgwNDE_1cb9ed4f-805d-4e7c-9c93-195bed2050d0"
      unitRef="usd">15106000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzgtMy0xLTEtMzgwNDE_b86d1102-d718-4e60-83d9-f8e6bb723ea0"
      unitRef="usd">15347000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEwLTEtMS0xLTM4MDQx_6f526aa4-0084-4d6c-b71a-3fdf8bd88c8b"
      unitRef="usd">5346000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEwLTMtMS0xLTM4MDQx_8c48c698-4ed9-4c50-8e43-b7f04fe5004d"
      unitRef="usd">3706000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzExLTEtMS0xLTM4MDQx_3518321a-e873-4001-88fb-95160815222e"
      unitRef="usd">-132000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzExLTMtMS0xLTM4MDQx_3277c118-5cbb-4c97-9b90-08096bcfe8d1"
      unitRef="usd">-59000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEyLTEtMS0xLTM4MDQx_48a2f275-8785-403e-8afc-8a75d4c0077f"
      unitRef="usd">11689000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEyLTMtMS0xLTM4MDQx_ce172b68-1079-4096-9d1e-0879ddedacbc"
      unitRef="usd">3055000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEzLTEtMS0xLTM4MDQx_ab1c9d74-abe0-4914-9e40-117e9cccef51"
      unitRef="usd">539000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzEzLTMtMS0xLTM4MDQx_41c6eb47-97b6-4792-9c07-824e1cf329bc"
      unitRef="usd">4370000</us-gaap:AmortizationOfFinancingCosts>
    <evh:GainOnTransferOfMembership
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE1LTEtMS0xLTM4MDQx_216b5e7d-4d8d-4cec-b4d2-589d6e501a07"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE1LTMtMS0xLTM4MDQx_e70dd052-86d6-4be0-ae14-27202eb2b2a4"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE3LTEtMS0xLTM4MDQx_b96d893f-05cd-4798-adc6-77e701895ebc"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE3LTMtMS0xLTM4MDQx_a3d9eb84-08ce-4dd5-a26d-7d2403546c98"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE4LTEtMS0xLTM4MDQx_f994a1e3-088f-476c-a212-dd51a0db7a04"
      unitRef="usd">357000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzE4LTMtMS0xLTM4MDQx_4ea4433d-f327-4e67-8ab0-e1d0c751a1b2"
      unitRef="usd">-2341000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIwLTEtMS0xLTM4MDQx_7c91db59-c2f0-483d-970e-54d6bd10a7fb"
      unitRef="usd">46299000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIwLTMtMS0xLTM4MDQx_33c87f60-f478-4752-ae78-6021a3d88bae"
      unitRef="usd">63233000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIxLTEtMS0xLTM4MDQx_debfb735-fa62-40cc-b23d-78addd766597"
      unitRef="usd">6071000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIxLTMtMS0xLTM4MDQx_f99787a1-00c6-4b0b-942f-53c7c477e682"
      unitRef="usd">-1037000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIyLTEtMS0xLTM4MDQx_f66bface-b970-44d5-84bf-72b49cb0955e"
      unitRef="usd">1106000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIyLTMtMS0xLTM4MDQx_ee9bfedd-348a-430d-a56a-3d3224150a4f"
      unitRef="usd">1690000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIzLTEtMS0xLTM4MDQx_9f079f59-4b00-4405-87a3-536320870727"
      unitRef="usd">426000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzIzLTMtMS0xLTM4MDQx_88e18232-93b0-4882-a804-efeacdf66745"
      unitRef="usd">9395000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI0LTEtMS0xLTM4MDQx_47e1133d-72a9-46a6-851e-5ff1dfc9f767"
      unitRef="usd">2220000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI0LTMtMS0xLTM4MDQx_06202b71-2fc2-458a-b62a-24ba22cd1be2"
      unitRef="usd">-9698000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI1LTEtMS0xLTM4MDQx_3eda37a9-999e-466e-9e5f-b58058a9faa7"
      unitRef="usd">-32435000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI1LTMtMS0xLTM4MDQx_0f3e7d17-8a62-4f52-84a5-2f1bb370963a"
      unitRef="usd">-28014000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI2LTEtMS0xLTM4MDQx_25ef9798-2c66-414d-850b-2aea444eef28"
      unitRef="usd">1344000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI2LTMtMS0xLTM4MDQx_1a65d362-2098-4a67-8354-5fb9694aeb86"
      unitRef="usd">2684000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI3LTEtMS0xLTM4MDQx_3d126dba-263f-4590-add3-c35c85a127d5"
      unitRef="usd">-7056000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI3LTMtMS0xLTM4MDQx_35a379f8-2599-48ad-b85c-8d68159bd8e7"
      unitRef="usd">32501000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI4LTEtMS0xLTM4MDQx_346457e9-f47b-485e-ac82-8d83b40bb460"
      unitRef="usd">-1718000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI4LTMtMS0xLTM4MDQx_8055c30a-3669-4f6e-ae4b-9a3ebbaf89cf"
      unitRef="usd">-2840000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI5LTEtMS0xLTM4MDQx_e2303a10-1541-4759-9b8b-b09f12d66c05"
      unitRef="usd">-1992000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzI5LTMtMS0xLTM4MDQx_4b7f8d79-0fd6-48c1-a0b4-28966ad4ccf4"
      unitRef="usd">-771000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMwLTEtMS0xLTM4MDQx_47d0801f-68ff-414d-8866-1416a4764038"
      unitRef="usd">-514000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMwLTMtMS0xLTM4MDQx_6bd51faf-7e0b-425c-81ac-84ba8c594ba7"
      unitRef="usd">1925000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMxLTEtMS0xLTM4MDQx_76641571-35fb-4bb0-be26-58d74c90bc7b"
      unitRef="usd">-57442000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMxLTMtMS0xLTM4MDQx_7f3abf4b-419c-425a-b908-bafa70acb84a"
      unitRef="usd">-48163000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMzLTEtMS0xLTM4MDQx_ee5c1a41-4435-40ed-aa6c-0b5e464c7321"
      unitRef="usd">70000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzMzLTMtMS0xLTM4MDQx_de255977-7bad-459f-965a-713856a029b0"
      unitRef="usd">1472000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM0LTEtMS0xLTM4MDQx_b4f6147e-c878-40d4-9f38-9b18e846da7e"
      unitRef="usd">22969000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM0LTMtMS0xLTM4MDQx_a4fa6526-80da-4399-9550-338e16eedfa4"
      unitRef="usd">42996000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM2LTEtMS0xLTM4MDQx_dbc47b0c-bba3-4baa-8d86-b2a8871a9e1a"
      unitRef="usd">0</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM2LTMtMS0xLTM4MDQx_758dc843-8df0-447d-8480-258f94677314"
      unitRef="usd">-3490000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM3LTEtMS0xLTM4MDQx_1d52c5db-fcbb-4b8e-88b1-4ea25f324354"
      unitRef="usd">2375000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzM3LTMtMS0xLTM4MDQx_9ef2f001-4561-43fd-9a6a-40f124af7b18"
      unitRef="usd">9372000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQxLTEtMS0xLTM4MDQx_fab48fb9-6866-4ba7-bce3-804e85cdcefa"
      unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQxLTMtMS0xLTM4MDQx_74c4adc7-76bd-4456-9f67-de33238be445"
      unitRef="usd">2994000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQyLTEtMS0xLTM4MDQx_3a53737f-c87a-4e89-bd3d-500a93345aea"
      unitRef="usd">0</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQyLTMtMS0xLTM4MDQx_66c00d50-8315-46ef-8fc5-507cc4fc0dcf"
      unitRef="usd">500000</evh:ProceedsFromMaturityOfInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQzLTEtMS0xLTM4MDQx_2b5deec2-e59e-4359-a62a-326db0ca1806"
      unitRef="usd">8508000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQzLTMtMS0xLTM4MDQx_c0b53325-1c59-4aa2-aa1b-9e2efda0a6a1"
      unitRef="usd">5941000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ1LTEtMS0xLTM4MDQx_6bc62432-7bd7-415c-9050-97721da9cf85"
      unitRef="usd">16766000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ1LTMtMS0xLTM4MDQx_82bab799-715f-40ec-9ce2-a659ff59c041"
      unitRef="usd">45951000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ3LTEtMS0xLTM4MDQx_12dc0bdb-f521-4a9c-9656-8bc7ad46c4d9"
      unitRef="usd">34371000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ3LTMtMS0xLTM4MDQx_feea45c4-6cbd-4c7f-b298-b9b307d02137"
      unitRef="usd">-39005000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ5LTEtMS0xLTM4MDQx_aa1c1571-256f-4733-96e8-943085700bc4"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzQ5LTMtMS0xLTM4MDQx_6ed21f59-2bdc-4dca-9f94-98515766f755"
      unitRef="usd">98420000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUzLTEtMS0xLTM4MDQx_a7458769-b4fd-45ca-b5ab-4fbebc86b8af"
      unitRef="usd">309000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzUzLTMtMS0xLTM4MDQx_e447279f-c767-4de3-a11d-b3196731f909"
      unitRef="usd">6518000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU0LTEtMS0xLTM4MDQx_f38796ae-4c00-4b50-b43e-17feeabe74fb"
      unitRef="usd">1100000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU0LTMtMS0xLTM4MDQx_c595338a-7c00-4818-966b-31400fde10e9"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU1LTEtMS0xLTM4MDQx_ec450b76-4389-49b8-9605-98e10c78f6a0"
      unitRef="usd">16214000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU1LTMtMS0xLTM4MDQx_5df6a3f9-1689-4bc0-8cc8-587795ae724d"
      unitRef="usd">2687000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU2LTEtMS0xLTM4MDQx_4c71b5f6-461b-4c49-a707-f848a088f980"
      unitRef="usd">-51376000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU2LTMtMS0xLTM4MDQx_7db3902b-58f5-4c4d-b846-919f66af71bd"
      unitRef="usd">-55584000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU3LTEtMS0xLTM4MDQx_6946f6b6-49ec-4a53-9c9c-72a0109b945d"
      unitRef="usd">-104000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU3LTMtMS0xLTM4MDQx_d0d6a118-b1c9-4f97-927c-b869100f9c2a"
      unitRef="usd">1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU4LTEtMS0xLTM4MDQx_668e4ed7-f764-4042-b971-203136eef524"
      unitRef="usd">-92156000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU4LTMtMS0xLTM4MDQx_beabbeb6-f8e9-46a3-98c4-a2dce3c29ac0"
      unitRef="usd">-57795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTEtMS0xLTM4MDQx_32c854fb-e4a9-4b6e-b7c4-d48591ef4ca9"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTMtMS0xLTM4MDQx_6fd0a3a8-040f-462e-b385-4744c51aa458"
      unitRef="usd">361564000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTEtMS0xLTM4MDQx_c7c39c63-a8f0-40c0-9113-19cd02f14912"
      unitRef="usd">262786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTMtMS0xLTM4MDQx_c943eec5-0a37-4672-8c00-04b3abf2821c"
      unitRef="usd">303769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTUvZnJhZzozZDYxNzQwZGMyNTM0ZDNmYTRkZDdjNTM0YjNmOWYwZC90ZXh0cmVnaW9uOjNkNjE3NDBkYzI1MzRkM2ZhNGRkN2M1MzRiM2Y5ZjBkXzE4MjY_18fe2fbf-d578-4303-b260-0437cd2f4732">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has incurred losses from operations. As of March&#160;31, 2022, the Company had unrestricted cash and cash equivalents of $210.2 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTUvZnJhZzozZDYxNzQwZGMyNTM0ZDNmYTRkZDdjNTM0YjNmOWYwZC90ZXh0cmVnaW9uOjNkNjE3NDBkYzI1MzRkM2ZhNGRkN2M1MzRiM2Y5ZjBkXzUzMA_b54b7fc6-2dad-46bc-98d8-751477ee6348"
      unitRef="usd">210200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTI4_12b3b727-764c-4fe8-9e76-0a13fa6e782e">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#x201c;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#x201d; in our 2021 Form 10-K for a complete summary of our significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March&#160;31, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $4.1&#160;million and $3.4&#160;million for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of March&#160;31, 2022 and December&#160;31, 2021, approximately 35% and 42% of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2022, approximately 39% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;See Note 6 for further discussion of our policies related to revenue recognition.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTI1_622b64ee-e892-415b-9faf-9fc38d0cb8d5">Basis of PresentationIn our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTY5_420f5c57-a6f2-45bf-8364-291f34b63959">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQ5NDc4MDIzNzA1NjQ_5c26909d-7cd3-4bda-93e9-29109f8d59ab">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTQx_34bdc171-630e-4ae8-be1d-fabb76c0d964">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTQz_875d9a40-c123-46cc-8b9f-eb23bd838bce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March&#160;31, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i644591fb6cc54e2096aefb6d12c9ee6d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzItMS0xLTEtMzgwNDE_eb239c37-8caa-4158-86fa-9d816c7e5c27"
      unitRef="usd">2269000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia68b009330794ef1888c6d5fc3c5dfc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzItMy0xLTEtMzgwNDE_e3ec3ac5-7a81-4092-aeff-9f92ef9fc7e3"
      unitRef="usd">3769000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="icedde2203c2f4932b7525a1653f8a386_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzMtMS0xLTEtMzgwNDE_aaa352d5-3ed7-43c9-b132-2bd633de436f"
      unitRef="usd">11499000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibff05ae2c51c48e6afd4afc199a1aa71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzMtMy0xLTEtMzgwNDE_50dfdaf4-9c82-4e9b-a9a5-138e4c5d19fe"
      unitRef="usd">11662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib729f13217c547b98e74d1bafa5ea4c9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzQtMS0xLTEtMzgwNDE_8ce5294f-9e91-4781-b6e5-90f9bd8e1aff"
      unitRef="usd">38855000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i4114c1a397b94102bce6ff2aa93691c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzQtMy0xLTEtMzgwNDE_4e3b6443-8984-4c56-9243-282a875b73b5"
      unitRef="usd">73226000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i746c3c635d6c45f5b87aefae016c4fb4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzUtMS0xLTEtMzgwNDE_511653bb-689b-493b-bd11-21b9cf6be49a"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i46ea15c7c5084899ae3932a21f7bcb6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzUtMy0xLTEtMzgwNDE_533c78cb-b35c-4d45-a00e-168d770a4143"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzYtMS0xLTEtMzgwNDE_db111ec5-cec2-4f3e-a859-7006cc696b7a"
      unitRef="usd">52628000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzYtMy0xLTEtMzgwNDE_01727218-7530-46d4-8e3d-109f8e04e52a"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzgtMS0xLTEtMzgwNDE_c5f7aa4c-5958-4293-9f92-95cab7c7cca1"
      unitRef="usd">39647000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzgtMy0xLTEtMzgwNDE_173d9752-8b8b-4dd2-adef-f22cd5a6d1c0"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzktMS0xLTEtMzgwNDE_284798e0-d064-4c0d-956d-c18804a76ebb"
      unitRef="usd">39647000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzktMy0xLTEtMzgwNDE_3a59ed05-d8b3-4a9e-a5e6-62ab3f6d2080"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzExLTEtMS0xLTM4MDQx_8dfffa29-e626-4d7b-a701-0431e479bca7"
      unitRef="usd">12981000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzExLTMtMS0xLTM4MDQx_75664d35-7b11-4a82-afd9-5b38ad787b56"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzEyLTEtMS0xLTM4MDQx_358601ec-e4bb-4009-a222-0bcee01b08d6"
      unitRef="usd">12981000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkN2M1NWM5OTg1MDE0YmY1OGU0ZDAxNzUwOWVlNWM1My90YWJsZXJhbmdlOmQ3YzU1Yzk5ODUwMTRiZjU4ZTRkMDE3NTA5ZWU1YzUzXzEyLTMtMS0xLTM4MDQx_8f822718-8e52-4c9c-91f9-c30eeda5ba34"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib82aee0d988d44d9af8cac23744c8699_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQyMDQ_48b1916c-d71a-42aa-8f73-7a7f50d9d722"
      unitRef="usd">11500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3f2b71e551c243ae81adfe5562d1b7c2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQyMTE_21f9e1b4-3caa-48d8-b2cd-4c081cfd2bde"
      unitRef="usd">11700000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQ5NDc4MDIzNzA2MDY_e67df718-d620-48c7-819b-1f9956187427">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzItMS0xLTEtMzgwNDE_5f8bf9e6-c84e-4b79-be19-be4005a743b4"
      unitRef="usd">210158000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzItMy0xLTEtMzgwNDE_ad144810-123b-43df-8a28-be2ec8b185c1"
      unitRef="usd">236032000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzMtMS0xLTEtMzgwNDE_bcbf2452-2549-4113-a046-245acc59059c"
      unitRef="usd">52628000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzMtMy0xLTEtMzgwNDE_0826400a-a064-41f4-aa39-7762abf26a3e"
      unitRef="usd">67737000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzQtMS0xLTEtMzgwNDE_2bf1da2a-dece-4a21-95bf-3a35d4c4bd36"
      unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzQtMy0xLTEtMzgwNDE_83d6755f-834e-4492-8cbf-14980076645a"
      unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzUtMS0xLTEtMzgwNDE_18694352-6875-4a4b-b641-a8d647f87feb"
      unitRef="usd">262786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTpkMTY1OGZmOTNkNWE0MWIzYjdiYTc5YTIxMGFmOWUwOS90YWJsZXJhbmdlOmQxNjU4ZmY5M2Q1YTQxYjNiN2JhNzlhMjEwYWY5ZTA5XzUtMy0xLTEtMzgwNDE_e1b998b9-c7f4-4a31-9810-ae5a0b8fdcd7"
      unitRef="usd">303769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTkx_d1ee08ae-beed-439a-91da-3074d5ed3b17">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTc3_6eafbade-5c0f-4dd8-a0b8-926a2dc99b72">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzEzNjAx_0af6db66-7f41-4ec4-b5d9-d4a3812ed8b1"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTMz_f97e7e2e-324a-490d-b97a-3508fe165566">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTg0_d14a9319-87d7-4d6f-879c-b948469af0e1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of March&#160;31, 2022 and December&#160;31, 2021  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icead5b03e4c6480db192188178d18afe_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzAtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNGNiMDQ0YjUyMGE0ZWVjYTE2NTI0MzVkMzkzMGE0OV80_e8731da5-b17e-4fee-b7fb-7b0f5b80f2fe">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i136d025dfa994cc69d43c0b193565b0a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzAtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNGNiMDQ0YjUyMGE0ZWVjYTE2NTI0MzVkMzkzMGE0OV85_67bc5930-94dd-455b-be63-523b0906702a">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2cdd074577da4a56beeac98f792d2af1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzEtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjpmZGJlNGRlOWM5ODY0MDc0ODA3OTYxODgyZjBlYWUyYl80_8c232509-255b-4071-8b21-a8e2cf7e5b5f">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idf4153f331bc4c5ba00b95d8e87a52dd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzEtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjpmZGJlNGRlOWM5ODY0MDc0ODA3OTYxODgyZjBlYWUyYl85_0c98cd7e-3544-4c53-8183-f699303c1f84">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i532067d6f1ec4a09974e220c6f9d2b9f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzItMS0xLTEtMzgwNDE_0de36afc-be7e-4b5e-b519-0544e9566cd6">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1244aeda3f374cbdb7295a1b9720eaca_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzMtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNmNkMDlhYzUyZmU0NzVhODJiYjUyN2YzMjU2N2QwMF80_cd2f29de-57c5-439c-a5f8-27c083817f57">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idcd76d84c4874414b5b69662bb989fcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90YWJsZTo5NWJiNjViOTUyY2E0NGNjOWU4YjBkY2MxNDE0MWQ3Ny90YWJsZXJhbmdlOjk1YmI2NWI5NTJjYTQ0Y2M5ZThiMGRjYzE0MTQxZDc3XzMtMS0xLTEtMzgwNDEvdGV4dHJlZ2lvbjphNmNkMDlhYzUyZmU0NzVhODJiYjUyN2YzMjU2N2QwMF85_454f15d1-0951-469b-b4df-3a7cbbdf96a7">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzQ5NDc4MDIzNzE1NjE_3e059319-d5ae-478c-9847-290b1be4abf5">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss)</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE2NDkyNjc0ODgxMDA_073e4071-a37c-4202-b8d6-b457f1a5d029"
      unitRef="usd">4100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE2NDkyNjc0ODgxMTQ_aae813ab-65d1-43ca-873a-1608b61cca01"
      unitRef="usd">3400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTk2_4723dce7-40a6-4a78-b5f2-05141f76ff9d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that &lt;/span&gt;&lt;/div&gt;have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</us-gaap:LiabilityReserveEstimatePolicy>
    <evh:RightOfOffsetPolicyPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTM0_2f12713b-495b-42dd-a2ee-7bb23bd506d4">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</evh:RightOfOffsetPolicyPolicyTextBlock>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE3NzAw_98c681e5-f4f0-4fa2-a25d-7574bc531a8b"
      unitRef="number">0.35</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE3NzA3_54e9706f-7330-43ba-9f33-7af0d1d4e3d0"
      unitRef="number">0.42</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzE3ODMy_7361dda1-e5d8-4cc1-82d9-337a7707bf47"
      unitRef="number">0.39</evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTg2_911e64b6-ce73-43f8-bfed-ea68bf6aa7aa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMTgvZnJhZzo4MzkzOTMzZDZmMGI0YjIzYjgzMDQwYjIyOTJhMTNhOS90ZXh0cmVnaW9uOjgzOTM5MzNkNmYwYjRiMjNiODMwNDBiMjI5MmExM2E5XzI3OTk3_b2f816f0-43e0-4e70-a991-e0ba60ba425e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzQ5MTE_d7cc7ff6-78cb-4c81-bfae-6dcdc85c8b34">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzQ5MTg_041ce27e-3cd2-4c4b-9c28-f483c5ef244e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="iae5bc002399c42d7a0dfe095133c2eea_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTUzODc_0040db08-574b-4bec-8e23-e53e50298442"
      unitRef="usd">39800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffd02a268c2f44e1b4b8a87043e3237b_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTUzNzE_cb1ea1f0-1fea-4cf7-8b6f-f3d05ed77607"
      unitRef="usd">106200000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i4fed4b10d9a94e43b4a7376d75e82ef5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTU0MDI_ed8dc5cd-cc9f-40c0-ab23-37294662d887"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i50dcc4c9e90649d88b6e4ebba21ccd70_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjEvZnJhZzo5ZDk4ZDhiNzg3MDQ0ZDMxYjRkNmEzZTU5M2U1YWNmNi90ZXh0cmVnaW9uOjlkOThkOGI3ODcwNDRkMzFiNGQ2YTNlNTkzZTVhY2Y2XzE2NDkyNjc0NTU0MTc_9632c727-cfe9-4c2b-9b72-1f4e614cea71"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwODE0_7898e5e4-23d9-4e28-97ae-ecde2e46e7d5">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vital Decisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach  end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized by the end of the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE1Ng_206c4b9c-0e6d-4a35-9b1a-12f59cbace29"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzcxNw_dd3bc47e-d03b-43e9-9b9f-c82b19d704a0"
      unitRef="usd">117700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3Xzg1Ng_3476e2ce-4303-4eea-9104-f8a31b810a66"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3Xzg4Mg_75c137dd-a1eb-44b9-a16b-cf6d8e312664"
      unitRef="shares">1800000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzkzMg_b35682ac-5917-454f-8718-38f1afb719ea"
      unitRef="usd">56600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3Xzk4Mw_d2d1e341-b3e2-44e1-97c8-cfd1ffd9611f"
      unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwMDI_e521b31f-8264-4a0d-8cbe-714b2112426f"
      unitRef="usd">14600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwODEx_29c90a2a-6046-4dbf-94c6-c3bdb66f6a61">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzEwODA2_ae9df10d-c6db-4a8e-b672-944029aca69a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzEtMS0xLTEtMzgwNDE_06ae427f-f8b2-4983-be91-5a7f99340401"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzItMS0xLTEtMzgwNDE_d2fdb66d-05a9-446f-af5f-c7f0cfeb741c"
      unitRef="usd">56626000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzMtMS0xLTEtMzgwNDE_db6160e9-465b-42cc-9c33-418a9a4968e9"
      unitRef="usd">14600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6f95a90340674372bb24519a80cf8b18_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzQtMS0xLTEtMzgwNDE_5a0dadc3-58d3-468c-b138-ec2e991b83a3"
      unitRef="usd">117726000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzctMS0xLTEtMzgwNDE_09758a06-d78a-43ee-8f6b-ecc0d14cfbb5"
      unitRef="usd">1430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzgtMS0xLTEtMzgwNDE_cf3b800f-97e4-4715-8519-d7b2c4160137"
      unitRef="usd">3301000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzktMS0xLTEtMzgwNDE_24380fe5-b65d-452a-89a1-2a65787043cb"
      unitRef="usd">78000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzEwLTEtMS0xLTM4MDQx_280d4bc6-a4da-4c0a-93f1-4498eea81222"
      unitRef="usd">2564000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzExLTEtMS0xLTM4MDQx_ac4ab145-f5df-44cc-9fcd-9b9afb9466d6"
      unitRef="usd">7373000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i486cd92f52f9444ea10b825521601fd1_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE0LTEtMS0xLTM4MDQx_185a9028-d158-408e-b1c7-37f3f15f3d83"
      unitRef="usd">32500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i5d8f0394dcea4227a602bc9f7748104e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE1LTEtMS0xLTM4MDQx_dd7d79da-635d-4977-9945-4ae3ec167daa"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id0dedbe6375f4957bda96aaf161bdfa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE2LTEtMS0xLTM4MDQx_36a9e0ff-1462-46bc-82b9-3424e9e14975"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzE3LTEtMS0xLTM4MDQx_01d0daa7-1d52-4588-be3b-d41397908681"
      unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIwLTEtMS0xLTM4MDQx_92e7565a-6b47-4e4f-967b-07a1e1e980ba"
      unitRef="usd">93000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIxLTEtMS0xLTM4MDQx_3bc19c7b-46c6-42e6-9dfa-1c47c41e996d"
      unitRef="usd">661000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIyLTEtMS0xLTM4MDQx_e4a1ca35-9afe-4398-86d9-095537ec5d54"
      unitRef="usd">970000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzIzLTEtMS0xLTM4MDQx_ad97ea23-72d0-4c50-b21e-c4e6b8cce2f7"
      unitRef="usd">499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI0LTEtMS0xLTM4MDQx_c43b6da4-691e-4c15-a2e6-829f69816b19"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI1LTEtMS0xLTM4MDQx_cccd7353-a7e4-4464-91bd-e7c06d4e4cfc"
      unitRef="usd">2712000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI2LTEtMS0xLTM4MDQx_497426c7-6a4a-4cf5-af1f-cc8515dcabb2"
      unitRef="usd">6935000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI4LTEtMS0xLTM4MDQx_eac05443-9107-4f0f-9bbc-cbbf9c191844"
      unitRef="usd">77288000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90YWJsZTo4MjNjZDE2YzJmMTY0MmJlYWRhOTc1NmRlNWQ2NWIzNy90YWJsZXJhbmdlOjgyM2NkMTZjMmYxNjQyYmVhZGE5NzU2ZGU1ZDY1YjM3XzI5LTEtMS0xLTM4MDQx_28e8da31-0677-42d5-9fd7-bb296fe32f96"
      unitRef="usd">117726000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i78f19f381f38447c990722124282e3f6_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE2Njg_11f57119-cea1-4577-98ff-f1d7c8b61eb1">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic05ac80824ef4e7e9360568c9bffff1a_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE2NzI_f29a651b-59cc-4614-9309-97ff7eda0035">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6b184513547b435b881d4872ab81bc09_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzE2ODA_e25e3a58-072e-43c5-8c28-1956adb7351c">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i80ff05debabc497c8b7183be3cf47025_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjQvZnJhZzowOWRhZTU1MGEyMzE0MDdmOGM3YjlkOTZiYWY2MjkwNy90ZXh0cmVnaW9uOjA5ZGFlNTUwYTIzMTQwN2Y4YzdiOWQ5NmJhZjYyOTA3XzMxNDY_6a4668c2-3275-4ba0-b7a0-b0280e06db53"
      unitRef="usd">69600000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzI5OTU_64038fdf-2005-4fe8-8ed2-198766a29023">Discontinued OperationsOn January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#x201c;True Health SPA&#x201d;) with Bright Health Management, Inc. (&#x201c;Bright HealthCare&#x201d;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#x201c;True Health Closing&#x201d;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzI5OTY_d12e9bba-d07f-4b95-91d1-ec6267d84bf2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;Cash flows related to the True Health business during the three months ended March 31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if2a872109d774e4da481cebe223eff04_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzMtMS0xLTEtMzgwNDE_11fe2111-502d-4718-954f-be3f8f0cb51f"
      unitRef="usd">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6f6ec7aba15341f6b7511d0a09ecf92a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzQtMS0xLTEtMzgwNDE_a12d9e2b-7eeb-42ea-a774-dad6fed2b746"
      unitRef="usd">44795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzUtMS0xLTEtMzgwNDE_bad940bb-e728-4e43-9bb9-6671fe4cdd11"
      unitRef="usd">44833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzgtMS0xLTEtMzgwNDE_38c60e8c-4d2b-41b2-8448-85102a3f8c14"
      unitRef="usd">5885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzktMS0xLTEtMzgwNDE_4dd90c40-3013-43bc-a8fd-878b448c4b6d"
      unitRef="usd">33954000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzEwLTEtMS0xLTM4MDQx_2d91c46c-656d-473b-b249-327cdf8d287e"
      unitRef="usd">5764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzExLTEtMS0xLTM4MDQx_58770323-d274-4755-bde3-1f50831fc619"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzEyLTEtMS0xLTM4MDQx_0b7ec3f0-438b-4669-b4ac-54f4518737ae"
      unitRef="usd">45763000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzEzLTEtMS0xLTM4MDQx_c07c398d-e240-43d4-b7aa-f7beee09b233"
      unitRef="usd">-930000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE0LTEtMS0xLTM4MDQx_6120d51e-2650-4b54-9735-ab7e0abb2335"
      unitRef="usd">112000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE1LTEtMS0xLTM4MDQx_3eed60e4-a5d2-4486-abcd-b54dc61eef7c"
      unitRef="usd">4000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE2LTEtMS0xLTM4MDQx_daadcef0-28d9-443d-9dfe-08be9f793907"
      unitRef="usd">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE3LTEtMS0xLTM4MDQx_25a07fc7-a4c0-4e7b-a8a6-5989ad2072a0"
      unitRef="usd">-847000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE4LTEtMS0xLTM4MDQx_ef62478c-213c-4f32-ad17-71ba403256cf"
      unitRef="usd">-326000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZTozNWIyMjk3MTJiMDk0NDA2OGI2MGVmMGE1MjlmNTk1MC90YWJsZXJhbmdlOjM1YjIyOTcxMmIwOTQ0MDY4YjYwZWYwYTUyOWY1OTUwXzE5LTEtMS0xLTM4MDQx_b5352268-40d1-4838-8fcc-3312f4069e6f"
      unitRef="usd">-521000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i39a4593df2ed48e8bf26fb1a8734b8ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzE5NDA_963bfdd7-1ba0-4b57-ac25-7a248e2c2b9e"
      unitRef="usd">2800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i39a4593df2ed48e8bf26fb1a8734b8ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90ZXh0cmVnaW9uOmNhZjkwZTI5MjVlOTQ4Y2Q5MWRlZDU4MzQ2YzA5NjhkXzIzMzQ_41244551-7f7b-4366-91dc-96b0639a4f63"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZToxMzY0YTg5Y2MyNTQ0MjA3YWI2ZjQ2NmIzODZmODZkOS90YWJsZXJhbmdlOjEzNjRhODljYzI1NDQyMDdhYjZmNDY2YjM4NmY4NmQ5XzItMS0xLTEtMzgwNDE_5d7425a4-7f9f-4284-8efe-f31fa638c0c0"
      unitRef="usd">5002000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMjcvZnJhZzpjYWY5MGUyOTI1ZTk0OGNkOTFkZWQ1ODM0NmMwOTY4ZC90YWJsZToxMzY0YTg5Y2MyNTQ0MjA3YWI2ZjQ2NmIzODZmODZkOS90YWJsZXJhbmdlOjEzNjRhODljYzI1NDQyMDdhYjZmNDY2YjM4NmY4NmQ5XzMtMS0xLTEtMzgwNDE_700d6183-d065-4bb1-91b9-4029f80cf54b"
      unitRef="usd">-2494000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMzQ5_c307e95e-f166-476c-9ba7-83aaa0d917f2">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transformation Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Transformation revenue is 0.7% of total revenue for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Platform and Operations Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $162.0 million of transaction price to performance obligations that are unsatisfied as of March&#160;31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 37%, 64% and 84% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the three months ended March 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $26.5&#160;million for the three months ended March 31, 2022 due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2022 and December 31, 2021, the Company had $3.9 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of  $1.4 million and $0.4 million for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2022 and December 31, 2021, the Company had $18.1 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of  $10.3 million and $2.7 million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i26bf389c6898466eb63379d01aaa71b6_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzE2NDkyNjc0NTI2OTA_78ee783a-727c-4ef4-a3cf-b0f85bdfd26e"
      unitRef="number">0.007</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMzUw_260af21a-e046-470d-b6ae-3384845dfdd2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ec4532a4742433aba9506e85893885b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtMS0xLTEtMzgwNDE_4cac7cf0-9f27-46db-82e9-285adf044027"
      unitRef="usd">66914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fad50bce4e049c5b3abd06d2db91799_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtMy0xLTEtMzgwNDE_5554e550-bada-4050-9fce-e1bdedede235"
      unitRef="usd">60929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fc0c2e998684f5f950bf9b71a352797_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtNy0xLTEtMzgwNDE_6a8c4ea0-ada6-45d8-8336-8851be90a24b"
      unitRef="usd">63587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19591c0223f84cb39b25c549e7cf2367_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzMtOS0xLTEtMzgwNDE_5ee17177-f08f-469e-81a7-413368f9e954"
      unitRef="usd">43339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76f20417b0b048728508db43ea6e2e8a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtMS0xLTEtMzgwNDE_18b8e9bc-0f2a-4bcb-a345-8e66e395e28e"
      unitRef="usd">4833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7af0d9f0068a4ecaa4d353078136bc50_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtMy0xLTEtMzgwNDE_c604e914-d00b-4f15-aa7e-bff3ad671a15"
      unitRef="usd">8338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768d2ed3578749dd919d8c01b59a765f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtNy0xLTEtMzgwNDE_a5f8dadc-ce4b-4f68-8c90-b522ab439e31"
      unitRef="usd">99566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54489df7b34f4bc5bd3764871ee2bbd8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzQtOS0xLTEtMzgwNDE_997d763d-b522-4da4-bcf1-e5d0e32c0556"
      unitRef="usd">85783000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia45d563122eb4be993ee23f5113a8e5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtMS0xLTEtMzgwNDE_eae75511-18a3-476c-9843-64056bfc52d0"
      unitRef="usd">35111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i526505192a4f43d58f8618791a968597_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtMy0xLTEtMzgwNDE_1f7baa3d-0c20-4603-a78b-81dbd4777375"
      unitRef="usd">15571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d4c945d2ec44cc996bde7e53fc1298c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtNy0xLTEtMzgwNDE_d2e529d2-948c-4b70-8bdd-31aafce498d8"
      unitRef="usd">27046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i649f6202bc224593b15c50af0d75b73c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzUtOS0xLTEtMzgwNDE_346b051b-126b-40ae-a29c-4891749e79cb"
      unitRef="usd">1111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtMS0xLTEtMzgwNDE_5ffa4604-2b53-4a88-a0bc-4c966194123a"
      unitRef="usd">106858000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtMy0xLTEtMzgwNDE_221e44db-2fba-42a7-8a23-02d8dbe473e9"
      unitRef="usd">84838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtNy0xLTEtMzgwNDE_d3f5822e-2af8-4991-9fe4-b04849eca2af"
      unitRef="usd">190199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTozMjEwYjZhYmMzYTg0ZmM5OWRmNmMzYTQyZTRlOGNmZi90YWJsZXJhbmdlOjMyMTBiNmFiYzNhODRmYzk5ZGY2YzNhNDJlNGU4Y2ZmXzYtOS0xLTEtMzgwNDE_9a712451-1d7e-4a68-9212-88809b9b784f"
      unitRef="usd">130233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzUxMTQ_5fc3fab6-aaa4-4eda-8fcc-bda9b9b351a4"
      unitRef="usd">162000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i5b0b219944a9403581d404035c8810ea_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzU3MzM_44dc41f1-6e06-48bb-8621-bf116b877426"
      unitRef="number">0.37</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i8940680e0d344f24a0605bc5abbeeab2_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzU3Mzc_0655ad80-a889-462e-87a2-e49b93314661"
      unitRef="number">0.64</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i4661a17748084b22847a6b4088c1f8c0_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzU3NDQ_bc1b33a4-ffb2-40d1-9c61-a45f6bf3b9e9"
      unitRef="number">0.84</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMzUy_062fc00c-295d-4a57-8e8c-699156f832fb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the three months ended March 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzItMS0xLTEtMzgwNDE_1d6d7b86-5981-45b5-8159-ba56ea142599"
      unitRef="usd">176300000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzItMy0xLTEtMzgwNDE_139c3f32-ea9b-4031-b23d-04968030ec51"
      unitRef="usd">129012000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzMtMS0xLTEtMzgwNDE_d3214735-ea4a-4ddc-9657-8fd33c5abf2a"
      unitRef="usd">4958000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzMtMy0xLTEtMzgwNDE_35d50cde-32a8-4737-8ac8-c71433df4648"
      unitRef="usd">4877000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzUtMS0xLTEtMzgwNDE_a63d7b9b-9620-49a9-973c-5b05d784e4fd"
      unitRef="usd">13288000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzUtMy0xLTEtMzgwNDE_5e513c37-32ba-459e-9b45-5d3948875be9"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzYtMS0xLTEtMzgwNDE_8a313f91-c2f0-4a05-8c9d-495b3fb2a7d3"
      unitRef="usd">4019000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZToyOThhMWIzNTlkOTQ0MmViOThhYzE3YzQzMTY5OGE0Ny90YWJsZXJhbmdlOjI5OGExYjM1OWQ5NDQyZWI5OGFjMTdjNDMxNjk4YTQ3XzYtMy0xLTEtMzgwNDE_15a850a5-7faa-4ff6-afbe-c8177fbb3b73"
      unitRef="usd">4437000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzEtMS0xLTEtMzgwNDE_551b572b-1be6-40eb-92ac-1456786edf5d"
      unitRef="usd">16381000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzItMS0xLTEtMzgwNDE_61e6eb95-82d9-43a4-ab8b-70fe9fd3dd44"
      unitRef="usd">10124000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzMtMS0xLTEtMzgwNDE_cbac8009-2210-4fe4-8289-836ecde047ae"
      unitRef="usd">11050000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90YWJsZTo2ZDRmYTU5MTQyYzM0YzAwOWY0ZjVkODI5Nzk3YjQxYy90YWJsZXJhbmdlOjZkNGZhNTkxNDJjMzRjMDA5ZjRmNWQ4Mjk3OTdiNDFjXzQtMS0xLTEtMzgwNDE_dbae582d-e209-48c5-817c-c1fc8428a5a8"
      unitRef="usd">17307000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzgwNjI_5d63562c-75cf-4e5a-a683-22085cfaa105"
      unitRef="usd">26500000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i0669761c388c4774877abc5d5d60ea1a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg3NjA_dee94c94-03d1-409e-8080-ff1221d25c20"
      unitRef="usd">3900000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i112e0050ecf247829efb6e3889c6f684_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg3Njc_74746879-40a3-4703-876d-f4dfbd20c95e"
      unitRef="usd">5200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i22dc575ff886464484317aca659befbb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg5ODI_efb9df2c-45c2-48e1-916e-591e28ac7f3f"
      unitRef="usd">1400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ie2526a6d68f44dd9a2d5c9c76f28f392_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzg5ODY_e968e9a2-7a84-4f53-aa47-c551201dfbd7"
      unitRef="usd">400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="if10ac0d0bbea4997a9ef4b8313c0f3d9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk3NzA_0a1dbbb4-2d46-4a93-ac96-b349f5913c92"
      unitRef="usd">18100000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i4101ecab0d224b7e94b0b16a3a6e2d35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk3Nzc_f58871a5-2f1d-48c1-8c84-f45fb9e7bda3"
      unitRef="usd">27400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i080f3a0bebf046f4b42c854af2f46b0b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk5OTE_af53a03d-5967-4e87-9140-5294a0a4a6a8"
      unitRef="usd">10300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i171aed87552d42e6b97ff67bc5456cba_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzk5OTU_5c5c76ea-91a9-4efb-b4ab-31f38c12ce84"
      unitRef="usd">2700000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzAvZnJhZzpmMTE3ZWYxMzAyZTA0ZjE5YTJjMTM2ZDg4MDM2N2RkMC90ZXh0cmVnaW9uOmYxMTdlZjEzMDJlMDRmMTlhMmMxMzZkODgwMzY3ZGQwXzEwMjM1_9cbb77ea-6d2c-47c8-8f93-fd321aadcac6">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzMxMjQ_2a5ecdd3-e5e5-4bd9-bfbf-1361a35a5635">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the three months ended March 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;March&#160;31, 2022,&#160;87% were current, 4%&#160;were past due less than 60 days, with 6% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;March&#160;31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$194.8 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$2.2 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the three months ended March 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzIzNTI_7e0c09a1-aa91-46e9-9c30-a69184161485"
      unitRef="number">0.87</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="iadbac2b94ee84dbaa1e6ae52b26777c8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzIzNjk_7ee5c0e8-17f2-48e1-9599-6fa70f009401"
      unitRef="number">0.04</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i7a483ad79bb04d958eac46a38e2f15c9_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI0MTA_c5f57b1d-35ae-474c-9aeb-eaa6560b74dc"
      unitRef="number">0.06</us-gaap:FinancingReceivablePercentPastDue1>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI0Njc_c1ec4aaf-6283-42b2-9d2b-812c3ba12dfa"
      unitRef="number">0.90</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i8804d1ca441342f88f29f050b52851ca_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI0ODQ_fb369e31-7ce4-44c2-af8a-d95d806f4823"
      unitRef="number">0.02</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="ice301424511e4396aff3b79bc7270a81_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI1MjU_8b8aa150-8160-48c0-91c2-80dc530bddcd"
      unitRef="number">0.03</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI2MzE_8e1c56bf-75b7-450b-869f-c24ca6085cbc"
      unitRef="usd">194800000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzI2Mzg_df75e1f2-d739-4f80-9abd-a4898de521f5"
      unitRef="usd">171500000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzQ5NDc4MDIzMjg2NTM_05f5ea4a-e8b3-43bd-9aba-d9d5f3793ff6"
      unitRef="usd">2200000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzQ5NDc4MDIzMjg2MzM_f3bc5f9f-4ea3-42d4-af66-c215c527e572"
      unitRef="usd">3400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90ZXh0cmVnaW9uOmE4YWVlZDA3MzY3YjQwODViMWM4MDRjZWIyOWVlZTI4XzMxMjU_223b3ea4-c9ea-4296-8bcd-b83315fb08b0">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the three months ended March 31, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzItMS0xLTEtMzgwNDE_c747fe55-6ef2-485d-9fe9-62d94490f3fd"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzItMy0xLTEtMzgwNDE_1de813f6-6c6a-49ea-907e-d52510bb33b6"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzUtMS0xLTEtMzgwNDE_84795591-7d15-4907-8c19-83f51f765ce4"
      unitRef="usd">-1203000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzUtMy0xLTEtMzgwNDE_769951c0-a3ea-4df4-9023-9342bbee9678"
      unitRef="usd">2327000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzctMS0xLTEtMzgwNDE_04a05e58-7c79-4535-9750-687d130c2806"
      unitRef="usd">2171000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzYvZnJhZzphOGFlZWQwNzM2N2I0MDg1YjFjODA0Y2ViMjllZWUyOC90YWJsZToyNjE5OTY5M2NhNzg0MmY2ODA5ZjE4NWJjOTU2MGM2Ny90YWJsZXJhbmdlOjI2MTk5NjkzY2E3ODQyZjY4MDlmMTg1YmM5NTYwYzY3XzctMy0xLTEtMzgwNDE_4ac15cdf-b59c-4f34-8356-33dd39d9c105"
      unitRef="usd">9383000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzY1OA_6dc8127c-707e-47b3-bf45-c9baaedcc331">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $6.4 million and $5.5 million of internal-use software development costs for the three months ended March 31, 2022 and 2021, respectively. The net book value of capitalized internal-use software development costs was $70.9 million and $71.2 million as of March&#160;31, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $7.6 million and $7.8 million for the three months ended March 31, 2022 and 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.7 million, $6.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzY2MA_0c750754-7b6b-44b3-9dfb-468e3fb4e07a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a7ffa70b61341d8b58e1e5e9dfe4d22_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzItMS0xLTEtMzgwNDE_382158f3-2634-4f06-8b33-8318a758d7ae"
      unitRef="usd">24409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id0854b7c841d4126a9365b4b0019cd6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzItMy0xLTEtMzgwNDE_4b58cee6-af54-4999-a408-db978402a7fe"
      unitRef="usd">21970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifd8439569a0148a890c18386790d2daa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzMtMS0xLTEtMzgwNDE_9b5d67ab-5573-4fb0-a8ed-a1795cd7c4e7"
      unitRef="usd">3769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68dcac57fee14e97b585767b7925b959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzMtMy0xLTEtMzgwNDE_8d425e0e-5f85-4319-8e7e-207d618406d7"
      unitRef="usd">3581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fa83669c1e34be09bf9a205994d7995_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzQtMS0xLTEtMzgwNDE_1b8cd8ba-2123-46c5-832d-54fc43848cb2"
      unitRef="usd">166033000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id61dcf9495af405097a6842ea0ed0697_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzQtMy0xLTEtMzgwNDE_7343051b-9f2b-45f5-b55f-eb469029c76b"
      unitRef="usd">159587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9118ab4a540a4a4a8d447fc14519b568_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzUtMS0xLTEtMzgwNDE_c23de175-848a-46c3-bb68-7dc1dd90ea06"
      unitRef="usd">15075000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib9b872c69d4344d69ce0a22b7183b681_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzUtMy0xLTEtMzgwNDE_f3613db5-bfe3-449f-8aa9-10b7fe63b873"
      unitRef="usd">15325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzYtMS0xLTEtMzgwNDE_bfd378be-b848-4386-bfa6-a162f41e8642"
      unitRef="usd">209286000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzYtMy0xLTEtMzgwNDE_ca0fa23c-184f-49c7-98b5-f7a9dbd70384"
      unitRef="usd">200463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzctMS0xLTEtMzgwNDE_2574596d-ff2c-4c1b-b39d-5e4dcb86794f"
      unitRef="usd">126409000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzctMy0xLTEtMzgwNDE_25914d9c-a670-4568-a577-21b0359fd613"
      unitRef="usd">119098000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzgtMS0xLTEtMzgwNDE_78d368ae-9244-455d-bca5-7e4627a79504"
      unitRef="usd">82877000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90YWJsZTphMjg3NjJhMjlhY2U0NWE4YmMwYWI0Zjg5ZDhkZWY0Zi90YWJsZXJhbmdlOmEyODc2MmEyOWFjZTQ1YThiYzBhYjRmODlkOGRlZjRmXzgtMy0xLTEtMzgwNDE_197a0a5a-e8e1-4b12-9013-f505b9855c11"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i9b1766ec32064dff97ec361a343c8c8d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzEzOQ_4e71d819-7ed0-449f-90ec-4c7b0d8286ba"
      unitRef="usd">6400000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i2f65ab021ad34abdbe85a6520f98dc68_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzE0Mw_c2b0558f-5d04-4902-9ebb-5024dab4ec1a"
      unitRef="usd">5500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0fa83669c1e34be09bf9a205994d7995_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzM0Mg_5217fa9c-fb46-49b4-9c6d-2278e97da681"
      unitRef="usd">70900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id61dcf9495af405097a6842ea0ed0697_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzM0OQ_3aa6682d-4e67-4c1b-85d7-94845816ce6a"
      unitRef="usd">71200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzQ0Ng_d50da9c5-bc23-409a-a8b0-c1a95fe01f31"
      unitRef="usd">7600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzQ1MA_98adf256-23aa-4027-ae6a-1807dd4a71b5"
      unitRef="usd">7800000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzYyNg_55d417f2-281d-4b46-b35f-a75ef90ce30d"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMzkvZnJhZzphNWQ5NGZiZDk1OGY0NWQ5YmZhYmViOWYzMTdhMjM1ZC90ZXh0cmVnaW9uOmE1ZDk0ZmJkOTU4ZjQ1ZDliZmFiZWI5ZjMxN2EyMzVkXzYzMA_8b26ff80-370e-4225-8601-1640ebe006c6"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzg3OTA_db3abeb0-d25f-4087-b7fc-503db135d734">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three reporting units, each with &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs on October 31 of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the three months ended March 31, 2022&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We will perform our annual impairment test of October 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of March&#160;31, 2022 and December&#160;31, 2021  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets for both the three months ended March 31, 2022 and 2021 was $7.5 million, excluding $0.2&#160;million of amortization expense related to discontinued operations for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the three months ended March 31, 2022, that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzM1Ng_b62475e8-a6d7-4052-ad69-8fe6c0cced3c"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="ic23605bda701483aa031c60b51c43b27_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzQ5NDc4MDIzNDA1NDY_0896582b-791e-4692-b866-1291938aac47"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzg3OTI_a1f77e18-63f8-4f3f-849f-d5a29ec5e5d7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i58d4563528a74ddc8daf7cfcc8df4f4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMS0xLTEtMzgwNDE_61c31cfc-983f-450d-b70a-08dc1705f762"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2dd83794d6dc499596834a18cd5a2a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMy0xLTEtMzgwNDE_3964ed10-14cc-4dc2-9945-29157023263a"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtNS0xLTEtMzgwNDE_46a37f1e-7393-4be3-8b9b-dfd82d2ea1ec"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMS0xLTEtMzgwNDE_79f9b295-73c0-4b07-9ce1-8996413a6745"
      unitRef="usd">-23000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMy0xLTEtMzgwNDE_f12c6bdc-39b3-41b3-8d10-c14f5f3efe6e"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctNS0xLTEtMzgwNDE_26da7f6d-61e4-42c1-acd2-f49d2a9e262b"
      unitRef="usd">-23000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzgtMS0xLTEtMzgwNDE_708c6548-9852-45d6-b307-8059d8f499ed"
      unitRef="usd">214311000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzgtMy0xLTEtMzgwNDE_01388d69-edd9-45d8-bf8f-224815654a1c"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzgtNS0xLTEtMzgwNDE_c1a7ba9e-c2a1-4f12-9281-ec8eed29f6ea"
      unitRef="usd">426274000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i431455fda9da407ea1273e3d11bbbb34_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMS0xLTEtNDc5Njg_65939184-e425-450d-a636-e9d2cdfacf4b"
      unitRef="usd">214354000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie9c9d5a6a37649e3b44edf8049cce4da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtMy0xLTEtNDc5Njg_55377ebe-77e0-4fc0-9c7d-d607ac44e246"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzUtNS0xLTEtNDc5Njg_d31ef0f1-1807-45f4-8f0a-4f82595bde18"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzYtMS0xLTEtNDc5Njg_5b4fddfc-105e-4830-89c3-c028342896a9"
      unitRef="usd">-7000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzYtMy0xLTEtNDc5Njg_44fee891-1ea8-457a-ada3-7caea6b788d6"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzYtNS0xLTEtNDc5Njg_201c6704-56c1-4569-9abe-2c29e92454ae"
      unitRef="usd">-7000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i946bb3ded8914db29f26e0bac8b58b89_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMS0xLTEtNDc5Njg_f37c9fe3-bdae-47f3-9182-30a6e2db6818"
      unitRef="usd">214347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctMy0xLTEtNDc5Njg_ef1e341f-2125-421e-a28c-58a2dce329a3"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpmMGM1MTAzZjVhMDY0ZmI1YWZlMmZmNGI4ZjUzMmU0Mi90YWJsZXJhbmdlOmYwYzUxMDNmNWEwNjRmYjVhZmUyZmY0YjhmNTMyZTQyXzctNS0xLTEtNDc5Njg_98f58a68-230a-4fac-860a-43236a29c741"
      unitRef="usd">349022000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzc2Mjk_105722ab-23b0-4d7b-809c-af3061b7b1d9"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzc2Mjk_bb3a9962-73b1-49fe-b740-64e40ef36c45"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i582b4bf2bda24ddea0c9c99086fae38b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMS0xLTEtMzgwNDE_348179ae-9c01-4316-bb40-0523b8d116df">P12Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i94f8e91e0319490e9d3eb0783a1bad61_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMy0xLTEtMzgwNDE_93fd1e5d-c33f-46e8-97d4-6e200e3ef9bc"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i94f8e91e0319490e9d3eb0783a1bad61_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItNS0xLTEtMzgwNDE_b515cb3a-5ae2-468c-a3e0-91963f208895"
      unitRef="usd">8079000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i94f8e91e0319490e9d3eb0783a1bad61_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItNy0xLTEtMzgwNDE_2ad7d295-4d64-448c-9b34-e14d92ccd615"
      unitRef="usd">17721000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia6249585dffb463e9e429c997c28422b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItOS0xLTEtMzgwNDE_e8c58816-114b-42aa-a633-50c1138c6a8a">P12Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0f06bb46081a46e18e26c25735932a5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMTEtMS0xLTM4MDQx_57084e23-1651-4f7d-96da-e2ce72445e09"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0f06bb46081a46e18e26c25735932a5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMTMtMS0xLTM4MDQx_d6a2a6d7-93db-4672-9e47-5c679dd055a4"
      unitRef="usd">7693000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0f06bb46081a46e18e26c25735932a5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzItMTUtMS0xLTM4MDQx_f0803850-cbbb-4de3-8f3f-d82ae3f614c1"
      unitRef="usd">18107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie600b5ba08a345c0a7fa00407c5f1679_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMS0xLTEtMzgwNDE_31a414e5-13a5-42ff-a322-a55fbe648629">P14Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMy0xLTEtMzgwNDE_b2d99ee3-6116-4040-86db-fecb9e48d7b3"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtNS0xLTEtMzgwNDE_3e62beb5-348b-4937-8036-9f88d04c1292"
      unitRef="usd">76912000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2f082d3c62174c3fadd1d5e12783d9bd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtNy0xLTEtMzgwNDE_ded66647-c290-47ee-9506-5b27c70487dd"
      unitRef="usd">234107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i699ad28e63e644d292dfeba6e6ddc59c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtOS0xLTEtMzgwNDE_c8c903ee-a83e-416d-a065-b6e0dd45ee5f">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMTEtMS0xLTM4MDQx_57b86d9c-d4db-4f8f-9098-4f7699e55325"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMTMtMS0xLTM4MDQx_4dfd536a-c17b-4ced-9886-3590a287fcc7"
      unitRef="usd">72697000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1f5fc8d8b96645d482bb8cbb57c0ae52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzMtMTUtMS0xLTM4MDQx_94433d93-7d26-474c-b71e-a5d2c2e1eb90"
      unitRef="usd">238322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i532067d6f1ec4a09974e220c6f9d2b9f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMS0xLTEtMzgwNDE_b67fee40-a062-44ea-a568-3527db53f3bc">P1Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMy0xLTEtMzgwNDE_4ab38408-31c5-4f83-9524-8fb00a1a0edf"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtNS0xLTEtMzgwNDE_6ad75947-edc5-444e-841d-429acde99851"
      unitRef="usd">75254000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i64feedc66ce949ecadb7bd18bdf9cc77_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtNy0xLTEtMzgwNDE_3e61d58b-0c5c-4859-a7d1-88fc34331ee1"
      unitRef="usd">12668000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if13595fd727041dbab088d6e82f53317_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtOS0xLTEtMzgwNDE_98a49051-7133-4a8e-8b9e-1bb93a23e7d5">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMTEtMS0xLTM4MDQx_f8a2bb60-c944-428a-b4d7-e11d18e68824"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMTMtMS0xLTM4MDQx_e302efe4-6870-43e9-bea4-01cba81b2d3b"
      unitRef="usd">73378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7342e6f5f83242c0bd8b579dcfa740f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzQtMTUtMS0xLTM4MDQx_af504759-6293-4055-bbc4-cfaf927a00af"
      unitRef="usd">14544000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie40a55a2d4af4c7eb637dd2db2488d47_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMS0xLTEtMzgwNDE_dc5b22a0-a707-4c04-a751-3f7436626f2d">P1Y1M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMy0xLTEtMzgwNDE_177bda43-cb40-4b22-b37a-00e2490d3d19"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtNS0xLTEtMzgwNDE_b904aa53-4448-4681-b49a-4ca735cea82e"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idf5599a715fb4a0b8d4e03c15c8c37b5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtNy0xLTEtMzgwNDE_7bf0c6f2-c951-4626-88a6-7598b9aade7a"
      unitRef="usd">218000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ife5ebfa2dbf6474580e79f3a4aa684de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtOS0xLTEtMzgwNDE_8ac888ca-84ab-4dbc-ac60-bdf031bf3d84">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib98f030bdbd848349b1157be06b79af8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMTEtMS0xLTM4MDQx_ee7d24eb-2394-4423-8198-57bafa56e32c"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib98f030bdbd848349b1157be06b79af8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMTMtMS0xLTM4MDQx_085b86bd-dcf4-41b9-a711-c8d40263af1a"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib98f030bdbd848349b1157be06b79af8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzUtMTUtMS0xLTM4MDQx_baa5ae82-3f58-4e27-8693-d1699b1d735c"
      unitRef="usd">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic7d8558f0a0f4aed8a935e56b9bcd543_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMS0xLTEtMzgwNDE_287fcb59-0bb4-4bae-ae40-69a8a50ffb29">P1Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7029f31fe5d346869ac6af84155da042_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMy0xLTEtMzgwNDE_46de5438-7fe0-463c-9924-70d1487cd5b9"
      unitRef="usd">16236000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7029f31fe5d346869ac6af84155da042_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtNS0xLTEtMzgwNDE_6f89dea9-614c-4367-bf2f-f164a3fb8ec6"
      unitRef="usd">8737000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7029f31fe5d346869ac6af84155da042_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtNy0xLTEtMzgwNDE_93e97798-fbb0-47fb-a49b-5db005c60f23"
      unitRef="usd">7499000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i96f0caaec00841cdb9b922302d272752_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtOS0xLTEtMzgwNDE_f3aa8039-0a6e-4f87-8f47-44c318ff72f0">P2Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5893e370c05e4fa4a36f9edae416eaee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMTEtMS0xLTM4MDQx_d2ef12db-583a-4f55-bdcd-a417aff53270"
      unitRef="usd">16417000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5893e370c05e4fa4a36f9edae416eaee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMTMtMS0xLTM4MDQx_da9ebe0e-c2b4-49bd-8119-692b070e3d98"
      unitRef="usd">7874000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5893e370c05e4fa4a36f9edae416eaee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzYtMTUtMS0xLTM4MDQx_6d8f5e3b-7714-4cc6-9e44-abaf1b83d2dd"
      unitRef="usd">8543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMy0xLTEtMzgwNDE_07c69233-46af-42d4-9103-67862f967a17"
      unitRef="usd">442195000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctNS0xLTEtMzgwNDE_c1c57381-4ec5-4668-99dc-fa9778ece966"
      unitRef="usd">169982000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctNy0xLTEtMzgwNDE_807c5fba-7eaf-40a8-8721-ca355b7e204d"
      unitRef="usd">272213000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMTEtMS0xLTM4MDQx_e403c038-cc3f-4d4b-8c1b-61f96d061a0d"
      unitRef="usd">442376000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMTMtMS0xLTM4MDQx_6e283e17-c536-4ca5-92f4-c0a36ffacc8c"
      unitRef="usd">162592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZToxZWRhNzIwNmViMDU0MGEyYmJlNTQyYjY5YjA0YTYzYi90YWJsZXJhbmdlOjFlZGE3MjA2ZWIwNTQwYTJiYmU1NDJiNjliMDRhNjNiXzctMTUtMS0xLTM4MDQx_91971b6c-826f-4620-9add-8037fe60058a"
      unitRef="usd">279784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgyNjI_afda52b7-9186-41b5-992b-eab201bb4d62"
      unitRef="usd">7500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgyNjI_bc5619cc-3971-4b26-89bc-bacc2f7229cb"
      unitRef="usd">7500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgzMDA_a2defb56-8351-40e7-a298-b3c10b764564"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5fcffe6ed74045c2a108455a95165df3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzgzMDA_b278dcc2-ebdb-43ed-9228-63354b5459cc"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90ZXh0cmVnaW9uOmM3MTUxMGY2OWU4MjRmN2JhY2Q4ZWE0ZDYxY2UxZjhkXzg3OTc_3bb4c37e-d71a-4316-9e6d-0953bfdbb20b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzAtMS0xLTEtMzgwNDE_713169f2-e28f-4681-afc9-6e4d47b76c73"
      unitRef="usd">21675000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzEtMS0xLTEtMzgwNDE_5dad5127-dcb3-4967-80ba-02429e35e445"
      unitRef="usd">26760000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzItMS0xLTEtMzgwNDE_b18f6421-91ce-4c55-8b04-2678f9b4c8a4"
      unitRef="usd">20875000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzMtMS0xLTEtMzgwNDE_c05956e7-ec3b-4a53-b69d-ab4ca6f0da05"
      unitRef="usd">19330000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzQtMS0xLTEtMzgwNDE_7cd4ffcf-9df2-460b-b60b-917ff95fbd38"
      unitRef="usd">19153000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzUtMS0xLTEtMzgwNDE_4d98f35f-fec2-444f-851c-63da71034410"
      unitRef="usd">164420000</evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDIvZnJhZzpjNzE1MTBmNjllODI0ZjdiYWNkOGVhNGQ2MWNlMWY4ZC90YWJsZTpjZjg2MmRmNWNjMjc0YmNiOGJiNDVlN2E0ZDU2YzA3OC90YWJsZXJhbmdlOmNmODYyZGY1Y2MyNzRiY2I4YmI0NWU3YTRkNTZjMDc4XzYtMS0xLTEtMzgwNDE_9b75d173-35f5-42d5-a971-e968d9488833"
      unitRef="usd">272213000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzIwMzA0_029a2efe-dd15-425d-89dc-0855f7e8eeef">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $1.0 million and $1.0 million for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded $0.2 million and $1.9 million of interest expense related to the amortization of the issuance costs for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#x201c;Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#x201c;DDTL Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;Senior Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $13.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.6 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million for the three months ended March 31, 2022 and 2021 respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded $0.3 million and $2.4 million for the three months ended March 31, 2022 and 2021 respectively, in interest expense related to the amortization of the issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#x201c;2021 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of March&#160;31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzc4_91f01612-0f6b-4594-8dbc-d8b9b3d802d9"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNQ_37ac25a0-67d6-4d91-a682-f23f015069e4"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMzMw_088d18d2-0529-4425-a798-a2f13484a354"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQwMQ_ada855a2-cfd5-4632-bb09-bc6ad0a5f2b1"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ5MA_bc79144d-ce76-47f7-b310-9dd047545260"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i916d7cde9f5c4098aafca8f1d4ec92b3_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzUwNQ_7c2ac4d8-28f8-47b9-9da9-315c895fd13e"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzU4NQ_6a5154e4-8050-46e5-b66c-68922bf74705"
      unitRef="usd">3000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEwNTc_af659a23-0d54-4459-a4fa-7f83bd8bec6c"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzNjU_f863ca0b-7e20-44bb-8781-edf41835f8f4"
      unitRef="usd">1000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i5ba9893300544569828a837db24cb5ab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzNzI_86224039-e69e-4b2a-83af-a6397c16644d"
      unitRef="usd">1000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4MjE_0316d408-2889-4021-a6d2-68901a672f63"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5Mzc_dfd84b1d-3056-4a94-832b-a6d79c0e8ce7"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzI4MTU_603d1df9-f558-4303-a370-eae82cd54193"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i6c1b52e308b74c7391b12b1ba506c1ee_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzI5NjQ_3cf70d73-6e79-48be-ab2e-07d11a42992c"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMxOTE_9b7ad27d-a157-4628-b9c3-35ac62dde2b9"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7475a5be608b4b7db53a995f1885030a_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMxOTg_d10107a8-9363-4c10-a355-df21532a3669"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i6c1b52e308b74c7391b12b1ba506c1ee_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMzMjk_33507f17-2a9e-4202-b01e-0499a6fc82fa"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i36781c6539d94067adff3cf0b6de6bba_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzMzMzM_da8c98af-0f14-471f-8ea5-37b60657737d"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:StockholdersEquity
      contextRef="ic3794041ed704c3192959c4746a76918_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ5NDc4MDIzNjA3OTE_9bcfc6f5-f8f8-4506-83eb-7db89a0f9d2b"
      unitRef="usd">-38100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifac955e87eb245cb84b816f8086941ca_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczOTQ_b07ebe0f-c27e-4af8-9e1e-e02f118d80aa"
      unitRef="usd">1300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f603d69a68045f6949859303a9e0100_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczNzg_3ecc01ec-961e-4692-aec4-94f409f58b23"
      unitRef="usd">-11700000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i4fed4b10d9a94e43b4a7376d75e82ef5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczMTQ_ed8dc5cd-cc9f-40c0-ab23-37294662d887"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzM3MjA_7ed3b2ed-7b2d-4d36-ae67-c716aaf94240"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5ba9893300544569828a837db24cb5ab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzM3Mjc_245ab96f-bdec-42a2-b896-5a8bfa429ebf"
      unitRef="usd">1900000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQwNzI_450635f1-f1b8-42c4-8b46-e2e4201b7513"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ0OTM_8a7d2fbd-ff42-44fa-9540-b7e53af72782"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ1NDg_6705f28f-bfd0-48b8-86a8-75fa8d30ffe2">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ2MDQ_8ad61c91-88a3-4b8e-b04a-66be34b07079">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzQ4NDI_17609fae-54c6-4da3-b4e9-7650cd7d5d55"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id15cf99071b0415f8897789050cdcac3_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzU1MTc_6b3d6a84-acf0-4f05-9135-ef553c3f05f6"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i758bcd0701c042ab91e1fdd9a3e0621c_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzU2NDk_dd52b2e6-59aa-4c3b-b574-622f55743a8c"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMDQ3_6cf84581-47b7-4175-9815-4b8437faa8b0"
      unitRef="usd">98600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <evh:PaymentsOfMakeWholePremium
      contextRef="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMDY2_0e5ac3e1-e158-4061-9576-a74c41e1b233"
      unitRef="usd">9700000</evh:PaymentsOfMakeWholePremium>
    <us-gaap:InterestPaidNet
      contextRef="ie613157434de4a24bdcfff3dd701e837_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMTA3_c65d82ef-b859-4785-8fd0-40d131082ad4"
      unitRef="usd">200000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMjIw_d80a01c8-5356-4901-9872-8017671bb8f7"
      unitRef="usd">19200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMjg2_d3fe241c-9ac1-467f-b59f-42120eb959b2"
      unitRef="usd">9500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LegalFees
      contextRef="i20a22379b7274bf590001dde5b14f6be_D20210108-20210108"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExMzE3_31c1a8f2-da6e-407d-a78e-f529d6ab1622"
      unitRef="usd">35000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i4df15ce9a58f43aa8838ebd2fc814e18_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNTQz_80791888-07c9-4579-adc8-d103f2fb6aef"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4df15ce9a58f43aa8838ebd2fc814e18_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNjE2_0d2a70a6-8f2c-42ae-b201-344fb609867a"
      unitRef="usdPerShare">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement
      contextRef="i8ad35dd656234df09077c620d5c6d635_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzExNjc4_b932b3b4-8f60-4c4a-a075-dd9ab30f47ba">P30D</evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="if8d4ffeef7fe43eab4715bab8e852043_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyMTA0_cf9e3ca7-7c4a-49d1-b49d-05bac8cb634c"
      unitRef="usd">13700000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyMTU3_04d50ca0-73d1-4f00-bbb4-2f7449041532"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyMTk0_c006be00-abe5-48a1-be2f-03c0babaa00a"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNDYy_31370b50-38fd-467a-a96d-d1bac2b23e9b"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie0e2e0f414904188a0bb7cf06671ce39_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNDc4_7844dbd1-465a-4674-a5f5-6ded8bf7ce93"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id3e67d706f964f1bb86ba26006bab411_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNTc5_a54e56c0-60a2-4ed8-97dd-1f1c41e1f487"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic618bc70943b4438aa6de0773ad42f41_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEyNzA3_e114ccda-58fd-4dee-8896-c444604a80af"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMDQ3_c006be00-abe5-48a1-be2f-03c0babaa00a"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMTAy_27c7d08b-7a7c-4ca3-a1e3-02eb068f57ef"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMTAy_ac8fbd92-ed63-45f8-8327-b455760c6931"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="if07f72d9ccda44d3b9275c10c3802ea0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzEzMTAy_ae922a4a-7a1d-4a0c-aa48-ea228ce89cfc"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE0MDMz_4251d73f-38eb-4f8c-9865-2b380df89405"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE0MTQ5_e7fea321-c8d3-4ad4-a0e5-4d04255f4a98"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1MDIw_55108c47-4665-4e7c-b060-0dc2da0142b4"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i9a5151cda805403099aabb0baf5abfe9_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1MTY5_f1312e0e-c534-4836-b6d7-603460cf4e58"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1Mzgw_a6834860-00ff-4fc0-bb2f-dce57faa1ae0"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i0d85629f38df40019f7bfaf802250bce_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1Mzg3_65f0042b-5a04-40d5-af4c-d019e1db5cf8"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i9a5151cda805403099aabb0baf5abfe9_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1NTE4_f1312e0e-c534-4836-b6d7-603460cf4e58"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i95a9a6090d0f49cd96fafd1325f2b417_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1NTIy_a6834860-00ff-4fc0-bb2f-dce57faa1ae0"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquity
      contextRef="i2cba20250d344f82bb7c7ee274ac2d08_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczMzQ_19862b0e-e0bf-46db-acee-eac2c9ee6b2d"
      unitRef="usd">-71800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecaf5b671d0f48838a69272ed492bd4a_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczNDk_e339c3b4-56c3-4075-a959-458b938f51d7"
      unitRef="usd">2500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7101f4c4fc704442967c163ed61da7dd_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczNjM_f0583771-1fee-4b7f-ab5b-f88503d2be36"
      unitRef="usd">-28100000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i50dcc4c9e90649d88b6e4ebba21ccd70_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NDkyNjc0NzczMzE_9632c727-cfe9-4c2b-9b72-1f4e614cea71"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1OTA5_e87eac58-33bc-4bbf-a7f0-bde1300cc578"
      unitRef="usd">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE1OTEz_a6e554dc-1299-46d6-b2a0-4e388e98d40f"
      unitRef="usd">2400000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2Mjcx_567d7c9b-ae13-40bb-b54c-ab5f497ac6ba"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2Njcw_0590da6c-27f9-4a8f-b279-f1e5e9e2aa96"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2NzI1_4ad591fa-9f1b-47ae-a814-d18b5bbe5420">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE2Nzgx_b08fbd59-f17a-40eb-9a70-d564e40964d5">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i275db3a5294f4618b9fcfa7b93c8985f_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3MDE5_91aa04eb-ade1-4c4c-b28c-dd6b412fc545"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie46a449af09c45a48017c23edc16be05_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3MTg3_56b7f715-4e30-4f86-b5ba-e643bb1715ec"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie46a449af09c45a48017c23edc16be05_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3MjI0_fcdd450b-6dc5-41ed-9097-6f406c613593"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i5c97925a37bb4a129ad535aed5cd5727_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3NDQ3_98863a47-cb19-454c-ade2-aa387f112694"
      unitRef="usd">120400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie46a449af09c45a48017c23edc16be05_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE3NDYz_782e3dfb-0382-4f45-aca0-ad9e0cf0ff16"
      unitRef="usd">4600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i4d058223ab834953b0a1d8931f0091bc_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4Mzg5_08e0bb72-a0cf-4581-a85e-be595d4ae3e5"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4NDUz_9b8de5a2-4823-49fb-a53c-f51cec063f8a"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4NTg2_1a49dcf0-75cf-4af4-877d-4b6a8eb4afd0"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4NzMw_a7aec461-24bf-413b-988d-2613f6315899"
      unitRef="usd">-4800000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4Nzcz_29d48128-675b-4edb-8f6e-1cf6a5542964"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4ODQ2_1552b8c2-1bff-4317-aa6a-769c406bc3e5"
      unitRef="usd">14000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i8df8447968a3446e9b7b015e663bd9e9_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE4ODcy_b151c322-d95b-4447-8d06-e5bd718f1ff5"
      unitRef="usd">13900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MDQ2_cc10082e-2ea0-46dd-a1e4-18789090941d"
      unitRef="usd">26700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MTA3_0b7a162d-cc47-401c-aa2e-9439f58ad911"
      unitRef="usd">26300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MTkw_d5551fc2-03d5-46f3-87f0-62bf2b7a30bc"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <evh:DebtConversionOriginalDebtFairValue
      contextRef="i32d97f3d7fab4028a29399bf3e18652f_I20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5MzQ1_bb5da9e6-5add-4d84-839c-ded0e1ad7aac"
      unitRef="usd">28500000</evh:DebtConversionOriginalDebtFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i05179c18e4294269bd473e6439df82c9_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzE5Mzk0_fde483a8-b9ae-4885-bca7-0105f9f69750"
      unitRef="usd">2200000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90ZXh0cmVnaW9uOjI1ZTVjYmZjZjJiNzQzNzg5Y2NhOWQwOGM3NGY2N2EzXzIwMzA2_cb13b0a0-ee5f-4782-bcc4-ab1b127a1d97">The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2022 and December 31, 2021 (in thousands):&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="if568378dc7914a2ca879a5b1dfdec339_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzMtMS0xLTEtMzgwNDE_7245a982-1e61-46b8-9357-3a8c708dfffc"
      unitRef="usd">114672000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i3b47e659a7674184bd5fb1e6489758c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzMtMy0xLTEtMzgwNDE_8852edd1-3e70-48cd-bec3-b0a0af12ea32"
      unitRef="usd">89361000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if568378dc7914a2ca879a5b1dfdec339_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzQtMS0xLTEtMzgwNDE_4a1521eb-9040-442b-ba21-131f816b4c95"
      unitRef="usd">2379000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i3b47e659a7674184bd5fb1e6489758c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzQtMy0xLTEtMzgwNDE_e0a874ca-f4a9-497f-8323-3bc003346b56"
      unitRef="usd">27690000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if568378dc7914a2ca879a5b1dfdec339_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzUtMS0xLTEtMzgwNDE_de2ffc32-deb0-4e26-90b3-dbc8f2e60d83"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3b47e659a7674184bd5fb1e6489758c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzUtMy0xLTEtMzgwNDE_db7ffd31-482a-44a2-8a3d-5baae76f6a81"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzYtMS0xLTEtMzgwNDE_78c9504c-7f50-419f-938b-41c22c3c2a86">P2Y8M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i5ba9893300544569828a837db24cb5ab_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzYtMy0xLTEtMzgwNDE_480b21ad-2386-4ddb-a095-8a99c5a7b83c">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i977484a58ef44f029d021443bc481e0d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzctMS0xLTEtMzgwNDE_b0653d7a-149c-4914-b162-eb01787ab4af"
      unitRef="usd">209973000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5ce62f0c759b43c0a265b0f75bccf470_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzctMy0xLTEtMzgwNDE_6160ac57-de5f-475b-bae9-b60c4f5fe66d"
      unitRef="usd">195445000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="ib26b528f69e84aa8bf0354a45f147957_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEwLTEtMS0xLTM4MDQx_47c1b1e8-5d98-421a-aceb-d1d3cf2001ca"
      unitRef="usd">167926000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i11e44058a9da4e57975c9afd2894c3fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEwLTMtMS0xLTM4MDQx_066fa7db-8cc5-4e4d-b75f-9f3a8b42ed31"
      unitRef="usd">126315000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib26b528f69e84aa8bf0354a45f147957_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzExLTEtMS0xLTM4MDQx_1887ba42-8873-46fb-bd0f-f3f6aa022e75"
      unitRef="usd">4574000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i11e44058a9da4e57975c9afd2894c3fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzExLTMtMS0xLTM4MDQx_d8592488-c77b-4cb7-b864-49e507315f91"
      unitRef="usd">46185000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib26b528f69e84aa8bf0354a45f147957_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEyLTEtMS0xLTM4MDQx_bf768c43-694a-4cb4-8a4b-218c5ba7898d"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i11e44058a9da4e57975c9afd2894c3fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEyLTMtMS0xLTM4MDQx_3406eced-65c7-4f9a-970b-d9ff2319980b"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i6fbe1266f2314b07b4131f3cf857841c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEzLTEtMS0xLTM4MDQx_d0d88a97-81aa-41b7-971d-741344efca97">P3Y6M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i25323d9d1d394812b15a388c65515a7f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzEzLTMtMS0xLTM4MDQx_2473ad2f-4e8b-4327-9273-e66dfb0f6f8a">P3Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7f5b100104fe48a2989954cdb98067ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzE0LTEtMS0xLTM4MDQx_be090238-3679-454a-99f6-7b92d1be44f6"
      unitRef="usd">203648000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if7fe6c4a84a34602b32ea482070a2644_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNDUvZnJhZzoyNWU1Y2JmY2YyYjc0Mzc4OWNjYTlkMDhjNzRmNjdhMy90YWJsZToxYjY1MzM1NTA0OTg0MGU2YTYyY2Q3ZjJiMTVmZDRmMS90YWJsZXJhbmdlOjFiNjUzMzU1MDQ5ODQwZTZhNjJjZDdmMmIxNWZkNGYxXzE0LTMtMS0xLTM4MDQx_9fb80921-29bf-466f-913b-232cfb479e77"
      unitRef="usd">177251000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEyNDM0_0d68a6fe-d385-4ff4-bf3a-eb86fa22d6bf">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.7&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.7&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of March&#160;31, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between June 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three months ended March 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March&#160;31, 2022, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reinsurance Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#x201c;Passport Closing&#x201d;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#x2019;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed on December 2, 2021. The case alleges that the Company&#x2019;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, and was again stayed pending a decision on the Company&#x2019;s third motion to dismiss. The Eastern District of Virginia granted in part and denied in part the motion to dismiss the third amended complaint on March 18, 2022. The case is again in discovery phase. Based on the Company&#x2019;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan. The case is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lincolnshire Police Pension Fund, derivatively on behalf o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. (&#x201c;Derivative Action&#x201d;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. The case had been stayed until the decision on the Company&#x2019;s motion to dismiss  the third amended was decided on March 18, 2022 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plymouth County Retirement System v. Evolent Health., Frank Williams, Nicky McGrane, and Seth Blackley&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in federal district court. Briefing on the motion to dismiss is ongoing and will be completed in July.  Based on the Company&#x2019;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March&#160;31, 2022, approximately 99.6% of our $262.8 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $44.8&#160;million of True Health premium revenue reclassified to discontinued operations for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ica8e454931494c86a0acbbb148cef7a4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzE2NDkyNjc0NjU3OTY_1461000e-3810-4fb3-981a-375909d88fe7"
      unitRef="usd">13700000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie4ae4f2c278c4ce8bb30f6cf187609dc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzE3Nw_7956c7a5-3638-4acc-b51b-f301d33dcf49"
      unitRef="usd">15400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1c587e607d8b406d82aa29c34afa0507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzQ5NDc4MDIzNDkxNzk_b5402c1d-c265-4bd8-af97-8d83170fb993"
      unitRef="usd">13700000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i32c3abf79b77492d8199a68542ed7752_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzMwNQ_735f211c-b2c5-4352-aaaf-2ea1b8da81de"
      unitRef="usd">15400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:EffectsOfReinsuranceTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEyNDQ2_462e3cfa-aec3-43d3-bf5d-fff480ea7988">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzItMS0xLTEtMzgwNDE_0566d688-aadd-4a62-8d65-3d38c1f662cd"
      unitRef="usd">-2000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzItMy0xLTEtMzgwNDE_25727b34-eeff-4251-bbe4-920a76ee18bf"
      unitRef="usd">8845000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzQtMS0xLTEtMzgwNDE_453e8ae8-1c39-45b6-816e-33bf112c2f0b"
      unitRef="usd">-37000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzQtMy0xLTEtMzgwNDE_08d77855-c5e2-486c-aee0-911f3f2b42f3"
      unitRef="usd">10494000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzYtMS0xLTEtMzgwNDE_3057f990-0ae9-4037-92fc-f1b72a1e757d"
      unitRef="usd">0</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzYtMy0xLTEtMzgwNDE_9732f88d-9ea7-4942-aac8-6825c46e8f48"
      unitRef="usd">545000</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzctMS0xLTEtMzgwNDE_6e998c14-7513-4522-b521-143e22944e15"
      unitRef="usd">35000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzctMy0xLTEtMzgwNDE_8ceae88d-931a-40d6-8d0f-5e45786ed80a"
      unitRef="usd">-2194000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzgtMS0xLTEtMzgwNDE_e91b5c5e-f2b4-4a47-a87f-29118cec57bf"
      unitRef="usd">90000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzgtMy0xLTEtMzgwNDE_193af5e4-5143-4e0e-9023-cdd14376d126"
      unitRef="usd">4002000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzktMS0xLTEtMzgwNDE_d080c36d-3aef-4d48-ab12-5597ece7360d"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzktMy0xLTEtMzgwNDE_dfef1c77-0892-43a3-b253-3e0296b2861b"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:ProceedsFromReinsurance
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzEwLTEtMS0xLTM4MDQx_77d83b4b-35b9-4ccf-ab81-bc163ecb1068"
      unitRef="usd">330000</evh:ProceedsFromReinsurance>
    <evh:ProceedsFromReinsurance
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzEwLTMtMS0xLTM4MDQx_7c642c9f-c6fc-4ef4-b366-af68e0be6092"
      unitRef="usd">0</evh:ProceedsFromReinsurance>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzExLTEtMS0xLTM4MDQx_a4793306-2cb8-45f8-b8fb-3771412d6c71"
      unitRef="usd">455000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo5NGYxNDhlMDIwMTk0MWQ4OTg3ZDMwOTRiZjdhY2ZjMS90YWJsZXJhbmdlOjk0ZjE0OGUwMjAxOTQxZDg5ODdkMzA5NGJmN2FjZmMxXzExLTMtMS0xLTM4MDQx_e6a4ad5f-ee4b-4328-89e7-efb5ad00b7d2"
      unitRef="usd">1808000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzYwNDc_a1cc361d-b68e-40c2-9436-089223f84c0f"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEwMDYw_3990ab43-aed9-4640-9d84-bc37bd98ad38"
      unitRef="number">0.996</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEwMDcw_fbe33cb8-33bf-40a0-9df4-37ff9de0cb59"
      unitRef="usd">262800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEwMjIx_d7e7eac9-1b6e-4b38-8409-1a99ad79a834"
      unitRef="number">0.004</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzEyNDM3_21fda8d2-2a38-412d-9903-fdca4ab921d6">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable as of March&#160;31, 2022 and December&#160;31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $44.8&#160;million of True Health premium revenue reclassified to discontinued operations for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i968714160637450486f094b7b1293b81_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzEtMS0xLTEtNDcxMjI_5220f3f3-beb5-423e-be0e-4c01d44457cd"
      unitRef="number">0.353</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe91cbc7315a4336b5abff786c768b62_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzEtMy0xLTEtNDcxMjI_e25cc4c9-bc7c-4cbf-8ee3-e7ccd89e9e1f"
      unitRef="number">0.464</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if2b4eec3a0cb4f27aaa8e6f384025a1e_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzItMS0xLTEtMzgwNDE_abde8831-1721-45b9-abfa-5e1d3132314b"
      unitRef="number">0.279</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id90c22c98c76421ea4011d8153a44a71_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTpiYzQ0NmQwMTQ5ZWQ0Yzg0YTk1MmNkOWU3YWRjNTFmZi90YWJsZXJhbmdlOmJjNDQ2ZDAxNDllZDRjODRhOTUyY2Q5ZTdhZGM1MWZmXzQtMy0xLTEtMzgwNDE_d1f19d74-4e9e-464c-a373-ee2e444d2bed"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie5794d71d0de4903b413840b815950f5_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzItMS0xLTEtMzgwNDE_a9922c45-8dd8-436a-9ca0-853e75523884"
      unitRef="number">0.239</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3b879fd6a8b140139241cedad3dd8363_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzItMy0xLTEtMzgwNDE_e8c52487-e480-4e81-aa5d-f5ea78abacec"
      unitRef="number">0.288</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icd121453f7584e4795edacc5006758f9_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzQtMS0xLTEtMzgwNDE_0f4f2a2c-3bb7-4479-96ac-920d6232e81f"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7c697c6c8a12472a8470f212680e6841_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90YWJsZTo3ZmJkYzFiMzhiMTM0ZDRhYjQ4YTZjOTQ4ODk5MWExNS90YWJsZXJhbmdlOjdmYmRjMWIzOGIxMzRkNGFiNDhhNmM5NDg4OTkxYTE1XzQtMy0xLTEtMzgwNDE_2dbbf4ac-592b-43e9-a745-d1a9422956e9"
      unitRef="number">0.147</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6f6ec7aba15341f6b7511d0a09ecf92a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTEvZnJhZzo4NWEzYzFhYmE1ZDU0OWQyOTViNWE4ZDM1OGQyNGM5Ny90ZXh0cmVnaW9uOjg1YTNjMWFiYTVkNTQ5ZDI5NWI1YThkMzU4ZDI0Yzk3XzExMzc4_2fa1f3dd-bcfa-4f75-af13-29cfe1f9383a"
      unitRef="usd">44800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyNTg_da9deca5-0b9b-4af4-a963-b20692c2fe0d">LeasesThe Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of March&#160;31, 2022 and December&#160;31, 2021. As of March&#160;31, 2022 and December&#160;31, 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of March&#160;31, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of March&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i55a0e80d686d4db398764b4e17532471_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzI2NjM_361d7829-4436-477e-ac12-46eb4bd30072"
      unitRef="usd">2300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic1a6b90e9de04a9795ddcc6e1d3d2f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyOTg1MzQ4ODY2MzA_f6d154ff-4e51-4a34-b0ec-b610ed722c5c"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i55a0e80d686d4db398764b4e17532471_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyOTg1MzQ4ODY2Mzk_af698761-c51d-475e-9535-6ebb0956a00b"
      unitRef="usd">2300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic1a6b90e9de04a9795ddcc6e1d3d2f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyOTg1MzQ4ODY2NDc_6f36dd28-af57-41c5-84a4-ac360629260d"
      unitRef="usd">3800000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyNTk_df281ee9-d67e-4c66-a2ca-a31f99a1ade8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of March&#160;31, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of March&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7a5f7ca552444d36af631fb4eeba482a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzEtMi0xLTEtMzgwNDE_33292197-bacb-4599-b682-93d88e0b5fb0">P9Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7a5f7ca552444d36af631fb4eeba482a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzEtNC0xLTEtMzgwNDE_2ba78ae8-4858-411e-8ada-32361c76a4d5"
      unitRef="usd">34798000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i7a5f7ca552444d36af631fb4eeba482a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzEtNi0xLTEtMzgwNDE_0048c33f-2924-4a69-b3c7-fe1f217bf532"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9859c6985307497fb25bf1057a6361e2_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzItMi0xLTEtMzgwNDE_db058b2e-35bf-4457-8608-87c2d9601262">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9859c6985307497fb25bf1057a6361e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzItNC0xLTEtMzgwNDE_58a24c2e-0e34-40c5-8444-f22b44228cf9"
      unitRef="usd">40569000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i9859c6985307497fb25bf1057a6361e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzItNi0xLTEtMzgwNDE_c9d19b8c-4440-49cd-bb84-83f028b0741f"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i69967c2e35354819ade6c5984bf3b729_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzMtMi0xLTEtMzgwNDE_18f31c0e-ec38-4bdb-a0ec-ac4efcd1b17b">P4Y1M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i69967c2e35354819ade6c5984bf3b729_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzMtNC0xLTEtMzgwNDE_a74b9fd9-6aad-46d2-9c0c-47738d084253"
      unitRef="usd">2081000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i69967c2e35354819ade6c5984bf3b729_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzMtNi0xLTEtMzgwNDE_eddc9c01-4fdb-4fae-b822-d07c010338c4"
      unitRef="usd">222000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzQtMi0xLTEtMzgwNDE_6bca6efd-e60a-4618-a694-498b3278090b">P1Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzQtNC0xLTEtMzgwNDE_c5b9b2ba-45ab-4c5f-b210-348e1bf5c0bb"
      unitRef="usd">1130000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id39a1a94fc59439d8da40d9c9e6d35c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzQtNi0xLTEtMzgwNDE_e1524c20-ac5e-4ab3-9bc2-8ebb7ee82764"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib68c9b6601e041919a7d54d7305442ef_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzUtMi0xLTEtMzgwNDE_4a5c2801-9e21-4242-bbe7-1de7b10c93dd">P0Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib68c9b6601e041919a7d54d7305442ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzUtNC0xLTEtMzgwNDE_296bc07f-1668-491f-a40e-7f0e44af17a8"
      unitRef="usd">185000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib68c9b6601e041919a7d54d7305442ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpjMjY2NjZmMzA3ZGI0NDk1YjhmN2Q1NmVhZjZiNWI4NS90YWJsZXJhbmdlOmMyNjY2NmYzMDdkYjQ0OTViOGY3ZDU2ZWFmNmI1Yjg1XzUtNi0xLTEtMzgwNDE_da4051f9-1507-47d8-ae71-bfb64aa66b86"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90ZXh0cmVnaW9uOjMzZTBiOTc4MDM1MTRjZDlhMzk4ZWJjYWU2ZDQxNGU3XzMyNjA_553f8aee-f02c-4151-97cf-65c64c0b9335">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzItMS0xLTEtMzgwNDE_dd8697d8-a116-4427-b81c-fc011d575ceb"
      unitRef="usd">2274000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzItMy0xLTEtMzgwNDE_4c3e42a2-2145-4af3-87b3-e82fe0ceeb75"
      unitRef="usd">4818000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzUtMS0xLTEtMzgwNDE_8f1db6e9-ad7e-439f-a7e7-90a367f7f4cc"
      unitRef="usd">1326000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzUtMy0xLTEtMzgwNDE_191ca1f8-4446-4841-a55d-afb465fcec50"
      unitRef="usd">1321000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzYtMS0xLTEtMzgwNDE_460a3402-bfd7-411b-a506-b4cb42da1ca8"
      unitRef="usd">3600000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTo4NTk1MWEwZDRmYjY0YTY3YWYxYmRkZDk0MDRkOGY1My90YWJsZXJhbmdlOjg1OTUxYTBkNGZiNjRhNjdhZjFiZGRkOTQwNGQ4ZjUzXzYtMy0xLTEtMzgwNDE_a3763369-69b8-46fb-a020-ebe7455b010d"
      unitRef="usd">6139000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzEtMS0xLTEtMzgwNDE_f1a88dcd-c829-429d-876a-7a9e9961ed48"
      unitRef="usd">7921000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzItMS0xLTEtMzgwNDE_2eb50af1-7960-43d6-9aea-9d2e890d53d8"
      unitRef="usd">9258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzMtMS0xLTEtMzgwNDE_a3da0e4b-0e80-41d0-a686-16a4338edfd4"
      unitRef="usd">8968000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzQtMS0xLTEtMzgwNDE_5d80b19c-79d1-4b3d-9df1-99a9bb8c6986"
      unitRef="usd">8653000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzUtMS0xLTEtMzgwNDE_c9544361-df92-4f3d-b5fa-ee7222d094e1"
      unitRef="usd">7988000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzYtMS0xLTEtMzgwNDE_f4040368-b2b5-456a-8753-70165f1b2ef6"
      unitRef="usd">39972000</evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzctMS0xLTEtMzgwNDE_98c8ebdb-6ef8-4390-8a64-be1bfa58ed37"
      unitRef="usd">82760000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzktMS0xLTEtMzgwNDE_fc5e6bfa-d256-4a87-bcf4-4c2b255df672"
      unitRef="usd">19961000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTplODcyNDBkN2NmZjc0ZjA1YTFlMWZmYzM4ZTFjOTk5ZS90YWJsZXJhbmdlOmU4NzI0MGQ3Y2ZmNzRmMDVhMWUxZmZjMzhlMWM5OTllXzEwLTEtMS0xLTM4MDQx_f99b7056-b37b-4a6f-89c2-63b07e0e8d7a"
      unitRef="usd">62799000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpkNzNhMjE1NDUwMjY0MmNjOWI0MzdhNzA2NTRlMDIyYi90YWJsZXJhbmdlOmQ3M2EyMTU0NTAyNjQyY2M5YjQzN2E3MDY1NGUwMjJiXzItMS0xLTEtMzgwNDE_d202c939-a561-4777-9a64-ca26f2fae655"
      unitRef="number">0.0640</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTQvZnJhZzozM2UwYjk3ODAzNTE0Y2Q5YTM5OGViY2FlNmQ0MTRlNy90YWJsZTpkNzNhMjE1NDUwMjY0MmNjOWI0MzdhNzA2NTRlMDIyYi90YWJsZXJhbmdlOmQ3M2EyMTU0NTAyNjQyY2M5YjQzN2E3MDY1NGUwMjJiXzMtMS0xLTEtMzgwNDE_8ab61e12-66ca-4b11-aeb2-74e10c95679d">P8Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90ZXh0cmVnaW9uOjJjMDc4NzhkY2M0NTRmODc5Y2RkYmM3OThmNTkwMGFkXzM1MQ_78de40af-4ccf-4720-adfd-f1973361260e">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available for common shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90ZXh0cmVnaW9uOjJjMDc4NzhkY2M0NTRmODc5Y2RkYmM3OThmNTkwMGFkXzM1OA_f0ad463b-3e7d-4128-9ac0-d12d425619ad">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available for common shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzItMS0xLTEtMzgwNDE_57f0dd20-8335-4301-96e4-84ddca884b17"
      unitRef="usd">-5350000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzItMy0xLTEtMzgwNDE_1d8a1e64-6a92-43e0-8702-d33d507cfc10"
      unitRef="usd">-11190000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzMtMS0xLTEtMzgwNDE_9a961152-7317-41c3-9951-60d1c12b2b55"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzMtMy0xLTEtMzgwNDE_a7749027-c4c8-4ee8-9c7c-0b01e3bb01ce"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMS0xLTEtMzgwNDE_9ba54fe5-83ce-448a-b6b3-c312f441dc20"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMS0xLTEtMzgwNDE_eeec7d83-a5c5-4e50-a788-71cb22150cde"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMy0xLTEtMzgwNDE_679c7ddc-6f4f-40c6-9a7b-aef415d27a7c"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzQtMy0xLTEtMzgwNDE_f190c853-9848-453d-b694-895a8718d8c1"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMS0xLTEtMzgwNDE_2e9d5031-9f9a-4199-9215-64564d1aacb6"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMS0xLTEtMzgwNDE_cf868fd8-1afd-49d0-acee-5a7af9ce7914"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMy0xLTEtMzgwNDE_7bc03da2-3c16-44b6-ad25-f05001fcd32a"
      unitRef="shares">84670000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzktMy0xLTEtMzgwNDE_99f00915-455f-468d-9856-d443da68441e"
      unitRef="shares">84670000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTEtMS0xLTM4MDQx_cd7dbb8c-c230-40fa-9e1c-89ddb5150c93"
      unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTEtMS0xLTM4MDQx_dce28e6f-1f46-4e94-8a30-e5f118457bd4"
      unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTMtMS0xLTM4MDQx_0eb11ff2-f1f0-4803-a92f-2075603e4ebc"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzEzLTMtMS0xLTM4MDQx_8fd0c4e3-e001-4289-9347-78c01f2ca1dd"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTEtMS0xLTM4MDQx_ba5bd89c-7bb2-45e5-beae-badadc91229f"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTEtMS0xLTM4MDQx_e9701e52-caa5-4c31-bba0-b33b00faf07c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTMtMS0xLTM4MDQx_25dad0cd-7e70-48be-8c0d-4160671153b1"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE0LTMtMS0xLTM4MDQx_59aff931-3805-409f-822b-3f363a611ead"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTEtMS0xLTM4MDQx_4143aa38-cafb-40ef-9f5b-83249cc588a4"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTEtMS0xLTM4MDQx_618b89bf-6770-462d-8d7c-741ac05aac7f"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTMtMS0xLTM4MDQx_23cbac1a-20cf-4cc2-8cb1-977e29fd27ed"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo5NTY4MzdiMTYyYWI0MDlkOTZmOTJlYzk3NTVkYTc0Yy90YWJsZXJhbmdlOjk1NjgzN2IxNjJhYjQwOWQ5NmY5MmVjOTc1NWRhNzRjXzE2LTMtMS0xLTM4MDQx_e7474cd7-30ed-4081-bd0f-8c35ff985f9c"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90ZXh0cmVnaW9uOjJjMDc4NzhkY2M0NTRmODc5Y2RkYmM3OThmNTkwMGFkXzM1Mw_73736635-65ba-441d-8f08-c9f07634aa5c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice2ce205b8df40f5a8ca6fb448494da9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzMtMS0xLTEtMzgwNDE_2be93ea5-1a80-494b-bf05-622be2944eed"
      unitRef="shares">2161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifc1ac30734004ea497e9ad4ec8f715ed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzMtMy0xLTEtMzgwNDE_78d38632-be22-4393-9a1d-bc0b690afaee"
      unitRef="shares">1531000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia647416262ac4cbc82f836c92f6093f2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzQtMS0xLTEtMzgwNDE_38be8822-fe98-4062-a735-92753af667f2"
      unitRef="shares">1756000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief06047c33e34d79987ca3e17332e58e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzQtMy0xLTEtMzgwNDE_30ea467b-2580-4199-bd03-7d37b5d4c141"
      unitRef="shares">1865000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i842788784c414a1a91580bb3f7277e7a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzUtMS0xLTEtMzgwNDE_a7d60452-2903-4718-aad6-30a26037aa92"
      unitRef="shares">11582000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b639b680fbf43b6814f6de3ecae64d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzUtMy0xLTEtMzgwNDE_ecd4af67-84dc-4a72-9fd7-02fc10592192"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzYtMS0xLTEtMzgwNDE_dc57be5e-bf98-4143-960b-86aad278dde1"
      unitRef="shares">15499000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNTcvZnJhZzoyYzA3ODc4ZGNjNDU0Zjg3OWNkZGJjNzk4ZjU5MDBhZC90YWJsZTo3MDA3MmUxZTVkNmE0YTA4YThlN2NkYmM5NTg4Mjk1MC90YWJsZXJhbmdlOjcwMDcyZTFlNWQ2YTRhMDhhOGU3Y2RiYzk1ODgyOTUwXzYtMy0xLTEtMzgwNDE_da8a29c5-893d-47c1-95af-dbeebc22cebd"
      unitRef="shares">16092000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzMzMA_33135634-af36-479b-bff6-69eba8700f81">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock-based compensation was capitalized as software development costs for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzMzMQ_ee74bb28-2c1e-4c08-ac4a-f91ce0b9e00c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic0a11d327f4c470ca2f791e8e1966028_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzMtNS0xLTEtMzgwNDE_66124c1d-c39a-4b8a-ae6c-1f1942682a15"
      unitRef="usd">162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia747290a8b204259b52b29bf6aa78a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzMtNy0xLTEtMzgwNDE_2d6b3719-b96d-4d17-85a8-d78b3fe892f8"
      unitRef="usd">404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i627eecec9e24428f888feae02bf5a094_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzUtNS0xLTEtMzgwNDE_0ca446d4-86d2-4f66-8204-ebffae5a8dce"
      unitRef="usd">3301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i696664e630804b529ae7bb6d3ca89106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzUtNy0xLTEtMzgwNDE_8c1bf336-afdc-4248-8d47-57ae8a20b8f7"
      unitRef="usd">1974000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebeb1fce40b34eeda2f1d368b211235e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzYtNS0xLTEtMzgwNDE_ffaaf996-81e5-4235-9351-c83c84b5ce45"
      unitRef="usd">775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibaf15ce52ede4d83af3ac051dc46f9b5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzYtNy0xLTEtMzgwNDE_280f1363-ae2d-4a95-8ec7-6f73607e30ad"
      unitRef="usd">1085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibbdfd1a6d91342e6a148aa56505db40e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzctNS0xLTEtMzgwNDE_a900f5f6-4f4a-4c6f-a4ae-eaacc14f1e21"
      unitRef="usd">1108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a81afc686ee45928654d3f1fd757c58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzctNy0xLTEtMzgwNDE_e2a618c5-36ee-4762-a677-c237120b1436"
      unitRef="usd">243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzgtNS0xLTEtMzgwNDE_b7a9b088-ce7a-4f71-a2dd-f86c459a50ef"
      unitRef="usd">5346000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzgtNy0xLTEtMzgwNDE_3c89c9fc-5646-4b06-a27a-ab4c621ded38"
      unitRef="usd">3706000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iabe9aab2682b4fc696fe56048ee7905a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzExLTUtMS0xLTM4MDQx_18505f20-c915-4048-a018-a2348a018578"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3909b5b33cda4a969569a089a54d7d90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzExLTctMS0xLTM4MDQx_9218c4fc-9edd-45d4-83f4-e897f739e957"
      unitRef="usd">595000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12dff91475cc4bc8b8681e67ab398b2e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEyLTUtMS0xLTM4MDQx_e5be4906-00fa-442e-aaea-25455eb4996d"
      unitRef="usd">4546000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie053af2f0b7f43e79aa116dad9847e40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEyLTctMS0xLTM4MDQx_9ae22f10-17ce-4473-b2fd-34790803b267"
      unitRef="usd">3111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEzLTUtMS0xLTM4MDQx_b7a9b088-ce7a-4f71-a2dd-f86c459a50ef"
      unitRef="usd">5346000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo2OWY1Njc2MTY2MzE0NWEyYWFmYzBjNDM1ZTFiNDczZi90YWJsZXJhbmdlOjY5ZjU2NzYxNjYzMTQ1YTJhYWZjMGM0MzVlMWI0NzNmXzEzLTctMS0xLTM4MDQx_3c89c9fc-5646-4b06-a27a-ab4c621ded38"
      unitRef="usd">3706000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzE3OA_b597c4cd-5b54-4131-9b3e-22333effd89e"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzE3OA_f8aba802-987a-46c7-963e-e5866a673ef8"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90ZXh0cmVnaW9uOmQ4MTVkODM1ZDVkMjQyNTdiOTE2MDlkMmRiYWIxZTNkXzMzMg_c0a3d829-a35f-4a75-a72b-0b026cd939f8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i627eecec9e24428f888feae02bf5a094_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzItNS0xLTEtMzgwNDE_23ab9db3-66ea-4c0a-9728-3dd16f2eb6d3"
      unitRef="shares">917000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i696664e630804b529ae7bb6d3ca89106_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzItNy0xLTEtMzgwNDE_0efabf35-479a-47f9-9477-7eb2b838effd"
      unitRef="shares">939000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibbdfd1a6d91342e6a148aa56505db40e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzMtNS0xLTEtMzgwNDE_6656da2f-0b11-4753-a63c-c0263224598b"
      unitRef="shares">479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6a81afc686ee45928654d3f1fd757c58_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yNjUvZnJhZzpkODE1ZDgzNWQ1ZDI0MjU3YjkxNjA5ZDJkYmFiMWUzZC90YWJsZTo1MDllYzM4Y2NkMmM0MjM5YmYyYWVkOTllNWZkYTc3MC90YWJsZXJhbmdlOjUwOWVjMzhjY2QyYzQyMzliZjJhZWQ5OWU1ZmRhNzcwXzMtNy0xLTEtMzgwNDE_f0a79745-b0f1-4d2c-9234-ae6a9d5b46c9"
      unitRef="shares">319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzE2MzU_50c66c01-5a80-4905-8c52-834f10a65fa9">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An income tax expense of $1.2 million and $0.6&#160;million was recognized for the three months ended March 31, 2022 and 2021, respectively, which resulted in effective tax rates of (29.0)% and (5.8)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three months ended March 31, 2022 primarily relates to foreign taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, the Company had unrecognized tax benefits of $0.6 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of March&#160;31, 2022, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzQ5NDc4MDIzMjY5OTU_b554041c-292e-4c01-89bd-e8fb85e5e695"
      unitRef="usd">1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzIxNw_220c9098-306b-47f0-af27-27a0fe186179"
      unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzIxOTkwMjMyNTc0ODk_cf67f111-cd08-4ac9-87dc-3e7d8116477d"
      unitRef="number">-0.290</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzIxOTkwMjMyNTc0ODU_859ce482-a8bd-4f8f-90ea-f8789fc01859"
      unitRef="number">-0.058</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzgxMg_e3faeacf-e6c3-4c61-8935-ff1c521089d5"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNjkvZnJhZzpjOGFiMzhhNTY2MTA0MmI0OTM2MWNhYmQ3MDgyMjk2My90ZXh0cmVnaW9uOmM4YWIzOGE1NjYxMDQyYjQ5MzYxY2FiZDcwODIyOTYzXzEzMzc_1631332e-f866-4160-a009-079e4218ddfb"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzMxNzA_8b75cf25-945c-4128-81d1-221f8e01e5f7">Investments in Equity Method Investees&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;March&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the gain from these investments was approximately $0.6 million and $7.8 million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $3.6 million and $6.3 million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="id9e68408fd524ee7853f44d2c3055dac_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEyNDY_b2413f6b-66ca-4b0c-b287-41a94378ae8e"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="if0bf322642904e678f0fb49d1674e122_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEyNTM_b343157e-19e8-4291-8766-57ec198973a7"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i80b281b7c3cb41b7b75ba0b670b05d6b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxOTkwMjMyNTk4MzM_9604f321-e124-4081-a59b-792339a54d4a"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i571e3a3a8fdb4e7fad04e7c5bfc9a5c7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxOTkwMjMyNTk4NDE_b18323c3-92fc-44eb-8a74-e4b2fcd24ef0"
      unitRef="number">0.39</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i80b281b7c3cb41b7b75ba0b670b05d6b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNTU_6a85c017-f80b-4ab6-ac2d-8c3abece3f4d"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="id9e68408fd524ee7853f44d2c3055dac_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNTU_d746efa5-1120-4d76-8e7c-64bce43a4ff1"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="if0bf322642904e678f0fb49d1674e122_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNjI_2857913b-cd26-422e-a5e9-389f1aefe42a"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i571e3a3a8fdb4e7fad04e7c5bfc9a5c7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzEzNjI_66318e1a-a171-4e1f-9a7f-82711b2166c2"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzE4MTE_01b1769d-72da-4a63-859c-40c90175e0c0"
      unitRef="usd">600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzE4MTU_f314f41d-26fc-4796-84f1-7357d9756bbb"
      unitRef="usd">7800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i459c224721e4472987d0810fa06039dd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxMjQ_9d41a992-4b2f-4695-b2ae-73d2f3500cb3"
      unitRef="usd">3600000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i179d7c9dfd6c48c396b1bae4ecd566f5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xNzUvZnJhZzpjMzQ0MDY1ZDFmMjQ0YmUyODJhMTk0NDQ1NTA1MTJjMS90ZXh0cmVnaW9uOmMzNDQwNjVkMWYyNDRiZTI4MmExOTQ0NDU1MDUxMmMxXzIxMjg_245166b2-4cb4-41c7-bdc9-2002da5d3d68"
      unitRef="usd">6300000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYwOTI_77e0cb39-05f0-43ec-abaf-2b7705996dad">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYxMDM_244c910c-a3bc-484a-994c-26e66b745418">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYxMDU_210f1496-0ba9-4da9-b97f-68d222acfde5">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3bdcd617addf439bb5ac7946fc074de1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtMS0xLTEtMzgwNDE_965f44cd-a215-4f81-a5b5-7073e67a0017"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia6dfc2db43b94f5d8aae9b35c10ee05b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtMy0xLTEtMzgwNDE_24abe4a2-b853-4894-bbeb-915cf78cc33b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie5813816202a4e338fe7f589fd013674_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtNS0xLTEtMzgwNDE_c4bf2830-f074-49a8-b90f-4ebc0de5f741"
      unitRef="usd">32600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9026d99a25d84c75985b0866b64b1bf5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzMtNy0xLTEtMzgwNDE_82a32403-720b-4b27-95ad-50a7d14cb38d"
      unitRef="usd">32600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3bdcd617addf439bb5ac7946fc074de1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtMS0xLTEtMzgwNDE_de9f00d5-1c20-4053-8585-bf85c90dac8d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia6dfc2db43b94f5d8aae9b35c10ee05b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtMy0xLTEtMzgwNDE_f822effe-d60a-450a-a01e-ba939a8b6c8c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie5813816202a4e338fe7f589fd013674_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtNS0xLTEtMzgwNDE_40f64c76-9316-4c73-984a-1deec9a78bbe"
      unitRef="usd">32600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9026d99a25d84c75985b0866b64b1bf5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2YWJiZDllOTBjZmQ0ZTlhOTg4YjFhMTE5NDFmM2YxOS90YWJsZXJhbmdlOjZhYmJkOWU5MGNmZDRlOWE5ODhiMWExMTk0MWYzZjE5XzQtNy0xLTEtMzgwNDE_c3dd4584-c949-4f27-bc76-d387263b7f1b"
      unitRef="usd">32600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9f0a5a638b704e06a6d4cda5851b17f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctMS0xLTEtMzgwNDE_a9ac25cb-df4a-4344-85ff-0ff1a7977a1d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib9d670a13d5045c0a62849c225ec6a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctMy0xLTEtMzgwNDE_7e911bb5-b072-4028-b9b3-9dc3d1e17c22"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0186fb7ca56e461b9781a47361dfd131_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctNS0xLTEtMzgwNDE_13a42278-14a2-4474-9b3c-c09863060584"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1e0612bc26c446988089e7cded45f213_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzctNy0xLTEtMzgwNDE_54d9edf0-46f5-43c2-9ffb-77f3e1986090"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9f0a5a638b704e06a6d4cda5851b17f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtMS0xLTEtMzgwNDE_9ae276e0-290b-4afa-92c4-c95449182d05"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib9d670a13d5045c0a62849c225ec6a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtMy0xLTEtMzgwNDE_788bec61-8688-427b-b988-5d1ca80cce3b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0186fb7ca56e461b9781a47361dfd131_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtNS0xLTEtMzgwNDE_c1d61995-183e-4f2c-be2e-f03bc1356425"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1e0612bc26c446988089e7cded45f213_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTplMmRmNmM1OWYwNDU0YmFiODlmYzM3ZWMwMmU1MzRlMi90YWJsZXJhbmdlOmUyZGY2YzU5ZjA0NTRiYWI4OWZjMzdlYzAyZTUzNGUyXzgtNy0xLTEtMzgwNDE_6768395f-7c58-4e57-b8fb-1bf1848c51f2"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYwODU_860d7f7f-7452-404f-baee-2a85371e99ea">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzItMS0xLTEtMzgwNDE_c21dc479-3318-47f8-b640-0f6334052f65"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzItMy0xLTEtMzgwNDE_906249db-fdf9-45d6-ae5c-bed848fb4066"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzQtMS0xLTEtMzgwNDE_c5e9acfe-389e-4c43-a20f-ade259e6865f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzQtMy0xLTEtMzgwNDE_c5239425-cf10-4576-8586-064ae9a8f28b"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzUtMS0xLTEtMzgwNDE_715e29ae-7237-4644-80f8-b33b0688c618"
      unitRef="usd">-3900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzUtMy0xLTEtMzgwNDE_88a9495a-f6bb-47c4-a0b5-eb20913817dd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzYtMS0xLTEtMzgwNDE_b2add986-918b-4943-9bea-72436551469a"
      unitRef="usd">32600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo2NWY1YzY4MjdmNGE0NTJiYmEyYzdlN2Y5MTI5YTE4Ni90YWJsZXJhbmdlOjY1ZjVjNjgyN2Y0YTQ1MmJiYTJjN2U3ZjkxMjlhMTg2XzYtMy0xLTEtMzgwNDE_b244e312-6272-4102-8b67-c0fac1d5cde0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90ZXh0cmVnaW9uOjYwYjdiMzUzNzc2ODQ2ZjE4MzE4YzIxMzY2MDI3NGEzXzYxMTQ_71c6b294-5a5c-4f87-a1f4-e5eba530ced1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie5813816202a4e338fe7f589fd013674_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo0OTRjYjUzNDExODU0ZTlmYjZiNzIyYjMyMTBiMDYwYS90YWJsZXJhbmdlOjQ5NGNiNTM0MTE4NTRlOWZiNmI3MjJiMzIxMGIwNjBhXzMtMS0xLTEtNDQ4OTE_bab4f669-e73c-4869-ad33-c3e8770b3b13"
      unitRef="usd">32600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i0100835413d340b082126f866d8b23d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo0OTRjYjUzNDExODU0ZTlmYjZiNzIyYjMyMTBiMDYwYS90YWJsZXJhbmdlOjQ5NGNiNTM0MTE4NTRlOWZiNmI3MjJiMzIxMGIwNjBhXzMtNy0xLTEtNDQ4OTc_02d51c43-a201-43e3-9a85-3d9e39672cfc"
      unitRef="usd">35185000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iaeb884e998ab4b6d877b8cc4a40ee355_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTo0OTRjYjUzNDExODU0ZTlmYjZiNzIyYjMyMTBiMDYwYS90YWJsZXJhbmdlOjQ5NGNiNTM0MTE4NTRlOWZiNmI3MjJiMzIxMGIwNjBhXzQtNy0xLTEtNDQ4OTc_96b29450-869f-4459-84e9-d5971fd202ff"
      unitRef="number">0.0743</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0186fb7ca56e461b9781a47361dfd131_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTowNGJlMjM3NGY1NzM0MjY3YjZjNGJlZDM2MDZjN2YxOS90YWJsZXJhbmdlOjA0YmUyMzc0ZjU3MzQyNjdiNmM0YmVkMzYwNmM3ZjE5XzMtMS0xLTEtMzgwNDE_627514f1-0402-4d44-a2d1-465c127e2e0c"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i41098b957dca4081a3d6580e8917b49c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTowNGJlMjM3NGY1NzM0MjY3YjZjNGJlZDM2MDZjN2YxOS90YWJsZXJhbmdlOjA0YmUyMzc0ZjU3MzQyNjdiNmM0YmVkMzYwNmM3ZjE5XzMtNy0xLTEtMzgwNDE_9cef639d-b98d-4bb8-882a-7c670d164208"
      unitRef="usd">30935000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i9dc670273a9f4d978fd0fa286c1d9c0c_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODEvZnJhZzo2MGI3YjM1Mzc3Njg0NmYxODMxOGMyMTM2NjAyNzRhMy90YWJsZTowNGJlMjM3NGY1NzM0MjY3YjZjNGJlZDM2MDZjN2YxOS90YWJsZXJhbmdlOjA0YmUyMzc0ZjU3MzQyNjdiNmM0YmVkMzYwNmM3ZjE5XzQtNy0xLTEtMzgwNDE_1e1ce715-00d7-44c1-8daa-970233401f6b"
      unitRef="number">0.0604</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90ZXh0cmVnaW9uOjYwODljMDQ1NTU3NzQ4OTA5NjNmNjU2MmRjZTVhMWNhXzEzMTM_54973900-6ed2-4f56-877e-e30c24be09ea">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties as of March&#160;31, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:427.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90ZXh0cmVnaW9uOjYwODljMDQ1NTU3NzQ4OTA5NjNmNjU2MmRjZTVhMWNhXzEzMTc_a884ee3d-fc66-493a-83da-99a2a4c356cf">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties as of March&#160;31, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:427.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzMtMS0xLTEtMzgwNDE_8ac9548f-5c56-4808-a6fe-bbf9c9685383"
      unitRef="usd">3225000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzMtMy0xLTEtMzgwNDE_664ee373-909d-463a-b70b-8976c6672df4"
      unitRef="usd">2719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzQtMS0xLTEtMzgwNDE_f9fc4bfd-7206-4046-b465-bd49bd9287eb"
      unitRef="usd">11000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzQtMy0xLTEtMzgwNDE_8f7c17bc-141c-4582-a2f3-3520474d0feb"
      unitRef="usd">15000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzUtMS0xLTEtMzgwNDE_41bd3d42-567d-482c-bf22-56cd08671bd4"
      unitRef="usd">4958000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzUtMy0xLTEtMzgwNDE_828d0002-3427-46bb-bc6c-417404db6670"
      unitRef="usd">4877000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzgtMS0xLTEtMzgwNDE_ccc93c5a-8725-4320-8dde-e6f9335c8539"
      unitRef="usd">334000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzgtMy0xLTEtMzgwNDE_e5af2d6f-3345-49b0-bf5e-41759a6d65b4"
      unitRef="usd">1967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzktMS0xLTEtMzgwNDE_4a8cb18a-eec1-42db-ad27-3fe02e6fbdc2"
      unitRef="usd">1222000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzktMy0xLTEtMzgwNDE_78c16d3b-a7c6-442f-b624-a79f03435078"
      unitRef="usd">1120000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i53f1f40c73a441669cb646b2f251c21b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzEwLTEtMS0xLTM4MDQx_d57a3ba6-2c9c-4c4b-9470-3c02c1692d4b"
      unitRef="usd">550000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i81fe5ead28f143cf8fde6c66ddd12eeb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZTpiYmFmNDA5NmQ2MDQ0NzI2YmU0MGI0YTI3YTA0NzdkMi90YWJsZXJhbmdlOmJiYWY0MDk2ZDYwNDQ3MjZiZTQwYjRhMjdhMDQ3N2QyXzEwLTMtMS0xLTM4MDQx_65275d89-40ef-4f61-8d07-d397d91cc8b7"
      unitRef="usd">734000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i84334888c1ce4f9596774398cccb24d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzQtMS0xLTEtMzgwNDE_023afedb-748b-48fd-a3e3-59c5045fc00a"
      unitRef="usd">32064000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i3c70b95cce0942dc8555c7160e7baec8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzQtMy0xLTEtMzgwNDE_5607e38c-d5a1-4cab-a805-8cdb7aa02cb6"
      unitRef="usd">15575000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i932695caa0e3475e8d26b62529c3f9e0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzctMS0xLTEtMzgwNDE_bd28f3f3-e51b-4feb-9afb-d253691c1fc1"
      unitRef="usd">26461000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i7a2176e74b934dfbab0732b31233603a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzctMy0xLTEtMzgwNDE_7f83af3d-60e8-4132-b4b0-f73e2fa78bf6"
      unitRef="usd">493000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i11b60b44365747aa9dddac9017e65fb6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzgtMS0xLTEtMzgwNDE_8213c725-315c-466f-8580-f67f330859c3"
      unitRef="usd">66000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="id0bbb5ca4f6640a98bc3bee2e63b3dd2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODQvZnJhZzo2MDg5YzA0NTU1Nzc0ODkwOTYzZjY1NjJkY2U1YTFjYS90YWJsZToyODEyMDE4Y2FkMWE0Yzk5YTVmMDZkNDE0MDE5Yjg5ZC90YWJsZXJhbmdlOjI4MTIwMThjYWQxYTRjOTlhNWYwNmQ0MTQwMTliODlkXzgtMy0xLTEtMzgwNDE_24330461-6476-40fe-a80c-96b3899b7bf9"
      unitRef="usd">31000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90ZXh0cmVnaW9uOjBiOThhNjMzYmNlNjRjNjk4MTYyMjdhYzQ3YTMzNGUyXzE1MTI_512eeb79-4a41-4fb4-9272-c399b2af3f4e">Repositioning and Other Changes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#x201c;Repositioning Plan&#x201d;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90ZXh0cmVnaW9uOjBiOThhNjMzYmNlNjRjNjk4MTYyMjdhYzQ3YTMzNGUyXzE1MTM_ec83b11d-919f-4281-a8c2-c672b9a6090d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i785637c478644f3baa2265dd139ec9f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzEtMS0xLTEtNDg4MjU_72242e77-f227-4346-938a-f2b301bc67d5"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i362167a0c9b34805a0af2b448541b5bb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzItMy0xLTEtMzgwNDE_b81382f5-1719-43f1-a99e-1558a7f1af35"
      unitRef="usd">109000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i1a7f05d669f4496886a6a7a00d768285_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzItMS0xLTEtNDg4MjU_7e8ac20a-63fd-4620-b928-3780692e029e"
      unitRef="usd">2742000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i64d445fb027342059acb0abc5062875b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzMtMy0xLTEtMzgwNDE_11a51662-223b-49a3-95c7-8946f1a85f21"
      unitRef="usd">2071000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="id24fa32341354c11976ef219f1db4536_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzMtMS0xLTEtNDg4MjU_353f3370-88e1-40a9-8b45-9671a1cbbdd3"
      unitRef="usd">5666000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i7e6a736386954271be092327c488a4c4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzQtMy0xLTEtMzgwNDE_8bb1486c-2595-4e5e-994c-378ffc69b18a"
      unitRef="usd">3200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzQtMS0xLTEtNDg4MjU_e027be72-ec72-4070-8f76-cbf28b526765"
      unitRef="usd">8593000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xODcvZnJhZzowYjk4YTYzM2JjZTY0YzY5ODE2MjI3YWM0N2EzMzRlMi90YWJsZTo1MDVkNTA1NjY2YTE0ODNhYTAyNDFjNGNmNThmN2MwMy90YWJsZXJhbmdlOjUwNWQ1MDU2NjZhMTQ4M2FhMDI0MWM0Y2Y1OGY3YzAzXzUtMy0xLTEtMzgwNDE_bb2d6799-c137-41f0-b614-b1a7d4886fcd"
      unitRef="usd">5380000</us-gaap:RestructuringCharges>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzM0Mzg_6eaa2606-05c1-46c7-85dd-02ded4a82a34">Segment Reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzI5Ng_d4102f92-f85a-4b42-8e65-d2714a079e9b"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzM0NDA_e1bfa57a-4d1e-499c-bb16-f62744735768">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecd6828c06c24f6caac1d47d36f0f87f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtMS0xLTEtMzgwNDE_c5443c34-5bc4-4fd5-b319-12865f051acc"
      unitRef="usd">107318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c783f7550a946bbaf1d21f6f1d5c181_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtMy0xLTEtMzgwNDE_3310c92b-9034-4854-9afc-0e7fa21043a4"
      unitRef="usd">190199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79be648cb3694442bbf24990de4e33be_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtNS0xLTEtMzgwNDE_9984645e-9edd-4961-8619-ebf82ca367ae"
      unitRef="usd">-460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1860fdb5d9754126b8f298b7c351df82_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtNy0xLTEtMzgwNDE_8ffa371b-5636-44a8-9bdb-2c52d9d60d38"
      unitRef="usd">297057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie409a91d5d8847ecb8729ff061b06528_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtOS0xLTEtMzgwNDE_9c61af7b-32b1-4a90-b7c9-381e6a552e0a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzUtMTEtMS0xLTM4MDQx_0000d229-98d3-4ad7-8f91-bb4eb64f33c4"
      unitRef="usd">297057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a20d756ebe344c49afc88a4c8988a92_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTEtMS0xLTM4MDQx_2fce27db-ec56-4620-ac56-da526829531d"
      unitRef="usd">85286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i532454a81aa1485d94751de5cd927545_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTMtMS0xLTM4MDQx_231964bf-38f5-4c17-8600-2b21d2750657"
      unitRef="usd">130223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a704469f121488395cdba78ef29222f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTUtMS0xLTM4MDQx_7ad7a558-e9f2-41f9-a908-73f62fdfb5a7"
      unitRef="usd">-438000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61686756cdc94fe487cf6ab99ac88a18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTctMS0xLTM4MDQx_13ef98b4-51e5-4147-ab9c-94a7ceafba8d"
      unitRef="usd">215071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dca42daa64b4aff97d52b7b8e251ed1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTktMS0xLTM4MDQx_9c1d0ad8-89e7-42af-8072-b036b7c12404"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzEwLTExLTEtMS0zODA0MQ_267bd634-607d-421b-be40-b5c58c7f1378"
      unitRef="usd">215071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="iecd6828c06c24f6caac1d47d36f0f87f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTEtMS0xLTM4MDQx_f90e7489-568b-4ce1-bcf0-bb87a5dd35c8"
      unitRef="usd">8217000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i0c783f7550a946bbaf1d21f6f1d5c181_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTMtMS0xLTM4MDQx_53b8e890-bf89-47d1-a7ff-4ee8db5f7a7e"
      unitRef="usd">22196000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1860fdb5d9754126b8f298b7c351df82_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTUtMS0xLTM4MDQx_d9e99a7b-4a58-43a8-8a6c-7c720bbed15a"
      unitRef="usd">30413000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie409a91d5d8847ecb8729ff061b06528_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTctMS0xLTM4MDQx_06f02fd2-0ff2-404c-a691-50992069226e"
      unitRef="usd">-6158000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzE5LTktMS0xLTM4MDQx_5737139e-709a-45e1-bfe3-d5581765e351"
      unitRef="usd">24255000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i0a20d756ebe344c49afc88a4c8988a92_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTEtMS0xLTM4MDQx_384c1214-08f9-4052-9b21-a8e8e3365e47"
      unitRef="usd">5942000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i532454a81aa1485d94751de5cd927545_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTMtMS0xLTM4MDQx_d3916846-ee9d-432a-9113-5851b9a98e4b"
      unitRef="usd">15976000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i61686756cdc94fe487cf6ab99ac88a18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTUtMS0xLTM4MDQx_5c907675-004d-43ec-8bcc-9986d7ed2978"
      unitRef="usd">21918000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4dca42daa64b4aff97d52b7b8e251ed1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTctMS0xLTM4MDQx_38f1e6a9-5610-426d-89dd-d3dcb536e7e6"
      unitRef="usd">-7011000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTowYjVlNmM0N2E2Nzg0N2QxYWQ4MTg4OGVkNDFjY2YyMS90YWJsZXJhbmdlOjBiNWU2YzQ3YTY3ODQ3ZDFhZDgxODg4ZWQ0MWNjZjIxXzIyLTktMS0xLTM4MDQx_d7bc7836-cd06-4a72-9e76-8a04f72ee5cb"
      unitRef="usd">14907000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzM0NDI_afbe4a8e-f2db-4d1b-9bac-3b8cc42c702f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzItMS0xLTEtMzgwNDE_bc4e44ba-1b60-4292-9160-554bd8346fdb"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzItMy0xLTEtMzgwNDE_e1c8e105-343a-4a66-bc22-c8b07072928e"
      unitRef="usd">-9807000</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzQtMS0xLTEtMzgwNDE_e922cac3-67b4-45bc-9eba-8abed983a24f"
      unitRef="usd">117000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzQtMy0xLTEtMzgwNDE_bd120e3c-5278-4f3e-931a-dc0c9a71501b"
      unitRef="usd">123000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzUtMS0xLTEtMzgwNDE_1661b0d8-678f-4585-b1ed-a5441f2c43c3"
      unitRef="usd">2241000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzUtMy0xLTEtMzgwNDE_1a43bbd8-fabf-49ad-9c96-07fd5a5b9ef1"
      unitRef="usd">6337000</us-gaap:InterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzYtMS0xLTEtMzgwNDE_d79a5e0f-2368-4b0c-9c0b-c9d1fe7746e6"
      unitRef="usd">1202000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzYtMy0xLTEtMzgwNDE_95859495-29f1-4c24-8118-a30ae70578a2"
      unitRef="usd">611000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzctMS0xLTEtMzgwNDE_3deee8a6-ba6b-4b93-b73d-27b511064e0a"
      unitRef="usd">15106000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzctMy0xLTEtMzgwNDE_54586aec-394a-4b3e-879e-c00dd952744d"
      unitRef="usd">15187000</us-gaap:DepreciationAndAmortization>
    <evh:GainOnTransferOfMembership
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzktMS0xLTEtMzgwNDE_59dce7d8-3de6-48b7-9eee-f7abcc25727a"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzktMy0xLTEtMzgwNDE_79fd5414-5bbc-4817-a138-97ab5bcbf28f"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEwLTEtMS0xLTM4MDQx_43f12d82-bcab-4f06-9478-418720bd50a5"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEwLTMtMS0xLTM4MDQx_19ae8b78-bdf6-43e7-9020-cf146a649e19"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEzLTEtMS0xLTM4MDQx_46e0ab21-34b1-47b2-b637-f965077a3fef"
      unitRef="usd">596000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzEzLTMtMS0xLTM4MDQx_251c7e4f-e044-4fdd-8861-0a5a0e641580"
      unitRef="usd">7783000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE1LTEtMS0xLTM4MDQx_676be44a-a679-4e97-b0e7-6249dc649dcd"
      unitRef="usd">6078000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE1LTMtMS0xLTM4MDQx_9de83ae0-e76d-4cba-8010-99c1eb774ee8"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE3LTEtMS0xLTM4MDQx_818d89a8-d2cc-4278-a7a2-2866dc2d990a"
      unitRef="usd">178000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE3LTMtMS0xLTM4MDQx_d8a51639-b63e-4a13-ac52-d8b9ba1644f3"
      unitRef="usd">-14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE5LTEtMS0xLTM4MDQx_1ed5d0c0-3e54-4076-98b4-dc3abbe1ee84"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzE5LTMtMS0xLTM4MDQx_2cb8f6d6-7850-4ea2-9eb7-72aadc64ff39"
      unitRef="usd">5380000</us-gaap:RestructuringCharges>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIwLTEtMS0xLTM4MDQx_c6539c79-c65f-4f19-ac54-a14aec7caee9"
      unitRef="usd">5346000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIwLTMtMS0xLTM4MDQx_74da227b-02d6-4ce0-8a40-dfb84e9bce92"
      unitRef="usd">3706000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <us-gaap:SeveranceCosts1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIxLTEtMS0xLTM4MDQx_2a43d66f-e1f8-4ac6-bdda-d35cff0dfb1c"
      unitRef="usd">39000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIxLTMtMS0xLTM4MDQx_0aef6bbe-4adb-4f99-818f-e591227be05c"
      unitRef="usd">52000</us-gaap:SeveranceCosts1>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIyLTEtMS0xLTM4MDQx_0be038f0-bd97-4e15-96e0-a61263edff20"
      unitRef="usd">27000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIyLTMtMS0xLTM4MDQx_b4e0beb9-2cd2-485e-8df0-19dbd26cfe28"
      unitRef="usd">127000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:ShareholderAdvisoryServices
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIzLTEtMS0xLTM4MDQx_6551c2cd-e682-4169-8587-b6e8e8f35fe1"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzIzLTMtMS0xLTM4MDQx_5cf5dee1-2022-451f-9a29-366fdcda981f"
      unitRef="usd">5000000</evh:ShareholderAdvisoryServices>
    <evh:TransactionCosts
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI0LTEtMS0xLTM4MDQx_219694df-ab44-4301-b604-94b7a79e0b65"
      unitRef="usd">457000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI0LTMtMS0xLTM4MDQx_6fb024fe-5508-471b-b346-fb41e40996e4"
      unitRef="usd">1994000</evh:TransactionCosts>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI1LTEtMS0xLTM4MDQx_2d5e4735-cd60-4f58-9648-6364ebe594d6"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI1LTMtMS0xLTM4MDQx_4d2b4a53-a0da-4287-9f26-6b281d2549ba"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI2LTEtMS0xLTM4MDQx_ff048afc-28a6-4358-87d0-b87653c154b4"
      unitRef="usd">24255000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90YWJsZTo1NzAyZjkxYzVjYjk0NWJjYTEwNmQ1MzIxMWY0NzAwMy90YWJsZXJhbmdlOjU3MDJmOTFjNWNiOTQ1YmNhMTA2ZDUzMjExZjQ3MDAzXzI2LTMtMS0xLTM4MDQx_ddbab18b-fc2f-4a0b-8e48-c28169fa26be"
      unitRef="usd">14907000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTAvZnJhZzozMTlhZGY2MzU1ZjQ0NzE4YWE1N2JmZTc5ODM4ZTk1ZS90ZXh0cmVnaW9uOjMxOWFkZjYzNTVmNDQ3MThhYTU3YmZlNzk4MzhlOTVlXzMyMDU_cdf04ab3-2ef2-4d3d-8dd6-d6e99cea8778"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90ZXh0cmVnaW9uOmQ5NmY5N2Y4OGFhMjRmMTVhNzQ4ZGM4ZTAwZjlkMzhmXzQ3NzM_84c5b98d-e9af-4ae5-b28e-2f942a1c5a1a">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on reserves for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90ZXh0cmVnaW9uOmQ5NmY5N2Y4OGFhMjRmMTVhNzQ4ZGM4ZTAwZjlkMzhmXzQ3NzU_bdaf24e4-4fb0-45bf-839a-61788ea90451">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on reserves for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i58d4563528a74ddc8daf7cfcc8df4f4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtMS0xLTEtMzgwNDE_9671389b-44d0-4c26-be38-d65a31ac50ec"
      unitRef="usd">25618000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2dd83794d6dc499596834a18cd5a2a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtMy0xLTEtMzgwNDE_6d4e4000-a13a-4d37-b183-e7cc12c54f88"
      unitRef="usd">145676000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if299fb55051e4d729c1f4c44566a6f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtNS0xLTEtMzgwNDE_bb84aed9-192e-4bf9-a965-ea40a7cb938c"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i431455fda9da407ea1273e3d11bbbb34_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtNy0xLTEtMzgwNDE_0db31cba-d5ce-4b8c-8af6-f8997094c8b8"
      unitRef="usd">122532000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie9c9d5a6a37649e3b44edf8049cce4da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtOS0xLTEtMzgwNDE_23301783-8f1d-446f-8708-ab27ee2664a3"
      unitRef="usd">56295000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie3df9d6bb9de4a3cb19ad59f19a3d13c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzMtMTEtMS0xLTM4MDQx_42eaf065-b918-46be-b261-e2a4c2efea05"
      unitRef="usd">178827000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtMS0xLTEtMzgwNDE_4c96b5da-f2e9-4cac-93fd-9445aba7762e"
      unitRef="usd">0</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtMy0xLTEtMzgwNDE_a6216665-967b-41fc-9038-97adc4221eb5"
      unitRef="usd">102664000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtNS0xLTEtMzgwNDE_fac81aa4-1abd-4ec3-9e9c-0e4abc9a9566"
      unitRef="usd">102664000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtNy0xLTEtMzgwNDE_25fc126c-acf5-4ae7-9bf3-198b4c98b204"
      unitRef="usd">104098000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtOS0xLTEtMzgwNDE_b4deafea-76e1-469b-8244-7ec507785591"
      unitRef="usd">4189000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzUtMTEtMS0xLTM4MDQx_6a4cb935-5b27-428d-b8e0-0fb8666c56e8"
      unitRef="usd">108287000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtMS0xLTEtMzgwNDE_f8274f0b-1adb-46a9-9e97-b46adc06d67a"
      unitRef="usd">-8465000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtMy0xLTEtMzgwNDE_51177393-66ac-4575-8454-63d043884088"
      unitRef="usd">14976000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtNS0xLTEtMzgwNDE_381c5428-60ca-437b-ad7c-0471da50d915"
      unitRef="usd">6511000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtNy0xLTEtMzgwNDE_079c141d-25e9-49cf-87ba-b52b535ccfbc"
      unitRef="usd">24000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtOS0xLTEtMzgwNDE_fad30ade-4956-464a-bbd9-278e30d66292"
      unitRef="usd">4151000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzYtMTEtMS0xLTM4MDQx_5c2b2466-ee8e-4ade-ac36-856291675f13"
      unitRef="usd">4175000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctMS0xLTEtMzgwNDE_e26209b7-001d-4b1d-88f9-1049c1a312d3"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctMy0xLTEtMzgwNDE_bbc2fd73-19a4-42b2-90cf-bcd12f0afd38"
      unitRef="usd">47724000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctNS0xLTEtMzgwNDE_18427b95-709a-4a24-a959-3bc15ac09632"
      unitRef="usd">47724000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctNy0xLTEtMzgwNDE_40e49ece-2e3d-4271-b3c6-05add52f66f3"
      unitRef="usd">30761000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctOS0xLTEtMzgwNDE_1ad4fb43-2a14-4275-9975-4f14eae264e3"
      unitRef="usd">11164000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzctMTEtMS0xLTM4MDQx_76b4a2c6-7731-442a-9608-c800f24b258e"
      unitRef="usd">41925000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtMS0xLTEtMzgwNDE_2acb5b86-80db-455f-9615-8636db5c0c94"
      unitRef="usd">-483000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtMy0xLTEtMzgwNDE_2bbb1d01-c3e0-4402-b9f9-21bf32ce759b"
      unitRef="usd">59974000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtNS0xLTEtMzgwNDE_391af99a-49e5-4411-9d6c-ae6ac28e7406"
      unitRef="usd">59491000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtNy0xLTEtMzgwNDE_62e3cc6c-4001-4810-8bf5-178cb76acbee"
      unitRef="usd">38053000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtOS0xLTEtMzgwNDE_4d0d78fc-e801-4853-af55-788008e490bb"
      unitRef="usd">10200000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzgtMTEtMS0xLTM4MDQx_2747e613-9294-4a1f-82dd-edba4915af07"
      unitRef="usd">48253000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktMS0xLTEtMzgwNDE_b8c304a4-1e99-4174-9db3-39ac92aea55a"
      unitRef="usd">-7982000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktMy0xLTEtMzgwNDE_71e79ba3-e926-4a4a-9720-c48740a940c4"
      unitRef="usd">9942000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktNS0xLTEtMzgwNDE_f2c3079d-ba03-46d1-8cbd-c680927c0c5a"
      unitRef="usd">1960000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktNy0xLTEtMzgwNDE_a6573786-7ea8-4bf4-8010-fd785d610586"
      unitRef="usd">35308000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktOS0xLTEtMzgwNDE_913caca7-3459-4c92-8c95-34c81a868601"
      unitRef="usd">-13024000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzktMTEtMS0xLTM4MDQx_47b9d962-c7a2-4405-be84-df3bfbe5b93c"
      unitRef="usd">22284000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="iaaa9611b5bd34f5681b047da95876c09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTEtMS0xLTM4MDQx_5023f5a5-8259-4363-bbd8-c7de0441e4dc"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i83fe73f5f83a453197905af8e88c3ef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTMtMS0xLTM4MDQx_29bb0e1f-13f2-49e1-8de0-ca00421e437d"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTUtMS0xLTM4MDQx_ba3dcd94-dc12-4718-a47e-a7a93f43f8bd"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i4de089ce7d704983b439a9b60ca027ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTctMS0xLTM4MDQx_eda4ec7f-bf49-4a81-95bd-44fb9d543c1f"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i771984e7093941f9ac5226bcd878fcae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTktMS0xLTM4MDQx_3bddb666-69fb-43d3-80fc-8035dbcd7110"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzExLTExLTEtMS0zODA0MQ_41bea09b-a54b-4f1f-a75e-2a4e01156be6"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTEtMS0xLTM4MDQx_edbf612f-e661-41a0-b18e-45af6da653c2"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTMtMS0xLTM4MDQx_6773646f-3a08-4c05-942a-61eda586ef22"
      unitRef="usd">9016000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTUtMS0xLTM4MDQx_da2246ca-dd8b-401e-914c-8f19b0532d0a"
      unitRef="usd">9016000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i946bb3ded8914db29f26e0bac8b58b89_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTctMS0xLTM4MDQx_0f0a4364-ff7f-42ba-848b-9774354a322b"
      unitRef="usd">-2658000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTktMS0xLTM4MDQx_da1a4699-c8e8-4920-adb0-f04764708acb"
      unitRef="usd">-4224000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEyLTExLTEtMS0zODA0MQ_33bb739d-3f4c-4a49-8724-1e2375d19369"
      unitRef="usd">-6882000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i310fa4fae15e4befbf8deae5c82cbb5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTEtMS0xLTM4MDQx_c9616fc3-a9f7-42da-95c3-b9de2f9a3921"
      unitRef="usd">17636000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i86024b277d3c4ec3ba4ff2a1d64cad9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTMtMS0xLTM4MDQx_fda207d5-0961-4c67-b7f6-dccd97d950b6"
      unitRef="usd">146602000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTUtMS0xLTM4MDQx_a54c8367-2c55-434e-890e-fbcd7b4baf7b"
      unitRef="usd">164238000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i946bb3ded8914db29f26e0bac8b58b89_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTctMS0xLTM4MDQx_c0a866d3-d512-46af-97ab-91eb4699aed8"
      unitRef="usd">160498000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i13c40e379efd4b09ae0ac13c05e0ee9a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTktMS0xLTM4MDQx_18ec019e-bbb6-476b-a752-8a64623d8739"
      unitRef="usd">47495000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i33645fe6fe6e4f2b970ee1650d578425_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xOTMvZnJhZzpkOTZmOTdmODhhYTI0ZjE1YTc0OGRjOGUwMGY5ZDM4Zi90YWJsZTowMDE0MmE0ZmYxY2I0M2FiYmQ1MTNiNGU5OGFmOTczMy90YWJsZXJhbmdlOjAwMTQyYTRmZjFjYjQzYWJiZDUxM2I0ZTk4YWY5NzMzXzEzLTExLTEtMS0zODA0MQ_3f774038-0d96-4f0b-a5c5-97ad5e9f0a57"
      unitRef="usd">207993000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90ZXh0cmVnaW9uOmEyZjJmNjhhNWY5YjQzNmZhN2U4ZDQ4NmI2YzMzMWZkXzEzOA_b862bc76-cc21-4e9b-99cb-23b215af9e8a">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets obtained in exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90ZXh0cmVnaW9uOmEyZjJmNjhhNWY5YjQzNmZhN2U4ZDQ4NmI2YzMzMWZkXzEzNA_62fe730e-b854-49fa-92f5-2e6c30bfa919">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets obtained in exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzgtMS0xLTEtMzgwNDE_9017f36f-e013-4bb4-9d2c-94cf7c1984dd"
      unitRef="usd">670000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzgtMy0xLTEtMzgwNDE_92673e09-c908-4c98-8877-e9dd3419f476"
      unitRef="usd">124000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OperatingLeasePayments
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzExLTEtMS0xLTM4MDQx_8887a09d-dbb9-4c7c-9df4-d2444d153a9a"
      unitRef="usd">3830000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzExLTMtMS0xLTM4MDQx_bcb2dd2f-88b1-4e91-8b31-76c25de15f14"
      unitRef="usd">3410000</us-gaap:OperatingLeasePayments>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzEyLTEtMS0xLTM4MDQx_144e1301-efab-49c4-962a-0cb9810037ad"
      unitRef="usd">3000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i1623fa44597143889f19c0188c630b48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8yMDIvZnJhZzphMmYyZjY4YTVmOWI0MzZmYTdlOGQ0ODZiNmMzMzFmZC90YWJsZTplNzgzZmExMWQ0YzQ0MmNhYmUxOTBiMjZlMDE1MmNhMS90YWJsZXJhbmdlOmU3ODNmYTExZDRjNDQyY2FiZTE5MGIyNmUwMTUyY2ExXzEyLTMtMS0xLTM4MDQx_f1a2561e-6205-45b2-a854-e05754a577e2"
      unitRef="usd">2157000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTMtMS0xLTM4MDQx_6fd0a3a8-040f-462e-b385-4744c51aa458"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTMtMS0xLTM4MDQx_6fd0a3a8-040f-462e-b385-4744c51aa458"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTEtMS0xLTM4MDQx_c7c39c63-a8f0-40c0-9113-19cd02f14912"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTEtMS0xLTM4MDQx_c7c39c63-a8f0-40c0-9113-19cd02f14912"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTMtMS0xLTM4MDQx_c943eec5-0a37-4672-8c00-04b3abf2821c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTMtMS0xLTM4MDQx_c943eec5-0a37-4672-8c00-04b3abf2821c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTEtMS0xLTM4MDQx_32c854fb-e4a9-4b6e-b7c4-d48591ef4ca9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTEtMS0xLTM4MDQx_32c854fb-e4a9-4b6e-b7c4-d48591ef4ca9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021. See Note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTMtMS0xLTM4MDQx_6fd0a3a8-040f-462e-b385-4744c51aa458"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTEtMS0xLTM4MDQx_c7c39c63-a8f0-40c0-9113-19cd02f14912"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzYwLTMtMS0xLTM4MDQx_c943eec5-0a37-4672-8c00-04b3abf2821c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90YWJsZTpkM2NiNmQxNjMwYzA0YzEwYTA2NzY1YjQ1NTlhMWU3OS90YWJsZXJhbmdlOmQzY2I2ZDE2MzBjMDRjMTBhMDY3NjViNDU1OWExZTc5XzU5LTEtMS0xLTM4MDQx_32c854fb-e4a9-4b6e-b7c4-d48591ef4ca9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDkvZnJhZzowNmY5ZGFiNTFiZDY0YzQ2ODgwNzFlOTBjNTZmZTdjMS90ZXh0cmVnaW9uOjA2ZjlkYWI1MWJkNjRjNDY4ODA3MWU5MGM1NmZlN2MxXzYzMg_9b435170-3c07-4d9a-947a-f4bf78f7e5b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMS0xLTEtMzgwNDE_661172f1-58ab-48c2-a568-759fa6e953b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMS0xLTEtMzgwNDE_661172f1-58ab-48c2-a568-759fa6e953b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMS0xLTEtMzgwNDE_81ef6c46-a72e-41e5-b111-18d2ff049ec4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMS0xLTEtMzgwNDE_81ef6c46-a72e-41e5-b111-18d2ff049ec4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMy0xLTEtMzgwNDE_8c8d976e-4caf-456d-b0e9-f2edbdbdca40"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMy0xLTEtMzgwNDE_8c8d976e-4caf-456d-b0e9-f2edbdbdca40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMS0xLTEtMzgwNDE_92c74fa3-30f6-4d04-badb-d1024124696d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMS0xLTEtMzgwNDE_92c74fa3-30f6-4d04-badb-d1024124696d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMy0xLTEtMzgwNDE_3f9314cc-6eeb-467f-867f-1275cae5becf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMy0xLTEtMzgwNDE_3f9314cc-6eeb-467f-867f-1275cae5becf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMy0xLTEtMzgwNDE_769e699f-2c7b-4b79-81b7-4f27e00c62a8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMy0xLTEtMzgwNDE_769e699f-2c7b-4b79-81b7-4f27e00c62a8"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMS0xLTEtMzgwNDE_661172f1-58ab-48c2-a568-759fa6e953b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMS0xLTEtMzgwNDE_81ef6c46-a72e-41e5-b111-18d2ff049ec4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzktMy0xLTEtMzgwNDE_8c8d976e-4caf-456d-b0e9-f2edbdbdca40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMS0xLTEtMzgwNDE_92c74fa3-30f6-4d04-badb-d1024124696d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzgtMy0xLTEtMzgwNDE_3f9314cc-6eeb-467f-867f-1275cae5becf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90YWJsZTo5NzFmNzU4YzBkMWM0NjRkODQ3YzM4ZTEzOTAyNjljMS90YWJsZXJhbmdlOjk3MWY3NThjMGQxYzQ2NGQ4NDdjMzhlMTM5MDI2OWMxXzUtMy0xLTEtMzgwNDE_769e699f-2c7b-4b79-81b7-4f27e00c62a8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDMvZnJhZzowMjc3MDQ4ZTFhYmY0Y2QxOGVmMGU2YjBiYmYyZWE5My90ZXh0cmVnaW9uOjAyNzcwNDhlMWFiZjRjZDE4ZWYwZTZiMGJiZjJlYTkzXzMxNg_5f185a13-d4d8-4111-9ff0-723a3e59b613"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTEtMS0xLTM4MDQx_03c06028-7880-493c-814e-235966f93b85"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTEtMS0xLTM4MDQx_03c06028-7880-493c-814e-235966f93b85"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTMtMS0xLTM4MDQx_b4e53bf8-d830-4b84-8101-e40711400838"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTMtMS0xLTM4MDQx_b4e53bf8-d830-4b84-8101-e40711400838"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTMtMS0xLTM4MDQx_b2ea2841-f141-4b34-b324-9c59f559db5b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTMtMS0xLTM4MDQx_b2ea2841-f141-4b34-b324-9c59f559db5b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTMtMS0xLTM4MDQx_0193734e-ac0b-42ec-a951-e4beb268ad60"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTMtMS0xLTM4MDQx_0193734e-ac0b-42ec-a951-e4beb268ad60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTMtMS0xLTM4MDQx_589fce9d-e9d4-4854-b765-72985b41428d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTMtMS0xLTM4MDQx_589fce9d-e9d4-4854-b765-72985b41428d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTEtMS0xLTM4MDQx_6b9c5b33-1c7b-477a-b6e8-54b6fcdf1e57"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTEtMS0xLTM4MDQx_6b9c5b33-1c7b-477a-b6e8-54b6fcdf1e57"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTEtMS0xLTM4MDQx_8cb7d434-69ac-4c33-975d-3a90e8560b2d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTEtMS0xLTM4MDQx_8cb7d434-69ac-4c33-975d-3a90e8560b2d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMS0xLTEtMzgwNDE_81bbfe1c-390a-4b05-9055-6f6690e0e0ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMS0xLTEtMzgwNDE_81bbfe1c-390a-4b05-9055-6f6690e0e0ee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTEtMS0xLTM4MDQx_752cd560-3755-4dbb-a489-b769fcc23884"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTEtMS0xLTM4MDQx_752cd560-3755-4dbb-a489-b769fcc23884"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMS0xLTEtMzgwNDE_196a7221-1ecc-4efc-a498-182fd87e1023"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMS0xLTEtMzgwNDE_196a7221-1ecc-4efc-a498-182fd87e1023"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMy0xLTEtMzgwNDE_3680218e-efe6-4126-9699-ed074a978f07"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMy0xLTEtMzgwNDE_3680218e-efe6-4126-9699-ed074a978f07"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMy0xLTEtMzgwNDE_97157884-4719-4910-82f6-a01524ef325e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMy0xLTEtMzgwNDE_97157884-4719-4910-82f6-a01524ef325e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTEtMS0xLTM4MDQx_03c06028-7880-493c-814e-235966f93b85"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTMtMS0xLTM4MDQx_b4e53bf8-d830-4b84-8101-e40711400838"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTMtMS0xLTM4MDQx_b2ea2841-f141-4b34-b324-9c59f559db5b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzE0LTMtMS0xLTM4MDQx_0193734e-ac0b-42ec-a951-e4beb268ad60"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTMtMS0xLTM4MDQx_589fce9d-e9d4-4854-b765-72985b41428d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzIzLTEtMS0xLTM4MDQx_6b9c5b33-1c7b-477a-b6e8-54b6fcdf1e57"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI5LTEtMS0xLTM4MDQx_8cb7d434-69ac-4c33-975d-3a90e8560b2d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMS0xLTEtMzgwNDE_81bbfe1c-390a-4b05-9055-6f6690e0e0ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzI0LTEtMS0xLTM4MDQx_752cd560-3755-4dbb-a489-b769fcc23884"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMS0xLTEtMzgwNDE_196a7221-1ecc-4efc-a498-182fd87e1023"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzctMy0xLTEtMzgwNDE_3680218e-efe6-4126-9699-ed074a978f07"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90YWJsZTpmNGNhOTFhMWJiYTA0N2ZjODlkMDdiOTA1NTdlMTY2Yi90YWJsZXJhbmdlOmY0Y2E5MWExYmJhMDQ3ZmM4OWQwN2I5MDU1N2UxNjZiXzYtMy0xLTEtMzgwNDE_97157884-4719-4910-82f6-a01524ef325e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJiNjRhNThjNTAxMDQ1OGRhNjUwYzNiN2M4ZGZhYjc0L3NlYzpiYjY0YTU4YzUwMTA0NThkYTY1MGMzYjdjOGRmYWI3NF8xMDAvZnJhZzo5Y2ExZWQ2M2RiODE0YzcxYjBmMGYxNDRjNmVmY2YwOC90ZXh0cmVnaW9uOjljYTFlZDYzZGI4MTRjNzFiMGYwZjE0NGM2ZWZjZjA4XzE3OQ_dcf988ba-ca68-46cb-946e-c5139c102939"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?5Y)*U$<<I)',%FZKHL1K(R XE+^F>#(G,%,?):KU$H.AQLJN#+7,L7(5?Y
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M"Z# #=L+NU2')SSF<^OX<B6,_\+A&-L.(-\;JZHCF!147-8K^SC6X0P0=2X
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MM&8BULSXP1IP6V\YF&?<&EP-0N_KD$>;=!AJ2,T)&ZHNQG"R]S(+@ZX*_36
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M<^50-+X@(6EJ'*]4 (PKN=/I'02E9<]<U<*%!,@*KG?1/K&%([#!89<U]:X
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M0K-OWN=%:LE%7ONDLHK=\)?1*Y4"N2T<ZAUX+QN/S.QC)7)B%Y+[WGZ!D-S
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MCAMJJ5INN#"%+JABPLV#\BM%SYQ(;7-*,Q*F+80-'?NI43:',5$TGD(A9&A
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MB%,-/Y8*%?0T =\7#C>8=D .MO\3N?@/4$L#!!0    ( %>1I%35'O01<@,
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MU$Z!WF^5LL>-<S!^D:S^ 5!+ P04    " !7D:14-#?]GHD(  "J%0  &0
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MX:3\CI5\(VL!?V>,?TBW2;GA+"FS*XF&OU)I)7;:^@ Y#L9<JP TO-ZR%'
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M& @P-H'3$SRC9/_; .TAR?LE!XQ70'Z(A_,$@-S!LH"M^$:4)1%9>JL"XPE
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M%XX>JNYA?]=/MTY:/Y9#+3#CGP3RE8N\E-_-U9_6OSH<RX_MFL?E)XO8;4;
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MD'B>H87I-=J$*Q[8-;X7_&'QJ,+; U+T]?()S;%8277(8Y*3#?D!;Z(P,%Q
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*U5;6_;-A#^*P>A'U9
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MX5J>'BM\![&7!9A?.1QMW8L ]%]6UW\#4$L#!!0    ( %>1I%3*3IF*Y0D
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M[F+4SKBBLXY]<6^:5E>(VE+EV@"#P),/!@X_WZTNDU36M]*/-V="[15ZC01
M3)A:,G(K5C#IHY^O(M(1M^AB.8196-B./JQE:\I>1WRX(1GG$SO+H'=N&.PQ
M="VXNPVM=+9K:EJ8OT6*),3$T1<APN<M0!#V0K0.TC\ "9(0NZXO[JN[.J(\
MB:ZCAEJD?J4.<K76<@A Y:$4O;LUKX.Z,%0%T5E<#E#;@I>3(>AB2S'8%?;W
MU"GRQSDC<DO:$-OB*MC(VRK%@LR.J#UM):AIJP@ TB_!""YY,,BV>$=_%9@K
M%G&8L*U[#(#@;(MQE(<*_.K[IKG!\/VHL#48.QD[(LRY"S[>)2S^65(K/[_8
MK<G2N5_K*I8::19;C2*VAKPYGDR'SZ9C]8EX%HAEJVNA!_$==\V4^AP6;>.Z
M6\RW L8;5/3I\#O0Z[9NBX JL,6\!Q_=\D=@O,Q:V^899B-1H&+9H+BFP?I;
MJ<>M"2[NG+0_^_(9-FK@50(15-X!ACUZC@)]RB2XX/.(51?D$6%_[@16O^3R
MO8_RR9^ZC/%X+\KJ[7FYKP*JRSP5Z88;-5RW/_E ZLGPY/D3.7G:I-VST>E4
M_6T/1OR_:)M"]W^B[7CXW717VZ>C\2FT_<DV[E%#4>JS'3Z\9_B0 3/.0H\>
M?H9;!25N]-^<M^Z2;7)5(F1&3/=#V>Q6)KF1^H$:V*:J;H<]\6\(O)^R[JHR
MHRD(;YRT,516!]]RF34Y<-FO1\\6JLY:SV>)/H=J<J 2)]L,(L%F"VO+M:DJ
MAFH!T63BH8Z7\R!&:[ ?-%Q5.LW2;(=5A(E+JLJC8(\ !H!HT*X ,:F#<]U:
M/(YG+_G;D?IU:2I&VE!4PR"/]S!WND!UM'9L3BU[@4&4 >CD4]%T6E5HF?6W
M[9J=I*8U( ,N8G.(<LOL>H -=((%Z?PL/ST4W&X]92=&PZV(CM)) K%;1(#4
M%-8P5L!(4=JU)$+'/J?_LQQ^W7.\+9VWDU77G(VB9J'],AYX\ 5;']3$&P=1
M6+8W>RTB %B,;KLA8PY,=BC3"8-4K@-,9)C.FKGT2$"0G"ISK6BDF_$IA[!?
MZ5M>)$]<2SMI!IFZYXA*WIR@$Y>B&X&3;#V3(Q">O0J=C@4C:&4PPW.3\DN,
M;T<,#E2*/F83UVTB!%SG2("F,-L'K2-T<(ISP\DXA<MF;'*TT*Z?6>XB(A3S
M4]GLNZGN2;P=[?O8<)Q]Q:D)*<W?JC@W8;7X0:=_VG\.NXA?@3;+X[<T=$^@
M$X_Y<XZMX]&S)P-@1_D^%6^"7<DWH9D-P=9RN22-".0%>#^W$#/=,(/^(^'Y
M?P!02P,$%     @ 5Y&D5/P8R0;U!   (PL  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&ULG59M;]LV$/XKA#<,+>#&EOR69$D )VW1 LM@I.GV8=@'
M6CI;1"E2)2D[V:_?<Z1LQ^D:%/LB6^3=<\^]ZBZVUGWQ%5$0#[4V_K)7A="<
M#P:^J*B6_L0V9'"SLJZ6 :]N/?"-(UE&I5H/\N%P.JBE,KVKBWBV<%<7M@U:
M&5HXX=NZEN[QFK3=7O:RWN[@3JVKP >#JXM&KND3A<_-PN%ML$<I54W&*VN$
MH]5E;YZ=7X]9/@K\H6CKG_P7[,G2VB_\\K&\[ V9$&DJ B-(_&SHAK1F(-#X
MVF'V]B99\>G_'?K[Z#M\64I/-U;_J<I07?9.>Z*DE6QUN+/;#]3Y,V&\PFH?
MGV*;9$<0+EH?;-TI@T&M3/J5#UT<GBB<#K^CD'<*>>2=#$66;V605Q?.;H5C
M::#QG^AJU 8Y93@IGX+#K8)>N+HC+0.58B%=4.0O!@&@?#4H.H#K!)!_!V D
M;JT)E1?O3$GEL?X 9/:,\AVCZ_Q%P%OI3L0HZXM\F.<OX(WV'HXBWN@'/'P4
M]TX:+V-%>/'7?.F#P]O?+]@9[^V,HYWQ_X_DBP#<?N>^D05=]M!?GMR&>L]1
MQ7U%@DQ0\:4D7SBUQ/62NTM(1Z* 8ZHDAT/7Z3:=KC2E"-!?2BU-D0X&UHGP
M-"9;%2J6JB.:H\8ZQE!&V-9%=*M5&7%7R@!'22U\P %:%?-!S,%+>92N3VJ_
MVT BF_:CZ1M;-](\BDJ6@@!F:U5 *("O#Y[%/6W( 7+O9*ADB%QD4=C61,,@
MW:+<7,2DKZU"9FL*E2V%7>T$E5F?Q'@=C,)EK6T1V2O8:YQE_^ X.U&Q%>@S
MJ#(;,"+RO_QTFF>S7P5)9X"8HJ@MO/,X*ZHN1+@2#3EERQ/Q$<.F+!7#]L6[
MC=7P)1JGZ"A')5C!"58Q"VM'*7@I^ 6Y(#G>B<DA$);Y;I#<O4@M#28GZ_8%
MYK23G2O,T;<-$SO8@7Y%NCD&30@"4S(Q2$:5VZGA8 6WX/AQ+*7V-@[<CO3G
MQ>T-.)@80 [M"BDH.2HIDM8= W1A]:E(N?(JU1R@A$)<X,(2-1([%!D_EJP0
MR20:T\HQ+-E%>J"B#8<0!>G!\57C%#XZ2F,"+.;[F+SN0$$3JCN5-':)J[VN
M5>CJ^KY2S]CBO6B=PS5@H;=5IGQ3VJU)GJXL:FT;L>52DXA-S3&6*)[0%9*2
M2Z53*F0(:.8V"8,.]]LW+1PSA!&)PMO-R CTE@JJE^#<G6;B%3M?V=;CVK\^
M?Z[TK<(\T9JG[F%?"U(;9M,7!NO!SV+4S_,)?O/^+#L3"U2^5.CC!VP(OILO
M%M7C=F'9>9IE(IN\)&^L>:8R[I]-3O$\G<W$;T^"M&?7R,<8*+ :C?',^F?3
M&5^[EH[CFH%UCF>6#\5=FJMQ@A1:JCJQ0.O$_093\0U_XTL,' S%==<4D\E0
MS&#EQ:PZ#"[3=FX=?/R!I#[/U'N;!MM]A:(^^KP^3V+,VUTRS)'(^\-I#,:D
M/YE-Q+L=BQOK Q=.QU&\HH="MQ[[$)^6!"<PQ].:!/:RYHGV3SK8N?):Y-/^
M>)J)\=E(?,(:A1CTQ9I,'-=1K<2"HOB+RIO6(0;3*1B+__K$#IXL+FBX=5S/
MT%6<XK3#[$_W&^ \+3X'\;0^(C)KA>^7IA54AR>S24^XM)*EEV";N 8M;4!W
MQ[\5MEAR+(#[E<6'JGMA _N]^.I?4$L#!!0    ( %>1I%0@%]]+# 4  "D+
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*U637/4.!#]*UVSU!94
M33)?20@A2542H.! D0HL'+;VH+%[QB*R9"0YD]E?OZ\EVV18R%[V,F-;ZM>O
M7W](IQOG;T/%'.F^-C:<C:H8FY/))!05URKLNX8M5E;.URKBU:\GH?&LRF14
MF\E\.CV:U$K;T?EI^G;MST]=&XVV?.TIM'6M_/:2C=N<C6:C_L.-7E=1/DS.
M3QNUYH\<_VBN/=XF TJI:[9!.TN>5V>CB]G)Y8'L3QL^:]Z$!\\DD2R=NY67
M=^79:"J$V' 1!4'A[XZOV!@! HUO'>9H<"F&#Y][]#<I=L2R5(&OG/FBRUB=
MC8Y'5/)*M2;>N,U;[N(Y%+S"F9!^:9/W'F!ST8;HZLX8#&IM\[^Z[W1X8' \
M_87!O#.8)][946+Y2D5U?NK=AKSL!IH\I%"3-<AI*TGY&#U6->SB^0TW+F@1
M2-LU*5O2AUBQIZM*V36'TTF$$]DZ*3K RPPX_P7@@MX[&ZM KVW)Y:[]!.0&
MAO.>X>7\4<#WRN_38C:F^70^?P1O,42\2'B+7T8<HF^+V/H^XALV*G))%U(A
MT((#_7FQQ"Z4S%^/>#P8/!XDCP?_G\:/ DJCGH1&%7PV0B<&]G<\^B\O](6I
M0&:T;94Q6U(A< CDFL;YV-H<=G2DZ\:[.\8">R5HRA"O5IRZQXJ)0..++C3;
M8BLV2XX1GI31:TNN]<3W&!K 1S''"KT+RY;#F#:5-@,-H0GC6MTR:7N'M*#9
M8\!SP@C.M.(?9F$;(M?9<\.N 4:L5*0-P[71@"?E6:@C%F6CP J$<7:]!V8U
MK9TR81\9]@X1H)*F8[$NM;A%ZAW8KSWC":;Y*RE0^^J\CEMRJX17L3*(IS'*
M)OTBN&E;F+:46 J&<]VOB,WKSV_I&J]"*P5?B!@I95:\*@I03$-*(=W)1"@\
M5C5AX")*IBM7-\IN]^F=I49Y)(]-UA6KH8]!HYZ3PEE>*5TX2-L4-FI?[L$8
MH<!'*<A._,G4E,"Z9".(VI6 %Z$QZ)75?_<U4+)P3<GQ)?N=4@$"GE8ZJJ4V
MT&M,!4*(3'?*M)(K[]IUM9O5Y".G74"EVR*O=?%#16)IU4IL2+S7K@Q)!]%E
M!3A$]ZU%6. #N8>T%JZN=8PYFWU:?BCHOGQ333TDGPX*(=B7F)165+>BSL/H
M50$WC=&A3X1;?LU=$NCI[[\=S^?3E[L]>8VZ20NSE\_VZ5,RZIWE,@+C.GOZ
M0?VB:V*5"UB47+9!YWY$F^%4DW^7.GXW'"U*JLQ+^K+H=$&YX.22D#R7[4!#
MZJ[@,3[NI7Y.9%:R&TX+_ID[%U'.&BP?D;AP(>X-CG9(99TU(*6<=,E]QI>8
M-PA$R.XT I2C?RLK==]IJ!^ID%FV7SF#^T@:06J)>=*Y#M*3^7[2-WUT41(
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M#$WVCPXBL/T\Z@UGVC #%L;Q1 G;FD<X6N_ ]Y4Q;F-X@>%/8?H34$L#!!0
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M9[UA\84#@E;28<%^.3HI2VJI_*98@2WR\^+#1D\?ZL!T),7VD1P#9)BV LU
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M8 1X JD8Z*&M4&"M'_'!H6E"N6I[M';#\@_@ S),-( 85?8#V4^V."7)=&6
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MZGX!BX"9GEJO8.K%_(=')]SM%?[1VXY^9VUI>XBSZ,^-5B"!. "^QQ]X"O_
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MF:RD?<9M=%]$&'Q@)RSD8;+ ;\13_&X!6DM;LD(V HT7I[(Q5MJNIS7\P(*
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MK[VF<7B9CN!WI?(]%P(FDS"93N$OM"^R\E2'9WK0J.]!HY_N0?*EL]=:SUG
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M_)&BFJ%A!J*OM';["ROHMNOY7U!+ P04    " !7D:148P0;[5@$   5"@
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M:J= ZTNE[&[@ NQ?@K-_ %!+ P04    " !7D:14)ONVKJ\"  #]!0  &0
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M:7PR/@U M\.F75C5^ 9?*4OCPHL5S6?43H'.UTK9W<(YZ"?^["]02P,$%
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M/?CL<04'K5R@7M<#RU U*FF;KFZU[4R<-Z/@GWDS4.DRUUP:$+@BU_!BT/-
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M)A8].KU).5B_[*V'SUB/X)UJ;6W@][;BU6/]"4:Z#3?<A'L9'C7XCNDQ1)1
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MN:/^#I/<JY]V_.32/\@ !(1Q@IX^S71WU_IK"V<1UIID:>#&,?Y@S?QZ K3
MB]^OIVY,$ZQBS?%S8V&Q*6@:DQ@ILR_LD+;OQ[PKZZ'"3?9>SXBAI?]&,-AX
M".S^(;U=W7Z&S/K7]VY[_PV#>5@*?/)(OD#58)SAQ:/[[X)^8M7*O\7QLD3
M^F&-GU)<NPTH7RAE-Q/G8/MQ=O$O4$L#!!0    ( %>1I%39GWNX2 ,  &,'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)55;6_;-A#^*P=M&!)
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MH,$M[Z6[UX=?<-13>KQ:2QO^<!A\V3*"NK=.MV,P,6B%&EK^<<S#4< B/1'
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MHO$.-+_5I'[L^ 6F=W7]+U!+ P04    " !7D:14GD(0S&T$  #("P  &0
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MQJ,+THIN7P)MQZK:5]^ULE3+?;.DQQ-JMX#F-XH<Z3IN@_XYMOP/4$L#!!0
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M+DNM&$&[XN;NG<2*2I( ?"CI64A4=&7M>54C50>#T=&!?R&HBDS1!L+A<)S
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MVOXZ4+D$>UY):0Z.V\[Q9Y3] U!+ P04    " !7D:14"!&34[L%  #P%@
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M!T"QHXIZ='U923M-V0?D*7A*/W/UE15D4L48RD&O5",F+(1W5"5IW;XY0W=
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M"YW/WEF_NA\$_8%4XWOIH,AVIM]6=G:B=@;VO5"*C@?G8)S&Z1]02P,$%
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MP?GEE@7^84#9 -Q?26GVADW0_K-&?P!02P,$%     @ 5Y&D5(?5[OL$!
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M!^?7]&W>;T@WH5.VFES?A67M)B,:;^#N=UK3?N,=C+,V_PM02P,$%     @
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M"#(LY7B2LH\@U<YM:Z_V%63WE=-EW/>%P ]13QG'PMH\M7V@(QN-QXC8M,%
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M*J@%837B4,RLN7NYF&I[8_"50"NVQDAGLF+L24^N\YGEZ(" 0B:U!ZP^S[
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M6, 3&/ ?S<$GU0G9E<A3;5-]%M(&KMRBW\[E,@HB!6::EJ<$CV%1TLAER4&
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M=@.NKZ4TQX'M/(MOF?&_4$L#!!0    ( %>1I%1D7),@SP(  *@&   9
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MF8O*-3/S*T%E%YCYC91TZ-C;JOTYS?X 4$L#!!0    ( %>1I%1V/A\Y$ @
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MN Y0]Q=,S:8YT0^HOYY,?@)02P,$%     @ 5Y&D5.D&;:_\ @  T0D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S8N>&ULO5;;:MM $/V51:200&M=? ^V
M(99;&DC )$W[4/JPED;6$DGK[(YL!_KQG944Q6EDM1#(B[27.7,Y,SN[DYU4
M]SH&0+9/DTQ/K1AQ<V[;.H@AY;HC-Y#13B15RI&F:FWKC0(>%J TL3W'&=@I
M%YDUFQ1K2S6;R!P3D<%2,9VG*5>/<TCD;FJYUM/"C5C':!;LV63#UW +>+=9
M*IK9M990I)!I(3.F()I:%^ZY[W8-H)#X+F"G#\;,A+*2\MY,+L.IY1B/(($
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M)QOH?\R'^8OU,"3QC #?^_/ >:]O@/2I"J.@+"%G$F+ &D[.>Q\KKZ?AA%W
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MW4?RDD4/M7C18F%[?C.AD6[L8P(L!FD$<'XN<,WEBS%0=;+'_P)02P,$%
M  @ 5Y&D5 K<\QUB @  408  !D   !X;"]W;W)K<VAE971S+W-H965T-SDN
M>&ULM55=;YLP%/TK5Z@/K90% @F)J@2I232M4C=5[;H]3'MPX!*L@LWL2]/]
M^]F&HE1-LDK37L ?]YQSS\6^S'=2/>H"D>"Y*H5>> 51?>G[.BVP8GHH:Q1F
M)Y>J8F2F:NOK6B'+'*@J_3 (8K]B7'C)W*W=JF0N&RJYP%L%NJDJIGXOL92[
MA3?R7A;N^+8@N^ G\YIM\1[IH;Y59N;W+!FO4&@N!2C,%][5Z'(UM?$NX!O'
MG=X;@W6RD?+13JZSA1?8A+#$E"P#,Z\G7&%96B*3QJ^.T^LE+7!__,+^T7DW
M7C9,XTJ6WWE&Q<*;>9!ASIJ2[N3N$W9^)I8OE:5V3]BUL9.Q!VFC258=V&10
M<=&^V7-7ASW Z!@@[ #A>P%1!XB<T38S9VO-B"5S)7>@;+1ALP-7&X<V;KBP
M7_&>E-GE!D?)#9H::/@ 7YA2S)84SM=(C)?ZPJP^W*_A_.P"SH +^%K(1C.1
MZ;E/1MH2^&DGLVQEPB,RGYD:0C0:0!B$X0'XZC1\C6D/'[V&^\9P[SKL78>.
M+SKJ6FO$ 3CW UBC3A6OW;GZ<6-BX9JPTC]/*$6]4N24QD>4[E"3XBEA!GES
MN'2KEB%V#/;6/26S61R;,CT=$![WPN.3PLX:7&T5HKETI$]XF?24D_]<M;A7
MBO^2/!$J#3*'5&'&"4P#TF3.'A?; ;!*-H(.G<+X32G#* CZ2K;U;H,F>T'1
M;"_H5<;3/N/IOW[GY?0]R;T-.I"<OW?A;;,UUVO+A882<P,+AE-C3K4-K)V0
MK%T/V$@R'<4-"]/S4=D LY]+22\3VU;ZOTCR!U!+ P04    " !7D:14#2=-
M(Y8#  !$$   &0   'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6RUF-MNVS@0
MAE]E(/0B ;R1.#[)A6T@<5ILBG372'JX*'K!6+1-5!)=DHJ;MU]24B1O9=%
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M?EO1L ?C NA\KC6N#9>@__LH_@)02P,$%     @ 5Y&D5#_O*4JC @  L <
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M1^<[#&MZ4-#X!%K?:.WZP!_RX8DJ_@)02P,$%     @ 5Y&D5'E2]"WP P
MU@X  !D   !X;"]W;W)K<VAE971S+W-H965T.#0N>&ULQ5=MC^(V$/XK5K0?
M=B66O/%Z J2%O>I.NJO0;;?WH>H'0PRQSK&I[<#VWW?LA!!8)\NV5?L%8F=F
M_#PSGIG,Y"#D#Y42HM%+QKB:>JG6NP^^K]8IR;#JBAWA\&8C9(8U+.765SM)
M<&*5,N9'03#P,TRY-YO8O:6<342N&>5D*9'*LPS+/^>$B</4"[WCQC>Z3;79
M\&>3'=Z2)Z*?=TL)*[^RDM",<$4%1Y)LIMY#^&$1#HR"E?B5DH.J/2-#927$
M#[/XG$R]P" BC*RU,8'A;T\6A#%C"7#\41KUJC.-8OWY:/TG2Q[(K+ B"\&^
MTT2G4V_DH81L<,[T-W'X1$I"?6-O+9BRO^A0R@8>6N=*BZQ4!@09Y<4_?BD=
M45, .VZ%J%2(+A5Z#0IQJ1!;H@4R2^L1:SR;2'% TDB#-?-@?6.U@0WE)HQ/
M6L);"GIZ]D4HA99$HH7(,G#K4XHE0?=FN<LUMJX6&_012T[Y5J$=B!8RMX]$
M8\K4'4@_/SVBVYL[=(-\I,Q;A2A'SYQJU:EM_)**7&&>P.;-V7KB:^!B$/GK
M$O>\P!TUX([15\%UJM!'GI#D7-\''U2.B(Z.F$>M!K]BV45QV$%1$$4./(OK
MU<,6.'$5E]C:BQOL50Y?5@[_[6&EM(1[_WN+_5YEOV?M]]KBOI$B0VOP(^4Y
M'(:@.$@;<F= "H,#:]!4A_WLOA_W@XF_K[O)(16&X?@D=@:W7\'MM\+]S-<B
M(P7@A*H2,TEJD#N(0]6#NZKQBPM^<4"_!NP2^FN),![%;N"#"OB@%?C/@(D9
M7V.M)5U!2JT805J VVV^V>1(!4N(5#;1]H(1KM$G@IE..PB(=R'!YEC1M8O5
MX!5F5U <4N-1,'13&U;4AO\%M4?*<GV9P@6YX54WSB'53&Y4D1NUDOMNZS])
M[O$>+MB6G)$".KE6&BJ7R9I[TT?H&MW2X^L[%YG1JQB,QOU@?$'&(=4;#!NR
M9UR1&?][9)(B'F_1&5]%QR'53"<,3DTK:*V.MGJ95E0GTBFR! &3(XF60AG6
M.F38ZKUY%=U$,(9E<;(]TNF9TMRP?B&#;C"X<(U;+&RH-V%T@ANUPEVXZGGG
M+*Q7\BC.&;W%PRG6R./4 ,.XE<=C4YG_&TSB-VM_*5)G 5S#!A*G+ANVM]E&
M$JOW7JK>VQ1Z[Z%PZKQA>^LMZW-1ZBN0_ZCHOX-V_[H[Z!0+HP;NI^8=MG?O
M(O7_'^:#ZZJ(4^P5<[\V(61$;NW@I !ZSG7QC5SM5L/9@QU)+O;G9FBSD\?)
M3#'QP1?PEG*%&-F R: [A)C(8H@J%EKL[!RR$AJF&ON8PN!)I!& ]QLA]'%A
M#JA&V=E?4$L#!!0    ( %>1I%0D]KRT3P,  *4+   9    >&PO=V]R:W-H
M965T<R]S:&5E=#@U+GAM;,U636_;.!#]*X0*% G01E^6;">V@<1-T0+IPHC;
MW<-B#[0TMHA0I):DXO3?[Y!29,>QA3WZ8I'4S.-[?&-J)ENIGG0!8,A+R86>
M>H4QU;7OZZR DNHK68' -VNI2FIPJC:^KA30W"65W(^"(/5+RH0WF[BUA9I-
M9&TX$[!01-=E2=7O.^!R._5"[W7AD6T*8Q?\V:2B&UB"^54M%,[\#B5G)0C-
MI" *UE/O-KR>A[%-<!%_,MCJO3&Q4E92/MG)]WSJ!981<,B,A:#X>(8Y<&Z1
MD,>_+:C7[6D3]\>OZ%^=>!2SHAKFDO_%<E-,O9%'<EC3FIM'N?T&K:#$XF62
M:_=+MFULX)&LUD:6;3(R*)EHGO2E/8B]!,0YGA"U"=%APN!$0MPFN)/S&V9.
MUA=JZ&RBY)8H&XUH=N#.QF6C&B:LC4NC\"W#/#-[D%J3!2@REV6)Q[HLJ +R
MF=P*PW+&:WO(9 E9K9AAH,G%%S"4<7V),=K&ZM<'$^1G(6M-1:XGOD%N=@<_
M:WG<-3RB$SQB\D,*4VAR+W+(W^;[J*D3%KT*NXMZ 7]0=47B\!.)@B@ZPF?^
M_]/#'CIQ=\ZQPXM/X)TZS_N7C->HF*R5+*T)56VH*W"Y)O=4"28VC4&-,W\_
M(##Y;J#4__30&G2T!H[6X 2M/^IRA=BX%]TGJ'<$X0U!4P#)*,]JWI&$AB2I
M$,>5 KG 4FB*XO)8(32,$L?(WC+/LS 9C,<3_WG?GB-1:3".NJ@W<I-.;M(K
M]Q&T42PS* ?_6=D3J04S6-3>X_*7]BX_61'N:A09?+:W0T[L&W+Q\<,HBH*;
M!4[<,+RYQ!/+"8=G4'C='>(].+P>@]*.<7I.=3/L: W/KFZ&[RHB"M/PH&S>
M!X5)'!ZOFE$G=M0K=NFLE95EKGL.;]SAC<_)TS#8?0N"LW.UI?3&L6&2'MAZ
M+&J4)L=]#?<^?F&OX+D4^/\U;,6M2L&D(D(:Z#,YC';@T5G9O/L4A?'YV1R_
M-S!,1M&AST?"HG2<'ACM[S4\):B-ZP,UR60M3-,B=*M=KWGK.JR#]3O;@[I&
M:@?3-+#8 &R8T'C#KQ$RN!HB)]7TA,W$R,JU52MIL$ESPP+[:% V -^O)592
M.[$;=)WY[#]02P,$%     @ 5Y&D5 SG7NYU P  Y@X  !D   !X;"]W;W)K
M<VAE971S+W-H965T.#8N>&ULS5==;]HP%/TK5K2'3>J:V$GXJ "II9LVJ9-0
M6;>':0\NN1"KB<UL4[K]^ME.2#("61]XX 5LY]Z3<^\)A]S15L@GE0)H]))G
M7(V]5.OUE>^K10HY59=B#=Q<60J94VVV<N6KM02:N*0\\TD0]/R<,NY-1NYL
M)B<CL=$9XS"32&WRG,K?-Y")[=C#WN[@GJU2;0_\R6A-5S '_;">2;/S*Y2$
MY< 5$QQ)6(Z]:WPU)<0FN(AO#+:JL4:VE$<AGNSF<S+V LL(,EAH"T'-US-,
M(<LLDN'QJP3UJGO:Q.9ZA_[1%6^*>:0*IB+[SA*=CKV!AQ)8TDVF[\7V$Y0%
MQ19O(3+E/M&VC T\M-@H+?(RV3#(&2^^Z4O9B$:"P3F<0,H$LI\0'4D(RX30
M%5HP<V7=4DTG(RFV2-IH@V87KC<NVU3#N)5QKJ6YRDR>GLRU6#R]MXU(T%3D
MYNE0U/7W/3IZZ<.+70-Z>PN:LDR],\$/\UOT]LT[] 8QCKZF8J,H3]3(UX:C
MO9._*/G<%'S($3XA^B*X3A7ZP!-(_LWW36U5@617X WI!/Q"Y24*\04B 2$'
M^$Q?GXX[Z(15OT.'%Q[K=THEE$V=T=_F!Z'1M924K\"N+W;-39#I'YK2-=,T
M8W\@N4#7N=B8Z!]W!A)]UI"KGQV$HHI0Y A%KR"T:*H,!9%#$A:(/8=H?>)Y
M$H=1;^0_-_O:#@K[01WT#]FX(AMWDIT*I9%8&O]X!KZ!CO)[%6+O//3H5X3Z
M)]>C0(P;K1X$P9X<[9AX&!]68U!1'713->;+^.H"K8"#I)EK$4V,2S&E);7^
MO&.M.CHSK&XW/ ^I<%";9W!RL4K(IA)1W/KU'(@*,<:'!<,-M\?=A*VG([&V
M)+LTP:1&)&>B2FVQ.#R]*F&KW[A']D5I!T5!=$23VH!QMP/?SQ\ZI:C-$<=G
M(D7MKKAW>BEZ[4<_#/"^%NTH/.P?$Z-V7]QMOW?_$:/V1CPX$S%J_\3#TXLQ
M;+6YWX_WM6@'X6!PY-^%U.Y*NMUUUJT%J5V/X//0@M2V2<C)M2@AFZ]4V/1Y
M3XP#420*][3P&Q-##G+E!BEEF)ABBW?KZK0:UJ[=B+)W?F.&N&+DJF&*"="\
M.:\85RB#I8$,+OOF\9#%4%5LM%B[N>11:#/EN&5J!E&0-L!<7PJA=QM[@VJT
MG?P%4$L#!!0    ( %>1I%3II7 Y3@(  $P%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;(U42V_;, S^*X*Q0PNLL6-G[5 X!O+8L!X*! VZ'88=
M%)N)A<B2)S%QNU\_2G:\K$B"7FQ*XO?QS;319FM+ &0OE51V')2(]7T8VKR$
MBMN!KD'1RUJ;BB,=S2:TM0%>>% EPSB*;L.*"Q5DJ;];F"S5.Y1"P<(PNZLJ
M;EZG('4S#H;!X>));$IT%V&6UGP#2\#G>F'H%/8LA:A 6:$5,[ >!Y/A_6SD
M]+W"=P&-/9*9BV2E]=8='HIQ$#F'0$*.CH'3;P\SD-(1D1N_.\Z@-^F Q_*!
M_:N/G6)9<0LS+7^( LMQ\#E@!:SY3N*3;KY!%\\GQY=K:?V7-:WN712P?&=1
M5QV8/*B$:O_\I<O#$8!X3@/B#A"_!8S. )(.D/A 6\]\6'../$N-;IAQVL3F
M!)\;CZ9HA')57**A5T$XS):H\^V-2T3!9KJBYK#<Y_>&38I".)%+]J#:?G$/
M5W- +J2])I7GY9Q=?;A.0R17'&&8=V:GK=GXC-F$/6J%I65?5 '%__B00NCC
MB ]Q3..+A(_<#%@R_,CB*(Y/^#-[/WQXP9VD3VOB^9)S:2VY@2ZM"_Y*;8]L
M8@Q7&_#RS\G*HJ$>_G7!V*@W-O+&1N^H87Y<PYS7 KD4?^B!6V;U&AORB]I\
M3^-;>T]R;=&>*F!K\];;=+M@GT5IN#].Z26--I#PJ#$K,!L_KY9L[A2VM>UO
M^Y4P\9/PYGY*JZ*=['\T[9ZARFV$LDS"FBBCP1T-FFEGMSV@KGW[KS32,'FQ
MI'4'QBG0^UIK/!R<@7Z!9G\!4$L#!!0    ( %>1I%3L3E0;A0(  !T'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;,U536_;, S]*X)/*[#6CIVO
M%HZ!)-U'@18(&G0[##LH-A,+D:5,4NKVWX^2'<]I$V.''7:Q18KO^9&TJ+B4
M:JMS $->"B[TQ,N-V=WXODYS**B^DCL0N+.6JJ &3;7Q]4X!S1RHX'X8!$._
MH$QX2>Q\"Y7$<F\X$[!01.^+@JK7&7!93KR>=W \LDUNK,-/XAW=P!+,TVZA
MT/(;EHP5(#23@BA83[QI[V8^MO$NX!N#4K?6Q&:RDG)KC;MLX@56$'!(C66@
M^'J&.7!NB5#&KYK3:SYI@>WU@?VSRQUS65$-<\F_L\SD$V_LD0S6=,_-HRR_
M0IW/P/*EDFOW)&4=&W@DW6LCBQJ,"@HFJC=]J>O0 B#/:4!8 \*W@/X90%0#
M(I=HI<RE=4L-36(E2Z)L-++9A:N-0V,V3-@N+HW"788XDRR-3+>7MA 9F<L"
M?PY-77TOR1+_F&S/@<@U6>9401TV+:G*-/FBJ#!H?K@%0QG7%PC1-DS'OD%E
MEM]/:Q6S2D5X1D5$'J0PN2:?1 ;9,=['C)JTPD-:L["3\(&J*Q+U/I(P",,3
M>N9_#^]UR(F:*D>.KW^&[W'YI#MH^@U-W]%$YYK5ZL)1LZ8*F[$!/%V&K%Z/
MNK6@K\[MND9^W",EN3-0Z)\=@@:-H$%G7LT_P$3=^XM3S:](!H[$CI7GY+HW
M"H(@]I_;/3D1%EVWPXXT#AN-PTZ-B^[:CQJ:T?]1^W$C:/PO:C]^5]3^Z/I]
M[=^'1;T3M?=;DZ8 M7$#6)-4[H6I3F?C;6;\U(VV-_X9SOYJ5/^AJ2X./'L;
M)C3AL$;*X&J$HE0UC"O#R)V;9RMI<#JZ98[W%R@;@/MK*<W!L!]H;L3D-U!+
M P04    " !7D:14?%"0!M$"  "*!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970X.2YX;6R-5<ENVS 0_96!D ()D%J+MS2P#<16BN:0PLC2'HH>:&DD$9%(
ME:3MI%]?DI)5.Y&57"0N\]Z;A1Q.MEP\R0Q1P7.1,SEU,J7*2]>5488%D3U>
M(M,["1<%47HJ4E>6 DEL047N!IXW<@M"F3.;V+6EF$WX6N64X5* 7!<%$2]S
MS/EVZOC.;N&.IIDR"^YL4I(4[U$]EDNA9V[#$M,"F:2<@<!DZESYE^'8V%N#
M'Q2W<F\,)I(5YT]F<A-/'<\XA#E&RC 0_=O@ O/<$&DW_M2<3B-I@/OC'?M7
M&[N.944D+GC^D\8JFSH7#L28D'6N[OCV&];Q# U?Q'-IO["M;,=:,5I+Q8L:
MK.<%9=6?/-=YV -HGG9 4 ."UX#!$4"_!O0_"AC4@('-3!6*S4-(%)E-!-^"
M,-::S0QL,BU:AT^9*?N]$GJ7:IR:W;"(%P@/Y!DE?(;O1 AB*@&G(2I"<WFF
M5Q_O0S@].8,3H P>,KZ6A,5RXBKM@*%QHUIL7HD%1\3Z<,N9RB1<LQCC0[RK
M'6^\#W;>SX-.PELB>M#WSR'P@J#%G\7'X7X+/.R&AQ@=@Q]$TV]JT;=\_7=K
M 2&54<[E6B#\NEI))?3]^-TA,6@D!E9B<$1B*?B&VBNK.X:NIA54IOAMU:RX
M1I;+](_-S->A3MS-?HK?&HU\O[$Y\'+8>#GL]/(Z2=#V ]"'$=L\Z\:?!E]Z
MGO?IK.U$O(,<]B[>  ]B&#4QC#J9'IG B*>,_L789!A6R#"AJBW1X>AM#CVO
M/8?C1G_<J6].D?8 Z8:L<@22"D3=KM4YE"@B/0">0$1D!I)L*$LEE(1J3SG(
MC C,>!ZC:#T5W;H70Y/ZM@2Z>UVJ0)':;B\AXFNFJBO?K#8/RI7MHZ_6Y_[E
MHGH7_M-4KY2^T"EE$G),-*77&^MJBZKS5Q/%2]L+5USISFJ'F7XL41@#O9]P
MKG83(] \O[-_4$L#!!0    ( %>1I%0\SDX^/0,   X,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#DP+GAM;+U7VV[B,!#]%2OJ2JVT)3>N%2"5TMU%6J2J
M;+L/JWUPDX%8C6UJ.]!*^_'K.!"@3=SRTA<27\Z9.3/#,/377#S*!$"A9YHR
M.7 2I987KBNC!"B6#;X$ID_F7%"L]%(L7+D4@&,#HJD;>%[;I9@P9]@W>S=B
MV.>92@F#&X%D1BD6+R-(^7K@^,YVXY8L$I5ON,/^$B]@!NIN>2/TRBU98D*!
M2<(9$C ?.)?^Q=AOY0!SXY[ 6NZ]HUS* ^>/^6(2#QPO]PA2B%1.@?5C!5>0
MICF3]N-I0^J4-G/@_ON6_9L1K\4\8 E7//U-8I4,G*Z#8ICC+%6W?/T#-H*,
M@Q%/I?E$Z^)NI^F@*).*TPU8>T )*Y[X>1.(/8#FJ08$&T#P&E!G(=P PH\"
MFAM TT2FD&+B,,8*#_N"KY'(;VNV_,4$TZ"U?,+RO,^4T*=$X]1PPE8@E4ZD
MDH@P=/V4$?6"IJ 2'J/B$$"BTS$H3%)YAL[1W6R,3D_.T$D.^)7P3&(6R[ZK
MM#LYJ1MM3(\*TT&-Z1!-.5.)1-<LAO@0[VH9I99@JV446 FG6#10Z']%@1<$
M%?Y<?1SN5\#'=O@8HCKX@9JPS$QH^,(:OIG^BL=9"HC/*]-2Y.S/3PU#$P54
M_K48;99&F\9HL\;H=]TIT%QPBJ P20N39%L)56DN*-N&,N\SJV&KU^Z[J_W0
MO[W3Z73#\M*!LZW2V9;5V>IB1?_0#,2*1+IL+Q<"P 3*$IMV::[]>0GIE$8[
M5HT3%G$*14I2SA;G"@1%<BL0;P56Y:7S)N9AV_->)>;MI7:X=^G Z6[I=-?J
M])0P0C-JD=\KF7J?%W/?VS5%SUY9$6><DDC7O8ZWMH.6(")M2_\45C8Z.UVS
MX7E?JCK*\;A#07M=WK<RW7-%V.+#<NQD0:M6S_' 0T'!3E!@+S'\_$Z)^;M&
MZW]BI_5WK=:W]]JCB\Q.%W9KL_(.L/=>5G8-V;=WY"/+S$[6]&H%'0\L!+E[
M@Q(%L3 #IT01SY@JYHQRMQQJ+\TH]VI_Y%]<%:/ICJ:8E/44L2!,HA3FFM)K
M=+2OHA@^BX7B2S../7"EASOSFNB!'41^09_/.5?;16Z@_ LP_ ]02P,$%
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M4G4VYG.ONE7@VD"M;YG*4C/0&[3][_Q?4$L#!!0    ( %>1I%0=Y%&+P0(
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M98'C&)0-P.>YE&:SL0F: 3_X!U!+ P04    " !7D:14;_=FL$8#   .#
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M8!\%02^]H17T$S<R9Q>VV876[.XV+-?;_(G@7*[47XAO:-JG_L!SU'J.SEU
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MBE?-X8;1G ECH.\_<*Z>3\P#VJ\PB_\!4$L#!!0    ( %>1I%32BL_5V (
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MJG<&Z)VKS=X O;/JG0%Z%]6[ /0NJG<!Z%U4[P+0NZC>!:!W4;T+0.^B>A>
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MFY]02P$"% ,4    " !6D:14!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %:1I%2H/E7X[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( %:1I%297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ 5Y&D5"9?AZI<!0  *Q8  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( %>1I%3_BN/@Q0<  %P?   8              " @9\-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !7D:14P+.VS98"  #!!@
M&               @(&:%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ 5Y&D5!RV%"I4!P  PQX  !@              ("!9A@  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %>1I%1NR=^140(
M *,$   8              " @? ?  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " !7D:141_9*I+<&  #B'@  &               @(%W
M(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 5Y&D5$+%
MFPY7"@  >2D  !@              ("!9"D  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( %>1I%36HP!#A@,  '4'   8
M  " @?$S  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !7
MD:14J$5,0#D7  !?1@  &               @(&M-P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ 5Y&D5/E3GN[J!@  !1$  !D
M         ("!'$\  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " !7D:14S4K&@Z (  !/%0  &0              @($]5@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %>1I%07+ !J!P8  *@0
M   9              " @11?  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ 5Y&D5$&^'], $   DS   !D              ("!4F4
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !7D:14/4P9
MBLP&   ?$0  &0              @(&)=0  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( %>1I%35'O01<@,  )T(   9
M  " @8Q\  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M5Y&D5#0W_9Z)"   JA4  !D              ("!-8   'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " !7D:14ID"J.5(3  #+3P  &0
M            @('UB   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( %>1I%3+6ZYKQQ,  )<Y   9              " @7Z<  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 5Y&D5-VYLC E"
MWA,  !D              ("!?+   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " !7D:14*M*P&M #  #""   &0              @('8
MN   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %>1I%1G
MU *0/@,  '$'   9              " @=^\  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ 5Y&D5(3J(CV.!   40H  !D
M     ("!5,   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %>1I%0."4-O70@  "$6   9              "
M@?;>  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 5Y&D
M5,@!?(ZF"0  !1H  !D              ("!BN<  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " !7D:148Z UR+("   @!@  &0
M        @(%G\0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( %>1I%33\]M%4QD  (5/   9              " @5#T  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 5Y&D5$39;27D!P  .QD
M !D              ("!V@T! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " !7D:14HAWT+_ #  #5#   &0              @('U%0$
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %>1I%2.+O\Y
M1@0  &D+   9              " @1P: 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ 5Y&D5&,$&^U8!   %0H  !D
M ("!F1X! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !7
MD:14)ONVKJ\"  #]!0  &0              @($H(P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %>1I%1 3HJG[@(  #4&   9
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M970T,"YX;6Q02P$"% ,4    " !7D:1486-UU/\#  ":"0  &0
M    @($I.P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M %>1I%08MX:9+P,  )L'   9              " @5\_ 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ 5Y&D5&ERO>I=!   V@P  !D
M             ("!Q4(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " !7D:148.K_L5<#  "!!P  &0              @(%91P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( %>1I%1SSYV;Y0(
M !4&   9              " @>=* 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ 5Y&D5#S21'I*!0  .0T  !D              ("!
M TX! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !7D:14
MKA+\QD@$  "_"0  &0              @(&$4P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( %>1I%208;&^R0(  !,&   9
M      " @0-8 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ 5Y&D5,L>RPD@ @  F 0  !D              ("! UL! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !7D:14"!&34[L%  #P%@
M&0              @(%:70$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( %>1I%3&%[J56@(  )D%   9              " @4QC 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 5Y&D5!9RY!HQ
M P  30T  !D              ("!W64! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " !7D:14U35A<_ "  #"!P  &0
M@(%%:0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( %>1
MI%1$4&7'(04  -8=   9              " @6QL 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ 5Y&D5%DY@@G"!@  <2$  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( %>1I%34P&90!0,  )D,   9
M  " @1"' 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M5Y&D5/>XX&AU P  =0H  !D              ("!3(H! 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    " !7D:14.9/F1A0#  !K"@  &0
M            @('XC0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( %>1I%1DRRV^! ,  +$*   9              " @4.1 0!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ 5Y&D5-<51*^K @
MOP8  !D              ("!?I0! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    " !7D:14A]7N^P0$  "@#P  &0              @(%@
MEP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( %>1I%0J
M&5I*2 (  '<%   9              " @9N; 0!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ 5Y&D5,P6U+D6!   Q0\  !D
M     ("!&IX! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %>1I%1D7),@SP(  *@&   9              "
M@0JX 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ 5Y&D
M5'8^'SD0"   %"T  !D              ("!$+L! 'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6Q02P$"% ,4    " !7D:14P)[\DPT$  #C$   &0
M        @(%7PP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0
M   ( %>1I%2QU!:81 0  $D1   9              " @9O' 0!X;"]W;W)K
M<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ 5Y&D5.D&;:_\ @  T0D
M !D              ("!%LP! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q0
M2P$"% ,4    " !7D:140"EAE7X#  !:"P  &0              @(%)SP$
M>&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( %>1I%2A71GQ
MG@4  -46   9              " @?[2 0!X;"]W;W)K<VAE971S+W-H965T
M-S@N>&UL4$L! A0#%     @ 5Y&D5 K<\QUB @  408  !D
M ("!T]@! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " !7
MD:14#2=-(Y8#  !$$   &0              @(%LVP$ >&PO=V]R:W-H965T
M<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( %>1I%10[4P?=0(  $H&   9
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M970X-2YX;6Q02P$"% ,4    " !7D:14#.=>[G4#  #F#@  &0
M    @(&N[@$ >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    (
M %>1I%3II7 Y3@(  $P%   9              " @5KR 0!X;"]W;W)K<VAE
M971S+W-H965T.#<N>&UL4$L! A0#%     @ 5Y&D5.Q.5!N% @  '0<  !D
M             ("!W_0! 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"
M% ,4    " !7D:14?%"0!M$"  "*!P  &0              @(&;]P$ >&PO
M=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( %>1I%0\SDX^/0,
M  X,   9              " @:/Z 0!X;"]W;W)K<VAE971S+W-H965T.3 N
M>&UL4$L! A0#%     @ 5Y&D5 VVR:SN @  NPL  !D              ("!
M%_X! 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " !7D:14
MP:R:G.P"  ")!P  &0              @($\ 0( >&PO=V]R:W-H965T<R]S
M:&5E=#DR+GAM;%!+ 0(4 Q0    ( %>1I%1'<IM/Y (  (()   9
M      " @5\$ @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%
M  @ 5Y&D5"Y/C;T.!   "P\  !D              ("!>@<" 'AL+W=O<FMS
M:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4    " !7D:14'>11B\$"  #L!P
M&0              @(&_"P( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+
M 0(4 Q0    ( %>1I%1O]V:P1@,   X,   9              " @;<. @!X
M;"]W;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ 5Y&D5-:O)P,)
M @  9 0  !D              ("!-!(" 'AL+W=O<FMS:&5E=',O<VAE970Y
M-RYX;6Q02P$"% ,4    " !7D:1438@B\I($   @%   &0
M@(%T% ( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( %>1
MI%2+J:?'P00  !41   9              " @3T9 @!X;"]W;W)K<VAE971S
M+W-H965T.3DN>&UL4$L! A0#%     @ 5Y&D5$$'_?9G!0  D1D  !H
M         ("!-1X" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#
M%     @ 5Y&D5-**S]78 @  *P<  !H              ("!U"," 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ 5Y&D5 6.WMLT P
MV!,   T              ( !Y"8" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !7D:14EXJ[',     3 @  "P              @ %#*@( 7W)E;',O+G)E
M;'-02P$"% ,4    " !7D:14"E0X-54'  !%0@  #P              @ $L
M*P( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 5Y&D5&/$$4K= @  7#L
M !H              ( !KC(" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 5Y&D5'_@0\Q; @  33D  !,              ( !PS4"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &T ;0#T'0  3S@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>268</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2159113 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2163114 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2168115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2170116 - Disclosure - Investments in Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</Role>
      <ShortName>Investments in Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2172117 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2177118 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2181119 - Disclosure - Repositioning and Other Changes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChanges</Role>
      <ShortName>Repositioning and Other Changes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2184120 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2189121 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2192122 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsTables</Role>
      <ShortName>Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Transactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LossPerCommonShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/StockbasedCompensation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2373313 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2378314 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2382315 - Disclosure - Repositioning and Other Changes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</Role>
      <ShortName>Repositioning and Other Changes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChanges</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2385316 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SegmentReporting</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2390317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2393318 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Transactions - Vital Decisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails</Role>
      <ShortName>Transactions - Vital Decisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Revenue Recognition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Long-term Debt - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails</Role>
      <ShortName>Long-term Debt - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Long-term Debt - Warrant Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails</Role>
      <ShortName>Long-term Debt - Warrant Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Reinsurance Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Leases - Primary Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails</Role>
      <ShortName>Leases - Primary Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2456433 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2457434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2458435 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2461436 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2469441 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2471442 - Disclosure - Investments in Equity Method Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails</Role>
      <ShortName>Investments in Equity Method Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2479446 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2480447 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2483448 - Disclosure - Repositioning and Other Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails</Role>
      <ShortName>Repositioning and Other Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2486449 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2487450 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2488451 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2491452 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="evh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2494453 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="evh-20220331.htm">evh-20220331.htm</File>
    <File>a33122exhibit101.htm</File>
    <File>a33122exhibit102.htm</File>
    <File>a33122exhibit311.htm</File>
    <File>a33122exhibit312.htm</File>
    <File>a33122exhibit321.htm</File>
    <File>a33122exhibit322.htm</File>
    <File>evh-20220331.xsd</File>
    <File>evh-20220331_cal.xml</File>
    <File>evh-20220331_def.xml</File>
    <File>evh-20220331_lab.xml</File>
    <File>evh-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="932">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>121
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 37,
   "contextCount": 268,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 669,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 11
   },
   "keyCustom": 50,
   "keyStandard": 345,
   "memberCustom": 39,
   "memberStandard": 52,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.evolenthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Recently Issued Accounting Standards",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2491452 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2494453 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Transactions",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Discontinued Operations",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Revenue Recognition",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Credit Losses",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Property and Equipment, Net",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Long-term Debt",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Leases",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159113 - Disclosure - Loss Per Common Share",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163114 - Disclosure - Stock-based Compensation",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168115 - Disclosure - Income Taxes",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170116 - Disclosure - Investments in Equity Method Investees",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees",
     "shortName": "Investments in Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172117 - Disclosure - Fair Value Measurement",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2177118 - Disclosure - Related Parties",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181119 - Disclosure - Repositioning and Other Changes",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
     "shortName": "Repositioning and Other Changes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2184120 - Disclosure - Segment Reporting",
     "role": "http://www.evolenthealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2189121 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2192122 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Transactions (Tables)",
     "role": "http://www.evolenthealth.com/role/TransactionsTables",
     "shortName": "Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Credit Losses (Tables)",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Leases (Tables)",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Loss Per Common Share (Tables)",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareTables",
     "shortName": "Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2373313 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2378314 - Disclosure - Related Parties (Tables)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2382315 - Disclosure - Repositioning and Other Changes (Tables)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables",
     "shortName": "Repositioning and Other Changes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2385316 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2390317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2393318 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization (Details)",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "ic23605bda701483aa031c60b51c43b27_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "icead5b03e4c6480db192188178d18afe_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "icead5b03e4c6480db192188178d18afe_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Recently Issued Accounting Standards (Details)",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Transactions - Vital Decisions (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails",
     "shortName": "Transactions - Vital Decisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i80ff05debabc497c8b7183be3cf47025_I20211001",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
     "shortName": "Discontinued Operations - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if4e2e27a5da8443db3816f738f8f169e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i26bf389c6898466eb63379d01aaa71b6_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Revenue Recognition - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails",
     "shortName": "Revenue Recognition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i26bf389c6898466eb63379d01aaa71b6_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i8ec4532a4742433aba9506e85893885b_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i3be7adf261ff427c874251aacfa02b7e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i1623fa44597143889f19c0188c630b48_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "ic23605bda701483aa031c60b51c43b27_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "ic23605bda701483aa031c60b51c43b27_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:GainLossOnDispositionOfAssetsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i53e876262cb54b3b8e471347fc1620a5_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Long-term Debt - Credit Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
     "shortName": "Long-term Debt - Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "id15cf99071b0415f8897789050cdcac3_I20191230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4df15ce9a58f43aa8838ebd2fc814e18_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Long-term Debt - Warrant Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
     "shortName": "Long-term Debt - Warrant Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4df15ce9a58f43aa8838ebd2fc814e18_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "ie0e2e0f414904188a0bb7cf06671ce39_I20181031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i6f6e3d5b205549aa95c847755a6df534_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if568378dc7914a2ca879a5b1dfdec339_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if568378dc7914a2ca879a5b1dfdec339_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails",
     "shortName": "Commitments and Contingencies - Reinsurance Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i55a0e80d686d4db398764b4e17532471_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Leases - Primary Office Leases (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails",
     "shortName": "Leases - Primary Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i7a5f7ca552444d36af631fb4eeba482a_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456433 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458435 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461436 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails",
     "shortName": "Loss Per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i627eecec9e24428f888feae02bf5a094_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i627eecec9e24428f888feae02bf5a094_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469441 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471442 - Disclosure - Investments in Equity Method Investees (Details)",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
     "shortName": "Investments in Equity Method Investees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i459c224721e4472987d0810fa06039dd_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i9026d99a25d84c75985b0866b64b1bf5_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i9026d99a25d84c75985b0866b64b1bf5_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i9026d99a25d84c75985b0866b64b1bf5_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i0100835413d340b082126f866d8b23d0_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i146f6ec95f5b4b9a92e6e8259fe36f1f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479446 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i53f1f40c73a441669cb646b2f251c21b_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i84334888c1ce4f9596774398cccb24d4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480447 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i84334888c1ce4f9596774398cccb24d4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483448 - Disclosure - Repositioning and Other Changes (Details)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
     "shortName": "Repositioning and Other Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "if299fb55051e4d729c1f4c44566a6f16_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486449 - Disclosure - Segment Reporting - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487450 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i79be648cb3694442bbf24990de4e33be_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488451 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220331.htm",
      "contextRef": "i4de8f8406bb24de8b951e3a602dc19e9_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:SharebasedCompensationIncludingOnetimeAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 94,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "label": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "negatedTerseLabel": "Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "totalLabel": "Total tangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "label": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "label": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks (less than)"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "label": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "terseLabel": "Period during which warrants or rights exercisable, after maturity of credit agreement"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_ClinicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Solutions Segment",
        "label": "Clinical Solutions Segment [Member]",
        "terseLabel": "Clinical Solutions"
       }
      }
     },
     "localname": "ClinicalSolutionsSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods and Services Sold, Excluding Depreciation and Amortization",
        "label": "Cost of Goods and Services Sold, Excluding Depreciation and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "CostofGoodsandServicesSoldExcludingDepreciationandAmortization",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "label": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "verboseLabel": "Incurred costs related to current period"
       }
      }
     },
     "localname": "CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtConversionOriginalDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Original Debt, Fair Value",
        "label": "Debt Conversion, Original Debt, Fair Value",
        "terseLabel": "Debt conversion, original debt, fair value"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtFairValue",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredFinancingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Fees",
        "label": "Deferred Financing Fees [Member]",
        "terseLabel": "Deferred Financing Fees"
       }
      }
     },
     "localname": "DeferredFinancingFeesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DelayedDrawTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delayed Draw Term Loan Facility [Member]",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "terseLabel": "DDTL Facility"
       }
      }
     },
     "localname": "DelayedDrawTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "label": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "terseLabel": "Claims expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationClaimsExpense",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_EmployeeSeveranceAndTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Termination Benefits",
        "label": "Employee Severance And Termination Benefits [Member]",
        "terseLabel": "Severance and termination benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTerminationBenefitsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityComponentOfLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component of Long Term Debt",
        "label": "Equity Component of Long Term Debt [Member]",
        "terseLabel": "Equity Component of Long Term Debt"
       }
      }
     },
     "localname": "EquityComponentOfLongTermDebtMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_GainLossOnDispositionOfAssetsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "label": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "negatedLabel": "Gain on discontinued operations"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsOperatingActivities",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainOnTransferOfMembership": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Transfer Of Membership",
        "label": "Gain On Transfer Of Membership",
        "negatedTerseLabel": "Gain on transfer of membership",
        "terseLabel": "Gain on transfer of membership"
       }
      }
     },
     "localname": "GainOnTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Services Agreement",
        "label": "Income (Loss) from Equity Method Investments, Services Agreement",
        "terseLabel": "Income from long-term services agreement"
       }
      }
     },
     "localname": "IncomeLossfromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "negatedTerseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightofUseAsset",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_InitialTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term Loan Facility [Member]",
        "label": "Initial Term Loan Facility [Member]",
        "terseLabel": "Initial Term Loan Facility"
       }
      }
     },
     "localname": "InitialTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Risk-neutral Expected Earnout Consideration",
        "label": "Measurement Input, Risk-neutral Expected Earnout Consideration [Member]",
        "terseLabel": "Risk-neutral expected earnout consideration"
       }
      }
     },
     "localname": "MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare",
        "label": "Molina Healthcare [Member]",
        "terseLabel": "Molina Healthcare"
       }
      }
     },
     "localname": "MolinaHealthcareMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "label": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "negatedTerseLabel": "Disposal of non-strategic assets and divestiture of discontinued operations, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsOfMakeWholePremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Make-Whole Premium",
        "label": "Payments Of Make-Whole Premium",
        "terseLabel": "Payments of make-whole premium"
       }
      }
     },
     "localname": "PaymentsOfMakeWholePremium",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PlatformsAndOperationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platforms And Operations Services [Member]",
        "label": "Platforms And Operations Services [Member]",
        "verboseLabel": "Platform and operations"
       }
      }
     },
     "localname": "PlatformsAndOperationsServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "label": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "terseLabel": "Claims-related administrative expenses"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PremiumsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Revenue [Member]",
        "label": "Premiums Revenue [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "label": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "terseLabel": "Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromMaturityOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Investments",
        "label": "Proceeds From Maturity Of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfInvestments",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromReinsurance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Reinsurance",
        "label": "Proceeds From Reinsurance",
        "negatedLabel": "Reinsurance payments paid (received)"
       }
      }
     },
     "localname": "ProceedsFromReinsurance",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProfessionalServicesRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services, Restructuring",
        "label": "Professional Services, Restructuring [Member]",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesRestructuringMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforOtherContractualCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Other Contractual Commitments [Member]",
        "label": "Restricted Cash for Other Contractual Commitments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestrictedCashforOtherContractualCommitmentsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs (\u201cPSUs\u201d) and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "label": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "terseLabel": "Right of offset, percentage of accounts receivable, net eligible for net basis settlement"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "label": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "terseLabel": "Right of offset, percentage of accounts receivable netted against claims payable"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Policy",
        "label": "Right of Offset, Policy [Policy Text Block]",
        "terseLabel": "Right of Offset"
       }
      }
     },
     "localname": "RightOfOffsetPolicyPolicyTextBlock",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_RightOfUseAssetAcquiredAndDisposedOf": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Acquired And Disposed Of",
        "label": "Right-Of-Use Asset Acquired And Disposed Of",
        "negatedTerseLabel": "Leased assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetAcquiredAndDisposedOf",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Credit Facilities [Member]",
        "label": "Senior Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorCreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationIncludingOnetimeAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Including One-time Adjustment",
        "label": "Share-based Compensation, Including One-time Adjustment",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationIncludingOnetimeAdjustment",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderAdvisoryServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Advisory Services",
        "label": "Shareholder Advisory Services",
        "negatedLabel": "Strategy and shareholder advisory expenses"
       }
      }
     },
     "localname": "ShareholderAdvisoryServices",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "label": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "terseLabel": "Tax receivable agreement, percent of cash savings paid to shareholders"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentofTaxSavingstobePaid",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs",
        "label": "Transaction Costs",
        "negatedLabel": "Acquisition costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TransformationServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transformation Services [Member]",
        "label": "Transformation Services [Member]",
        "terseLabel": "Transformation Services"
       }
      }
     },
     "localname": "TransformationServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TrueHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health",
        "label": "True Health [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_VitalDecisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Decisions",
        "label": "Vital Decisions [Member]",
        "terseLabel": "Vital Decisions"
       }
      }
     },
     "localname": "VitalDecisionsMember",
     "nsuri": "http://www.evolenthealth.com/20220331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r449",
      "r624",
      "r625",
      "r627",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r144",
      "r212",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r234",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r144",
      "r212",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r234",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r149",
      "r160",
      "r166",
      "r261",
      "r477",
      "r478",
      "r479",
      "r498",
      "r499",
      "r555",
      "r558",
      "r561",
      "r562",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r149",
      "r160",
      "r166",
      "r261",
      "r477",
      "r478",
      "r479",
      "r498",
      "r499",
      "r555",
      "r558",
      "r561",
      "r562",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r149",
      "r160",
      "r166",
      "r261",
      "r477",
      "r478",
      "r479",
      "r498",
      "r499",
      "r555",
      "r558",
      "r561",
      "r562",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r241",
      "r425",
      "r431",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r351",
      "r390",
      "r452",
      "r454",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r719",
      "r723",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r351",
      "r390",
      "r452",
      "r454",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r719",
      "r723",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r241",
      "r425",
      "r431",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r237",
      "r425",
      "r429",
      "r648",
      "r718",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r237",
      "r425",
      "r429",
      "r648",
      "r718",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r351",
      "r390",
      "r441",
      "r452",
      "r454",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r719",
      "r723",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r351",
      "r390",
      "r441",
      "r452",
      "r454",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r719",
      "r723",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r238",
      "r239",
      "r425",
      "r430",
      "r721",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r238",
      "r239",
      "r425",
      "r430",
      "r721",
      "r742",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Edison, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r152",
      "r153",
      "r154",
      "r156",
      "r248",
      "r249",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r331",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r498",
      "r499",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r590",
      "r591",
      "r620",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r36",
      "r50",
      "r77",
      "r243",
      "r244",
      "r692"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r65",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Accounts receivable, allowance for credit loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r50",
      "r692",
      "r746"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r36",
      "r50",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r302"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r80",
      "r81",
      "r82",
      "r698",
      "r731",
      "r735"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life",
        "verboseLabel": "Useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r51",
      "r481",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r477",
      "r478",
      "r479",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r152",
      "r153",
      "r154",
      "r156",
      "r166",
      "r248",
      "r249",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r331",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r496",
      "r497",
      "r498",
      "r499",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r590",
      "r591",
      "r620",
      "r650",
      "r651",
      "r652",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r455",
      "r457",
      "r483",
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r457",
      "r469",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r57",
      "r245",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r100",
      "r125",
      "r371",
      "r602"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r125",
      "r289",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of antidilutive securities excluded from the calculation of earning per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r79",
      "r82",
      "r88",
      "r89",
      "r90",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r141",
      "r220",
      "r226",
      "r232",
      "r256",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r345",
      "r346",
      "r541",
      "r546",
      "r580",
      "r630",
      "r632",
      "r673",
      "r694"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r37",
      "r38",
      "r78",
      "r141",
      "r256",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r345",
      "r346",
      "r541",
      "r546",
      "r580",
      "r630",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r712",
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.",
        "label": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense",
        "periodEndLabel": "Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period",
        "periodStartLabel": "Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssumedPremiumsWritten": {
     "auth_ref": [
      "r737"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums assumed from other entities.",
        "label": "Assumed Premiums Written",
        "terseLabel": "Reinsurance premiums assumed"
       }
      }
     },
     "localname": "AssumedPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r459",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r451",
      "r453",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r526",
      "r527",
      "r529"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r526",
      "r527"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of Class A common stock issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r524",
      "r526",
      "r527",
      "r531"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r124",
      "r536"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration arrangements (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r525",
      "r528",
      "r533"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Assumption or Input Ranges"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Transactions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Tangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Identifiable intangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r516",
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r764",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r280"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized contract cost, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r35",
      "r60",
      "r127"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r121",
      "r127",
      "r133"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r121",
      "r592"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r24",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash flows used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r24",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r139",
      "r141",
      "r172",
      "r173",
      "r178",
      "r181",
      "r183",
      "r191",
      "r192",
      "r193",
      "r256",
      "r332",
      "r337",
      "r338",
      "r339",
      "r345",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r580",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r402",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r402",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.",
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Warrants agreed to be sold (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r74",
      "r328",
      "r677",
      "r702"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r49",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 91,587,896 and 90,758,318 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r84",
      "r86",
      "r87",
      "r97",
      "r683",
      "r708"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r577",
      "r578",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r577",
      "r578",
      "r739",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r577",
      "r578",
      "r739",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk (in percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r198",
      "r201",
      "r202",
      "r203",
      "r577",
      "r579",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r577",
      "r578",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with customer, asset and liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r403",
      "r404",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r403",
      "r404",
      "r426"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r403",
      "r404",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r46",
      "r675",
      "r696"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r351",
      "r361",
      "r362",
      "r363",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r199",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r130",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r130",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r365",
      "r372",
      "r373",
      "r375",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r140",
      "r144",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r381",
      "r382",
      "r383",
      "r384",
      "r603",
      "r674",
      "r675",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r350",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r71",
      "r350",
      "r394",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r71",
      "r350",
      "r394",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r348",
      "r381",
      "r382",
      "r601",
      "r603",
      "r604"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r70",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r72",
      "r140",
      "r144",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r381",
      "r382",
      "r383",
      "r384",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r72",
      "r140",
      "r144",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r381",
      "r382",
      "r383",
      "r384",
      "r394",
      "r396",
      "r397",
      "r398",
      "r600",
      "r601",
      "r603",
      "r604",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r361",
      "r376",
      "r381",
      "r382",
      "r602"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r64",
      "r361",
      "r602"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r125",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r125",
      "r300"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedLabel": "Depreciation and amortization expenses",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r125",
      "r215"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r8",
      "r10",
      "r14",
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r22",
      "r95",
      "r705"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Loss before income taxes and non-controlling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r14",
      "r22",
      "r28",
      "r490",
      "r504",
      "r507"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r23",
      "r31"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r12",
      "r13",
      "r23",
      "r32"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r23",
      "r31"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r33",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r98",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r172",
      "r181",
      "r182",
      "r183",
      "r187",
      "r188",
      "r562",
      "r563",
      "r684",
      "r709"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Loss per common share",
        "verboseLabel": "Loss per common share, Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r98",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r172",
      "r181",
      "r182",
      "r183",
      "r187",
      "r188",
      "r562",
      "r563",
      "r684",
      "r709"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.",
        "label": "Effects of Reinsurance [Table Text Block]",
        "terseLabel": "Summary of premiums and claims assumed"
       }
      }
     },
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized as software development costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r88",
      "r89",
      "r90",
      "r146",
      "r147",
      "r148",
      "r153",
      "r163",
      "r165",
      "r190",
      "r261",
      "r393",
      "r399",
      "r477",
      "r478",
      "r479",
      "r498",
      "r499",
      "r561",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r726",
      "r727",
      "r728",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r253",
      "r658",
      "r660",
      "r662",
      "r664",
      "r666",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Face amount of debt repaid"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Office space consolidation"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Valuation techniques and significant unobservable inputs of Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r564",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r565",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r564",
      "r565",
      "r567",
      "r568",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r363",
      "r442",
      "r443",
      "r448",
      "r450",
      "r565",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r442",
      "r443",
      "r448",
      "r450",
      "r565",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r565",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of liabilities at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r569",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in contingent consideration measured at fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Realized and unrealized losses, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Customer Receivable"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r246",
      "r270",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r246",
      "r270",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r290",
      "r292",
      "r295",
      "r298",
      "r649",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r295",
      "r656"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r295",
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r125",
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on repayment of debt",
        "terseLabel": "Loss on repayment of debt, net",
        "verboseLabel": "Loss on repayment of debt, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "negatedLabel": "Net loss on extinguishment of debt, including fees paid to lenders"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r281",
      "r282",
      "r632",
      "r671"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r102",
      "r126",
      "r158",
      "r159",
      "r160",
      "r161",
      "r179",
      "r183",
      "r538"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r93",
      "r220",
      "r225",
      "r228",
      "r231",
      "r234",
      "r669",
      "r680",
      "r687",
      "r710"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r91",
      "r98",
      "r152",
      "r158",
      "r159",
      "r160",
      "r161",
      "r172",
      "r181",
      "r182",
      "r563",
      "r678",
      "r681",
      "r684",
      "r704"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r91",
      "r98",
      "r152",
      "r158",
      "r159",
      "r160",
      "r161",
      "r172",
      "r181",
      "r182",
      "r183",
      "r563",
      "r684",
      "r704",
      "r707",
      "r709"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r28",
      "r31",
      "r508",
      "r705"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss",
        "verboseLabel": "Gain from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r22",
      "r28",
      "r539"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r95",
      "r98",
      "r173",
      "r181",
      "r182",
      "r684",
      "r705",
      "r707",
      "r709"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r173",
      "r181",
      "r182",
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r94",
      "r125",
      "r217",
      "r254",
      "r679",
      "r703"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Gain from equity method investees",
        "terseLabel": "Gain from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r6",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r26",
      "r29",
      "r30",
      "r31",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r304",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r492",
      "r494",
      "r495",
      "r503",
      "r505",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r164",
      "r165",
      "r218",
      "r490",
      "r504",
      "r506",
      "r711"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r124",
      "r643"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r124",
      "r613"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r136",
      "r294",
      "r645",
      "r646",
      "r647",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r288",
      "r293"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r92",
      "r214",
      "r599",
      "r602",
      "r685"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r106",
      "r369",
      "r380",
      "r383",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r119",
      "r122",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r212",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r105",
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r616",
      "r618"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of primary office leases and maturity of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r67",
      "r141",
      "r227",
      "r256",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r345",
      "r346",
      "r542",
      "r546",
      "r547",
      "r580",
      "r630",
      "r631"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r56",
      "r141",
      "r256",
      "r580",
      "r632",
      "r676",
      "r700"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r69",
      "r141",
      "r256",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r345",
      "r346",
      "r542",
      "r546",
      "r547",
      "r580",
      "r630",
      "r631",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r712",
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r695",
      "r712",
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "negatedTerseLabel": "Impact of consolidation on reserves for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r714"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Paid costs related to current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r714"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Paid costs related to prior period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments": {
     "auth_ref": [
      "r716"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments",
        "negatedTerseLabel": "Other adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r716"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "totalLabel": "Change during the year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r50",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term receivables"
       }
      }
     },
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r46",
      "r362",
      "r377",
      "r381",
      "r382",
      "r675",
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r72",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r121",
      "r123",
      "r126"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r83",
      "r85",
      "r90",
      "r96",
      "r126",
      "r141",
      "r152",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r179",
      "r220",
      "r225",
      "r228",
      "r231",
      "r234",
      "r256",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r345",
      "r346",
      "r563",
      "r580",
      "r682",
      "r706"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r169",
      "r170",
      "r180",
      "r183",
      "r220",
      "r225",
      "r228",
      "r231",
      "r234"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r171",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r183"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r150",
      "r151",
      "r154",
      "r155",
      "r166",
      "r167",
      "r168",
      "r250",
      "r251",
      "r262",
      "r263",
      "r436",
      "r437",
      "r438",
      "r439",
      "r480",
      "r500",
      "r501",
      "r502",
      "r559",
      "r587",
      "r588",
      "r589",
      "r621",
      "r653",
      "r654",
      "r655",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r149",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r160",
      "r166",
      "r187",
      "r248",
      "r249",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r331",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r496",
      "r497",
      "r498",
      "r499",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r590",
      "r591",
      "r620",
      "r650",
      "r651",
      "r652",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units for goodwill testing"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r220",
      "r225",
      "r228",
      "r231",
      "r234"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r611",
      "r618"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Gross Difference, Amount [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r606"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r606"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r606"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r607",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r615",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r614",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r34",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r539",
      "r540",
      "r544"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash inflows (outflows), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments to settle outstanding warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Repayment and termination of Credit Agreement including settlement of warrants"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r110",
      "r530"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions and business combinations",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r109",
      "r252"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-maturity Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r37",
      "r58",
      "r59"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "netLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r43",
      "r672",
      "r693"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r108",
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r112",
      "r472"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r308",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r62",
      "r301"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r41",
      "r42",
      "r303",
      "r632",
      "r688",
      "r701"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r41",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r41",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r99",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Adjusted EBITDA to net loss"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r224",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r224",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of revenue from segments to consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of policy benefits and costs incurred for policies assumed.",
        "label": "Policyholder Benefits and Claims Incurred, Assumed",
        "terseLabel": "Claims assumed"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r449",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r449",
      "r624",
      "r625",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r449",
      "r624",
      "r627",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r622",
      "r623",
      "r625",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of senior debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r486",
      "r644",
      "r765"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r40",
      "r127",
      "r133",
      "r670",
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted funds"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r35",
      "r40",
      "r127",
      "r133"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r39",
      "r43",
      "r127",
      "r133",
      "r744"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r743",
      "r745"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r60",
      "r743",
      "r745"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r743",
      "r745"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r743",
      "r745"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Investments",
        "negatedTerseLabel": "Restricted investments included in restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r310",
      "r312",
      "r315",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Repositioning and Other Changes"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChanges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r311",
      "r314",
      "r320",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r125",
      "r309",
      "r318",
      "r320"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Repositioning costs",
        "terseLabel": "Repositioning costs incurred"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r311",
      "r312",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r52",
      "r399",
      "r481",
      "r632",
      "r699",
      "r730",
      "r735"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r146",
      "r147",
      "r148",
      "r153",
      "r163",
      "r165",
      "r261",
      "r477",
      "r478",
      "r479",
      "r498",
      "r499",
      "r561",
      "r726",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r211",
      "r212",
      "r224",
      "r229",
      "r230",
      "r237",
      "r238",
      "r241",
      "r424",
      "r425",
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r201",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r414",
      "r415",
      "r428",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r101",
      "r335",
      "r337",
      "r338",
      "r344",
      "r345",
      "r346",
      "r741"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Revenue, remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of allocation of purchase price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of cash flow, supplemental disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r6",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r26",
      "r29",
      "r30",
      "r31",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r457",
      "r468",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r31",
      "r141",
      "r255",
      "r256",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r290",
      "r294",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets",
        "verboseLabel": "Schedule of intangible assets details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Activity in claims reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of net assets acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r40",
      "r133",
      "r670",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r40",
      "r133",
      "r670",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r316",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Costs associated with the Repositioning Plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r462",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of share-based awards granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r459",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future estimated amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r198",
      "r201",
      "r202",
      "r203",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r241",
      "r314",
      "r322",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r209",
      "r210",
      "r220",
      "r223",
      "r228",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "negatedLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r456",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r15",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r241",
      "r286",
      "r305",
      "r314",
      "r322",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r139",
      "r141",
      "r172",
      "r173",
      "r178",
      "r181",
      "r183",
      "r191",
      "r192",
      "r193",
      "r256",
      "r332",
      "r337",
      "r338",
      "r339",
      "r345",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r580",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r76",
      "r88",
      "r89",
      "r90",
      "r146",
      "r147",
      "r148",
      "r153",
      "r163",
      "r165",
      "r190",
      "r261",
      "r393",
      "r399",
      "r477",
      "r478",
      "r479",
      "r498",
      "r499",
      "r561",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r726",
      "r727",
      "r728",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r190",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r48",
      "r49",
      "r393",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r48",
      "r49",
      "r393",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r49",
      "r393",
      "r399",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r393",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r48",
      "r49",
      "r399",
      "r458",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r393",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r49",
      "r54",
      "r55",
      "r141",
      "r247",
      "r256",
      "r580",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedTerseLabel": "Stockholders' equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r713"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Incurred costs related to prior period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r75",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r75",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r75",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r152",
      "r153",
      "r154",
      "r156",
      "r166",
      "r248",
      "r249",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r331",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r496",
      "r497",
      "r498",
      "r499",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r590",
      "r591",
      "r620",
      "r650",
      "r651",
      "r652",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r311",
      "r312",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r487",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r612",
      "r618"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r171",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r169",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "http://asc.fasb.org/topic&trid=2303980"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r767": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r768": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r769": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r771": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r772": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r773": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0001628908-22-000063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-22-000063-xbrl.zip
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MW6M8?CK_W M(%F-5>*C.C, B1Z6H2+U96KJJUF4:HSQZIU5<C'U4K)97M59
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MI.7)Y_@E2:]B'3+.$ZG0LMN>=TYI2_Q&WB1RXF@(I@^ZA3 FGF#Y '\+]#*
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MGU^BEJ!R,Q5O=YO0:WHE>CWLI-</V L*TRF:9N&!U"B_@7\'Z27E!BP9K>D
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M9-Q$14IL:R0EJU1T:>U)MSA7B%)F!2'AV<>H]CWFC@8)<)0R8[-2S2:F6>5
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M6NH<[ GFO3-4;3+W,MFBNA_^&NN!HE=VWLV#*8U;D&3:3]EFU)V[]S1DQJ]
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MYI31O"GVN\FT([#3(WQ(S,ZN;#A1U!,<M9AFB9XQ6=&[L70QGC4;@>(I01W
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M7JZ+W /X%I?$*$"^C'-"N"!-0E(XB>I5(MP%'@6J+E0VTH67E.,!<!CXO)\
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M8J0;J0#.$)*KA@2G<2_N/NTB:,Q_&=;N2VREG*\RI/10^9NY1I\P#Q4ID(1
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M(;<U?H>I;:*SG)HAB0@:JZ_1&-0DP#>4YU5?62"E6%VCBOL=6NY]:'6@YY!
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MQN@#.38 =F,5V0Q&.3 Z5:KY$6&8T4@RZTFEU@I.;RC;D</9D>S&UH/-N5&
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M'BEM#&]B,/KKA%)\D,N"2D8M%NWV:A8M<4_)@++<]P$U:%ZU1 KL@W/HBCA
M:?S;.3G)BJ5K23^\H^1J*=SSG;\4/R&MJ<T-;'E8_ZUG,X"D!_KX9E/@1,R9
M+31%J9IZ.AF!MH!N*K9(*>(73\E21,.UK0'PAO#P:F;GIKB]W-46^!+>NH@T
M=YPG:N?4ZR&Y2N,KKNKEQF].=-M.0W,<G _;K%V S)KSQ=P+$O$83TTZ )HE
M6.V(LE/"%4U_1NO$6^/?W]W;HN;ZJ'/AB!BGK66])65SU?H\7-]I@8(RV>F9
M?:$SV"!V.=EHAGC:,Y"X@1Z\]#JA]EQ@:=$/RJ@AOMM.T/?^F4:P'^Q! II2
M9E;%9&J9K 9?P)!T&8.64?C2TYB? '0%E7."Y3U%A@-J"+%!(.DDQ\_9V*O<
MTSF85['"KA,3%5 /;;BL/$5W)GDB)7)2#[Z(!KKAQ%\:X:K-Q</2WT@99#[T
MF#(..@F#V17SONN$+%*%[=K09<C(H./86 _:-^XSWU3YIIQ%'N$U%]JDOA-R
MH=IL%F0+F!?E1%\5HR$AZSJ..<H\0CYJYO:EF3O#S^>PB,F5JP8LPWL2:7_I
MUQD]"5+K"2%ZW=AE*\,.S,*$Z;U-,]V93 >;+&1-9TM0$@"\U"J&Q6@*L#;G
MJ&P5WSP0 75PD[N@L@ ,KL\\@T8878;T[N.+X$"B5?8;PJTVKY1'>]09SP2M
M"-OSZ ;F,SL\A%.ES+LW<+04IG_U6A<QVG"ZU':N1ANAGEOU_O&-(".8'"C!
M@%9]&T17 8FIYMTHKSH<VL*YHR1&B*? ,/.(.^C7<]XV3C;%WUZ;=""K8FO'
MAK.27V)K1.I$9>?5RDLJEU.:561C.V51?$*-L<V8SX,DA 9PS!!Q /8K-O'/
MOKUU^8U5P$*X[D_.YL]E\WW 3':[G !BU+5+QCWC$6DB#=U1A2!^3042EP66
M$H%P0+F 6A3P2!I,3&QN?HLVZDE%KW00G10K_ "IP^::4&J(BX.<^3 /ZM\W
M"'%__SYJ"&\Z-00U <@2P\_9E^ S@RDPU@N29(AV"HM=Q!YJQ7>MIG[==B4]
M >0[*@.F>LJT=.?!8IR30_4.Z.X::VP0!HS"^K>81V"3V:+I3?19+S0%CDZ.
ML'A$KARN8H0^C_:KQ,,:$P@3#CLQ 34TN"S*0,BH@M)BQ"6H1OAWS"OR*Y4-
M6[=IR1ZB=M^M)@,UAT%L"C5.OD/VXEH1;D+"IJO\@^2#2^90%OPH]60407;4
MH6=-3>@&$QJTOY#*RORZ#BIV?=VF%QL&6(RVV+\.DBP0).F@@F6-'+.UG%4N
M%RGU(:<SR0W;:@!!0)1:)IW!0VTN17V^F3[GAA'JV.P%-(7)^6;]V5E%G+#-
M,-U9RT?"=DP[PE2=S;BK XJ#H:"3&=\%.4*$3L7HGDD@:R>&!9U/"[/-_C+)
M7JN<UB74 ^U2G%:8&]%2V@S8=0"2/0J4Q3Q&,ZS*P<$0S2KQ1EDX%?^Z+M*!
MAM<-&\K!W?>063$O:;>;M&FBVA%GC8%E[J0 :[EVE;G[UJM=E<C">N1N0K\D
M:.V4R,Z>25 3<TI;@WO5.>K]&X0%26I=CY(")FD7U!S3]ZY2GCG'O3+AH2L<
M %?]*AY&B5&/4M!@K>NI]ETPO\L)U^.F">TY0-ZYL?M?F\Q[=6Z+T6T6"T %
M187X(HWZZ=KI#]LS?S77,R^3NJJ20.-UIS0BXZ%JA/!SJC_\'F>T[[BB10>M
M)[_..ELL(EG#AJ_<G[%@.R( 3D)[6_BF,?L'BP7!@![I.?D#Z7 (IT#SR$ C
M=S1P+>:N]0.!KIY>LT>]2L5OT/+5IK,'^.)E-."V# A; "AZ>;.RN,2T<\IE
M@B-.33$!V5QQ+!Y+^/L5X&0HI9BF6P@2G?-G4[J9V8Y1YLD6OYEE2I@1$25-
MWD3M4,Q<QO9$_DG&3=6E%I][R\K(2/(P<):ZK2RM]TFI> JV>PXQ*PN_:RNY
MJ^)27A@=>97*UVBA;?+A4RJP *O::;N95HU@C"[9["M@^UM39AJ_M65_PJY
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MR*$"P@4#!/E029M2#Q++,'-3]J9G(6VLM"VQ'^5THU4 7F%T# )?6W:(.!.
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MZ?LB_W+AMWPV=X_V%G3W'U!+ P04    " !7D:14-_J9ALP$   8%0  %
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M>/\I.95X,*BWA"'WC$@';*"T"(1;C]$A$D";I<RLI5S>E_+SVX._/4B L6*
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M]]PPHUFR.D6OG)9Z:>3XI$'^#,UAH$PD ]XS+TP,3D<P.7R4GJ+8EL<</MV
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M(8P:*" !QG&4J<(J:PN(1 N7B\>1%0_X3J]NW@<KX8$HPDR!U)4@:^6A,%1
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M=O'/5.\_OQ;76%K"@PA$[1!77G<8E]QX>T[+.6/ J=?]_,S&G_;28A\/MB[
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M>J;!XR":[GY!T+OT^=<Y"C/'_I-0_QS15N1Q=SM:YRS)<38NM]?=[^4XB)R
M7!OJ54>?#$;M89'0,B4TR9&I3N*&5>>\7520'*$WD>&<$5*G[.5TG!H9X]6Z
M.9BFCI'*)Z33Z6PY$R.=H]>YJ.=&0X+1D_INQJ<@T$1P<L19+\=4C8V5VI%C
M1YFFGE_X/$^G+)>E.@/\8-AO3P7J1:,C6J"YX<'%^,_CE.1L:X$Y/=33^81)
MLXN<EBFG/.,I5ZE.-NKW1[EDQ,2Q%G2[D[M<)U=VO]_KGSG5!J>#J$@7 N]3
MGN_X^_'U6M'S]6LN7B19-*[(:>W,:S8UZ^/C[[0K=E*L\:A.N(X6>4JHG:)
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M9OCKW1J>A.6V,)82)WTOSOE&G/+2268IF'4ZW^;;*,@\TT!I'C'+<ALY"Q?
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MX@@Q-JD[:T74?A#JW@2'2<[D7:ZN7M[2[GGOZ*@]K).A4\9TJDT0'\!W;3K
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M.Y??^IGXSA)[4CN2^,:%+B6O=;Q,Z;)[PRWPDKQAHP@E#@&N4N!37 1 $NH
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M2V,4>2/#R'E!+7/&<,&IP418HBWRQ;G5#(#=G0%8;+FG06F@I0Z 2B: -$8
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MV/KU(!9>HB $YX9[X1!S$OZQWB+#'$%<*I=[GF&=M45$'JTF/V@1D>NH<LM
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MW/CDZWJ:](C.Q)XM-*P__ZF%AH>&AL7ZT\Y0E1&#N P\0H-#1K(<*:Q"GNL
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MQ=BU8"RE.>/!Y_ _SP(Q2F3>XYQGC@O)"*]]"RW&/BJ,72Q HACUWG($1H<
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M/31X!JSTS[HQ6QD#FBX&Y:>T^F.P1LM,)\8M84Q[IX%1"&:-,X(HKK%1@F3
M45OC=A,@8*FJ];)Q>W;XZ6"O=PK/?/G^[&UV^/7OTZ.]_Q31V#TD[[X>?'Q+
M#LE?%P<O@9E:1P)1,3)46![362W2/$A$A,TDE5B$F#U!;TI,@:'D3C++I& ,
M RR97.4Y,49)%:QM5])36TG\ ^,L8.XPRA3'B.7*(,-<K%TJK#$NJ%R+[^]$
M"[QTODS'7>70;^)AU.I$I^\&%,R>S<^=3S<AN"G@=AKN4H2%F+$F&-<O)135
MY1@ZZ:!J.!@'#TTSBB;!-XM!3+/)QTWPE*^FP4<I72,>HXUCH^)/QY%M\>K
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ML-6I?_0AL-]$C-U8LK,^BHP<H5F\;I"FZ+S.NFK"F %BB[JM4#>6E(U1VG7
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M*9D;?Q&XXQ57&*<*U!TB:J?.PE<NXCELK!V=$H_BEQ,K&[O_HS=,C_KV=&R
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M<7 Z@WX\'EAF)54MKG9TJJWK8DK&)*R30=,5R3[%H!=%HBZ2U%X9VM>3PQ_
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MA<?Z1XJC5Q_O#BW >@.6[D;CE_(:$U][ VY(=97U:#)[ ]U.9/7RM F/,_'
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M:Q%I2<XZ,)D84NZ?]J(3#]><Y&._/4X(INSNBJZD?)28QJ O>OZWZL7OT#7
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MB@S\/'5S\?5NE"POO]6#]O3"5>I[@++4PK:%%AB8^54G3;9]F/#0:RST.X#
M&]^=<CVH,"&3R@H95>N%-R++<N4P 6N9$R/F,I*1ZS$;0>FTH[)V*?K1['U]
M[[OQ#7WBR=!E0/3UL1.ZM_WU:@_:NW>P0_</MHYSZ7T.K 3E-+>(^<"0SFQ
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MHO]"$_Z$IRR[J7@9+].(X[9>0.)%JUGLHL<N*=R#V-=ESQ:WF<2>"DGBZ Z
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MEYNS4[+F\;)%A'!.L'"]/%BV*,+<'L3=VJ4<1J3CA]9+Q[I],C+S[WTWYBB
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M ^P$L4P*@#8MD":"!D:\%(S&HIQJG<K9.DLKNIO\!*&25PP#RZH[6</ (\+
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M!10NI.04 #(*66*V"KOP*YDL!;E/Y6+']_%!5-)Z>A2=^BQN-C'@5CRS<IC
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M:=!)>>YR5%DE\P2GZ#8C;J>S="O;>FK@K7%\C_D=S.B+!E3J&^7#6J:-LT-
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M48<4B7 !E!$&_UBTMR(#E"YPJEGG9Z!T6,[XSX]H<%G+W'<MH;^T\4$KH1^
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MWW8%_8QJDW1A.4I/G3,R<TZC+B[QX$H;=WS$L/-F*>X8M"DY2XH6*R=29@^
MHRW(?6Y24*((K*AFMPH[WKZ8Y:JQMRLXZMN3Z!KG'Z>H=<Q.NAQ]"B8D9D,J
M#C0QTP8J'R5S+7ADI0_"2@K<Q*)"6U<0I[@DM@1*/?,T8U<4:[;<G4VY>43Y
MDBTW?T5N;JWFK\#?BR%/[9-13AH"APO\#=*36,D2D=SYF+)S5C$PFM465[+E
M[Y:_6_O[$?'RQ5+Z DO*!D*CBD1:Y8@WB1%K2Q1@F;.<,0N8;VEMOV%>_JYL
MV<*$<JHDPPT%W X^4&N3SI87!2=NVCCLHV;AQ3BLLUXZJA@Q3 @BO05Q'%PF
M+ 0G/!?9)/7L.=^FK2W[-:6C$9)G7128/USR2$.R01F78O%&TK)NO&!KRSZL
M+;L8N"W6\Q T)=%)"2JN]23(!+HO8Z#J9&TMEZTQV[)S&P)^*@R^$ +.@O)<
MLB3:&DJDR(Z$["6A+ 9O6>!)!+!FQ98PW[(&W#+X_3-X:\W>.3,O1)-]450:
M,&(U=Z +4Z5("%$2.,3BN/&4^BHG<4O)Q^2:^L;K5O^)LTT[QW[X*9]V>MF/
M\E:GGV\RWN/;,;JSI%XISY/T14:3@Q8F)9X"EV!\2],&D!\QTKQ="B"GJ +G
MGA)OJ"$R4@D_@0TNBI%":ZX+3QA 9FWN\^U%<BI*.><-4R5(3P/P2:8B,A5M
M%":H-AS\*%EEP<7,C G)2T$BCL:0P#8D".,)I9E+1Y-(#&N\MSC;4+]N4RR_
M!0YLK=ZOP)-+O=0=E=XK@=%;B[W4&0G2>1!DW@@5L[<\(T_239O^M3SY+?!D
M9:BV++89BRV(/1,*IH=R$ATVU@25D%CK-0'KU ;G?<K&/WO^E(3>MVB6E:QR
M*&"6A:*ED<K2;%P1'M!16YER&PM]U$RW& NU/EIKHR=6>FQJ%B+Q45,24J&"
MA2*2E6B6B=8LN[T "L[";M*0 NRF%=(%QI0)F>I@G"^VC6P^1E99BFSF;!*7
M.1 N'(Z7X()8YBR!H_3%*YT%CZU=]MVRX%J[K.6[#?EN(>!(K0I6AT12+,!W
M+&#*'6,D@B)/N1:^,% ,G6HMK^^0ZUK+ZS8<MA %#-XKGRTGHBA+9.:&6.T$
M24P[.+.$+@XPO3;-:+V_2)_XJO6DJ?OWP[#:'\/!W]V4AQC\.Q\,/U7<A5L_
MZHRW_$Z7I;?5#=;U\\E@U,73_ZENJ_MW_AD[%!-1?7MQ$_THXPV>/?^!_3BA
MDVI'O^^DXFB250KPT=,B?4[6.Z&RTL&%F)04;7SS$6/H^Z7X9M7[(BA': B@
MI 2?B<=Z6>V\]8J6$JK&O+?J[=0F*=T^28ER5P0K624A-0@U'S4H'I(IE3R5
MO(V(/DKF6BR0U2D#)%IB2J9$:A&)<UP20Q.3U@!>!F0NO<6%?D192BTW/SUN
M;J.K7X&_EPIDBW4I>T=PB :10AL2"B^D,"V]*,'FJ'%2M1%W-5FC9>_OD[W;
MC.*[9N4%4>U$=L8X2TH(V%VX!.*E"T2E0*F*FA8N<"Z8='<U=/XQLO)W9<DZ
M76CT/D=*@5=C @O6<2XH3]QPHW@;$G[4'+P8$B[">TL%6+)>9^Q&8X@MTA I
MHV"V%,,+-IC;YJTE^S6%H[( K<+02%66Q8->I(O+R6?)=/8YMT'DQ\A<2T'D
MQ'-A/(% M,(#=V'!38H)A"0SOA0EN*&5*0N_?\,"LF7G^V?GUI3]*@R^.!C7
MNQPRS21R= 2[D(AE#$Q;QP,U-(OD+"K UCRF@KJ6OY\>?[>V[)WS\D)<7"=;
M5!:!&,. EV/4..1:$A]\8<&*Q'%4CMU2\JZ&7#]0R'S58\VV48^\3G9_<.I[
MG>Z$+SJ^8HQ-BV4W2.!>-^R['M1;;\9/ G8P#<YP0>,]^%Z&?M_=/GPSDH!)
M772.3A459'#>\8RMPY0K&60"*VT(\O')@K@4@J0F@@:'_<*T+T3R)(EC5!!M
MK.;%:>.9>?9<2K[%G-I0&-P9TWR=-,86\UK,>WC,:ZW;KX""BX':R*(RPC(B
M,W8RUMH2YU($>G/&V!RSTQJ]5V[+V4V[N[4HV*)@BX*M#^"!$6]![[.@^*D2
M/#$9]3[J+;&&,Q*]4"J8S*G$:;F&;W&VJ1/@B2%>:T&W./H@.%JX<R4H117+
M,AGN(BLR2JFT]H"C;6?@1XFDR_6SDHI(A24Q"H#2) .QD06B&=C/B6KF::I-
M:&$V3>-]8E#:@EX+>@\/>JT)_55@<"% K#.W(C-#HA(:&T@IXGB1)%*,$18?
MH\4V IIO*=?:T"T,MC!XSS#8VM!W#GF+,XN9,RSH2"S7!5M[4>* 6HFEPI2L
M*5466WL9MV7LIEDQ#PYY5;C]'Z<>'CJI;(8W0"KN]L\JB5J5D(]7/'/WCV>C
MTVZY:+CP^?\;AO]X/E\C?9/O?47NY<B]L[I")W\^R?U1[E2EX#EU3@?+\7AD
MK@YLVE'G]"C#?X<Y=X[A,4>C3NXG^-*N'\:CCF!;'72(=7P_X0^L<^Y'G?_:
MQ.&FN2@>P '(30IK76$N4F9MU((&:1<RT9<\;VHI+WWF55^71>"X&6KH)XH:
M'_YS1./QO_O^G3M[?;PK@*L_[_[VGK]^]U;N?OSS>(__Z^@]?R,_O'M)/[QX
M__D]?_OYP\>C3_^Y/+S8^_CJP)?D%0^&.&8UMFU16+092/:!4Q:"3)IO) ID
MRK98274(''\.#F2"\)KR%)G+;F7%?'NZ]W.Z(2H-S!6) %[#)L6:6!<B":"_
M\F(X"&J< K*]' M?^D,',*H'/VP!F,3>&0+R1EQ?9.:9&Z^2MU**%(1ENA@!
MQ (*@EML2=C2Q3W1Q>7NBYT#SU,&?0VH06 73YH-\=Q9$D1D-!@-BIO<+)&R
MQ (Z0DY&4JDB]XQ:J90'YM<JE=5],MK3O9_3#=S8! Q.<D@!9_\DL%VY)5H(
M)8,"P1O!=J7;RW;K&JVN8?W.H'3\-6I%ZHX:G0I^'YSD875EK5S<1*]@VPOM
M9^Y#21LG6VK0I);;Y)QWT^G1V ::^5:CO=+I5WP 1?7L=/U7ELH%'T@9Q"J5
MN5V=^?=H.'4 '&82AME_(K[ 8G_RO7-_,7KVC[EW.N[VR>P&+K[[^A.H_UTX
MT)I%E9,A!FJU%$PF(%9G=.+%,@%B@V-?JZMJ&V^E<\SCS5_Q**>S7AZ4*VS0
M7\].SX9Y%II>UARPCW;%/JSGG[U!_/3]P8YXO1\/!&B+49A,DF$>8(=A'K9.
MA#HE0DEP-C0\ZV0 YQ-DC>%97LLL#VLZU<<,*ST%<8*X-@=Z (++MM,/W3Y
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M)%UVTN!?%DRPYMY+9%K!<*^W>/D">U0/WZ QRO<WX,\^\@%_U[;+6&BO <:
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M24.6J<?EEW'?M:G27%M1K!4Q:T2,W(7/#JC-.,0"] D0*)B>RXBW"M@J*Z>
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M4PG3IW\>[VQ]I =;F]]WMMKM@ZU/Q[M;GXYV]SY?[E-H:\\?'?S1),TO!Z?
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M2F$+XAR6Q'"&J2H*XZDUT 1CE+CI+;BE]!?NR'W.!:BG?,W*C;MQ2?\E;RR
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M(_]CD/]DEJTZ$21@//)42,2-*I!UD2/NJ*5"^"@+NO:& %N5RZ3M]1K _0.
M$K"?QC?3/@]S3X4^U$^H4PU^7@?5X']K98T1[-?POL"S=Q<9VC/$-SGTP?>O
M46M;8(!VRPH+^"XC4MI1))G%1<!!^<*LO9' [/6BM->7-N-@/%5@WF]^- MA
M[+K*R)@$*SSK]ENIX=]ZH0UW^!:NS[G_:S('H>HJ?'V)L= KYX.;+YDY%?Y,
M60MC&^!E/X_]>302_#@SAP'97C G*$>$?S/M"W/97_OOR92$5@>-=^#TN]\\
M K=D@S!)<4&=Q QH3;#$"$X"QXH)3#VA=NVF+)*[BM\N9Q;)[GFO47XA>&3
M2J#G&T-BW0  #@W3\;G([?!KC5X^$WU]AA\&Z+3,.$GJ%RG;I!?NE5/RHU:S
MXLDG;*.0/U;(]M;D$[Z!F:Z33VY)/AG5G&W,I%^\AG#VEZ$!S[7S)PELOZA
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M!T3JF?.4,R>$X JO&#+""2 , B-3*(4*XBRE1&#GPTUQXQ4(HM2!Y'II7;E
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M7V]<A$9O>):B <_4*KMT8+XWSGK=;ZU^>NM?;.B$V!K\VB@W/.%7W?,>#,8
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M9C.!_PP; 5ZZN%"NU =35D_,<M"5_5FJ<Q:^&?B$E]%#F,;6@V)0:5WI9M
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M1X^LS63KZ)$7%CTRWYIA:=W..H"D#B"I TCJ )+G1+HZ@*0.(*D#2.H DCJ
MI X@J4^9UK9Q?!U LMP?>+[W^Q_MYDF3[OU^B/<NFUGSY!#&.#J)GQ_M-$ES
M!WXG,,Z"/_!M=MCY= '/RHY./M'FY8>+O1-7['6:\/G?IS#3<_B='IWL\ND
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M-:4?LY?N1+T\<:;5@U9BBO1+%!A@@"1 /Y7\%44D"EJ4;!V9W .KZ_XI2'(
M1>+GS0@?0]AAHX\M#A(_L+Y(IZ%)ACVPGDM^N&YJR*&M+1]_IB_B1>F3_LC/
M(2/,:?PY $F\N=Q_D[OT&^BO(#BPE+",5WP[:!AO]0BF7=4:Z_LVW/75@WP.
M6KW^$($P=1H58,3'E-=="34\-0!F=6VAV_#*\&:C$C%>+FO\Y7UCKP?4Q%D%
M7:6'*!*[[X]UWZ5Z<K/EXRKZ@DW!TLTEZ>!/7OXY1Z]_SVE1RSZY#TV34F:,
M8*"*69[AC''0F 7/+#6YE2YHD[,O6+*-J;N>2@>+I)8 L0];,_)C9'WO_M2P
M@1[T8<*EA3"X@KOUJ?SXX<I,VSGFAY?Q^D]@<MEL?^?T?/_@\/+H!$RPDS].
M#\DG?'CPVTF,V9^O_+B_TSZ)<X-[Z=YEC,5_R_=.]CHP3]+L?#PY.OB[U?R\
MU_KG<O<23+XOG*F<JBQ#PCN"6. "R3SWR-/,$F9\IKS>&._QWKV-/E.B"#&9
MS9DACBGFM0)3C3O%@,T\]W:^4F2U"HVX#!%O%LR2:7Y^"NE?;M_\^#5GR6(P
M5Y(Y1T10+%/P.R=6L)P(G7OO0.P:RS#@AW;6#\>=FX<7SDGJ<Q';F/K@E0_$
MY)ZX7"@,QO.3VV77[\ZPRY1;$JC9ME^8J.O[=N]\7I7K5QQU5G%4Q-T(Q:9L
MZI ^^#? ^'!*YAOGQ; 5K^I41L(9[(6EMAYK=\;1H]LXC7NU_0V&\,$+WOTP
M24&-#0>(. *U.=$CPG/I1,%BUJ1K:=!B@%2]#J!U$<^40?&)IE%CX+_Z=-8X
M7L*)_5CI.I51 /I2TN7]G&4"FVEU(>RTT>*:?B@L:!M .JU-$;4F,(I@]6!9
MXQ*UXE.JS;@T<+P?I+K-^2_IR#/VP"G-M=0/#3ZSK8H!XK9>%F--]L38-MYL
M['[M11TP/3P=GB?2@*40H]R*Q&-@F%2%71-KC<W<:B97A.C%^7X%UIU< BNF
MCWUIP47S3E>ODFK-CL[BQ*Z> _>#\GDV.V@Y0L-7C1"KAX)J4MT&'P0?S;;!
MR[!CKL>,,9?H]J '1F7_M%J.3W\VWP%UNXDU(M.$Z/2+ZUWR")BE,VQ6,<R@
MTI<!#EK%V=50T1+5L#@F@FWT- (OSUX))I4O+TT,&[G#Q<7SW\"$'EXM_E /
M8(X_G?6+6)88M/*#/]].5OOG:M"H;?8FMX!H#GNP648KH%.,[??DE9B9 _Q=
M&;+MZ F V7<=BB;N#U71J=6M*$P%+,%9K_12O!D;$5>Y6?^:W4>JS*[LZA9M
M %#AQ:^]92$^Y8FXB*@YZDS];$V:))V!O"'3]_H4Z0"3?:/;Y_IBL/'OF7?J
M%%TT3<#Y=[]>ONXGG4LUAQMH @^K?_]E6]Z-VGX_7*>)KUGY]:=0PNT7'=.>
M/74H6"$04U0C29U&2FFBF:5<V/!LRZ]7)<ZO=9OJX1 TO5%Y,6!>5,86]+NT
MP:62Q*5>,JY+G$9;2#:;*^Q^?6WU*BLUQ@WP90%SSRGG5; MF9/59SOR+2[$
M<TG-C).]6=+K:TW7^4Y=[U=&B7OEJ#ZS1(UKD]G\C?)T;A]XM9)HW >-Z%T^
M^GT#O9Y9%\RWXW.(J_.*I=W"[QU:M'9O?NO&:2\S*I?3@ /+;$XU8U@(98U@
MPI! .+8$FYN6=1LSTL<)'^WYX;O2%GTNX;9W4_[+0"EX5N>WSMX.*/J=#W#_
MAVSO\CTY['S*FK^_ASF\IX?Q^9?NM#G?QBRV+/M\F#5W3LG1SN'YWLX'VCPY
M*HX./IP?POLV3UP+QJ-[Y,/%LLP:J:WB3 ;$+0?C0682:1' 5#5!624DIS*6
M9MTDY-[1MJN)E%IE^&.-2R\4ER0.GGOMB R841MD<%Z =>R<P\1[<]-L@1J7
M'@V7Y@(XA8@^C9PBE2F'F* :F3PS2*H\+F1.7& ;VV0SQVJ-<&E%:O]ST?_^
MG(M,2?Z47HH.&D=$56Z;:ZV$[P6>+R'.<P\\?S@5JEJ+W7(IWG9=BM(J;;0)
M8M6@= M0^K"@+ 45+#/!H9QDH"QE3"##!$?&,66<(C+W9F,;XQ7E):UCEO&K
ME]=5J1:UO#Z O,XI$3+D%N?&(LRP18Q+@C0)%%%.,I8SEX4DKZO*(UR'5,&7
MHT' >LPJ$7?2(5Y@\MK3Z!![D^6H#9_58=:G!1V#8>.H8P1QD8/A(XE%)I#X
MIW69%#E\#88/VU1<KI'A4^>C/D,UHQ;I!Q+I>36$2 >,11!E)$< S 89*T A
MP3G8$,X(D6=1I&6>KY%(5YK(7%P7YDE@G^ H;JW'6)':MB:ZVO+SWO]<A=T\
M:"V"IQSCE3GPWLXEDMW'XGEI!R3+7O'%J!>K/KC]L^2?VG%Q%XWA>,$(L-8J
M:KE&,B<<,4HR))WSR(N@*.56<JHVMBF]=_6*]?,TUI#S0B%GU6>R\Y!36S K
MQ*,Y"\9S'8@3 0'D !XIDR$3N(\6#%=:.,$-V]C&FTK<VX*I?:GW4.;F:P#4
M+M-'4( BT:=LHQJ05@Y(IXM>4BVMP5(C[RU&C#B#8&?)$0T^(Z E&6=)!"02
M@]37QJ52>TG75Z>HI?@1I'A.K<BEQ<)1D-W<"L08"<@(PN!/%3+**,]R&:48
MDWM7=:^#O.Y>:3UF%_N4?F_;NJAJ_)SY?A*-KO7(Z)CZK_O]V+%DM@1>'3_R
M0(K'I'CH;[W^;Z/AJ.__[+4+>_&K[_I0# =ON^Y3-Q[]O$MK!G]6O[B8Y!D7
MJ3H3JE'L5BBV>YX0+.DC30:??_OB>*ZIT0(1JRQBEAFD6)XA:C," *>(8V9C
MF_-5M:98(V]-+=>K5D5JN7XZN6[.RK7@).=.*L0R'Q +(A81SG+DJ,J=PM9*
MDV]LYVOEA7WD/M!K52*@[[_Z[J@*(KN**+M!A8#[9_P_59MKSF+*?WDFOSSE
M?YEWO?R2D7Q\[W6Y\G?\DJD'&A@G?7GUXW*V16XZ\/+ ",*^$QCQP^U3/=,L
M^-]Z936N@U;?^T83KF\-&KO=6,=X4BI@66+\?%3)O8CW\OK$WK"X0MU;=Y9F
M2VLPW(;57D1=AH_E-ECWRWRH]W\Y-@NCE$DI+;:>!<65R'-&E;36QJ)=;&F-
MKN\9+Q7K_=;O=:9*=H&&]1K\J+V+_9W=B^;.+CLDOYTV/^]FAY>G_/#@[TYS
MY^AT;V<7+)%=?GARS(_>S7<[><^:!^]A?JV3P\\?OAT>?#S9/VBW]C['+B<?
MLB98+,V#=K&_TSY=EI>6$:J#=P;E3!K$P/1$FGJ*N+(\8SS8+-,;VY1L9F)5
MMLIS:8]9HUZ->G.H1VV>&<6! )EBQ%G).;<Y"('/C?96)M3#8]3#->JM"^K-
MG1YQD>6>2HL<UQ@QJPW2,N-(6F=RK3-BC8C9?9L\?VZ= N=U5G(KG?4Y!%JO
M,%C[U2GXE8/W7J77GD,VQ?T6]GD'<[WK#5(_J<JGV?C)?[/MT:#XF@I2.W_6
MAUVD:N<2^[QT8C7RR_*#L>OSYSK\ZSH=0%$B0 6 7<)3EG,O'1%&$$Z4I4'Y
M[ Z6S](*Q6-1C;K!=.'BS\6P-7U+K2FL3E.P"_:1B:=R-%#D.0;[*'B#E X&
M.<*I4-CB8/'&-A&;3-R[=D<=+K:^4I]K@G/A<V8492X8;;*<$D,QH51D5-]!
M\[^GU->"?3O!G@\@"Y+J0!T"XTTBABE!AID,A9QZ$G0N30 3@"FZ1E+]@%KK
M<U%N_O)M^/!XLW%<=N L51C7*;K%8-A/G2(F2DP=278=FF%L1&88HX+G# Q>
MY9S35F4X]X('(QY?AZG1[!9HMICU)PFF-B;\4<PM8D($)+D$-!-YH#23')33
MC6TAUBC<I XC6[%0N\P8 X8)"T*P3"MI+#7>$R^HH<Z16D59=Z&>4U$( ]$%
MNP()EL>:@<%'+Z5%2A@JE3*Y"3&5=YUJ!MZ@%?S3]![--[;7H_>H>H3>H[%Q
MKHU==KO';[NNDLFWP!M?4X+*.C8AM6,)/3\\.65PW663_'%R= !C7!YRD$#2
M/'E/#S\WLSVR>]F\_-B.,9NS_8]^+?8/6C G&+^SUX;YGNS!6,V#PXL8KWEX
M^8$>'C0O]W[_%&,V,4CF%Y[B:W.%F&88K'O#D"(Y09:">!$P#P+S\UTN*1@.
M6=!2YIEB7#$3K%*$YUSFTA*ST"_IHQ\W)DO=GT%=+9M@OVO%E(?!HGS,L?@M
M6V_]<'KK&9WY>;:?>RS;-Q@T>JDC8=SSJGZ&12=V-/0SO0L!NWSD;9_ZWJ<
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M)L#'5;.4E/.:,D]*V@\:9<>W7IDK!O!2)ID!*VVFWVRK\*'AOWD[&I8E"V.
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MH6CWC##MI]L4J%+&"R:MH4(QQH@Q@3"E,N>9I]3X&X!:; H(OZT$W6H NQ6
M[<VI>$I))EBL4.6=0TP)C*0 %<^;((G55.3:;VPSL9A0__-]Y*%&IQJ='J3(
MAQ19<(8[E7.&B3 R$"5-;BG'#CBZUKB>'6#-%]<+0=,<&\0%%8@Q+9$RSB!B
M.7'*B<Q1N;%-5+Z9\?R%E=>KD>OE(I=GF=(*#$,G)<N]-3(G*H1,8),)3N3C
M(U<HOGF'+GV_5X/6+4%K?U[+L@+KD!M$B<&(:94AV),4HA)[H3DG/M-E>B\F
MO]2@58/6,P&M>Y;5J-6MM4.NYL&X%5Z3 0V^?8G,Y@A12$E' ;I<CF10&!G#
MO!$L4&K9.NI;*SGB7>$Y])37;JZ,W+TC4^I9UK.L9_DP(5//,+)SE4V?'S0,
MKA[C&8VQROVT#IFZ+2U>FE5TNY=_,?92IDGF<BZ\\90QR^)9<6KK(A7\H\@=
M:E#7]M(3VDN[Y_^9MY=(L)[DSB!ON2@[3NKXF].<"$D4I]AM;$N^2>2]^SC=
M"4X?N SU"D.F:H1\?0C)*6&<:8FUQDQRIUC.L?/<.D5RSGB-D,\/(9MS"$FQ
M$LP$1&7@B%F<(RFR#!%#L(-%S@3/-[8QS38)67$CE/6 R+L"X2N NV<$:K>)
MF6(ZSQ@3*F "J":I CPS.I<^$$4("3= M3IFZ@D1[-,L@N7:Y9ISB;P*)/8A
M44BK3**<!D&""X9K0#!&%V/B;QXTM3Q7KX:G&IY6WQT="RG *K7.*A8\D[D-
M0ANE=#1.\5TZ(]4ZUQ,CEIU%+$Q]4-(PQ+$'G0NS',$"6Z1@9[)>!Z,E6*4$
M\Q?8/[V&KI<+7<Q9S8C3&@P*ID-0N>/$Y$9Z ISN\.-#5QTU=0_4.IU%+66Q
MR[232"J?(T9T0#++"3(9%2:WF+",K2QLJD:M&K6>;RO*6N%ZZF. ;]51P.7^
MSMNL^>$+$;EQ@C(DLMP!>&&#C&<9,MQR:?. :2[74>5ZB()8*RJ6L^H E7J6
M]2SK6=XLTN.[A64?(_:K*JG]???]FM<BO'N=VIK"#UCV]E$*4#T/^MVB'NQ3
M4:VN(+N>%61K*;IIS=DU+X/'ZA#I>U65K,N9UI-\[I'7:R*^RUUM<PV^ZI#K
M.J#PX:M4^J^M-V/&V]7]V#%P\&MJNOB^:K%X$'LH[DQU4'S;=6^G.@/6+M<5
MNESY0N1U4)G/F52("VD0LQXC8T.&C)&YYLY1;N7&MMPD^-YYJNL855@'7M<X
MN0ZU*FN<7#><G(N_YM1(+V,)D@!@"5LA1CH/ 3'OI3,\Y#H'RY^03:Q>9(9*
M?=S^VH[;5U44KH:V=8.VN<!LI[Q2.@?M3W.)&-4222TLRFU.,F.\PUQO;--L
MD^%599;4 %8#V(/GCZR@.-Q<_D@-9>L&97,1VYD(&0F.H"S$').,6:2%PHAG
M2I%,*$($:&EB$_,ZRZ0&L6>@A:VL5EP-7>L&77-AVSRG.:;*HQQV+<1X=,0%
M3Y'C7.)<< ]Z-QB8;)-P_O*TL(<ZE:T#,.M9UK-\=K-\P,"+>X9*K7/@Q=UJ
MTSTT,M=CK.<83]+.<TWD;+41$K-$J *"EZ#KZSP:7#%U7HQIM[*R=K5IMTZF
MW?N+A1@+*IF--6Q0)H-"+.,$*4,PTM)+3RG8=BS?V.:;BI'5=KN[K[ ]M%'X
MT U#:RBNH?A1Z^?54+QN4#P7QN&HPD(R@;Q7#C%*-%(84\0EQT9I)3TS&]L8
ML#B_=QC'L\3B!T/<&E=?*GJNK!)6C9[KAIYSD2+<JBR'I499QB)Z>HNDL18I
M)87+O2.JK,ZPJ5;=V?YF,E5C9(V1:QJ,LH*:6W4PRIJCI9TW^T-L5!A3*W"&
M&!$.2>4<<M19PZGPN1<;V_EFAA<KV=RZ3W2-DS5.KBM./D61KQH=UPT=Y^)=
M7&YB\HQ UF4",9T3I'PND-09"SGQGMMHB;--4#E?H2ZYFM/R?P\UO-^X#,54
MF8_J%A2!\@V6L^@9I:8(%^5'1=?Y[O -BA<]/GZ0B!]5K<I;_S-;A&/MWIYO
MD1N\_G4U2,B6O&$-DI5.6MYHRC/TQ5LJQ6A<E70INK&T(CSMJ^X7O=&@$8JN
M[EJ_V6B-X-$-@.?>J&_]8+/1]L>ZO=GPW[P=Q9=OZ*YK](8MWP<1N1HO]/5@
MV!_9X:COX>(SWQWXP=9<%9821/9&'7@G6_X=-Y^B.TJ OSH6V?Z_IO_O[6O9
M;UP<3,"HBZM[7KAA:[QS3MU5P59V=8LV@UBOZ?I;'K^8SW(!IGAN):9^MOI7
M)#_VR/2]/D4ZP&3?Z/:YOAAL_'OFG3I%%TT3</[=KU^!\N?<HI>[-Z.@;W F
MM>,Y4U1H8W+8C6BF=/".\8D.4S'/"H)TYVN1PHBV:)>:R'[8/_/ V<" ?_9[
MH1C^IS<8Q#JE?_GC#BSDX* W72SG &;R:[MG3Y^I+G+T3RNSG;^[^K,:[9\T
MO^U__NWTZ 1F=/!W9P_TBN9!JP5SH(>=H_;>Y2EK7K;:^P=_M_^Y!+UEY_T7
M'8QG6GH4B#.(.6R0@LT242.M9<3F&0D;#0\:VUD4BO[(7RLFE60_D9P<M#PH
MG>UV[QQ6OI'V[@;HIX.XY U 1 #&:39I]$)DQ*NB28.*/1JI&EEC+IX%/FUT
M_;#1!F9JZ.&P7YA1^0SXPO8Z'1AQT-)]W^JU04\:Q.%G:^]M-MYW[5;CIZ+;
M&+8 MP&+!S^_:5P+=!W=/P9QC?L57XJ@,=(HS6""<4E# WJW]=G OQG_\HLK
M!F=M??&FZ":JI9M^J8:O@'%)2:[TP/+K"B<XR[:RK QQZD\KC16,;&7++-7R
M2T;I5LZO__Z[-W]_9+E%'F1@O 837AYG1KY7&?.'2K%:N/1YE#B[223GC%5S
MAR"]VU@4=PG;6T.RWK3HV*WC3%XVS?!]6>U%E+7;6\&6>$=/Q/?KJKU\[^8-
MWG^]/9NW.P&Z=RK?->WL@(.!"7L='\V$5^&VQ'N7;R^.3DZ_'5[^?7)X<IKM
M??[CY/!@]WRO\P$W+]]_:WX^A''>GC<OYMV6GVASYX_._L%O)WN?]XK]@P_X
ML+/7@OF2HYU/E\V3W6\P![CF[>4_E^\KE^7NL'EY?+ZWL_O%6.89,QIA(^*9
MCB)(8?B-<V:<I$P$9V(H)^79RLYT?BPES^,\IT:[5X1V*SC(J='NT='N8A;M
M/+;2XXPCRJA&3 N!C"4$66FR/,L!_:3?V%:;<LD1S?JAW2I+PJZG@KM<;/_C
M!X,W+S8U\ '-EL1E>7*AK/4"CT^TX[D*X.*U2WW+>N1+=^/UVY6>HIK&>"]Z
MW_T*=(\^UW)+&J]$O?/<:N?YL*!G>T6(U98BD1N&&#<6*0]JM]3&.R6I)BQL
M;./[%Z7]CN0_]<G_JQ?7E7?\J\5U5>(ZIR@:ATGFJ46<Y!*Q0#U2%&OD;&:5
MSC'/< SF(?>N'[A"<7U =?#9*0Y5Q,2=-(>;EAA;/RAZ9._=/!:5M-\M25\;
MLJO#IT\+Z@06L>BCDZ!.R #JA.3(8.^0YHSA0"RCEFYLDTW"[A.*O<9EM6H!
M?@!EHA;@AQ/@.04#:T:- 0$.VH  *^V0LDJ@+ ^.:VZ4#S@6]J3T/IZH%0IP
M[9;8_K/?^UH,HEB"9%2^B<8P1MV_,@_%$^L9D>X'^EN%4[_ZK@_%L(:KU<'5
MX8*^X7*EN<\"(E2 /60R"W"5&625P\'G.1,Q]0MOPA+>WW%>^R[649 ?0-^X
M1I!K6;V=K,ZI%@JL <441P26"#%+&)(82Z1IIGV>\5QJ JK%*I(TUT:Q>-YN
MB^FDO90/HJ?2]B;9'[4SX_&4C->>1OE(X&47% WJO/=2"V2T,*!H*(I,3ATB
MN>$89X+Y3*=Z1O#[>AA&M6=C[36-6IH?2YKG5!'.N!3:6T05TR#-U".9*X]L
MECFG.,D9<Z4TR]K-L2ZB^KLNN@V0T&$?!@F^'V/$.[YC?'_0*LY>F:OCJ5J;
MQ$78[QY42[ ?FI,%F$6L4'SS#EWZ?J\&JUN!U>F"ZL&5LSYW$H$.(A"3)D<*
ME!$4<FVL)3PGN9[D[J_1N6_MZEC7,(W;"'*M>MQ3FN=4CUP%QQEFB!MC09IQ
MCC2F$BF09FZL"42&U-]6";5&PEQ[0[9C&'S4/_K^3%_$V*:H@#AOAILQV_N5
M>4&>T@D2H6L05\,/]KN[WV+UAE$Q:,4EV0\[L""U*K(2\-H]7ZBPSVC Q$F"
MC-4&L9 )I%B,1 -#B63&\4SSE>DBM3/D93M#KLD[NJ5XUPK*?65\KG0[5AI
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MUWZ1E6HJ'F83V]V^2I_(D\::3$C_+E*^/O&])?Y\6U OB&;4"1&0QT$BIJU
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M#,O);"REL8P09-Y(F&FZ-@B^$Z2#Y#\!R3^ N.X@^?<J^;]V)3]F3IJDD6O
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M7!/[\/\L\SEYL>9+.*-8M<H]=\8:/3A*[!S4.LVPU-Z;)IRS>0Z*BR)0:;[
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M1I&G1K,4#GJNF,*7BSGN'!JNU^K$WKQ,79[65RTE3X<&MO;*,W@(OP-J=\)
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M@/WI;&[+ &ZX].J.^136?H&^6>FH0^A#<1YJ10QD8'4,LB_5];V$' B2@L!
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M>.;4V"%M(T):>*C1:;>_Y0; +<A )\&W")A"8*C]J,0$6:AM!?9LRC1/!<J
M\-M<MWO%RQU"-=+QK;0O -7RX@*+>;M6@W SSBXF*ZK]BJTU:*1]<-8TPMIL
MW*R[ZES)WM_UZ?YH-J=MV9X=W2,#_;9FTY!OUE[OFHU:E/D%PBUN056\U"NW
MTKV@Z6ZYTFU0->P;)GCO6T'VD"CUE=>REN>N3U 0BY[@VR?AG%@?6#IKQ=5P
MR%9$Z9.*JYW"ZC?6]-<%A;:)+;"1E]^<??I1(>B=??I5>U^,Z%/#LO7[%K0=
M0R:?1+O&:^6W:&T?GC=OQ:W@,_O:! 8?@\[";&0@9&F-($+3!>J"98E^#H67
M(%",5#=GPEU%P R!+Z$MV%=$PRJ2.@R(%QYINEU0=)_Z-:<YHJ42V-$JP Y=
MG8I9TW]2O&?*%V-X!=G0(D8C(BM$P@62D+I9HUL\GTK B_;KA5%*3ZK)I0CC
M0_=LF/<D%]@(Z+O!S4$@2X0= ,L8;\ARQMAL$^__"NU'=FV%?;A8PK40XQ^J
M1R>A(N"EIK:)67?[,RQG'.>5FCY=&R>L%,^N>:"-Q"H.I0:N@0$!^=Q8SM7F
MX9K$W%N!E6[XA*+VY(E$1"^I3Y"*-2R;4+#:N+A">U1'5XPZ-2FO@C49%:H+
M[IJ+\EH4I9-66PK&F;!'UBDM_,0P_4-36#T%=2Z!5?$F\W96+<IE$U;'?NRB
M[RIRWTQ[C=90DQ'RX0K^1&AXCZ_9D. MJ5PC64J]-9R:MY8K8J"K]]RVRB!O
M JVW#6F4M B8]PB8] C(NP0L@(!BP)'V2=ZXA7^[JYKEG9PCO!$I-D(A$CJL
M_7J"8Y681G0+;^&B9ERVG2XWSE@^*6JMB4)KGI?N0G3A( 0,=5(7\\,[NM2"
MB-!4(3@V 7 KO4[G BPP(80!Q,M3KAD81@#R]B\VY+(1F4?J?/WT:TT_I8_I
M?D;6)6HM22=T=TDH*:2^A&W$30!C(T7S>!UU,N$40DJ.2!XX2YOA)4O5:2,]
MTC?$5*"5B%R'GRQGY"5]GG_?>Z[U2)T=)R=3ZW^!NA[GV;*4IRX3*71E?BGN
M)C"=Y_G*V"MS8C4L,07?$<@0H< H?B,::/3C+'T^5$+4\H8A+21Q%61?HO+)
M)DQA,6TK"-IS/KH8 <7AO@M3J[X7+J$I-4%7;Z_/X=8;!*[?=+Y<U(;)*GNM
M2,QF@2V^);#K3UG>'+)+ >J(PBI@#$N^* LR%W#/I% P4C.]TUCF9#38FE6-
MCH9QWK2-1 AWI]0@I'SA^8NOM>\LT^^C.K=]73051K&(FD;XF!/UVZQTGQ)V
MT&+%+]_@AKL29QN?@U\]^2L.;GLC:W7P[URK!^:]1ZMAN[3CT/Y&VO%C=405
M&(NO/_WZS\^?M ]OM \?7_]R]OGMA_>?CM>S1VOJ=KP0;>A$NY2QP-\5X;&9
MB$'C^=("74=O*WU90/(*_%7XJV"BNO6#< &#7*RVUU!0@YA:)%"%Y5A=J#^5
MCS5+VYH2E7KS[1J+3:0,XS]T=9*]8&I3HY42N:[=1]G#)%4X9FN,ZM4A>FW\
MAM2EX+A2EPY/:M=KHO_FUW3@R7N[E(!?&L[^4(='C_KBM^-]ZA<1[COJ)7\K
M999,S2:L"MH8T[8QLQ1->O)9-&4$#=XU(FR"GA%I.+,.;K/ZT@G["#YWR?))
MD>7D&>;S!GZ@$+/P[^--7>3K=[]RA?4\F -"X3?\,MGU!#[/2^I#PI;H44._
M(-H%Q9PNDS"&!!XNNA#$\[*X*-E4>/3JVPM8LY6^D6\3A"[&F+C*D*O3"7I@
MF12\DSED[>YN"!P)!(4OS5(CQ4L#>O0N&\=C,LFE45_0X<^_YL+DT"@N#6/5
MAD51MA;9:@ZU3MY*O(2+E&]5TB!F"I.R;!D;HE",S'2 +Y8\X13M!&OC*SKR
M.&\<D1N$NLF@5Y01.>ZX9GGKF8E,.'7+J7,1QL52I!X*V+Q^&I2 )FVB_.+K
M*E;9=#ZX%J#*K93T(@;.%T0Z? FY1:+?0T_Q8UMQ-R?['M38WE82G22MUQR2
M HGZ>BZ\@R)53/;60"_)!6_[,*6NI."-PE6^A-.Z6%:H=T3;.7*J=!M+U,CC
MI"I1O#8WJ=/[6.4EEP#H0D@GQ96L>5'=.VJT>VDV8O;N#&<I/0RD9[O@Q"*=
M2;H<-W?EJRT)->W>!:MFV"WGKFC6S>YKGRG]-,"51AYJ2K)#1OLH(;4JHU.E
M5BYG!N;9U1N-KK)Z X5JSD5W,&EP??YXUEKQ:28,USG[Z_6[O!UC3F";^_,.
MQS,1)[PH11KG$K.RT+E;[TSCP&<)58#),N':8!5YR97<#ZI1Q$X,7/9*D0Q)
M?Y]15JHJ7Z[WC[('*;0-6_63.G%;WF3,*I>N?>IG5/LUY6FX8?T$Q"Z"<_VN
M+E3%1.<P>>U47G-*K6B2A:A8J9D))  7 &<_*@C*!L;C'UVB";G#97)NQ5L<
M2CEHM2Z2?%V1GQ/,"W2ZR]YK-0&EQ[_= 8^I#$.>DG=6D$G\B,-0UJ2NDF+Q
M6[&@U&Q)7P1:2\J*UW15BE(0(I<JI5P>RILR5$>ELL,\FFC/Q$OT6V V)0PO
MK4?RBF.+TV5/V6+.74>R18%#FY!5VS\M"2A*W)I60-BY8TP6D-*4%;L4Z:KM
MMS45%&V>$-4%J C^I5[;+>,#ZC>VE+#,2"FC=I5Y]BKONIT%-P9V*<I:;XMV
M2S2'&/-S,&M8))4)44!^.]':!17L_=9Q"/)(+B_1>DRXXH6LMG>16)4Z24N>
M:6VF9,W^KO\=6).R*D3X0D:&2(X;*[SUOMH@1QF[H)X1(D, $TYKM0&["-R2
M5V,N0Q[%I"E3;2YCXN9 QV4"AU[/]M_T5HP0=-^9%DTZP?:O.V66>K6LE?RL
MCCP6/1VC-RDY=8(T<D\LQ!Q,"5+\>2;+9^#LBTD)$)^M-L\I*S9I)ZC3(415
MB&*G*(@[D^_$!B(5=?^87&(-2(?AU CD_OF6BV?E<JATAL:IYP)6\2Z:NR*6
M^7\5?-G59/7K4SP=8*'7#1.IN!V!AHOLG01[EY*:K!M;](Y9$EN9R\0;S=U]
M<7,44_93T2I/::GX(\ZU%G@0==R3B/5.%:-\;)TV'VH+Y!;^W>'2M\[ 3;ID
M;TQ'%'.9#]!4!JTW!T%--!9=+<>URVS,A/]$]/"*"Q2%._AK-2K'[UB$=(&2
M!J;0" 755I"] HH#I\0:"<4)?7M);<E<]!JB"VP&*L< 2=Q@)'>:+:MPEPS.
M3W""V-<S5YV76YJIKE*B.Z@HUA'-,N%MZ(##V*/\57FFJI:&;E!T!+''RN;#
MC(0L0U]A+ML>+;"M6\NG]2V;7S1?(K73]$X211_HPTNEL8O#U-H,EU<W+B,U
M3E;K0G246Q0]=5?S3<JGZ#F=@[;#@PC==;/%:C&42!$1YD'K?E6#,ZA*834-
MV<=,1'9;C;.(<=5M1FW%IMTZX:"!K#LMD(.HG2LZ0#L>8;U5ZR1:&@DCM&I;
MH)TT4N&K[LID3LDO\'WY=/<)\C=1L6E*]P2MW2&OFZ+:+HM78W6*P87\B>Z&
M(H5.N8):!WJL[L$7G:NC.-JQI+&4[RY6M 'YSR<Y 1/5O3\;F'9ZI31 )9A1
M)]0N(_/[9ZFG%W</CRON_OBAXW/IY92N=.TY_PKW0O(W4NKZO$0?4\W%$O.'
M_O#]2:I 4?='AI&@C+IHU&ZF%$[;9-'H$/(-"P=*TZF0U(<J-*J/)- ,\NEV
MS$Y$XD:RVY4*4386%9[:T_FDN.;<4.Z<^NW/VVG 4_RCA =0_8K$_# )5KF>
M6E_[7F]&0D\;^7;EU!J'3\N9O*[?8XTCCV;!NBAGL8:<;<=5I1S8 J"MOM-+
M-U[;JRI]FO4G..DY$'_*$KX4X(IT:O1]5M)YGHA09ZO86?44N]D/,M*T3RL]
MM[M*OM=,5J-X^WPAO(HBJ=)<3XJ:"MU!)41!4B<WEDMT32SZ;VI20^<-/(KD
M(FFOB,0UP4K+>4I&(BQB[2AR*S!MN;QL%;G+7N@JU" WX,@])+M66@D34%>N
M=&*PLVX0Z[64IZ.FRS>OC96BQ$6+$KUP7JU96ED7]Z;(2!,H$[T!3: Y)D4)
M+([WN!2O0<5<>$Q%;B.7$$&Z-EX":1H=WGZNC5&ZX,EX!J2^N-97U5]+Y31/
M-T?%:JO3"EO.SA*92<TPS1DA*'>@;B<$L+ZE*FD=CK=?$2V"Y92LB;$(IVK%
MJ5:7C-6&3.V\D19>$8XXXPN$B>A\&[1W7:VBWQB7;+;[XX_O.HNC>K>:R+W)
MZDT$62;6=&>+LT?P3:HVQQ*:X[ZI[:B@7O4-MK.6P:94TU$39+?EM^W5M?I(
MXOXT7\+,L!5@C74MBK$04A.%D%T\A=7LZ@; N,GG[A>"XI ?L/H3)>(7WN[!
MK6\Q0[S(EJF [%2P9"BC*NVB3N8"I1E+ -T:ZP21/Q'RL\J;/W=,?PQ&EFA>
M+*[K$C2I1!LQ7D=*61%"2J<JLL45%E@=-?_M*)#_)-<2$*.38//QW<=WVAM^
MRD;"IA28-00A5*<F0']-&,CD,)3Q=1D37HV?KR!@M7-D>N>E<BN/UD51=YF5
M*/?88@@926P',$06",X;R7P.!,(214FCS\V91XC2==80/;0R_I8+V3R+;]*=
M<'PD<% Q2\34>FE0'7?KN@<3=$7?_*@LB9-Q"'23"2_RV:</O5O8W:FVYV7K
MMUWS)G*Q])+VB+Z-?#QKFTT]4FTBT[LU Q.R(6'DH1\6HQH7!4)LELJ_28Y+
MBF>H#X_\<G<K_:30S-:F!#U7N/"@OR6J^_>4KT3HAIF 5JPV1K#JX@7A'B%E
M(EP)WT@8;.-&RS!P#24(Q,W3QG^MYB]MFYA?Y(*%Z-R>T4G]K;=)OASG\QU>
MW$J+HB1O54$F'ENKK%9UTIF</1V0VQ.V%H_U%-Z0.K/Z^OV2>:M7W@NM=U:3
MMZ3[9H;>>0;[)7WO]3>\_=.][<+IZLYW3>KS$N]3$W7(SE>,7/*)Q%S )[:
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M<ID"<$ D8S:?3\#$EA88$)PGXQEPV47^Q#"HSI&EW^ 9=-2K_B;F5(,*(O!
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MX>E3P;*U/)"),]6 XY>Z>8B..,%'38,;M<#9:KL4#6'IX5=4D@K?JBQS_%G
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MD]^&ZFK*T$"7H%N&,UC322A+T,TCQM?L(<Q=QD7N*^JBO\$#5)*6F,WC,^8
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MTC4#CS3^B"HC#V>4ZYKH5)[X-J!78LQI*H(IR@[\'L[RB;,HYB&)V9RD2)-
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MSW[O"_;[F6'+-/#?5=#)<=-+M56MK_)G-O>1_%Y<5 QSST5E<P=?0E26>8S
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M'V.9G7*^?!;Z- DC+!")_H@(#]>#1VI54S\VX.&0 W ?G]^Y8J9/;C>K5;,
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MVX?* 7^/B2\4"FE$Z["]5A145X86^$'7ZE5LUY 4O!:W&8JT,W;2@")^P/%
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M M:!OSCP@)(5ZVPDS(L(^YU23_+FT7#S"U[.,$NJ0151::&(JHJ!5*R90^%
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M'FW"R%P8M0=/U_>L:CUH(6U#1QTYAQO&QU--W%OJ3T6E SPG=M24(6D2[);
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MU@J(@7J6N[/B]C+8=N*KGF)WR_!PL0]Q6\<U"9-8 *F@D[5!$L%Y,?O*^@Z
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MM@_2EVXV[2\^0?^EBS ;*1:URHX2X4K#&1H<\=D:HI5S.MA,HUZ')P\\8L-
MYG.@0*T)K2+=X]Y/9DC"[K*MSX@!$HG&2'32[G++<VC.TV2HM=PF"WD-D=[^
MW@TCBL]!CCM-7;6HX/HNU$&/@#\O@A:SPY/RX]O),C_K*#_F=;$1+6<R5"(5
M)4Z5-#@XZU4FP!VZ8((RGED34W1/ ]PP"CET@@Z9'I5;@)4^2,L+'R]A KF;
MCWB*DDE@).E%,1) @\OBD@1JM-+"H=75)NAU#Z!UN&6>'[=J3'\U+GR$<NDJ
MEO2VR6?D;_\9M].@!9=,"9*Y3D1*EG%TI6^T2S%*ZY.V;7*L[T*S#@OL\V/!
MSA/?J"-@J9L[O_@5YB?3],W!GXUB$-1R)DFD3I8LTT@"DY1 L)JEG('1-FDC
M:\%;AR3NV3C/[22SCZ;.(W 4J$Z1,%D<]XANEC<A$&8XM4 9$[?=F_;MF]>*
MP-'GIT9JR:$:,7[QW616A@6SH\GKK\7^.>]F)X6J1WEQ3SCK#,H82V*D&6T>
M4"0$84K+"HJ"5<G(-O1X%-I:)'E^<=JZ(JEWT:2TA'H_G4QO]C&[[E6ODN,B
M"F*LQQ&'I(F+T1 .-.F@$5=H8X0\C&LMCCR?.&T#850)L!3.'DT6L8)<$KY_
MA=, _>RD.QLQ)367T1'.%*HUACY32%$1X]%XYL$I3]=)[[K_"6N)>%^)IW6"
M+I6FLZ+->;/%5LB"*^$IB4E95$ X),\S)88G\$4S9=6F8-46;=/8,PJ<UICO
MIVD]GJ.DZ TIXI"%2,N4B*4*2A,M4]HQ<QW;7#?<OO7X/7395\9G*[^CHJ#J
MG:P$/RM'0:>%S@M UVW2CB8P[T[AV^'/R$@T@H-*!"2@=2.Y+5ZU)HQY"H9'
M%N&Q/))MGKL6.9Y1;+3YW%=3-)_@"]+TJJP4&QG+E!<!"$3CT7IA)>LT>6*8
M,-9P+[-N8TK> K(6(YYA1'.7^6Z?:_819M!_@5F>]H=CWYV6K-,/T./+TX+Y
M96'S:A1_^VRS;9]4+=^LRE K9]A>O)GVOTW.?)>6D XF5S]<:XE+JP21=B6T
M%?N2VOT*EG^/A+1> =JF:) :W& L$*\L)9IGAI:JY?*VO5\Y%W?7$>RLSL[/
MD'OE,7[\=K(09N$'HKIJ>G;H9^?(A(NWD]GY8B'^5J[)_M&C NAG'Q#3X@[&
M8^A'5"OF#: K8"+J *D9"=):DK*E-"A-G6Q3OFI?(QQ2'MZ3K(_O-/<0J57O
MZL_&4[Q\N]Q<.CSO>WR_#(Z-7$K4"2&)BH#H8ZE'Z+Q")BM*70Z4JD9W@BJ-
M8% -KP;!_"?AQB"8?;UHT5)C.E.6-)IF*9<[4A&(4RP2YKC+3I5<A$95&.L,
M8%"ICL^>U]LRHT[V[;=%]1CB:W^S^!M'N71(*Y^^2@?\-!V7.EJ77=,?."!C
M*0F1*:Y56TJ'R."+SZ.)!E-.1-"+L6OEZ^X=^:#NJ3\EZY\!<=9T<"_?+W^4
M^,K?__3_ 5!+ P04    " !7D:14B;4\]7:*   ,(P8 %    &5V:"TR,#(R
M,#,S,5]D968N>&UL[+W=<ELYDBYZOY^B3LWMP13^?SJF9X?+=O4XPF7[V.[I
M?:X8"2 A<9HB/23E*L_3[P0IVC)%B:2XL$C3GNA1292\UH?,#T!F(I'Y;__[
MSZO13Q]Q.AM.QG_]6?PK__DG'*=)'HXO_OKSW]__QOS/__O?_]?_^K?_A['_
M\^O;ES\]FZ3K*QS/?WHZ19AC_NF/X?SRIW]DG/WSIS*=7/WTC\GTG\./P-B_
M+_[1T\F'3]/AQ>7\)\FE7/_M]"_9J"1R2 Q$5$Q+3]_%()@0*EA;T"CE_M^+
MOV3.I;+6L^QM8AJ<8QYB80!122.M!LD7#QT-Q__\2_T2888_T>#&L\6/?_WY
M<C[_\)=??OGCCS_^]<\X'?WK9'KQB^1<_;+ZZY]O_OS/.W__AUK\M0@A_++X
M[><_G0TW_2$]5OSR?WY_^2Y=XA6PX7@VAW'Z\@)Z?9Y__H>WT9A?EK^D/YT-
M_S);_/N7DP3SA7JV#N&G>_^B_L16?\;J1TQ(IL2__CG+/__[__KIIZ7D8)JF
MDQ&^Q?+3S;=_?_OB+M+A>/Y+'E[]<O,WO\!H1(@73YA_^H!__7DVO/HPPM5G
MEU,L]Z)?#;F",A7.O]2G_7(PIDL",DW7$1E]BN-*\ XQ;GKZX9@_/XME+' ]
MFG>(^.ZS.\4[N8)AEP*^\^@.T"X>Q*[P*N*T2ZA?/?<6SA7(=83UD?B1/AS/
M+Q%&\\M_39.K7Q88G[Y^]>[URQ?/GKQ__NS=>_KZ^_-7[]^]_NWI?SQY];?G
M[UZ\>O<?3]X^_X_7+Y\]?_ON^?_W]Q?O___M(\&/EZPNOUPM)_R_/.8MM\9%
M!!J.AW5->DD_WKRJPN]EA/CG',<9\\\_#?-??QY:FR.7B2LAHD;%(8$)6+B0
M 8JU;O"8%]:QKD8[FJ2OWC^JZ_'D,X%&$'&T^'1P/6,7 !\&[^:T-=9=DL2#
M+^C;V: X (?6,2,\,&VR94%QR=#2SRA-2'$#_68K.A>8Q04!;UY!1)3B%QS-
M9ZM/JH(%X^)F3?^7^[$L-?GXT;T8)]K[9_@,E_]],7XWGZ1_7DY&F>R(Y_]]
M/9Q_>CL9C7Z;3/^ :1Y$KWP&KYCG0C/M8V#>Y\BB0, DM5-@FPQ]3Z!?R^4+
MQY],5Q*Z64@>N=)4\ZA3GLPG_2EF20X:W\\_3:;TN+_^S _ET;M+F.+LQ6QV
MC7D 'G-RVC".H3"=8V91&<>"RUY9DD-1ILW\N(6B?P8T5=FD(WG?U;TX6/=W
M1CF()?"0(S#IDF Z%L_ 2TEV/I!_X'T2D3=:(=>QG#D/#I/]73;(0]GP)/_7
M]6Q>%\+9^\F3G!?"AM$;&.87XZ?P83B'T8*]U7G)3R=7'\@T7/A$;Y$&,!O.
M\1U./PX3OL'I<)+?8II<+%7VGS"ZQD&4SDDG%#.9?$OM:'S1.<7(Q11$=4UV
M@FK"K=8C.V^FGA0O[O)>=;(*+A?D9]?3X?AB"7.Y4"]^^?I#!3M[_B<YFT,:
MXZ @INSJ:HW",5V0!(LBL5*<3CG8F'3#57(OK.?-S<:ZN\LVW8AMBYFP&;#W
M$M"!8,Z[NBW81#N"0D;N5M B.,F=[I-L]T/]+KG6D>;N4LTT7=C>XFP^':8Y
MYL6?/:GB>87SUX5$57 XOZ:_&:@H%1:M&#GT2'/%"P8H#*W1T7M+[CTJZ'^=
MVP7Z=TG%1IJ]2TW;<A7<"3\GTR!D@\QF;@FU][2*DR-EDQ6HE0N\M(KD'(;\
MNR1F&[W>Y:5K:PO6K[^N&[D#+\AO=RDQZW1D6H?,O,; L"2-X(254AS!&-P(
M]KMD7V?:NTLXW]0<W(S89&D]TNRP'@+3@M;O:()A*I3$732^N%[Y]@#6[Y)N
M7>GN+MO"H6Q[/;_$:04TQ<MZKO>1Y),F5TC2P.'%^.GU=(KC].G]% AP6FAJ
MG!<_C1;XOX0"%@OW>_CSS62Z^,6<EO9X/8<XPO>3-S3V\7R@DPZ0"BWC6&BP
MM'8S2%HS([AR6DIO4#8A:J_#/&^.GRYC-L3##SX,(8S+X;V<S&8#::34PAHF
M#"?+.-$\#3E))JTR14#1,N8F_/T*QGGSZ_$2WZ#_PP]$;A_.9/+5R65'AAP(
M3"F%$3D=P\BMX=&3O= H[G+O85@G1SQ!99&, Z:\"W5<B05$R; &6Z6 ($6C
M0[XM1SR/.+)(:7(]GM/6^VX.XTQDG/W]0X8Y/J_9";,AK2TOA[/Y ++C.IK,
MDG98C;S(@BF>\>(\=Z9PX]L<?N\(\)L_]&ZAB"8'GC>C?E^WG0$*Q("D.%I9
M:(9S&1@H^B)<*#'J+(IIL\!_C:-#[=]* 6RN\P.$N4FU/RT3NOZ21A.RFO_Z
M\WQZC5\^G(SG^.?\^6CQPK_^/,.+JSNVUP%\6"Y'U<Z9C.M!UY,_A[.!Y: 0
M:"/#Y'F-D146 9&9(G5P-"CC&M-C$ZP.V?) <N8#['F$NN]CSL%B;[!&K&%Z
MMEA/=P(U6$L7[903&V%UN6_<E_3Z !,.5]^DE>Q[(P9XJ[06- ^4C62R9L\B
M6B IQJ!#,9@;16-Z),176<7'Y\,^(F_  X)S-5FZ1+\OK*R!@^)!(KD&%FB(
MH606DO6,1AB+CSDHU6:CN .E?T.R Q5-NI1O@Q3)>W)>;L"E%+C,F9.;:"QM
MA%$SR+I&D0T&F7TBR[915M,#L,Z!"-W)O<$J\&22AB_&:71=+VEMC&F]FHRK
MV4HRI&=<O" #EKSZ^8K2,5@?>*R17S*\$<A\BB(Q0]YYQ)0B>4EM6',0[K.@
M57^::Y"E^1;G) #,SV$Z)G"S&U08T8",F65-7S1A8\'JPK)"J8W1*'(;/FW&
M<PX\Z4#2#;(5W]>0[/7TT^W]D99!<MBS8RE@O9<I?0V;*F:Y-LK2J 5ODPRQ
M <PY:/Y0&7>8-CB;S@=/KZ^NZVG*1WQ>"J;Y\ICQ=7F2)XN,LX69'8Q66+)E
M+A-('2+ATZ*F4(C"M9+<A[@+!^B%M_1//ZWK?E=$WW"<HHG0.]P+=L%W,PUV
M0;A/W*(3>APC>-%&IWL0Y@"%=&B^[H&4UC4I+&DV&Q7KB:QFGJ? '#JNC-!D
M _FSH,P]X8U38<P^>NB9*5].]V]V2:M=XD8E5F(B4= FS""4PK@J);C@N-<[
M14*ZV876T/5GFK32[C[[TR&JN3>(\F^_K,GN)?UXT%7[7V$VG$W*&_*PZ+>+
MG)%WUU=7,/TT*>^&%^-A&288S[\<,+Z9C(9IB#,8YZ>7,+[ X?C6+Z?#<1I^
M&-W.@GX*,_J[_.6#%^./>'.AZ5FU\4>SK\>]T^7]T\#=53F TQC-5UI8*S#@
MR()/,4JG [E93GKRPQ8)(0#90A"#TQC"H<[][7<]&2_^4_V;CU"U-EL<VGXY
MO14Q%,3HF$)/KJC5R  5,N5XT)&VH- HK6$_G(>'/!Y^VT#0\+V,@A$YD.F,
MY.L%*YBT1H7D0.E&U]:W(>O?&6[(H+OQD0[5TB!LOPW?D_E3F$X_T61?7D/E
MP4E;G7L/2I'QYB0+EG9)3^M.0'3"FW(4%JT!_:Y)=8C2&IP"W(%[:TM8YL;.
M!T1YA=)9EC)]T4)X1K-"L<B]*R%;@AKZX=5=<-\7EPY43I-H_L/2J"<1-TB%
M3T:IFJ7ELV%:YES346V])5^ ?E1"'F>S_X+Q^V)3-ZIJ<$3P$.]OH2Q:)$G_
MSQ0O]>:3YPR<=(QG"<&172VA37[S;OB^+S(=KJ(.#QW(V1WLM/T^__/F&/79
M<%9/3(?C:\RO/^!TX7[-!A(#DO$G& JL$V&1^Z,<2Q#JT;VGKW:+G]T5EK.D
MTU$4U:!2P4/385!L,-%ER8H3@NE"OD1T@"RHY+A#0^Y_3QO?+51G2:?.U=&@
M<L#&Z,L@%Z&"%Y&!+8GIH&FA#/6& ;<R2.NRCFVR,#?"^4[(\5@%-+BW7X>[
M-N0[(OGZ@]N!BN0@9FXD U5$#8T# Y.!81;<.2>"\CN=G>^?OWD([+-F67\*
M;7&I/UUBOA[AZ[)-8LL<A6Q,L3%:EGD]0"PZLB"%9H%;%-9QJ4.;'6Y/H'U=
M5.J19RU5=2JWG+:-[!X+LAYMN^"C4!)J$99"HA7DQ')OF3"66^-E M6F9./C
M,1\M[Z@ED_:,172DT3X"ICLA7Z7>[H"]Z26L0] ?YZY67TSIA* 'J/G4J*I2
MX<ERSU1"2[,;.(N8@$G+H^*U^E]N4_OD]"BZY?;8M\C0?;3;(3-KN.=KW&4R
M?8GS.4YGD_)TBGDXIT]^@S0<#>>?7M;B'2O()@4A(J&U7)-)K"1!MN2[(P3T
MZ 3Z=1]G8RCND:\_/5^E._U.^E5.AR?EB_#A9#0"P@BCVD/JM^$8QFD(HQ?C
MV7PXOUY$!V] "NZ5(UN;U;P;IB5W+/JDF2?1")-TN9/;MSF8N^L+OQ/.M%%
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M6_OKSS.\J-\T6"P79:8Y3Z"$R,R*6E>K<%K$L08 A/.B@':(;?-RUP =JP%
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M2V;<;=C9B?";-);=B.S)U60Z'_[/8LD>Z,(S61..65/KP%DDB$E+YC"A5"I
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M8K+17",D-WCL2P];"59/^Q(W\D440_8*<[G46&!-^ZJ!Y2B"0% F(&\S_^]
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MO3#,INP3!P#MVMP(W0/D\4^JNJ7)[CO=0>KJUP#_ O057*TR?'>!V[KHZ3Z
MCU;\M T!=B=:9]H[ =)A460#BEH%J"BF4Q3,._ L>B.@E@62(IPOV;:71CU)
MKNVCM 8<>S^%C!7.YSL$/FI:RI&54!MA.MHQ(D9@/"M:RG7PIE'8:1W)2=GL
MAZMNTJ'<&X0CGU[/YI,KG+[%92;F['+XX3,T&5*,/K*H2F":_ H&0I(EX3%I
MFA!*-FH?]0"H\V9'5]IHL&#<7$G#_![3Y7@RFEQ\>EM#["MXQ%:?#)<LYWI
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M#V->"RT'::P)GA0@R7E,)AHG' 83I \IZC1X\,EM*A@EFZ,C! P2N%HD)#$
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M%!&PMJ#-G$D=M&"H;0=]=WC4,]#WT )]\/UNF^:]F[:O<#[_.IE^7$8YATD
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MT%)+'1BFDW31)]G&LG\Z['TLVG[>Y.VCX :D?3A&)K5CV6D#83F.5SL.P6*
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MY5Z/ VXP[7KD(\?& +8U?;4HQ]VF7I>/HMK);7QJ^66?][*05*0B#2,8"9E
M1#&&F.@B$7',>,XXHW%D<48USHJY'E,)MB1U7<B"M52[+K<,?0-(#8@N3+99
M-LRM>E.6U6-3Q;NDR^*AS:@'6G2QEH4X_YZ[Z$4SUO70*5,%ZK6&MQ)*6].?
MZ2)UYO<R$5T&W(W!S7$<G94)$X?'C8'G..IMU%.<Y8K?KGASUM/$%M2-$JIE
MP*S=0V?T>IW*Z6WFF8WMH&>\EWC6<;CYSK(=,N&E,V8-X#'(?C5YRG6O5__)
MNLXPRN(P1A&%4<)RB#*10YJ3#*9I'(98!$F(LC'Z"0?MS&UUMWN_GK])]E6<
MS^%JQT]7H#45$5D -9INSL#@A5<.VWH1 CGC\#FF.'>Y?=S<%_)=C=RB:,0!
MZ]N'2C3)E-V.5*D#VS^3;WJ;?EU2H37,%VD<T23!!$J2$X@8RF'.*8<XEF$8
M1"3DV*CPTKCFYT8@G:EZG:%U4^K66KT<H0(\*8/-8[A&],4PN_A'V#/I:,61
MGO5@9_YN8[S+ P*?G^'^T3?NYN%S?O&?*(+.2S]8Q="-AW$@C&[$0R>+I!OO
M<#^8[HJGV(\E7<'D@S+)M^L[4E4_5!N--FU[''Q6YG 1Y3+G&4\@EEQ"))(0
M$AQR**@401H&%$FC>:@K@^8VWNPJL#/]@]B[9<YW3OKI\L@S-?J^-[JVP!_7
MNR=KL'5J*RZ^\^N<].O$W64^8$W=;1,-85-UG]6HYA+K@7'.23.3C7PN0>F/
MA4Z?Z[\J[EY(&_$@I@D.8<A)!E% ,T@XYY#H8A\X14D66H4HC;)B;N/@Y\WC
M(ZE^Z'EG3ZM2O\M2UWCXIOW3U4JK7<$&JOWQ5X+65OC<>R]X'@]'E(H%OWUI
M8NJ]")U?A>>+E71](4GSJ\"ZIO2J*_'R5GMA)_[UBBSU\>[GKT*L]=[YKNK>
M7C:]?O7#2G"]V;T584;BB&4PT:R+1( A#:E:C40B17&*LC"PHMYIS)X;5S\/
MQ@$?U*6C]M@GZG0S_IY?5WHF_!&]:$WBTX+JE/4G,GW286+:[C@<5R9N?=Q
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M$5W*]):QS>.F:;+]2.\^ZE+T"Y$'>2JD@)R1$"(>24@I)U#7#D%<LB3 5AN
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MQ1 AED.",84A2^)0(H%E:+68G,KPN5%I8YV:HHPNYSE9CYO1[QS[T3-U-_Y
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MH><FZ "X 1T$_3_>@-VWYM.%;XV+U$S_O><[B=.C!R^=[NF_<PP20R<P8MS
M^&&C,]?4T+N5@O\L'IJMG04E6 U5D5IHA(1 %*NO$A$TAYSF+,U($D295<#;
MV9;F-N"TANH97[FK;%!WMMH-/N?!-1LHG$#FF=3W:.WK0'R^A)8UZ5Y$PBE!
MGF]M4C*[Z/0A\5R^862>^>;I:=D<JY+ENY4LJ\>&U-Z6U38N[H[4&[)<_WBW
MJC<54=[]NE*/_[TJ] N[BZFX%(:QH$E(69@0F&2"0I0''.9Q(M7$F>(T8#GC
MR"Y]?2+#YT9ANV1-AR%NDWT)S+AQCEWKF6KWP6U&H7$.\_XGQMJMG,!4QD^K
M4C!QEQR)'TS=_DL&X;W?Y2-$2<"C($]A0I(8(BHP)"'#,*4HC[,TERB7TP??
MO9]KRLC%(*VNE]O5?2]>9A>^-3Z[Q'77FPU++]BAGD>?B?KRA6+QCA"?80S>
M^Y?)FO$$L)^8N^-F1@X<!Y*ORI*"+1C)$*>9A'F0!! %/($YTV>Q<1#') H3
M'K'%NE1??$/Z/]6*%8GOVO*X;:N- LNRKO6Z =2-PC)9KZN";M;-5JU:5[#R
M\;%<M7_\6BX5T$V\RIMORDKUZO^[4%.!KTT1X3^"GXH5X.5R2:K>$W^V9/>3
M_6/(T=>B[IEICP6M;T!CHT/2'(+ +?6=;&E: AMR]HB&!B\>F=PW5&VS&TOK
MUQNA)\1?%/IB(;,0L31+8<"9%D\-A"(:1F&.)0H#$89Q:G6":&W!W&:2ZMN5
M6*;D68-NQAY>H?3,+"8E>Q69TVW)WF:OH7'"83;=6/S<YLU96S%MAMQ8D(YR
MX48_Z/H\YK<;+3C6!G*\$BLABR9BV"PE;R&R .&$"RB33,>]\102FD0P"W">
M9Z%@.;)2!W-FV=RH\9.HU919-)FS;+\OJ+J\V991W[=NU4;VJS7+@RQWO6K(
ML2_15[ZY]UF*<^O5-D1OZU?3<1;9SWYRG)T@[BW+^3KK7BS/V0FH0YG.;AH8
M6\RDB45H"Z>LFJ#HOQ7KKW>JD?)15/M8T3A):20C G&FB_1AAJ B\P 2D;"$
M$T;BS&I>:]KP_#B[K2#9[6$,"@M>A[@9X?K T3.?;B'L2D*U1H/?E=5@:[:G
MBLBV8#FN;F+8^,2U3>P@.:YL8GG_6)ZJUU7!UH+K3 Y%A^]6WT1+A'47:;5@
M(F413@7$<19#%!+%3E&4PE 2*:(PP8&T.N(Q:'-^[+0U&3"=-J3G(-7^LV+O
M@"UI788_033%>11!BCA1(T2D2U$' 0Q#$05)%N,@$S9;K*[AGV##]8MN8RMZ
MV0=^\LXP'3R<0NQ]W-AA=[?%LV?P+I[8Y7AAC(_CH>)RNQ./$L9 ' \0YK>.
MW:15B^3;ATJT"^2N)HBDD4""9E!D!.L#_P!2$3)(>*8 $$2PP"H*]F0K<^/_
MQDBPM])VX_44D*:;JU?"XWT#]3DR'HJL#$+@> _T5$L3[W,..'N\ESET\;BW
M_BTIJK^2I2Y'ORO-I&>>OZY*JK?5]/EF4ZJIUDNU%5.K[>;X6?^J:*=8/>@#
MHGJW$&^>M< HR:- ")AG,H4H"_7)393HK4P>*OJ0:K&[:(,P/Z])M3;C#B^V
MVKQ<AQ;[/'->ZHU++<A52D#%0['2IW+ZES&QJWYZ&:F!@>A]#)H2"E&B-UH#
M&<,D()QB27&0HZZ7WZSX/U4?;^V=JH>%FH3-JF_-AJL7[RW/PYWV#S1&/:]V
MV.RR])ULZQ_6X+F;37)?ZV<3P%#W#AK;Q[H;-KUVA=-AUX^EDP[;7L$^'/;]
M-C:ZX-%369/EGZMR\_1NI>N&JW9.U@VY7W\5U?;X*Q,L)2E.(8N#'**0IC#G
M>0Q)C#'',<M3@1<K\:#3-;Y853X:8XX1T^0MTQP9Y8]U&A.;@#/KDD>C.L6,
MZWUB/%G9H\8#T+C0!..U3IPI=70#VIYP?MAX)92N:Q^-LF7JZD?7 ':B_M%5
MCQO'F>]6:Z$W+KNGZ;J9"Y$HYD.$0,H# 1%A7%&AE)#'N8Q0E.<1MA*I/-'&
MW#97MB8"<>&U,@;1C+^NA,8S-^U0V>FZ#U;TM::< >^=TLFI=B:EB@%'#VE@
MZ-+1TR+R\%#IJ4(7HM\<ZWW14[3]D30)!8LBB6":X@0BCC.U@HX)C%@B2!Q%
M*(ACR[J/EUN=&PT\-[HM>39"W\8,<>,9CEL<_<]G#B#<Q@3\UMALI'@V9O)B
MCI+KJ8I!RU-/3,S!.#$-L;C97EQ1S6PJO67\6K3_OUOULM*V808Z:^B#6"]"
MQ$6<XQ"FF*B5&<$YI#+/=6U:GA&U+(L2:;$RLVU_IDNQ75R-%A( I-&K,1</
MM.J 88[R@N=44YO67/#3UO"?U=*KGR&Y#U_2UM^ #S9"EU8@FVLU^@)[(M5&
MMZ!;:3J.06Y W='J<9/I/(YQLJ_X..I^-ZF<KXOE1M'G3NPY3V@:L"B .$T#
MB'*D2#_D:@".,B(0CD0H['+ZA]N;WT2T,>^Z],M#3,TFG Z1\LSAIU(R.VN]
M5#$P1,9KIN9AFR^:LWD&@$O9F^=N&UF A=1?/U;EMX(+_NK'K[7@[U9M'))J
M\Y:MBV^M0M^IC;1Z@22/ B0Q3!%C$&6Q6O9R1F!*)-*Z(K&(A55!EFNLF1L+
M-:%X<EG^7H--W80U=I&->GN:[)RQ+,IR57^9<=ADO>"9X9H.V#H"Z _PTZ]M
M/_P,=NZ O3\W9\X,'&K^.4'6;667JRR:MM*+"_".*K\X>>C+*WB_4\N/U4.A
M+JX7&8D#1FD(<<AU76\N89YP"GG.:9"Q#"=!MO@F*EJ^A%IWSU(;KNC;ZW&-
MU9=K+G:66FT3^.Y>,Q*?09=YIG=/VMMOBU6Q%O!]\4T_8N_Y/.6V3W3-;(6U
M^[;^TTIHGP#<IUCVJ>;&SO3/;J&1-$0YB0F4H0@ABE@,\YQ@&,=!G'%$PXA9
MU=]ULZTV31'%L9O!!K":SK;_"39\?6\RFH/A>/;[LMN.YFX?SUL=;RW6U7IQ
MMWG<+!5??1-M?;Y6A.Y>WO+RJ9&JV^78=QDP/$OC1*888IE*B! +81ZG.60H
M"Z-4HDPR;D(<8QJ?'97L[ >M S>@=4&?XFZ=N.DI7ICQS*A^&68>WVC[YB);
MH!UF-%T#W1!SJ>?V6$O]=LA8HQJ>A,.N@63+:E<]8TZ+[_;B)L+PRU>R^G-9
M\M^+Y7)WB( 09P*E#,9-G!#+,22$!>J?.&0A1V&6A"]51LO8B[DQ[_"B'9#.
MZ3_-8?E^Z0ORDHM[A]W^S[GTWT/1W;,-%U\K., 6#R^G8R_:H_\$.P:7//DO
ML)]@V%G3[#:8&C-N\'TNWKC5;%P@$4G,<:06$1E6RPF"8)Y$#$9)C$D29C)(
MK4+G3S<SM^%KKUS*]B>&C034OEC7TJ)(^@60S4:8ZZ'S/ 0<Z;UN;73'R<,8
M."7-,TU-RFK#[A[2SH6K1_*"YIL/RESU(KQ;L?)1[*13$T%3+"1,<:[KSZ8!
MI(% D.29+B7.XB F([(,SS8XT^#5=CJRU5$JGS-'L6JYXZ=RLVY^^OD&K$SC
M+B]W@2%Q7(7H1-S1H-@9"5HKP4^=G>=5^^T)Y!(6;CGD;&O3TL@EIX^8Y.(-
MK@\\=&.='!B/,[429P12RD.(A&(83"B#7# 1829D1*P6Y":-SFT"XO,0I ?U
MM<<AXP!\T8.1&[ W>HI#DF.()CHNZ34\DX.38RC,CU!.W.M(G%/_]T8MP+Z1
M93,9EXSE:9((& B2J14/XC"7$86$D#0-! LYMQ0/'FYP;M334RZ4FQ6_5N_Q
M$%XSRG$)FF>Z.:7TV/S0,]>CRN,98/Q*/!XV^K+ZCF<@N"CN>.Z^T<0BU$WZ
MP:_%-[$LGWK*YZU@^B+B 0E2B6&>AQ%$>9Q#$JG%4Y 3(DF>RB@P.IRU:'.&
M]-*8W+PG/:.;$=J>;"Y";LPW+H'T3SFG,=S)&G05'W[K_O<D4&Z,F6LVNMCN
MU(1D"L0)3C*^]:JB"9_$(RETTLK'?<&6>[HLVJQHW: FQB_%H[KD7GY6G]92
M)T24J_>[VJ09BM(XIA$D5(MF1RR"&,4"\ECDL<RXR.Q22]R9-C^2:SS3YU^=
M;Z#G'-A[U]8S;28/K8,Z8*+OXA6E:1WVO"F)OD1_>N?::;MR;)T(AZC[J"3A
MPKR7J#7A$-8SU2A<MN L[D:MONN"=TDU7RJRJJ50JV\>+C(>*.;/,QCA$$.$
MLQQ2+C!,.&9IA#D/P\2F<H)-XU8T/UT)A;ZY5P>TG$=^=!R*$SQ?)'SDF>6@
M9[K7*(^+>/D.SCAOP$O'5%R$QB 4XO(SQM%8DS-8JV>^+:O7Y8:NY69YRY@N
M"E\ON,0AP2*%2<@91$+-8BDF DJ$,(OB#&?J#;,_K!QJ<Z;GE3N3VU*."OAB
MW<B@V@8S#.)M1E97PS<-.6U-TN%LHFBD@!4WM<B]UQ7+NP4;^$F/Z55-E@Y/
M+$TP<DI(@PU.2D FKA\2CM$]8Z5%]4GHY[5Z4_4JO=.6__Q5B+5:O]]RWE38
M(TN=F:Q>J(WZ"K[Z\4P%M1Z60:T;4;)%CF42A4D&*1.13N&@D&28P"!+<)+R
MF$B[W*^)[)[;(ORY$'%]68FX[A3]+-?94WTMS"AUAIWMF9T]]/,(X==)47<L
M)CN-[1,+U$[:(<>BM],V/VY VX80?RJ72S5<_DXJOHB27!#&4YA%8:.5C6&.
MU9>&)3C/(I&E&;,*^#W1QMP&BGT6@382=%9:C@*GL#1C["L1\LRNMN!84^>
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M2/6FQBN-=5=@9Q]H&0CV%K9J3]9&VL.-MIE7H#(46$M[U3\/_!ZX,=S;C>[
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M+-<S%/,X5M)V9V=F8H^4AAQE#.::8H4QXR+5?GFYP71S^BQ&S>3]8ALY&\M
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M]9UP&6O<V.>/9D< W2L7^]1O4L(> =A35A]#Q,#ZD!^U0A_TC\4BX:G C".
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M@F]'IR-".C)[-IH'OS2Z_QKDJZ!1OTS."1H#6A'1_HBR)W9>>=%5ATEIL"=
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M[5[K]/5N76RUC,/1;'U WSJ?+TR#0%Y^^EZ=/\,UHQ1ORL[/I]W[<!+#&"4
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MCWX'_<]=7N2ER\*-BHX%K-K87;\X[H7'A(6]*M7*<X8A0#A6[^H)R)05NZR
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MDHA!34@N5&0I=VYT5+X^6M!3( :UJ[*%W8Z"1@!S9!JZVH>J.C&J]/;'28Y
M>>4E6]F3<I,C(*?\Y/IX7X[:/*_--:RYCY4/AO]J#Y])DF580B"0-"U.PAC@
M+-9_30GE*!$\C1U9Z8*DN?'07E%7VKF$I"W1>,!G=&JI=;RIXD,J-4<X2;D*
MAF?ZN"1M8L*X8O1+BKCV0,_:(]587Z0>W>R.]V'&F:)$B(P#J' "4"H98"8[
M.@QQQ!.8,9RY%8&Z(&ANE-!\T?>*]H[?O@BM'4GX &QDCNB%E7M]BRM ^"U!
M<4G8M%4BKIC\HI##M<\/.5XM*R#M^+:LC%0=E2U(EE!(, /85(=#1)KP*:9
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M:VV?U\ZE'O'VW<W4AVI3=SCU".>9KJ<^1Q^:/-_*JEPHQA(D4 @DBR! B#)
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MV.>6E\5W\M7#5W/633>B^/U9:)I[]V,K5X41_#$OM@L(*=)<$X(D) B@.)2
M0BCTKE3!F!'M$3*K8!1'N7-CHH/:P5[OH%(\^..@>O!NM7NJRV4ZGD793H@=
M6XT \\B<Y15A9[)RQ,LK9=G*GI2X' $YI2_7Q]T#Z7[3^V%.<W&W*[9K_8UH
MJ@K&/ HYTH2ETD0!1 D%3,02I!"2",5QBI%U]-P%&7,CIT9-^_BN2^!UDXLG
M2$8FDD;#8*]BCP"X2P#91[UY &JB4+>7@/F);KN"0$=(VZ4G)XMCNZ)Z.WCM
MVD=[WNG55;SNU1?3GVG']8[3%+Q=B2]R:2J!FWRMHJI:1AEC<:80(-I1,_%J
M%& 992#**"%QR&()4Z<;/WO9<V/"=O&S(^7+<YU:_3+_L&?5.)=YL;Q/' ?M
ML6\;/0+M?A_I#IG?VTH'^=/>9;H#\^*FL\<0CJFBV^?-XM-_+3!F/$TP!A&B
M"4 J4H!BS6)QI##!<9(18I5+7H\W-RIZ)_+"]'?Y]%^669\U+-VLT</8D9G@
MT[M_!/_U[LO7=__M(8'SV+HS+VTA^;\]K+__N_ED]<*:G\H7M4K0K$>8)A7S
M6-U]TN7)/[OO;;[*5;[>W*U7W^5F:_9*G]9;6;S=26TG:NK2RP1*0AB(">;Z
M]8$QT'_C (L,HEBD@J3(=I]C(6]NKY?1+"C5M'?J;6"]O@/R#-;8"W6I;=!2
MMT(MT H')8CNFR,;'.TW2I[QG&C3=!57/WLH!W Z]E,VHTRVMW(PJ;W/<GFL
M9^&;]=/S1CZ:XZGO\L.*Z]W<)[F]5]_HCX5V2A)*)04B%GJ/I8@".&(Q2%F8
M(9B)1&692[!VARPGIIT@8/N;D5'6]M\K7 5O#PC9=BR6TS$Q=ILL3W"/S-5'
M6@:5FG77HO+BTZ"I-;X);D^0_TPW7G(2'>#R6TNG0]ZTM72N&_ZBEH[%(WX"
M!/2P[W[PY<XDIOQMO19_Y<OE@F.4A"B, 99* 12%#% $$T!@%F40)E&<6+7L
M=1$Z-U^P==U-Z^ONU= P@;-@VY&-;PA'9IWS01;!+WN=@T;IRRDU@X,#NC :
M-3[@K.!7#1'H@N):E$#GLWV]HJI V#_R[6-SQMVTZ_RY(%G$$\H9B%*] 44R
M)H#2#(%(IE)1[1QA&"^>Y29?BZ];NMG:>D<=,EU>G5/)X[U%;^BR##2DI<_#
MY$.^,JD^8*U I82KR].%.H.0*$89@"E) 4()!"2C7/\5*96&B0P34J/^;G6E
M<^E(F#=RIT)<KH3YPS_6M@ZF)_1&=S'K&HQ_:47W%WXW^S[1/WTZD1:0>'8C
MNR1.[$A:&/_2E;1YJ!^--VV<R_[,53O-S_I+]4@+^7F3<WF[+&=4_W.S;KS[
M\2SY5@KMR+Z58L?+37=5GGHAA.EJ)R2 !$F 6!0"%B<(9$(H(E*$I5N&DE?M
MYN:>-BK?E,WPC-+!EOX(Q%[M@)9ZN[&6WPFU8[E7FZ:16;&Q*V@9=A,<YJVQ
MPNR^@X,=P6WWO#E3YBCX>J58OQI.2LFC@'M*X>,(Z4?YOZ\VLBKR>^BFW$IX
M6""(2!AE!,1IJ "*(P2H0!AD4:08CCG1[N2B;CS_S9[+KXBU>NV/N]Y_FX"D
M#UI7AYOK59VQ52KM1LW7@+<C6Q\X3D.?+>S:C=8UA!\L('1F24M@O/+>-9F3
M,IDE *?<9/M8/[;Y)+=WM'C\O%E_S[5K\^;G[X44'U;O\Y7>I1WU:E\H'J4H
M#@4@D2( I1IN[4XR@+&@*!4Q2;+8Y3+%7O3<[E;,01O7JI=14QL3<).7?D;Y
M;SO38E"_3JJQ(Z![0]P(R6%N[+AI',1'IBD#MM$Z:-0.V,_@E]\KE'\-]LH'
MM]=A=B8M=\2\\I>#^$FIS!V64U;K,4(_@KO?/LK-F=L>0Z3-C<_G\OBIZ2OZ
MMNXJNF\2A#F*)*4,9)((4YLG!1C)$- $9TD241:YU38<KM+<]LJE16<NF\L;
M'7/ IW?.)DU[4T>8;M?_X4:%'F;1CB*GG9N1J;.:%LO[Z5%Z1/F#TRNO>E!K
M4K[U!^,I#WL<N1\_?S.#[38_OV[7_,^_T^5.+@C)((NEWM>&(08HY)IJ8XZ!
MQ"R1"D4IEVF/'>Y+23/=U#:*!H71]":@VMM<%]O_/XAN$IC=)#AN*LGF1;$S
MB>'Z9W,<H6=O>?DJP!9^.Z+LB>8TQ+='\&N%8*F?/U:[;+M7ECHC9E+6N6SF
M*8MT?+(?*[R52IJ^FA49:0YJ+E2T0V@:<X>4APBEFB+2E $4T0C@E,2 1XQQ
M1@@74>SBDEV1-S=_JU&WO)%8'E3M$4%S#6D[-O"(W\C4L(>N=H2,Y_.QC:"7
MYN6.N'BEC6LR)^402P!."<7VL;ZU',MMR&>ZV?[\MJ&KPIS0K%<?\Y7\L)5/
MQ4*$:4R8R@"GV@U!61;IS1XC0+$X@CA*8XJ<<C.O"9P;OS29@*7"04OCX ^C
M<U J[9B#>15T.Z;Q">7(5#,0Q1Y5'.V@\5S$\8K0B6LXVD'PLH2CY7/]".?S
M9LVE%,5[K?#;W)S=YZ86V;WZL-*OL_[KA]51\;*5.%0U6\0XB9D4FHP(I]K7
M81E@/!& ZWV0R*" ";9*&?.AS-R(JK$E,%^%8&MF3E4-'Y[*W)+B,7^N3^F7
M9M-J?O.9%L7S>K,-9*&_6W^YL=B@F;1CN*GF9V3V.YZ:EB%F#AI3S$5)VYBJ
M^N/>''_<Z -4K[PY2*%).=4'=*=\ZV7,OOD9S?F6$?ZNK/;Z6UGLM7W9+VF2
MIB$F@$)#NI(S0&@:@C!-$BC2!$4<NB5H6$B=&[N680'EZ^NI**X-\CP,,1<J
M!;%B$* 8I8!1)8# ,%3:*4]51)O3OZFQ/SX+_-^(OMT2Y?W;//):='3I46%:
M*1U46H\3\>*$DN=T&1O)$^?+.(#Q,F'&Y6%OH=;ECQLIZTXC<<A22?1*$"-B
MU@0H >4Q!HE**(%<<!H[K0E7)<YM/3@?<-OHW+.;RW7<[3C)*YHC\]%0('V$
M*)\'9^RPXQ.IKQU*?!X$B_#@"P_Z<$E-/DF^VN6KA_OGNF2J:3U5-K4K^T\M
M< IY;/+UH.EWB@16IGY,"O2_0IC0D'&2N+9T<-+ Y56:IHG#0>5@O=?92XLY
MU\F1",699*9^J4P!8DA/CF08"!*B*(DB 973V?&(4S/)FK%O;SKU1/1Q9;W"
M.[U3VWH+#OK?E,T#JWDH;1C+P[4&;T1?][H.K^CU6@/4[?_:#^-C.7J;%[P2
M*,5!WKZ2"V,I(0HS !/) :*I)CX3'PX5"C.D8A$1X1(5[B+<B>LFB@LW88]#
M>.T*W$()RIE>^ADC!)B5!N T%D!CG6:09J$*XR%+OS_ IUGW#X<DHJ5YRP<8
M<2[Z+##^\)U^=6GK?K2^M(L<Z>?J^B.?UYORLO.T[-$G39TF95J[ ^9CS8GO
M6*N2'>(C+DE7%'C%]<@.FN[%R'(,]VJ:[2N"WZBI9[O]:>X'#F>5J?:T8V**
M*,5Q"!"$'% 88L"DHCA2D(O0RM.VDC8WO[I6LKDS*^BR:@WIG/YHAW4WUWE'
M<*J[2:-LT&@;W"NK@^ >\-G7U?0*XT15-8?!Z519TQJ>CKJ:U\>8K*JFM3GM
MFIKV#_7S_]_3?%,&\1INU_ZLZ9IG>HV5K<8644JAPI&I8B3,*7C, )82 PG#
MB"8H@HE=!6,K:7-C7:-L%4T>_%:&/,NGKA*./>"U<RJ]@38RT;;P:FD:_#%*
MZSHK4+PZ>MT2)_7LK(P_=>7L'NK'(OL22%]D(3??Y;MBFS_1K:S;-X8XIH2*
M"'!%!4 $(H %50"'0J4B236[."55=HN;&X_42A:!,M6HES1_JMRXSW*C_^7)
M5$@#C)H<Y]O-1C\H>]2SN#(!=D3C#]:1F6:O:%!K&C2J3M,WTPXHK^QS1>2D
M]&-G_BG_6#[5-\J_U0GE[I%N'F2Q8"EB4:0$8"'* %)*TP[)(I IE@C%>8:8
MTQW^.2'S(YOG=75K:<Y;>-G=)U_QG4FP<(WA/P-I+&0D98( 9SP&ICP1T#\@
MP+(8Q1&3,:616\!6;U GC<\Z ZL'-.UH>>C7;F0R/NXM5>OG,]'ALO6>DQO.
M")HXH>&RJ2^3&#H^.ZC?</&9_C3'MW>&,U;;!<XDED1O^DPHK&91F@*:(04H
M5SB%BH4JI&ZW$.<%S>^^H=$S>*X4[=4M^ 6<:9QIOS<%"<]"@%)-HV:= B%/
MLY (ED8Q[M&M>0"8$S9G]@NE'7T.!VAD MUC4VMX$]0Z>N^=? &#,5HEGXIZ
MC<[(%\R]T CYTJ?=;S/>/3TOUS^E_"HU3YGMW>W*U))XRE?EV>P;N9(JWS;]
M:B5F,8E2TUK/>*D1Y0 G* :"JXPG881#N]Z@SI+GQA%[I<O=\?:@=L!JO>U/
MZ=VFX/J%QVC CLPMC=[! 5RM>=!2/6AT[]%ES UE^WN1T=">Z([$ 74_-R6]
M .NX-7$;;[(;E%YFMF]3^@W@O@*\E4OZ4XJW&_J7&?[CFJ[>4UZ>?M0O Z9Q
MA"1,@ R9]JHY"P&6$ /M64L(*<?,+N?,2MK<F/[MVV\?@T9%>[JYCNIU(O>*
MU<CD7>L:&&5+\@B,NGO@>A#V=03M2=HKDA,1\V!$G5C9&J$.)KX^QF3L:VU.
MFW'M'^K=^XA+TY/#?'&^Y,6?;WY^TR/=_LB+A1!0\*CDV(@ Q$((6)1$@*8R
MQ1PBB+'3M5.'K+DQ[)&J@=$U,*H&?QAE'9.VNB"VVX)[ FYDNNV)69^N.]?0
M\-USYZ*\J3ON7#/\3+^=JX_TK3KWO)$\+P?6/R]EF>FU$K=/)I3U7]7Z%\(0
M(R)2$"4(Z[TY@H!@4Q*8P@S',I))XI3?8R-T;E32UKG<F=.6LF6_G%7AFI]N
M!;X=M_B&='2?[J#N3;!7N*J%TE+99UDZ>X \UZ:S$#QQ@3I[*%Y6J7-XUGW'
M>%L4V@$6^TOR]^O-[ZMGFHLJ8$0+JG\0_[.K(O_>56_>AR?]3=O>*\V4Q7J9
MBU*1^U5]F%DL0IXI%/$$I)A*TWTV U1%(4 9DW$4IU'(75K(C*EKCVO?*4KT
M5EJ;>&O>UMLT3ZEO,\K('GZ(['E^$=E#6Y$]+[IR;Q]E\$7FJV)7GQ4];*1#
MK.&H7Y_K.^I7_39,=$-3F7AHP1AH(X/*RB:BRQSP-3_N+0UJ4V^"^DMTKX(C
M<X/[57/MXW"Z/=ILV^_^YS#K$QT:O/+L.QTYC#TM'2<5HXF>[(!C;/#:YR*C
MR^J9#I"O\JW\F'\WY7B/&U>W'9U:E_^6=/--?R7D@D*"2"P0R"*< <1)!@@4
M"H09RU*IHI1BIQK=/?68V]Y)OR2)8\) SPFPVRQ- .O(2W%E 2A-" XV!*41
MK3:@;7-N F-)4)KB,0-A&)9^<Q-ZZC)MUL(PP%[D,PP<SGV/]E6N\O5&$^]W
MN2E[@'Y:;V7Q=B?-:U[?GS N0YE&"6")0@!1&0/]3P103#B'$8NB-+*]U[.0
M-T?""THU[;U9&UBO;T,\@S4RC57:!BUU*]0"K7!0@NA^N6>#H[V#[QG/B7QU
M#[@Z^=L.*'6XSC:C3.8%.YC4=FA='AM6M/%N_<3J@(VBSF^*8$@4Q2F0"$<
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MFXA>223)9 B3-',BY,NRYL:UC:K!IJVK(W=V0&M)BWX &YOQ&JR.U/28%.
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M$*T*[>R8RYV5*/]6E?:[%?^S*[9UR:A[]8W^.)OT\9F6>0(T5$@2[<>PE$J
M(D0!@2@"A&N_)A08Q]*)HR;5?FZ45QL9\-K*8'LP+*![RWHD>4SV?;"\#)KK
M+(]]AW0MW?$F:+X##09!"X22RULP! <<RG(0)@I-8W%S,96O L1SSLO4\^@_
MC68R"Z;/S)EZ<LXF^TRN1+^5LZYWH\?:MA6JFP@BI<(T#CE@.#4K'0X!C84
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MP41W*P=3#A?+QIB;H^)UFEAK@X*#1:V0Q"GGQ[Z"[)3S-%'QV-'GRZEJK"^
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M7EK,F5 NYNB:8("?)[\>2#HN$^=*22--QX2$Y74F!I!:#R1'HCP735Z)$'N
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MA[*T]0+&&%*>IB#E+ )(H1B8'L(@3/7&'-&,)4PX45>'L-G1U4G1.R&KX+9
M-6KW*3;?";<E,WD"<6PV.L'/U+@)/A3%;HS2]#:8^.6<+H'3\HR%Z2^XQ>89
M;Y'RQIE^6)D2:1^$)J]<Y;2YJBINN=YIZK?J=M6.&M6_VST=Q9$N."0$)@(!
M21(,$,0,T#1%@,5Z#YC!4*1"+K;K+5W:4=%(>CJQV%[;$:,?C(Q@V0K7II7.
M@\/IO<RJ'>/-8*Y&)LOS ?@'(X.VE=7]?1$T=I9W+^V(_-K4HS#]4:/S?<[&
MV&'[7G1][7A^GX!;!/I[%>>Q9^;MC[Q8J(@(D3$)2)AD ,64 X9H!%B"<4PI
M"V$XO"^FD30W#_5BV\7@#Z.NX_[Y,L!V).T%MI%IMC=B?CI1MM$8O]MD*>WU
M.TJVC;;J&GGT0$^R*&,^RM%OZQ9 4C(4<R8 B[3KB$3" :$Q @G%29(2A%CF
ME#?^4L0\Z>$VJ#0-OF[7_$]'2G@)HR47# )G;!*H\&C@\=]!Z;+U?E_ZEV*F
M?=LOFOGB-;_\R9[O-RT>S?^;:\KO="G+8[)BN\E-V*/YA79&CO^A]<D%D2%*
MI/80*#$'\@D, 8&<@23%,<,9IHR0Q;/<Y&OQ=4LW6TM"&**3R^MQJMF(;XI6
MLMQ<</.#/*A;_N-F;TSU>UJNK$P^Y"L36036"E2J.I+.H+E-%(4HSA* 4L4!
MXC0#+ P9@#%*,($R,LY@I=:[E67[RXEGMM%K7O,J5^)U9A1'E'(:10#'B6G.
M8M):2$R BB,DPA0*SC.7@Y_)9G.ZXQWN-)_%X_JO59"O@NVC+$LLK)>Y*.LX
M%5O]1Y6O:@HQF ^KY?HOQR/N8=--B2"""03TGDZ_Q3C3Y,RE E+%-"*,L3AF
M;B',DTWX-('-EU_>7_)54]'_9,X=^Z0-FT%+%W&J61G;F]2:W03EI+04-&=W
M^QG8S]CIO[4>\.A]^@#6KZ,Z2*-I?5H?X+UP?[T,VK-PAHGM+LRUFQ2++"*Q
M8"0"*C(YY3A%@&8I 93&FEA#" 7#[HYO6\0\_=@WC4\:,+HLKQ]--\DR(Z1P
MI,8C/",6P=AT7HTX%L"<( "6A 0P3)-0R%A@&+LZF\/0'-]WU!+\ VFW9/2%
M9N05H%+K)J@4\UC<XXRY?LMWM 5,6Z#CC&DO2G"<^\R0X\#R .PSW=QO3)J^
M%&6A\";]9<%%A*,4(J 89)H;]6M,$BH!##&G**44VV7/.\B<W8%AG2EG=+X)
MGFE3E,U'ZUV;*7 Y6_0&[#2'C5\K3+7"YLJA4KEN-;#/I/-] &D%T0@GDMUR
M7^&(T@J(\V>6=H_V8Z7?)#4-"LQ^^\/J>;<MF^7N5EL3KUR?MA.8"9I&(1!8
M*.U@( 1(&")S )(F49J)F#E=6EP7.3=.:C3LD>-@@:\=X_A%;63":2D;E-K>
M!'L,R]0&__<=]OAX91L+L9.2C3T,IUSC\.2P\HG%O;HSQIA&I57LWY>\^//-
M3_/?]Y3K:?XF?VS?:*O^7*0Q%A#3%,1IE &4*0DP))GVBC*F0H(@BWIU-G'0
M86YD]'7W]$0W/\WAZ!/]'[V0\YUVEIZTY'Z%$UVFPW*+-"[(8^^D&NT-PD?Z
ME\T(M.Y5VP']P_^M[LN:V\BQ-=_OK\!C580PDPMRP7VX$?+6[8CJDJ*LFHJ>
M>F!@M;.+(MU,RK;FUP^ S.0B;@ (I+(?;-,2F3CG.\2' ^ LH-.BSV0 6AM@
MU(E07=$#S"AE%EWD>)5ZBQY G2J\Z/,H/V[L2[ZW#\L^DNWO8LX?EGTOW.=/
M@O4]<6>T%JS":0H+25*(D*Q@+:6$#,N,")X)2<1L(3YK1]&.$ZW'MIJDN)ND
MNQ+$FZM#5VLS5YMM84PW)K0'WX[_P@(Z#NL-,H/U<@CI!5ILN%["QUYPL)4\
M'+\Y@Q64U>Q''Y7+G$%YR6#N#_!,W#+1MWT%RDWAH1K7.<\J F5:*:\-Y37$
M%2:PQ"5A95*H7SL%PQX=96I^V5#]E!AA_]LQ(^LHCG9T<S4ZD:FED^]F4QXV
M1F&FLQB$S;DZ.M*XR5;GE#W(LCK[9K]9?[KJ7_NWU;)M9PFI..*HAJRN]!T?
M+B#A',.2I'DI4:;[)[D0P*4!I\8%1BCPEJQ6S_J>ZO91;Z3=&.$BQG;D$!*Y
MR#QQME"HX@\C;SC*L$4F*'M<''14(K&%X"6G6'_.L^>VT"[]9A4DG"6<U0S2
ME.NDRX(K;T*WJM2E+$JD_(G:B4SV'S\UZNBDLUDD;;"S(PE_1")3@CT8[MVO
MC^H<MLOU_A#C=K,^JMY!U^KC[[JV/<X9?C G9=L#19(20E&:PDI0#!%3TYJP
M6LUM4E/&944(<NI)YB'#U A@MY5+LUT%NVV%;V\<>XOP/,G3HBHA+S/%MC1'
MBG=U-F.!LHJ6'"/ENCF%OD:VR3@!KV>M KA8DV8^@G7<#N C(3[2 ;R&^KQ/
M.,K!NP>(D?H;V<OQ2HV.G($ZW?'(_5&^H:G+U9H_=>?['Q>M>J64UI7:](K8
M[I?@NY-OYZ1Y;-^);V*^_*I/V!Z60W;Y\R^;1F."92C/&8(5XZG:_F8%K)DD
M4"9)*HCR8F59.ZUJ$82<W+*G=82#DF"C)=BH>?.B(**YGS.J@AU=]0'V1MMK
M^LK%^&)8TO<KFSLVO[^>I3W"7^.9(G 8;01!1P['C0?U85AOQ+%\LXF_-FLR
MU^5-=.?H)\6YGY9R_9VLQ&ZAK'3&**HY*CGD.C(8D9Q#BA(*<5T4-!<$T<JM
MTHCEP%-;,';D-MWGM>"@[26_ 61'=M?$,TM+V+%Y#'PC,_0NM(/,X-,&VEL;
M:#U2QMQP"IP=9CGXR(E@;I <YGPY?M[SO';@P@_+54>5MPO>O^#_>NK+MO_X
M*A:MF(DL*\JZTG%\.C=>Q_;5B&-(<YKA-,$)YQ[I7RXBN$RT5TP/<SSW=;$!
M+AD2$E60L+R&"-<EI&E&8*)LD$N$<I8*UY2QN!88.Z4L(OB61_*1X(Q]8+_Q
MQ^5R-?CL.NNX?[F5'?3"!SS1]X L['F_BP#CW@9X0'-P5^#S#+\%Y5W3?EVV
M9/ZWU?+IJZG8T\B&F;7JW?*1-(L9P22I,U9 4F:Y<H)U_G"=$I@J'N,(*QK#
M3B<L%T><FO<[" R,Q&!?9/!G)[3CD<=EV.VX*RB8D0GK2AR=2<H:FZ#,='G4
M4>G(&H27'&3_03_BZ=IUZ*Z-'Y30)@/&M.P0?-NQXU>QOI,/Y,?M>KUJZ-/:
MG$8O-]VWWYN>W+-$4)Z*1$(J%$LA3 BL$XF485*9T5IFJ:Q<""J89%,CLK[I
MC?Z2 +ZC%EAN]+H!"['69X!K\L.-T<+9TX[Y7L5*D1FR-]!/6JN?.SOM*@;N
M=NST:V<GI=T-V-5/']7>DU70YD7!L0[*N.&D&Y69@X/ZDL'##^#&]%PTL^X!
MMYRK:=+>+]LUF?_?YNO;)1>SE!1YF6(*I?(C(:KS'-9EFD&>5E59(I1Q:=4F
MZ?PP4^/@3E+0BWH#.F&!DA9H<>TX]P*RYPDT'%Z1V= 7*FMZLT/B"%>U@OVO
MS\MO_UL]P-#4OY%^";N7AILN/'H4HK%3;V -RW?[.7N_B6]"$8_FH>'FYX]F
M_>5MGTY[OYPW['DG5"U)2,H4*Q1532"B1/EV28TA8QEC925K43FE(KL-/S7*
MZ*4?ND.XW[(XHF_G?\7#-#*M#' :]VH0'7Q7LH-!>/!G)WZ<:"<_Y(*Z3(XB
MC.H7^<'STOGQ?(IG9).N&M-5KGKWM%)^TWUWEV$J6IE?WGTU[M;['V+%FE;P
M&:[*'"<YAS@CYE2MA#6E%)8XR1#/*L8%<8I;<A9A:C0W"*9W-:8DE=J6&HFO
MJ#GG;A<[\HN+=F0"-%)"2MK^REDLVNX([E9W9?C<E9*ASV#W?7V2*[C]3E;\
M!O3:W8!!OU;7%[X_7RO:/2+(&^6P\3[N8HP;S>,-TT&LCO^3_(CS#Z$;@ A^
M^TUM2#^+7Y]T[9L[^:Z9/ZF?=N/>/:V5(VJN#&>E*(C@BC#3BBG'L"@*B&M%
MG33!"2)IRHHT=8N8=Y3 91J/$RW?2^I/DJXVD%0*7.<)1%A4$#&*(-9E][$4
MK%9_22%REY4KH@7&6+8&\2'IY-<!4J:JHA$<++>2 PCXV,:R6\XBFB#R6C9(
M#GK102>[]B$ZL<&.W+HRFM$HW!+EB5S0]<E5AE$7)T^ 7JY,OH_QO!07=*UV
M#6JL5@>EKIK/S8+,]4^[]/)T5B<E%Y5..ZA)!E&6UY"F:08+R9*4EK5 R*E1
M\L41IT9[IKLOVTA\H_#M9 9<_<;$A#KGX5^&W?)2/"28L2_%-8YO=W <Q#7]
MDV\NU3-POQ2WQ2;LI?C%4<>]%+<%X>!2W/J#GM4^2+,R)6=W*D3J$/FGE?;&
M^R*F15U+B>H<9@PCG<B;0UKB!#+,9"UPEB<9<7.";8:=GN>KI>YJ*ILDEDY8
MQ\H?-GC;D4YH#"/SSE'P(M2*=8$E;/D/FX''+0'B ,5!&1"7STZJD?NF/H:.
M12_2A,-<W^>@E&%(J6(Q6A6ESJ91M.441QA9WJDY7+O]OON6[HZ%SV(;V(XG
M)V2VR!0;O\=[E&HM(QGH/Z'M^^O4DQG) ".U@0]4\:8+9GH@/W0<TWRIU\#=
MTN6",8$YY((SB/)*0I+5&.9)+O.TR#@13KOQ<X--;5WH8P:5L&=*Q;I#:D?F
MH8"*S,1;C,!64/!GE-M]&T@BA#^>&/ 5(AK/JWX\2/'"9WR#CN:Z+O8]6:V?
M^Z0*AI.DR&0"*]-?!5<9K&F2F;JY,BF%K)A3J/CA$%.CAUY"8$3T3%8Y J0=
M/5P'3V12<$3&(\SGE/*!0WD.AADY7.>4FH<A.2??Z9D,O5Q\5G/H49^_/:A'
MW/YHVEDB*EXR5$*2%KF:V#6#F-4()C3'*$]$0K!3[."Q0:8VR;6,4 O9'QIK
M.=7>0$GJ6M+R&*)V<_U:G"+/=A^(W--BSV 0-OWUV$#CIKF>4?4@G?7<>WW7
M]OVR,3OA?I_$Y[X>_]N=7N>FDME,4D[KI"IA4@L.$9<EQ#E'D- $B1+1K'9+
M%?,38VKT<5@!:B]&=M!$9Q;MZM*7!'1V)KPL9^MPQ+9'=*<DCBD\O)=KD SL
MX7B),K(7= U<AY[254^[MJ;P7NIOJW9H\R<=5'$\@ZS;P)ENF5JP-UU1CT]?
MA%C?+O@MYR9A@<RW^[MV)]%#9#F5*(6U*&N(3*EQ?7"3ICFMJ?+6JKSPJTD\
MF@Y3(_/=DJXGDGQ]:^>.][VP8_N)6SMVY,A>.07=CWQ0^U32\$@U?$<W1J0:
MP./I\4HUA$<WU.D:Q..+XK9(BF]?9K_I$,0[^7O;W8#L7(!TTBL1Y4Q4!28,
M"\@)T<4H,(=$5CEDB!=)AM5R)]#0,_#A\L)F.ZX5+^WW"WP8XV!"F.R1OG3[
MDJY)LU#_;Q9 _&!?=+*)*5[5+TV*N>;Z V"^O3ZR6ZNLS7-^80F*]D@;!BTN
MO)-0"=S=(6^OD)7,8! :W,G 4/(E>]+3S\S)42'=&WG:T%HOHZXX=6N>^I1>
MQ[(D[U<QZ\>,LN2X*C6L#\Z?NW;'<ZO6&).;T7P3VX:-[W_H94CP+HE4%_7L
M]V/OR4J7CVSOQ<J$GF\=UTIFG&2E@%5528A*'=_$,@9IQ:4D59KBU*EB<'@1
MI[Q?(3LZ@G:CI%XLC);=(0C;ZJD_)'I-P5==E%CKZKN_"?8M<-V^O(9M(Z]+
MNV;=56^GL2UXOV?6M_MF'9346:5=+L](VY?0QHBT.PDFYBMM/D+#?'IO$7PD
M]ZW#)['ZUC#1WGY>B2YVMX\M3]7B7>9U C.:8(@HKB$N:PR3I"BJ"K%<4JO;
MRG.#3([Q>SG!5E![U_0DDI<]^Q#XQ&;-0V@NQ^3;8V3OLH? :B0WW0LS)[_\
M$AAG?/&3'QW-_[XD_*[/??&]ON51^I.:._F6M%\^S)??MU'CA7*-!<H)+'A2
M0I0KC[E.<PHSJ9QG*@DFU*H,G,U@DV/"05;3=4=)"XRXWAU)SP)MZ90&@B\V
M4?HCYU&&Y#(D@0N.G!EPY-(BEU4_+")B\9G73U'J&W:8$\H[.F\^]XMB(J4L
M$(:2X@JB2A!8%UQ"CD6M"*I(F5N$:'R1IT9J=]<>YHYH;3M.G)8-(S.K1];2
M\:2EYYV4)?-%V*H[S62E\Z:9;+[2";'_8U.6SILA9M;2A9$]F\VIT9KU!\+,
MG# !M:@F(N%J>4E*'868)!R2DG H24$*3NJLXDX5E Z'F-J:T$D(!A&]8I./
M &E'W]?!$YEN'9%Q;_5V4OFP3=T.AQFW?=M)-0\:M9U^IV?-CM/MD_]!_F4:
M^+3MK^HKT*?.8"X9S[($\@I+B#*:0E*C F9YF6>,5(36R&7V.XX_-6HXWW;\
M!A@=NF8Q0&OAF</D:B4[:HF(?63>"0^[>VD0/_#"5@EQE&'<@B%^ !W4#O%\
MS)7='OI_?E'N63I#)$\EKK#B.U[K#.T$8E1P2$F6H2PI:UY:W7.<'65JU/:R
M@4'_ FAAP=W"M]G#'K#G>2H87)'9R!LI_UX/QY (T^IA[\FOT^GAF'(G&ST<
M?;.?+_2K6.LSO_O5\EO#!7_S_'NK2>?CXIMH]9'0+5LWW\R6:U9AEB9$EE"P
MM(*H%CH)0+=\2#DI6:YV0E3.UDN]'[-:BNV'=J*)C0#QOORZDQ/31]CZ]$0]
M>+UJF,[I,3_[VNNC"W(W@RZ ;)1Q\X(<[&/G ,5!/3+;:,#-G<']#K@_:<D5
MQ#^#C?#@]C+,SEZ/.V)!'1Z'X4?U==QA>>GF>#PAG(>3S;*\3O-,EY^IA:[*
M6*MM749J6..4X#HIE0>47.OA9/]1'L[#]^7U'DYVA8?C!-=K>CCGD KBX631
M/)SL]3V<S,7#R:[T<%ZF9FYNNQ3OR&8]=-L[D::YB1 M<E&4!$G(29% )#,,
M"==5*LJT8+A"),/9-8GH?F)-C5X.LZ&[]M=JH7[_YN/#NUN=!ZT;ELZ5?M>E
MH7O:T<Y+&M\ZD=GLT##;6]].I[TFIA?2UF.UV0H)>M2,=D_17C7#_3HX+V6\
M7_ET[QJ#*WWW]TYT_WY<;,3HKP8WP515+HN<20%K2I3+)S"")$698G)29!+3
M#',G_K8?>FH<_=:D\9G^3WV:G][&[@1];%I*$WWWVIK<S-:Q=*V#9>P8.0[>
MD5EW$!K\-(C]LX9]2[V]Z%&BX-P1"UWET';XL6L>.L)RI *BZQ/\Z.V6L:?'
M)U.#[9WXNA*L(UOU>B[T"YT[_:C[/O\_\W/%O$J.]?.]^@[JO.KW:O9^U>P[
MHU4I4EZ6,-<="Q%)""25$+!(>"DDR4F:<(<<Y]#R6<W8\7.A=]0#?$<_PY=D
M1S$@?NB>?*YG>\',:\>@HUIK''[=M="N3C=@HY4QUJY>-V#03+W2NMV8MVS4
M"T? H0$/2L_!A!N5O$-#^I+:@S\_Z*W,9IG9GHQNO"B6) 5)&()EE@N(.$Y@
MG2("62U85C*656[-&MQ%F)R?NTTR,#<%'W<=+XN+@E"6N>I>)A#>KWL_<PSV
M*"ZO/XAC7-F<$V,*5S<6,%E>X=@\R3,X=W.*H.EWOR?X+"%8UEBD4)!,[?&S
M!$/*J8"I^F$BZHR)U.I&QV:PJ;'=_:I9L$8M4ZU)L-J5W#%J]QS"=EP6"K?(
MK+4GIG(&C:#@S_[?*$><-LB$#?,]-^"X ;\6JA^$_MI\QO=.^-,7,9_K0@)D
M\3Q+!2H+04J8T(+KZYT$TAHEL*I2CDN"*UHRM\O@W<=/C2SZNTTC(NAE=+WY
MW8//]LK7%Y1Q[GKM\/"XWSVF]I47NWN/'/E&]Y@ZAU>Y1]_EV3=@>SC]]FFU
MTF<>)<*$% 6"N,!JOR,(@T2B"A)1U)P3E*>2ND2C'0XQM:BS!ST&8)UP_DF:
M1["T6]6O0RCR#/YE]_JB%R]@FX"3JH=M$G XS+@M DZJ>= @X/0[/?UZ'=)^
M)S^MU<K>)W34149(1CBD):TAJJ4^T:@RF,H")ZQ,N:!.)QJ'0TQM6>Z2-Y3[
M;F3TS)LY@J2EUWX5/K%]=4=HW#WSD]J']<</AQG7"S^IYH'O??J=?E/\GCSW
M37#-^>K#\H'\^*-9?_FRG.O*P1^67?6N-[H K78;Q*+M<OYIB5):<>6,9Y7:
MUE..(,6H@(7(J>1YEE:H]KB]\I5GHK=5II\@^*X5$/,NL?\K:;@IUSN$1^OB
MB_]^TJXN^4Y6W-%S\#:@'?]$M<<X+-6K<&,:%^[(?M/50X34%%?NWP5N5RL=
MB1'VTNE:%(.RG;<PHW+BM9"]9,ZKG^<;#&5\%!-O]7[>//;%%?I*<D1D!>6Z
MMYI,)40Y4=Z4S"44*!-I5909PTZ-.\Z.-C7':E=8L".M<__5<PC;L5PPW")3
MV4G( I;J<\(D<'#2N1%'CD>R4/XP!,GF0WX\LM?9X7QC!R.&\BW>=_$O,UKP
MNB9EJ18ZJ4,K\QK6%)50E@6K4E9*BIF'I^8OT41]M4'*(7#(C8:N,) =1T7&
M^S6Z[5QNMJ/?T5OE_06K.!/<]8 &9;\KQ!F5&J^'[25O!GCB=9O?AV5?T&HH
M@R5:)4O;SE)2Y*A.2UC6O(((R0(J*N4PHWG*4<5()=,K-KFGQITH09I@DLWV
MU82I[T6CF^TM'0K?L6TI,<\M[4FSU&5>9UG"U"RJU8K&E6TPT;9):"&*K"B+
MW*DY<1![C!Q$%1A2M]. $$"-L^LWR5*]L& K[0TP\H;?X5]")LI._N2@K[)C
MOP3!J9WYQ<]YQNMW50GO5^*Q>7IL_U@UZ[58S%!*:4T8@PSA!")<Y-H_SG4Q
MP9)7")<TY2X<<GR8J3'';Z)9M$\KW>@-?.U%U4RN17>,DS\.JQV/7 ]69/;H
M!02#A* 7,6 <^ED(PD:5'Q]JW!CQL^H>1'R??[=OSOE0$T:OG[<+WM6T,-PS
M(VE2%&F"89$G$B*A4,1UA6#%2_USPA+EZ3EEDI\>;'JDL%\LYT4!G68KN6MR
M^!G [8@B%(R1Z6('P;<#@A\M8//(QKZ,1^ <ZS,#CIPY?5GUPWQHB\^X]R&Z
M%RNU WK4JZBY+]@.8RYF?U\TZ_;^T^]#OYA2R 0AQ2U8)A2B0B20IJB"7.0%
MIW7%:F)5JM1]Z*DQC9;,O@&/(\SG&24N>+$W,UO!H9$<[#!.%WQAA <_:?%_
M]FAVY(BU?0ND>)B/U!@I./9.39/\X#O32LGQ@:,U6/)3=+?MDN<3?(-?%^).
M[E?!_@?YT3P^/;Y9KE;+[UW>N?K-^GF&DYJD-:U@6NJ]9LTXK 5!ZB]65FH5
MT)ZFBW/I,OC4EH!>3D '097/V4GJ&C'K8  [9S,6K)$7!RVV22_:KX&OBT]W
M4&^$!V\O0>T1A.N.6>#P7 <!1@[<=8?F,*37XQE^C/:WY9)_;^;S#\N5:#XO
MN@AB]ORP(HMV;M;8OY%FH4L(S0A**XP*"6M<UA!EHE"NK:BA\F:S1.9)S=V"
M@.V'GAJ;]1+W"0#L&:RW,KOQF0/\=FP6!]3(7#8(?0,&9 >YP8[@0$O>ET8+
M1V7N@ 4E,H?A1Z4Q=UA>DIC'$Z;0V,X<&.CB$=_(W!Q9I7DI$LDRF-8\ARA7
M&P)*N82"TIQ7:9D)XG1E$%?<J5'EYF#,G#&*K:"OV<[NP,9VW#H=RT7F8X\V
M=NWQ/G:ZNL2FD]WFN_#>XFOPRMWL3EEGPIWL#D3^#^YB=PK^N!WL3H[J?EB\
M?P8MEZLW8B%DL_X'69 NSV#H%SV<K54BH3(GL*2EA*A,!2128"@205$B44%R
M;'M<[#KXY!:-.6D>6]V^08G8ZBULV\MK?[3I;(#+!\DQ81WYJDJ'<O72@ZWX
M8-,.WOTHV?T+;WV8'!/WD8Z3@^/O=)SL"^"9 V7G1XYVI.RK[.ZALO<SW N@
M]#G;'YJ6D?D_!5F]7_!W9"UF)*^E3*H"RD3FNE!H"@DI,D@$0;E@->7(ZOCX
MW""3(_Z^HD(G*-"2 B4JT++:%T4Y">EYB@\%5&0J]\+(J5#*)1"\RZ6<?/!H
M15,NJ;9;.N7B>SUS>@1=?UPH?C'KSN^+OGJMX";T_6FQ[N.?E"MJWJJ<4WVY
M]7;9KMM?Q7J6Y8)D"2X@YU1G#Z8(THQ+**4D>8E$FM-\]DVLZ-(ZI^<ZB5SF
MQJY<\:;(C@J *XD![Q4QN\^FEQ\PK8!COL^5QK,[:!C1()')2HL'MJK<@%W3
M#-J GWI]?C;VZ3XS&,DH=0.46@%S@,+@&S81Z$J9QLT&"@/@04I0H,>Z;]?U
M(Y92'UFWZBLX.'>?EG/^_L>0F;13A)CLUQZ>U9)+) H)D[JJ(:IR"2FJ)4QK
M4O",8)[6E>WF_3I1)N?1*6WT-?5*?!.+)P%^$EJ)MOEF+J_M2KGKF/56?2$4
M9;3B*UFI-7C^#)38R^^G+X)"F_CR\<!XAHOM8?8V,ZH8LVSVI5J;&[#19Z_2
M^T%Y]]%L8W^4,)Z-1CI8B&XKIX.&,/">.7:X<H#1#B'" +%[)!'HB3Y+X_*O
MMWKQ??Z[(/.U/B+_^[(UO57:3\_M6CSV!WH98DADC,."\P(B6F-8(\EA)864
M59H7LK(J:^(RZ/26N^5?H!,<=)*;F;:1'73"NS"C)?HVZU-X3*.O1 =PWAZ!
MT^.XVAI7E[4E/+ZCK2*!<'9<+=P .[LN6#YJQ!7 3;E]KG?\;(B3J%_5]Z,O
M4EF6E.!<Y\&Q*H,H20J(RZ* %=859;),D)RZA+R<&FAJ['UP6J%%]:S]>1)<
MGR,@/\C&/MNQ0^O*TYI#*"(>P^P,]HKG*X<JGS\X.?)^/X+XI-8=<]ME.LW.
M\K10,Y]SF*$2*UI($TB%9)!11D3)LP1QZ4(+^X^?&AELI.L;[3K._Q?8V<UZ
M?T0BSW5[,)RG]W&=@T[J%T.,.I6/J_=R I]XEV_+LN^WS)R7=CV %^HE,T]O
MN\8=+UO)2)+0A%<"RIH2M7/+,<1)E< R1ZC@&:<D<\I4<A5@:E/_EB^_#KVY
ME2Y@JPQ0AEIP7:_7[.M^$\Q4C]W^?E];\.MR#?XIUN"]E$+W7W(L+^=L23N:
MB6F?R$3TPAS[PH_3.,@7O<!]S1R%&+FKF1]$ASW-/)_C1YQWZR]B]7;Y^-AT
MQ0)N?S3MK$QSR65>P(QE%"*N7!\B4 4IDIQ5=49*XI3V=&R0J1&@D1'L" G^
MU&(ZND!'X;1CJ&M!BLQ"SO@XD\PY ((2R=&!1B6+<ZJ^)(2S[[VB0- 36S^M
M=)/$!>]+A>OS=OWGX\)D^?&'I8[]26>(U;7 &8(9I05$F%-(2IE!(I.:936C
M=6'5G<QO^*D1Q9[TO4O4]8#6PM^8O\&@@R[*9Q_)YVD?.WZ)AWIDY@D+N%\E
M(F?<PM<FLA=A_&I%SO <K5_D_A0W^FM7Z]EONN>%695S44HD1 (E+72U<)PK
M5DLI3&6=<)36*9:Y#:OM/75J9*4WV4V[;G38[#\$:9]6_9&&@V^S#]MYLO$&
M8X3#' \<K,GBJ-[G.$!]8&?^J_^]G/O[3QQE2A]58IBIQW_I>PNSO;5_T=/^
M:#'L5E<6HZ2N:\AKJ5R04A!(."?J54U+SM6OF=-QC;,$4YO8!Y$M1\/(7.]O
M7,UB>[$3$>SH-SYG(HAN3A3S#YCBZXU=X"LB5RE&OCOR!.GP4LGW0=[-3HZ5
M_F?+1Z&K1'Q0FAY]RQLAERO1O?&!_)@1@A"3N="M3@1$&2:PIJ2 *1(H2=(T
M8R5W:4<;2"XGTARAAZV6'5 C(VB,D&!M^M;IB;U8+J#62$DSUQN-IN_ X$JB
M@4QJ2:WC&RHVX9YLCV+LU=7" 9H#3G92Z2W<?T*I%[252DB\0_=5"2+;V$U6
M0@)ZI.-*T,?[T?R'9M&LQ2_--\$_+M;JV]YLRC.8]+:D(&F1Z^:BI6)OGI60
MB#J#-)6BIDR4I, N['U^N*F1<M=87#ZIO;_8]V*74I-P+W_7AL61C"\ ;\>Q
MX>",3)V=H-!("K:B]M5J B>4V:$2E. N##DJ;]FI_Y*.+#]U75W#&<D8KQ*J
M6"1+U!8YQQSBFE0PPSDJ$U*G29;Y5"V<VAYXD,NO_N LR?*B3+$IZ9A#A%+U
MJI(<DDIDI2!EH6AYIA:$9LD_K<EJ'0^LEX/$@^P-F9L44V*ZF5/QN5DL^M;,
MG1"^6%:HJ$52P$P2#E&)*:RKG, $933%N<BJI.JQ?+_@L9$<AA@+1Z&V#]<B
M:+<6^6 2>=6Y. N]ZU-&640V#W^5VI*G%H:#W_LM >]_Z*B1IZ;]HD^W[Z0.
MDKU]U,$D,UDF:5XJUU)-1JG83M00ZS;V/,5U4E5Y3G*KZX[+0TUMF?A F'$L
M==J]2<"E:[ 2NKV?VU0] Z[=Y T#6>3IO"^D!DR+>0,Z0<--\LM@!)WV9X8;
ME0@NJ_V2&BP^X='8I6]%]V&YNM<EYP0W>^&N"MW]I@B=\E?5,J>O9'4DIZD<
M.*O2E+(:5S#'N2*2K"X@P26&DI4\3429$<X=6H5>)XW5Q'F%!J)?]$U9J[:O
MX/MR]5=?_%\G,P':>0ZMHJ NB&&]!.R@^)_:_5+QA<RE\2N47[A04CLT.?$W
M[WDJ&\%:(W?-5%KH8BR='D K\C/HBS%N=;D!&VW 5IU1[.'0@&84NXS5C":F
M?=P:TUP-Z[DF-?X/'Z]AS=4 [#6ON?YIGH>PI%G]'S)_&NKB[M7#[6-"^)VN
MI?NTZJ.0?ETN5L-_WY"V:?7GS1?_0; OB^;?3Z(UV2O;; 21I1*G!=8G+@@B
M@06DE:A@6:M5L^ T31*GTNFC2#TUCWTC,%AO)#9W=&WS>='(AA'EF3XMEE37
MR#4%N9O%UZ>UV8O_(KXIX^= *N# -XT<>-P&_+B>'X_RG;$\AI[:-R'V:;8V
MH%%X+V+K8V=I_6W8?DVVZO3)>G'28$8U0=BC\U$D'_<$?DQC'!SDCSJXWX*G
M V?OY"<RW]2?)EBRA!8(\CRO($(5@:2LU$ZN8H)CM7G+"ZN:;2='F-I"\J(4
MFQOY'^)G1]17H1*95 = C'0!:YM<U#THFQV.,BKSG%3R)4N<?J-O+\:.8YZ5
M\_S[0I]@=FZS8I?^!?_74]?U]WT7 7IOKB0^+MA*<9)X)[I_9RS#A,@*PXHG
MRDOE-8$8"0$K)BM:U0371>$2<1!*L*G%)G3G.(!WJ2?K+P(\"[)R[=\8R&AV
M[/,:IHA,6AN53 ^!3JGA#$#[@?W+K6*@U^P&=+J!03GPTZ!>P'9JH1$/W#4R
MD' C=Y0,"^EAM\G S_?C\S]6S5K<2:D/]:70"4XO:_S.RJ)D*3:7=;I'#JMR
M2%%9P0*Q1-2)*#*[E@CV0T[-ASNH;+Y7S-R-BRT MV/9L#!&YD\CK/+Z9'>;
MU\E[I.9X.$JTAR<HV5D,.RJ-V</PDJ </NE'/=L:$YOR+K]_Y60M%+1)4@[U
M34N>9T6FR^*D1&T840FQHAR8U81RGHN:N96_LAIU:@1TM!1.)S;0<L.D=&,A
M.^SMB"@XHI&YR +,"-M2)Y2"4I+=R*.RDA,8+XG)[</N@0D?/II['S(W!VN_
MB+9]4'NP,GE'GH=3F#3+JK0N$:R0R'0D$X)8$@*S M-*,9,HN; MNGQYN*FQ
MT3UIUVI#*L!<=RM=*VE!F0"NY+6_CK8 ^7(80%CH8E\F#,)VP? W0,L+'GKT
MM,@>!94M8+2_O0\+YTBW]"%@=;J,MT?IS*6[Q4-&NURW5VCW$MWA4YYE4-D7
MP9_FR@4=(E.WUY6T$J)4>$*:I25$"<HA+BB!F)6%2(LJ2YA3J>0S8TV-? =1
M]4;JLU?VP3E@[3R^0'!%)MQ=I 8YH][-6L 2ML#JF?'&K;9Z6?&#TJL6'_'<
M5F[.S=J'I6Y+K5AJ+GX5ZVW.Y<-2-QB]7RV_-5SP-\^_MSH9JL^\W(WWN:7M
M>D78>H8$P1+A J8R50Y?5B%8EPG7K).*'"554I9.N] (0DZ-J79TU!&FJT%+
ML!!K,-=Y\.JG^C4;.M2OMOUZS<^>E,HZ@'4Y* W(1NO_=MSPQOA66.Z/7]G6
ML;?3^V;>**AS/5^DS*M?FS[,@Z* /H.??N^,_#/8J+L3/PG^'#0.N16/:)"P
M._<8@HZ[T8\(]<&Y0,RQ?*M,?1-SQ5[<Q-<LY\O/S[\UG[^LA[V9D*A"+)40
M)[(_1R"TJF&)BHR6&4]3XA0-<V&\J:T06RE=JT2=AS6C.$US-:6J&B.(:*9@
ME3B%$A&NBZTS@;%KL]Y@P([3C#<6M'9+7D"X(J]>&TG!5E30R1KA$-@2E\"%
ML\Z/.7*9+"L #HMBV7W,LP#YP/^_Z MU<P5;E247(A4PI9Q")$4%B>[*)*I:
M9FG!T@I9==4[/<34N'CK?<U-F(K[S?81&.W8XCIP(A/$%A<CW4W@:^K3NH>M
M-WXXS+C5QD^J>5!K_/0[?6.0'[\^J1GT_M]/S5?M'?8K69TEI523&E8YP1"E
M#$&*$(597NL6 U7.B-,9XHEQIC;/!S'!%[+BW\G*.2+Y.)IV,ST 1I&G^P:>
MC8A10I3/PA X4/GX6".'*Y]5^#!H^?S;W>]TC;=P)^^D;,7Z7JQT R'R6=S)
M_C*YU3V%&I/(I3:,:\%O/Y-FT:[[G$#R;-J)42DQ33*NO +)("H+"DF%,UA6
M&'&<YJ1"V/;:-XA$4R,7HY0^;U\:M6YT/9I>,?U3TJNFSP)[W?0!H#[O(YUV
MFSST3C_[B] P!KY\Y3RZV2+SW<9B=[W%[O<L-F@%MFJ!3B_0*[;)A'X=B]G?
M;H]NN9$NP$>SH-,M>5"TSURDAQEGM+OVH+#L7L>'?;!O3Q]33N2>K-;/#RNR
M:/5MS7+1ZO*F\Z7.1]Q)4F>2R"K+H13J+Y25%:0L19!@GDM!$YI)XM;0QWKL
MR2V:?146+;MU20\?S.U\]$A(QE['=D!\!KMR@ZW@X,\H]_X>B 7NS6,__LB-
M>9R!.>S*X_X(WW."A2;-KOCR;TW[UYOG-V+!OCR2U5^F[4S":)Y*4D(I:091
MRBFL"<.Z90_***$)X4XM"2\-.#6>VI,7:('!1EZO3H47$;<]5 B'8_33!7\(
M/4X9[' )?-QP8="1SQWL(#@\@+#\W%69+SL^V>U\OORN\VH^+%=O5X(W:W-=
MO5^D)44E*?,B@Z7D B*9Z)2\#,&"I#Q)2YEPX=0$T4^,J='2[>&AP@T@@R(F
M7Y<954S,D5>:C*NA['@K/OR1V>S(UO(&W.XAWVD!3->3F*&7UV$9(]W&5937
MR+_QA.M$0H[OTZX-#S]3T=Z,.$-)SFC&<YAP+B'BC,%:Y^V4E#."RJPLD%,*
MH?W04^/*W9#H\ZT:^MGJZ-$Y&,6.(^- '9D7 Z)\10RZ+6"10M(O#O]*$>JV
ML)P.6+=^PE@5=H8S//5.W:)VL?ZG(*MT5J<RPT69J VJ[LA&2PYQ7F.(:9D0
MFF6%S)V.V$()-C52U/*9<)?]@LB=Q%X=%8*9T(XD7\,PD2GTBGH[F]N,AJO_
M]%;\Y[F:22.4VSD/^"N7VSDAW,3+[9R']/IR.Q>>'SL&X?V\,0N+DE?]SU1K
M_"36Z[DI03HK%+$7>:9#EE@%42Y*6,N:*H*G6/"4<92F<2(1SLHU-6IWCT>X
M,1E)HE?2L(_^ =5Z@G:C:*QK[O-6#QV>$,R6DPM2,)WFP/M=,^H?&!7!IU<V
M8ZR8A6#FG&SDPK5FC1C"8 5^L$"&\Z---)S!"B+_H :[QY]:MW>_,[^H5__S
M7\-/U%^*_L7__-?_!U!+ P04    " !7D:14MF60D7K:   Z\@D %    &5V
M:"TR,#(R,#,S,5]P<F4N>&ULY+U9<UM)DB[XWK\B)^=UHC+VI:R[KU&4LDIW
ME**NI*RZ=UY@L7B(Z (!-A:E5+]^/ !P!TDL)W""*K,J)0&".+Y\X>'NX>'^
M[__CV\7HIZ\PG0TGX__XF?V)_OP3C.,D#<=?_N/GWS__2NS/_^,__^W?_OW_
M(N1_O_KX[J?7D[BX@/'\I],I^#FDG_X8SL]_^GN"V3]^RM/)Q4]_GTS_,?SJ
M"?G/Y1^=3BZ_3X=?SN<_<<KY_=]._YR4B"RY2#P+@DAN\:?@&&%,.*TS*"',
M__/ESXE2+K2V)%D=B?3&$.M#)MX'P177TG.Z_-+1</R//Y=_@I_!3\C<>+9\
M^1\_G\_GEW_^Y9<__OCC3]_"=/2GR?3++YQ2\<O5IW]>?_S;@\__(9:?9LZY
M7Y:_O?[H;+CI@_BU[)?__=N[3_$<+CP9CF=S/X[E ;/AGV?+-]]-HI\O9?XL
M73\]^HGRBEQ]C)2W".-$L#]]FZ6?__/??OII)8[I9 0?(?]4_OO[Q[=W'@E?
M\<WQ_!S\:'[^ISBY^*5\ZI?3"6+B@_]2:%Y^Q_S[)?S'S[/AQ>7H^KWS*>3_
M^!F^GI.B6RI6#_Z_;_[VEQL:+J<PP^<L>7Z';ZR_HCSL 'K@VQS&"5;,7CUJ
M-(EW/C0JHIY,K_YRY .,EN\.$@P'RV\^";/YU,?YP'H7=+ &\1<3D2$$XJA0
M)&MOC<+7F;F[[!?:9TC\4C,SB'_Z,OGZ"WXQ:HBS_Y;E1[+Z<2F<!X]<"6D_
MVJ\6XV?\[$ H<%$Q3XQAEDCA,K':41*YDS$H*T34!Y-^^XEW*;^MX)-I_&DR
M33!%BW+U2#^-#Y1]%\WK3_QRZ:?X122>#T?IZJ^+:>E"9_-)!]);J0;)_?DG
MY#K#= KIW4HSCS*WY&R.=A:6G^Q"Z_]KX:?XC:/O'^%R,IT/1 A.6^.)5P'E
M@-:3!(,22< R5S9%GE)G +CW\*VPP-O'PB$R;006'V ZG*0WX_0:]^<!CS)F
MPS51N@A$&R A"D$";F;XBRP#Y9V!XLZCMX*$:!\2^\NS$4!\GOKQ;%@$OP8U
M&,\-!$5T"HY(R)DX1#/R(**2E$LJ57<[Q;VG;P4+V3XL#I)JS\AX,YX/Y]]_
M'8[@_>(BP'3 F4B@,R<R(=DR28G^.$L$W\W@-&@AX6!$W'_J5DA0[2+A("DV
M@8"/\&58A#">O_<7,)#,(,,>XRN>?8G%,,A*/)#BV;.<O,KQ< =BTY.W0H)N
M'0D'2+,)-+S%N'^*IFPI^$\H?SB=+,;SZ??328*!4ME8:QB)CC%TD,$1GQ1:
M.\I\8MEHC'D[ L>3A&R%%=,Z5KJ3=1/0^>R_O4THOF$>KM(::XM(C779*T>H
M<Y)(J3"JBAAD!>$S12:SA:Y \P@)6\'%M@Z7+N3;!%!.4D(5S-;_>3<< QN(
MS!F%((BSR(ED'-%NA2?<"2%\D,+JV!%(-CQ^*X"XU@%RJ%P;!0<?4!<%(IP2
M*XW%751$XE$B1%GNP'$TD-I7 P??+L5%7QXZ=A-L2^@XQ1_/II\G?XP'%!QX
M;2)1C*._[3T*)21+M)1<!VJE-(?G-AYY^';(:#C[V8506\+%THDZFWZ83KX.
MQQ$&/$M 9PD%P='FR01H!UE21#E@DB6G@!V>Y'B*@NT0TG!.M#/QM@23#Y/9
MW(_^O^'ETM%.)H&*WI"<I"+2,$><1B>*B@@>-\L09.@6)'>>OQU$&LZ1=B3:
MG@%2K-_)%/R2;AH=2"4C,6@)B43JB0=TG5*F#L-WD2 <;C=N/W$[$#2<$=U;
M?#VKO1S!CSZ<3\9P'4TE92SW)):3=!F8)$YD03# ,I8&+H4[/ MZ_ZG;J;_A
M-.A!8NP9 I\@+J8(7\;#Y^%\! .#5LD9=(@]TQR]XH"Q-#69F"A !#1H(1Z^
M^N\_=3L(-)S_/$B,/4/@\]278J=/WR_"9#1(*4<G/!#N2^8V"D,P9$;S11,+
M#+CGP1ZL_SN/W$[Y#2<T]Q=@(XO_S;=X[L=?8)FU#PA-?% DB=& ^U>4Q%*-
MOHO-V2@04HG#]X!-3]X.!PUG*@\69Q-APNEB6L2U.M,ML$8=+&8#'66RC#(B
MC"WUARR3 #P2'K/Q)@B,C.G!L'B*@NW@T7R>L@/Q-@&3MV/\-A3'\"N\]G._
M9FN0E)-(=R(1HV,BK4.O!S(EUD245LG6T]S9(=DF"K:KPVH^8=F!>)N 22D.
MF)[Z.7R93+\/(&OMC&8$L@'TBA#OUE!'*"1N!8;)271UOG[GP=N!HOE<Y?["
M; (+GR[\:/1J,1N.838;2 ')<*X(Y0H]9*<-\<*48QK@-(J 8717&\J=!V^'
MA>:SDOL+LPDLO+F Z1?<_OXRG?PQ/S^=7%SZ\?>!=I$Z9RW)% ,FF8,ESJ#'
M)$$KSH((EG5UUK61@.VPT7PZ\G#A-H&13^<P&EU1;]%5]C9:HL$;M':(=:NC
M*$<S*FCGE.[L-./V<[=#1,.YR0-%V000D/"+4B0TB?_X=(YRFYTMYN5"48FZ
M!PHM',T>31\MW-@42##H'&46O<XV**8/O_7Q/!W; :7A+&;'HFX#."BYJ1^]
M'2?X]O_"]T$YKT/W61*(3*#AHX8$5<YWL[? P,>DNCHOO_?H[>#1<(;S<('V
MC(B3"QBG4K?^Z\A_&<B@I-802$*C5^+M2"Q-Z#S[* 5*0D9Q^'9RYY';(:#A
M-.?^ FSD&LBOPUGTH_\#?OHKOC,;"'1Z! ;.! ,E#*!TY,1!9H3J$'50-&MY
M> 3RR,.W0T/#R<XNA-H4+E:WG%9,Y" EY3P1P0TZR(I&$C"D)D;PR)U0NLO[
M00\>OQTV&LYT=B/8OFLB5BFW&WQ?78 S!B@/R1"C$O+@.<91#,KIKD_*4:]<
M%@>#X[&G;W>GL.'T9B=B[0P:__[+ SF^PS<.ZQQP]O[3V;NWKT\^OWG]ZN3=
MR?O3-Y_^^N;-YT]WJ=^ND\"CW]5A9X'MZ#VPT\!B1KYX?SE8EM$5XW"6?QV.
M_3@.T4),5O<(K\%%672::T-$QIU$:B>)S1R("D8SX;)6]JDEEOTL+!6_?NAR
MG?T"H_GLZIWE<B/EN&4EYUVHV]>H7#WC9#:#^>R:5\,RM0I)48#>E PZEW)U
M141DSF23(3S9M6!_7N_2T4\O@VJHN#(Y'0B]QWWH+O5KTWG-!$;<D04*!$"B
M"38:"/KBM-Q]X1Y L$B?NC9R*'+ND=,O@ [1[T:H'"+L!A!SZF?G)^-4_O/F
MOQ?#K[Y8_MG)_-1/I]^'XR]_\Z,%#"(-A@5I" ^NU*JPA$RQ3#)&<")[SAQ[
MZCQN?P1M15X+B#H(!I/:.FD :!\!)3.,<TAK]MZ.O^);Q99?"6\0&:?H]I<J
M^25+@1,TV8YDA4Z=I8(F)ZO ; OB^NG;4@]D7>NC 8B=Q%BN!L\^0@1<-6$$
M[V%^Q0L&DS:P;(ED%O^A!L.&9!RQ*@G&@P?/*FV"3U#53^>7>J#J3 ,-H.G#
M%"[],+WY=@GC&> ".<.(:'I'9@-E>-):*@)4&2*E5\1KK0GWD45(TM G:R#W
M!]46Q/73/J8>MKK61P,0NTM\D$DXP0)ARH9B;8%8;R7)3'(>0XK9/]4"H",W
MO9]>,Q5-TMXRWA\@D[D?57>:WD_&<<V5=-F+@ )A/-*22V?$,H\OM:?1B7(7
MM4X:9#OZ6G"=.HGX*JAC;Y!]A6F8=&2';K'Q=GR2\W T]'.8?5J$V3 -_70(
M,Y3B)"[?1;;_YV0XGO\-/[Y 70Z &2/0[B(^4BJM-1QQ*E$"ADNG8V(B/E6,
MM3_Z#B*[!=>K$U >3WE-8/7#='()T_GW#R./.\0XE0CYLG"/GN8@B.2,89SH
MG$N/Y%*ZYF0F2LAH0TY4J#H!Y%-4M>"(=8*TSD3?@.MUAISX<J_B'?@9?"Q]
MM\_R[^A7%G$-J $:K5 DA.)P6$ WH224\1\*+#MM[5.WW??'T9-DM>":=0*D
M[H3? )*>BDMN.071<,#8!#4.4+ABR!4D1T2*2F5J7'JRO6R=4'%''ZWSLK,J
M1JIS=32Q[YWZRR&&%<-_HO,Y&2_E=#J9%=-[BROEO-(0@9B<+.[FW)/ ."4Q
ME8XTB0>(3S5E/R1/_SQU_?0CK "QSE71@!5[BZH8?QF&$:R7"LS??(NC1:GG
M_<MDDOX8CD8#3Y7A&EU$YDI2.#A*O+*14$TY#T$PJ9\JA#O$TW^>NG[Z%U9Q
MZ#M610/PNJ;;2>639Y:82!6ZB5&2LDY0.M)S"89Y5L>SV@DFG=?,58#)7B)M
M  HK$0P<\Y"YL21:AP 6-!+'+2/."$6IM4F:.EO5ZOD]]2NL5H:PDSP;R&R^
M&_HP' WGPV5.8GF/Y'PR0JG/2E0Y_WZ3^S7,4BXX\9%K(B--^)-%G,N4 P=I
M )ZZ*+X_3K:EL-_L9O6"J"J*:L ,W>;KBH4BI.1=(I"]+'U@*0F*!Z(23V A
M)I#UL=9$F50=K3\!K7U4T!:*[A]:R<2-]@+*9 /DA$9!;(B&2&6LULXREDUM
M,#55>G>PNA^'SR&R;P!%5V43'_SW4C-Q=5A)0\PT!TF2HKBV)*"/+]#;=UIF
MP0)XDY]JL75XR<I=>II!ST':?J1BY0#1-Y$>0CZF"WSN RF5/F-,9,9)%*4F
MPEM-?+"!""<UV*RDI'5J5!XEJ5^/J1Z0.E! $UBZFYZ_XNC[-3_:2,\DD$Q+
MIS*IRXU.C#2D+X?;D8G G[KTUM7AR'VZ^CW0K82J#E71P#[WYN)R-/D.\!%&
M92+NAK6"D6H*2EG"O(BE6;9&?R!DDK/,S.*/G-9)#SU+6K^GN)7@U:U"&D#8
M53[^[\/Y^>EB-I]<P/3!JHDA9!=*TV7/].J T5N3R@U%GST5W%0JM-N&NGX/
M>2OAK'.U] @U^'I^+:;OOTZFORY*)<V'R6@8O[^",>3AO,3,OX_+,>3IR \O
MRLOU#^F_%JM:G9OSR0\PS9/I11E[_0IM?#J93DM3T&5!S\#*+%FPD3 *N/RL
MH,2!!J(X9(?VG<I\K[;JP=708]+;[RERQ^!M5M$-V-D-.X7-(H#VABBI</D*
M(3!:<ID$%JW55,3DZVS=>^[5U4Z:*]G0 T7>0LY_,O[R&:87KR'</BGW20GO
M8RE!!$5D5HR$)$-I70K4")>RJI1UW4A/,]%I-TFRPV7>@+E9UO#<$LTM3G*(
M2><R3R>5 E;A%+'"2@)&8O #VGI5IR;A<9J:B40[05!'LF\!19N#Z5L,.28D
MR\7Q%&59B)R)IQY(@F08>!DUK9.S?Y:T9L+/;C#5J28:@-;K]6/+M-H+^.R_
MW5XP@!N_XAGW_!+;6/Q'1$]P;0B2C(VX4+00J4[UYS.$-1-M=@*K+K70 *AN
M43\HUS,2SX'H#)S(R-'+\]F0[ T&>\I;6O\TL9GHKNOCPYVDVX C79JO#E=7
M?DK$.1D74PKC6%C123@>=6D+8<O)E?,DE&ER.>-N'2#J$.H Y0FBVG&IJ]4R
M=*62!LS.0PFA/5V5GWXHLTA0:_/Y=!@6\W)B^GE2=NV2WYN,\!N_+ =2P.PF
MYK4BLI2])D+Q5%K.4XQYG2!&9>5"*&6L=<*[;OEHQZFOAN$>%=\ [&]UM%XU
MV'&0;&(Y$<-TZ5QK(KJ@3A,N/,]91Z-3I:9']RCIN^5:?ZC88&3W5E$#$#M)
M:5F8Z4<?_!"]U/5%DH$2VG$-B0AI&)'91Q*,H20SQ9C06G%>Y]KJ(P3U7=+:
M#."Z4%@+N(MQ<;%8'O$NLSEEP,,4SF$\&WZ%5;#T;C(K(=)9QJAIP!VG*7)%
M8BX5*QH$NM5 "=6&&>M0CJY./XD=">UW3VX)IQ45W !^/\+<#\>0WOCI&$4W
MN\4NAOS#."PM8B [$3$2Y*KDBPP0*Y4H=^XX6"E!^EJMXYZCK=_474,H[5B-
M#0#S\Q3\;#']?LLET>AM.^HXB48 D<:',GD/5UK0"5])KRM5,#VDI=_D7D/
M.U!-NP/-K8 VAB\%W)\KAN8#II)3SH5RD1U7#,V!V*2 ,)2+=EF&#'4RRP]I
MZ3<_V!#>#E13 QG&Y_(-@V H,&2*1"ASRW7RQ-$RL]CYB$8Z1J?JW$UXCK)V
M#LJ.<F_J8.5T!K:CCDCXL-3&.<R'$</5.ZP<-B_A[A<?87C"$YP<=9*"E%PY
M4R:LE$OD+B?BO"LYE2Q9-"$P6J>H_QB3%&[EC5#<9]/E,]/2$?@ T^7\NH'P
M4;*0([$>I2!S:0@3/'J> )3KE*#6??0MB.L[ =@Q?IY(ZW6BG@8"@P?C$4\6
M\_/)M+2,&:#G8(S'N#OF@*PPHXE'TT3 @L_1Z4B?'$39"=+N$]5WQN]X"#M(
M'2TBZ^ULMD V,CJL.92N#Q'7A@P)'8H C)B8E$9W4ZM*=]<?(:COW-RQ$;6'
M&AI TYW(>,7(0(#C5GA%7#86O4>*D8^0)?P)U#D,FE.L@Z0-Q/2=.ZN,HD/%
M_V+FFWWZC/_^]N;]YT]GOYY]>//QY/-;_.W)^]>G9[]]^/CFKV_>?WK[MS=O
MW^/+-^_./ATZ FWGQ]5Q] _CNB/W?Y7^OX;R-6YQ7_.:,4,RT[K,9$!GRBTG
MZF&H"#0I5VEVP2,$'7Y(\!7&"_@55_&FZV;7+=1*OR3\7RKG(-)8IQ,W1*:(
MUMH)31R+GH1D($N!8;FJ<Q-P#V+[#0*Z0-'#\X"Z&FM@?[TN=%Y? [LI72R#
M=&@9:4J#*!.QLR?>6T8PGA&"*U#H?=8M-;]/4K\Q0 V =2/]GN^:EM:BDURZ
M_<W\.'V"Z==AA-FGR2A=+Y#7@(25!N^E5&&<3BY*OON?RY>#G#)C/ H2/<<%
M@QXI<4KA2QJ9E@I7T?W$SL8;I(=1T:_MZ@@&DUYTTH 1^P3+(Y*_P!CE.#I!
M9M+%<#PL,IP/O\):J@-F79" !EF;8I^C4B1P'TBB&/,(D#'$.D?PV]'7KWGK
M%H,5-=-$!YK;B^?D_N+)7%-K E&Z-+HT(A-7"EB$TX$R9;6NU+WA":+Z37;4
MP597.FC @+U:S(9C="%/)Q<!X_C"PG6%_AQ_F@W34H)%73=W\D_/RX]OQ\CY
MHJ0 'OF3Z]MK;)"D]T9:16Q>WL<N4^L95T1%%;,V&+NS.M \$H/]9F/JP+Q%
M;#2P9!X(>Z"<9MR6_C\@.0J9 OZ4- $NP8D8"GO'"5CZK6NJ \/#Y-U Q<@U
M S?EI@.F8\REFB\RBML$SY8$H1+QR86D/'CO*W>*NR&FWRVZ:G2[I\0; ,W-
M[+(5#U=56(,$B868&$&[B-)0Y> W)B J,1^8XAF@3A7E8Q3UN_75@$\GLF]@
MI[JB^SK8"3XX[@RALDSV 92)DYH1YHU)25L779U!S_<(Z7>7JH.8_27=3@WM
MC;4LB>=5Q=QO,#^?W)[F.: N1*]$P+U<ESQSD,1JY0E7"HR 2 .O>3KR#'G]
M5MK6P5;76NDY;?L7/QR?C3]CR###9Y_EW^ BX!>?#R\')IJ@RVC8,@T60P%<
M,A:B(F4(2 S1>';_8NG&E.SC3^BW_UF7\.A0D@UL58636<$XS,[&;[X5WVTQ
MG)VO*@Q*AZY!B%+S5,[]RT0ZR1DEE@E'=&8Q>J-BTI7&(SU'6K_CM6J8G&ZU
MT0"\EE?_WD_&D[N!P=5VC7]@:7*:V  464J1>!%9Z6F/X228R'.=NL.GZ>IW
M(%>5P*P[/32 JKL[\RK1M4"FUN'G9#Q[!7DRA>NF2S##Q33UJ+GAV$^_OT7)
MSC9?MAE(HS)CLD09!L-5I11Q2:O2]508KBB7MLXA>$6F>IXL5M\YZP\"360L
MUBRN5_.Z$? @).V%X(X$ZT.Y3\A($+B\#<\I:BFC-G7:+CU"T'8H?%'E0EV(
M_D78TT%&MS9S$XE6$MU:ZR/!P ?7A. V":<RONK)+&Z'JQ=5)=2Q0IHQ4E<<
MO1[.XHHI2#<\7?6"N'LI]B-<EF/>\9<W^ ?S[P,AP#A9QA;K,L78Y$2L%9D8
MSUV*P21*Z_B,G;&P'6!?5.*_'_4V8#J1J1O>3[[ZX6C%UJW+&.N+L*_\;!@'
M0H,4MK0Y$08][1AL.7U-)'J-[H5+QD&=/C8[$KH=1E_4Z4)-535@8;=G[_5P
MM)A#0B]%\*R$)KA=E 8 Z.(Z)8$(D:U)4E-3:6K6SJ1NA\87=7)15UT-X/&J
MI<[5?=GEHCH9IS4[UT(4-DL3C2"6\5@2IH$$ZB(IEVB-5JE,-ZR"PBT)W Y[
M+^IDHX9J&MB+-[-UW=Y"0J:0/$F,84R6+">E94H9%) ]I^"DJ-,[\TFR^BU#
MKP*$K<"VCU8:@-CS@1FRN>1PU2,@ #(G/:Y2[G"54J6),\BCLL$ZZR2CE8S;
MCH2V",.](+)S(+V_OIHH2]\E\+K+JI#*,<$2\5"N!J,TEYTK"%?14(%QEXS]
MQ]&[@[1:GN=8(*VEPR;@NE&(@\Q9=HY&PE)P&/,#)U:7SG?99\F%0V;J-(S;
M2$Z_99GU8':X[!N,*NY[*@H%D"T'PC/+1)92,$O!$)U%<L&#I[E.2?@SA+5H
MN^KZ>8=HYJ5X>FL>5\98Y^ M^@>$+V\@15R;RT2F"SD;DYG0LL[8MYU);<O;
M.P@H^_A[>VNMB2UT1V_A#K,I0M+":Z(#1?<V1X'NK41O5^BH:<3M)!_C%&\G
MHMNRG/7 6D^33<#V$4$.;. R!LG0A2E5;?B">!0=<10W'>6S$_PXOM\NJ>:C
M>7]=PJT+#33H =[S99:5;F4MC2:SQ?3653@;O)8V1)*,I*5[LB+6,$F$SUQK
MZBW:_S[RS(\1O-TF_2)*IH^IN@9<Q[_#\,MY6;5H/_T7>+\HQ>%G>=5,[6PQ
MG\W]N/3C6!\S*J8$2$42H%2E$.B I)!($MY1D9T%5@>7.Y'9ELM8!3B38VFQ
MB?WX$?9N.QFWN1P(9CV5P(FW'AFD*1/+%7(99!2)2V]#G73ACH2VY2[V"-1.
M--D$5#>,#KIRBP^:I\!Y#"SS0#3-RX$;H@QT+G<I@D)/JHBG6M?C&@QM9Z-?
MU(68%E3?@$=QIUAD$!SU*#='1*()Q8A1H'<^$>]+&P81M5-U;F3=(:-?CZ )
M8#Q5TK.3EAJ V#9#VG!7&Y;;K['T"(;7L/KOS>$$LL>"\20$4WIZ149L&?E!
M6;F8EB&E7">4/YSV?KV&%L%\9#PTO )^G4S1PQJ?+I"F<?R^O/6+[*UZD"U?
MC59(2?^U6-T*OY;/)IVMIJL,T#1P)J,G+#'T^ *W))BL"!5, /6):ZA3&7)4
M-GONLGED#&^YA/H'5 .K[0F;-\A1VI@91X\Q0>GB08DWEN'66<ZD'1?<5QMS
M_1A1_>:%6]PANM+@BQGWM6OO_"XG@AWV[#9F"=2?*_98"*H51R#:1#ACKIR6
M&6*3YR1""HGSA-YXS7//S@<+;#PK+,TCRLYV-L9?7TYF?E220!L^>+U*%;=9
MEZ/#(#$PD49;XEDY1(S> 01\KJHS8*P;^ML</[ +UAXTN#V^7E_DO);3OYZ\
M_\N;3V_??_KK"1J:LW>OWWS\].9__?[V\__IT,X^]93Z%G5K'KN?R?C$D%!+
MHV>6I3+L0A/)T<OT92XV55I'HZ5SJOI0QL?).WR8\?HAGXOW-  &X #)0:>E
MW+CBCOARJY\9ET.0B655QP^]2T<SLQ8[PL7#V<1[2[V!0.::^I5$BE<\&9?6
M<"??AK.!IEZ 3X% 1!]89IM)\ !$92Z=R65J<V4(;2*K$43MH>_'H'.P\!M
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MY /^Y!-:;ADCE\(E=)'K'(5NIJ??"X%'AUZ'RFD 8L^)[^T<+F;OAF-8_C!
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M1_J/,,4LT<"CB(0Q8Q$9",R0)2,0I5;*49#^Q5U:>'PJYLF5FSU[NWF2W/4
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MT0[7\S/ V4/H#4!G96N7!O:J9XM5,41;2G2#))(*2D(,RQ8N8!U$RRHU9WI
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MKQ&9V7NC=)0L\SI8/X3J[0#]\IIQ'DV3317&W&X]NIC&<_3Z/TR'$4Y&R^_
MMZ]6;+E'$>?+;-AK2(LX7\KEHARZ#KQV*3(.Q#J#B]:46= :+*&E8LFX'%BJ
MZQ9WPL9VR/XA>G0>2==-C^@L<\:7+?%*>]++=5^&?>9R/O)%W0WCW(;2CB9P
M;GX4[M;XB\O)S(_^,ITL+F]"+.-3+!@DVF8@TJ+A"]YAB$69,F5F2M1UK@WM
M2.C!<RCN?.O;<1PMTG#\93,5FR;8 P\^)/1F>(QEZAJ44W,P1!L7-+=&!U5G
M(LJAE/=;T%03CP\F61Q3QR_0-'Y>W2GORD!^OG5%O:*9W$1U3\8R&6MDF5>0
M+:Y3J90D3CA%%#"?J,N*0AU__\C&\F::PTY+"G\]N8!/J/]E"^57?N3'$3Z=
M \S+7-Z4EJZ+']TLO=G-VI-9"' L$.Z6%WJY)U;X2!)$=,R39E[6J<3N@=F7
M99)W0?WC<Y/;1-(+M.*?%A<7?OI]DC_";('XGN1;F]K>L^GW?U9M^[\SOWUM
M#AC9<<K*S%4:2U]X27R0@AA@B3DF0(DZY4I'WASV6)NOON^T^E<3@G(P)E"I
MBS.&<:I0CKCH.4G"6NIT1,KJ5*(<B<$7M@GL@.[[FT"+B&G@!.8.A\OA:\,\
M7.5Q5G.^-3>",D&<%A[W70HD6)J(,RR"T3ERY>I'G \)ZQ>X38+IJ4#T0,VV
M#=3UJ$">693H#9)0_"X9!2=!9TV"I!Z%1BG5=0Z7GR6M=RO;'1"V!]D>6FD#
M9IOS-,@FOI-???_D1[">)QD,S\DD0U0(AD@'D7B;,\& 1$O\I8BJ3IW<+E0V
M"[Y] /(0?G6TU0 2Z^\QR]5O +P-*A)-/1#)HT*?*J)/Y92F7%-5J];Z./SU
M>]WO)?@)#>*L@=6W$X.WYA53&L&ZX$@4EI;L/24.T*[E+%)45N<4ZS1:WI/@
M']V/WAU[AYSG[ F$GB^X?IXNX*_+--AZIZ11)IJ5)-HI1:2F&'&[C,&VU@GW
M3=!1W.N=M?&RZ?WO;<@3J:7(24=2[1$1L^E\\&$Z*04;9]-/,/U:BCO**K(B
M KAR' F2$VGS,@7/2'3,J B! ]_*M.$#;IDU?'7?I#U&0;\7AUO>RSO161N8
M*^F_-0>S]0I,*6:&BX3D@'&!##(2BW(@X!/W(%S29JO^SKL [R$9_5BO;C3[
M$"8'BKGG'>O#R,_S9'I1N+AU2+/FY\K>!IXE5Y8XYAG&>]F4A51&%ACM($GO
MLMYB%]OF6;UCXU!U3BK*MO>^O!^F<#%<7,S6%SZO6. ^:AUP[812(VZ$*X<)
M)?>5'0N*0[I_M+,9'IN^O)^HLQ(>#I9>S\;B2@XG7Z:P&JM]Q0-P8%9DXAPK
MW9T8[K2,98);+K7 4T3';PL$//;]_;@K=4#0B0P;".OK.W'OKJNMDT@ZE( S
M^1!PB:"U]$910KG)*DM%F:M33'1$)OOM(=*R2]XZXAI8C.L=Y>9\WVO&4S*"
MI"2 2'Q!O!.>4/!!) , J4YIXWU*?O2LV)Z0F72HOP;P=T=D3TOLJE<([F_2
MQJA(IAPM@?>.6(<R,THX3G,4.58[\=N1UGXQ?!@VGLK!=J^H!J"XIG_\93UH
MZ$9N3*(_%;0A+ ETL)S6)  -)(08M%:"TEQGCL&C)/WH1VK=&,=N--H -'=8
M?*>3V7QVELL%P-FGR2@-C.4R18P-4Y)I507M:;1$ E,Q)V^%.T+UV&Y$]VLW
M.X+-_@;T(!WV'.GOPN;(#R]F:R$/9'(Z9>V(Y+3<O,Z"6 D>]XV$T:UT2MA[
MCN?&3,"^S^_7HG8+N:/IX669QK_ &'\:+;>HB^%X6"0\'WZ%*\ZC1O](<"@-
MAI!S< Y761GQ))+D40:MH$ZRH#L>^CV>Z]UP=JGA%K -^.0X7.D/>;J83.?#
M?ZX*]S:Z30.NDL3UF8G7W*[GND"D1*@$1H%R4E>Z>[(KJ?UFK2HAM:J^6@#D
M]DOQOH0'DEO&93:EW409'FDD\;BE$,UDQA>1FEK0W)_H?MO#]FY.#])A SV=
M]F%U%=N^F\QF ^E,,L%'$ADKZ9*0B*/ B8G&9JN#SI7ZCA]&]X]>HM--;N"(
MV'A9*^'M&/<+F,U7S XTM=3QP ESQF!,4,Z7-=4D.6X#MQQ_56>P^]XD_^CG
M84?'_P&(>%D^RQ6C5]L=9/__L_>ES4TFR;J_*./6OGP$NIDA@FX(8.[$^>3(
MVD#31N)(-MV<7W^SM-C&EFTM;^DM]3TG)C@T!BF7I[(RLW)11D@#A<)>BADL
MW;!HB5V)T3%+#(__TG"/YG$]EK\Q^ _!Q/[H]ROT3_-GK%/;1G'<ZR+3#;<I
MF:@D]Y!$'7(L8@;'@@6+Q8N<D@M^=.M_E^!Q1\O_#>%_,!JZPOZV8[UQY5Z3
M&K?^E9>YS.9Y]1<_X5\7QB81O;1@F"")NU1?3S5=@ZX(XI\7(4_8:;H_ ^..
MB#^CLW%RM/01(#SDB?CXM90<KY93FQ[^_(+9DCFOC_LV411$I$-(AM5\JE?.
M8XRFV?6P/[GC[D(^ZP,P*!(Z" IV.-"+WS-Q6X\RYE+0209<.@\JNEAC_=K$
M&)*G_SDNVY3$[4/EN%L5S@7<S?0^F D?87[<*UQ\>7TY^[/=U+@'WW"R67%/
M\S;2A#@M)%>.<"LH6@2%7H(S2 BVN?#@2M"EG.[://\)<3+IP"7/X)WD%)-+
M319!"A F:S2"K()V#0WT_TZ(.QC=8TV(VP<QW;@K[6<TJ%*,]0A)*E?C^P3>
M& \ZH14B%L%5FP>OCN;0G'%'P0'0'FD.S1XXZ^#T[<7@G:D5*7 CK(U01+2@
M-"KP2@CPUOG"A56&MUFF<B#!?_?SL3_V!II#LP\0>IM#(PVB]$: YE[4"B4%
M%!-EX!YS2(F9;,HSP<'?9P[-7HI\:@[-/E+MS0)N&5]9#)-TK"1Y>['.#S04
M*1>=0.L2LV 4G;,35,H<.*'VC-MDCK_QA]1LWT!='^$L YEX;R%P,OV*._I=
MW>):&^&<8B[$4[3#G-^$VKV L/>$VGVTT@?,=I]Y&DUB=!PEQ*@9'4\NZ7A6
MJ\]R2=EZF?W_3J@=%"#'3*C=1UL=(/&4B??,8PSDJX!-Z$%E6><%ISK'A!=M
MG7,IMYFKV=LPC3,NGCV'',%AB.O@,-;'AO?SV?=)RNGECW\MZN+9F^+A%_%J
M\GVY)'D[UQ<6K;8\(AC4M:[2.W"UPMA;RYP,3J=&B]F/(OOOGC0X$(RSL9#1
MZ3%X,_V>%SLQ2P$Q:EG=2XUT 4?A2<R>09T0KUUF.33:K7<4V7_W2+/=,6B#
MC*[WN:T'I'S(<?9YNE3- 4_N6SYDN%?UYR@<Z.%\_36U%N,5*;P^'_Y[<O7E
MU?7BBO \OWU2]#$NY\>$3/ZX(BF QZ0AREJ)D;/.C0KQ=R1PH"E<CWW-[4I#
MBU$95SC8P!"410T^6PJ($D]2Z!1%;+,I8E<*NYAX-"B>'IFX-:RNSLQ<';Q
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MY357D+*3T6BAH@U-CG@/#\@!43@C&3 ZM: *=Q#(HP5;+%>LR))LLP;',W]
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MM9X*:SK30+!HZM+18&2;LWX*:W?;\/(>%U>_;.83H\DFA>PA:%E %1G >:7
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MS'#JO0^<@V4]\A*17U>>[3^7GNW'//\^B7DCEDW'I(BR:!_!&*RI(<[ )>X
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M@/*"6$ 48!7]>X<EZ'QO;,O6RH='/G[<R5"G@,I0LNW 'KV:39=!^$MBX:'
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M[6,B1&_(/427YPE80F"^4"67Z!-"J4D,5:P"M(E"CEB$*R):E;N!;"5XW,Q
MUZ#=6Y]G"=O7L^OYA;*)SJ934'*,H- N/2,)OH3";9$ZEC;CC ^C=]Q<0\^@
MW5N;(Q=I/,YA92K>2Q:_*/2M-VRR&(N3B@&7M7>X, OD^R!=*TH@DQG3_;3_
MUGJ.(T@8=Q5S>QR>4D-]&\^:1I9*)%Y];#2>N'%,@(\J@]8N:Y,%1M6F9VB
MW+X]7Q VT,Y@2?X6&=BWL^EGPO377W(X9/WW3_]\N)SHXU0-E-RL'[P%,4'2
M9859 !>8R(0HOJY0E\(SY-FZV*;N93L]Q_=*W_W4VR5[A>QD]L:#RS6<QQS
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M7$<W3^+K/JKEB^0J72>-%4[5D>4BDW",@A!1@ \E1UVR%;S-J+A'2>IIU."
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MA?+:8U#6<> Z\\J&![0I@(\R\.A-)%^SNQ:%DY<A'6>=CI=\%P *5[=5 .L
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M^$@^'P_,,\6+:'.YG4O[P#X8V*5]8!^!=^ 3;2US-D7;$K2$)+T$)70&-#8
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M#SD_Q3/LWH3W%%X. \13:K*+-4./=L%:R8Q7,4&*@=>9(0F<DG31D_,0!1U
MDSOL0#Y]_]Y@8#M0]AVBZ(XU_Y"K-UHG"J_/S]UE%._S?#)+_$)HX;RDL,CQ
M5//+R]G614.B'WCN- G5G0!J>Y+=D\O6 H\MM=B!<W=W.]QM(:'6@4)S7O?"
M.0TJ<0=!2 ?$0/ L&I98F\7)6\GIM!?P"(@=+_6NRS=?S;Y^G5PM(W.<)CI!
MM3@^3^,D'U*C^=2G#5>(N3/- U5;WOF^%_>^;TL!7BA6<V2&P)8DJ. R8/2E
M5@UK@5RJD-M,'=V+S.,CS1V^[!,IX"7]JS\N0O;)&F&!"T.Q>:X5'X5S\+'4
MS6":&]XF.;8?G>/&J>UP]C!Z;::]<[5VRQS2P#9O_9DGL7S;Z!_%_M6]"2;2
MK9BLLG5(%@='GPDF!BT](91AFP*XD]J_7TO)L?;_?,B3*7UPC:F7*K@]-<DY
M)ZN;X<G+J$4H#C P"T4'Y5%XE5IU\SU+VSG9N7WP]*#7;U@M=1 $?(Q?<KJF
MD[[<(5+',,W7:Q(_3!9_O/Q1?Z6XG#[DEL68 W<\6LB,U8T"28%G(@"3BEF1
M%84_C29:[T_LN FZTR&SM1[/]1I^D=*D?@=>OIF6V?SK\@L/;QH[])M.<F7O
MSNLH%WE160CN=7V&I:C9^ R!XEK(2JFL-,I<VKPXGO0BWQS$>D?0)T[B54ZO
M</&E?C/]O[K,^#M6Q:X\K LC TIC'&A5<PG>*W!9:# *0Y!"BN3;1#)[$GI.
M5_P^2'O,D+;07P?W_2OZRDG-M$\N)U<_EM4YENZ=PI6C:Z=6YP0=P2?) 96-
M66J76<0VY_(!+>."K*GJ[T?,Q^FA.R2MBVZ,1^2"U04P-I-(V'(SL07CK-7.
M,B]9FW&%VZ@9V60=J>$G 7. N#N S-M\11]&'NJ2EW4]E7!>J,1K"ET'4(QT
M&R1&**P$IH-.#VK!AWIPV$)-3Y Y1,?W'QN.%7@/H-G6*1HU8U9%!9Q).DG2
MDND-=09_<G4WNG"EM$D*'=R!W2S&/.6M=;0N.L33^I@ID46I#$@D3U$%#% '
MG4/FWB/QH*5K9(;.I3M[+SWOUIV]C]![@,YDFN\9TU(LTXX1\<LQTRXOB]PE
M"<5ZDHMBF!KM!'Q 2U^0.43#]T%SG+@[ ,QS%GG[GZXV5A6ZDYEF0)%L724M
M"@1#7@ WAA"!G&[K-L ZG.9QZ]-.>0^>2*]GB^#U:944\"AA2::Y)#JRVH$W
M,4/D+CII9'2LU>3 PZD>UXR>"EF# /H -8^^!^_R$NFC\/+/R=67U<C_2<V7
M+ZXF5]=5R3>C0+PQS&=%$+.>HJ2 @)D%T!A$TD9F%9Y[+-CK"\\1=H?H?]9:
M&6=@-)=5A&]OR@E32,;4P9Y9QF6O!X7F/"A(*1<;1"D8VX0>^]$Y;KEO3]?[
M$?KK )UWW>I-KNDW_&OR]?KKR]E\/OMS,OW\"K_13ZY^7$@O,2.KNY19O52R
M (?D<"-ZQ34*9(T>[?:ALF_;>0Q:GHB(!E5=![!\3HP7J(E\%3QDM+(R9< %
M"BHQ>:U+K!79;1KRGZ-LW/S?">$WJ(I&]@0_X5\?<LQ$>JUS?/%YGI?]Y.M=
M=+-"/_^(W^D\+:YF(;_'2;I $I3P"LG%B72E6(,02N'D[!27LO2H_2X+DO?_
MYG$#ZQ, [ 0*.=<"ICN5AC<R630I8'KRFTY2P+0[KZ,4,"EN..>! IODZT2)
M2-9-L B6+E*'+"G/V_CI)RU@>K%87'_-:=WFNZ@K4TC6%YD1JRY(,+'.@6;"
M -;!&B(&S1 5TZ[-B]MV>LZI'&D?W-R_<@?01A>^W<W!7I50OYN^NL3)URJ]
MEWF:RX2ND6F\KJ2M.H#7?%^HP)AC&LF/</6Q.G (6"S8&+E@.3MR9ALY?0>2
M?$X5Q\<@\S0Z'=E+?#^[G,0?7V:7I+4-4U6N2T9ON%OQ]>M?W_)T46^QFM5*
MGV:KOW6!O"CBMX!5A56G.(+710 W(J00>#;W)]=M=1L'(&5</[(]-,?0V-@
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M_/IN/(Z26Q>19\UR+5XKY"\ZNE.=P 1"V>2LE5RJOT%N_8$"5K4JCC/N;!)
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MQY(]4BB_V_>-\[S:!BM-9#PR;GZ;T9_BBI\*_C4'+,4H4.<Z^D"#$A[!.:,
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M4KU!<N%,%+]VO3@C)\PH< 61]MHH=<*D-6\T1W!_8KNR+OM@9A?K,J2B.@C
MUCR]FB]7=]B0# 4J8X%IPH2*&,#QHD K,M+))*55FX*?1P@:-T<T**:.%_@9
M;%7OPJ(NFA]X>!O81QXT]/;U-*5M-C+&,(GL&812^U'9G,A<" 5),+0R%-)U
MF_M)+3:R]3-_PV5:3+]736P/?)+U'&V$Y"@&5,5Y6B.J@.9.6%><-*757OTH
M45UM3/M@X.&-Z7C!=[ !O:=EN;C=L[96*7 ,.I(40(G:K0MKO3=%!Z"R%Q'3
M^ABZ"7@>HF9LU RDZOG <N\0.]LRA92YRDHCQ"0HH!2Z@/.8H8A,&VRP.C?J
MM/ P/>/BYW@]/P.< X3> 736"^IF2.I5&2LCI[UHO4E<UIXF=4'1E^BLL)P'
M'MJD@1\DIR_@'*+GAWS?HX3>!7(>,LBWTN R!!48@^B2)P'5T0^UZ99E$HT0
M9+!5/*'C\W:OLJ"&$52;;6Q(;70!KE5]V/ORBMX]7;V_7"U785;/0C:%+1/'
MC<P8!(2$]9"E+AL5)- 2RH)[+7VSR.%IRGKTD@Z$P3V(#:B3+@Y(GYM(/['%
M!*/)-0@\*5"1U>1\YJ"9CH8BDVQ,&P_J.<IZ-&+#H&Q0G9Q!@NC#8OHM+'Z^
M+V6:-B)]>%+]'JFB)QXY=-)H5^H;G8-@]EH)!"2MUXY2' AW9'],9($E(4IN
M<\_W=.DCGS"9X!WH(AFHQ!.X$#.('*3FR@G5J(//N:2/]L' /NFC?00_<O>,
MZ\LR?^#\RR)\_SI-X6(=WVICL2BKP,A:&R+B>@!U@>!L0&UB3FJX 2V/DC$V
M7@92\GQHB8\-&_QREX5M;.N9H%V6\SIJDM:4L;3%BN"A9!U\<,%*NU/HMAML
M'B-CO+8; ZEW/K2LQP3,ZOMB\L\7D^!]\IDCZ!ALS=8'B(S6CF?9:6>C0_;4
MB+DEIO_^9?[C?]3';:!1/UO#8@.(S6M&5/TPBIH?+K6QE?SF[<0K;3+W!K25
M6,]@-3A?Z#.?BM0Q:<>>NLRUDY+?O!UO D\#)>\IM;&5_.X_)E*77(2JMQ9K
M31BKX5J*%H0*KLYP$)B?JFS82<GO_F.\D3H-E+RGU$94\KK7Y>+GY,V[B2CD
MX\@40"?!:E:&@T\V@A2UGETE%N0NBWG[Q(VJMU_<:/OF?>/<"QA>X0=*<.R%
M_>K%A)'5H=W%0K U02+7K<$< LO11\.#()P>N[!?[;9%#UY^WVAA[RFU+A+D
M3Z?@/-,$2_(SC"VI;D$U2Z82V""<B9(K?7?:XO_OIR^'Q((MM-$-N'ZM]_R,
MBV_ORU5[]XG/UB6G(R0M*!#"4">>UL&")J>0N!8ZMVEJ\CQM/:8;#H3"#G6X
M1^BE4Z1=5Q9_"#\W)^Z7.,' %$;KH%"\#4H5BJ"D3+7>5&$]-C6VS6CS72GL
MT;"U0]W1.NH">\^<9P9&MI\6%!3BC-82N7R1>P7(8^$^\NA**\P-<,;<[%)W
M6ZP-J),S./U[-?_V?3ZK"VA>UM]Y_==WG"V/KA9_[KE#GP/NQ4>;PT"4PEF?
M$R'#!7+@L192J0RY1)3U^AR3;9H,#GL8^*N=K1<D)CI;[Z(20&&,V=0%1<$]
M&(*\-D(1[MOX\O=I&=NW.ECC]ZHWCQ-S!]O7/\-B6@.7&P921NZ#]1"29M7P
M2@C&J=ID-R3:@H7/;<Z*[Y$RMC,T&$R.$W('*+DAG+EHE Y(^JL%SYX+B(8)
MD"XKY90+*C6^R3:VVS(8*@X3ZN%HF*_"Q4G<D:N[G-M-_,K+GQY?D_3\DX=V
M2?;DI8U3PAUG,L< .3M6;T@F<&0CP!@"F2P!C3Z?"V[/A( ?L29A:1&_+[]/
MERE<_">&Q<0&HX)(%H3.M$(XJU<LM*N3)H2Q!@,_8>>'W6CNRLG9!T$'1>['
MJZV+;6ZW',4[6N:?_XT7/_ ?<S(<RXF09.B9+, #!94*N87H2-H"BS,D<;3-
M2@@/H[@KUZHY.(]5V1E!LRZ[S_^>3TQ@3@63P=8V+2IB!')4&'#-E$-'2S&U
M&:FW)Z%=>7.G .(A"CHW_!&@<.*DLRF1"".*>B/;YUI-2SZN#P934DGFEE?6
M]R!UW":$8V%P;R6=&0I_GU\N)E%E"L0*IWC*>5 D/G")%4CDCZB,)JF[#>='
M &&E=-P^A"-A<&\5C=QT_$G>/L]?XH<PS2\*O>R:.U]*%%(DX,(6$B6K%PN\
M!&\L2T&C+OK."?>#;7KW?_.X4^(& -0)!'Y&%FT2M/8I>PTAA'HDKQR0\5:0
MI3"%QV29.(.CZV;SBT:P8'NI9+"TW5!G0K<R67\LYLOE;]-"5.$LX>:,]$:4
MF1LI28I9Z-I0H(XEJYUAN:DW<C-Z94YQ;K0KO>/.ZQ@0AB=05^_V[\]9KCV+
MB3W,K_]*]*O;\_MD4.F<$D$F"E!:&P@L%!*N=-%KG2UO>9]Q3W)'[CQR ASM
M8T$'46H'R'V$/7) M(F>6^ \9J (RH'/S ,S3B+W$E5J$W(\0M!.Z/-G:Q#W
M$_@9%/,\>^(TN>._#GE^-N&G/T&[R\_U&=K_&$":_QNG7[Z2I0D_"#Q?\+>M
MZ?D85AAF^>JGB_7IQ>UBV*./*H]^\=!Z&%82;0XZZ[&0MKH E^1,*UXGR&L>
MP92<66"%<=,J7=.N^NI*M"_N"WX[&&0BE%5*!0<E*=KZ+";:^GRLUSN]8I@X
MSVVJSO:EM*M#S7W0\O1F,K"*NO-.[O#W\=XBYQ..2:&I'<.45R3,9"'X0OPA
M[9\Y2F5<FQ/V?2GMZNBR&02/55'?C@X%'A\V[1#GLT]?2?"';+/W'S+@EOD,
MA0-M?Z_#HNJXOFK]DFM<I:@9UIKWF.J S^P%.,\1I Q1!>N5E&U6XV,4'6N/
M[C[WIE6[JU-KC>$0R#<APZHC.)<CB*09]YP77=I4%#Y*TKB;W""8N&MKAA'_
MF1F5PP>\//:HE@:FX>"71R$52M0!A:!8F4E0S-..@B6 X<R8R)F+O,VA0BLS
M\RE]Q7QY@>_+W3>\#,MI>C'+OTTO+FF;O3,OHE[,3K0"R)WCEK96I%U5,DN"
MD,F()()C;8S0@01W:J+VP=-=$W4*U77@F-^P^6*VFN;*TO0'?L)4DR137+[^
MJX[KP_P[2;W>A[K<J/6^5&XDD#R2ZX>:G- ZP(_'6DKD$'S63J7"K=5MIAD-
MS\NXSGUC7(^B\#/;LV])8'XM@>];"1R1DSOL12WW^_TY;>T-*+1.NN+( 5R/
M')6.;*KQ$)QWW @?<VASTMO*&W@S(_EC%?UF<:V'G]*+KJ>?+B<V%!$,1>PE
MU@*XPCQX77</N^YTH&CWV*FWY=X\/T];IWO\/BBY:PL'5D@'V_FO'#TX8G?Y
M#E?OR^?PUXO5:C&-M.:K_S+_B-_GBYK^>4U_L/HYT632K?(&?%&\IG@07/5C
MK..9.R.$QC:K;S 6.MV\AP/LJ=3; :Z)J1O>7_R@S6C#UG8#6Y$;\G5^01I=
MKKWS"4IN>,D1;)0)E'6"Y)L+&*V",L%XV>CD9D]"Q[UOT 2C+5750=G:[NQM
MX\-)Y#['$"R@M@H4F@(NYUQ39H$+AA$;#<O;F]1Q;QZ,C,9#U-4!'N\<U+R[
MK&.7WI>U!)>W6LUL%EMQ,6O%/12QON;#(D5I*8 0KB1BF\3:QB[N1>:XMP^:
MX+"=FCK8G1]A;KNB[O$XT4$;4XOY=,J,%I; NL3LVNY'@<ZG<E(4/D;HN)<6
M3HG#0535 1*?R=7>-,HHG+'HZFAG7D#YHL$39B"PVO@X:N*S#0)W)'#<VPM-
MD-="-5T,W'H^BT LK[E=\SV)@J=L18 @-(5> FM#7ZN!*95*+H9;,5:.YQ="
M^TKX# *7O?,_AVNN V.X$WNW+?^DL*PD^;^@,X5A2HH,KM2Q=P69T=F;5I=K
M]B:UK^3.:. \6'O=P?/I9-9=5KDQ1EG#P.9(*]$P$JRI8_EL9L$*^B^WF>5[
M!-%]Y7K:0[:=1L\/O+<V$:6EUZBQ7@@A 0=GZG8BP:*.,3KOZ;\>H+NG(W"R
MM% 'P#U0FQW ]JXPKY)>6G@;:NH5U[6\,4MBPPJ0D263JF?OGIJG,EP\M$\F
M\F09H!:0&T(3':0?'Q351*+D&2V#4A*OC=8R>&VPMA32+A:./+49I/ @.7VE
M<4X!IOVUT'<?SWO5*@_7+@U9D//T&UI6XNS!6_,2G*)3$"%"<3911%$L1+4>
M?"T9P30;:=M<!&M?D'ML]=MZO(YS(LMB#.143]$-\>)K9BRJ;'6@U1=#&SLW
M+!]]97H.0E^[,L>]%=V!FW<DSR]_/OR ];18G[G3"3V44'<51 91V@"6.:-J
M'M@W&I+4D*EQ%\"86)WW"9QNU]"[\ VW@_ED"885GH 5KT$5;L GK< P%!(U
M25NT">2?HVQ<-'<#H9V@?: ^1^[\]Q%IBYRFFCRK%2Q_SJ:KY<=/?U8AEOGB
M6YBE&@)@?NCW/KRLOTD!R%O<G '?^ME;^LD_L!X)3P3WS%HN(1M51T<*51O7
M)1#>H,G2932[= IL3VF/:#\45?-N5=R!07Y-<=S\)^*:E_?K^5Q;1K)D:"V%
MSJ9.Z%*JMMRI$U,9RS$&492[V]5RJ##E,9+&/9YJ LIAU= !GE[-9[0Z5E/R
MF7[#N-HR877V4EL-D0=B(HD(WG*$F(SC029==)M=_4%RQCTS:HJCX\7? 8:.
M=';>7L\75.2Z$(L22O&%/)M,DM32 KJ@HDF!L=#FTN10'(QK\?X^(=1AD#C_
MI7#5=9'1*D=>^\G4@=5!!G"U<W(1@K3@%,_.]+@.>FBM.0[RAH7_ 3#H^DKQ
MVDN*U5&O;.-LN7[L 2<4CSQHN(.(72@=Z+RA'K!?S)>7"ZQ#OF]>]A$OPJJ^
M?[E:KM&P)N>JQ_5U7IAQ'T5)"-+7&QK*) B)64*K,S)RSQ';7*@YCNYC#>S.
M;W]Y^^TWU_1+<KSDX$#&4D>!>@8NU*ZV@45!$9\0L<T,GB,)']>HGA"K=TWI
M*15^AD;TX'Y*3SZNM4%MV%?I2*A:KKT5Y/0*5R>?9,4@QIQ!1$O?QY*U;3,U
M;ERS>A,ZW'YW?>GO\\6]Y?5BL0BS+[BAX&+]]+4?<_.+=Y^R?/GSPT68W6D3
MY!5//!H!16D$Q6I1N5$2DN=9TU)-J5&;N5'8/6L3OL^Z>/P8NE=P=1 YW@CI
M849?) HFZH2=7[F,P7#ELJ^CF6AK]5I#L$(#AD)A H4PN5&OE,/H'3=!TL4:
M:*;>,_1>'O[NZ[_JIT=TECKB9:T]G_TY[L,OTBQJ])ZPKYVL#0$L."Y\'=*:
M-4M9I=!FNDLO?M'UB0\N?DP3/K**;^U7'S'-O\RF_T5$X6(ZWU"ZR:S6H<M!
MZ 1)!4WQ4,I01[> 8R:49!46UN9XI0D[9^W7[(/K)[ICC@2.#OR6%_\.B_R9
M?GE=FQ*R]B$3]M"Z3-&VH$ [(<F4]DB%(A6.C3+7M\GHI9)M-%C<34<?K*,.
M /:(U&Y%"2]_W@\B*L<W;,]R#1!NG=F*:)SD+H++IH#B.@*)I !FJ;-TR6?9
MJ#UK VY&/G Y'%QW[>G8FNX [8\7EDCM&#IM(";F0&G'(=H0(7MMU[.V=*-#
MP>/J>]J9V='1LG--T#ZJZP"#CU3=;9D)VFA$GH K$T%)17N0LQ$,-R([@RF+
M-J;S2;)&KKSH#8O#J7#T\=Y/%6_*HH/WTD 2M-$HJ1&\%@ZXUB8R(60*=V8E
M/#+)^]C2VF;59]T@:UAEC-JSJ+*R4P7Q#6^&I9)8K0,I)6UNN$=I*6H4Y.W$
MHEQ)90>@[??6<5L.=(6\ANKJ8,/==%[X1+I="_;M-AY<.]21("2842!1"U B
M%@@V)\C.T3:90A&R93>B!XGJI<RQE_AZ*/WU"\7M\DV8:6DE"\748@I5,D3'
M#1CE3$:..=LV=PR>)&O<.&0PY>\&J@,TT0&LZD)[7SZ%"[PRT<ZY$(V5X .K
M,\Y0@8NAELYS78B?6%B;</8>*5W"YQ UW[M;<(S,.P#-)[R@'WWY V?D=5Z0
M,_$B?YO.IC5S7PMKMX=F5\QY;SEG@9&H@@=%9AR"<!F*XBX'G1*F-I5]>Y$Y
M[M;9#FSM=-4!$(?Q,]Y>EY:GPKC7"2%97]G/Q+[E5>3):Y]B8K%-"F5@1D8.
MC;OS \?$20?+9,O9MIGA/<:W-F#"N?3120M9Z'JW@6L2+B_ K;9"\TP_;E.Y
MOAM](_>!&1-"=X\-A]?G&=8HO<AY6O\-%V]FZQS$>L<<N#;IR9>TKDG:G<,^
M:I%$88K+8($^D!M;)Y&15ZL@<A5]"?4T9>0['$UJD88Q#:_"]^DJ7-3O;J^9
M"0H+#))-T,GX>M<L@"^(0%S84D1,*??LC=QCZ*SKD?;!=AOWXSB G*&!O_(C
MY^5&+^L4]O*/19B1S@8O1-WUA<V+40_BO(]-0#K)F=(17+$6E+$<@E(2E"C&
M*<L3NC9Y\5X*4@\_G]D$.E)*%WG6D#'2JM8VUS,2 3:C86BSE+Y-1>]@+)RU
MH=\'OWM?)F@"@AXBS%]JS;1F+GBC@*=ZU,=CS5=E SE[D90G,RS:S"_JLMCT
MI%!XLL!T'[UT *HF!]TI%%FBXI!0RIKA9.!Y="!"'>V0"\N-MJ>_>X'I7N Z
M18'I/IKN .U/5X89Q4P2HD#VM?%^JA.1=5&0? XIZEPD2TU@>WQQWWD5FNZ%
MFKV*^_91X<C%?7M6]?AL HL^@L@F@4*%M$,E#9@3)ZZ*D7?ONIZJ".N\"DL/
MP5YC=75@&)\5]6.2OIUL3U;$P$$[GFO?/A*L2PERL=J$6,>/-;J,?33MO91T
MC>G%GA@!YXSYU_^ZG*Y^OIF1 ;A<:^7]ZBLN/G\-L\W%ATT":?EFMDDL3DS$
M).I9JHVU*VIA"5Q&#T22B,(HKD2;:I]3<=BYBS(P<H=:."UAU'4F>E.(\SG\
M=5#OIMM_/5R.^%&:!DKX7C__)G-V,_<IJVA\"2"E)O1E\E>=EKH>-D0*^!SF
M1JF<)X@:II3VET??-/805J&WP5#PJG(]C2\0N(H@5;$8C2G%M&E]]!15/51"
M'H^/APMI!]##N5B4=V&QJ;H[_.#JJ:<UL3A/TWP""V2,\4(I =K7]@^6/D3+
M(]2V/J)DEKEO<PI^"@NT+=5YB3,LTWKVX+QRVH.SQH'RPD(HM2(84^$NN^)M
MFP**1PCJU^[L@XI'[<X1TN\@1GA="M;F5'C-S\>PPH=&<4_01DERJ9?_&'TP
M9*"#0@EHD2D;HXVAS::V.XT]U%\/#[5&.NH ?7_.%M=%*L36=@TM)SQ:&9R(
M8 K2(C*<@H!L)?"42&K>VA+:#&5\A*!Q2Z%;X6H(Z8^<8ZYK 1-.?]3TT(LO
M"UP'I!1/)OIG7EZ%Y==/X<>Z^WJ8YM5\':A^G5^0PHA/7TSQH4"IMYF5E J"
MX!IL<6AU<BS;^(PG=2P-XUX"'AI8)]5(Y_[Z#URNUDF/Z6R3!_D'KK[.\^8'
M>&!BX-F'#NF][\?!4'-Z[[UI4U@SR_\QG\Y6_Z0O"*4WA38I:N,,\V!8B 13
M3J&C9P6X0,\39X2G-JF%/0D]VD][^'4/!;U*.&&=3+67: $EZCW 5#S8;+SD
MV1>F&PVZWYG&D6]A-,38/=^MC=[.W/@=D[K8]=FG-(5-)Y?OB=:@N%T[_E(5
M0FL6LH:BI<(H$[JBYHW&;)W8(MZZ(/CPBS='AE%86CI1@\\4E*LB'425''!N
M3'*:*^G:M/S?C;[SLH3[8.N)?JI#Z6O$X&.Y6$T^U@.P==E:<JF.C1(0 M;N
MLKI 8-J!<5YBM.B,VRE>I:?> AA]=1=<O[RVE]K4X?0Y/U:X/2#B>LRCI_]5
MBF7M)^]KER*A*8IVY$WP''/..Y6+[(Z),<OICE#97:4?(+^1U?Z/Z6SZ[?+;
MEO!"@;-A*D%AY,PI3LY<]);4%:.L$[Q+B#M56>ZD^%]>/;+J#U'<? @ICJW^
M\-<MPG4V@:?@(/':8D ;"]&2((1*4D>&Y./O5 RSF_IOOWJ<[/=@ZC]8BATD
MLK?7@CZ$Q>KGYT68+<E;J@GYES]O_V1M&ZWA*@FRB$[R ,H1>[[VL?.,.65(
M0%ZT*L+>E<9>R@4'=RP:JZLS(&X+@IF+LMZ; "64!66]@)A4 >V"#PPQ^-P>
M<#U<-6FE]2? =8 *.@#10SF.K5W.IG@?)#&!C+9E@Q)"J</+M<L%LR?9M+GY
M]#A-_8#J$&T_FR\\2/0=@.B1U;9>7I*;I(L30*21[7;<@T-:7DYA<-)+6]-F
M)]P#=][T3M'NZL2;WMX*Z1=;5^LO!L:#59!TI-623:R3W"38I- KX975)T57
MQWO?_LK?#50':&+D2H)M6Y7E]9'U=;=I,K(F6;+ANC; \A221H$:7/W:<L\Y
MWBFG>[!*X+'G=PF+0]0W'UB6'9B99XWRV^L+%@:3\R2K>B\S@XJUTKBV*,]*
M,8ICHXZ^];#;YV@<N>%\^PVND;I&-DP/\_(ZS6?S;]/T9D9OH>]M"VS"%YQP
M(47((8/ET9"S* TX5QAYH\)SYD+QRNQ@L/9];^>G$0?J?GXB170)LG_.5]/9
MEP<X2REQBFL,I)K:5YF112^T2IE5*?L<L]*[[(G[O;7SK%0K@ VBA XVTTVQ
MX=OY<OD["?<1(4ZLL\X7<@Y,4.0AV.IRB!S!9H;>:U5B8@TO+SQ#7N<QXG$0
M;*>HD8W;#4/E<8;N^:P3'@0M,120@N:@C)/@M4G  [&=C)#E;AW=@T;NL+=W
M[JP=;^Q.H)2NB^1^#]/%/\/%)?X#0ZT#7"M]_WJX!Q\S7.G;\U0.5.5V_:*;
MRLB;LJ/J^Y,KQ8AU(\B1"@JB+ A&2B08T*>Z34_QIZ@Z=C]\Z-FW;JZB*RHG
M!=XHVMP3.O!66N"*984J.-OHPN*39(WKXP^&D;L[WG"J.#N3LXZZ#RG$?>)A
M;<W/0Q2?P@@59IDHFOSK:$N]SDDP")R!#=&9%'@NKLTQZDF,T-MIB-.+Z6I:
MI[BL99W?SSYBNEPL*/IX&9;36RLB2(&T(A*XB/642]*>[ZP 5F_H%*>3:Y1@
M/XC<CHW6/IAZU&@U4UT'0>,^3/XYF\<E.8S5/KR9?;]<U0;HLT1_M5;V+8,>
MO6',:4)7(:E[8M\7#) *"@Q>&F4;NQ,#<C-N5J0+=#=1?$_@?[%<XKHJ_VEA
MT"^\F]<[O;=D4_]^*X7T=3;]UR5N$NTW0G&^+GIF0 N.%,@[2[:!2PA21:D-
M,U:V:6MW$O;&S=BT7Q[=0./L/-^-Y,(ODIO?L2R'WU,[]HUM?>B#>3^%H^W)
M10D\&'!2K#NH:/ \U ;ZCNRSR\[;-O=73^)HO_SY,ES4)JN?OB*N_EC,+[^3
MQ#>'GT6(Y"7+@"65FE,E&:3:M*^.:-3%*28;.R9/4->Q&[T/8AZUI$,IIB?'
MX>7/ZT__UQ071-37GV_Q!UZLZWZ*EK62U8.)CF(!'0KX1.Z0Y_5V12B9MX?;
M$_1U KC!</$X\(924D_0N[7;+._SMRTPTLH&K5F"DC/)3]>;]12# JJB?9'*
MI]WNRAR.P%W([ :(@^'D,2@.KK2>$+D.#9=KB?%M/9HT1<F(]6X1R4O%0/**
M-H+V:+F,W+C8IL_4$T1U@K;AH? 8Z([42Z<0$UM66$S)Q."!"U$G#EL/(=!F
M$8TJSNK@X]UJK(80$SU,/1@78H?HI5.(R:L;E]Q&41R#S&HA4#0,7+UQ*20+
M@GQCYW.;FIDGB.HD[S(*Q [12T\0>_GSEMA^7^"_+G&6-O?B:C E-2I(HD9:
M@45P-B%DHZ0G,RV0^]8APV/$=6+53A O#**>GA#W$$-7XVPB.LE(6B)D7NN+
M),22R1]0+A0FLDNE3?^>'8CKQ%4;"A [1 7':*=3P"VOTYY;LYUL],[2(C6^
MSJ#+/D!4.4-0+)"X0LJNS56.7:CK!')#06*70/08_1R,N1^XB//!-]8'-H;?
MIS/ZWC1<?"(UKAE^%3;34=Y>UUBR%(--04%!3[%](&D&&R1(S7S(PNAL&I>>
M'$AY)UY@^RWY!(KMP'S>.BUZ(!]_G8YW*5N./$*JE;DJ&0>QU@4;C8*IX.N>
MU 2NN]'7B0D]"6;FS178 2Q?7BY).LOEJ_FW2 *L\MHTQ_]2!4C"F^9M@_PK
M_G].BD3CI$V@M66T2U%8%A%-G9=H!$^8LF\S)., 8L<%; O,S$^KP XP^K04
M)]XA9R@U^%A;[M=\@4<F 3WM08P7$QLUQ'B:KG%#ZA,@;T"U' ZR^2I<C%
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MC- 6"OD<PC/OT"6N3)MRL><H.]9 /O;\FQJNFQ$*!KF2+&@0B@E0J21PM!U
M;5'@& 8K'#^I$!X@LLL1](?AZ*[!:J6JKJ==_+KX#Y[P]N!C6IFHAE/=G@=8
M]L2SM<!L"J!LSA"CTJ!M<$QEITIJDW-I;:ANQK@^]J8[ U^\-\R@IAU9(2??
M@-8;B:#VNPC&9\^#$6TDL2^EO9NL/1!UUV0U5=H9V:V'9M0<?HUB]V>WLG [
M\W,JLU=OYNA,&RG7M9%8J>7EH;8]CEY;GB6!JLT]K_'-WLN?O_QDG2*KA7+,
M9@G%1(I+7!80A"Z0O.8^$HZ,;E,S<1"YG1O ?;"UOP$\5GT=)!%W8VUS;HM,
M:>\T,,7KA/5<8W6AH.2@K(P%.6\#S-UI'!>-)P#,CF'%D=KK#)?;X[7@1;&,
M_)@4,@E*< ;>U/B+2\5%\2PTNG!PGY8^K=ZQ6G\"7 >H8$00+1>KR8M2UM>$
M,;^>K=;YO\U)?=&T%?!"(75V=:*+A.A+'=:FLT7!:B_'74!$K[@%(/KJ+G@>
MIZ$?\!RBU?F@(N[,TMQ:33>):B5HK0AB14A>^SI:3SZ$0\"@=8BFB)#;],1\
MCK)Q#PBZV>T.TU0'R-N>K%RWK2NHHLT6$(,AT3@)W@4&PB0A2T:K39N+X+_2
MT8]Y.E['\\$$W@-<TKHBJ%Z[PNFZ<\$[7+VZ7%2Q3@K))3'F0*O R=2BIW5E
M24!HC4-IN2IM#CJ?HFI<*!VC[;O &4KT1[3K&:8'W8<%?@_37&L:9TM\L6TK
MNQ'5%4.T1VLEK0*OZD&'-@$BL0&&2RU0>A2Y36'5#L2-N^<-"*FA%=$ULM[-
M9VG+DU52&5G(V<RZRLPPB#P;<A&-*XGYP!N=QNY&W[@7.$Z$KP/5T455T*VL
M]<W<;:X8,QG!<A2U\%:LI_R +YS)5,NQ2YLNRP\0,ZZ!:NH^'2OZCGRH#^%G
MW<6O#&UF,7)&4C&&5IM*44)0VI'&633HL^"BC5%ZF)YN!FT<IN9'G*<C9-X'
M<A:7>/O0[(H1D4U-DP@HDE:3(N,,KJ;<"A'*4K9.E49QVV,D=3,N8RC\#"#Y
M#B!T78OX^WSQ^^7J<H$?YA?3]/,ESK!,US66?\[JIOWJ(DR_U2^WG^3_<[E<
MU<K%[6X^,3RB+D;0VN&.U@[!PY%A!XR9<<^*"K9--==@+(SK9PT-T7$T>T9%
M%!_Q!\XV71BWG Y60_'$HUN54.S*S:DJ*)BN_2>8 B84;:6N#@I2DG96Y3&C
M%E+HDV:HQZZ@R(IB8^O !EI(JIX]A)(+,)?K*M9.IC;]>OZ.%13[8&N@"HH]
MU-?!KK[':6SR0B3I(VTQFCB+,4 4RD/"G'6NVXQN,[7\;UY!L0]@#J^@V$=[
MG>'R:B2R]974FN?1"DAHY-TP5B 9X9E!SBVV2>R><07%7EI_OH)B'Q7T64$A
M/8E#KL=>FUAG$5H(WEE@L3@KI!+6[>1L_)TJ*/;2ZO,5%/N(N -+\V9&?C)>
MCPI^6_^@ZJ(N'V_16FD,>),H1$=4$),*P%A"X4/TW+6IY'^"J+.LFSABCQM*
M/_U";;L,E8A*)%IW)45:BX;S.D)% IIHLN?6R$:'X$^2-:ZU&DSYNX'J $UT
M *M7\^7J??D4+NK5YK4)%FAR,A*A*%-HVR<'P->>]PZM#)'7_[>!TCU2NH3/
M(6J>#RGS#D#S"2_H1U_^P!DNPL6+67Z1OTUGTQHWKZ8_\"HSM&4.:0?W@G9R
MSSS6B84&G.()K#>>FURD5FUBO[W(''=K; >V=KKJ (C/'OIJS>C_R,AE2!94
M9JG&,!QT%B9997Q@;4ZH!JE@;78*T$VVX3!-=8&\=2+\=Q+MKQGR2;8B&249
M<"5IL0KF('H48*,JF+QGLEG3A4=(ZB=H/%[S]V UA!JZP-.#4KHRSY7!V\NS
MSHB[_2=DN(6G_VAC,(P,MRD97+ :6(FZ:,]LQI/>H-^5\,Z+AH[#YNE4VGV;
MGN_SY;0^BER1L*W(>_4US+X<V!?CB<<->?2Y*]6#'7>26W:95I?;ME);.+P@
M@/SX]<@^UM$E)='>BRA!I5H?R\DC3)[5&8^6:=MJD]F1Q.,-XC,O>JB!C(K&
MLQ)TO5[C:TJ2EHRO!:0B8F'"FI)&$DN'37]:8.V^#6RLQ<XK01XW($<T!7KV
MH:<Q@4T;!NT*3FX<QTB1B%>68A(M"GB,D6(2+;7QF"QO4_%P,D-X.U9[\)4U
MG;2\63U2V9)DUA!MD+595QW<DA@X+KF0B:,]00W(#H2>B_G;!V%/E8$,K;NS
MM7S'E+\]_]33V+ZV16^[0M-H;Z*ED$!HI.W1V@*Q#JIU.=*N+(LJIE7_H+Z,
MWSH]A2J00+0$'J*C6,W4"]8^@>;*L*"M3*Q-A^<]B#P7H[</L@XT>GOKK(LL
MS2V&*AMKINHX]<V %R%Y41(+4-Q>W5?M(4J9 +/$Z&5D@9W &[E/6#^U;8,"
MXJE@XTCM= "V.E_CCLBNBFZ24T(&!9[5V]:I('V6%$27I&'%!X9M8/8H21W9
MM6,5/V^AA9''+KTFYVK^$_$3_L!%F*5Z*_8S+KYM.XA?7=;8'@(6Y JC,N!S
M)(^WNJ*.NP*"UI\M,<ODW#.>VMXO'1=  REY?@J)=V"9?@]I?>?GU04YR-=#
MD*7PG+,2:T<;$E5.%D)1&7),T;&0@VTVI/H!<L8]6!@64,/)?60[]&$Q+[A<
MDA+"Q2<RS]-4KQ3=$M*6)<V\#<%X,%'7OEQV79YE02CM&#D!7O&X@P7:\77C
MGL4/;WM:2+D#J_/$+G]S8!=32853S((NUTED%,)$+P*8''WA-GK<K49[2 _\
M;7]MRT9RPP_34W?8^QH67W Y<;0O(RH).DA;NP<B"2D)L-Y;VL<I3'9M9HP_
M1$VW'OB!.G\25 <HH#<0_;KLZG]O-JUI\N?Y;_1M/B&I<$M&GM:@(O//R3*[
MX#DXXWSD14=A3YK=>X3.L2LX3@F\8976=0;_$WZIE:@U";ZHXZ4.2-??>\1P
MN?FGJ1LH$7_W)=?949&X"C[0VDGD9Y.7Q&N?,@^L9&&U5":I-E6ECU%T?$'W
MK\]]Z%2>YR*XEDAQA: 8M=8'.YUK"6A 5[P+W+0JXWZ6N)'SFT/@Y'[=]K J
M.2MC<W!QQ",/:F=X&A9!/ HKDSA/(CF(N?:/PL(A1O+5-6K%N"VRA#9-WUJ9
MGX^8YK.TO@]*6JGQR755[_:5R\_S.MQP?C'-=?>]-3),.28M*DA94@P;6!W"
M0R%M885)GVG+%6UD<3C-G1JK?5!UWTDZB0*[\.%_Y?3]]_6XS=F7FG29KM[.
ME\M=N"ZB).&C@>+J2%H1+'@?!>3,H\F&L^1;^?9#T#]R(N,4$#Z!8L]J2WZ1
M\[H6)ER\F97YXMOF?MK!I3Q[/;[=]KT[5ZTW=8G.2NT8F)KG5:C)5]1" D/K
MBHF6!=4FF=1J4W]W69/,MQ;2U=*9*!.*%^0,2^0<5,Z2/%:F08? 7=;)L%*:
ML/HH29UNR?M@XJX]&T;\9V6BMEY'N66F5[^8Z>',U<ZO:F>Z#N.VM1FC;2X)
MY3,@T[6!2P[@F+>0M2]6NY*\;',#HY_89'V DIA"YFE5!<<"R4%:B 4#!,NU
M28*C$6V*$0^CMU,#N ^:CH])]E;<R&VJ;H@G!M>9[DUODU2*="%#9)6#["(X
M:R4!QC!M1")'=*?M=:<V50_3,/9A5'O-SP=50W= VE8@F& -+SE!CJ;>O^(%
MHDV)')"H:OM+'MQ.UOQ *(U96SB49I\$R@%B[B '\F:V?M9Z);V^F%[5M&VK
M2IA4G%OC@)M20'%!$7!<UZ](KSE9].#;=.A^DJR>0'2(UN_UH!I*!1W@Z5Z(
M<E45*;-3(A2P/%&@PE"!]SZ )D<@!I=1\38%A8\0-$[6JQF&AA![!^AY-5^0
MVTC;^+OY;,O)EA&NF19U/%D(.A,C-;7,1*QW6D(B^ZUHLV^"GT=)&J?2L!F"
MAA%]!QBZ;KSU\G(YG>%R>;4D-M<'%+<.:_MOG00HR3RX0%]RG:5V)B:28)N8
M]BFRQJZ[.9F//;R2>D#<AO;M(LQ&6LY)(FF=Z,N%!.19+>%&;:(/(8<V ^9_
M(6/D),!PZGVXE.( 68]];6>3"?Q?ZTS@527W'4.;M%,A)G+P:L/DH(@;YC=V
M%S&6HO2=8/_ANSK/OJF+#-$A*IPWD^?(Z'A%WYRF</%I?G&Y[B#U*R=*,)5R
M%I 9JY?>0H3JO(&-)![NB[+H=T#&TV_IXB#X2%0,*,=^-I:[QP37^_7L2_7^
MWE[7QA*@$3D38%(=@XED72,6"ZA9-LRA4K[IUK,KH>->TAG#W6FHR YP>DN"
M)+=UNK]VP'MUN5S-O^'B]5_IXC+7LX#EDGR!*M"_)IK)9#DZB%I25*$5V>5Z
M/\H$7IL5."Z$:72HLC>Q7>R7;<#S> _.)IH<;;YSW1PV<^HPOPZ+V@9F^1++
M?('K]!LN5\1*[05#9*6-9:C]E;]5D?_7^LN)*:7>X8N09""W%3U"R"6"3CDJ
M(7(2/NVP"1]'11>;=%,HGEA39U85<7OKFI=K.;U\\_FW%T.61.SRGI;U$'OS
MV?R>"//%RB"!9QEJ/6*N@WXM04Q%SPT+A9U7,<0[7&TZU==RR(DPF18-)@BF
MKE1.?H[CK(!6)8LD8K:^31N27\CH:Z,]2/?W:K<.%O/AEFF^"A<#G0[^P,UD
MUPT/5Q9X(J(4R$4!-,'3GA\Y.)($",N3=UX1'VU6PV,4];4O#H*<083?071P
M1??5<.#LN?+>%"@84SU/B!"3%N"P&.%1**7:>/YW"!EY;$,;R!PNZB-<\R^;
MNOEAQV.1E[=E8]M@AW!O69;,@B?WCG!O/9";9T$7PT2,BON[6;#!@/,@03L!
M2)T9@(X7_;% &@1#3X4'04J=G/? 9*Y-L)6&& 2QQ3AMSH[)D-OT%3DVKM-G
MA:6A5# JGFHT^D>8SM[/UO,=2BW#WR23EU^GWR<^V"Q*M!!$K<XI%-L&+@N0
M+Q>"1^>ENS-@[<&<P.-OV D7YBQP,: H._!J*B?+ZM/C\OWL]5]5.I?3Y=<J
MKO?E-XRK"085;2@"4FWTI*PQX$K@P+UR1;N<+&_C(S]+VDZ@LF<!JC;J&' $
MR[%NT-5EQ=?_NER/UEU]G>>;R& YL=9@#EY"UNA 2>YH9[8)1+W_HT0TAK>Y
M@+43>3LAS9T5TH972P?6[*I.X]7\6]S6G];\/\F,N*EG8=.\+C"L>EO4KNEK
M+C<-U-_,:&N_K.OLD3]Y.PUQW>N03U0(SNL<@?Q%"DATRA"-$$ F7D6=HBJV
MS>SV$S&X$][]6>&]1VAT$6*L9PB\F\_F5[6W&\MP%7L+XZ001M &4V^/*^<A
MF*!JOB](-.AT:@/UI^G:+<7*S@JB VJB UO\8'N\X"V+BM$&(I0 901"E$F"
MS,[*B(QE/,$TK+WZ$YY7GOYHJ8\>IGXBHC&&96UH]ZTB?U,?/ML>V;^?X6KZ
M#3=':55^$RG(J#I70!;!*.*2$6)V"JR5FAA73MX=//=@\+KO>W=#SWGDZIO+
MO8N=[KKQ^;JK+)]PQY''*,"3^$&QF&IO%K*J-B7-E8Q!-IK.\BLANR'IO%+X
MQ\AZ=!/T*GR?KL+%]+_J6MB4#ZW[>-Y*_7VX7*2OM%A>I%0]PW7?EJN5008W
M":ZYU("IWE?2NA"W3$"0*I>44I1LEWS:L73L!JSS2.V?7"^CHW!MD+_.+TA+
M+_*/Z7*^^'E5(#Y17MD@E(>H120)4H#A0ZY>86(ABIC,W;+#Q_>\AU^Q&W;.
M(Y4_I#1'A\6M <UKVSJQREE1HP&K+.W#BA>22-V,M5*,\1P5LAVP</>YNP'@
M?'+V1\FM"__EUY1=[;ZZSD9<8M[>FYW/EN]P];[4<M;HI Z\>! QY]I2*4!4
M+@*R5.JH\!)+J]*6W:G<#6/GE<)OIJ51L_D#E+-Z'K/)*D(VQH.R9&6C\ P$
M6B,R;<8\[W+[YP2%Q_P\4ODGUDD'.:4'5U,],ZO+[?V,?OQ]O@P7[\N#OWB]
MZJQ,UA6>P)E4F]@)VOF+KKTI!#KD(O%@F]C&8>C?#</GE9X?0;-=E\QO!T8L
M:36_N@C3;\LPRQ]PL6X(2E'URYJGN7U0<4"U_-ZO&'*.\3'<#50C_V:VO-S,
MP;L"L/,RZV(D>83.@0IH(20?@1?!:2_6Q<=6/M,=4HYW%;</?*A'OXXEIF1K
M$PQ10,48P!6#8!A]&T6RD;>J7'V<JG%KYH_#PGT7<"#I_ZU,U,$3% Y\T7CF
MJN$$AOM E<;J)+D'KNL=<X\40E0\A9Q\BL8K(]L<T YNM&ZFP5V?I_\^7_PY
M^QZF>2-W<E^WGUPG]:Y/1QE&$;("4UBIDP,-!&[)#4FNL(RUUK=1L^HCJ.[-
MZ.V#I<=GK#?6WM_**!Y^V?'0-XUG%EM>>+R/Y<)CBKX.5W..@.32NG1-P/J\
MB1N=G6DSAF5XN_B5 JU\N=@>R&Z??G4"LKS;"&*CB]_P!U[,OU?!?YY?K\A-
M#PAE92S9!* @25.4E .$2!^2B-QGBI38W0X]0]G*@3GIS7[N@[E[]G-,+7>0
MVWFZV19YQ=E(C&"#(==9$;:"C A2<>]1<J*Y44^8HQO>M2L@&A4Q>[7"VT=]
M/6#QERY.DN) I[D%AL'5@R)R3AQW((H6!H41A;6)E\^F%=Y>ZGVR%=X^LNZ_
M%5Z2CD5.L7Z,J=2^M0Z\5'48%(_1)F)4Y&?<O/-KA;>7"O=KA;>///MNA9=*
MR3JP",;7PV>*?B PS:!VY\)@HD.M=T#&^;3".Q05 \JQAXUEN"W[[75[(IUC
MT<@8..'JS'%6KX39>@9BM(G)F,RZ=^??[M54KQUFNW*IQ@9+!POF'_,?N.D=
MLG]6Z1VN/LXO+NCW_QT6F9R4)+,6#GCM=ZBXK%7P-?O.M+39%2-5FX3 <#S\
M;>*- _$X[P(<'2R+V_P^FUP-7IK@K 1<7QS"S,&12PY2,A2Q.*UY&^#O0^6X
MT!X+2?,3J?5@R'['Q72>*?I;'-^X\M7EHNKB/S$\R]SUM9-:JOF^_#&?Y_K;
MUU'!_")?-_%\JKZIH)$A"DG;;R#KPA0';S56UU-8%\A5O#O"]&$W^^24C^L&
MC;P<S@ L7;16^'3Y_?O%6E&_# LFT7]8U$NDJY^OPO*2PNF?U[OUGS-"SK\7
MT[H5?:"EO=A%P!.2AW?""A ^UOFL)H)/(M"';*P5G$?1Z'#U1!R.VT2MD]VG
M2SAUYFSMII3-MS_4W[PQ8WR",@?-C ?OE:R] 0Q$9@1YO4K(8*7/P35WQ([A
M8-Q6<9TLDU'@<.;+X-HV+/G$\2*S*0Z4K1-T?6(0A8A@A'?:>&^<;G.4-Q #
MX_:X^QLL@D/!<)9KX,,Z@"(7=8%AB;_AYM])1AV-B;76*5#P5OO>1O2T(Y;,
MF4@<76Z3LQV*@W$[^IWM*A@ #ATTU-Z?[ZMCXQ?I7Y?3Y71]DC-A*0N!A<*L
M0!]4T@R\D(ZBKF!\9M:E;ORAA^@?M__@V2Z!HZ'03XOG_9E_3Q^GLR\OP\6Z
M<.Q6;P(CBQ,LT":H?;T<$!(XAPZ,0F&,\T+S-I?2!F1BW#Z)9[LBA@%%G\OB
MV60 %\EG90SDG(A/1I\%FR-87USBR489VGM"@^2'FMVX[!#8@ZKUR-.)U[/;
M_16:##"ZE1E[%99??[^8__M6ANR ZOWGGCC@4*)]:!]J_- #[WR]^<;RNEC:
M^N"%BQD\5Q4A4H-+M5UV4;YDE+3]-RJKW(&ZHT? ;Y][^UTWMP&7-]<!G73>
MV" @%491<$0+T4AR_ZV6.@F3?&HSL6A7"D>N.1@:2?<&QK=05-=7E)XQ" =?
MT]SMN2<S; TO8>X$2E='1EKMP69#<;UV!)7@"E@N7$$7>?1XMN;MYK+?<^NG
M:N%F$;&2O)$B@Q !R?TH"#X1"]RI0BM8\%(:M5P\C. S,'[[X.SQ.YOMU'C.
MMO"(492[/?ADUK#IL,E=8*I#TD')=5,6!BIX!RXJ \5Y);WDS-_M4G=&YO#J
MN>_FLT2?;B8HU-8XL_S[=$9!??T\K:8_IJLI+F_6U4WKG"(5QL@@,EJ_*O($
M@5D#"0U/V8L8&MU>/Y;R,S"0^R#O,>_P)(KMX'QKVV%U'<3GZ:J:_C>S5 ^M
M\\O+U;OYZC]Q58_P)DY9JRVYOYZ9ZG+S"$%9!R([3%F$FEUJ!-C=*!P7F*?%
MS3W0-E#BV->IM@)]6^>UWX@I,(DF%@^:N7KK.BEP.3DP]*$$BLH<[G+![N&G
MCWP5I95M&TB<'5BK]U>#,M[60]0/X><F:2Y3\%Y(#\RD!,I(!B'Z#+GP&)5W
M(HDV)RD/TS..)1I*RW=GE!PO\I$MR<?IEZ^K]^7/);X@J:S6IY!$ 5GF39-!
MS._+)&<RM*9(X'6FHT+)ZWE\@>RBS4Q+8=US$<"N[QK'R@P,CR:"'?I Z]$
M<ON#^J$.P/B?_^W_ 5!+ 0(4 Q0    ( %>1I%1&W61")S8  !B5 0 4
M          "  0    !A,S,Q,C)E>&AI8FET,3 Q+FAT;5!+ 0(4 Q0    (
M %>1I%2*&&0F<C<  &.H 0 4              "  5DV  !A,S,Q,C)E>&AI
M8FET,3 R+FAT;5!+ 0(4 Q0    ( %>1I%0O#0]./P@  /<K   4
M      "  ?UM  !A,S,Q,C)E>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( %>1
MI%26GYMD-P@  "HL   4              "  6YV  !A,S,Q,C)E>&AI8FET
M,S$R+FAT;5!+ 0(4 Q0    ( %>1I%1$KON$W00  & 5   4
M  "  ==^  !A,S,Q,C)E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( %>1I%0W
M^IF&S 0  !@5   4              "  >:#  !A,S,Q,C)E>&AI8FET,S(R
M+FAT;5!+ 0(4 Q0    ( %>1I%0;_D=!$+D" #QL'  0              "
M >2(  !E=F@M,C R,C S,S$N:'1M4$L! A0#%     @ 5Y&D5+:<C#"V&0
MG2,! !               ( !(D(# &5V:"TR,#(R,#,S,2YX<V102P$"% ,4
M    " !7D:14+JA:I%XO   =Z@$ %               @ $&7 , 979H+3(P
M,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    " !7D:14B;4\]7:*   ,(P8 %
M            @ &6BP, 979H+3(P,C(P,S,Q7V1E9BYX;6Q02P$"% ,4
M" !7D:14/%SSM-=  0!Q0PT %               @ $^%@0 979H+3(P,C(P
M,S,Q7VQA8BYX;6Q02P$"% ,4    " !7D:14MF60D7K:   Z\@D %
M        @ %'5P4 979H+3(P,C(P,S,Q7W!R92YX;6Q02P4&      P #  0
) P  \S$&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
